FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Jong, EC Macek, PV Perera, IE Luxbacher, KD McNair, HM AF Jong, Edmund C. Macek, Paul V. Perera, Inoka E. Luxbacher, Kray D. McNair, Harold M. TI Ultra-Trace Analysis Technique for SF6 Using Gas Chromatography with Negative Ion Chemical Ionization Mass Spectrometry SO JOURNAL OF CHROMATOGRAPHIC SCIENCE LA English DT Article ID SULFUR-HEXAFLUORIDE; PERFLUOROCARBON TRACERS AB Sulfur hexafluoride (SF6) is widely used as a tracer gas because of its detectability at low concentrations. This attribute of SF6 allows the quantification of both small-scale flows, such as leakage, and large-scale flows, such as atmospheric currents. SF6's high detection sensitivity also facilitates greater usage efficiency and lower operating cost for tracer deployments by reducing quantity requirements. The detectability of SF6 is produced by its high molecular electronegativity. This property provides a high potential for negative ion formation through electron capture thus naturally translating to selective detection using negative ion chemical ionization mass spectrometry (NCI-MS). This paper investigates the potential of using gas chromatography (GC) with NCI-MS for the detection of SF6. The experimental parameters for an ultra-trace SF6 detection method utilizing minimal customizations of the analytical instrument are detailed. A method for the detection of parts per trillion (ppt) level concentrations of SF6 for the purpose of underground ventilation tracer gas analysis was successfully developed in this study. The method utilized a Shimadzu gas chromatography with negative ion chemical ionization mass spectrometry system equipped with an Agilent J&W HP-porous layer open tubular column coated with an alumina oxide (Al2O3) S column. The method detection limit (MDL) analysis as defined by the Environmental Protection Agency of the tracer data showed the method MDL to be 5.2 ppt. C1 [Jong, Edmund C.; Luxbacher, Kray D.] Virginia Tech, Dept Min & Minerals Engn, Blacksburg, VA 24061 USA. [Macek, Paul V.] Shimadzu Sci Instruments Inc, Columbia, MD 21046 USA. [Perera, Inoka E.] OMSHR, CDC, Pittsburgh, PA 15236 USA. [McNair, Harold M.] Virginia Tech, Dept Chem, Blacksburg, VA 24061 USA. RP Jong, EC (reprint author), Virginia Tech, Dept Min & Minerals Engn, Holden Hall,445 Old Turner ST, Blacksburg, VA 24061 USA. EM ejong@vt.edu FU National Institute for Occupational Safety and Health (NIOSH) FX The authors wish to thank Shimadzu Scientific Instruments, Inc. for their support in providing the tools and assistance necessary to complete the study outlined in this paper and to thank Dr Carl Wolf, Virginia Commonwealth University, for his guidance in enhancing detection sensitivity through the replication of SIM channels. This publication was developed under Contract No. 200-2009-31933, awarded by the National Institute for Occupational Safety and Health (NIOSH). The findings and conclusions in this report are those of the authors and do not reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices or organizations imply endorsement by the US Government. NR 26 TC 0 Z9 0 U1 2 U2 19 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0021-9665 EI 1945-239X J9 J CHROMATOGR SCI JI J. Chromatogr. Sci. PD JUL PY 2015 VL 53 IS 6 BP 854 EP 859 DI 10.1093/chromsci/bmu154 PG 6 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA CS1OZ UT WOS:000361837600003 PM 25452581 ER PT J AU Kardous, CA Shaw, PB AF Kardous, Chucri A. Shaw, Peter B. TI Do Sound Meter Apps Measure Noise Levels Accurately? SO SOUND AND VIBRATION LA English DT Article AB Worldwide adoption rate for smartphones is expected to hit 2 billion devices by 2015. As of the end of 2013, smartphone ownership in the U.S. market has reached more than 67% of all mobile subscribers, or more than 140 million devices. Apple iOS and Google Android platforms account for 93% of those devices [Nielsen, 2014]. Smartphones have evolved into powerful computing machines with exceptional capabilities; most now have built-in sensors such as microphones, cameras, global positioning system (GPS) receiver, accelerometers, gyroscopes, and proximity and light sensors. Smartphone developers now offer many sound measurement applications (apps) using the devices' built-in microphone (or through an external microphone for more sophisticated applications). Interest in such sound measurement applications is growing among audio enthusiasts, educators, acoustic and environmental researchers, and the general public. C1 [Kardous, Chucri A.; Shaw, Peter B.] NIOSH, Cincinnati, OH 45226 USA. RP Kardous, CA (reprint author), NIOSH, Cincinnati, OH 45226 USA. EM cyk5@cdc.gov NR 13 TC 0 Z9 0 U1 0 U2 6 PU ACOUSTICAL PUBL INC PI BAY VILLAGE PA 27101 E OVIATT RD, PO BOX 40416, BAY VILLAGE, OH 44140 USA SN 1541-0161 J9 SOUND VIB JI Sound Vib. PD JUL PY 2015 VL 49 IS 7 BP 10 EP 13 PG 4 WC Acoustics; Engineering, Mechanical; Mechanics SC Acoustics; Engineering; Mechanics GA CS0GE UT WOS:000361735500002 ER PT J AU Wolff, BJ Morrison, SS Pesti, D Ganakammal, SR Srinivasamoorthy, G Changayil, S Weil, MR MacCannell, D Rowe, L Frace, M Ritchie, BW Dean, D Winchell, JM AF Wolff, Bernard J. Morrison, Shatavia S. Pesti, Denise Ganakammal, Satishkumar Ranganathan Srinivasamoorthy, Ganesh Changayil, Shankar Weil, M. Ryan MacCannell, Duncan Rowe, Lori Frace, Michael Ritchie, Branson W. Dean, Deborah Winchell, Jonas M. TI Chlamydia psittaci comparative genomics reveals intraspecies variations in the putative outer membrane and type III secretion system genes SO MICROBIOLOGY-SGM LA English DT Article ID CHLAMYDOPHILA-PSITTACI; EFFECTOR PROTEINS; FERAL PIGEONS; INFECTIONS; PNEUMONIAE; TRACHOMATIS; SEQUENCE; HUMANS; BIRDS; STRAINS AB Chlamydia psittaci is an obligate intracellular bacterium that can cause significant disease among a broad range of hosts. In humans, this organism may cause psittacosis, a respiratory disease that can spread to involve multiple organs, and in rare untreated cases may be fatal. There are ten known genotypes based on sequencing the major outer-membrane protein gene, ompA, of C. psittaci. Each genotype has overlapping host preferences and virulence characteristics. Recent studies have compared C. psittaci among other members of the Chlamydiaceae family and showed that this species frequently switches hosts and has undergone multiple genomic rearrangements. In this study, we sequenced five genomes of C. psittaci strains representing four genotypes, A, B, D and E. Due to the known association of the type III secretion system (T3SS) and polymorphic outer-membrane proteins (Pmps) with host tropism and virulence potential, we performed a comparative analysis of these elements among these five strains along with a representative genome from each of the remaining six genotypes previously sequenced. We found significant genetic variation in the Pmps and T3SS genes that may partially explain differences noted in C. psittaci host infection and disease. C1 [Wolff, Bernard J.; Pesti, Denise; Ritchie, Branson W.] Univ Georgia, Coll Vet Med, Infect Dis Lab, Athens, GA USA. [Wolff, Bernard J.; Morrison, Shatavia S.; Winchell, Jonas M.] Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30329 USA. [Ganakammal, Satishkumar Ranganathan; Srinivasamoorthy, Ganesh; Changayil, Shankar; Weil, M. Ryan; MacCannell, Duncan; Rowe, Lori; Frace, Michael] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis Branch, Atlanta, GA USA. [Dean, Deborah] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA. [Dean, Deborah] UCSF & UC Berkeley Joint Grad Program Bioengn, Oakland, CA USA. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, Resp Dis Branch, Atlanta, GA 30329 USA. EM Zdx2@cdc.gov FU NIH [RO1 AI098843]; UGARF Health Technology Development Fund; UGA Infectious Disease Laboratory; Advanced Molecular Detection (AMD) initiative at Centers for Disease Control and Prevention FX This work was supported in part by NIH grant RO1 AI098843 to D. Dean, the UGARF Health Technology Development Fund and UGA Infectious Disease Laboratory, and by the Advanced Molecular Detection (AMD) initiative at the Centers for Disease Control and Prevention. NR 47 TC 4 Z9 4 U1 2 U2 4 PU SOC GENERAL MICROBIOLOGY PI READING PA MARLBOROUGH HOUSE, BASINGSTOKE RD, SPENCERS WOODS, READING RG7 1AG, BERKS, ENGLAND SN 1350-0872 J9 MICROBIOL-SGM JI Microbiology-(UK) PD JUL PY 2015 VL 161 BP 1378 EP 1391 DI 10.1099/mic.0.000097 PN 7 PG 14 WC Microbiology SC Microbiology GA CR5VG UT WOS:000361411900009 PM 25887617 ER PT J AU Faul, M Dailey, MW Sugerman, DE Sasser, SM Levy, B Paulozzi, LJ AF Faul, Mark Dailey, Michael W. Sugerman, David E. Sasser, Scott M. Levy, Benjamin Paulozzi, Len J. TI Disparity in Naloxone Administration by Emergency Medical Service Providers and the Burden of Drug Overdose in US Rural Communities SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SUSPECTED OPIOID OVERDOSE; UNITED-STATES; INTRANASAL NALOXONE; DISTRIBUTION PROGRAMS; PAIN RELIEVERS; VENTILATION; PREVENTION; PATIENT; DEATHS; HEROIN AB Objectives. We determined the factors that affect naloxone (Narcan) administration in drug overdoses, including the certification level of emergency medical technicians (EMTs). Methods. In 2012, 42 states contributed all or a portion of their ambulatory data to the National Emergency Medical Services Information System. We used a logistic regression model to measure the association between naloxone administration and emergency medical services certification level, age, gender, geographic location, and patient primary symptom. Results. The odds of naloxone administration were much higher among EMT-intermediates than among EMT-basics (adjusted odds ratio [AOR] = 5.4; 95% confidence interval [CI] = 4.5, 6.5). Naloxone use was higher in suburban areas than in urban areas (AOR = 1.41; 95% CI = 1.3, 1.5), followed by rural areas (AOR = 1.23; 95% CI = 1.1, 1.3). Although the odds of naloxone administration were 23% higher in rural areas than in urban areas, the opioid drug overdose rate is 45% higher in rural communities. Conclusions. Naloxone is less often administered by EMT-basics, who are more common in rural areas. In most states, the scope-of-practice model prohibits naloxone administration by basic EMTs. Reducing this barrier could help prevent drug overdose death. C1 [Faul, Mark; Sugerman, David E.; Levy, Benjamin; Paulozzi, Len J.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Dailey, Michael W.] Albany Med Ctr, Dept Emergency Med, Albany, NY USA. [Sasser, Scott M.] Greenville Hlth Syst, Dept Emergency Med, Greenville, SC USA. RP Faul, M (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway, Atlanta, GA 30341 USA. EM mfaul@cdc.gov NR 46 TC 10 Z9 10 U1 2 U2 9 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUL PY 2015 VL 105 SU 3 BP E26 EP E32 DI 10.2105/AJPH.2014.302520 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ9LH UT WOS:000360935700005 PM 25905856 ER PT J AU Johnson, CY Luckhaupt, SE Lawson, CC AF Johnson, Candice Y. Luckhaupt, Sara E. Lawson, Christina C. TI Inequities in Workplace Secondhand Smoke Exposure Among Nonsmoking Women of Reproductive Age SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID ENVIRONMENTAL TOBACCO-SMOKE; HEALTH AB nonsmoking women of reproductive age as a proxy for workplace secondhand smoke exposure during pregnancy. Methods. We included nonsmoking women aged 18 to 44 years employed during the past 12 months who participated in the 2010 National Health Interview Survey. We estimated the prevalence of workplace secondhand smoke exposure and its associations with sociodemographic and workplace characteristics. Results. Nine percent of women reported workplace secondhand smoke exposure. Prevalence decreased with increasing age, education, and earnings. Workplace secondhand smoke exposure was associated with chemical exposure (prevalence odds ratio [POR] = 3.3; 95% confidence interval [CI] = 2.3, 4.7); being threatened, bullied, or harassed (POR = 3.2; 95% CI = 2.1, 5.1); vapors, gas, dust, or fume exposure (POR = 3.1; 95% CI = 2.3, 4.4); and worrying about unemployment (POR = 3.0; 95% CI = 1.8, 5.2), among other things. Conclusions. Comprehensive smoke-free laws covering all workers could eliminate inequities in workplace secondhand smoke exposure, including during pregnancy. C1 [Johnson, Candice Y.; Luckhaupt, Sara E.; Lawson, Christina C.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Johnson, Candice Y.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Johnson, CY (reprint author), NIOSH, 1090 Tusculum Ave,MS R-15, Cincinnati, OH 45226 USA. EM cyjohnson@cdc.gov FU US government FX The National Health Interview Survey and preparation of this article were funded by the US government. NR 23 TC 1 Z9 1 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUL PY 2015 VL 105 SU 3 BP E33 EP E40 DI 10.2105/AJPH.2014.302380 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ9LH UT WOS:000360935700006 PM 25905837 ER PT J AU Lucchi, NW Okoth, SA Komino, F Onyona, P Goldman, IF Ljolje, D Shi, YP Barnwell, JW Udhayakumar, V Kariuki, S AF Lucchi, Naomi W. Okoth, Sheila Akinyi Komino, Franklin Onyona, Philip Goldman, Ira F. Ljolje, Dragan Shi, Ya Ping Barnwell, John W. Udhayakumar, Venkatachalam Kariuki, Simon TI Increasing Prevalence of a Novel Triple-Mutant Dihydropteroate Synthase Genotype in Plasmodium falciparum in Western Kenya SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article ID HUMAN MALARIA PARASITE; DRUG-RESISTANCE; DIHYDROFOLATE-REDUCTASE; ANTIFOLATE RESISTANCE; PREGNANT-WOMEN; PREVENTIVE TREATMENT; MOLECULAR MARKERS; SELECTIVE SWEEPS; SULFADOXINE; ALLELES AB The molecular basis of sulfadoxine-pyrimethamine (SP) resistance lies in a combination of single-nucleotide polymorphisms (SNPs) in two genes coding for Plasmodium falciparum dihydrofolate reductase (Pfdhfr) and P. falciparum dihydropteroate synthase (Pfdhps), targeted by pyrimethamine and sulfadoxine, respectively. The continued use of SP for intermittent preventive treatment in pregnant women in many African countries, despite SP's discontinuation as a first-line antimalarial treatment option due to high levels of drug resistance, may further increase the prevalence of SP-resistant parasites and/or lead to the selection of new mutations. An antimalarial drug resistance surveillance study was conducted in western Kenya between 2010 and 2013. A total of 203 clinical samples from children with uncomplicated malaria were genotyped for SNPs associated with SP resistance. The prevalence of the triple-mutant Pfdhfr C50I51R59N108I164 genotype and the double-mutant Pfdhps S(436)G(437)E(540)A(581)A(613) genotype was high. Two triple-mutant Pfdhps genotypes, S(436)G(437)E(540)G(581)A(613) and H(436)G(437)E(540)A(581)A(613), were found, with the latter thus far being uniquely found in western Kenya. The prevalence of the S436G437E540G581A613 genotype was low. However, a steady increase in the prevalence of the Pfdhps triple-mutant H(436)G(437)E(540)A(581)A(613) genotype has been observed since its appearance in early 2000. Isolates with these genotypes shared substantial microsatellite haplotypes with the most common double-mutant allele, suggesting that this triple-mutant allele may have evolved locally. Overall, these findings show that the prevalence of the H(436)G(437)E(540)A(581)A(613) triple mutant may be increasing in this population and could compromise the efficacy of SP for intermittent preventive treatment in pregnant women if it increases the resistance threshold further. C1 [Lucchi, Naomi W.; Goldman, Ira F.; Shi, Ya Ping; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30322 USA. [Okoth, Sheila Akinyi; Ljolje, Dragan] Atlanta Res & Educ Fdn, Decatur, GA USA. [Komino, Franklin; Onyona, Philip; Kariuki, Simon] Kenya Govt Med Res Ctr, Ctr Dis Control & Prevent Collaborat, Kisumu, Kenya. RP Lucchi, NW (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Ctr Global Hlth, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30322 USA. EM NLucchi@cdc.gov FU Centers for Disease Control and Prevention Antimicrobial Resistance Working Group; Atlanta Research and Education Foundation; CDC-based American Society FX This work was supported by the Centers for Disease Control and Prevention Antimicrobial Resistance Working Group and the Atlanta Research and Education Foundation. S.A.O. was partially supported by a CDC-based American Society for Microbiology postdoctoral fellowship. NR 39 TC 0 Z9 0 U1 1 U2 2 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD JUL PY 2015 VL 59 IS 7 BP 3995 EP 4002 DI 10.1128/AAC.04961-14 PG 8 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA CQ8YF UT WOS:000360896000036 PM 25896703 ER PT J AU Phillips, V Njau, J Li, S Kachur, P AF Phillips, Victoria Njau, Joseph Li, Shang Kachur, Patrick TI Simulations Show Diagnostic Testing For Malaria In Young African Children Can Be Cost-Saving Or Cost-Effective SO HEALTH AFFAIRS LA English DT Article ID FEBRILE ILLNESS; CASE-MANAGEMENT; CARE-SEEKING; TANZANIA; MICROSCOPY; UGANDA; FACILITIES; IMPROVE; FEVER AB Malaria imposes a substantial global disease burden. It disproportionately affects sub-Saharan Africans, particularly young children. In an effort to improve disease management, the World Health Organization (WHO) recommended in 2010 that countries test children younger than age five who present with suspected malaria fever to confirm the diagnosis instead of treating them presumptively with antimalarial drugs. Costs and concerns about the overall health impact of such diagnostic testing for malaria in children remain barriers to full implementation. Using data from national Malaria Indicator Surveys, we estimated two-stage microsimulation models for Angola, Tanzania, and Uganda to assess the policy's cost-effectiveness. We found that diagnostic testing for malaria in children younger than five is cost-saving in Angola. In Tanzania and Uganda the cost per life-year gained is $5.54 and $94.28, respectively. The costs projected for Tanzania and Uganda are less than the WHO standard of $150 per life-year gained. Our results were robust under varying assumptions about cost, prevalence of malaria, and behavior, and they strongly suggest the pursuit of policies that facilitate full implementation of testing for malaria in children younger than five. C1 [Phillips, Victoria] Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Njau, Joseph] Ctr Dis Control & Prevent CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Li, Shang] Anal Grp, New York, NY USA. [Kachur, Patrick] CDC, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30333 USA. RP Phillips, V (reprint author), Emory Univ, Dept Hlth Policy & Management, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. EM vphil01@sph.emory.edu FU Intramural CDC HHS [CC999999] NR 31 TC 1 Z9 1 U1 0 U2 3 PU PROJECT HOPE PI BETHESDA PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA SN 0278-2715 J9 HEALTH AFFAIR JI Health Aff. PD JUL PY 2015 VL 34 IS 7 BP 1196 EP 1203 DI 10.1377/hlthaff.2015.0095 PG 8 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CQ9NS UT WOS:000360942500021 PM 26153315 ER PT J AU Farnham, AC Zimmerman, CM Papadouka, V Konty, KJ Zucker, JR Nattanmai, GV Jose, S Rosen, JB AF Farnham, Andrea C. Zimmerman, Christopher M. Papadouka, Vikki Konty, Kevin J. Zucker, Jane R. Nattanmai, Geetha V. Jose, Sherly Rosen, Jennifer B. TI Invasive Pneumococcal Disease Following the Introduction of 13-Valent Conjugate Vaccine in Children in New York City From 2007 to 2012 SO JAMA PEDIATRICS LA English DT Article ID UNITED-STATES; RACE/ETHNICITY; DISPARITIES; IMPACT AB IMPORTANCE Invasive pneumococcal disease (IPD) is a leading cause of pneumonia, meningitis, and bacteremia in children. In March 2010, a 13-valent pneumococcal conjugate vaccine (PCV13) was introduced to the routine childhood immunization schedule. The PCV13 contains 6 serotypes not included in the previously recommended 7-valent pneumococcal conjugate vaccine, including serotype 19A, the predominant cause of IPD prior to the introduction of PCV13. OBJECTIVES To describe changes in the epidemiology and incidence of IPD in children t 5 years in New York City (NYC) after the introduction of PCV13 and assess PCV13 coverage in NYC. DESIGN, SETTING, AND PARTICIPANTS Retrospective analysis of population-based IPD surveilla 1. tile general population residing in NYC between January 1, 2007, and December 31, 2012. Invasive pneumococcal disease cases were identified by laboratory reporting of positive pneumococcal cultures from a normally sterile body site in NYC residents younger than 5 years. Isolates were serotyped. Participants included 468 cases younger than 5 years with IPD reported through routine surveillance to the NYC Department of Health and Mental Hygiene. MAIN OUTCOMES AND MEASURES Absolute differences and percentage changes in IPD incidence before and after the introduction of PCV13 by serotype grouping, age, and race/ethnicity. The number of PCV13 doses administered to children younger than 5 years was calculated using the NYC immunization information system. RESULTS There were 468 IPD cases from 2007 to 2012. The incidence of IPD decreased by 69.6% (95% CI, -79.3% to -55.5%) from 21.0 cases per 100 000(2007-2009 mean) pre- PCV13 to 6.4 cases per 100 000 (2011-2012 mean) post- PCV13. Estimates of disease caused by serotypes included in the PCV13 decreased by 82.5% (95% Cl, -90.0% to -69.3%), including a 79.7% reduction in serotype 19A (95% CI, -89.0% to -62.4%). Reductions in 1PD incidence were seen in all age groups, with the largest reduction in children younger than 12 months (80.4%; P =.005). Incidence decreased significantly in all racial/ethnic groups. The percentage of children younger than 5 years in NYC with 1 or more doses of PCV13 increased from 47.8% in 2010 to 89.8% in 2012. CONCLUSIONS AND RELEVACE The incidence of IPD in NYC children younger than 5 years and, particularly, the incidence of IPD caused by serotype 19A decreased dramatically following the introduction of PCV13, with reductions among all age and racial/ethnic groups. This represents a significant achievement for public health immunization programs and underscores the importance of achieving high immunization coverage. C1 [Farnham, Andrea C.; Papadouka, Vikki; Zucker, Jane R.; Rosen, Jennifer B.] New York City Dept Hlth & Mental Hyg, New York, NY USA. [Zimmerman, Christopher M.; Zucker, Jane R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nattanmai, Geetha V.; Jose, Sherly] New York State Dept Hlth, Wadsworth Ctr, Albany, NY 12237 USA. RP Rosen, JB (reprint author), New York City Dept Hlth & Mental Hyg, Bur Immunizat, 42-09 28th St,CN21, Queens, NY 11101 USA. EM jrosen4@health.nyc.gov FU Centers for Disease Control and Prevention [5U5OCK000199] FX This work was supported in part by cooperative agreement 5U5OCK000199 from the Centers for Disease Control and Prevention. NR 20 TC 12 Z9 13 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD JUL PY 2015 VL 169 IS 7 BP 646 EP 652 DI 10.1001/jamapediatrics.2015.0612 PG 7 WC Pediatrics SC Pediatrics GA CR0BF UT WOS:000360982500011 PM 25938798 ER PT J AU Frank, GM Angeletti, D Ince, WL Gibbs, JS Khurana, S Wheatley, AK Max, EE McDermott, AB Golding, H Stevens, J Bennink, JR Yewdell, JW AF Frank, Gregory M. Angeletti, Davide Ince, William L. Gibbs, James S. Khurana, Surender Wheatley, Adam K. Max, Edward E. McDermott, Adrian B. Golding, Hana Stevens, James Bennink, Jack R. Yewdell, Jonathan W. TI A Simple Flow-Cytometric Method Measuring B Cell Surface Immunoglobulin Avidity Enables Characterization of Affinity Maturation to Influenza A Virus SO MBIO LA English DT Article ID ANTIBODY-RESPONSE; IMMUNE-RESPONSE; PLASMA-CELLS; MEMORY; HEMAGGLUTININ; INFECTION; ANTIGEN; EXPRESSION; RECEPTOR; VACCINES AB Antibody (Ab) affinity maturation enables an individual to maintain immunity to an increasing number of pathogens within the limits of a total Ig production threshold. A better understanding of this process is critical for designing vaccines that generate optimal Ab responses to pathogens. Our study describes a simple flow-cytometric method that enumerates virus-specific germinal center (GC) B cells as well as their AC(50), a measure of Ab avidity, defined as the antigen concentration required to detect 50% of specific B cells. Using a model of mouse Ab responses to the influenza A virus hemagglutinin (IAV HA), we obtained data indicating that AC(50) decreases with time postinfection in an affinity maturation-dependent process. As proof of principle of the utility of the method, our data clearly show that relative to intranasal IAV infection, intramuscular immunization against inactivated IAV in adjuvant results in a diminished GC HA B cell response, with increased AC(50) correlating with an increased serum Ab off-rate. Enabling simultaneous interrogation of both GC HA B cell quantity and quality, this technique should facilitate study of affinity maturation and rational vaccine design. IMPORTANCE Though it was first described 50 years ago, little is known about how antibody affinity maturation contributes to immunity. This question is particularly relevant to developing more effective vaccines for influenza A virus (IAV) and other viruses that are difficult vaccine targets. Limitations in methods for characterizing antigen-specific B cells have impeded progress in characterizing the quality of immune responses to vaccine and natural immunogens. In this work, we describe a simple flow cytometry-based approach that measures both the number and affinity of IAV-binding germinal center B cells specific for the IAV HA, the major target of IAV-neutralizing antibodies. Using this method, we showed that the route and form of immunization significantly impacts the quality and quantity of B cell antibody responses. This method provides a relatively simple yet powerful tool for better understanding the contribution of affinity maturation to viral immunity. C1 [Frank, Gregory M.; Angeletti, Davide; Ince, William L.; Gibbs, James S.; Bennink, Jack R.; Yewdell, Jonathan W.] NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA. [Khurana, Surender; Golding, Hana] US FDA, Ctr Biol Evaluat & Res, Silver Spring, MD USA. [Wheatley, Adam K.; McDermott, Adrian B.] NIAID, Vaccine Res Ctr, NIH, Bethesda, MD 20892 USA. [Max, Edward E.] US FDA, Ctr Drug Evaluat & Res, Silver Spring, MD USA. [Stevens, James] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA USA. RP Yewdell, JW (reprint author), NIAID, Viral Dis Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA. EM jyewdell@mail.nih.gov OI Wheatley, Adam/0000-0002-5593-9387; Angeletti, Davide/0000-0002-5256-1972 FU National Institute of Allergy and Infectious Diseases Division of Intramural Research; Food and Drug Administration Centers for Drug Evaluation and Research FX This work was generously supported by the National Institute of Allergy and Infectious Diseases Division of Intramural Research and Food and Drug Administration Centers for Drug Evaluation and Research. NR 49 TC 2 Z9 2 U1 1 U2 3 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 2150-7511 J9 MBIO JI mBio PD JUL-AUG PY 2015 VL 6 IS 4 AR e01156-15 DI 10.1128/mBio.01156-15 PG 11 WC Microbiology SC Microbiology GA CQ8EN UT WOS:000360839400046 PM 26242629 ER PT J AU Thompson-Paul, AM Wei, SC Mattson, CL Robertson, M Hernandez-Romieu, AC Bell, TK Skarbinski, J AF Thompson-Paul, Angela M. Wei, Stanley C. Mattson, Christine L. Robertson, McKaylee Hernandez-Romieu, Alfonso C. Bell, Tanvir K. Skarbinski, Jacek TI Obesity Among HIV-Infected Adults Receiving Medical Care in the United States: Data From the Cross-Sectional Medical Monitoring Project and National Health and Nutrition Examination Survey SO MEDICINE LA English DT Article ID BODY-MASS INDEX; ANTIRETROVIRAL THERAPY; GENERAL-POPULATION; WEIGHT-GAIN; MORTALITY; COHORT; PREVALENCE; DISEASE; RISK; DEATH AB Our objective was to compare obesity prevalence among human immunodeficiency virus (HIV)-infected adults receiving care and the U.S. general population and identify obesity correlates among HIV-infected men and women. Cross-sectional data was collected in 2009 to 2010 from 2 nationally representative surveys: Medical Monitoring Project (MMP) and National Health and Nutrition Examination Survey (NHANES). Weighted prevalence estimates of obesity, defined as body mass index >= 30.0 kg/m(2), were compared using prevalence ratios (PR, 95% confidence interval [CI]). Correlates of obesity in HIV-infected adults were examined using multivariable logistic regression. Demographic characteristics of the 4006 HIV-infected adults in MMP differed from the 5657 adults from the general U.S. population in NHANES, including more men (73.2% in MMP versus 49.4% in NHANES, respectively), black or African Americans (41.5% versus 11.6%), persons with annual incomes <$20,000 (64.5% versus 21.9%), and homosexuals or bisexuals (50.9% versus 3.9%). HIV-infected men were less likely to be obese (PR 0.5, CI 0.5-0.6) and HIV-infected women were more likely to be obese (PR1.2, CI 1.1-1.3) compared with men and women in the general population, respectively. Among HIV-infected women, younger age was associated with obesity (60 years). Among HIV-infected men, correlates of obesity included black or African American race/ethnicity, annual income >$20,000 and <$50,000, heterosexual orientation, and geometric mean CD4+ T-lymphocyte cell count >200 cells/mu L. Obesity is common, affecting 2 in 5 HIV-infected women and 1 in 5 HIV-infected men. Correlates of obesity differ for HIV-infected men and women; therefore, different strategies may be needed for the prevention and treatment. C1 [Thompson-Paul, Angela M.; Wei, Stanley C.; Mattson, Christine L.; Robertson, McKaylee; Hernandez-Romieu, Alfonso C.; Skarbinski, Jacek] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Thompson-Paul, Angela M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Thompson-Paul, Angela M.; Wei, Stanley C.] US PHS, Rockville, MD USA. [Robertson, McKaylee] Emory Univ, Rollins Sch Publ Hlth, Oak Ridge Inst Sci & Educ, Atlanta, GA 30322 USA. [Hernandez-Romieu, Alfonso C.] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Bell, Tanvir K.] Univ Texas Med Sch Houston, Dept Internal Med, Div Infect Dis, Houston, TX USA. RP Skarbinski, J (reprint author), CDC OID NCHHSTP, Div HIV AIDS Prevent, 1600 Clifton Rd NE,Mail Stop E-46, Atlanta, GA 30329 USA. EM jskarbinski@cdc.gov FU CDC; [PS09-937] FX The CDC provides funds to all states and the District of Columbia, through a Cooperative Agreement (PS09-937), to conduct the HIV surveillance used in this study and to selected areas to conduct the MMP, and provides technical assistance to all funded areas. NR 56 TC 5 Z9 5 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7974 EI 1536-5964 J9 MEDICINE JI Medicine (Baltimore) PD JUL PY 2015 VL 94 IS 27 AR e1081 DI 10.1097/MD.0000000000001081 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA CQ8SP UT WOS:000360879100001 PM 26166086 ER PT J AU Jones, MEB Schuh, AJ Amman, BR Sealy, TK Zaki, SR Nichol, ST Towner, JS AF Jones, Megan E. B. Schuh, Amy J. Amman, Brian R. Sealy, Tara K. Zaki, Sherif R. Nichol, Stuart T. Towner, Jonathan S. TI Experimental Inoculation of Egyptian Rousette Bats (Rousettus aegyptiacus) with Viruses of the Ebolavirus and Marburgvirus Genera SO VIRUSES-BASEL LA English DT Article DE Ebolavirus; Marburgvirus; Rousettus aegyptiacus; Egyptian rousette bat; reservoir host; experimental infection study ID SUBTYPE RESTON VIRUS; HEMORRHAGIC-FEVER; FRUIT BATS; PHILIPPINES; OUTBREAK; UGANDA; ANTIBODIES; ZAIRE; INFECTION; SUDAN AB The Egyptian rousette bat (Rousettus aegyptiacus) is a natural reservoir for marburgviruses and a consistent source of virus spillover to humans. Cumulative evidence suggests various bat species may also transmit ebolaviruses. We investigated the susceptibility of Egyptian rousettes to each of the five known ebolaviruses (Sudan, Ebola, Bundibugyo, Tai Forest, and Reston), and compared findings with Marburg virus. In a pilot study, groups of four juvenile bats were inoculated with one of the ebolaviruses or Marburg virus. In ebolavirus groups, viral RNA tissue distribution was limited, and no bat became viremic. Sudan viral RNA was slightly more widespread, spurring a second, 15-day Sudan virus serial euthanasia study. Low levels of Sudan viral RNA disseminated to multiple tissues at early time points, but there was no viremia or shedding. In contrast, Marburg virus RNA was widely disseminated, with viremia, oral and rectal shedding, and antigen in spleen and liver. This is the first experimental infection study comparing tissue tropism, viral shedding, and clinical and pathologic effects of six different filoviruses in the Egyptian rousette, a known marburgvirus reservoir. Our results suggest Egyptian rousettes are unlikely sources for ebolaviruses in nature, and support a possible single filovirussingle reservoir host relationship. C1 [Jones, Megan E. B.; Schuh, Amy J.; Amman, Brian R.; Sealy, Tara K.; Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. [Jones, Megan E. B.; Towner, Jonathan S.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA. [Zaki, Sherif R.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA 30333 USA. RP Towner, JS (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM mjones@sandiegozoo.org; wuc2@cdc.gov; cxx1@cdc.gov; tss3@cdc.gov; sxz1@cdc.gov; stn1@cdc.gov; jit8@cdc.gov FU University of Georgia Graduate Assistantship through the Department of Pathology in the University of Georgia College of Veterinary Medicine FX Megan E.B. Jones was supported by a University of Georgia Graduate Assistantship through the Department of Pathology in the University of Georgia College of Veterinary Medicine. We thank Libby White, Patricia Greer, Mitesh Patel, Cynthia Seales, Maureen Metcalfe, Cynthia Goldsmith, Clifton Drew, and Jana Ritter in the Infectious Diseases Pathology Branch, CDC; Pierre Rollin, Anita McElroy, Brian Bird and Kimberly Dodd in the Viral Special Pathogens Branch, CDC; and, the CDC Animal Resources Branch, for support during these experiments. Corrie C. Brown, Elizabeth Howerth, and Nicole Gottdenker reviewed an earlier version of the manuscript. NR 43 TC 19 Z9 19 U1 3 U2 22 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 1999-4915 J9 VIRUSES-BASEL JI Viruses-Basel PD JUL PY 2015 VL 7 IS 7 BP 3420 EP 3442 DI 10.3390/v7072779 PG 23 WC Virology SC Virology GA CQ1JJ UT WOS:000360353200005 PM 26120867 ER PT J AU Kaser, AK Arguin, PM Chiodini, PL Smith, V Delmont, J Jimenez, BC Farnert, A Kimura, M Ramharter, M Grobusch, MP Schlagenhauf, P AF Kaeser, Annina K. Arguin, Paul M. Chiodini, Peter L. Smith, Valerie Delmont, Jean Jimenez, Beatriz C. Faernert, Anna Kimura, Mikio Ramharter, Michael Grobusch, Martin P. Schlagenhauf, Patricia TI Imported malaria in pregnant women: A retrospective pooled analysis SO TRAVEL MEDICINE AND INFECTIOUS DISEASE LA English DT Article DE Imported malaria; Pregnancy; Chemoprophylaxis ID PLACEBO-CONTROLLED TRIAL; VIVAX MALARIA; VISITING FRIENDS; 1ST TRIMESTER; DOUBLE-BLIND; HIGH-RISK; MEFLOQUINE; EXPOSURE; CHEMOPROPHYLAXIS; SAFETY AB Background: Data on imported malaria in pregnant women are scarce. Method: A retrospective, descriptive study of pooled data on imported malaria in pregnancy was done using data from 1991 to 2014 from 8 different collaborators in Europe, the United States and Japan. National malaria reference centres as well as specialists on this topic were asked to search their archives for cases of imported malaria in pregnancy. A total of 631 cases were collated, providing information on Plasmodium species, region of acquisition, nationality, country of residence, reason for travel, age, gestational age, prophylactic measures and treatment used, as well as on complications and outcomes in mother and child. Results: Datasets from some sources were incomplete. The predominant Plasmodium species was P. falciparum (78.5% of cases). Among the 542 cases where information on the use of chemoprophylaxis was known, 464 (85.6%) did not use chemoprophylaxis. The main reason for travelling was "visiting friends and relatives" VFR (57.8%) and overall, most cases of malaria were imported from West Africa (57.4%). Severe anaemia was the most frequent complication in the mother. Data on offspring outcome were limited, but spontaneous abortion was a frequently reported foetal outcome (nZ14). A total of 50 different variants of malaria treatment regimens were reported. Conclusions: Imported cases of malaria in pregnancy are mainly P. falciparum acquired in sub-Saharan Africa. Malaria prevention and treatment in pregnant travellers is a challenge for travel medicine due to few data on medication safety and maternal and foetal outcomes. International, collaborative efforts are needed to capture standardized data on imported malaria cases in pregnant women. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Kaeser, Annina K.; Schlagenhauf, Patricia] Univ Zurich, Travel Clin, Infect Dis, Inst Epidemiol Biostat & Prevent, CH-8001 Zurich, Switzerland. [Arguin, Paul M.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. [Chiodini, Peter L.; Smith, Valerie] Publ Hlth England, London Sch Hyg & Trop Med, Malaria Reference Lab, London, England. [Chiodini, Peter L.] NHS Fdn Trust, Univ Coll London Hosp, Dept Clin Parasitol, Hosp Trop Dis, London, England. [Delmont, Jean] Hosp Nord, AP HM, Univ Hosp, Inst Infect & Trop Dis, Marseille, France. [Jimenez, Beatriz C.] Univ Hosp Fuenlabrada, Dept Internal Med, Madrid, Spain. [Faernert, Anna] Karolinska Inst, Dept Med Solna, Infect Dis Unit, Stockholm, Sweden. [Kimura, Mikio] Japan AntiTB Assoc, Shin Yamanote Hosp, Dept Internal Med, Tokyo, Japan. [Ramharter, Michael] Med Univ Vienna, Div Infect Dis & Trop Med, Dept Med 1, Vienna, Austria. [Ramharter, Michael] Univ Tubingen, Inst Trop Med, Tubingen, Germany. [Grobusch, Martin P.] Univ Amsterdam, Acad Med Ctr, Ctr Trop Med & Travel Med, Dept Infect Dis,Div Internal Med,Acad, NL-1105 AZ Amsterdam, Netherlands. RP Schlagenhauf, P (reprint author), Univ Zurich, Travel Clin, Infect Dis, Inst Epidemiol Biostat & Prevent, Hirschengraben 84, CH-8001 Zurich, Switzerland. EM pat@ifspm.uzh.ch RI Ramharter, Michael/C-5273-2013 OI Ramharter, Michael/0000-0002-9259-1885 FU Public Health England; National Institute for Healthcare Research, University College London Hospitals Biomedical Research Centre FX PLC is supported by Public Health England and by the National Institute for Healthcare Research, University College London Hospitals Biomedical Research Centre.; VS is supported by Public Health England. NR 45 TC 2 Z9 2 U1 0 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1477-8939 EI 1873-0442 J9 TRAVEL MED INFECT DI JI Travel Med. Infect. Dis. PD JUL-AUG PY 2015 VL 13 IS 4 BP 300 EP 310 DI 10.1016/j.tmaid.2015.06.011 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CQ2PL UT WOS:000360443300006 PM 26227740 ER PT J AU Mardekian, SK Fortuna, D Nix, A Bhatti, T Wiley, CA Flanders, A Urtecho, J Sloane, J Ahmad, J Curtis, MT AF Mardekian, Stacey K. Fortuna, Danielle Nix, Allan Bhatti, Tricia Wiley, Clayton A. Flanders, Adam Urtecho, Jacqueline Sloane, Jennifer Ahmad, Jowairiyya Curtis, Mark T. TI Severe human parechovirus type 3 myocarditis and encephalitis in an adolescent with hypogammaglobulinemia SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Human parechovirus; Myocarditis; Encephalitis; Flaccid paralysis; Hypogammaglobulinemia; Rituximab ID INFECTION; CHILDREN; SAMPLES; PCR AB Human parechovirus (HPeV) belongs to the Picornaviridae family of RNA viruses. HPeV infections can be asymptomatic, lead to mild respiratory and/or gastrointestinal symptoms, or less frequently cause severe diseases such as sepsis, meningitis, encephalitis, and myocarditis. Severe neurological HPeV infections occur most commonly in infants and neonates. There are currently 16 recognized types of HPeV. HPeV type 3 (HPeV3) has been the predominant type associated with severe central nervous system disease in neonates and newborns since its discovery in 1999. Although HPeV-related infections have been reported in adults, symptomatic HPeV3 infections in adolescents and adults are uncommon. A case of severe HPeV3 myocarditis and encephalitis in an adolescent is described. (C) 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [Mardekian, Stacey K.; Fortuna, Danielle; Curtis, Mark T.] Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA. [Nix, Allan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA USA. [Bhatti, Tricia] Childrens Hosp Philadelphia, Dept Pathol, Philadelphia, PA 19104 USA. [Wiley, Clayton A.] UPMC Presbyterian Hosp, Dept Pathol, Pittsburgh, PA USA. [Flanders, Adam] Thomas Jefferson Univ Hosp, Dept Radiol, Philadelphia, PA 19107 USA. [Urtecho, Jacqueline] Thomas Jefferson Univ Hosp, Dept Neurol, Philadelphia, PA 19107 USA. [Sloane, Jennifer; Ahmad, Jowairiyya] Thomas Jefferson Univ Hosp, Dept Rheumatol, Philadelphia, PA 19107 USA. RP Curtis, MT (reprint author), Thomas Jefferson Univ Hosp, Dept Pathol, Philadelphia, PA 19107 USA. NR 11 TC 3 Z9 3 U1 1 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD JUL PY 2015 VL 36 BP 6 EP 8 DI 10.1016/j.ijid.2015.05.008 PG 3 WC Infectious Diseases SC Infectious Diseases GA CP7KM UT WOS:000360066200003 PM 25975649 ER PT J AU Acacio, S Verani, JR Lanaspa, M Fairlie, TA Nhampossa, T Ruperez, M Aide, P Plikaytis, BD Sacoor, C Macete, E Alonso, P Sigauque, B AF Acacio, Sozinho Verani, Jennifer R. Lanaspa, Miguel Fairlie, Tarayn A. Nhampossa, Tacilta Ruperez, Maria Aide, Pedro Plikaytis, Brian D. Sacoor, Charfudin Macete, Eusebio Alonso, Pedro Sigauque, Betuel TI Under treatment of pneumonia among children under 5 years of age in a malaria-endemic area: population-based surveillance study conducted in Manhica district- rural, Mozambique SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Pneumonia; Mozambique; Guideline Adherence ID CHILDHOOD ILLNESS GUIDELINES; COMMUNITY CASE-MANAGEMENT; INTEGRATED MANAGEMENT; HEALTH-WORKERS; RANDOMIZED-TRIAL; ORAL AMOXICILLIN; BANGLADESH; IMCI; FACILITIES; PAKISTAN AB Background: Integrated Management of Childhood Illness (IMCI) guidelines were developed to decrease morbidity and mortality, yet implementation varies across settings. Factors associated with poor adherence are not well understood. Methods: We used data from Manhica District Hospital outpatient department and five peripheral health centers to examine pneumonia management for children <5 years old from January 2008 to June 2011. Episodes of IMCI-defined pneumonia (cough or difficult breathing plus tachypnea), severe pneumonia (pneumonia plus chest wall in-drawing), and/or clinician-diagnosed pneumonia (based on discharge diagnosis) were included. Results: Among severe pneumonia episodes, 96.2% (2,918/3,032) attended in the outpatient department and 70.0% (291/416) attended in health centers were appropriately referred to the emergency department. Age <1 year, malnutrition and various physical exam findings were associated with referral. For non-severe pneumonia episodes, antibiotics were prescribed in 45.7% (16,094/35,224). Factors associated with antibiotic prescription included age <1 year, abnormal auscultatory findings, and clinical diagnosis of pneumonia; diagnosis of malaria or gastroenteritis and pallor were negatively associated with antibiotic prescription. Conclusion: Adherence to recommended management of severe pneumonia was high in a hospital outpatient department, but suboptimal in health centers. Antibiotics were prescribed in fewer than half of non-severe pneumonia episodes, and diagnosis of malaria was the strongest risk factor for incorrect management. (C) 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [Acacio, Sozinho; Lanaspa, Miguel; Nhampossa, Tacilta; Ruperez, Maria; Aide, Pedro; Sacoor, Charfudin; Macete, Eusebio; Alonso, Pedro; Sigauque, Betuel] Ctr Invest Saude Manhica, Manhica, Mozambique. [Acacio, Sozinho; Nhampossa, Tacilta; Aide, Pedro; Sigauque, Betuel] Minist Saude, Inst Nacl Saude, Maputo, Mozambique. [Verani, Jennifer R.; Fairlie, Tarayn A.; Plikaytis, Brian D.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Lanaspa, Miguel; Ruperez, Maria; Alonso, Pedro] Univ Barcelona, Hosp Clin, Ctr Recerca Salut Int Barcelona, E-08036 Barcelona, Spain. RP Sigauque, B (reprint author), Ctr Invest Saude Manhica, Rd 12,POB 1929, Manhica Maputo, Mozambique. EM sozinho.acacio@manhica.net; jverani@cdc.gov; miguel.lanaspa@cresib.cat; t.fairlie@gmail.com; taciltanha@yahoo.com; maria.ruperez@cresib.cat; Pedro.Aide@manhica.net; bdplikaytis@gmail.com; Charfudin.Sacoor@manhica.net; Eusebio.Macete@manhica.net; pedro.alonso@isglobal.org; betuel.sigauque@manhica.net FU GAVI Alliance Global Alliance through the Hib Initiative [90022369]; Spanish Agency for the International Cooperation and Development (AECID) FX The study was supported by the GAVI Alliance Global Alliance through the Hib Initiative; Award No. 90022369 and also partially by the CISM core funding provided by the Spanish Agency for the International Cooperation and Development (AECID) NR 24 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD JUL PY 2015 VL 36 BP 39 EP 45 DI 10.1016/j.ijid.2015.05.010 PG 7 WC Infectious Diseases SC Infectious Diseases GA CP7KM UT WOS:000360066200009 PM 25980619 ER PT J AU Kissin, DM Zhang, YJ Boulet, SL Fountain, C Bearman, P Schieve, L Yeargin-Allsopp, M Jamieson, DJ AF Kissin, Dmitry M. Zhang, Yujia Boulet, Sheree L. Fountain, Christine Bearman, Peter Schieve, Laura Yeargin-Allsopp, Marshalyn Jamieson, Denise J. TI Reply: CDC analysis of ICSI/autism: association is not causation SO HUMAN REPRODUCTION LA English DT Letter ID AUTISM C1 [Kissin, Dmitry M.; Zhang, Yujia; Boulet, Sheree L.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Fountain, Christine] Fordham Univ, Dept Sociol & Anthropol, New York, NY 10023 USA. [Bearman, Peter] Columbia Univ, Interdisciplinary Ctr Innovat Theory & Empir, New York, NY USA. [Schieve, Laura; Yeargin-Allsopp, Marshalyn] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP Kissin, DM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM dkissin@cdc.gov FU Intramural CDC HHS [CC999999] NR 3 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD JUL PY 2015 VL 30 IS 7 BP 1746 EP 1746 DI 10.1093/humrep/dev107 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CP2XS UT WOS:000359741800029 PM 25976658 ER PT J AU Gangaiah, D Webb, KM Humphreys, TL Fortney, KR Toh, E Tai, A Katz, SS Pillay, A Chen, CY Roberts, SA Munson, RS Spinola, SM AF Gangaiah, Dharanesh Webb, Kristen M. Humphreys, Tricia L. Fortney, Kate R. Toh, Evelyn Tai, Albert Katz, Samantha S. Pillay, Allan Chen, Cheng-Yen Roberts, Sally A. Munson, Robert S., Jr. Spinola, Stanley M. TI Haemophilus ducreyi Cutaneous Ulcer Strains Are Nearly Identical to Class I Genital Ulcer Strains SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID POPULATION-STRUCTURE; ANALYSIS TOOLS; SKIN ULCERS; INFECTION; YAWS; RESISTANCE; CHILDREN; SEQUENCE; RECOMBINATION; LOCALIZATION AB Background Although cutaneous ulcers (CU) in the tropics is frequently attributed to Treponema pallidum subspecies pertenue, the causative agent of yaws, Haemophilus ducreyi has emerged as a major cause of CU in yaws-endemic regions of the South Pacific islands and Africa. H. ducreyi is generally susceptible to macrolides, but CU strains persist after mass drug administration of azithromycin for yaws or trachoma. H. ducreyi also causes genital ulcers (GU) and was thought to be exclusively transmitted by microabrasions that occur during sex. In human volunteers, the GU strain 35000HP does not infect intact skin; wounds are required to initiate infection. These data led to several questions: Are CU strains a new variant of H. ducreyi or did they evolve from GU strains? Do CU strains contain additional genes that could allow them to infect intact skin? Are CU strains susceptible to azithromycin? Methodology/Principal Findings To address these questions, we performed whole-genome sequencing and antibiotic susceptibility testing of 5 CU strains obtained from Samoa and Vanuatu and 9 archived class I and class II GU strains. Except for single nucleotide polymorphisms, the CU strains were genetically almost identical to the class I strain 35000HP and had no additional genetic content. Phylogenetic analysis showed that class I and class II strains formed two separate clusters and CU strains evolved from class I strains. Class I strains diverged from class II strains similar to 1.95 million years ago (mya) and CU strains diverged from the class I strain 35000HP similar to 0.18 mya. CU and GU strains evolved under similar selection pressures. Like 35000HP, the CU strains were highly susceptible to antibiotics, including azithromycin. Conclusions/Significance These data suggest that CU strains are derivatives of class I strains that were not recognized until recently. These findings require confirmation by analysis of CU strains from other regions. C1 [Gangaiah, Dharanesh; Fortney, Kate R.; Toh, Evelyn; Spinola, Stanley M.] Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA. [Webb, Kristen M.; Humphreys, Tricia L.] Allegheny Coll, Dept Biol, Meadville, PA 16335 USA. [Tai, Albert] Tufts Univ, Sch Med, Genom Core, Boston, MA 02111 USA. [Katz, Samantha S.; Pillay, Allan; Chen, Cheng-Yen] Ctr Dis Control & Prevent, Lab Reference & Res Branch, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Roberts, Sally A.] Auckland Dist Hlth Board, Dept Microbiol, Auckland, New Zealand. [Munson, Robert S., Jr.] Ohio State Univ, Coll Med, Res Inst, Ctr Microbial Pathogenesis,Nationwide Childrens H, Columbus, OH 43210 USA. [Munson, Robert S., Jr.] Ohio State Univ, Coll Med, Dept Pediat, Columbus, OH 43210 USA. [Spinola, Stanley M.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA. [Spinola, Stanley M.] Indiana Univ Sch Med, Dept Pathol & Lab Med, Indianapolis, IN 46202 USA. [Spinola, Stanley M.] Indiana Univ Sch Med, Ctr Immunobiol, Indianapolis, IN 46202 USA. RP Gangaiah, D (reprint author), Indiana Univ Sch Med, Dept Microbiol & Immunol, Indianapolis, IN 46202 USA. EM sspinola@iupui.edu FU National Institutes of Allergy and Infectious Diseases (NIAID) [AI27863]; Indiana University School of Medicine FX This work was supported by grant AI27863 to SMS from the National Institutes of Allergy and Infectious Diseases (NIAID) and by funds provided by the Indiana University School of Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 6 Z9 6 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD JUL PY 2015 VL 9 IS 7 AR e0003918 DI 10.1371/journal.pntd.0003918 PG 20 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CO3SM UT WOS:000359079700027 PM 26147869 ER PT J AU Meurs, L Brienen, E Mbow, M Ochola, EA Mboup, S Karanja, DMS Secor, WE Polman, K van Lieshout, L AF Meurs, Lynn Brienen, Eric Mbow, Moustapha Ochola, Elizabeth A. Mboup, Souleymane Karanja, Diana M. S. Secor, W. Evan Polman, Katja van Lieshout, Lisette TI Is PCR the Next Reference Standard for the Diagnosis of Schistosoma in Stool? A Comparison with Microscopy in Senegal and Kenya SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID REAL-TIME PCR; CIRCULATING-CATHODIC-ANTIGEN; POLYMERASE-CHAIN-REACTION; NEGLECTED TROPICAL DISEASES; NORTHERN SENEGAL; KATO-KATZ; HAEMATOBIUM INFECTION; MANSONI INFECTIONS; URINE SAMPLES; STRIP TEST AB Background The current reference test for the detection of S. mansoni in endemic areas is stool microscopy based on one or more Kato-Katz stool smears. However, stool microscopy has several shortcomings that greatly affect the efficacy of current schistosomiasis control programs. A highly specific multiplex real-time polymerase chain reaction (PCR) targeting the Schistosoma internal transcriber-spacer-2 sequence (ITS2) was developed by our group a few years ago, but so far this PCR has been applied mostly on urine samples. Here, we performed more in-depth evaluation of the ITS2 PCR as an alternative method to standard microscopy for the detection and quantification of Schistosoma spp. in stool samples. Methodology/Principal findings Microscopy and PCR were performed in a Senegalese community (n = 197) in an area with high S. mansoni transmission and co-occurrence of S. haematobium, and in Kenyan schoolchildren (n = 760) from an area with comparatively low S. mansoni transmission. Despite the differences in Schistosoma endemicity the PCR performed very similarly in both areas; 13-15% more infections were detected by PCR when comparing to microscopy of a single stool sample. Even when 2-3 stool samples were used for microscopy, PCR on one stool sample detected more infections, especially in people with light-intensity infections and in children from low-risk schools. The low prevalence of soil-transmitted helminthiasis in both populations was confirmed by an additional multiplex PCR. Conclusions/Significance The ITS2-based PCR was more sensitive than standard microscopy in detecting Schistosoma spp. This would be particularly useful for S. mansoni detection in low transmission areas, and post-control settings, and as such improve schistosomiasis control programs, epidemiological research, and quality control of microscopy. Moreover, it can be complemented with other (multiplex real-time) PCRs to detect a wider range of helminths and thus enhance effectiveness of current integrated control and elimination strategies for neglected tropical diseases. C1 [Meurs, Lynn; Brienen, Eric; van Lieshout, Lisette] Leiden Univ, Dept Parasitol, Med Ctr, Leiden, Netherlands. [Meurs, Lynn; Polman, Katja] Inst Trop Med, Dept Biomed Sci, B-2000 Antwerp, Belgium. [Mbow, Moustapha; Mboup, Souleymane] Aristide Le Dantec Teaching Hosp, Lab Bacteriol & Virol, Dakar, Senegal. [Ochola, Elizabeth A.; Karanja, Diana M. S.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Meurs, L (reprint author), Leiden Univ, Dept Parasitol, Med Ctr, Leiden, Netherlands. EM lvanlieshout@lumc.nl RI Meurs, Lynn/J-8661-2016 OI Meurs, Lynn/0000-0002-6973-1237 FU European Union's sixth framework program [INCO-CT-2006-032405 SCHISTOINIR]; University of Georgia Research Foundation through Bill and Melinda Gates Foundation; USAID FX The Senegalese study received funding from the European Union's sixth framework program (INCO-CT-2006-032405 SCHISTOINIR to KP and SM; http://cordis.europa.eu/fp6/). The Kenyan study received financial support from The University of Georgia Research Foundation through a grant from the Bill and Melinda Gates Foundation and also from USAID-supported NTD control activities at the CDC, Atlanta. The PCR analysis at Leiden University Medical Center was partly supported by the Prof. Dr. P.C. Flu-Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 46 TC 3 Z9 3 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD JUL PY 2015 VL 9 IS 7 AR e0003959 DI 10.1371/journal.pntd.0003959 PG 16 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CO3SM UT WOS:000359079700055 PM 26217948 ER PT J AU Yan, MY Yang, B Wang, ZG Wang, SK Zhang, XH Zhou, YH Pang, B Diao, BW Yang, RS Wu, SY Klena, JD Kan, BA AF Yan, Meiying Yang, Bo Wang, Zhigang Wang, Shukun Zhang, Xiaohe Zhou, Yanhua Pang, Bo Diao, Baowei Yang, Rusong Wu, Shuyu Klena, John D. Kan, Biao TI A Large-Scale Community-Based Outbreak of Paratyphoid Fever Caused by Hospital-Derived Transmission in Southern China SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID TYPHOID-FEVER; RISK-FACTORS; SALMONELLA-ENTERICA; UNITED-STATES; CLINICAL-RESPONSE; FLUOROQUINOLONES; SUSCEPTIBILITY; SURVIVAL AB Background Since the 1990s, paratyphoid fever caused by Salmonella Paratyphi A has emerged in Southeast Asia and China. In 2010, a large-scale outbreak involving 601 cases of paratyphoid fever occurred in the whole of Yuanjiang county in China. Epidemiological and laboratory investigations were conducted to determine the etiology, source and transmission factors of the outbreak. Methodology/Principal Findings A case-control study was performed to identify the risk factors for this paratyphoid outbreak. Cases were identified as patients with blood culture-confirmed S. Paratyphi A infection. Controls were healthy persons without fever within the past month and matched to cases by age, gender and geography. Pulsed-field gel electrophoresis and whole-genome sequencing of the S. Paratyphi A strains isolated from patients and environmental sources were performed to facilitate transmission analysis and source tracking. We found that farmers and young adults were the populations mainly affected in this outbreak, and the consumption of raw vegetables was the main risk factor associated with paratyphoid fever. Molecular sub-typing and genome sequencing of S. Paratyphi A isolates recovered from improperly disinfected hospital wastewater showed indistinguishable patterns matching most of the isolates from the cases. An investigation showed that hospital wastewater mixed with surface water was used for crop irrigation, promoting a cycle of contamination. After prohibition of the planting of vegetables in contaminated fields and the thorough disinfection of hospital wastewater, the outbreak subsided. Further analysis of the isolates indicated that the origin of the outbreak was most likely from patients outside Yuanjiang county. Conclusions This outbreak is an example of the combined effect of social behaviors, prevailing ecological conditions and improper disinfection of hospital wastewater on facilitating a sustained epidemic of paratyphoid fever. This study underscores the critical need for strict treatment measures of hospital wastewater and the maintenance of independent agricultural irrigation systems in rural areas. C1 [Yan, Meiying; Yang, Bo; Pang, Bo; Diao, Baowei; Kan, Biao] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China. [Yan, Meiying; Yang, Bo; Pang, Bo; Diao, Baowei; Kan, Biao] Collaborat Innovat Ctr Diag & Treatment Infect Di, Hangzhou, Zhejiang, Peoples R China. [Wang, Zhigang; Zhang, Xiaohe; Zhou, Yanhua; Yang, Rusong] Ctr Dis Control & Prevent Yuanjiang Cty, Kunming, Yunnan, Peoples R China. [Wang, Shukun] Ctr Dis Control & Prevent Yuxi City, Kunming, Yunnan, Peoples R China. [Wu, Shuyu; Klena, John D.] US Ctr Dis Control & Prevent, Int Emerging Infect Program, Beijing, Peoples R China. [Wu, Shuyu; Klena, John D.] Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Yan, MY (reprint author), Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, State Key Lab Infect Dis Prevent & Control, Beijing, Peoples R China. EM kanbiao@icdc.cn FU Ministry of Science and Technology of the People's Republic of China [2012ZX10004215, 2008ZX10004-008] FX This work was supported by the Priority Project on Infectious Disease Control and Prevention [BK grant numbers 2012ZX10004215, 2008ZX10004-008] from the Ministry of Science and Technology of the People's Republic of China. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 36 TC 1 Z9 3 U1 2 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD JUL PY 2015 VL 9 IS 7 AR e0003859 DI 10.1371/journal.pntd.0003859 PG 14 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CO3SM UT WOS:000359079700008 PM 26186586 ER PT J AU Boyle, MJ Jagannathan, P Farrington, LA Eccles-James, I Wamala, S McIntyre, TI Vance, HM Bowen, K Nankya, F Auma, A Nalubega, M Sikyomu, E Naluwu, K Rek, J Katureebe, A Bigira, V Kapisi, J Tappero, J Muhindo, MK Greenhouse, B Arinaitwe, E Dorsey, G Kamya, MR Feeney, ME AF Boyle, Michelle J. Jagannathan, Prasanna Farrington, Lila A. Eccles-James, Ijeoma Wamala, Samuel McIntyre, Tara I. Vance, Hilary M. Bowen, Katherine Nankya, Felistas Auma, Ann Nalubega, Mayimuna Sikyomu, Esther Naluwu, Kate Rek, John Katureebe, Agaba Bigira, Victor Kapisi, James Tappero, Jordan Muhindo, Mary K. Greenhouse, Bryan Arinaitwe, Emmanuel Dorsey, Grant Kamya, Moses R. Feeney, Margaret E. TI Decline of FoxP3+Regulatory CD4 T Cells in Peripheral Blood of Children Heavily Exposed to Malaria SO PLOS PATHOGENS LA English DT Article ID PLASMODIUM-FALCIPARUM INFECTION; TGF-BETA; REGULATORY-CELLS; FOXP3 EXPRESSION; TRANSMISSION INTENSITY; SOLUBLE EXTRACTS; DENDRITIC CELLS; CORD BLOOD; IN-VIVO; ACTIVATION AB FoxP3+ regulatory CD4 T cells (T-regs) help to maintain the delicate balance between pathogen-specific immunity and immune-mediated pathology. Prior studies suggest that T-regs are induced by P. falciparum both in vivo and in vitro; however, the factors influencing T-reg homeostasis during acute and chronic infections, and their role in malaria immunopathogenesis, remain unclear. We assessed the frequency and phenotype of T-regs in well-characterized cohorts of children residing in a region of high malaria endemicity in Uganda. We found that both the frequency and absolute numbers of FoxP3+ T-regs in peripheral blood declined markedly with increasing prior malaria incidence. Longitudinal measurements confirmed that this decline occurred only among highly malaria-exposed children. The decline of T-regs from peripheral blood was accompanied by reduced in vitro induction of T-regs by parasite antigen and decreased expression of TNFR2 on T-regs among children who had intense prior exposure to malaria. While T-reg frequencies were not associated with protection from malaria, there was a trend toward reduced risk of symptomatic malaria once infected with P. falciparum among children with lower T-reg frequencies. These data demonstrate that chronic malaria exposure results in altered T-reg homeostasis, which may impact the development of antimalarial immunity in naturally exposed populations. C1 [Boyle, Michelle J.; Jagannathan, Prasanna; Farrington, Lila A.; Eccles-James, Ijeoma; McIntyre, Tara I.; Vance, Hilary M.; Bowen, Katherine; Greenhouse, Bryan; Dorsey, Grant; Feeney, Margaret E.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA. [Boyle, Michelle J.] Burnet Inst, Ctr Biomed Res, Melbourne, Vic, Australia. [Wamala, Samuel; Nankya, Felistas; Auma, Ann; Nalubega, Mayimuna; Sikyomu, Esther; Naluwu, Kate; Rek, John; Katureebe, Agaba; Bigira, Victor; Kapisi, James; Muhindo, Mary K.; Arinaitwe, Emmanuel] Infect Dis Res Collaborat, Kampala, Uganda. [Tappero, Jordan] CDC, Atlanta, GA 30333 USA. [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Feeney, Margaret E.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. RP Feeney, ME (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94115 USA. EM margaret.feeney@ucsf.edu OI Boyle, Michelle/0000-0002-0268-232X FU National Institute of Health, National Institute of Allergy and Infectious Diseases [R01AI093615, K24AI113002, U19AI089674, K23 AI100949]; Centers for Disease Control and Prevention [U62P024421]; University of California San Francisco, Centers for AIDS Research [P30AI027763]; University of California San Francisco Resource Allocation Global Health Policy Award Program; Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene; National Health and Medical Research Council Australia; Victorian State Government Operational Infrastructure Support FX This work was supported by National Institute of Health, National Institute of Allergy and Infectious Diseases (http://www.niaid.nih.gov/Pages/default.aspx) R01AI093615 (MEF), K24AI113002 (MEF), U19AI089674 (MEF, BG and GD) and K23 AI100949 (PJ), Centers for Disease Control and Prevention (http://www.cdc.gov/) Cooperative Agreement No U62P024421, the University of California San Francisco, Centers for AIDS Research (http://cfar.ucsf.edu/) P30AI027763 (MEF), the University of California San Francisco Resource Allocation Global Health Policy Award Program (http://globalhealthsciences.ucsf.edu/) (MJB), the Burroughs Wellcome Fund/American Society of Tropical Medicine and Hygiene (http://www.astmh.org/) (PJ), the National Health and Medical Research Council Australia (https://www.nhmrc.gov.au/) Early-Career Fellowship (MJB). The Burnet Institute is supported by the National Health and Medical Research Council Australia Infrastructure for Research Institutes Support Scheme and by the Victorian State Government Operational Infrastructure Support. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The findings and conclusions in this paper are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 62 TC 11 Z9 12 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD JUL PY 2015 VL 11 IS 7 AR e1005041 DI 10.1371/journal.ppat.1005041 PG 21 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CO7TQ UT WOS:000359365200048 PM 26182204 ER PT J AU Mody, L Meddings, J Edson, BS McNamara, SE Trautner, BW Stone, ND Krein, SL Saint, S AF Mody, Lona Meddings, Jennifer Edson, Barbara S. McNamara, Sara E. Trautner, Barbara W. Stone, Nimalie D. Krein, Sarah L. Saint, Sanjay TI Enhancing Resident Safety by Preventing Healthcare-Associated Infection: A National Initiative to Reduce Catheter-Associated Urinary Tract Infections in Nursing Homes SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE nursing homes; post-acute care facilities; patient safety; CAUTIs ID LONG-TERM-CARE; QUALITY IMPROVEMENT; FACILITIES; MORTALITY; IMPLEMENTATION; COLONIZATION; SURVEILLANCE; DEFINITIONS; GUIDELINE; CRITERIA AB Preventing healthcare-associated infection (HAI) is a key contributor to enhancing resident safety in nursing homes. In 2013, the U.S. Department of Health and Human Services approved a plan to enhance resident safety by reducing HAIs in nursing homes, with particular emphasis on reducing indwelling catheter use and catheter-associated urinary tract infection (CAUTI). Lessons learned from a recent multimodal Targeted Infection Prevention program in a group of nursing homes as well as a national initiative to prevent CAUTI in over 950 acute care hospitals called "On the CUSP: STOP CAUTI" will now be implemented in nearly 500 nursing homes in all 50 states through a project funded by the Agency for Healthcare Research and Quality (AHRQ). This "AHRQ Safety Program in Long-Term Care: HAIs/CAUTI" will emphasize professional development in catheter utilization, catheter care and maintenance, and antimicrobial stewardship as well as promoting patient safety culture, team building, and leadership engagement. We anticipate that an approach integrating technical and socio-adaptive principles will serve as a model for future initiatives to reduce other infections, multidrug resistant organisms, and noninfectious adverse events among nursing home residents. C1 [Mody, Lona] Univ Michigan, Sch Med, Geriatr Res Educ & Clin Ctr, Vet Affairs Ann Arbor Healthcare Syst, Ann Arbor, MI 48109 USA. [Mody, Lona; McNamara, Sara E.] Univ Michigan, Sch Med, Div Geriatr & Palliat Care Med, Ann Arbor, MI 48109 USA. [Meddings, Jennifer; Krein, Sarah L.; Saint, Sanjay] Univ Michigan, Sch Med, Div Gen Med, Ann Arbor, MI 48109 USA. [Meddings, Jennifer] Univ Michigan, Sch Med, Department Internal Med, Div Gen Pediat, Ann Arbor, MI 48109 USA. [Meddings, Jennifer] Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Div Gen Pediat, Ann Arbor, MI 48109 USA. [Edson, Barbara S.] Hlth Res & Educ Trust, Chicago, IL USA. [Edson, Barbara S.] Baylor Coll Med, Ctr Innovat Qual Effectiveness & Safety IQuESt, Michael E DeBakey Vet Affairs Med Ctr, Houston, TX USA. [Trautner, Barbara W.] Baylor Coll Med, Dept Med, Sect Infect Dis, Houston, TX USA. [Edson, Barbara S.] Baylor Coll Med, Dept Surg, Houston, TX USA. [Stone, Nimalie D.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Krein, Sarah L.; Saint, Sanjay] Ctr Clin Management Res, Ann Arbor, MI USA. [Saint, Sanjay] Vet Affairs Ann Arbor Healthcare Syst, Med Serv, Ann Arbor, MI USA. RP Mody, L (reprint author), Univ Michigan, Sch Med, Div Geriatr & Palliat Care Med, 300 N Ingalls Rd,Rm 905, Ann Arbor, MI 48109 USA. EM lonamody@umich.edu FU Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services [HHSA 2902010000251]; National Institutes of Health (NIH) [R01 AG032298, R01 AG41780, R18 HS019979, NIH DK092293]; University of Michigan Claude D. Pepper Older Americans Independence Center (NIA) [P30 AG024824]; AHRQ [1K08-HS019767-01]; National Institutes of Health Clinical Loan Repayment Program; Department of Veterans Affairs [VA] [RRP 12-433]; Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, Texas [CIN13-413] FX This work was supported by a contract from the Agency for Healthcare Research and Quality (AHRQ), US Department of Health and Human Services, Contract Number: HHSA 2902010000251. Other Funding/Support provided by the National Institutes of Health (NIH) (R01 AG032298, R01 AG41780, R18 HS019979 to L. M.; NIH DK092293 to B. W. T.); the University of Michigan Claude D. Pepper Older Americans Independence Center (NIA P30 AG024824 to L. M.); AHRQ (1K08-HS019767-01to J. M.); National Institutes of Health Clinical Loan Repayment Program (2009-2015 to J. M.); Department of Veterans Affairs [VA RRP 12-433 to B. W. T.]; Center for Innovations in Quality, Effectiveness and Safety at the Michael E. DeBakey VA Medical Center, Houston, Texas [CIN13-413 to B. W. T.]. NR 51 TC 9 Z9 9 U1 1 U2 14 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUL 1 PY 2015 VL 61 IS 1 BP 86 EP 94 DI 10.1093/cid/civ236 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CO7EX UT WOS:000359323500015 PM 25814630 ER PT J AU Colby, D Srithanaviboonchai, K Vanichseni, S Ongwandee, S Phanuphak, N Martin, M Choopanya, K Chariyalertsak, S van Griensven, F AF Colby, Donn Srithanaviboonchai, Kriengkrai Vanichseni, Suphak Ongwandee, Sumet Phanuphak, Nittaya Martin, Michael Choopanya, Kachit Chariyalertsak, Suwat van Griensven, Frits TI HIV pre-exposure prophylaxis and health and community systems in the Global South: Thailand case study SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Review DE HIV; PrEP; Thailand; prevention; prophylaxis ID INJECTING DRUG-USERS; TRANSGENDER WOMEN; MEN; SEX; INFECTION; BANGKOK; PREVENTION; PREVALENCE; EPIDEMIC; COHORT AB Introduction: Pre-exposure prophylaxis (PrEP) is recommended by the World Health Organization as an effective method of HIV prevention for individuals at risk for infection. In this paper, we describe the unique role that Thailand has played in the global effort to combat the HIV epidemic, including its role in proving the efficacy of PrEP, and discuss the opportunities and challenges of implementing PrEP in a middle-income country. Discussion: Thailand was one of the first countries in the world to successfully reverse a generalized HIV epidemic. Despite this early success, HIV prevalence has remained high among people who inject drugs and has surged among men who have sex with men (MSM) and transgender women (TGW). Two pivotal trials that showed that the use of oral antiretroviral medication as PrEP can reduce HIV transmission were conducted partially or entirely at Thai sites. Demonstration projects of PrEP, as well as clinical trials of alternative PrEP regimens, began or will begin in 2014-2015 in Thailand and will provide additional data and experience on how to best implement PrEP for high-risk individuals in the community. Financing of drug costs, the need for routine laboratory monitoring and lack of awareness about PrEP among at-risk groups all present challenges to the wider implementation of PrEP for HIV prevention in Thailand. Conclusions: Although significant challenges to wider use remain, PrEP holds promise as a safe and highly effective method to be used as part of a combined HIV prevention strategy for MSM and TGW in Thailand. C1 [Colby, Donn; Phanuphak, Nittaya] Thai Red Cross AIDS Res Ctr, SEARCH, Bangkok 10330, Thailand. [Colby, Donn; Phanuphak, Nittaya; van Griensven, Frits] Thai Red Cross AIDS Res Ctr, Bangkok 10330, Thailand. [Srithanaviboonchai, Kriengkrai; Chariyalertsak, Suwat] Chiang Mai Univ, Res Inst Hlth Sci, Chiang Mai 50000, Thailand. [Srithanaviboonchai, Kriengkrai; Chariyalertsak, Suwat] Chiang Mai Univ, Fac Med, Dept Community Med, Chiang Mai 50000, Thailand. [Vanichseni, Suphak; Choopanya, Kachit] Bangkok Tenofovir Study Grp, Bangkok, Thailand. [Ongwandee, Sumet] Minist Publ Hlth, Dept Dis Control, Bur AIDS TB & STI, Nonthaburi, Thailand. [Martin, Michael] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, Nonthaburi, Thailand. [Martin, Michael] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [van Griensven, Frits] Univ Calif San Francisco, Div Prevent Med & Publ Hlth, San Francisco, CA 94143 USA. RP van Griensven, F (reprint author), Thai Red Cross AIDS Res Ctr, 104 Rajdumri Rd, Bangkok 10330, Thailand. EM fritsvg@trcarc.org OI Srithanaviboonchai, Kriengkrai/0000-0002-1683-4259 NR 44 TC 0 Z9 0 U1 2 U2 7 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2015 VL 18 SU 3 BP 42 EP 47 DI 10.7448/IAS.18.4.19953 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN8FQ UT WOS:000358675400007 ER PT J AU Domercant, JW Puttkammer, N Lu, L Francois, K Duncan, D Grand'Pierre, R Lowrance, D Adler, M AF Domercant, Jean Wysler Puttkammer, Nancy Lu, Lydia Francois, Kesner Duncan, Dana Grand'Pierre, Reynold Lowrance, David Adler, Michelle TI Attrition from antiretroviral treatment services among pregnant and non-pregnant patients following adoption of Option B plus in Haiti SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Domercant, Jean Wysler; Lowrance, David] Ctr Dis Control & Prevent, Port Au Prince, Haiti. [Puttkammer, Nancy] Int Training & Educ Ctr Hlth, Seattle, WA USA. [Lu, Lydia] Eagle Appl Sci, Atlanta, GA USA. [Francois, Kesner; Grand'Pierre, Reynold] Minist Hlth Govt Haiti, Port Au Prince, Haiti. [Duncan, Dana; Adler, Michelle] Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. EM viw5@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2015 VL 18 SU 4 MA TUAD0204 DI 10.7448/IAS.18.5.20391 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN8FS UT WOS:000358675700102 ER PT J AU Duwve, J Hoover, K Conrad, C Galang, R Hillman, D Hoots, B Patel, M Peters, P Pontones, P Roseberry, J Shields, J Waterhouse, D Weidle, P AF Duwve, Joan Hoover, Karen Conrad, Caitlin Galang, Romeo Hillman, Daniel Hoots, Brooke Patel, Monita Peters, Philip Pontones, Pam Roseberry, Jeremy Shields, Jessica Waterhouse, Dorothy Weidle, Paul TI Community outbreak of HIV infection linked to injection drug use of oxymorphone - Indiana, 2015 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Duwve, Joan; Conrad, Caitlin; Hillman, Daniel; Pontones, Pam; Roseberry, Jeremy] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Duwve, Joan] Indiana Univ, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA. [Hoover, Karen; Galang, Romeo; Hoots, Brooke; Patel, Monita; Peters, Philip; Weidle, Paul] Ctr Dis Control & Prevent, Atlanta, GA USA. [Shields, Jessica; Waterhouse, Dorothy] Clark Cty Hlth Dept, Jeffersonville, IN USA. EM jduwve@iu.edu NR 0 TC 0 Z9 0 U1 0 U2 6 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2015 VL 18 SU 4 MA MOAC0303LB DI 10.7448/IAS.18.5.20488 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN8FS UT WOS:000358675700038 ER PT J AU Galang, RR Gentry, J Peters, PJ Blosser, SJ Chapman, EL Conrad, C Duwve, JM Ganova-Raeva, L Heneine, W Hillman, D Jia, HW Liu, LX Luo, W Lovchik, J Masciotra, S Owen, SM Perez, A Peyrani, P Pontones, P Ramachandran, S Roseberry, JC Sandoval, M Shankar, A Thai, H Xia, GL Khudyakov, Y Switzer, WM AF Galang, Romeo R. Gentry, Jessica Peters, Philip J. Blosser, Sara J. Chapman, Erika L. Conrad, Caitlin Duwve, Joan M. Ganova-Raeva, Lilia Heneine, Walid Hillman, Daniel Jia, Hongwei Liu, Lixia Luo, Wei Lovchik, Judy Masciotra, Silvina Owen, S. Michele Perez, Andrea Peyrani, Paula Pontones, Pam Ramachandran, Sumathi Roseberry, Jeremy C. Sandoval, Michelle Shankar, Anupama Thai, Hong Xia, Guoliang Khudyakov, Yury Switzer, William M. TI HIV-1 and HCV molecular epidemiology of a large community outbreak of HIV-1 infection linked to injection drug use of oxymorphone - Indiana, 2015 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Galang, Romeo R.; Peters, Philip J.; Heneine, Walid; Jia, Hongwei; Luo, Wei; Masciotra, Silvina; Owen, S. Michele; Sandoval, Michelle; Shankar, Anupama; Switzer, William M.] CDC, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Galang, Romeo R.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Gentry, Jessica; Blosser, Sara J.; Chapman, Erika L.; Conrad, Caitlin; Duwve, Joan M.; Hillman, Daniel; Liu, Lixia; Lovchik, Judy; Perez, Andrea; Pontones, Pam; Roseberry, Jeremy C.; Sandoval, Michelle] Indiana State Dept Hlth, Indianapolis, IN 46202 USA. [Duwve, Joan M.] Indiana Univ Indianapolis, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN USA. [Ganova-Raeva, Lilia; Ramachandran, Sumathi; Thai, Hong; Xia, Guoliang; Khudyakov, Yury] CDC, Div Infect Dis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Ganova-Raeva, Lilia; Ramachandran, Sumathi; Thai, Hong; Xia, Guoliang] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Peyrani, Paula] Univ Louisville, Louisville, KY 40292 USA. EM ydh0@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 3 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2015 VL 18 SU 4 MA MOAC0304LB DI 10.7448/IAS.18.5.20489 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN8FS UT WOS:000358675700039 ER PT J AU Henderson, F Taylor, A Chirwa, L Williams, T Borkowf, C Kasonde, M Mutanhaurwa, R Matlhaba, O Hageman, K Casillas, P AF Henderson, Faith Taylor, Allan Chirwa, Lovemore Williams, Tiffany Borkowf, Craig Kasonde, Michael Mutanhaurwa, Rodreck Matlhaba, Onkabetse Hageman, Kathy Casillas, Paula TI Characteristics and oral PrEP adherence in the TDF2 open-label extension in Botswana SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Henderson, Faith; Taylor, Allan; Williams, Tiffany; Borkowf, Craig; Hageman, Kathy] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chirwa, Lovemore] Ctr Dis Control & Prevent, Francistown, Botswana. [Williams, Tiffany] ICF Macro, Atlanta, GA USA. [Kasonde, Michael; Mutanhaurwa, Rodreck; Matlhaba, Onkabetse; Casillas, Paula] Ctr Dis Control & Prevent, Gaborone, Botswana. EM inh3@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2015 VL 18 SU 4 MA TUAC0203 DI 10.7448/IAS.18.5.20372 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN8FS UT WOS:000358675700078 ER PT J AU Holtz, TH Chitwarakorn, A Curlin, ME Hughes, J Amico, KR Hendrix, C Dye, BJ Anderson, PL Ou, SS Elharrar, V Eshleman, SH Stirratt, M Grant, RM AF Holtz, Timothy H. Chitwarakorn, Anupong Curlin, Marcel E. Hughes, James Amico, K. Rivet Hendrix, Craig Dye, Bonnie J. Anderson, Peter L. Ou, San-San Elharrar, Vanessa Eshleman, Susan H. Stirratt, Michael Grant, Robert M. CA Bangkok HPTN 067 ADAPT Study TI HPTN 067/ADAPT study: a comparison of daily and non-daily pre-exposure prophylaxis dosing in Thai men who have sex with men, Bangkok, Thailand SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Holtz, Timothy H.; Curlin, Marcel E.] US Ctr Dis Control & Prevent Collaborat, Thailand Minist Publ Hlth, HIV STD Res Program, Bangkok, Thailand. [Holtz, Timothy H.; Curlin, Marcel E.] Ctr Dis Control & Prevent, US Div HIV AIDS Prevent, Atlanta, GA USA. [Chitwarakorn, Anupong] Minist Publ Hlth, Dept Dis Control, Nonthaburi, Thailand. [Hughes, James] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [Hughes, James; Ou, San-San] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Amico, K. Rivet] Univ Michigan, Dept Hlth Behav & Hlth Educ, Ann Arbor, MI 48109 USA. [Hendrix, Craig] Johns Hopkins Univ, Dept Med, Baltimore, MD USA. [Dye, Bonnie J.] FHI 360, Durham, NC USA. [Anderson, Peter L.] Univ Colorado, Dept Pharmaceut Sci, Aurora, CO USA. [Elharrar, Vanessa] NIAID, Clin Prevent Res Branch, PSP, DAIDS,NIH, Bethesda, MD 20892 USA. [Eshleman, Susan H.] Johns Hopkins Univ, Dept Pathol, Baltimore, MD USA. [Stirratt, Michael] NIMH, Div AIDS Res, Bethesda, MD 20892 USA. [Grant, Robert M.] Univ Calif San Francisco, Gladstone Inst, San Francisco, CA 94143 USA. EM tkh3@cdc.gov RI Hendrix, Craig/G-4182-2014 OI Hendrix, Craig/0000-0002-5696-8665 NR 0 TC 0 Z9 0 U1 0 U2 7 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2015 VL 18 SU 4 MA MOAC0306LB DI 10.7448/IAS.18.5.20539 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN8FS UT WOS:000358675700041 ER PT J AU Pyra, M Heffron, R Mugo, NR Nanda, K Thomas, KK Celum, C Kourtis, AP Baeten, JM AF Pyra, Maria Heffron, Renee Mugo, Nelly R. Nanda, Kavita Thomas, Katherine K. Celum, Connie Kourtis, Athena P. Baeten, Jared M. CA Partners Prevention HSV HIV Partners PrEP Study Team TI Effectiveness of contraception for HIV-infected women using antiretroviral therapy: combined data from three longitudinal studies SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Pyra, Maria; Heffron, Renee; Mugo, Nelly R.; Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Pyra, Maria; Heffron, Renee; Thomas, Katherine K.; Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Mugo, Nelly R.] Univ Nairobi, Dept Obstet & Gynaecol, Nairobi, Kenya. [Mugo, Nelly R.] Kenya Govt Med Res Ctr, Sexual Reprod Adolescent & Child Hlth Res Program, Nairobi, Kenya. [Nanda, Kavita] FHI 360, Integrated Hlth Sci, Res Triangle Pk, NC USA. [Celum, Connie; Baeten, Jared M.] Univ Washington, Dept Med, Seattle, WA USA. [Kourtis, Athena P.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. EM mpyra99@uw.edu NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2015 VL 18 SU 4 MA MOPDB0103 DI 10.7448/IAS.18.5.20427 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN8FS UT WOS:000358675700145 ER PT J AU Tih, PM Katayi, E Mboh, E Bonje, E Lem, E Awa, JC Lim, JR Duncan, D Petit, L Bianchi, F Welty, T Achu, MN Tayong, G Tene, G Mosoko, JJ Bolu, O AF Tih, Pius Muffih Katayi, Edouard Mboh, Eveline Bonje, Esther Lem, Edith Awa, Jacques Chirac Lim, Jennifer R. Duncan, Dana Petit, Leah Bianchi, Flavia Welty, Thomas Achu, Mbamulu Nkemontoh Tayong, Gladys Tene, Gilbert Mosoko, Jembia J. Bolu, Omotayo TI Evaluation of early experience implementing Option B plus in the northwest and southwest regions of Cameroon 2013-2014 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Tih, Pius Muffih; Bonje, Esther; Lem, Edith; Awa, Jacques Chirac; Welty, Thomas] Cameroon Baptist Convent Hlth Serv, Bamenda, Cameroon. [Katayi, Edouard; Mboh, Eveline] Cameroon Baptist Convent Hlth Serv, Mutengene, Cameroon. [Lim, Jennifer R.] US Ctr Dis Control & Prevent, Assoc Sch & Programs Publ Hlth, Allan Rosenfield Global Hlth Fellowship, Washington, DC USA. [Lim, Jennifer R.; Tene, Gilbert; Mosoko, Jembia J.; Bolu, Omotayo] US Ctr Dis Control & Prevent, Yaounde, Cameroon. [Duncan, Dana] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Petit, Leah; Bianchi, Flavia] Elizabeth Glazer Pediat AIDS Fdn, Washington, DC USA. [Achu, Mbamulu Nkemontoh] Minist Publ Hlth, Dept Dis Control, Dist Hlth Serv, Kumba, Cameroon. [Tayong, Gladys] Minist Publ Hlth, Dept Dis Control, Dist Hlth Serv, Bamenda, Cameroon. [Tayong, Gladys] QED Grp LLC, Washington, DC USA. EM piustih@cbchealthservices.org NR 0 TC 0 Z9 0 U1 0 U2 1 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2015 VL 18 SU 4 MA TUAD0205 DI 10.7448/IAS.18.5.20392 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN8FS UT WOS:000358675700103 ER PT J AU Wimonsate, W Pattanasin, S Sriporn, A Luechai, P Satumay, K Tippanonth, N Promda, N Holtz, T Chitwarakorn, A Dunne, E AF Wimonsate, Wipas Pattanasin, Sarika Sriporn, Anuwat Luechai, Pikunchai Satumay, Kesinee Tippanonth, Narongritt Promda, Nutthawoot Holtz, Timothy Chitwarakorn, Anupong Dunne, Eileen TI Repeat HIV voluntary counselling and testing within one year among men who have sex with men, Bangkok, Thailand 2006-2013 SO JOURNAL OF THE INTERNATIONAL AIDS SOCIETY LA English DT Meeting Abstract C1 [Wimonsate, Wipas; Pattanasin, Sarika; Sriporn, Anuwat; Luechai, Pikunchai; Satumay, Kesinee; Tippanonth, Narongritt; Promda, Nutthawoot; Holtz, Timothy; Dunne, Eileen] Thailand MOPH US CDC Collaborat, HIV STD Res Program, Nonthaburi, Thailand. [Holtz, Timothy; Dunne, Eileen] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Chitwarakorn, Anupong] Minist Publ Hlth, Dept Dis Control & Prevent, Nonthaburi, Thailand. EM tkh3@cdc.gov NR 0 TC 0 Z9 0 U1 0 U2 0 PU INT AIDS SOCIETY PI GENEVA PA AVENUE DE FRANCE 23, GENEVA, 1202, SWITZERLAND SN 1758-2652 J9 J INT AIDS SOC JI J. Int. AIDS Soc. PD JUL PY 2015 VL 18 SU 4 MA TUAC0302 DI 10.7448/IAS.18.5.20374 PG 1 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CN8FS UT WOS:000358675700083 ER PT J AU Wu, Y Cho, M Shore, D Song, MK Choi, J Jiang, T Deng, YQ Bourgeois, M Almli, L Yang, H Chen, LM Shi, Y Qi, JX Li, A Yi, KS Chang, M Bae, JS Lee, H Shin, J Stevens, J Hong, S Qin, CF Gao, GF Chang, SJ Donis, RO AF Wu, Ying Cho, MyungSam Shore, David Song, Manki Choi, JungAh Jiang, Tao Deng, Yong-Qiang Bourgeois, Melissa Almli, Lynn Yang, Hua Chen, Li-Mei Shi, Yi Qi, Jianxu Li, An Yi, Kye Sook Chang, MinSeok Bae, Jin Soo Lee, HyunJoo Shin, JiYoung Stevens, James Hong, SeoungSuh Qin, Cheng-Feng Gao, George F. Chang, Shin Jae Donis, Ruben O. TI A potent broad-spectrum protective human monoclonal antibody crosslinking two haemagglutinin monomers of influenza A virus SO NATURE COMMUNICATIONS LA English DT Article ID NEUTRALIZING EPITOPE; MAXIMUM-LIKELIHOOD; GLOBAL MORTALITY; RECEPTOR-BINDING; HUMAN INFECTIONS; H7N9 VIRUS; H2 STRAINS; IN-VIVO; CELLS; RECOGNITION AB Effective annual influenza vaccination requires frequent changes in vaccine composition due to both antigenic shift for different subtype hemagglutinins (HAs) and antigenic drift in a particular HA. Here we present a broadly neutralizing human monoclonal antibody with an unusual binding modality. The antibody, designated CT149, was isolated from convalescent patients infected with pandemic H1N1 in 2009. CT149 is found to neutralize all tested group 2 and some group 1 influenza A viruses by inhibiting low pH-induced, HA-mediated membrane fusion. It promotes killing of infected cells by Fc-mediated antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. X-ray crystallographic data reveal that CT149 binds primarily to the fusion domain in HA2, and the light chain is also largely involved in binding. The epitope recognized by this antibody comprises amino-acid residues from two adjacent protomers of HA. This binding characteristic of CT149 will provide more information to support the design of more potent influenza vaccines. C1 [Wu, Ying; Shi, Yi; Qi, Jianxu; Li, An; Gao, George F.] Chinese Acad Sci, Inst Microbiol, CAS Key Lab Pathogen Microbiol & Immunol, Beijing 100101, Peoples R China. [Wu, Ying; Shi, Yi; Qi, Jianxu; Gao, George F.] Chinese Acad Sci, Ctr Influenza Res & Early Warning, Beijing 100101, Peoples R China. [Cho, MyungSam; Yi, Kye Sook; Chang, MinSeok; Bae, Jin Soo; Lee, HyunJoo; Shin, JiYoung; Hong, SeoungSuh; Chang, Shin Jae] Celltrion Inc, Biotechnol Res Inst, Inchon 406840, South Korea. [Shore, David; Bourgeois, Melissa; Almli, Lynn; Yang, Hua; Chen, Li-Mei; Stevens, James; Donis, Ruben O.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Song, Manki; Choi, JungAh] Int Vaccine Inst, Seoul 151919, South Korea. [Jiang, Tao; Deng, Yong-Qiang; Qin, Cheng-Feng] Beijing Inst Microbiol & Epidemiol, Dept Virol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China. [Shi, Yi; Gao, George F.] Chinese Acad Sci, Beijing Inst Sci, Res Network Immun & Hlth, Beijing 100101, Peoples R China. [Li, An] Guangxi Univ, Coll Vet Med, Nanning 530004, Peoples R China. [Gao, George F.] China CDC, Chinese Ctr Dis Control & Prevent, Off Director Gen, Beijing 102206, Peoples R China. RP Qin, CF (reprint author), Beijing Inst Microbiol & Epidemiol, Dept Virol, State Key Lab Pathogen & Biosecur, Beijing 100071, Peoples R China. EM qincf@bmi.ac.cn; gaof@im.ac.cn; ShinJae.Chang@celltrion.com; rvd6@cdc.gov OI Qin, Cheng-Feng/0000-0002-0632-2807 FU Korea Healthcare Technology R&D Project 'Ministry of Health and Welfare' Republic of Korea [A103001]; National Natural Science Foundation of China (NSFC) [81401671]; Strategic Priority Research Program of the Chinese Academy of Sciences [XDB08020100]; China National Grand S&T Special Project [2015ZX09304005, 2014ZX10004002]; NSFC Innovative Research Group [81321063] FX We thank Dr Jun Myung Kim and Dr Sang Hoon Han for providing blood samples from Severance Hospital, and Dr Yasuo Watanabe of SC World, Inc. for assistance in ISAAC assays for antibody screening. This study was supported by a grant of the Korea Healthcare Technology R&D Project 'Ministry of Health and Welfare' Republic of Korea (grant no. A103001), the National Natural Science Foundation of China (NSFC; grant no. 81401671), the Strategic Priority Research Program of the Chinese Academy of Sciences (grant no. XDB08020100) and the China National Grand S&T Special Project (grant no. 2015ZX09304005 and 2014ZX10004002.). G.F.G. is a leading principal investigator of the NSFC Innovative Research Group (grant no. 81321063). NR 60 TC 14 Z9 16 U1 2 U2 16 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2041-1723 J9 NAT COMMUN JI Nat. Commun. PD JUL PY 2015 VL 6 AR 7708 DI 10.1038/ncomms8708 PG 11 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CO0RA UT WOS:000358858500014 PM 26196962 ER PT J AU Lewis, S AF Lewis, Sarah TI Qualitative inquiry and research design: Choosing among five approaches, 3rd edition SO HEALTH PROMOTION PRACTICE LA English DT Book Review DE health promotion; qualitative research AB Qualitative Inquiry and Research Design provides an overview of the five main traditions of qualitative research. The author explains the uniqueness of each approach and its applicability to different types of inquiry. Illustrative examples from public health and social science fields are provided. The book details study design, question development, data collection and analysis, and summarizing and interpreting results, and how the research process differs according to each approach. This resource can serve as a useful guide for public health practitioners and graduate-level students interested in the theory and practice of rigorous qualitative research. C1 [Lewis, Sarah] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Lewis, S (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway NE,MS F-62, Atlanta, GA 30329 USA. EM irr6@cdc.gov NR 4 TC 0 Z9 1 U1 5 U2 15 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1524-8399 EI 1552-6372 J9 HEALTH PROMOT PRACT JI Health Promot. Pract. PD JUL PY 2015 VL 16 IS 4 BP 473 EP 475 DI 10.1177/1524839915580941 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL9LX UT WOS:000357301300001 ER PT J AU Sambol, NC Yan, L Creek, DJ McCormack, SA Arinaitwe, E Bigira, V Wanzira, H Kakuru, A Tappero, JW Lindegardh, N Tarning, J Nosten, F Aweeka, FT Parikh, S AF Sambol, N. C. Yan, L. Creek, D. J. McCormack, S. A. Arinaitwe, E. Bigira, V. Wanzira, H. Kakuru, A. Tappero, J. W. Lindegardh, N. Tarning, J. Nosten, F. Aweeka, F. T. Parikh, S. TI Population Pharmacokinetics of Piperaquine in Young Ugandan Children Treated With Dihydroartemisinin-Piperaquine for Uncomplicated Malaria SO CLINICAL PHARMACOLOGY & THERAPEUTICS LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; REGIMENS; SAFETY; CYP3A4 AB This prospective trial investigated the population pharmacokinetics of piperaquine given with dihydroartemisinin to treat uncomplicated malaria in 107 Ugandan children 6 months to 2 years old, an age group previously unstudied. Current weight-based dosing does not adequately address physiological changes in early childhood. Patients were administered standard 3-day oral doses and provided 1,282 capillary plasma concentrations from 218 malaria episodes. Less than 30% of treatments achieved 57 ng/mL on day 7. A three-compartment model with first-order absorption described the data well. Age had a statistically significant effect (P < 0.005) on clearance/bioavailability in a model that accounts for allometric scaling. Simulations demonstrated that higher doses in all children, but especially in those with lower weight for age, are required for adequate piperaquine exposure, although safety and tolerance will need to be established. These findings support other evidence that both weight-and age-specific guidelines for piperaquine dosing in children are urgently needed. C1 [Sambol, N. C.; Yan, L.] Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA. [Sambol, N. C.; Yan, L.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Sambol, N. C.; Creek, D. J.; McCormack, S. A.; Aweeka, F. T.] Univ Calif San Francisco, Dept Clin Pharm, San Francisco, CA 94143 USA. [Creek, D. J.] Univ Melbourne, Dept Biochem & Mol Biol, Parkville, Vic 3052, Australia. [Arinaitwe, E.; Bigira, V.; Wanzira, H.; Kakuru, A.] Makerere Univ, Sch Med, Kampala, Uganda. [Tappero, J. W.] Ctr Dis Control & Prevent CDC, Ctr Global Hlth, Atlanta, GA USA. [Lindegardh, N.; Tarning, J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok 10700, Thailand. [Lindegardh, N.; Tarning, J.; Nosten, F.] Univ Oxford, Nuffield Dept Med, Ctr Trop Med, Oxford, England. [Nosten, F.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Shoklo Malaria Res Unit, Mae Sot, Thailand. [Parikh, S.] Yale Sch Publ Hlth & Med, New Haven, CT USA. RP Sambol, NC (reprint author), Univ Calif San Francisco, Dept Bioengn & Therapeut Sci, San Francisco, CA 94143 USA. EM nancy.sambol@ucsf.edu OI Creek, Darren/0000-0001-7497-7082 FU Eunice Kennedy Shriver National Institute of Child Health and Human Development [R01HD068174]; President's Emergency Plan for AIDS Relief (PEPFAR) through the Department of Health and Human Services/Centers for Disease Control and Prevention [U62P024421]; National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP); Global AIDS Program (GAP); Wellcome Trust of Great Britain [089275/Z/09/2] FX We thank the clinical study team and our administrative staff. We are grateful to the children who participated in this study and to their parents and guardians. We thank Dr. Grant Dorsey and Moses Kamya for their support with the primary drug efficacy study. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the U.S. Centers for Disease Control and Prevention. This work was supported by funding from the Eunice Kennedy Shriver National Institute of Child Health and Human Development under award number R01HD068174 as well as the President's Emergency Plan for AIDS Relief (PEPFAR) through the Department of Health and Human Services/Centers for Disease Control and Prevention under the terms of U62P024421. Patients in this study were also enrolled in programs supported by the National Center for HIV, Viral Hepatitis, STD, and TB Prevention (NCHHSTP), and Global AIDS Program (GAP). Mahidol-Oxford Tropical Medicine Research Unit is supported by the Wellcome Trust of Great Britain (grant: 089275/Z/09/2). We thank Holley-Cotec Pharmaceuticals (Beijing, China) for providing Duo-Cotecxin for the study. Neither the funders nor drug supplier had a role in study design, data collection or analysis, decision to publish, or preparation of the article. Accession Number: ClinicalTrials.gov #NCT00527800. NR 34 TC 5 Z9 5 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0009-9236 EI 1532-6535 J9 CLIN PHARMACOL THER JI Clin. Pharmacol. Ther. PD JUL PY 2015 VL 98 IS 1 BP 87 EP 95 DI 10.1002/cpt.104 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA CN5WK UT WOS:000358502900024 PM 25732044 ER PT J AU Gargis, AS Kalman, L Bick, DP da Silva, C Dimmock, DP Funke, BH Gowrisankar, S Hegde, MR Kulkarni, S Mason, CE Nagarajan, R Voelkerding, KV Worthey, EA Aziz, N Barnes, J Bennett, SF Bisht, H Church, DM Dimitrova, Z Gargis, SR Hafez, N Hambuch, T Hyland, FCL Luna, RA MacCannell, D Mann, T McCluskey, MR McDaniel, TK Ganova-Raeval, LM Rehm, HL Reid, J Campo, DS Resnick, RB Ridge, PG Salit, ML Skums, P Wong, LJC Zehnbauer, BA Zook, JM Lubin, IM AF Gargis, Amy S. Kalman, Lisa Bick, David P. da Silva, Cristina Dimmock, David P. Funke, Birgit H. Gowrisankar, Sivakumar Hegde, Madhuri R. Kulkarni, Shashikant Mason, Christopher E. Nagarajan, Rakesh Voelkerding, Karl V. Worthey, Elizabeth A. Aziz, Nazneen Barnes, John Bennett, Sarah F. Bisht, Himani Church, Deanna M. Dimitrova, Zoya Gargis, Shaw R. Hafez, Nabil Hambuch, Tina Hyland, Fiona C. L. Luna, Ruth Ann MacCannell, Duncan Mann, Tobias McCluskey, Megan R. McDaniel, Timothy K. Ganova-Raeval, Lilia M. Rehm, Heidi L. Reid, Jeffrey Campo, David S. Resnick, Richard B. Ridge, Perry G. Salit, Marc L. Skums, Pavel Wong, Lee-Jun C. Zehnbauer, Barbara A. Zook, Justin M. Lubin, Ira M. TI Good laboratory practice for clinical next-generation sequencing informatics pipelines SO NATURE BIOTECHNOLOGY LA English DT Letter ID ACMG RECOMMENDATIONS; INCIDENTAL FINDINGS; STANDARDS C1 [Gargis, Amy S.; Kalman, Lisa; Zehnbauer, Barbara A.; Lubin, Ira M.] Ctr Dis Control & Prevent, Div Lab Syst, Atlanta, GA USA. [Bick, David P.; Dimmock, David P.; Worthey, Elizabeth A.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53226 USA. [da Silva, Cristina; Hegde, Madhuri R.] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA USA. [Funke, Birgit H.; Gowrisankar, Sivakumar; Rehm, Heidi L.] Partners Healthcare Personalized Med, Lab Mol Med, Cambridge, MA USA. [Funke, Birgit H.; Gowrisankar, Sivakumar; Rehm, Heidi L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA USA. [Kulkarni, Shashikant] Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA. [Kulkarni, Shashikant] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA. [Kulkarni, Shashikant; Nagarajan, Rakesh] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO USA. [Mason, Christopher E.] Cornell Univ, Dept Physiol & Biophys, New York, NY 10021 USA. [Voelkerding, Karl V.; Ridge, Perry G.] Univ Utah, Dept Pathol, Salt Lake City, UT USA. [Voelkerding, Karl V.] Associated Reg & Univ Pathologists ARUP Labs, Inst Clin & Expt Pathol, Salt Lake City, UT USA. [Aziz, Nazneen] Coll Amer Pathologists, Northfield, IL USA. [Barnes, John] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Bennett, Sarah F.] Ctr Medicare & Medicaid Serv, Div Lab Serv, Baltimore, MD USA. [Bisht, Himani] US FDA, Ctr Devices & Radiol Hlth, Silver Spring, MD USA. [Church, Deanna M.] NIH, Natl Ctr Biotechnol Informat, Bethesda, MD 20892 USA. [Dimitrova, Zoya; Ganova-Raeval, Lilia M.; Campo, David S.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA USA. [Gargis, Shaw R.] Ctr Dis Control & Prevent, Div Select Agents & Toxins, Atlanta, GA USA. [Hafez, Nabil; Resnick, Richard B.; Skums, Pavel] GenomeQuest, Westborough, MA USA. [Hambuch, Tina] Illumina, Clin Serv, San Diego, CA USA. [Hyland, Fiona C. L.] Thermo Fisher Sci, San Francisco, CA USA. [Luna, Ruth Ann] Texas Childrens Hosp, Texas Childrens Microbiome Ctr, Houston, TX USA. [Luna, Ruth Ann] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA. [MacCannell, Duncan] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Mann, Tobias] Illumina, San Diego, CA USA. [McCluskey, Megan R.] SoftGenetics, State Coll, State Coll, PA USA. [McDaniel, Timothy K.; Wong, Lee-Jun C.] Illumina, Oncol, San Diego, CA USA. [Reid, Jeffrey] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA. [Salit, Marc L.; Zook, Justin M.] NIST, Mat Measurement Lab, Gaithersburg, MD 20899 USA. RP Gargis, AS (reprint author), Ctr Dis Control & Prevent, Div Preparedness & Emerging Infect, Atlanta, GA 30322 USA. RI Zook, Justin/B-7000-2008 OI Zook, Justin/0000-0003-2309-8402 FU NHGRI NIH HHS [U01HG006500, U41HG006834] NR 11 TC 26 Z9 28 U1 2 U2 12 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1087-0156 EI 1546-1696 J9 NAT BIOTECHNOL JI Nat. Biotechnol. PD JUL PY 2015 VL 33 IS 7 BP 689 EP 693 DI 10.1038/nbt.3237 PG 5 WC Biotechnology & Applied Microbiology SC Biotechnology & Applied Microbiology GA CN4JJ UT WOS:000358396100018 PM 26154004 ER PT J AU Jemmott, JB Jemmott, LS O'Leary, A Icard, LD Rutledge, SE Stevens, R Hsu, J Stephens, AJ AF Jemmott, John B., III Jemmott, Loretta Sweet O'Leary, Ann Icard, Larry D. Rutledge, Scott E. Stevens, Robin Hsu, Janet Stephens, Alisa J. TI On the Efficacy and Mediation of a One-on-One HIV Risk-Reduction Intervention for African American Men Who Have Sex with Men: A Randomized Controlled Trial SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Men who have sex with men; African Americans; Intervention; Sexual behavior ID HUMAN-IMMUNODEFICIENCY-VIRUS; SOCIAL-COGNITIVE THEORY; BLACK-ADOLESCENT WOMEN; CONDOM-USE INTENTIONS; SOUTH-AFRICAN; SELF-EFFICACY; PREVENTION INTERVENTIONS; BEHAVIORAL INTERVENTION; PHYSICAL-ACTIVITY; NATIONAL-INSTITUTE AB We examined the efficacy and mediation of Being Responsible for Ourselves (BRO), an HIV/STI risk-reduction intervention for African American men who have sex with men (MSM), the population with the highest HIV-diagnosis rate in the US. We randomized African American MSM to one of two interventions: BRO HIV/STI risk-reduction, targeting condom use; or attention-matched control, targeting physical activity and healthy diet. The interventions were based on social cognitive theory, the reasoned-action approach, and qualitative research. Men reporting anal intercourse with other men in the past 90 days were eligible and completed pre-intervention, immediately post-intervention, and 6 and 12 months post-intervention surveys. Of 595 participants, 503 (85 %) completed the 12-month follow-up. Generalized-estimating-equations analysis indicated that, compared with the attention-matched control intervention, the BRO intervention did not increase consistent condom use averaged over the 6- and 12-month follow-ups, which was the primary outcome. Although BRO did not affect the proportion of condom-protected intercourse acts, unprotected sexual intercourse, multiple partners, or insertive anal intercourse, it did reduce receptive anal intercourse compared with the control, a behavior linked to incident HIV infection. Mediation analysis using the product-of-coefficients approach revealed that although BRO increased seven of nine theoretical constructs it was designed to affect, it increased only one of three theoretical constructs that predicted consistent condom use: condom-use impulse-control self-efficacy. Thus, BRO indirectly increased consistent condom use through condom-use impulse-control self-efficacy. In conclusion, although BRO increased several theoretical constructs, most of those constructs did not predict consistent condom use; hence, the intervention did not increase it. Theoretical constructs that interventions should target to increase African American MSM's condom use are discussed. C1 [Jemmott, John B., III] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Jemmott, John B., III] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Jemmott, Loretta Sweet] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [O'Leary, Ann] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Icard, Larry D.; Rutledge, Scott E.] Temple Univ, Sch Social Work, Philadelphia, PA 19122 USA. [Stevens, Robin; Hsu, Janet] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Stevens, Robin] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Jemmott, JB (reprint author), Univ Penn, Annenberg Sch Commun, 3535 Market St,Suite 520, Philadelphia, PA 19104 USA. EM jjemmott@asc.upenn.edu FU National Institute of Mental Health [1 R01 MH079736] FX The authors appreciate the contributions of Sonya Coombs, MS, Mikia Croom, MSEd, Lynette Gueits, MS, Janet Hsu, BA, Dionne Samuel, BA, Brian Taylor, BA, Pandora Woods, BA and the late Dennis Clegg to the implementation of the research. The contributions of Christopher Coleman, PhD, and the late Thomas Ten Have, PhD, to the conception and design of the trial are gratefully acknowledged. This study was funded by research Grant 1 R01 MH079736 from the National Institute of Mental Health. The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript. The corresponding author, J. Jemmott, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The findings and conclusions are those of the authors and do not necessarily reflect the official views of the Centers for Disease Control and Prevention. NR 73 TC 4 Z9 5 U1 5 U2 8 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD JUL PY 2015 VL 19 IS 7 BP 1247 EP 1262 DI 10.1007/s10461-014-0961-2 PG 16 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CN2KA UT WOS:000358248600010 PM 25449552 ER PT J AU Mineva, EM Schleicher, RL Chaudhary-Webb, M Maw, KL Botelho, JC Vesper, HW Pfeiffer, CM AF Mineva, Ekaterina M. Schleicher, Rosemary L. Chaudhary-Webb, Madhulika Maw, Khin L. Botelho, Julianne C. Vesper, Hubert W. Pfeiffer, Christine M. TI A candidate reference measurement procedure for quantifying serum concentrations of 25-hydroxyvitamin D-3 and 25-hydroxyvitamin D-2 using isotope-dilution liquid chromatography-tandem mass spectrometry SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY LA English DT Article DE Vitamin D; 25-Hydroxyvitamin D-3; 25-Hydroxyvitamin D-2; Reference method; LC-MS/MS ID VITAMIN-D METABOLITES; STANDARDIZATION; TESTOSTERONE; ACCURATE; PROGRAM; D2; D3 AB The inaccuracy of routine serum 25-hydroxyvitamin D measurements hampers the interpretation of data in patient care and public health research. We developed and validated a candidate reference measurement procedure (RMP) for highly accurate quantitation of two clinically important 25-hydroxyvitamin D metabolites in serum, 25-hydroxyvitamin D-2 [25(OH)D-2] and 25-hydroxyvitamin D-3 [25(OH)D-3]. The two compounds of interest together with spiked deuterium-labeled internal standards [d (3)-25(OH)D-2 and d (6)-25(OH)D-3] were extracted from serum via liquid-liquid extraction. The featured isotope-dilution LC-MS/MS method used reversed-phase chromatography and atmospheric pressure chemical ionization in positive ion mode. A pentafluorophenylpropyl-packed UHPLC column together with isocratic elution allowed for complete baseline resolution of 25(OH)D-2 and 25(OH)D-3 from their structural C-3 isomers within 12 min. We evaluated method trueness, precision, potential interferences, matrix effects, limits of quantitation, and measurement uncertainty. Calibration materials were, or were traceable to, NIST Standard Reference Materials 2972. Within-day and total imprecision (CV) averaged 1.9 and 2.0 % for 25(OH)D-3, respectively, and 2.4 and 3.5 % for 25(OH)D-2, respectively. Mean trueness was 100.3 % for 25(OH)D-3 and 25(OH)D-2. The limits of quantitation/limits of detection were 4.61/1.38 nmol/L for 25(OH)D-3 and 1.46/0.13 nmol/L for 25(OH)D-2. When we compared our RMP results to an established RMP using 40 serum samples, we found a nonsignificant mean bias of 0.2 % for total 25(OH)D. This candidate RMP for 25(OH)D metabolites meets predefined method performance specifications (a parts per thousand currency sign5 % total CV and a parts per thousand currency sign1.7 % bias) and provides sufficient sample throughput to meet the needs of the Centers for Disease Control and Prevention Vitamin D Standardization Certification Program. C1 [Mineva, Ekaterina M.; Schleicher, Rosemary L.; Chaudhary-Webb, Madhulika; Maw, Khin L.; Botelho, Julianne C.; Vesper, Hubert W.; Pfeiffer, Christine M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Schleicher, RL (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,Mail Stop F55, Atlanta, GA 30341 USA. EM zwa5@cdc.gov FU Intramural CDC HHS [CC999999] NR 34 TC 6 Z9 6 U1 2 U2 14 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1618-2642 EI 1618-2650 J9 ANAL BIOANAL CHEM JI Anal. Bioanal. Chem. PD JUL PY 2015 VL 407 IS 19 BP 5615 EP 5624 DI 10.1007/s00216-015-8733-z PG 10 WC Biochemical Research Methods; Chemistry, Analytical SC Biochemistry & Molecular Biology; Chemistry GA CN0XE UT WOS:000358136900007 PM 25967149 ER PT J AU Dahm, MM Schubauer-Berigan, MK Evans, DE Birch, ME Fernback, JE Deddens, JA AF Dahm, Matthew M. Schubauer-Berigan, Mary K. Evans, Douglas E. Birch, M. Eileen Fernback, Joseph E. Deddens, James A. TI Carbon Nanotube and Nanofiber Exposure Assessments: An Analysis of 14 Site Visits SO ANNALS OF OCCUPATIONAL HYGIENE LA English DT Article DE carbon nanofibers; carbon nanotubes; exposure assessment; nanomaterials ID SECONDARY MANUFACTURERS; ENVIRONMENTAL-HEALTH; INHALATION EXPOSURE; ELEMENTAL CARBON; EMISSIONS; MOUSE; NANOMATERIALS; MESOTHELIOMA; WORKPLACE; AEROSOLS AB Recent evidence has suggested the potential for wide-ranging health effects that could result from exposure to carbon nanotubes (CNT) and carbon nanofibers (CNF). In response, the National Institute for Occupational Safety and Health (NIOSH) set a recommended exposure limit (REL) for CNT and CNF: 1 mu g m(-3) as an 8-h time weighted average (TWA) of elemental carbon (EC) for the respirable size fraction. The purpose of this study was to conduct an industrywide exposure assessment among US CNT and CNF manufacturers and users. Fourteen total sites were visited to assess exposures to CNT (13 sites) and CNF (1 site). Personal breathing zone (PBZ) and area samples were collected for both the inhalable and respirable mass concentration of EC, using NIOSH Method 5040. Inhalable PBZ samples were collected at nine sites while at the remaining five sites both respirable and inhalable PBZ samples were collected side-by-side. Transmission electron microscopy (TEM) PBZ and area samples were also collected at the inhalable size fraction and analyzed to quantify and size CNT and CNF agglomerate and fibrous exposures. Respirable EC PBZ concentrations ranged from 0.02 to 2.94 mu g m(-3) with a geometric mean (GM) of 0.34 mu g m(-3) and an 8-h TWA of 0.16 mu g m(-3). PBZ samples at the inhalable size fraction for EC ranged from 0.01 to 79.57 mu g m(-3) with a GM of 1.21 mu g m(-3). PBZ samples analyzed by TEM showed concentrations ranging from 0.0001 to 1.613 CNT or CNF-structures per cm(3) with a GM of 0.008 and an 8-h TWA concentration of 0.003. The most common CNT structure sizes were found to be larger agglomerates in the 2-5 mu m range as well as agglomerates >5 mu m. A statistically significant correlation was observed between the inhalable samples for the mass of EC and structure counts by TEM (Spearman rho = 0.39, P < 0.0001). Overall, EC PBZ and area TWA samples were below the NIOSH REL (96% were < 1 mu g m(-3) at the respirable size fraction), while 30% of the inhalable PBZ EC samples were found to be > 1 mu g m(-3). Until more information is known about health effects associated with larger agglomerates, it seems prudent to assess worker exposure to airborne CNT and CNF materials by monitoring EC at both the respirable and inhalable size fractions. Concurrent TEM samples should be collected to confirm the presence of CNT and CNF. C1 [Dahm, Matthew M.; Schubauer-Berigan, Mary K.; Deddens, James A.] NIOSH, Industrywide Studies Branch, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Evans, Douglas E.; Birch, M. Eileen; Fernback, Joseph E.] NIOSH, Chem Exposure & Monitoring Branch, Div Appl Res & Technol, Cincinnati, OH 45226 USA. RP Dahm, MM (reprint author), NIOSH, Industrywide Studies Branch, Div Surveillance Hazard Evaluat & Field Studies, 1090 Tusculum Ave,MS R14, Cincinnati, OH 45226 USA. EM mdahm@cdc.gov FU NIOSH [AES12029-001]; National Institute of Environmental Health Sciences [AES12029-001]; NIOSH Nanotechnology Research Center FX This research was supported in part by an interagency agreement between NIOSH and the National Institute of Environmental Health Sciences (AES12029-001) as a collaborative National Toxicology Program research activity, and the NIOSH Nanotechnology Research Center. NR 40 TC 14 Z9 15 U1 1 U2 16 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0003-4878 EI 1475-3162 J9 ANN OCCUP HYG JI Ann. Occup. Hyg. PD JUL PY 2015 VL 59 IS 6 BP 705 EP 723 DI 10.1093/annhyg/mev020 PG 19 WC Public, Environmental & Occupational Health; Toxicology SC Public, Environmental & Occupational Health; Toxicology GA CN1HH UT WOS:000358168900003 PM 25851309 ER PT J AU Simeone, RM Oster, ME Hobbs, CA Robbins, JM Collins, RT Honein, MA AF Simeone, Regina M. Oster, Matthew E. Hobbs, Charlotte A. Robbins, James M. Collins, R. Thomas Honein, Margaret A. TI Factors associated with inpatient hospitalizations among patients aged 1 to 64 years with Congenital heart defects, Arkansas 2006 to 2011 SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE Congenital heart defects; hospital costs; Healthcare Cost and Utilization Project; Arkansas; Person-level; One-year readmission ID METROPOLITAN ATLANTA; RESOURCE UTILIZATION; GENERAL-POPULATION; DISEASE; PREVALENCE; SURGERY; CARE; SURVIVAL; INFANTS; ADULTS AB BackgroundIndividuals with congenital heart defects (CHDs) have high hospital resource use. We sought to identify factors associated with hospital costs and multiple hospitalizations among individuals with CHDs. MethodsData from the 2006 to 2011 Healthcare Cost and Utilization Project Arkansas State Inpatient Databases were linked across encrypted patient identifiers to develop a cohort of Arkansas residents aged 1 to 64 years who were hospitalized at least once with a CHD during this time period. Infants were excluded because patient identifiers were missing for 18 to 52% each year. CHDs were identified using principal and secondary International Classification of Diseases, Ninth Revision, Clinical Modification diagnoses codes. All hospitalizations of individuals ever admitted with a CHD were included. Mean and median patient-level costs were estimated; the association of hospital costs and patient readmissions were examined with linear and logistic regression. ResultsThere were 1,185,868 inpatient hospitalizations of Arkansas residents aged 1 to 64 years between 2006 and 2011; these were accrued by 603,925 patients. Of those, 2542 patients (0.42%) had at least one hospitalization with a CHD diagnosis. Total costs for these 2542 patients were $126,999,837 and they accumulated 7898 hospitalizations. Factors associated with increased costs included patient age, CHD type, cardiac procedures, and comorbidities. Factors associated with hospital readmission within 1 year included age, CHD type, expected payer, and comorbidities. ConclusionIndividuals with CHDs in Arkansas experience variation in hospital use and costs by patient characteristics. Future research should investigate factors associated with readmissions, cardiac procedures, and comorbidities, as these are strongly associated with hospital costs. Birth Defects Research (Part A) 103:589-596, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Simeone, Regina M.; Oster, Matthew E.; Honein, Margaret A.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Oster, Matthew E.] Childrens Healthcare Atlanta, Sibley Heart Ctr, Atlanta, GA USA. [Hobbs, Charlotte A.; Robbins, James M.; Collins, R. Thomas] Univ Arkansas Med Sci, Little Rock, AR 72205 USA. RP Simeone, RM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,MS E-86, Atlanta, GA 30333 USA. EM rsimeone@cdc.gov OI Robbins, James/0000-0003-2200-1947 FU Intramural CDC HHS [CC999999] NR 31 TC 1 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JUL PY 2015 VL 103 IS 7 BP 589 EP 596 DI 10.1002/bdra.23402 PG 8 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CN3CY UT WOS:000358302700003 PM 26172576 ER PT J AU Strassle, PD Cassell, CH Shapira, SK Tinker, SC Meyer, RE Grosse, SD AF Strassle, Paula D. Cassell, Cynthia H. Shapira, Stuart K. Tinker, Sarah C. Meyer, Robert E. Grosse, Scott D. TI What we don't know can hurt us: Nonresponse bias assessment in birth defects research SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE nonresponse bias; response rates; orofacial clefts; barriers to care ID OROFACIAL CLEFTS; NORTH-CAROLINA; RATES; CARE; BARRIERS; CHILDREN AB BACKGROUNDNonresponse bias assessment is an important and underutilized tool in survey research to assess potential bias due to incomplete participation. This study illustrates a nonresponse bias sensitivity assessment using a survey on perceived barriers to care for children with orofacial clefts in North Carolina. METHODSChildren born in North Carolina between 2001 and 2004 with an orofacial cleft were eligible for inclusion. Vital statistics data, including maternal and child characteristics, were available on all eligible subjects. Missing responses' from nonparticipants were imputed using assumptions based on the distribution of responses, survey method (mail or phone), and participant maternal demographics. RESULTSOverall, 245 of 475 subjects (51.6%) responded to either a mail or phone survey. Cost as a barrier to care was reported by 25.0% of participants. When stratified by survey type, 28.3% of mail respondents and 17.2% of phone respondents reported cost as a barrier. Under various assumptions, the bias-adjusted estimated prevalence of cost as barrier to care ranged from 16.1% to 30.0%. Maternal age, education, race, and marital status at time of birth were not associated with subjects reporting cost as a barrier. CONCLUSIONAs survey response rates continue to decline, the importance of assessing the potential impact of nonresponse bias has become more critical. Birth defects research is particularly conducive to nonresponse bias analysis, especially when birth defect registries and birth certificate records are used. Future birth defect studies which use population-based surveillance data and have incomplete participation could benefit from this type of nonresponse bias assessment. Birth Defects Research (Part A) 103:603-609, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Strassle, Paula D.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Strassle, Paula D.; Cassell, Cynthia H.; Shapira, Stuart K.; Tinker, Sarah C.; Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Meyer, Robert E.] North Carolina Div Publ Hlth, State Ctr Hlth Stat, North Carolina Birth Defects Monitoring Program, Raleigh, NC USA. [Meyer, Robert E.] Univ N Carolina, Dept Maternal & Child Hlth, Chapel Hill, NC 27599 USA. RP Strassle, PD (reprint author), Univ N Carolina, Dept Epidemiol, Chapel Hill, NC 27599 USA. EM pstrass@live.unc.edu FU Intramural CDC HHS [CC999999]; NCBDD CDC HHS [U01 DD000488, 5U01 DD000488] NR 15 TC 0 Z9 0 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JUL PY 2015 VL 103 IS 7 BP 603 EP 609 DI 10.1002/bdra.23408 PG 7 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CN3CY UT WOS:000358302700005 PM 26173046 ER PT J AU Singleton, R Lescher, R Gessner, BD Benson, M Bulkow, L Rosenfeld, J Thomas, T Holman, RC Haberling, D Bruce, M Bartholomew, M Tiesinga, J AF Singleton, Rosalyn Lescher, Rachel Gessner, Bradford D. Benson, Matthew Bulkow, Lisa Rosenfeld, John Thomas, Timothy Holman, Robert C. Haberling, Dana Bruce, Michael Bartholomew, Michael Tiesinga, James TI Rickets and vitamin D deficiency in Alaska native children SO JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM LA English DT Article DE arctic; pediatric; rickets; vitamin D ID NUTRITIONAL RICKETS; FED INFANTS; HOSPITALIZATIONS; PREVENTION; DISEASE; HEALTH AB Background: Rickets and vitamin D deficiency appeared to increase in Alaskan children starting in the 1990s. We evaluated the epidemiology of rickets and vitamin D deficiency in Alaska native (AN) children in 2001-2010. Methods: We analyzed 2001-2010 visits with rickets or vitamin D deficiency diagnosis for AN and American Indian children and the general US population aged <10 years. We conducted a case-control study of AN rickets/vitamin D deficient cases and age-and region-matched controls. Results: In AN children, annual rickets-associated hospitalization rate (2.23/100,000 children/year) was higher than the general US rate (1.23; 95% CI 1.08-1.39). Rickets incidence increased with latitude. Rickets/vitamin D deficiency cases were more likely to have malnutrition (OR 38.1; 95% CI 4.9-294), had similar breast-feeding prevalence, and were less likely to have received vitamin D supplementation (OR 0.23; 95% CI 0.1-0.87) than controls. Conclusions: Our findings highlight the importance of latitude, malnutrition, and lack of vitamin D supplementation as risk factors for rickets. C1 [Singleton, Rosalyn] CDC, Arctic Invest Program, Anchorage, AK 99508 USA. [Singleton, Rosalyn; Lescher, Rachel; Benson, Matthew; Rosenfeld, John; Thomas, Timothy; Tiesinga, James] Alaska Native Tribal Hlth Consortium, Anchorage, AK USA. [Singleton, Rosalyn; Bulkow, Lisa; Bruce, Michael] Ctr Dis Control & Prevent CDC, Arctic Invest Program, Div Preparedness & Emerging Infect, NCEZID, Anchorage, AK USA. [Gessner, Bradford D.] Epidemiol & Vaccinol Consulting, Anchorage, AK USA. [Holman, Robert C.; Haberling, Dana] CDC, NCEZID, Div High Consequence Pathogens & Pathol, Anchorage, AK 99508 USA. [Bartholomew, Michael] Indian Hlth Serv, Rockville, MD USA. RP Singleton, R (reprint author), CDC, Arctic Invest Program, 4055 Tudor Ctr Dr, Anchorage, AK 99508 USA. EM ris2@cdc.gov FU Intramural CDC HHS [CC999999] NR 29 TC 3 Z9 3 U1 6 U2 11 PU WALTER DE GRUYTER GMBH PI BERLIN PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY SN 0334-018X EI 2191-0251 J9 J PEDIATR ENDOCR MET JI J. Pediatr. Endocrinol. Metab. PD JUL PY 2015 VL 28 IS 7-8 BP 815 EP 823 DI 10.1515/jpem-2014-0446 PG 9 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA CN3EX UT WOS:000358308400015 PM 25741788 ER PT J AU Griffing, SM MacCannell, DR Schmidtke, AJ Freeman, MM Hyytia-Trees, E Gerner-Smidt, P Ribot, EM Bono, JL AF Griffing, Sean M. MacCannell, Duncan R. Schmidtke, Amber J. Freeman, Molly M. Hyytiae-Trees, Eija Gerner-Smidt, Peter Ribot, Efrain M. Bono, James L. TI Canonical Single Nucleotide Polymorphisms (SNPs) for High-Resolution Subtyping of Shiga-Toxin Producing Escherichia coli (STEC) O157:H7 SO PLOS ONE LA English DT Article ID UNITED-STATES; BACILLUS-ANTHRACIS; GENOMIC DIVERSITY; TYPING METHODS; PULSENET USA; EVOLUTION; SURVEILLANCE; INSERTIONS; DELETIONS; OUTBREAKS AB The objective of this study was to develop a canonical, parsimoniously-informative SNP panel for subtyping Shiga-toxin producing Escherichia coli (STEC) O157:H7 that would be consistent with epidemiological, PFGE, and MLVA clustering of human specimens. Our group had previously identified 906 putative discriminatory SNPs, which were pared down to 391 SNPs based on their prevalence in a test set. The 391 SNPs were screened using a high-throughput form of TaqMan PCR against a set of clinical isolates that represent the most diverse collection of O157:H7 isolates from outbreaks and sporadic cases examined to date. Another 30 SNPs identified by others were also screened using the same method. Two additional targets were tested using standard TaqMan PCR endpoint analysis. These 423 SNPs were reduced to a 32 SNP panel with the almost the same discriminatory value. While the panel partitioned our diverse set of isolates in a manner that was consistent with epidemiological data and PFGE and MLVA phylogenies, it resulted in fewer subtypes than either existing method and insufficient epidemiological resolution in 10 of 47 clusters. Therefore, another round of SNP discovery was undertaken using comparative genomic resequencing of pooled DNA from the 10 clusters with insufficient resolution. This process identified 4,040 potential SNPs and suggested one of the ten clusters was incorrectly grouped. After its removal, there were 2,878 SNPs, of which only 63 were previously identified and 438 occurred across multiple clusters. Among highly clonal bacteria like STEC O157:H7, linkage disequilibrium greatly limits the number of parsimoniously informative SNPs. Therefore, it is perhaps unsurprising that our panel accounted for the potential discriminatory value of numerous other SNPs reported in the literature. We concluded published O157:H7 SNPs are insufficient for effective epidemiological subtyping. However, the 438 multi-cluster SNPs we identified may provide the additional information required. C1 [Griffing, Sean M.; MacCannell, Duncan R.; Schmidtke, Amber J.; Freeman, Molly M.; Hyytiae-Trees, Eija; Gerner-Smidt, Peter; Ribot, Efrain M.] Ctr Dis Control & Prevent, PulseNet Next Generat Subtyping Methods Unit, Div Foodborne Waterborne & Environm Dis, Enter Dis Lab Branch, Atlanta, GA USA. [Bono, James L.] ARS, US Meat Anim Res Ctr, USDA, Clay Ctr, NE 68933 USA. RP Bono, JL (reprint author), ARS, US Meat Anim Res Ctr, USDA, Clay Ctr, NE 68933 USA. EM Jim.Bono@ars.usda.gov FU American Society Microbiology/CDC Postdoctoral Research Fellowship FX Sean Griffing was funded through the support of the American Society Microbiology/CDC Postdoctoral Research Fellowship. NR 26 TC 2 Z9 2 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 1 PY 2015 VL 10 IS 7 AR e0131967 DI 10.1371/journal.pone.0131967 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1CG UT WOS:000358153000147 PM 26132731 ER PT J AU Maurer, JJ Martin, G Hernandez, S Cheng, Y Gerner-Smidt, P Hise, KB D'Angelo, MT Cole, D Sanchez, S Madden, M Valeika, S Presotto, A Lipp, EK AF Maurer, John J. Martin, Gordon Hernandez, Sonia Cheng, Ying Gerner-Smidt, Peter Hise, Kelley B. D'Angelo, Melissa Tobin Cole, Dana Sanchez, Susan Madden, Marguerite Valeika, Steven Presotto, Andrea Lipp, Erin K. TI Diversity and Persistence of Salmonella enterica Strains in Rural Landscapes in the Southeastern United States SO PLOS ONE LA English DT Article ID FIELD GEL-ELECTROPHORESIS; ESCHERICHIA-COLI; ANTIMICROBIAL RESISTANCE; RISK-FACTORS; GENETIC RELATEDNESS; MULTISTATE OUTBREAK; ALFALFA SPROUTS; SURFACE-WATER; DAIRY-CATTLE; INFECTIONS AB Salmonellosis cases in the in the United States show distinct geographical trends, with the southeast reporting among the highest rates of illness. In the state of Georgia, USA, non-outbreak associated salmonellosis is especially high in the southern low-lying coastal plain. Here we examined the distribution of Salmonella enterica in environmental waters and associated wildlife in two distinct watersheds, one in the Atlantic Coastal Plain (a high case rate rural area) physiographic province and one in the Piedmont (a lower case rate rural area). Salmonella were isolated from the two regions and compared for serovar and strain diversity, as well as distribution, between the two study areas, using both a retrospective and prospective design. Thirty-seven unique serovars and 204 unique strain types were identified by pulsed-field gel electrophoresis (PFGE). Salmonella serovars Braenderup, Give, Hartford, and Muenchen were dominant in both watersheds. Two serovars, specifically S. Muenchen and S. Rubislaw, were consistently isolated from both systems, including water and small mammals. Conversely, 24 serovars tended to be site-specific (64.8%, n = 37). Compared to the other Salmonella serovars isolated from these sites, S. Muenchen and S. Rubislaw exhibited significant genetic diversity. Among a subset of PFGE patterns, approximately half of the environmental strain types matched entries in the USA PulseNet database of human cases. Ninety percent of S. Muenchen strains from the Little River basin (the high case rate area) matched PFGE entries in PulseNet compared to 33.33% of S. Muenchen strains from the North Oconee River region (the lower case rate area). Underlying the diversity and turnover of Salmonella strains observed for these two watersheds is the persistence of specific Salmonella serovars and strain types that may be adapted to these watersheds and landscapes. C1 [Maurer, John J.; Hernandez, Sonia; Cheng, Ying] Univ Georgia, Dept Populat Hlth, Athens, GA 30602 USA. [Martin, Gordon; Cole, Dana; Lipp, Erin K.] Univ Georgia, Dept Environm Hlth Sci, Athens, GA 30602 USA. [Hernandez, Sonia] Univ Georgia, Warnell Sch Forestry & Nat Resources, Athens, GA 30602 USA. [Gerner-Smidt, Peter; Hise, Kelley B.; Cole, Dana] Ctr Dis Control & Prevent, Atlanta, GA USA. [D'Angelo, Melissa Tobin] Georgia Dept Publ Hlth, Atlanta, GA USA. [Sanchez, Susan] Univ Georgia, Dept Infect Dis, Athens, GA 30602 USA. [Madden, Marguerite; Presotto, Andrea] Univ Georgia, Dept Geog, Athens, GA 30602 USA. [Valeika, Steven] Univ Georgia, Dept Epidemiol & Biostat, Athens, GA 30602 USA. RP Lipp, EK (reprint author), Univ Georgia, Dept Populat Hlth, Athens, GA 30602 USA. EM elipp@uga.edu FU National Institutes of Health (National Institute of Allergy and Infectious Disease) [1R15AI089565-01] FX This work was supported by grant 1R15AI089565-01 from the National Institutes of Health (National Institute of Allergy and Infectious Disease) to EKL, JJM, SH, SS, MM and SV. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 71 TC 4 Z9 4 U1 0 U2 11 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUL 1 PY 2015 VL 10 IS 7 AR e0128937 DI 10.1371/journal.pone.0128937 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1CG UT WOS:000358153000023 PM 26131552 ER PT J AU Rohan, E Slotman, B Morrissey, KG Murillo, J DeGroff, A Schroy, P AF Rohan, Elizabeth Slotman, Beth Morrissey, Kerry Grace Murillo, Jennifer DeGroff, Amy Schroy, Paul TI Patient navigation: scope of practice asmembers of the oncology multidisciplinary care team SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Rohan, Elizabeth; DeGroff, Amy] Ctr Dis Control & Prevent, Atlanta, GA USA. [Slotman, Beth; Morrissey, Kerry Grace] WESTAT Corp, Rockville, MD USA. [Murillo, Jennifer; Schroy, Paul] Boston Med Ctr, Boston, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD JUL PY 2015 VL 24 SU 2 SI SI MA I-4 BP 61 EP 62 PG 2 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA CN2MG UT WOS:000358255000112 ER PT J AU Hawkins, N Soman, A Rodriguez, J Buchanan, N AF Hawkins, Nikki Soman, Ashwini Rodriguez, Juan Buchanan, Natasha TI Use of prescription medications for treating anxiety and depression among self-identified cancer survivors in the National Health Interview Survey 2010-2013 SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Hawkins, Nikki; Buchanan, Natasha] Ctr Dis Control & Prevent, Atlanta, GA USA. [Soman, Ashwini] Northrop Grumman, Falls Church, VA USA. [Rodriguez, Juan] CDC, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD JUL PY 2015 VL 24 SU 2 SI SI MA J-1 BP 62 EP 62 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA CN2MG UT WOS:000358255000113 ER PT J AU Buchanan, N Ragan, K Aketch, M Smith, JL Roland, K Hawkins, N Saraiya, M AF Buchanan, Natasha Ragan, Kathleen Aketch, Millicent Smith, Judith Lee Roland, Katherine Hawkins, Nikki Saraiya, Mona TI Assessment of Male and Female Reported Barriers and Facilitators to Cervical Cancer Screening in Kenya SO PSYCHO-ONCOLOGY LA English DT Meeting Abstract C1 [Buchanan, Natasha; Roland, Katherine; Hawkins, Nikki; Saraiya, Mona] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ragan, Kathleen] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Aketch, Millicent; Smith, Judith Lee] Kenya Govt Med Res Ctr, Nairobi, Kenya. NR 0 TC 0 Z9 0 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1057-9249 EI 1099-1611 J9 PSYCHO-ONCOLOGY JI Psycho-Oncol. PD JUL PY 2015 VL 24 SU 2 SI SI MA P1-7 BP 107 EP 107 PG 1 WC Oncology; Psychology; Psychology, Multidisciplinary; Social Sciences, Biomedical SC Oncology; Psychology; Biomedical Social Sciences GA CN2MG UT WOS:000358255000188 ER PT J AU Ma, HY Xu, XX Ursin, G Simon, MS Marchbanks, PA Malone, KE Lu, YN McDonald, JA Folger, SG Weiss, LK Sullivan-Halley, J Deapen, DM Press, MF Bernstein, L AF Ma, Huiyan Xu, Xinxin Ursin, Giske Simon, Michael S. Marchbanks, Polly A. Malone, Kathleen E. Lu, Yani McDonald, Jill A. Folger, Suzanne G. Weiss, Linda K. Sullivan-Halley, Jane Deapen, Dennis M. Press, Michael F. Bernstein, Leslie TI Reduced risk of breast cancer associated with recreational physical activity varies by HER2 status SO CANCER MEDICINE LA English DT Article DE Breast cancer; ER; HER2; luminal A breast cancer; p53; physical activity; PR; Triple-negative breast cancer ID HORMONE-RECEPTOR STATUS; ESTROGEN-RECEPTOR; REPRODUCTIVE EXPERIENCES; PROGESTERONE-RECEPTOR; P53 MUTATIONS; UNITED-STATES; WHITE WOMEN; BODY-SIZE; GENE; EXPRESSION AB Convincing epidemiologic evidence indicates that physical activity is inversely associated with breast cancer risk. Whether this association varies by the tumor protein expression status of the estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), or p53 is unclear. We evaluated the effects of recreational physical activity on risk of invasive breast cancer classified by the four biomarkers, fitting multivariable unconditional logistic regression models to data from 1195 case and 2012 control participants in the population-based Women's Contraceptive and Reproductive Experiences Study. Self-reported recreational physical activity at different life periods was measured as average annual metabolic equivalents of energy expenditure [MET]-hours per week. Our biomarker-specific analyses showed that lifetime recreational physical activity was negatively associated with the risks of ER-positive (ER+) and of HER2-negative (HER2-) subtypes (both P(trend)0.04), but not with other subtypes (all P-trend>0.10). Analyses using combinations of biomarkers indicated that risk of invasive breast cancer varied only by HER2 status. Risk of HER2-breast cancer decreased with increasing number of MET-hours of recreational physical activity in each specific life period examined, although some trend tests were only marginally statistically significant (all P(trend)0.06). The test for homogeneity of trends (HER2- vs. HER2+) reached statistical significance only when evaluating physical activity during the first 10years after menarche (P-homogeneity=0.03). Our data suggest that physical activity reduces risk of invasive breast cancers that lack HER2 overexpression, increasing our understanding of the biological mechanisms by which physical activity acts. C1 [Ma, Huiyan; Xu, Xinxin; Lu, Yani; Sullivan-Halley, Jane; Bernstein, Leslie] City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, Duarte, CA 91010 USA. [Ursin, Giske] Canc Registry Norway, N-0304 Oslo, Norway. [Ursin, Giske] Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway. [Simon, Michael S.] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI 48201 USA. [Marchbanks, Polly A.; Folger, Suzanne G.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Malone, Kathleen E.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98109 USA. [McDonald, Jill A.] New Mexico State Univ, Coll Hlth & Social Serv, Las Cruces, NM 88003 USA. [Weiss, Linda K.] NCI, Canc Ctr Branch, Bethesda, MD 20850 USA. [Ursin, Giske; Deapen, Dennis M.] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90033 USA. [Press, Michael F.] Univ So Calif, Keck Sch Med, Dept Pathol, Los Angeles, CA 90033 USA. RP Ma, HY (reprint author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Populat Sci, Div Canc Etiol, 1500 E Duarte Rd, Duarte, CA 91010 USA. EM hma@coh.org FU National Institute for Child Health and Human Development [N01-HD-3-3175]; National Cancer Institute [K05-CA136967]; National Cancer Institute of the National Institutes of Health [R03CA188549]; National Cancer Institute, NIH; Fred Hutchinson Cancer Research Center [N01-HD-2-3166]; Karmanos Cancer Institute at Wayne State University [N01-HD-3-3174]; University of Pennsylvania [N01-HD-3-3276]; University of Southern California [N01-HD-3-3175]; Centers for Disease Control and Prevention [Y01-HD-7022]; California Department of Health Services; National Institute of Child Health and Human Development [N01-HD-3-3175]; Breast Cancer Research Foundation (MFPress); Emory University [N01-HD-3-3168]; [N01-CN65064]; [N01-PC-67010] FX This work was supported by the National Institute for Child Health and Human Development grant N01-HD-3-3175, National Cancer Institute grant K05-CA136967, and the National Cancer Institute of the National Institutes of Health under Award Number R03CA188549. Data collection for the Women's CARE Study was supported by the National Institute of Child Health and Human Development and National Cancer Institute, NIH, through contracts with Emory University (N01-HD-3-3168), Fred Hutchinson Cancer Research Center (N01-HD-2-3166), Karmanos Cancer Institute at Wayne State University (N01-HD-3-3174), University of Pennsylvania (N01-HD-3-3276), and University of Southern California (N01-HD-3-3175) and Interagency Agreement with Centers for Disease Control and Prevention (Y01-HD-7022). Collection of cancer incidence data in LA County by University of Southern California was supported by California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code, Section 103885. Support for use of SEER cancer registries through contracts N01-CN65064 (Detroit) and N01-PC-67010 (LA). Biomarker determination and analyses were supported by a contract from the National Institute of Child Health and Human Development (N01-HD-3-3175) and a grant from the Breast Cancer Research Foundation (MFPress). NR 59 TC 3 Z9 3 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD JUL PY 2015 VL 4 IS 7 BP 1122 EP 1135 DI 10.1002/cam4.465 PG 14 WC Oncology SC Oncology GA CM7TJ UT WOS:000357899100017 PM 25924995 ER PT J AU Philippat, C Bennett, D Calafat, AM Picciotto, IH AF Philippat, Claire Bennett, Deborah Calafat, Antonia M. Picciotto, Irva Hertz TI Exposure to select phthalates and phenols through use of personal care products among Californian adults and their children SO ENVIRONMENTAL RESEARCH LA English DT Article DE Endocrine disruptors; Parabens; Personal care products; Phenols; Phthalates; Temporal variability ID NUTRITION EXAMINATION SURVEY; URINARY BISPHENOL-A; UNITED-STATES; NATIONAL-HEALTH; PREGNANT-WOMEN; METABOLITES; PARABENS; VARIABILITY; PREDICTORS; COHORT AB Introduction: Certain phenols and phthalates are used in many consumer products including personal care products (PCPs). Aims: We aimed to study the associations between the use of PCPs and urinary concentrations of biomarkers of select phenols and phthalates among Californian adults and their children. As an additional aim we compared phenols and phthalate metabolites concentrations measured in adults and children urine samples collected the same day. Methods: Our study relied on a subsample of 90 adult-child pairs participating in the Study of Use of Products and Exposure Related Behavior (SUPERB). Each adult and child provided one to two urine samples in which we measured concentrations of selected phenols and phthalate metabolites. We computed Spearman correlation coefficients to compare concentrations measured in adults and children urine samples collected the same day. We used adjusted linear and Tobit regression models to study the associations between the use of PCPs in the past 24 h and biomarker concentrations. Results: Benzophenone-3 and parabens concentrations were higher in adults compared to their children. Conversely children had higher mono-n-butyl phthalate and mono-isobutyl phthalate concentrations. No significant difference was observed for the other compounds. The total number of different PCPs used was positively associated with urinary concentrations of methyl, propyl and butyl parabens and the main metabolite of diethyl phthalate in adults. Among children, the use of a few specific products including liquid soap, hair care products and sunscreen was positively associated with urinary concentrations of some phenols or phthalate metabolites. Discussion: These results strengthen the body of evidence suggesting that use of PCPs is an important source of exposure to parabens and diethyl phthalate in adults and provide data on exposure to selected phenols and phthalates through use of PCPs in children. (C) 2015 Elsevier Inc. All rights reserved. C1 [Philippat, Claire; Bennett, Deborah; Picciotto, Irva Hertz] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA. [Philippat, Claire; Picciotto, Irva Hertz] Univ Calif Davis, MIND Inst, Davis, CA 95616 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Philippat, C (reprint author), Univ Calif Davis, MIND Inst, Davis, CA 95616 USA. EM cphilippat@ucdavis.edu FU U.S. EPA through its Office of Research and Development [RD-83154001]; NIEHS [R01-ES020392, P01-ES011269] FX The U.S. EPA through its Office of Research and Development funded this research through a Science to Achieve Results (STAR) Grant RD-83154001. Further support was provided by the NIEHS Grants #R01-ES020392 and #P01-ES011269. NR 38 TC 13 Z9 13 U1 5 U2 38 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD JUL PY 2015 VL 140 BP 369 EP 376 DI 10.1016/j.envres.2015.04.009 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CM7VH UT WOS:000357904100041 PM 25929801 ER PT J AU Jung, KH Lovinsky-Desir, S Perzanowski, M Liu, XH Maher, C Gil, E Torrone, D Sjodin, A Li, Z Perera, FP Miller, RL AF Jung, Kyung Hwa Lovinsky-Desir, Stephanie Perzanowski, Matthew Liu, Xinhua Maher, Christina Gil, Eric Torrone, David Sjodin, Andreas Li, Zheng Perera, Frederica P. Miller, Rachel L. TI Repeatedly high polycyclic aromatic hydrocarbon exposure and cockroach sensitization among inner-city children SO ENVIRONMENTAL RESEARCH LA English DT Article DE Polycyclic aromatic hydrocarbons; Urinary metabolites; Cockroach IgE; Childhood; Inner-city ID AIR-POLLUTION; BIRTH COHORT; ALLERGIC SENSITIZATION; RESPIRATORY SYMPTOMS; PARTICULATE MATTER; METABOLITE LEVELS; DIESEL EXHAUST; BLACK CARBON; DUST-MITE; ASTHMA AB Background: Exposures to traffic-related air pollutants including polycyclic aromatic hydrocarbons (PAH) have been associated with the development and exacerbation of asthma. However, there is limited evidence on whether these pollutants are associated with the development of cockroach sensitization, a strong risk factor for urban asthma. We hypothesized that repeatedly high PAM exposure during childhood would be associated with increased risk of new cockroach sensitization. Methods: As part of the research being conducted by the Columbia Center for Children's Environmental Health (CCCEH) birth cohort study in New York, a spot urine sample was collected from children at age 5 years (2003-2008) and again at age 9-10 years (2008-2012; n=248) and analyzed for 10 PAM metabolites. Repeatedly high PAM (High-High) exposure was defined as measures above median for age 5 PAH metabolites at both time points. Child blood samples at age 5 and 9 years were analyzed for total, anti-cockroach, mouse, dust mite, cat and dog IgE. Relative risks (RR) were estimated with multivariable modified Poisson regression. Results: Individual PAH metabolite levels, except for 1-naphthol (1-OH-NAP), increased by 10-60% from age 5 to age 9-10. The prevalence of cockroach sensitization increased from 17.6% (33/188) at age 5 to 33.0% (62/188) at 9 years (p=0.001). After controlling for potential covariates including cockroach sensitization at age 5 in regression analyses, positive associations were found between repeatedly high exposure (High-High) to 1-OH-NAP, 3-hydroxyphenanthrene (3-OH-PHEN), or 1-hydroxypyrene (1-OHPYR) and cockroach sensitization at age 9 (p-values < 0.05). Compared to Low-Low exposure, the relative risk (RR) [95% CI] with repeatedly high exposure was 1.83 [1.06-3.17] for 1-OH-NAP, 1.54 [1.06-2.23] for 3-OH-PHEN, and 1.59 [1.04-2.43] for 1-OH-PYR. Conclusions: Repeatedly high levels of urinary PAH metabolites during childhood may increase likelihood of sensitization to cockroach allergen in urban inner-city children at age 9 years. (C) 2015 Elsevier Inc. All rights reserved. C1 [Jung, Kyung Hwa; Maher, Christina; Gil, Eric; Torrone, David; Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Med, Div Pulm Allergy & Crit Care Med, New York, NY 10032 USA. [Lovinsky-Desir, Stephanie] Columbia Univ, Coll Phys & Surg, Dept Pediat, Div Pediat Pulm, New York, NY 10032 USA. [Perzanowski, Matthew; Perera, Frederica P.; Miller, Rachel L.] Columbia Univ, Mailman Sch Publ Hlth, Dept Environm Hlth Sci, New York, NY 10032 USA. [Liu, Xinhua] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA. [Sjodin, Andreas; Li, Zheng] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Organ Analyt Toxicol Branch, Atlanta, GA USA. [Miller, Rachel L.] Columbia Univ, Coll Phys & Surg, Dept Pediat, Div Pediat Allergy Immunol & Rheumatol, New York, NY 10032 USA. RP Jung, KH (reprint author), Columbia Univ, Coll Phys & Surg, Dept Med, PH8E-101,630 W 168th St, New York, NY 10032 USA. EM kj2237@cumc.columbia.edu; s13230@cumc.columbia.edu; mp2217@columbia.edu; x126@columbia.edu; cem2184@cumc.columbia.edu; eng2113@cumc.columbia.edu; dt2339@cumc.columbia.edu; zrq4@cdc.gov; kz14@cdc.gov; fpp1@columbia.edu; rlm14@cumc.columbia.edu FU NIH [R01ES013163, P50ES015905, P01ES09600, R01ES08977, P30ES09089]; US. Environmental Protection Agency (US EPA) [RD832096, R827027, RD832141, RD834509]; Educational Foundation of America; John & Wendy Neu Family Foundation; New York Community Trust; Trustees of the Blanchette Hooker Rockefeller Fund FX This work was supported by NIH (R01ES013163, P50ES015905, P01ES09600, R01ES08977 and P30ES09089), and by US. Environmental Protection Agency (US EPA Grants RD832096, R827027, RD832141 and RD834509). Its contents are solely the responsibility of the grantee and do not necessarily represent the official views of the US EPA. Further, the US EPA does not endorse the purchase of any commercial products or services mentioned in the publication and also supported by the Educational Foundation of America, The John & Wendy Neu Family Foundation, The New York Community Trust, and the Trustees of the Blanchette Hooker Rockefeller Fund. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 44 TC 6 Z9 6 U1 0 U2 7 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0013-9351 EI 1096-0953 J9 ENVIRON RES JI Environ. Res. PD JUL PY 2015 VL 140 BP 649 EP 656 DI 10.1016/j.envres.2015.05.027 PG 8 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CM7VH UT WOS:000357904100074 PM 26073203 ER PT J AU Conway, KC Mathews, KD Paramsothy, P Oleszek, J Trout, C Zhang, Y Romitti, PA AF Conway, Kristin Caspers Mathews, Katherine D. Paramsothy, Pangaja Oleszek, Joyce Trout, Christina Zhang, Ying Romitti, Paul A. TI Neurobehavioral Concerns Among Males with Dystrophinopathy Using Population-Based Surveillance Data from the Muscular Dystrophy Surveillance, Tracking, and Research Network SO JOURNAL OF DEVELOPMENTAL AND BEHAVIORAL PEDIATRICS LA English DT Article ID ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; AUTISM SPECTRUM DISORDER; BEHAVIOR PROBLEMS; UNITED-STATES; PARENT-REPORT; MD STARNET; CHILDREN; PREVALENCE; ADOLESCENTS AB Objective: To describe the occurrence of selected neurobehavioral concerns among males with a dystrophinopathy and to explore the associations with corticosteroid or supportive device use. Methods: Medical record abstraction of neurobehavioral concerns was conducted for 857 affected males from 765 families, born since 1982 and followed through 2011, and enrolled in the population-based Muscular Dystrophy Surveillance, Tracking, and Research Network. Cumulative probabilities for attention-deficit hyperactivity disorder (ADHD), behavior problems, and depressed mood were calculated from Kaplan-Meier estimates for the subsample of oldest affected males (n = 765). Hazard ratios (HRs) and 95% confidence intervals (95% CIs) for corticosteroid and supportive device use were estimated from Cox regression models with time-dependent covariates. Results: Of the 857 affected males, 375 (44%) had at least 1 of the 3 selected neurobehavioral concerns; a similar percentage (45%) was found among the 765 oldest affected males. The estimated cumulative probabilities among these oldest affected males were 23% for ADHD, 43% for behavior problems, and 51% for depressed mood. Corticosteroid (HR = 2.35, 95% CI = 1.75-3.16) and mobility device (HR = 1.53, 95% CI = 1.06-2.21) use were associated with behavior problems. Use of a mobility device (HR = 3.53, 95% CI = 2.13-5.85), but not corticosteroids, was associated with depressed mood. ADHD was not significantly associated with corticosteroid or mobility device use. Respiratory assist device use was not examined due to low numbers of users before onset of neurobehavioral concerns. Conclusion: Selected neurobehavioral concerns were common among males with a dystrophinopathy. Reported associations highlight the importance of increased monitoring of neurobehavioral concerns as interventions are implemented and disease progresses. C1 [Conway, Kristin Caspers] Univ Iowa, Dept Epidemiol, Coll Publ Hlth, Iowa City, IA 52242 USA. [Mathews, Katherine D.; Trout, Christina; Romitti, Paul A.] Univ Iowa, Carver Coll Med, Dept Pediat, Iowa City, IA 52242 USA. [Mathews, Katherine D.; Trout, Christina; Romitti, Paul A.] Univ Iowa, Carver Coll Med, Dept Neurol, Iowa City, IA 52242 USA. [Paramsothy, Pangaja] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Oleszek, Joyce] Univ Colorado, Sch Med, Dept Phys Med & Rehabil, Denver, CO USA. [Oleszek, Joyce] Childrens Hosp Colorado, Denver, CO USA. [Zhang, Ying] Indiana Univ, Coll Publ Hlth, Dept Biostat, Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA. [Zhang, Ying] Indiana Univ, Sch Med, Indianapolis, IN 46204 USA. RP Romitti, PA (reprint author), Univ Iowa, Dept Epidemiol, S416 CPHB,145 N Riverside Dr, Iowa City, IA 52242 USA. EM paul-romitti@uiowa.edu FU Centers for Disease Control and Prevention [U01 DD000189, U01 DD001119] FX Supported by cooperative agreements (U01 DD000189 and U01 DD001119) from the Centers for Disease Control and Prevention. NR 32 TC 0 Z9 0 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0196-206X EI 1536-7312 J9 J DEV BEHAV PEDIATR JI J. Dev. Behav. Pediatr. PD JUL-AUG PY 2015 VL 36 IS 6 BP 455 EP 463 DI 10.1097/DBP.0000000000000177 PG 9 WC Behavioral Sciences; Psychology, Developmental; Pediatrics SC Behavioral Sciences; Psychology; Pediatrics GA CM9CA UT WOS:000358002400009 ER PT J AU Torso, LM Voorhees, RE Forest, SA Gordon, AZ Silvestri, SA Kissler, B Schlackman, J Sandt, CH Toma, P Bachert, J Mertz, KJ Harrison, LH AF Torso, Lauren M. Voorhees, Ronald E. Forest, Stephen A. Gordon, Andrew Z. Silvestri, Sharon A. Kissler, Bonnie Schlackman, Jessica Sandt, Carol H. Toma, Paul Bachert, Joel Mertz, Kristen J. Harrison, Lee H. TI Escherichia coli O157:H7 Outbreak Associated with Restaurant Beef Grinding SO JOURNAL OF FOOD PROTECTION LA English DT Article ID TANDEM-REPEAT ANALYSIS; FIELD GEL-ELECTROPHORESIS; UNITED-STATES; PULSENET; SURVEILLANCE; PATHOGENS; NETWORK AB Escherichia coli O157:H7 is a common cause of foodborne illness in the United States. Beef ground at establishments regulated by the U.S. Department of Agriculture, Food Safety and Inspection Service is routinely tested for E. coli O157:H7. Prior to December 2013, boxed beef product (wholesale cuts of beef, such as beef loin, packaged into bags and boxed for shipping) was not always tested for this pathogen. Downstream processors or retailers may grind the product; and, if the ground beef is not cooked to the recommended temperature, pathogens on the exterior of the beef introduced to the interior through grinding may survive. On 18 October 2013, the Allegheny County Health Department identified two E. coli O157:H7 cases, both of whom were food handlers at restaurant A, a restaurant that ground locally produced boxed beef for hamburgers on site. Case finding was conducted through public messaging, employee surveys, and disease surveillance. All potential cases were interviewed using a standard questionnaire. A confirmed case was defined as laboratory-confirmed E. coli O157:H7 with exposure to restaurant A. A probable case was defined as a patient with compatible symptoms and exposure to restaurant A but without laboratory confirmation. All human and food isolates were characterized by pulsed-field gel electrophoresis and multilocus variable-number tandem repeat analysis. The analysis identified 14 confirmed and 10 probable cases of E. coli; 18 nonintact ground beef samples tested positive for E. coli O157:H7. Nine confirmed cases were restaurant A employees. All confirmed cases recalled eating a restaurant A hamburger in the 10 days before illness onset; most cases reported consuming medium, to 'rare hamburgers. Multiple pulsed-field gel electrophoresis and multilocus variable-number tandem repeat analysis patterns were identified among both the human and ground beef isolates, and the patient isolates matched those found in ground beef samples. Restaurant A voluntarily closed for 1.5 days, changed beef suppliers, ceased grinding beef in-house, and has had no new cases since reopening. C1 [Torso, Lauren M.; Voorhees, Ronald E.; Forest, Stephen A.; Gordon, Andrew Z.; Mertz, Kristen J.] Allegheny Cty Hlth Dept, Off Epidemiol & Biostat, Pittsburgh, PA 15219 USA. [Gordon, Andrew Z.] Ctr Dis Control & Prevent, Publ Hlth Associates Program, Chamblee, GA 30341 USA. [Silvestri, Sharon A.] Allegheny Cty Hlth Dept, Program Infect Dis, Pittsburgh, PA 15213 USA. [Kissler, Bonnie] USDA, Food Safety & Inspect Serv, Atlanta, GA 30329 USA. [Schlackman, Jessica; Harrison, Lee H.] Univ Pittsburgh, Dept Epidemiol, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15261 USA. [Schlackman, Jessica; Harrison, Lee H.] Univ Pittsburgh, Dept Med, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15261 USA. [Sandt, Carol H.] Penn Dept Hlth, Bur Labs, Exton, PA 19341 USA. [Toma, Paul] USDA, Food Safety & Inspect Serv, Pittsburgh, PA 15222 USA. [Bachert, Joel] USDA, Food Safety & Inspect Serv, Wilkes Barre, PA 18702 USA. RP Torso, LM (reprint author), Allegheny Cty Hlth Dept, Off Epidemiol & Biostat, 542 Fourth Ave, Pittsburgh, PA 15219 USA. EM ltorso@achd.net NR 16 TC 4 Z9 4 U1 5 U2 11 PU INT ASSOC FOOD PROTECTION PI DES MOINES PA 6200 AURORA AVE SUITE 200W, DES MOINES, IA 50322-2863 USA SN 0362-028X EI 1944-9097 J9 J FOOD PROTECT JI J. Food Prot. PD JUL PY 2015 VL 78 IS 7 BP 1272 EP 1279 DI 10.4315/0362-028X.JFP-14-545 PG 8 WC Biotechnology & Applied Microbiology; Food Science & Technology SC Biotechnology & Applied Microbiology; Food Science & Technology GA CM5YS UT WOS:000357765500005 PM 26197277 ER PT J AU Hyde, TB Sato, HK Hao, LJ Flannery, B Zheng, Q Wannemuehler, K Ciccone, FH Marques, HD YinWeckx, L Safadi, MA Moraes, ED Pinhata, MM Neto, JO Bevilacqua, MC Tabith, A Monteiro, TA Figueiredo, CA Andrus, JK Reef, SE Toscano, CM Castillo-Solorzano, C Icenogle, JP AF Hyde, Terri B. Sato, Helena Keico Hao, LiJuan Flannery, Brendan Zheng, Qi Wannemuehler, Kathleen Ciccone, Flavia Helena Marques, Heloisa de Sousa YinWeckx, Lily Safadi, Marco Aurelio Moraes, Eliane de Oliveira Pinhata, Marisa Mussi Neto, Jaime Olbrich Bevilacqua, Maria Cecilia Tabith Junior, Alfredo Monteiro, Tatiana Alves Figueiredo, Cristina Adelaide Andrus, Jon K. Reef, Susan E. Toscano, Cristiana M. Castillo-Solorzano, Carlos Icenogle, Joseph P. CA CRS Biomarker Study Grp TI Identification of Serologic Markers for School-Aged Children With Congenital Rubella Syndrome SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE congenital rubella syndrome; CRS; biomarkers; rubella; serology; immune response ID DEVELOPING-COUNTRIES; IMMUNOBLOT ANALYSIS; VIRUS; AVIDITY; BURDEN; ELIMINATION; INFECTION; PREGNANCY; DIAGNOSIS; OUTBREAK AB Background. Congenital rubella syndrome (CRS) case identification is challenging in older children since laboratory markers of congenital rubella virus (RUBV) infection do not persist beyond age 12 months. Methods. We enrolled children with CRS born between 1998 and 2003 and compared their immune responses to RUBV with those of their mothers and a group of similarly aged children without CRS. Demographic data and sera were collected. Sera were tested for anti-RUBV immunoglobulin G (IgG), IgG avidity, and IgG response to the 3 viral structural proteins (E1, E2, and C), reflected by immunoblot fluorescent signals. Results. We enrolled 32 children with CRS, 31 mothers, and 62 children without CRS. The immunoblot signal strength to C and the ratio of the C signal to the RUBV-specific IgG concentration were higher (P <.029 for both) and the ratio of the E1 signal to the RUBV-specific IgG concentration lower (P =.001) in children with CRS, compared with their mothers. Compared with children without CRS, children with CRS had more RUBV-specific IgG (P <.001), a stronger C signal (P <.001), and a stronger E2 signal (P <=.001). Two classification rules for children with versus children without CRS gave 100% specificity with >65% sensitivity. Conclusions. This study was the first to establish classification rules for identifying CRS in school-aged children, using laboratory biomarkers. These biomarkers should allow improved burden of disease estimates and monitoring of CRS control programs. C1 [Hyde, Terri B.; Hao, LiJuan; Flannery, Brendan; Zheng, Qi; Wannemuehler, Kathleen; Reef, Susan E.; Icenogle, Joseph P.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Flannery, Brendan; Andrus, Jon K.; Toscano, Cristiana M.; Castillo-Solorzano, Carlos] Pan Amer Hlth Org, Washington, DC USA. [Sato, Helena Keico; Ciccone, Flavia Helena] Univ Sao Paulo, Univ Hosp, Sao Paulo State Hlth Dept, Sao Paulo, Brazil. [Marques, Heloisa de Sousa] Univ Sao Paulo, Univ Hosp, Childrens Inst, Sao Paulo, Brazil. [YinWeckx, Lily] Univ Fed Sao Paulo, Hosp Sao Paulo, Sao Paulo, Brazil. [Safadi, Marco Aurelio] Catholic Univ Sao Paulo, Sch Med Sci Santa Casa, Sao Paulo, Brazil. [Tabith Junior, Alfredo] Catholic Univ Sao Paulo, Div Educ & Rehabil Commun Disturbances, Sao Paulo, Brazil. [Monteiro, Tatiana Alves] USP Med Sch, Div Otorhinolaryngol, Sao Paulo, Brazil. [Figueiredo, Cristina Adelaide] Adolfo Lutz Inst, Sao Paulo, Brazil. [Moraes, Eliane de Oliveira] Univ Sao Paulo, Sch Med Sci, Campinas, SP, Brazil. [Pinhata, Marisa Mussi] Univ Sao Paulo, Univ Hosp, Ribeirao Preto, Brazil. [Neto, Jaime Olbrich] Univ Sao Paulo, Univ Hosp Botucatu, Bauru, Brazil. [Bevilacqua, Maria Cecilia] Univ Sao Paulo, Hosp Rehabil Cranofacial Abnormal, Audiol Res Ctr, Bauru, Brazil. RP Icenogle, JP (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,MS-C22, Atlanta, GA 30333 USA. EM jicenogle@cdc.gov FU CDC; Sao Paulo State Health Department; Pan American Health Organization FX This work was supported by the CDC, the Sao Paulo State Health Department, and the Pan American Health Organization. NR 33 TC 2 Z9 2 U1 1 U2 3 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUL 1 PY 2015 VL 212 IS 1 BP 57 EP 66 DI 10.1093/infdis/jiu604 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM6SA UT WOS:000357818900008 PM 25362195 ER PT J AU Li, J Berkowitz, Z Hall, IJ AF Li, Jun Berkowitz, Zahava Hall, Ingrid J. TI Decrease in Prostate Cancer Testing Following the US Preventive Services Task Force (USPSTF) Recommendations SO JOURNAL OF THE AMERICAN BOARD OF FAMILY MEDICINE LA English DT Article DE Cancer Screening; Prostate Cancer; Prostate-Specific Antigen ID OLDER; MEN AB Purpose: To assess changes of prostate-specific antigen (PSA) testing following recent US Preventive Services Task Force (USPSTF) prostate cancer screening recommendations using 2005 to 2013 National Health Interview Survey data. Methods: We calculated the percentage of PSA testing among men >= 40 years by age group and age-adjusted race for each survey year. Differences between years were assessed with linear contrasts after combining all years' data. Results: The overall percentage of PSA testing was highest in 2008 and decreased significantly in 2013. Compared with 2008, each age group had significantly lower screening percentages in 2013, especially men >= 75 years old (-14.0% points; P < .001). Both men aged 50 to 74 and men aged >= 75 had significantly lower percentages in 2013 than in 2010. For white and black men, the PSA testing percentages were highest in 2008 and decreased significantly in 2013. Only white men had a significantly lower percentage in 2013 than in 2010. Conclusions: Significant declines in PSA testing from 2008 to 2013 in men >= 75 years old may reflect the impact of the 2008 USPSTF recommendations. While the cause of the decreases in PSA testing between 2010 and 2013 among men aged 50 to 74 years old and white men is unknown, the decreases may suggest the early effects of the 2012 recommendations. C1 [Li, Jun; Berkowitz, Zahava; Hall, Ingrid J.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Li, J (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,Mail Stop F-76, Atlanta, GA 30341 USA. EM ffa2@cdc.gov NR 5 TC 11 Z9 11 U1 0 U2 1 PU AMER BOARD FAMILY MEDICINE PI LEXINGTON PA 2228 YOUNG DR, LEXINGTON, KY 40505 USA SN 1557-2625 EI 1558-7118 J9 J AM BOARD FAM MED JI J. Am. Board Fam. Med. PD JUL-AUG PY 2015 VL 28 IS 4 BP 491 EP 493 DI 10.3122/jabfm.2015.04.150062 PG 3 WC Primary Health Care; Medicine, General & Internal SC General & Internal Medicine GA CM3YZ UT WOS:000357622600010 PM 26152440 ER PT J AU Monroe, BP Doty, JB Moses, C Ibata, S Reynolds, M Carroll, D AF Monroe, Benjamin P. Doty, Jeffrey B. Moses, Cynthia Ibata, Saturnin Reynolds, Mary Carroll, Darin TI Collection and Utilization of Animal Carcasses Associated with Zoonotic Disease in Tshuapa District, the Democratic Republic of the Congo, 2012 SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Bushmeat; carcass; Ebola; monkeypox; primate; rodent; spillover ID FOOD SECURITY; EBOLA-VIRUS; BUSHMEAT; WILDLIFE; AFRICA AB The collection and consumption of animal carcasses is a common activity in forested areas of the Congo River basin and creates sustainability, conservation, and health concerns. Residents of the Tshuapa District reported collecting the remains of 5,878 animals from >30 species when surveyed about their wildlife consumption habits. Carcasses were discovered in varying degrees of decomposition and were often consumed at home or sold in local markets. The most commonly collected animals were Cricetomys gambi anus (Northern giant pouched rat), Cercopithecus ascanius (red-tailed monkey), and Hehosciurus rufobrachium (red-legged sun squirrel). Many of the species recorded may be hosts of zoonotic pathogens, creating concern for spillover events. C1 [Monroe, Benjamin P.; Doty, Jeffrey B.; Reynolds, Mary; Carroll, Darin] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Program, Atlanta, GA 30333 USA. [Moses, Cynthia; Ibata, Saturnin] Int Conservat & Educ Fund, Washington, DC 20003 USA. RP Monroe, BP (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Program, Mailstop A-30,1600 Clifton Rd, Atlanta, GA 30333 USA. EM BMonroe@cdc.gov NR 11 TC 4 Z9 4 U1 6 U2 15 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 EI 1943-3700 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD JUL PY 2015 VL 51 IS 3 BP 734 EP 738 DI 10.7589/2014-05-140 PG 5 WC Veterinary Sciences SC Veterinary Sciences GA CM5YR UT WOS:000357765400023 PM 25932665 ER PT J AU Iwanowicz, DD Sanders, LR Schill, WB Xayavong, MV da Silva, AJ Qvarnstrom, Y Smith, T AF Iwanowicz, Deborah D. Sanders, Lakyn R. Schill, W. Bane Xayavong, Maniphet V. da Silva, Alexandre J. Qvarnstrom, Yvonne Smith, Trevor TI Spread of the Rat Lungworm (Angiostrongylus cantonensis) in Giant African Land Snails (Lissachatina fulica) in Florida, USA SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Angiostrongylus cantonensis; Lissachatina fulica; parasite; quantitative PCR; rat lungworm ID INFECTION AB The rat lungworm (Angiostrongylus cantonensis) is a parasitic nematode that causes rat lungworm disease. It is the leading cause of eosinophilic meningitis and is a zoonotic health risk. We confirmed the presence of A. cantonensis using species-specific, quantitative PCR in 18 of 50 (36%) giant African land snails (Lissachatina fulica) collected from Miami, Florida, US in May 2013. These snails were collected from seven of 21 core areas that the Florida Department of Agriculture and Consumer Services monitor weekly. Rat lungworms have not previously been identified in these areas. Duplicate DNA extractions of foot muscle tissue from each snail were tested. Of the seven core areas we examined, six were positive for A. cantonensis and prevalence of infection ranged from 27% to 100%. Of the 18 positive snails, only five were positive in both extractions. Our results confirm an increase in the range and prevalence of rat lungworm infection in Miami. We also emphasize the importance of extracting sufficient host tissue to minimize false negatives. C1 [Iwanowicz, Deborah D.; Schill, W. Bane] US Geol Survey, Fish Hlth Branch, Kearneysville, WV 25430 USA. [Sanders, Lakyn R.] US Geol Survey, Cherokee Nation Technol Solut, Fish Hlth Branch, Kearneysville, WV 25430 USA. [Xayavong, Maniphet V.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. [da Silva, Alexandre J.; Qvarnstrom, Yvonne] US FDA, Div Virulence Assessment, Off Appl Res & Safety Assessment, Ctr Food Safety & Appl Nutr, Laurel, MD 20708 USA. [Smith, Trevor] Florida Dept Agr & Consumer Serv, Gainesville, FL 32608 USA. RP Iwanowicz, DD (reprint author), US Geol Survey, Fish Hlth Branch, 11649 Leetown Rd, Kearneysville, WV 25430 USA. EM diwanowicz@usgs.gov OI Schill, William/0000-0002-9217-984X NR 14 TC 5 Z9 5 U1 1 U2 6 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 EI 1943-3700 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD JUL PY 2015 VL 51 IS 3 BP 749 EP 753 DI 10.7589/2014-06-160 PG 5 WC Veterinary Sciences SC Veterinary Sciences GA CM5YR UT WOS:000357765400026 PM 25973628 ER PT J AU Rhyan, J Tyers, D Zimmer, J Lewandowski, K Hennager, S Young, J Pappert, R Panella, A Kosoy, O AF Rhyan, Jack Tyers, Dan Zimmer, Jeremy Lewandowski, Kristen Hennager, Steve Young, John Pappert, Ryan Panella, Amanda Kosoy, Olga TI Serologic Survey of Snowshoe Hares (Lepus americanus) in the Greater Yellowstone Area for Brucellosis, Tularemia, and Snowshoe Hare Virus SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Brucella abortus; brucellosis; Francisella tularensis; Greater Yellowstone Area; snowshoe hare; snowshoe hare virus; tularemia; Yellowstone ID CALIFORNIA ENCEPHALITIS-VIRUS; FRANCISELLA-TULARENSIS; SEROGROUP VIRUS; NOVA-SCOTIA; ANTIBODIES; INFECTIONS; EUROPAEUS; SEROPREVALENCE; POPULATION; WILDLIFE AB We examined sera from snowshoe hares (Lepus americanus) livetrapped in the northern Greater Yellowstone Area (GYA), US, for antibodies to Brucella abortus, Francisella tularensis, and snowshoe hare virus (SSHV). Zero of 90, 0 of 67, and 40 of 100 samples were antibody positive for B. abortus, F. tularensis, and SSHV, respectively. Hares were trapped from 2009 to 2012, and of the six animals that were captured twice with at least 1 yr between captures, four developed antibody to SSHV, indicating active exposure to the agent. These findings suggest snowshoe hares in the GYA do not play a significant role as a reservoir of B. abortus, but do maintain the zoonotic, encephalitic SSHV in the population. C1 [Rhyan, Jack; Lewandowski, Kristen] US Anim & Plant Hlth Inspect Serv, USDA, Natl Wildlife Res Ctr, Ft Collins, CO 80521 USA. [Tyers, Dan] US Forest Serv, Interagency Grizzly Bear Study Team, Northern Rockies Sci Ctr, Bozeman, MT 59715 USA. [Zimmer, Jeremy] US Forest Serv, Custer Gallatin Natl Forest, Gardiner, MT 59030 USA. [Hennager, Steve] US Anim & Plant Hlth Inspect Serv, USDA, Natl Vet Serv Labs, Ames, IA 50010 USA. [Young, John; Pappert, Ryan; Panella, Amanda; Kosoy, Olga] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. RP Rhyan, J (reprint author), US Anim & Plant Hlth Inspect Serv, USDA, Natl Wildlife Res Ctr, 4101 LaPorte Ave, Ft Collins, CO 80521 USA. EM jack.c.rhyan@aphis.usda.gov NR 27 TC 1 Z9 1 U1 3 U2 12 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 EI 1943-3700 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD JUL PY 2015 VL 51 IS 3 BP 769 EP 773 DI 10.7589/2015-01-021 PG 5 WC Veterinary Sciences SC Veterinary Sciences GA CM5YR UT WOS:000357765400030 ER PT J AU Amman, BR Albarino, CG Bird, BH Nyakarahuka, L Sealy, TK Balinandi, S Schuh, AJ Campbell, SM Stroher, U Jones, MEB Vodzack, ME Reeder, DM Kaboyo, W Nichol, ST Towner, JS AF Amman, Brian R. Albarino, Cesar G. Bird, Brian H. Nyakarahuka, Luke Sealy, Tara K. Balinandi, Stephen Schuh, Amy J. Campbell, Shelly M. Stroeher, Ute Jones, Megan E. B. Vodzack, Megan E. Reeder, DeeAnn M. Kaboyo, Winyi Nichol, Stuart T. Towner, Jonathan S. TI A Recently Discovered Pathogenic Paramyxovirus, Sosuga Virus, is Present in Rousettus aegyptiacus Fruit Bats at Multiple Locations in Uganda SO JOURNAL OF WILDLIFE DISEASES LA English DT Article DE Bats; paramyxovirus; Rousettus aegyptiacus; Sosuga virus; spillover; wildlife biologist ID GENOME SEQUENCE; MALAYSIA AB In August 2012, a wildlife biologist became ill immediately following a 6-wk field trip to collect bats and rodents in South Sudan and Uganda. After returning to the US, the biologist was admitted to the hospital with multiple symptoms including fever, malaise, headache, generalized myalgia and arthralgia, stiffness in the neck, and sore throat. Soon after admission, the patient developed a maculopapular rash and oropharynx ulcerations. The patient remained hospitalized for 14 d. Several suspect pathogens, including viral hemorrhagic fever viruses such as Ebola viruses and Marburg viruses, were ruled out through standard diagnostic testing. However, deep sequencing and metagenomic analyses identified a novel paramyxovirus, later named Sosuga virus, in the patient's blood. To determine the potential source, bat tissues collected during the 3-wk period just prior to the onset of symptoms were tested for Sosuga virus, and several Egyptian rousette bats (Rousettus aegyptiacus) were found to be positive. Further analysis of archived Egyptian rousette tissues collected at other localities in Uganda found additional Sosuga virus positive bats, suggesting this species could be a potential natural reservoir for this novel paramyxovirus. C1 [Amman, Brian R.; Albarino, Cesar G.; Bird, Brian H.; Sealy, Tara K.; Schuh, Amy J.; Campbell, Shelly M.; Stroeher, Ute; Jones, Megan E. B.; Nichol, Stuart T.; Towner, Jonathan S.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Atlanta, GA 30333 USA. [Nyakarahuka, Luke] Uganda Virus Res Inst, Entebbe, Uganda. [Balinandi, Stephen] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Entebbe, Uganda. [Jones, Megan E. B.; Towner, Jonathan S.] Univ Georgia, Coll Vet Med, Athens, GA 30602 USA. [Vodzack, Megan E.; Reeder, DeeAnn M.] Bucknell Univ, Dept Biol, Lewisburg, PA 17837 USA. [Kaboyo, Winyi] Uganda Minist Hlth, Kampala, Uganda. RP Towner, JS (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jit8@cdc.gov OI Reeder, DeeAnn/0000-0001-8651-2012 FU US Department of Health and Human Services FX We thank the Uganda Virus Research Institute, the Uganda Ministry of Health, and the Uganda Wildlife Authority for their assistance during past collection efforts. We also thank E. Ervine for assistance with creating the map of Uganda. Funding for this study was provided by the US Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or Health and Human Services. NR 14 TC 2 Z9 2 U1 1 U2 9 PU WILDLIFE DISEASE ASSOC, INC PI LAWRENCE PA 810 EAST 10TH ST, LAWRENCE, KS 66044-8897 USA SN 0090-3558 EI 1943-3700 J9 J WILDLIFE DIS JI J. Wildl. Dis. PD JUL PY 2015 VL 51 IS 3 BP 774 EP 779 DI 10.7589/2015-02-044 PG 6 WC Veterinary Sciences SC Veterinary Sciences GA CM5YR UT WOS:000357765400031 PM 25919464 ER PT J AU Pitman, JP Basavaraju, SV Shiraishi, RW Wilkinson, R von Finckenstein, B Lowrance, DW Marfin, AA Postma, M Mataranyika, M Sibinga, CTS AF Pitman, John P. Basavaraju, Sridhar V. Shiraishi, Ray W. Wilkinson, Robert von Finckenstein, Bjorn Lowrance, David W. Marfin, Anthony A. Postma, Maarten Mataranyika, Mary Sibinga, Cees Th. Smit TI Namibia's transition from whole blood-derived pooled platelets to single-donor apheresis platelet collections SO TRANSFUSION LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUB-SAHARAN AFRICA; CHILDHOOD-CANCER; TRANSFUSION; COMPONENTS; SERVICES; SAFETY; PLASMA; MALAWI; AUDIT AB BACKGROUNDFew African countries separate blood donations into components; however, demand for platelets (PLTs) is increasing as regional capacity to treat causes of thrombocytopenia, including chemotherapy, increases. Namibia introduced single-donor apheresis PLT collections in 2007 to increase PLT availability while reducing exposure to multiple donors via pooling. This study describes the impact this transition had on PLT availability and safety in Namibia. STUDY DESIGN AND METHODSAnnual national blood collections and PLT units issued data were extracted from a database maintained by the Blood Transfusion Service of Namibia (NAMBTS). Production costs and unit prices were analyzed. RESULTSIn 2006, NAMBTS issued 771 single and pooled PLT doses from 3054 whole blood (WB) donations (drawn from 18,422 WB donations). In 2007, NAMBTS issued 486 single and pooled PLT doses from 1477 WB donations (drawn from 18,309 WB donations) and 131 single-donor PLT doses. By 2011, NAMBTS issued 837 single-donor PLT doses per year, 99.1% of all PLT units. Of 5761 WB donations from which PLTs were made in 2006 to 2011, a total of 20 (0.35%) were from donors with confirmed test results for human immunodeficiency virus or other transfusion-transmissible infections (TTIs). Of 2315 single-donor apheresis donations between 2007 and 2011, none of the 663 donors had a confirmed positive result for any pathogen. As apheresis replaced WB-derived PLTs, apheresis production costs dropped by a mean of 8.2% per year, while pooled PLT costs increased by an annual mean of 21.5%. Unit prices paid for apheresis- and WB-derived PLTs increased by 9 and 7.4% per year on average, respectively. CONCLUSIONNamibia's PLT transition shows that collections from repeat apheresis donors can reduce TTI risk and production costs. C1 [Pitman, John P.; Basavaraju, Sridhar V.; Shiraishi, Ray W.; Marfin, Anthony A.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Wilkinson, Robert; von Finckenstein, Bjorn] Blood Transfus Serv Namibia, Windhoek, Namibia. [Mataranyika, Mary] Namibia Minist Hlth & Social Serv, Directorate Clin Support Serv, Windhoek, Namibia. [Lowrance, David W.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Windhoek, Namibia. [Sibinga, Cees Th. Smit] Univ Groningen, ID Consulting Int Dev Transfus Med, Groningen, Netherlands. [Postma, Maarten] Univ Groningen, Dept Pharm, Unit PharmacoEpidemiol & PharmacoEcon PE2, Groningen, Netherlands. [Pitman, John P.; Postma, Maarten] Univ Groningen, Univ Med Ctr Groningen, Inst Sci Hlth Aging & Hlth caRE SHARE, NL-9713 AV Groningen, Netherlands. RP Pitman, JP (reprint author), US Ctr Dis Control & Prevent, HIV Prevent Branch, Div Global HIV AIDS, Ctr Global Hlth, 1600 Clifton Rd NE,MS E-04, Atlanta, GA 30333 USA. EM cgx5@cdc.gov OI Pitman, John/0000-0001-5983-7241 FU President's Emergency Plan for AIDS Relief (PEPFAR) through Centers for Disease Control and Prevention FX This project has been supported by the President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 36 TC 1 Z9 1 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD JUL PY 2015 VL 55 IS 7 BP 1685 EP 1692 DI 10.1111/trf.13049 PG 8 WC Hematology SC Hematology GA CM8LQ UT WOS:000357953000015 PM 25727921 ER PT J AU Levy, B Rao, CY Miller, L Kennedy, N Adams, M Davis, R Hastings, L Kabano, A Bennett, SD Sesay, M AF Levy, Benjamin Rao, Carol Y. Miller, Laura Kennedy, Ngozi Adams, Monica Davis, Rosemary Hastings, Laura Kabano, Augustin Bennett, Sarah D. Sesay, Momodu TI Ebola infection control in Sierra Leonean health clinics: A large cross-agency cooperative project SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Infection control; Health education; Occupational health; Primary health care; Health clinic; Health care workers AB The Ebola virus disease outbreak occurring in West Africa has resulted in at least 199 cases of Ebola in Sierra Leonean health care workers, many as a result of transmission occurring in health facilities. The Ministry of Health and Sanitation of Sierra Leone recognized that improvements in infection prevention and control (IPC) were necessary at all levels of health care delivery. To this end, the U.S. Centers for Disease Control and Prevention, United Nations Children's Fund, and multiple nongovernmental organizations implemented a national IPC training program in 1,200 peripheral health units (PHUs) in Sierra Leone. A tiered training of trainers program was used. Trainers conducted multiday trainings at PHUs and coordinated the delivery of personal protective equipment (gloves, gowns, masks, boots) and infection control supplies (chlorine, buckets, disposable rags, etc) to all PHU staff. Under the ongoing project, 4,264 health workers have already been trained, and 98% of PHUs have received their first shipment of supplies. Published by Elsevier Inc. on behalf of the Association for Professionals in Infection Control and Epidemiology, Inc. C1 [Levy, Benjamin; Adams, Monica] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30329 USA. [Rao, Carol Y.] Ctr Dis Control & Prevent, Div Global Hlth Protect, Beijing, Peoples R China. [Miller, Laura] Int Rescue Comm, New York, NY USA. [Kennedy, Ngozi; Kabano, Augustin] UNICEF, Freetown, Sierra Leone. [Davis, Rosemary; Hastings, Laura] Concern Worldwide, Dublin, Ireland. [Bennett, Sarah D.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Sesay, Momodu] Minist Hlth & Sanitat, Freetown, Sierra Leone. RP Levy, B (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM xew6@cdc.gov NR 7 TC 4 Z9 4 U1 2 U2 12 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD JUL 1 PY 2015 VL 43 IS 7 BP 752 EP 755 DI 10.1016/j.ajic.2015.03.011 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CM1CD UT WOS:000357416600024 PM 25891979 ER PT J AU Esona, MD Buteau, J Lucien, MAB Joseph, GA Leshem, E Boncy, J Katz, MA Bowen, MD Balajee, SA AF Esona, Mathew D. Buteau, Josiane Lucien, Mentor Ali Ber Joseph, Gerard A. Leshem, Eyal Boncy, Jacques Katz, Mark A. Bowen, Michael D. Balajee, S. Arunmozhi TI Rotavirus Group A Genotypes Detected through Diarrhea! Disease Surveillance in Haiti, 2012 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID VACCINATION PROGRAMS; LATIN-AMERICAN; COSTA-RICA; GASTROENTERITIS; METAANALYSIS; DIVERSITY; COUNTRIES; MORTALITY; CHILDREN; IMPACT AB Samples collected in 2012 through diarrheal disease surveillance in Haiti were tested for rotavirus by enzyme immunoassay and real time RT-PCR and positive samples were genotyped. The predominant genotypes were G1P[8] (29% prevalence) and G9P[8] (21%). The observed genotype prevalence was similar to that reported previously for other Caribbean countries. C1 [Esona, Mathew D.; Leshem, Eyal; Bowen, Michael D.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Buteau, Josiane; Joseph, Gerard A.; Boncy, Jacques] Natl Publ Hlth Lab, Port Au Prince, Haiti. [Lucien, Mentor Ali Ber] Quisqueya Univ, Dept Microbiol, Port Au Prince, Haiti. [Balajee, S. Arunmozhi] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Katz, Mark A.] Ctr Dis Control & Prevent Haiti, Port Au Prince, France. RP Bowen, MD (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, NCIRD, 1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM mdi4@cdc.gov; jolib2@gmail.com; lucienmentor@gmail.com; gerardajo944@gmail.com; wgp9@cdc.gov; jboncy2001@yahoo.fr; markakatz@gmail.com; mkb6@cdc.gov; fir3@cdc.gov NR 17 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUL PY 2015 VL 93 IS 1 BP 54 EP 56 DI 10.4269/ajtmh.14-0403 PG 3 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CM5YG UT WOS:000357764300011 PM 25962775 ER PT J AU Dahlgren, FS Heitman, KN Drexler, NA Massung, RF Behravesh, CB AF Dahlgren, F. Scott Heitman, Kristen Nichols Drexler, Naomi A. Massung, Robert F. Behravesh, Casey Barton TI Human Granulocytic Anaplasmosis in the United States from 2008 to 2012: A Summary of National Surveillance Data SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID IXODES-SCAPULARIS ACARI; NEW-YORK-STATE; EHRLICHIOSIS; IXODIDAE; AGENT; PHAGOCYTOPHILUM; PREVALENCE; VECTOR; WISCONSIN; INFECTION AB Human granulocytic anaplasmosis is an acute, febrile illness transmitted by the ticks Ixodes scapularis and Ixodes pacificus in the United States. We present a summary of passive surveillance data for cases of anaplasmosis with onset during 2008-2012. The overall reported incidence rate (IR) was 6.3 cases per million person-years. Cases were reported from 38 states and from New York City, with the highest incidence in Minnesota (IR = 97), Wisconsin (IR = 79), and Rhode Island (IR = 51). Thirty-seven percent of cases were classified as confirmed, almost exclusively by polymerase chain reaction. The reported case fatality rate was 0.3% and the reported hospitalization rate was 31%. IRs, hospitalization rates, life-threatening complications, and case fatality rates increased with age group. The IR increased from 2008 to 2012 and the geographic range of reported cases of anaplasmosis appears to have increased since 2000-2007. Our findings are consistent with previous case series and recent reports of the expanding range of the tick vector I. scapularis. C1 [Dahlgren, F. Scott; Heitman, Kristen Nichols; Drexler, Naomi A.; Massung, Robert F.; Behravesh, Casey Barton] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Atlanta, GA 30329 USA. Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. RP Dahlgren, FS (reprint author), Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, 1600 Clifton Rd NE,Mailstop A-30, Atlanta, GA 30329 USA. EM iot0@cdc.gov; wwd7@cdc.gov; isj3@cdc.gov; rfm2@cdc.gov; dlx9@cdc.gov FU Centers for Disease Control and Prevention; U.S. Department of Energy; CDC FX This study was supported by the Centers for Disease Control and Prevention. This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. NR 35 TC 4 Z9 4 U1 1 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUL PY 2015 VL 93 IS 1 BP 66 EP 72 DI 10.4269/ajtmh.15-0122 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CM5YG UT WOS:000357764300013 PM 25870428 ER PT J AU Newby, G Hwang, J Koita, K Chen, I Greenwood, B von Seidlein, L Shanks, GD Slutsker, LM Kachur, SP Wegbreit, J Ippolito, MM Poirot, E Gosling, R AF Newby, Gretchen Hwang, Jimee Koita, Kadiatou Chen, Ingrid Greenwood, Brian von Seidlein, Lorenz Shanks, G. Dennis Slutsker, Laurence M. Kachur, S. Patrick Wegbreit, Jennifer Ippolito, Matthew M. Poirot, Eugenie Gosling, Roly TI Review of Mass Drug Administration for Malaria and Its Operational Challenges SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Review ID FALCIPARUM-MALARIA; PLASMODIUM-VIVAX; PRIMAQUINE; PYRIMETHAMINE; TRANSMISSION; ELIMINATION; ERADICATION; COMBINATION; SULFADOXINE; ARTESUNATE AB Mass drug administration (MDA) was a component of many malaria programs during the eradication era, but later was seldomly deployed due to concerns regarding efficacy and feasibility and fear of accelerating drug resistance. Recently, however, there has been renewed interest in the role of MDA as an elimination tool. Following a 2013 Cochrane Review that focused on the quantitative effects of malaria MDA, we have conducted a systematic, qualitative review of published, unpublished, and gray literature documenting past MDA experiences. We have also consulted with field experts, using their historical experience to provide an informed, contextual perspective on the role of MDA in malaria elimination. Substantial knowledge gaps remain and more research is necessary, particularly on optimal target population size, methods to improve coverage, and primaquine safety. Despite these gaps, MDA has been used successfully to control and eliminate Plasmodium falciparum and P. vivax malaria in the past, and should be considered as part of a comprehensive malaria elimination strategy in specific settings. C1 [Hwang, Jimee] Univ Calif San Francisco, Malaria Eliminat Initiat, Global Hlth Grp, San Francisco, CA 94158 USA. Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Slutsker, Laurence M.; Kachur, S. Patrick] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. [Greenwood, Brian] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England. Mahidol Univ, Mahidol Oxford Trop Med Res Unit, Bangkok 10700, Thailand. [Shanks, G. Dennis] Australian Army Malaria Inst, Enoggera, Australia. [Ippolito, Matthew M.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Baltimore, MD 21205 USA. [Newby, Gretchen; Hwang, Jimee; Koita, Kadiatou; Chen, Ingrid; Wegbreit, Jennifer; Poirot, Eugenie; Gosling, Roly] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94158 USA. [Hwang, Jimee] Ctr Dis Control & Prevent, San Francisco, CA USA. RP Hwang, J (reprint author), Univ Calif San Francisco, Malaria Eliminat Initiat, Global Hlth Grp, 550 16th St,3rd Floor, San Francisco, CA 94158 USA. EM gretchen.newby@ucsf.edu; gdq1@cdc.gov; koitak@globalhealth.ucsf.edu; ingrid.chen@ucsf.edu; brian.greenwood@Ishtm.ac.uk; lorenz@tropmedres.ac; dennis.shanks@defence.gov.au; Ims5@cdc.gov; spk0@cdc.gov; jennifer.wegbreit@ucsf.edu; mippolito@jhu.edu; eugenie.poirot@ucsf.edu; roly.gosling@ucsf.edu FU Bill and Melinda Gates Foundation; U.S. President's Malaria Initiative FX This article derives from a background paper commissioned and funded by the Bill and Melinda Gates Foundation. Jimee Hwang receives salary support from the U.S. President's Malaria Initiative. NR 40 TC 21 Z9 22 U1 1 U2 9 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUL PY 2015 VL 93 IS 1 BP 125 EP 134 DI 10.4269/ajtmh.14-0254 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CM5YG UT WOS:000357764300023 PM 26013371 ER PT J AU Barbour, KE Lui, LY Nevitt, MC Murphy, LB Helmick, CG Theis, KA Hochberg, MC Lane, NE Hootman, JM Cauley, JA AF Barbour, Kamil E. Lui, Li-Yung Nevitt, Michael C. Murphy, Louise B. Helmick, Charles G. Theis, Kristina A. Hochberg, Marc C. Lane, Nancy E. Hootman, Jennifer M. Cauley, Jane A. CA Study Osteoporotic Fractures Res TI Hip Osteoarthritis and the Risk of All-Cause and Disease-Specific Mortality in Older Women: A Population-Based Cohort Study SO ARTHRITIS & RHEUMATOLOGY LA English DT Article ID CARDIOVASCULAR-DISEASE; OSTEOPOROTIC FRACTURES; RHEUMATIC CONDITIONS; COMPETING RISKS; UNITED-STATES; WHITE WOMEN; COMMUNITY; ARTHRITIS; SURVIVAL; ADULTS AB ObjectiveTo determine the risk of all-cause and disease-specific mortality among older women with hip osteoarthritis (OA) and to identify mediators in the causal pathway. MethodsData were from the Study of Osteoporotic Fractures, a US population-based cohort study of 9,704 white women age 65 years. The analytic sample included women with hip radiographs at baseline (n=7,889) and year 8 (n=5,749). Mortality was confirmed through October 2013 by death certificates and hospital discharge summaries. Radiographic hip OA (RHOA) was defined as a Croft grade of 2 in at least 1 hip (definite joint space narrowing or osteophytes plus 1 other radiographic feature). ResultsThe meanSD followup time was 16.1 +/- 6.2 years. The baseline and year 8 prevalence of RHOA were 8.0% and 11.0%, respectively. The cumulative incidence (proportion of deaths during the study period) was 67.7% for all-cause mortality, 26.3% for cardiovascular disease (CVD) mortality, 11.7% for cancer mortality, 1.9% for gastrointestinal disease mortality, and 27.8% for all other mortality causes. RHOA was associated with an increased risk of all-cause mortality (hazard ratio 1.14 [95% confidence interval 1.05-1.24]) and CVD mortality (hazard ratio 1.24 [95% confidence interval 1.09-1.41]) adjusted for age, body mass index, education, smoking, health status, diabetes, and stroke. These associations were partially explained by the mediating variable of physical function. ConclusionRHOA was associated with an increased risk of all-cause and CVD mortality among older white women followed up for 16 years. Dissemination of evidence-based physical activity and self-management interventions for hip OA in community and clinical settings can improve physical function and might also contribute to lower mortality. C1 [Barbour, Kamil E.; Murphy, Louise B.; Helmick, Charles G.; Theis, Kristina A.; Hootman, Jennifer M.] CDC, Atlanta, GA 30333 USA. [Lui, Li-Yung] Calif Pacific Med Ctr, San Francisco, CA USA. [Nevitt, Michael C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Hochberg, Marc C.] Univ Maryland, Sch Med, Baltimore, MD 21201 USA. [Lane, Nancy E.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA. [Cauley, Jane A.] Univ Pittsburgh, Pittsburgh, PA USA. RP Barbour, KE (reprint author), Ctr Dis Control & Prevent, Arthrit Program, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, MS F-78,4770 Buford Highway NE, Atlanta, GA 30341 USA. EM Iyk1@cdc.gov RI Cauley, Jane/N-4836-2015 OI Cauley, Jane/0000-0003-0752-4408 FU NIH (National Institute on Aging) [R01-AG-005407, R01-AR-35582, R01-AR-35583, R01-AR-35584, R01-AG-005394, R01-AG-027574, K24-AR-048841, AR-052000, P50-AR-060752] FX The Study of Osteoporotic Fractures is supported by the NIH (National Institute on Aging grants R01-AG-005407, R01-AR-35582, R01-AR-35583, R01-AR-35584, R01-AG-005394, R01-AG-027574, K24-AR-048841, AR-052000, and P50-AR-060752). NR 40 TC 17 Z9 18 U1 1 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2326-5191 EI 2326-5205 J9 ARTHRITIS RHEUMATOL JI Arthritis Rheumatol. PD JUL PY 2015 VL 67 IS 7 BP 1798 EP 1805 DI 10.1002/art.39113 PG 8 WC Rheumatology SC Rheumatology GA CL5QA UT WOS:000357013500015 PM 25778744 ER PT J AU Carver, S Mills, JN Parmenter, CA Parmenter, RR Richardson, KS Harris, RL Douglass, RJ Kuenzi, AJ Luis, AD AF Carver, Scott Mills, James N. Parmenter, Cheryl A. Parmenter, Robert R. Richardson, Kyle S. Harris, Rachel L. Douglass, Richard J. Kuenzi, Amy J. Luis, Angela D. TI Toward a Mechanistic Understanding of Environmentally Forced Zoonotic Disease Emergence: Sin Nombre Hantavirus SO BIOSCIENCE LA English DT Article DE human-reservoir interactions; Sin Nombre virus; hantavirus pulmonary syndrome; Peromyscus maniculatus; emerging infectious disease ID SOUTHWESTERN UNITED-STATES; MICE PEROMYSCUS-MANICULATUS; EMERGING INFECTIOUS-DISEASES; VIRUS-ANTIBODY PREVALENCE; DEER MICE; PULMONARY SYNDROME; POPULATION-DYNAMICS; PUUMALA VIRUS; GENETIC IDENTIFICATION; RESERVOIR POPULATIONS AB Understanding the environmental drivers of zoonotic reservoir and human interactions is crucial to understanding disease risk, but these drivers are poorly predicted. We propose a mechanistic understanding of human-reservoir interactions, using hantavirus pulmonary syndrome as a case study. Crucial processes underpinning the disease's incidence remain poorly studied, including the connectivity among natural and peridomestic deer mouse host activity, virus transmission, and human exposure. We found that disease cases were greatest in arid states and declined exponentially with increasing precipitation. Within arid environments, relatively rare climatic conditions (e.g., El Nino) are associated with increased rainfall and reservoir abundance, producing more frequent virus transmission and host dispersal. We suggest that deer mice increase their occupancy of peridomestic structures during spring-summer, amplifying intraspecific transmission and human infection risk. Disease incidence in arid states may increase with predicted climatic changes. Mechanistic approaches incorporating reservoir behavior, reservoir-human interactions, and pathogen spillover could enhance our understanding of global hantavirus ecology, with applications to other directly transmitted zoonoses. C1 [Carver, Scott; Harris, Rachel L.] Univ Tasmania, Sch Biol Sci, Hobart, Tas, Australia. [Mills, James N.] Ctr Dis Control & Prevent, Special Pathogens Branch, Div Viral & Rickettsial Dis, Atlanta, GA USA. [Mills, James N.] Emory Univ, Populat Biol Ecol & Evolut Grp, Atlanta, GA 30322 USA. [Parmenter, Cheryl A.] Univ New Mexico, Dept Biol, Museum Southwestern Biol, Albuquerque, NM 87131 USA. [Parmenter, Robert R.] Natl Pk Serv, Dept Interior, Jemez Springs, NM USA. [Richardson, Kyle S.] Massey Univ, Hopkirk Res Inst, Palmerston North, New Zealand. [Carver, Scott; Richardson, Kyle S.; Douglass, Richard J.; Kuenzi, Amy J.] Univ Montana, Montana Tech, Dept Biol, Butte, MT USA. [Luis, Angela D.] Univ Montana, Coll Forestry & Conservat, Missoula, MT 59812 USA. RP Carver, S (reprint author), Univ Tasmania, Sch Biol Sci, Hobart, Tas, Australia. EM scott.carver@utas.edu.au RI Carver, Scott/J-7654-2014 OI Carver, Scott/0000-0002-3579-7588 FU National Center for Research Resources [5P20RR016455-11]; National Institute of General Medical Sciences from National Institutes of Health [8 P20 GM103474-11]; US Centers for Disease Control and Prevention, in Atlanta, Georgia; Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate (US Department of Homeland Security); Fogarty International Center (National Institutes of Health); Sevilleta LTER Program (NSF) [DEB 9411976, DEB 0080529]; National Institutes of Health (DHHSPHS/NIAID) [PO1 A1 39780-02]; Federal Centers for Disease Control and Prevention (CDC) [U50/CCU613416] FX This project was supported by grants from the National Center for Research Resources (no. 5P20RR016455-11), the National Institute of General Medical Sciences (no. 8 P20 GM103474-11) from the National Institutes of Health, and the US Centers for Disease Control and Prevention, in Atlanta, Georgia, through cooperative agreement. AL is additionally supported by the Research and Policy for Infectious Disease Dynamics (RAPIDD) program of the Science and Technology Directorate (US Department of Homeland Security) and the Fogarty International Center (National Institutes of Health). Funding for the original New Mexico field data collection was provided by the Sevilleta LTER Program (NSF DEB 9411976 and DEB 0080529), the National Institutes of Health (DHHSPHS/NIAID PO1 A1 39780-02), and the Federal Centers for Disease Control and Prevention (CDC U50/CCU613416). The findings and conclusions presented here are those of the authors and do not necessarily represent the views of the funding agencies. We also acknowledge the anonymous reviewers who provided helpful comments on the current and earlier versions of the manuscript. NR 68 TC 2 Z9 2 U1 8 U2 36 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0006-3568 EI 1525-3244 J9 BIOSCIENCE JI Bioscience PD JUL PY 2015 VL 65 IS 7 BP 651 EP 666 DI 10.1093/biosci/biv047 PG 16 WC Biology SC Life Sciences & Biomedicine - Other Topics GA CM7BO UT WOS:000357845600006 PM 26955081 ER PT J AU Mirabelli, MC Golan, R Greenwald, R Raysoni, AU Holguin, F Kewada, P Winquist, A Flanders, WD Sarnat, JA AF Mirabelli, Maria C. Golan, Rachel Greenwald, Roby Raysoni, Amit U. Holguin, Fernando Kewada, Priya Winquist, Andrea Flanders, W. Dana Sarnat, Jeremy A. TI Modification of Traffic-related Respiratory Response by Asthma Control in a Population of Car Commuters SO EPIDEMIOLOGY LA English DT Article ID AIR-POLLUTION; EXPOSURE; QUESTIONNAIRE; INFLAMMATION; POLLUTANTS; UPDATE AB Background: Effects of traffic-related exposures on respiratory health are well documented, but little information is available about whether asthma control influences individual susceptibility. We analyzed data from the Atlanta Commuter Exposure study to evaluate modification of associations between rush-hour commuting, in- vehicle air pollution, and selected respiratory health outcomes by asthma control status. Methods: Between 2009 and 2011, 39 adults participated in Atlanta Commuter Exposure, and each conducted two scripted rush-hour highway commutes. In-vehicle particulate components were measured during all commutes. Among adults with asthma, we evaluated asthma control by questionnaire and spirometry. Exhaled nitric oxide, forced expiratory volume in 1 second (FEV1), and other metrics of respiratory health were measured precommute and 0, 1, 2, and 3 hours postcommute. We used mixed effects linear regression to evaluate associations between commute-related exposures and postcommute changes in metrics of respiratory health by level of asthma control. Results: We observed increased exhaled nitric oxide across all levels of asthma control compared with precommute measurements, with largest postcommute increases observed among participants with below-median asthma control (2 hours postcommute: 14.6% [95% confidence interval {CI} = 5.7, 24.2]; 3 hours postcommute: 19.5% [95% CI = 7.8, 32.5]). No associations between in-vehicle pollutants and percent of predicted FEV1 were observed, although higher PM2.5 was associated with lower FEV1 % predicted among participants with below-median asthma control (3 hours postcommute: -7.2 [95% CI = -11.8, -2.7]). Conclusions: Level of asthma control may influence respiratory response to in-vehicle exposures experienced during rush-hour commuting. C1 [Mirabelli, Maria C.] Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Atlanta, GA 30341 USA. [Flanders, W. Dana] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [Golan, Rachel; Greenwald, Roby; Raysoni, Amit U.; Kewada, Priya; Winquist, Andrea; Sarnat, Jeremy A.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA. [Holguin, Fernando] Univ Pittsburgh, Dept Med, Div Pulm Allergy & Crit Care, Pittsburgh, PA USA. RP Mirabelli, MC (reprint author), Ctr Dis Control & Prevent, Air Pollut & Resp Hlth Branch, Natl Ctr Environm Hlth, 4770 Buford Hwy NE,Bldg 106, Atlanta, GA 30341 USA. EM zif7@cdc.gov FU Air Pollution and Respiratory Health Branch of the National Center for Environmental Health, Centers for Disease Control and Prevention; Environment and Health Fund, Jerusalem, Israel FX The Atlanta Commuter Exposure (ACE-1) study received funding from the Air Pollution and Respiratory Health Branch of the National Center for Environmental Health, Centers for Disease Control and Prevention. R Golan gratefully acknowledges support by a post-doctoral fellowship from the Environment and Health Fund, Jerusalem, Israel. NR 23 TC 4 Z9 4 U1 3 U2 16 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1044-3983 EI 1531-5487 J9 EPIDEMIOLOGY JI Epidemiology PD JUL PY 2015 VL 26 IS 4 BP 546 EP 555 DI 10.1097/EDE.0000000000000296 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL7YR UT WOS:000357189400015 PM 25901844 ER PT J AU Olmstead, AD Joy, JB Montoya, V Luo, I Poon, AFY Jacka, B Lamoury, F Applegate, T Montaner, J Khudyakov, Y Grebely, J Cook, D Harrigan, PR Krajden, M AF Olmstead, Andrea D. Joy, Jeffrey B. Montoya, Vincent Luo, Iris Poon, Art F. Y. Jacka, Brendan Lamoury, Francois Applegate, Tanya Montaner, Julio Khudyakov, Yury Grebely, Jason Cook, Darrel Harrigan, P. Richard Krajden, Mel TI A molecular phylogenetics-based approach for identifying recent hepatitis C virus transmission events SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Hepatitis C virus; Recent transmission clusters; British Columbia; Epidemiology; Sequencing; Phylogenetics; Surveillance; Seroconversion ID INJECT DRUGS; IATROGENIC TRANSMISSION; SEQUENCE EVOLUTION; CHRONIC INFECTION; HIV TRANSMISSION; UNITED-STATES; EPIDEMIOLOGY; HCV; OUTBREAK; COHORT AB Improved surveillance methods are needed to better understand the current hepatitis C virus (HCV) disease burden and to monitor the impact of prevention and treatment interventions on HCV transmission dynamics. Sanger sequencing (HCV NS5B, HVR1 and Core-E1-HVR1) and phylogenetics were applied to samples from individuals diagnosed with HCV in British Columbia, Canada in 2011. This included individuals with two or three sequential samples collected <1 year apart. Patristic distances between sequential samples were used to set cutoffs to identify recent transmission clusters. Factors associated with transmission clustering were analyzed using logistic regression. From 618 individuals, 646 sequences were obtained. Depending on the cutoff used, 63 (10%) to 92 (15%) unique individuals were identified within transmission clusters of predicted recent origin. Clustered individuals were more likely to be <40 years old (Adjusted Odds Ratio (AOR) 2.12, 95% CI 1.21-3.73), infected with genotype la (AOR 6.60, 95% CI 1.98-41.0), and to be seroconverters with estimated infection duration of <1 year (AOR 3.13, 95% CI 1.29-7.36) or >1 year (AOR 2.19, 95% CI1.22-3.97). Conclusion: Systematic application of molecular phylogenetics may be used to enhance traditional surveillance methods through identification of recent transmission clusters. (C) 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). C1 [Olmstead, Andrea D.; Montoya, Vincent; Cook, Darrel; Krajden, Mel] BC Ctr Dis Control, Vancouver, BC, Canada. [Olmstead, Andrea D.; Montoya, Vincent; Luo, Iris; Montaner, Julio; Krajden, Mel] Univ British Columbia, Vancouver, BC V5Z 4R4, Canada. [Joy, Jeffrey B.; Poon, Art F. Y.; Montaner, Julio; Harrigan, P. Richard] St Pauls Hosp, BC Ctr Excellence HIV AIDS, Vancouver, BC V6Z 1Y6, Canada. [Jacka, Brendan; Lamoury, Francois; Applegate, Tanya; Grebely, Jason] UNSW Australia, Kirby Inst, Sydney, NSW, Australia. [Khudyakov, Yury] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Olmstead, AD (reprint author), Univ British Columbia, BC Ctr Dis Control, Dept Pathol, 2155-655 12th Ave, Vancouver, BC V5Z 4R4, Canada. EM andrea.olmstead@bccdc.ca OI Poon, Art/0000-0003-3779-154X; Jacka, Brendan/0000-0002-5910-853X FU Canadian Institutes for Health Research (CIHR) [HES115697]; National Canadian Research Training Program in Hepatitis C (NCRTP-HepC) FX This work was supported by the Canadian Institutes for Health Research (CIHR) [Grant No. HES115697] and by the National Canadian Research Training Program in Hepatitis C (NCRTP-HepC) [ADO]. NR 61 TC 6 Z9 6 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD JUL PY 2015 VL 33 BP 101 EP 109 DI 10.1016/j.meegid.2015.04.017 PG 9 WC Infectious Diseases SC Infectious Diseases GA CM1JX UT WOS:000357438300014 PM 25917496 ER PT J AU Morris, U Xu, WP Msellem, MI Schwartz, A Abass, A Shakely, D Cook, J Bhattarai, A Petzold, M Greenhouse, B Ali, AS Bjorkman, A Froberg, G Martensson, A AF Morris, Ulrika Xu, Weiping Msellem, Mwinyi I. Schwartz, Alanna Abass, Ali Shakely, Deler Cook, Jackie Bhattarai, Achuyt Petzold, Max Greenhouse, Bryan Ali, Abdullah S. Bjorkman, Anders Froberg, Gabrielle Martensson, Andreas TI Characterising temporal trends in asymptomatic Plasmodium infections and transporter polymorphisms during transition from high to low transmission in Zanzibar, 2005-2013 SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Asymptomatic; Plasmodium; Low transmission; Molecular surveillance; Antimalarial drug resistance markers ID POLYMERASE-CHAIN-REACTION; FALCIPARUM DRUG-RESISTANCE; MALARIA PARASITE CARRIAGE; RAPID DIAGNOSTIC-TESTS; MOLECULAR SURVEILLANCE; IN-VITRO; ARTEMETHER-LUMEFANTRINE; ARTESUNATE-AMODIAQUINE; COMBINATION THERAPY; PFMDR1 GENES AB Background: Improved understanding of the asymptomatic malaria parasite reservoir is a prerequisite to pursue malaria elimination efforts. We therefore characterised temporal trends and transporter polymorphisms in asymptomatic Plasmodium infections during the transition from high to low transmission in Zanzibar. Methods: Healthy individuals participating in cross-sectional surveys conducted 2005-2013 were screened for asymptomatic malaria by PCR. Complexity/diversity of infection and transporter polymorphisms were assessed in Plasmodium falciparum positive samples. Symptomatic samples were included for comparison of polymorphisms in 2013. Results: PCR-determined parasite prevalence declined from 21.1% (CI95% 17.4-24.9) to 2.3% (CI95% 1.7-2.9) from 2005 to 2013. P. falciparum remained the predominant species; prevalence was highest in children and young adults aged 5-25 years. Parasite densities and complexity of infection, but not population genetic diversity of P. falciparum, decreased from 2005-2009. pfcrt 761 (99.2-64.7%, p < 0.001) and pfmdr1 86Y frequencies (89.4-66.7%, p = 0.03) decreased over time. Pfmdr1 (a.a.86,184,1246) YYY and YYD haplotypes were more frequent in asymptomatic than symptomatic infections in 2013 (p < 0.001). Conclusions: There is a declining, albeit persistent, reservoir of parasites present at low-densities in asymptomatic individuals in Zanzibar. This study revealed important characteristics of the remaining parasite population, including intriguing temporal trends in molecular markers associated with antimalarial resistance, which need to be further investigated. (C) 2015 Elsevier B.V. All rights reserved. C1 [Morris, Ulrika; Xu, Weiping; Shakely, Deler; Cook, Jackie; Bjorkman, Anders; Martensson, Andreas] Karolinska Inst, Malaria Res, Dept Microbiol Tumor & Cell Biol, S-17177 Stockholm, Sweden. [Msellem, Mwinyi I.; Abass, Ali; Cook, Jackie; Ali, Abdullah S.] Minist Hlth, Zanzibar Malaria Eliminat Programme ZAMEP, Zanzibar, Tanzania. [Schwartz, Alanna; Greenhouse, Bryan] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shakely, Deler] Kungalv Hosp, Dept Med, Kungalv, Sweden. [Bhattarai, Achuyt] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Petzold, Max] Univ Gothenburg, Sahlgrenska Acad, Hlth Metr, Gothenburg, Sweden. [Petzold, Max] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg 2050, South Africa. [Froberg, Gabrielle] Karolinska Inst, Dept Med, S-17177 Stockholm, Sweden. [Martensson, Andreas] Karolinska Inst, Dept Publ Hlth Sci, S-17177 Stockholm, Sweden. [Martensson, Andreas] Uppsala Univ, Ctr Clin Res Sormland, Uppsala, Sweden. RP Morris, U (reprint author), Karolinska Inst, Nobelsvag 16, S-17177 Stockholm, Sweden. EM ulrika.morris@ki.se OI Greenhouse, Bryan/0000-0003-0287-9111; Morris, Ulrika/0000-0003-4734-5754 FU Swedish Civil Contingencies Agency (MSB) [2010-7991]; Swedish Medical Research Council (VR) [2009-3785, 2013-6594]; Goljes Foundation FX We would like to thank all participants, staff members, and ZAMEP employees involved in the cross-sectional surveys for their dedicated participation. This work was supported by the Swedish Civil Contingencies Agency (MSB) [Grant number 2010-7991], the Swedish Medical Research Council (VR) [Grant numbers 2009-3785 and 2013-6594], and Goljes Foundation. In memoriam of Ali K. Abass, a much missed friend and colleague. NR 54 TC 3 Z9 3 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD JUL PY 2015 VL 33 BP 110 EP 117 DI 10.1016/j.meegid.2015.04.018 PG 8 WC Infectious Diseases SC Infectious Diseases GA CM1JX UT WOS:000357438300015 PM 25917493 ER PT J AU Gautam, R Mijatovic-Rustempasic, S Roy, S Esona, MD Lopez, B Mencos, Y Rey-Benito, G Bowen, MD AF Gautam, Rashi Mijatovic-Rustempasic, Slavica Roy, Sunando Esona, Mathew D. Lopez, Beatriz Mencos, Yolanda Rey-Benito, Gloria Bowen, Michael D. TI Full genomic characterization and phylogenetic analysis of a zoonotic human G8P[14] rotavirus strain detected in a sample from Guatemala SO INFECTION GENETICS AND EVOLUTION LA English DT Article DE Rotavirus; G8P[14]; Reassortant; Interspecies transmission ID GROUP-A ROTAVIRUS; POLYMERASE-CHAIN-REACTION; MOLECULAR CHARACTERIZATION; INTERSPECIES TRANSMISSION; VP7 GENES; BOVINE; CHILD; GASTROENTERITIS; IDENTIFICATION; REASSORTMENT AB We report the genomic characterization of a rare human G8P[14] rotavirus strain, identified in a stool sample from Guatemala (GTM) during routine rotavirus surveillance. This strain was designated as RV A/Human-wt/GTM/2009726790/2009/G8P[14], with a genomic constellation of G8-P[14]-I2-R2-C2-M2-A13-N2-T6-E2-H3. The VP4 gene occupied lineage VII within the P[14] genotype. Phylogenetic analysis of each genome segment revealed close relatedness to several zoonotic simian, guanaco and bovine strains. Our findings suggest that strain RVA/Human-wt/GTM/2009726790/2009/G8P[14] is an example of a direct zoonotic transmission event. The results of this study reinforce the potential role of interspecies transmission and reassortment in generating novel and rare rotavirus strains which infect humans. (C) 2015 Elsevier B.V. All rights reserved. C1 [Gautam, Rashi; Mijatovic-Rustempasic, Slavica; Roy, Sunando; Esona, Mathew D.; Bowen, Michael D.] Ctr Dis Control & Prevent, Div Viral Dis, Gastroenteritis & Resp Viruses Lab Branch, Atlanta, GA USA. [Lopez, Beatriz] Univ Valle Guatemala, Ctr Hlth Studies, Guatemala City, Guatemala. [Mencos, Yolanda] Lab Nacl Salud, Guatemala City, Guatemala. [Rey-Benito, Gloria] Pan Amer Hlth Org, Washington, DC USA. RP Gautam, R (reprint author), 1600 Clifton Rd NE,Mail Stop G04, Clifton Road, NE 1600 USA. EM ijs0@cdc.gov OI Lopez, Beatriz/0000-0003-1353-9948 NR 37 TC 8 Z9 8 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1567-1348 EI 1567-7257 J9 INFECT GENET EVOL JI Infect. Genet. Evol. PD JUL PY 2015 VL 33 BP 206 EP 211 DI 10.1016/j.meegid.2015.05.004 PG 6 WC Infectious Diseases SC Infectious Diseases GA CM1JX UT WOS:000357438300028 PM 25952569 ER PT J AU Wyld, MLR Lee, CMY Zhuo, X White, S Shaw, JE Morton, RL Colagiuri, S Chadban, SJ AF Wyld, M. L. R. Lee, C. M. Y. Zhuo, X. White, S. Shaw, J. E. Morton, R. L. Colagiuri, S. Chadban, S. J. TI Cost to government and society of chronic kidney disease stage 1-5: a national cohort study SO INTERNAL MEDICINE JOURNAL LA English DT Article DE chronic kidney disease; expenditure; health economics; Australia ID LIFE-STYLE; AUSTRALIA; OBESITY; ADULTS; POPULATION; AUSDIAB AB BackgroundCosts associated with chronic kidney disease (CKD) are not well documented. Understanding such costs is important to inform economic evaluations of prevention strategies and treatment options. AimTo estimate the costs associated with CKD in Australia. MethodsWe used data from the 2004/2005 AusDiab study, a national longitudinal population-based study of non-institutionalised Australian adults aged 25 years. We included 6138 participants with CKD, diabetes and healthcare cost data. The annual age and sex-adjusted costs per person were estimated using a generalised linear model. Costs were inflated from 2005 to 2012 Australian dollars using best practice methods. ResultsAmong 6138 study participants, there was a significant difference in the per-person annual direct healthcare costs by CKD status, increasing from $1829 (95% confidence interval (CI): $1740-1943) for those without CKD to $14545 (95% CI: $5680-44842) for those with stage 4 or 5 CKD (P < 0.01). Similarly, there was a significant difference in the per-person annual direct non-healthcare costs by CKD status from $524 (95% CI: $413-641) for those without CKD to $2349 (95% CI: $386-5156) for those with stage 4 or 5 CKD (P < 0.01). Diabetes is a common cause of CKD and is associated with increased health costs. Costs per person were higher for those with diabetes than those without diabetes in all CKD groups; however, this was significant only for those without CKD and those with early stage (stage 1 or 2) CKD. ConclusionIndividuals with CKD incur 85% higher healthcare costs and 50% higher government subsidies than individuals without CKD, and costs increase by CKD stage. Primary and secondary prevention strategies may reduce costs and warrant further consideration. C1 [Wyld, M. L. R.; White, S.; Morton, R. L.; Chadban, S. J.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia. [Lee, C. M. Y.; Colagiuri, S.] Univ Sydney, Boden Inst Obes Nutr Exercise & Eating Disorders, Sydney, NSW 2006, Australia. [Wyld, M. L. R.; White, S.; Chadban, S. J.] Royal Prince Alfred Hosp, Sydney, NSW, Australia. [Shaw, J. E.] Baker IDI Heart & Diabet Inst, Melbourne, Vic, Australia. [Zhuo, X.] CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Morton, R. L.] Univ Oxford, Nuffield Dept Populat Hlth, Hlth Econ Res Ctr, Oxford, England. RP Wyld, MLR (reprint author), Univ Sydney, Charles Perkins Ctr, Sydney Med Sch, 2W65, Sydney, NSW 2006, Australia. EM melwyld@gmail.com OI Lee, Crystal/0000-0001-6613-5491 FU NHMRC; National Health and Medical Research Council (NHMRC), Australian Government Department of Health and Ageing [233200]; Abbott Australasia Pty Ltd; Alphapharm Pty Ltd; AstraZeneca; Bristol-Myers Squibb; City Health Centre-Diabetes Service-Canberra; Department of Health and Community Services - Northern Territory; Department of Health and Human Services - Tasmania; Department of Health - New South Wales; Department of Health - Western Australia; Department of Health - South Australia; Department of Human Services - Victoria; Diabetes Australia; Diabetes Australia Northern Territory; Eli Lilly Australia; Estate of the Late Edward Wilson; GlaxoSmithKline; Jack Brockhoff Foundation; Janssen-Cilag; Kidney Health Australia; Marian FH Flack Trust; Menzies Research Institute; Merck Sharp Dohme; Novartis Pharmaceuticals; Novo Nordisk Pharmaceuticals; Pfizer Pty Ltd; Pratt Foundation; Queensland Health; Roche Diagnostics Australia; Royal Prince Alfred Hospital, Sydney; Sanofi Aventis; Sanofi Synthelabo; Victorian Government's OIS Program FX M. L. R. Wyld is supported by a NHMRC Postgraduate Scholarship. C. M. Y. Lee is supported by the NHMRC training fellowship. J. E. Shaw is supported by a NHMRC senior research fellowship. R. L. Morton is supported by a NHMRC Sidney Sax Overseas Public Health Research Fellowship. The AusDiab study co-coordinated by the Baker IDI Heart and Diabetes Institute gratefully acknowledges the generous support given by: National Health and Medical Research Council (NHMRC grant 233200), Australian Government Department of Health and Ageing. Abbott Australasia Pty Ltd, Alphapharm Pty Ltd, AstraZeneca, Bristol-Myers Squibb, City Health Centre-Diabetes Service-Canberra, Department of Health and Community Services - Northern Territory, Department of Health and Human Services - Tasmania, Department of Health - New South Wales, Department of Health - Western Australia, Department of Health - South Australia, Department of Human Services - Victoria, Diabetes Australia, Diabetes Australia Northern Territory, Eli Lilly Australia, Estate of the Late Edward Wilson, GlaxoSmithKline, Jack Brockhoff Foundation, Janssen-Cilag, Kidney Health Australia, Marian & FH Flack Trust, Menzies Research Institute, Merck Sharp & Dohme, Novartis Pharmaceuticals, Novo Nordisk Pharmaceuticals, Pfizer Pty Ltd, Pratt Foundation, Queensland Health, Roche Diagnostics Australia, Royal Prince Alfred Hospital, Sydney, Sanofi Aventis, Sanofi Synthelabo and the Victorian Government's OIS Program. NR 23 TC 3 Z9 3 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1444-0903 EI 1445-5994 J9 INTERN MED J JI Intern. Med. J. PD JUL PY 2015 VL 45 IS 7 BP 741 EP 747 DI 10.1111/imj.12797 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA CM1HP UT WOS:000357432200009 PM 25944415 ER PT J AU Coleman, EW AF Coleman, Erik W. TI Equipping Environmental Health Workers With Environmental Assessment Tools SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article AB Editor's Note: NEHA strives to provide up-to-date and relevant information on environmental health and to build partnerships in the profession. In pursuit of these goals, we feature a column from the Environmental Health Services Branch (EHSB) of the Centers for Disease Control and Prevention (CDC) in every issue of the Journal. In this column, EHSB and guest authors from across CDC will highlight a variety of concerns, opportunities, challenges, and successes that we all share in environmental public health. EHSB's objective is to strengthen the role of state, local, tribal, and national environmental health programs and professionals to anticipate, identify, and respond to adverse environmental exposures and the consequences of these exposures for human health. The conclusions in this article are those of the author(s) and do not necessarily represent the views of CDC. Erik W. Coleman is a health scientist (informatics) in EHSB's Division of Emergency and Environmental Health Services at the National Center for Environmental Health. RP Coleman, EW (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Emergency & Environm Hlth Serv, 4770 Buford Highway NE,MS F-58, Atlanta, GA 30341 USA. EM HYE1@cdc.gov FU Intramural CDC HHS [CC999999] NR 2 TC 0 Z9 0 U1 0 U2 1 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD JUL-AUG PY 2015 VL 78 IS 1 BP 36 EP 38 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CM3BO UT WOS:000357556900007 PM 26427267 ER PT J AU Eatman, S AF Eatman, Shana TI A Millennial's Take on CDC's Environmental Public Health Tracking Network SO JOURNAL OF ENVIRONMENTAL HEALTH LA English DT Article AB Editor's Note: As part of our continuing effort to highlight innovative approaches and tools to improve the health and environment of communities, the Journal is pleased to publish a bimonthly column from the Centers for Disease Control and Prevention's (CDC's) Environmental Public Health Tracking Network (Tracking Network). The Tracking Network is a system of integrated health, exposure, and hazard information and data from a variety of national, state, and city sources. The Tracking Network brings together data concerning health and environmental problems with the goal of providing information to help improve where we live, work, and play. Environmental causes of chronic diseases are hard to identify. Measuring amounts of hazardous substances in our environment in a standard way, tracing the spread of these over time and area, seeing how they show up in human tissues, and understanding how they may cause illness is critical. The Tracking Network is a tool that can help connect these efforts. Through these columns, readers will learn about the program and the resources, tools, and information available from CDC's Tracking Network. The conclusions of this article are those of the author(s) and do not necessarily represent the views of CDC. Shana Eatman is a project officer in the Environmental Public Health Tracking Program of CDC's Environmental Health Services Branch. C1 [Eatman, Shana] CDC, Environm Publ Hlth Tracking Program, Environm Hlth Serv Branch, Chamblee, GA 30341 USA. RP Eatman, S (reprint author), CDC, Natl Ctr Environm Hlth, Environm Publ Hlth Tracking Program, Environm Hlth Tracking Branch,Div Environm Hazard, 4770 Buford Highway NE,MS 60, Chamblee, GA 30341 USA. EM seatman@cdc.gov NR 7 TC 0 Z9 0 U1 1 U2 2 PU NATL ENVIRON HEALTH ASSOC PI DENVER PA 720 S COLORADO BLVD SUITE 970, SOUTH TOWER, DENVER, CO 80246 USA SN 0022-0892 J9 J ENVIRON HEALTH JI J. Environ. Health PD JUL-AUG PY 2015 VL 78 IS 1 BP 40 EP 43 PG 4 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CM3BO UT WOS:000357556900008 PM 26427268 ER PT J AU Bailey, LB Stover, PJ McNulty, H Fenech, MF Gregory, JF Mills, JL Pfeiffer, CM Fazili, Z Zhang, M Ueland, PM Molloy, AM Caudill, MA Shane, B Berry, RJ Bailey, RL Hausman, DB Raghavan, R Raiten, DJ AF Bailey, Lynn B. Stover, Patrick J. McNulty, Helene Fenech, Michael F. Gregory, Jesse F., III Mills, James L. Pfeiffer, Christine M. Fazili, Zia Zhang, Mindy Ueland, Per M. Molloy, Anne M. Caudill, Marie A. Shane, Barry Berry, Robert J. Bailey, Regan L. Hausman, Dorothy B. Raghavan, Ramkripa Raiten, Daniel J. TI Biomarkers of Nutrition for Development-Folate Review SO JOURNAL OF NUTRITION LA English DT Review DE BOND; folate biomarkers; serum folate; RBC folate; homocysteine ID NEURAL-TUBE DEFECTS; ONE-CARBON METABOLISM; TANDEM MASS-SPECTROMETRY; FOLIC-ACID SUPPLEMENTATION; PLASMA TOTAL HOMOCYSTEINE; METHYLENETETRAHYDROFOLATE-REDUCTASE GENE; PERFORMANCE LIQUID-CHROMATOGRAPHY; PERIPHERAL-BLOOD LYMPHOCYTES; GLOBAL DNA HYPOMETHYLATION; B-VITAMIN STATUS AB The Biomarkers of Nutrition for Development (BOND) project is designed to provide evidence-based advice to anyone with an interest in the role of nutrition in health. Specifically, the BOND program provides state-of-the-art information and service with regard to selection, use, and interpretation of biomarkers of nutrient exposure, status, function, and effect. To accomplish this objective, expert panels are recruited to evaluate the literature and to draft comprehensive reports on the current state of the art with regard to specific nutrient biology and available biomarkers for assessing nutrients in body tissues at the individual and population level. Phase I of the BOND project includes the evaluation of biomarkers for 6 nutrients: iodine, iron, zinc, folate, vitamin A, and vitamin B-12. This review represents the second in the series of reviews and covers all relevant aspects of folate biology and biomarkers. The article is organized to provide the reader with a full appreciation of folate's history as a public health issue, its biology, and an overview of available biomarkers (serum folate, RBC folate, and plasma homocysteine concentrations) and their interpretation across a range of clinical and population-based uses. The article also includes a list of priority research needs for advancing the area of folate biomarkers related to nutritional health status and development. C1 [Bailey, Lynn B.; Hausman, Dorothy B.] Univ Georgia, Dept Foods & Nutr, Athens, GA 30602 USA. [Stover, Patrick J.; Caudill, Marie A.] Cornell Univ, Div Nutr Sci, Ithaca, NY 14853 USA. [McNulty, Helene] Univ Ulster, Northern Ireland Ctr Food & Hlth, Biomed Sci Res Inst, Londonderry, NH USA. [Fenech, Michael F.] CSIRO, Genome Hlth Nutrigen Lab, Food Nutr & Bioprod Flagship, Adelaide, SA, Australia. [Gregory, Jesse F., III] Univ Florida, Food Sci & Human Nutr Dept, Gainesville, FL USA. [Mills, James L.; Raghavan, Ramkripa; Raiten, Daniel J.] Eunice Kennedy Shriner Natl Inst Child Hlth & Hum, NIH, Bethesda, MD USA. [Pfeiffer, Christine M.; Fazili, Zia; Zhang, Mindy] CDC, Nat Ctr Environm Hlth, Atlanta, GA 30333 USA. [Ueland, Per M.] Univ Bergen, Dept Clin Sci, Bergen, Norway. [Molloy, Anne M.] Trinity Coll Dublin, Inst Mol Med, Dublin, Ireland. [Shane, Barry] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA. [Berry, Robert J.] CDC, Nat Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Bailey, Regan L.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. RP Bailey, LB (reprint author), Univ Georgia, Dept Foods & Nutr, Athens, GA 30602 USA. EM folate@uga.edu; raitend@mail.nih.gov RI Ueland, Per/C-7340-2013; OI Molloy, Anne/0000-0002-1688-9049; Berry, Robert/0000-0002-7162-5046 FU Bill & Melinda Gates Foundation; PepsiCo; Division of Nutrition Research Coordination (DNRC, NIH); Office of Dietary Supplements (ODS, NIH); Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, NIH) FX Published in a supplement to The Journal of Nutrition. The Biomarkers of Nutrition for Development (BOND) project was developed by the nutrition program staff of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the NIH within the US Department of Health and Human Services (DHHS). The initial 6 nutrients selected, iodine, vitamin A, iron, zinc, folate, and vitamin B-12, were chosen for their high public health importance. Expert panels on each nutrient were constituted and charged with developing comprehensive reviews for publication in the BOND series. The BOND program received its core funding from the Bill & Melinda Gates Foundation, PepsiCo, the Division of Nutrition Research Coordination (DNRC, NIH), the Office of Dietary Supplements (ODS, NIH), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, NIH). The Supplement Coordinators for this supplement were Daniel J Raiten (NICHD, NIH) and Lynn B Bailey (University of Georgia). Supplement Coordinators disclosures: no conflicts of interest. This supplement is the responsibility of the Guest Editor to whom the Editor of The Journal of Nutrition has delegated supervision of both technical conformity to the published regulations of The Journal of Nutrition and general oversight of the scientific merit of each article. The Guest Editor for this supplement was Kevin L Schalinske. Guest Editor disclosure: no conflicts of interest. Publication costs for this supplement were defrayed in part by the payment of page charges. This publication must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors or the publisher, Editor, or Editorial Board of The Journal of Nutrition. NR 445 TC 20 Z9 21 U1 6 U2 28 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD JUL PY 2015 VL 145 IS 7 BP 1636 EP 1680 DI 10.3945/jn.114.206599 PG 45 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CM1FE UT WOS:000357425600035 PM 26451605 ER PT J AU Williams, DJ Edwards, KM Self, WH Zhu, YW Ampofo, K Pavia, AT Hersh, AL Arnold, SR McCullers, JA Hicks, LA Bramley, AM Jain, S Grijalva, CG AF Williams, Derek J. Edwards, Kathryn M. Self, Wesley H. Zhu, Yuwei Ampofo, Krow Pavia, Andrew T. Hersh, Adam L. Arnold, Sandra R. McCullers, Jonathan A. Hicks, Lauri A. Bramley, Anna M. Jain, Seema Grijalva, Carlos G. TI Antibiotic Choice for Children Hospitalized With Pneumonia and Adherence to National Guidelines SO PEDIATRICS LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; INFECTIOUS-DISEASES-SOCIETY; NONSUSCEPTIBLE STREPTOCOCCUS-PNEUMONIAE; PENICILLIN SUSCEPTIBILITY BREAKPOINTS; CLINICAL-PRACTICE GUIDELINES; INTERRUPTED TIME-SERIES; QUALITY IMPROVEMENT; UNITED-STATES; MANAGEMENT; ETIOLOGY AB INTRODUCTION: The 2011 national guidelines for the management of childhood community-acquired pneumonia (CAP) recommended narrow-spectrum antibiotics (eg, ampicillin) for most children hospitalized with CAP. We assessed the impact of these guidelines on antibiotic prescribing at 3 children's hospitals. METHODS: Children hospitalized with clinical and radiographic CAP were enrolled from January 1, 2010, through June 30, 2012, at 3 hospitals in Tennessee and Utah as part of the Centers for Disease Control and Prevention Etiology of Pneumonia in the Community study. Antibiotic selection was determined by the treating provider. The impact of the guidelines and hospital-level implementation efforts was determined by assessing the monthly percentage of enrolled children receiving third-generation cephalosporins or penicillin/ampicillin. Segmented linear regression was used to compare observed antibiotic selection in the postguideline period with expected antibiotic use projected from preguideline months. RESULTS: Overall, 2121 children were included. During the preguideline period, 52.8% (interquartile range 47.8-56.6) of children with CAP received third-generation cephalosporins, whereas 2.7% (2.1, 7.0) received penicillin/ampicillin. By 9 months postguidelines, third-generation cephalosporin use declined (absolute difference -12.4% [95% confidence interval -19.8% to -5.1%]), whereas penicillin/ampicillin use increased (absolute difference 11.3% [4.3%-18.3%]). The most substantial changes were noted at those institutions that implemented guideline-related dissemination activities. CONCLUSIONS: After publication of national guidelines, third-generation cephalosporin use declined and penicillin/ampicillin use increased among children hospitalized with CAP. Changes were more apparent among those institutions that proactively disseminated the guidelines, suggesting that targeted, hospital-based efforts are important for timely implementation of guideline recommendations. C1 [Williams, Derek J.] Vanderbilt Univ, Sch Med, Vanderbilt Vaccine Res Program, Monroe Carell Jr Childrens Hosp,Div Hosp Med, Nashville, TN 37212 USA. [Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Vanderbilt Vaccine Res Program, Monroe Carell Jr Childrens Hosp,Div Infect Med, Nashville, TN 37212 USA. [Williams, Derek J.; Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Vanderbilt Vaccine Res Program, Dept Pediat, Nashville, TN 37212 USA. [Self, Wesley H.] Vanderbilt Univ, Sch Med, Dept Emergency Med, Nashville, TN 37212 USA. [Zhu, Yuwei] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37212 USA. [Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37212 USA. [Ampofo, Krow; Pavia, Andrew T.; Hersh, Adam L.] Univ Utah, Sch Med, Div Infect Dis, Salt Lake City, UT USA. [Ampofo, Krow; Pavia, Andrew T.; Hersh, Adam L.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA. [Arnold, Sandra R.; McCullers, Jonathan A.] Univ Tennessee, Ctr Hlth Sci, Div Infect Dis, LeBonheur Childrens Hosp, Memphis, TN 38163 USA. [Arnold, Sandra R.; McCullers, Jonathan A.] Univ Tennessee, Ctr Hlth Sci, Dept Pediat, Memphis, TN 38163 USA. [Hicks, Lauri A.; Bramley, Anna M.; Jain, Seema] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Williams, DJ (reprint author), S2323 Med Ctr North, 1161 21st Ave S, Nashville, TN 37232 USA. EM derek.williams@vanderbilt.edu FU National Institute of Allergy and Infectious Diseases of the National Institutes of Health [K23AI104779]; Agency for HealthCare Research and Quality [1R03HS022342]; Influenza Division in the National Center for Immunizations and Respiratory Diseases at the Centers for Disease Control and Prevention; National Institutes of Health (NIH) FX Supported in part by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award K23AI104779 to Dr Williams and the Agency for HealthCare Research and Quality under Award 1R03HS022342 to Dr Grijalva. The Etiology of Pneumonia in the Community (EPIC) study was supported by the Influenza Division in the National Center for Immunizations and Respiratory Diseases at the Centers for Disease Control and Prevention through cooperative agreements with each study site and was based on a competitive research funding opportunity. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the National Institutes of Health. Funded by the National Institutes of Health (NIH). NR 30 TC 6 Z9 6 U1 1 U2 5 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUL PY 2015 VL 136 IS 1 BP 44 EP 52 DI 10.1542/peds.2014-3047 PG 9 WC Pediatrics SC Pediatrics GA CL9KB UT WOS:000357296000046 PM 26101356 ER PT J AU Williams, HA Dunville, RL Gerber, SI Erdman, DD Pesik, N Kuhar, D Mason, KA Haynes, L Rotz, L St Pierre, J Poser, S Bunga, S Pallansch, MA Swerdlow, DL AF Williams, Holly Ann Dunville, Richard L. Gerber, Susan I. Erdman, Dean D. Pesik, Niciu Kuhar, David Mason, Karen A. Haynes, Lia Rotz, Lisa St Pierre, Jeanette Poser, Sarah Bunga, Sudhir Pallansch, Mark A. Swerdlow, David L. CA MERS-CoV Working Grp TI CDC's Early Response to a Novel Viral Disease, Middle East Respiratory Syndrome Coronavirus (MERS-CoV), September 2012-May 2014 SO PUBLIC HEALTH REPORTS LA English DT Article ID INFLUENZA PANDEMICS; LESSONS; CHALLENGES; SARS AB The first ever case of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) was reported in September 2012. This report describes the approaches taken by CDC, in collaboration with the World Health Organization (WHO) and other partners, to respond to this novel virus, and outlines the agency responses prior to the first case appearing in the United States in May 2014. During this time, CDC's response integrated multiple disciplines and was divided into three distinct phases: before, during, and after the initial activation of its Emergency Operations Center. CDC's response to MERS-CoV required a large effort, deploying at least 353 staff members who worked in the areas of surveillance, laboratory capacity, infection control guidance, and travelers' health. This response built on CDC's experience with previous outbreaks of other pathogens and provided useful lessons for future emerging threats. C1 [Williams, Holly Ann; Bunga, Sudhir] Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA 30341 USA. [Dunville, Richard L.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Atlanta, GA 30341 USA. [Gerber, Susan I.; Erdman, Dean D.; Mason, Karen A.; Haynes, Lia; St Pierre, Jeanette; Poser, Sarah; Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30341 USA. [Pesik, Niciu; Rotz, Lisa] Ctr Dis Control & Prevent, Div Global Migrat & Quarantine, Atlanta, GA 30341 USA. [Kuhar, David] Ctr Dis Control & Prevent, Div Hlth Care Qual & Promot, Atlanta, GA 30341 USA. [Swerdlow, David L.] Ctr Dis Control & Prevent, Off Sci & Integrated Programs, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30341 USA. RP Williams, HA (reprint author), Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, MS F-57,4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM hbw2@cdc.gov NR 21 TC 2 Z9 2 U1 2 U2 5 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2015 VL 130 IS 4 BP 307 EP 317 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM5DN UT WOS:000357707100007 PM 26345122 ER PT J AU Gooch, B Goodman, J Gracia, JN Griffin, SO Grummer-Strawn, L Hirschman, J Hyman, F Iafolla, T Kohn, W Lester, AM Makrides, NS Manski, R Osorio, AM Silverman, B Sinks, T AF Gooch, Barbara Goodman, Jesse Gracia, J. Nadine Griffin, Susan O. Grummer-Strawn, Laurence Hirschman, Jay Hyman, Frederick Iafolla, Timothy Kohn, William Lester, Arlene M. Makrides, Nicholas S. Manski, Richard Osorio, Ana Maria Silverman, Benson Sinks, Thomas CA US Dept Hlth Human Serv Federal Pa TI US Public Health Service Recommendation for Fluoride Concentration in Drinking Water for the Prevention of Dental Caries SO PUBLIC HEALTH REPORTS LA English DT Article ID UNITED-STATES; ENAMEL FLUOROSIS; INFANT FORMULA; CHILDRENS INTELLIGENCE; RISK-FACTORS; ORAL-HEALTH; OSTEOSARCOMA; COMMUNITY; IMPACT; NEEDS C1 [Gooch, Barbara; Griffin, Susan O.; Kohn, William] US Dept HHS, Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Oral Hlth, Washington, DC USA. [Goodman, Jesse] US Dept HHS, Sci & Publ Hlth, US FDA, Washington, DC USA. [Gracia, J. Nadine] US Dept HHS, Off Assistant Secretary Hlth, Washington, DC USA. [Grummer-Strawn, Laurence] US Dept HHS, Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Nutr Phys Act & Obes,Maternal & Child Nutr Br, Washington, DC USA. [Hirschman, Jay] Food & Nutr Serv, USDA, Off Res & Anal, Washington, DC USA. [Hyman, Frederick] US Dept HHS, US FDA, Ctr Drug Evaluat & Res, Div Dermatol & Dent Prod, Washington, DC USA. [Iafolla, Timothy] Natl Inst Dent & Craniofacial Res, US Dept HHS, NIH, Off Sci & Policy Anal, Washington, DC USA. [Lester, Arlene M.; Makrides, Nicholas S.] US PHS, Washington, DC USA. [Lester, Arlene M.] US Dept HHS, Off Secretary, Washington, DC USA. [Makrides, Nicholas S.] US Dept Justice, Fed Bur Prisons, Washington, DC USA. [Manski, Richard] US Dept HHS, Agcy Healthcare Res & Qual, Ctr Financing Access & Cost Trends, Washington, DC USA. [Osorio, Ana Maria] US PHS, US Dept HHS, Off Assistant Secretary Hlth, Washington, DC USA. [Silverman, Benson] US Dept HHS, US FDA, Ctr Food Safety & Appl Nutr, Washington, DC USA. [Sinks, Thomas] US Dept HHS, Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Agcy Tox Subst & Dis Registry, Washington, DC USA. RP Gooch, B (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Oral Hlth, 4770 Buford Hwy NE,MS F-80, Atlanta, GA 30341 USA. EM bgooch@cdc.gov NR 90 TC 0 Z9 0 U1 5 U2 17 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2015 VL 130 IS 4 BP 318 EP 331 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM5DN UT WOS:000357707100008 ER PT J AU Balaban, V Marks, SM Etkind, SC Katz, DJ Higashi, J Flood, J Cronin, A Ho, CS Khan, A Chorba, T AF Balaban, Victor Marks, Suzanne M. Etkind, Sue C. Katz, Dolly J. Higashi, Julie Flood, Jennifer Cronin, Ann Ho, Christine S. Khan, Awal Chorba, Terence TI Tuberculosis Elimination Efforts in the United States in the Era of Insurance Expansion and the Affordable Care Act SO PUBLIC HEALTH REPORTS LA English DT Article ID INFECTION; HEALTH; SERVICES; BARRIERS; REFORM; COSTS AB The Patient Protection and Affordable Care Act can enhance ongoing efforts to control tuberculosis (TB) in the United States by bringing millions of currently uninsured Americans into the health-care system. However, Much of the legislative and financial framework that provides essential public health services necessary for effective TB control is outside the scope of the law. We identified three key issues that will still need to be addressed after full implementation of the Affordable Care Act: (1) essential TB-related public health functions will still be needed and will remain the responsibility of federal, state, and local health departments; (2) testing and treatment for latent TB infection (LTBI) is not covered explicitly as a recommended preventive service without cost sharing or copayment; and (3) remaining uninsured populations will disproportionately include groups at high risk for TB. To improve and continue TB control efforts, it is important that all populations at risk be tested and treated for LTBI and TB; that testing and treatment services be accessible and affordable; that essential federal, state, and local public health functions be maintained; that private-sector medical/public health linkages for diagnosis and treatment be developed; and that health-care providers be trained in conducting appropriate LTBI and TB clinical care. C1 [Balaban, Victor; Marks, Suzanne M.; Katz, Dolly J.; Cronin, Ann; Ho, Christine S.; Khan, Awal; Chorba, Terence] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, Atlanta, GA 30329 USA. [Etkind, Sue C.] Massachusetts Dept Publ Hlth, Jamaica Plain, MA USA. [Higashi, Julie] San Francisco Gen Hosp, San Francisco Dept Publ Hlth, TB Control Sect, San Francisco, CA 94110 USA. [Flood, Jennifer] Calif Dept Publ Hlth, Ctr Infect Dis, Div Communicable Dis Control, TB Control Branch, Richmond, CA USA. RP Chorba, T (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div TB Eliminat, 1600 Clifton Rd NE,MS E-10, Atlanta, GA 30329 USA. EM tlc2@cdc.gov NR 38 TC 4 Z9 4 U1 0 U2 2 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2015 VL 130 IS 4 BP 349 EP 354 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM5DN UT WOS:000357707100013 PM 26345625 ER PT J AU Beltran-Aguilar, ED Barker, L Sohn, W Wei, L AF Beltran-Aguilar, Eugenio D. Barker, Laurie Sohn, Woosung Wei, Liang TI Water Intake by Outdoor Temperature Among Children Aged 1-10 Years: Implications for Community Water Fluoridation in the US SO PUBLIC HEALTH REPORTS LA English DT Article ID MINORITY CHILDREN; BOTTLED WATER; FLUID INTAKE; ADOLESCENTS; ASSOCIATIONS; DIETARY; CLIMATE; HEALTH; TAP AB Objective. The U.S. water fluoridation recommendations, which have been in place since 1962, were based in part on findings from the 1950s that children's water intake increased with outdoor temperature. We examined whether or not water intake is associated with outdoor temperature. Methods. Using linked data from the National Health and Nutrition Examination Survey (NHANES) 1999-2004 and the National Oceanic and Atmospheric Administration, we examined reported 24-hour total and plain water intake in milliliters per kilogram of body weight per day of children aged 1-10 years by maximum outdoor temperature on the day of reported water intake, unadjusted and adjusted for age, sex, race/ethnicity, and poverty status. We applied linear regression methods that were used in previously reported analyses of data from NHANES 1988-1994 and from the 1950s. Results. We found that total water intake was not associated with temperature. Plain water intake was weakly associated with temperature in unadjusted (coefficient = 0.2, p=0.015) and adjusted (coefficient = 0.2, p=0.013) linear regression models. However, these models explained little of the individual variation in plain water intake (unadjusted: R-2=0.005; adjusted: R-2=0.023). Conclusion. Optimal fluoride concentration in drinking water to prevent caries need not be based on outdoor temperature, given the lack of association between total water intake and outdoor temperature, the weak association between plain water intake and outdoor temperature, and the minimal amount of individual variance in plain water intake explained by outdoor temperature. These findings support the change in the U.S. Public Health Service recommendation for fluoride concentration in drinking water for the prevention of dental caries from temperature-related concentrations to a single concentration that is not related to outdoor temperature. C1 [Beltran-Aguilar, Eugenio D.; Barker, Laurie] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Oral Hlth, Atlanta, GA 30341 USA. [Sohn, Woosung] Univ Michigan, Sch Dent, Ann Arbor, MI 48109 USA. [Wei, Liang] DB Consulting Grp Inc, Atlanta, GA USA. RP Barker, L (reprint author), Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Oral Hlth, 4770 Buford Hwy NE,MS F-80, Atlanta, GA 30341 USA. EM lub2@cdc.gov FU Oak Ridge Associated Universities FX Dr. Sohn's work was supported in part by an ORISE joint research fellowship from Oak Ridge Associated Universities. NR 36 TC 3 Z9 3 U1 0 U2 7 PU ASSOC SCHOOLS PUBLIC HEALTH PI WASHINGTON PA 1900 M ST NW, STE 710, WASHINGTON, DC 20036 USA SN 0033-3549 J9 PUBLIC HEALTH REP JI Public Health Rep. PD JUL-AUG PY 2015 VL 130 IS 4 BP 362 EP 371 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CM5DN UT WOS:000357707100015 PM 26346578 ER PT J AU Seguel, M Howerth, EW Ritter, J Paredes, E Colegrove, K Gottdenker, N AF Seguel, M. Howerth, E. W. Ritter, J. Paredes, E. Colegrove, K. Gottdenker, N. TI Encephalitozoonosis in 2 South American Fur Seal (Arctocephalus australis) Pups SO VETERINARY PATHOLOGY LA English DT Article DE Encephalitozoon; encephalitis; fur seal; marine mammal; microsporidia ID CUNICULI INFECTION AB Cerebral and disseminated encephalitozoonosis was diagnosed by histopathology, electron microscopy, and immunohistochemistry in 2 free-ranging South American fur seal pups found dead at Guafo Island (43 degrees 33S 74 degrees 49W) in southern Chile. In the brain, lesions were characterized by random foci of necrosis with large numbers of macrophages containing numerous microsporidial organisms within parasitophorous vacuoles. In addition, occasional histiocytes loaded with numerous mature and immature microsporidia spores consistent with Encephalitozoon sp were observed in pulmonary alveolar septa, splenic red pulp, glomerular capillaries, and proximal renal tubules by Gram and immunohistochemical stains. To our knowledge, microsporidial infection in a marine mammal species has not been previously reported. C1 [Seguel, M.; Howerth, E. W.; Gottdenker, N.] Univ Georgia, Coll Vet Med, Dept Pathol, Athens, GA 30602 USA. [Ritter, J.] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Paredes, E.] Univ Austral Chile, Dept Anim Pathol, Valdivia, Chile. [Colegrove, K.] Univ Illinois, Zool Pathol Program, Maywood, IL USA. RP Seguel, M (reprint author), Univ Georgia, Coll Vet Med, Dept Pathol, 501 Brooks Dr, Athens, GA 30602 USA. EM mseguel@uga.edu FU Intramural CDC HHS [CC999999] NR 10 TC 0 Z9 1 U1 2 U2 8 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0300-9858 EI 1544-2217 J9 VET PATHOL JI Vet. Pathol. PD JUL PY 2015 VL 52 IS 4 BP 720 EP 723 DI 10.1177/0300985814551424 PG 4 WC Pathology; Veterinary Sciences SC Pathology; Veterinary Sciences GA CM2MT UT WOS:000357515400019 PM 25248519 ER PT J AU An, YL Zhang, P Wang, JP Gong, QH Gregg, EW Yang, WY Li, H Zhang, B Shuai, Y Chen, YY Engelgau, MM Cheng, YL Hu, YH Bennett, PH Li, GW AF An, Yali Zhang, Ping Wang, Jinping Gong, Qiuhong Gregg, Edward W. Yang, Wenying Li, Hui Zhang, Bo Shuai, Ying Chen, Yanyan Engelgau, Michael M. Cheng, Yiling Hu, Yinghua Bennett, Peter H. Li, Guangwei TI Cardiovascular and All-Cause Mortality Over a 23-Year Period Among Chinese With Newly Diagnosed Diabetes in the Da Qing IGT and Diabetes Study SO DIABETES CARE LA English DT Article ID CORONARY-HEART-DISEASE; IMPAIRED GLUCOSE-TOLERANCE; 20-YEAR FOLLOW-UP; DEATH; RISK; PREVALENCE; MELLITUS; HYPERGLYCEMIA; METAANALYSIS; POPULATION AB OBJECTIVEDespite its growing prevalence in China, the extent to which diabetes leads to excess cardiovascular disease (CVD) mortality and all-cause mortality is unclear.RESEARCH DESIGN AND METHODSWe compared death rates and causes of death among 630 people with newly diagnosed diabetes (NDD) and 519 with normal glucose tolerance (NGT) who, in 1986, were identified as a result of screening 110,660 adults aged 25-74 years for diabetes in Da Qing, China.RESULTSDuring 23 years of follow-up, 338 (56.5%) participants with NDD and 100 (20.3%) with NGT died. CVD was the predominant cause of death in those with diabetes (47.5% in men and 49.7% in women), almost half of which was due to stroke (52.3% in men and 42.3% in women). The age-standardized incidence of all-cause death was three times as high in those with NDD as in those with NGT with incidences (per 1,000 person-years) of 36.9 (95% CI 31.5-42.3) vs. 13.3 (10.2-16.5) in men (P < 0.0001) and 27.1 (22.9-31.4) vs. 9.2 (7.8-10.6) in women (P < 0.0001). The incidence of CVD deaths in men and women with NDD (17.5 [13.8-21.2] vs. 13.5 [10.5-16.5]) did not differ significantly. Significantly higher death rates attributable to renal disease and infection were also found in the NDD group.CONCLUSIONSDiabetes is associated with a substantially increased risk of death in Chinese adults, especially from CVD, almost half of which is due to stroke. C1 [An, Yali; Gong, Qiuhong; Shuai, Ying; Chen, Yanyan; Li, Guangwei] Chinese Acad Med Sci, Dept Endocrinol, Fu Wai Hosp, Beijing 100730, Peoples R China. [Zhang, Ping; Gregg, Edward W.; Cheng, Yiling] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. [Wang, Jinping; Li, Hui; Hu, Yinghua] Da Qing First Hosp, Dept Cardiol, Da Qing, Peoples R China. [Yang, Wenying; Zhang, Bo; Li, Guangwei] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China. [Engelgau, Michael M.] NHLBI, Ctr Translat Res & Implementat Sci, Bethesda, MD 20892 USA. [Bennett, Peter H.] NIDDK, Phoenix Epidemiol & Clin Res Branch, Phoenix, AZ USA. RP Li, GW (reprint author), Chinese Acad Med Sci, Dept Endocrinol, Fu Wai Hosp, Beijing 100730, Peoples R China. EM pzhang@cdc.gov; guangwei_li@medmail.com.cn FU Centers for Disease Control and Prevention/WHO Cooperative Agreement [U58/CCU424123-01-02]; China-Japan Friendship Hospital FX This work was supported by the Centers for Disease Control and Prevention/WHO Cooperative Agreement U58/CCU424123-01-02 and the China-Japan Friendship Hospital. NR 27 TC 8 Z9 11 U1 0 U2 5 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUL PY 2015 VL 38 IS 7 BP 1365 EP 1371 DI 10.2337/dc14-2498 PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CL4OW UT WOS:000356933600033 PM 25887356 ER PT J AU Anh, PH Cuong, NV Son, NT Tue, NT Kosoy, M House, MEJW Baker, S Bryant, JE Thwaites, G Carrique-Mas, JJ Rabaa, MA AF Pham Hong Anh Nguyen Van Cuong Nguyen Truong Son Ngo Tri Tue Kosoy, Michael House, Mark E. J. Woo Baker, Stephen Bryant, Juliet E. Thwaites, Guy Carrique-Mas, Juan J. Rabaa, Maia A. TI Diversity of Bartonella spp. in Bats, Southern Vietnam SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Pham Hong Anh; Nguyen Van Cuong; Nguyen Truong Son; Ngo Tri Tue; Baker, Stephen; Bryant, Juliet E.; Thwaites, Guy; Carrique-Mas, Juan J.; Rabaa, Maia A.] Univ Oxford, Ho Chi Minh City, Vietnam. [Nguyen Truong Son] Vietnam Acad Sci & Technol, Hanoi, Vietnam. [Kosoy, Michael] Ctr Dis Control & Prevent, Ft Collins, CO USA. [House, Mark E. J. Woo; Rabaa, Maia A.] Univ Edinburgh, Edinburgh, Midlothian, Scotland. [Baker, Stephen] London Sch Hyg & Trop Med, London WC1, England. [Baker, Stephen; Bryant, Juliet E.; Thwaites, Guy; Carrique-Mas, Juan J.] Univ Oxford, Oxford, England. RP Carrique-Mas, JJ (reprint author), Univ Oxford, Clin Res Unit, TP, 764 Vo Kiet,Ward 1,Dist 5, Ho Chi Minh City, Vietnam. EM jcarrique-mas@oucru.org OI Rabaa, Maia/0000-0003-0529-2228; Thwaites, Guy/0000-0002-2858-2087 FU Wellcome Trust [095831, 100087, WT/093724, 089276] NR 10 TC 5 Z9 5 U1 1 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUL PY 2015 VL 21 IS 7 BP 1266 EP 1267 DI 10.3201/eid2107.141760 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CL5KF UT WOS:000356998100037 PM 26079810 ER PT J AU Dodge, LE Williams, PL Williams, MA Missmer, SA Toth, TL Calafat, AM Hauser, R AF Dodge, Laura E. Williams, Paige L. Williams, Michelle A. Missmer, Stacey A. Toth, Thomas L. Calafat, Antonia M. Hauser, Russ TI Paternal Urinary Concentrations of Parabens and Other Phenols in Relation to Reproductive Outcomes among Couples from a Fertility Clinic SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID BISPHENOL-A CONCENTRATIONS; IN-VITRO FERTILIZATION; SPERM DNA-DAMAGE; SPERMATOZOAL RNA; HUMAN EXPOSURE; SEMEN QUALITY; CANNED FOODS; MEN; WOMEN; PREGNANCY AB Background: Human exposure to phenols, including bisphenol A and parabens, is widespread. Evidence suggests that paternal exposure to environmental chemicals may adversely affect reproductive outcomes. Objectives: We evaluated associations of paternal phenol urinary concentrations with fertilization rate, embryo quality, implantation, and live birth. Methods: Male-female couples who underwent in vitro fertilization (IVF) and/or intrauterine insemination (IUI) cycles in a prospective study of environmental determinants of fertility and pregnancy outcomes were included. The geometric mean of males' specific gravity-adjusted urinary phenol concentrations measured before females' cycle was quantified. Associations between male urinary phenol concentrations and fertilization rate, embryo quality, implantation, and live birth were investigated using generalized linear mixed models to account for multiple cycles per couple. Results: Couples (n = 218) underwent 195 IUI and 211 IVF cycles. Paternal phenol concentrations were not associated with fertilization or live birth following IVF. In adjusted models, compared with the lowest quartile of methyl paraben, paternal concentrations in the second quartile were associated with decreased odds of live birth following IUI (adjusted odds ratio = 0.19; 95% CI: 0.04, 0.82). Conclusions: To our knowledge, these are some of the first data on the association of paternal urinary phenol concentrations with reproduction and pregnancy outcomes. Although these results do not preclude possible adverse effects of paternal paraben exposures on such outcomes, given the modest sample size, further understanding could result from confirmation using a larger and more diverse population. C1 [Dodge, Laura E.; Williams, Paige L.; Williams, Michelle A.; Missmer, Stacey A.; Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Williams, Paige L.] Harvard Univ, TH Chan Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA. [Missmer, Stacey A.; Toth, Thomas L.] Harvard Univ, Sch Med, Dept Obstet Gynecol & Reprod Biol, Boston, MA 02115 USA. [Missmer, Stacey A.] Brigham & Womens Hosp, Dept Med, Channing Div Network Med, Boston, MA 02115 USA. [Missmer, Stacey A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. [Toth, Thomas L.; Hauser, Russ] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Boston, MA 02114 USA. [Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA. [Hauser, Russ] Harvard Univ, TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA. RP Hauser, R (reprint author), 665 Huntington Ave,Bldg 1,Room 1409, Boston, MA 02115 USA. EM rhauser@hsph.harvard.edu FU National Institute of Environmental Health Sciences [ES009718, ES022955]; [T32 ES 07069] FX This work was supported by National Institute of Environmental Health Sciences grants ES009718 and ES022955 and training grant T32 ES 07069, which supported L.E.D. NR 50 TC 7 Z9 7 U1 2 U2 18 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JUL PY 2015 VL 123 IS 7 BP 665 EP 671 DI 10.1289/ehp.1408605 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CL9KQ UT WOS:000357297500016 PM 25767892 ER PT J AU Guidry, VT Longnecker, MP Aase, H Eggesbo, M Zeiner, P Reichborn-Kjennerud, T Knudsen, GP Bertelsen, RJ Ye, XY Calafat, AM Engel, SM AF Guidry, Virginia T. Longnecker, Matthew P. Aase, Heidi Eggesbo, Merete Zeiner, Pal Reichborn-Kjennerud, Ted Knudsen, Gun P. Bertelsen, Randi J. Ye, Xiaoyun Calafat, Antonia M. Engel, Stephanie M. TI Measurement of Total and Free Urinary Phenol and Paraben Concentrations over the Course of Pregnancy: Assessing Reliability and Contamination of Specimens in the Norwegian Mother and Child Cohort Study SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID BISPHENOL-A CONCENTRATIONS; TANDEM MASS-SPECTROMETRY; HPLC-MS/MS METHOD; ENVIRONMENTAL PHENOLS; PRENATAL EXPOSURE; BIRTH OUTCOMES; VARIABILITY; WOMEN; PREDICTORS; BEHAVIOR AB BACKGROUND: Exposures to environmental phenols and parabens may be harmful, especially in utero. Prior studies have demonstrated high within-person variability of urinary concentrations across pregnancy. OBJECTIVES: We sought to measure phenol and paraben biomarker concentrations for the Norwegian Mother and Child Cohort (MoBa) study, assess within-person variability, and investigate any possible external phenol or paraben contamination of specimens. METHODS: We collected three spot urine samples at approximately 17, 23, and 29 weeks gestation in a hospital setting and added a preservative containing ethyl paraben. We measured urinary concentrations and within-person variability for phenols and parabens in a MoBa sample (n = 45), including a subgroup of 15 participants previously randomly selected for a bisphenol A (BPA) exposure study who had unusually high total BPA concentrations. Additionally, we compared reliability results for total, conjugated, and free concentrations of phenolic compounds. RESULTS: We detected total and free BPA, butyl paraben, propyl paraben, and methyl paraben in 100% of samples, total benzophenone-3 in 95% of samples, and infrequently detected free benzo-phenone-3 and total and free 2,4-dichlorophenol and 2,5-dichlorophenol. Intraclass correlation coefficients (ICCs) for total, conjugated, and free concentrations ranged from relatively low for BPA to moderate for propyl paraben. ICCs were generally similar overall and by subgroup. CONCLUSIONS: Using conjugated concentrations improved reliability estimates only for BPA. Measuring total and free concentrations, an approach that may be useful for future studies, allowed us to identify likely BPA and butyl paraben contamination of archived MoBa urine specimens. C1 [Guidry, Virginia T.; Engel, Stephanie M.] UNC Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC 27599 USA. [Longnecker, Matthew P.] NIEHS, Epidemiol Branch, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA. [Aase, Heidi] Norwegian Inst Publ Hlth, Dept Child Dev & Mental Hlth, Oslo, Norway. [Eggesbo, Merete] Norwegian Inst Publ Hlth, Dept Genes & Environm, Oslo, Norway. [Zeiner, Pal] Oslo Univ Hosp, Div Mental Hlth & Addict, Oslo, Norway. [Reichborn-Kjennerud, Ted; Knudsen, Gun P.] Norwegian Inst Publ Hlth, Dept Genet Environm & Mental Hlth, Oslo, Norway. [Bertelsen, Randi J.] Haukeland Hosp, Dept Occupat Med, N-5021 Bergen, Norway. [Ye, Xiaoyun; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA USA. RP Guidry, VT (reprint author), UNC Gillings Sch Global Publ Hlth, Dept Epidemiol, CB 7435, Chapel Hill, NC 27599 USA. EM virginia.guidry@unc.edu OI Longnecker, Matthew/0000-0001-6073-5322; Eggesbo, Merete/0000-0002-0006-5336 FU National Institute of Environmental Health Sciences (NIEHS), National Institute of Health (NIH) [P30ES010126, R01ES021777]; Intramural Research Program of the NIEHS/NIH; NIEHS [ES07018]; Norwegian Ministry of Health; Ministry of Education and Research, NIEHS/NIH [NO1-ES-75558]; National Institute of Neurological Disorders and Stroke, NIH [UO1 NS 047537-01, UO1 NS047537-06A1]; Norwegian Research Council/Bioinformatics and Functional Genomics (FUGE) [151918/S10] FX This study was supported by grants from the National Institute of Environmental Health Sciences (NIEHS), National Institute of Health (NIH) (P30ES010126, R01ES021777) and the Intramural Research Program of the NIEHS/NIH. V.T.G. was supported by NIEHS grant ES07018. The Norwegian Mother and Child Cohort Study is supported by the Norwegian Ministry of Health and the Ministry of Education and Research, NIEHS/NIH (contract NO1-ES-75558), National Institute of Neurological Disorders and Stroke, NIH (grants UO1 NS 047537-01 and UO1 NS047537-06A1), and the Norwegian Research Council/Bioinformatics and Functional Genomics (FUGE) (grant 151918/S10). NR 46 TC 9 Z9 9 U1 7 U2 29 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JUL PY 2015 VL 123 IS 7 BP 705 EP 711 DI 10.1289/ehp.1408325 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CL9KQ UT WOS:000357297500021 PM 25782115 ER PT J AU Calafat, AM Longnecker, MP Koch, HM Swan, SH Hauser, R Goldman, LR Lanphear, BP Rudel, RA Engel, SM Teitelbaum, SL Whyatt, RM Wolff, MS AF Calafat, Antonia M. Longnecker, Matthew P. Koch, Holger M. Swan, Shanna H. Hauser, Russ Goldman, Lynn R. Lanphear, Bruce P. Rudel, Ruthann A. Engel, Stephanie M. Teitelbaum, Susan L. Whyatt, Robin M. Wolff, Mary S. TI Optimal Exposure Biomarkers for Nonpersistent Chemicals in Environmental Epidemiology SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Article ID BISPHENOL-A CONCENTRATIONS; PHTHALATE METABOLITE CONCENTRATIONS; CHROMATOGRAPHY-MASS-SPECTROMETRY; 24-H URINE SAMPLES; TEMPORAL VARIABILITY; PREGNANT-WOMEN; BLANK PROBLEMS; PUERTO-RICO; HUMAN BLOOD; PREDICTORS AB We discuss considerations that are essential when evaluating exposure to nonpersistent, semivolatile environmental chemicals such as phthalates and phenols (e.g., bisphenol A). A biomarker should be chosen to best represent usual personal exposures and not recent, adventitious, or extraneous exposures. Biomarkers should be selected to minimize contamination arising from collection, sampling, or analysis procedures. Pharmacokinetics should be considered; for example, nonpersistent, semivolatile chemicals are metabolized quickly, and urine is the compartment with the highest concentrations of metabolites. Because these chemicals are nonpersistent, knowledge of intraindividual reliability over the biologic window of interest is also required. In recent years researchers have increasingly used blood as a matrix for characterizing exposure to nonpersistent chemicals. However, the biologic and technical factors noted above strongly support urine as the optimal matrix for measuring nonpersistent, semivolatile, hydrophilic environmental agents. C1 [Calafat, Antonia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Longnecker, Matthew P.] NIEHS, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA. [Koch, Holger M.] Ruhr Univ Bochum, Inst Prevent & Occupat Med German Social Accident, Bochum, Germany. [Swan, Shanna H.; Teitelbaum, Susan L.; Wolff, Mary S.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Hauser, Russ] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Goldman, Lynn R.] George Washington Univ, Milken Inst, Sch Publ Hlth, Washington, DC USA. [Lanphear, Bruce P.] British Columbia Childrens Hosp, Vancouver, BC, Canada. [Rudel, Ruthann A.] Silent Spring Inst, Boston, MA USA. [Engel, Stephanie M.] Univ N Carolina, Chapel Hill, NC USA. [Whyatt, Robin M.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. RP Wolff, MS (reprint author), Mt Sinai Med Ctr, Prevent Med, One Gustave L Levy Pl, Box 1057, New York, NY 10029 USA. EM mary.wolff@mssm.edu RI Koch, Holger/B-3277-2011; OI Koch, Holger/0000-0002-8328-2837; Longnecker, Matthew/0000-0001-6073-5322 FU Intramural Research Program of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Department of Health and Human Services FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This research was supported in part by the Intramural Research Program of the National Institute of Environmental Health Sciences (NIEHS), National Institutes of Health, Department of Health and Human Services. We thank Sandra Chambers at the NIEHS for help in identifying articles listed in Figure 1. NR 48 TC 12 Z9 12 U1 4 U2 20 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JUL PY 2015 VL 123 IS 7 BP A166 EP A168 DI 10.1289/ehp.1510041 PG 3 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CL9KQ UT WOS:000357297500001 PM 26132373 ER PT J AU Goede, SL Kuntz, KM van Ballegooijen, M Knudsen, AB Lansdorp-Vogelaar, I Tangka, FK Howard, DH Chin, J Zauber, AG Seeff, LC AF Goede, Simon L. Kuntz, Karen M. van Ballegooijen, Marjolein Knudsen, Amy B. Lansdorp-Vogelaar, Iris Tangka, Florence K. Howard, David H. Chin, Joseph Zauber, Ann G. Seeff, Laura C. TI Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening SO MEDICAL CARE LA English DT Article DE colorectal cancer; screening; computer simulation; prevention and control ID SOCIETY-TASK-FORCE; LARGE-BOWEL; AMERICAN-COLLEGE; LARGE-INTESTINE; UNITED-STATES; COLONOSCOPY; POLYPS; AUTOPSY; COLON; CARE AB Background:Many individuals have not received recommended colorectal cancer (CRC) screening before they become Medicare eligible at the age of 65. We aimed to estimate the long-term implications of increased CRC screening in the pre-Medicare population (50-64 y) on costs in the pre-Medicare and Medicare populations (65+ y).Methods:We used 2 independently developed microsimulation models [Microsimulation Screening Analysis Colon (MISCAN) and Simulation Model of CRC (SimCRC)] to project CRC screening and treatment costs under 2 scenarios, starting in 2010: current trends (60% of the population up-to-date with screening recommendations) and enhanced participation (70% up-to-date). The population was scaled to the projected US population for each year between 2010 and 2060. Costs per year were derived by age group (50-64 and 65+ y).Results:By 2060, the discounted cumulative total costs in the pre-Medicare population were $35.7 and $28.1 billion higher with enhanced screening participation, than in the current trends scenario ($252.1 billion with MISCAN and $239.5 billion with SimCRC, respectively). Because of CRC treatment savings with enhanced participation, cumulative costs in the Medicare population were $18.3 and $32.7 billion lower (current trends: $423.5 billion with MISCAN and $372.8 billion with SimCRC). Over the 50-year time horizon an estimated 60% (MISCAN) and 89% (SimCRC) of the increased screening costs could be offset by savings in Medicare CRC treatment costs.Conclusion:Increased CRC screening participation in the pre-Medicare population could reduce CRC incidence and mortality, whereas the additional screening costs can be largely offset by long-term Medicare treatment savings. C1 [Goede, Simon L.; van Ballegooijen, Marjolein; Lansdorp-Vogelaar, Iris] Erasmus Univ, Dept Publ Hlth, Med Ctr, NL-3000 CA Rotterdam, Netherlands. [Kuntz, Karen M.] Univ Minnesota, Div Hlth Policy & Management, Minneapolis, MN USA. [Knudsen, Amy B.] Massachusetts Gen Hosp, Dept Radiol, Inst Technol Assessment, Boston, MA 02114 USA. [Tangka, Florence K.; Seeff, Laura C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA USA. [Howard, David H.] Emory Univ, Dept Hlth Policy & Management, Atlanta, GA 30322 USA. [Chin, Joseph] Ctr Medicare Serv, Coverage & Anal Grp, Baltimore, MD USA. [Chin, Joseph] Ctr Medicaid Serv, Coverage & Anal Grp, Baltimore, MD USA. [Zauber, Ann G.] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA. RP Goede, SL (reprint author), Erasmus Univ, Dept Publ Hlth, Med Ctr, POB 2040, NL-3000 CA Rotterdam, Netherlands. EM s.goede@erasmusmc.nl FU National Cancer Institute at the National Institutes of Health [U01-CA-088204, U01-CA-097426, U01-CA-115953, U01-CA-152959]; Centers for Disease Control and Prevention FX Supported by the National Cancer Institute at the National Institutes of Health (grants: U01-CA-088204, U01-CA-097426, U01-CA-115953, and U01-CA-152959) for the Cancer Intervention and Surveillance Modeling Network with supplemental funding from the Centers for Disease Control and Prevention. D.H.H.'s time on the project was supported by an Interagency Personnel Agreement with the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the Centers for Medicare and Medicaid Services, the National Cancer Institute, or the National Institutes of Health. NR 47 TC 2 Z9 2 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD JUL PY 2015 VL 53 IS 7 BP 630 EP 638 DI 10.1097/MLR.0000000000000380 PG 9 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CL4QE UT WOS:000356937400010 PM 26067885 ER PT J AU Broussard, CS Sahin, L Tassinari, MS AF Broussard, Cheryl S. Sahin, Leyla Tassinari, Melissa S. TI Getting to safer and smarter medication use during pregnancy REPLY SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Letter C1 [Broussard, Cheryl S.] Natl Ctr Birth Defects & Dev Disabil, Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. [Sahin, Leyla; Tassinari, Melissa S.] Ctr Drug Evaluat & Res, Food & Drug Adm, Div Pediat & Maternal Hlth, Off New Drugs, Silver Spring, MD USA. RP Broussard, CS (reprint author), Natl Ctr Birth Defects & Dev Disabil, Ctr Dis Control & Prevent, Div Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. FU Intramural CDC HHS [CC999999] NR 3 TC 0 Z9 0 U1 0 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JUL PY 2015 VL 213 IS 1 BP 116 EP 116 DI 10.1016/j.ajog.2014.12.036 PG 1 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CL3FQ UT WOS:000356836200049 PM 25557207 ER PT J AU Hatia, RI Dimitrova, Z Skums, P Teo, EYL Teo, CG AF Hatia, Rikita I. Dimitrova, Zoya Skums, Pavel Teo, Elrond Yi-Lang Teo, Chong-Gee TI Nosocomial hepatitis C virus transmission from tampering with injectable anesthetic opioids SO HEPATOLOGY LA English DT Article ID INJECTING DRUG-USERS; HEALTH-CARE WORKERS; HCV; INFECTION; ABUSE; DIVERSION; PREVENTION; DEPENDENCE; ADDICTION; OUTBREAKS AB The extent of provider-to-patient hepatitis C virus (HCV) transmission from diversion, self-injection, and substitution (tampering) of anesthetic opioids is unknown. To quantify the contribution of opioid tampering to nosocomial HCV outbreaks, data from health care-related HCV outbreaks occurring in developed countries from 1990 to 2012 were collated, grouped, and compared. Tampering was associated with 17% (8 of 46) of outbreaks, but 53% (438 of 833) of cases. Of the tampering outbreaks, six (75%) involved fentanyl, five (63%) occurred in the United States, and one each in Australia, Israel, and Spain. Case counts ranged from 5 to 275 in the tampering outbreaks (mean, 54.8; median, 25), and 1-99 in the nontampering outbreaks (mean, 10.4; median, 5); between them, the difference in mean ranks of counts was significant (P<0.01). To estimate HCV transmission risks from tampering, risk-assessment models were constructed, and these risks compared with those from surgery. HCV transmission risk from exposure to an opioid preparation tampered by a provider of unknown HCV infection status who is a person who injects drugs (PWID; 0.62%; standard error [SE]=0.38%) exceeds 16,757 times the risk from surgery by a surgeon of unknown HCV infection status (0.000037%; SE=0.000029%) and 135 times by an HCV-infected surgeon (0.0046%; SE=0.0033%). To pose a 50% patient transmission risk, an infected surgeon may take 30 years, compared to <1 year for a PWID tamperer, and weeks or days for a PWID tamperer who intensifies access to opioids. Conclusion: Disproportionately, many cases of HCV infection from nosocomial outbreaks were attributable to provider tampering of anesthetic opioids. Transmission risk from tampering is substantially higher than from surgery. (Hepatology 2015;62:101-110) C1 [Hatia, Rikita I.; Dimitrova, Zoya; Skums, Pavel; Teo, Chong-Gee] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Teo, Elrond Yi-Lang] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA. RP Teo, CG (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Mailstop A33,1600 Clifton Rd Northeast, Atlanta, GA 30333 USA. EM enz0@cdc.gov FU Oak Ridge Institute for Science and Education FX This research was supported in part by an appointment to the Research Participation Program at CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the Department of Energy and CDC. NR 38 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD JUL PY 2015 VL 62 IS 1 BP 101 EP 110 DI 10.1002/hep.27800 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CL3QH UT WOS:000356864800016 PM 25808284 ER PT J AU Petticrew, M Anderson, L Elder, R Grimshaw, J Hopkins, D Hahn, R Krause, L Kristjansson, E Mercer, S Sipe, T Tugwell, P Ueffing, E Waters, E Welch, V AF Petticrew, Mark Anderson, Laurie Elder, Randy Grimshaw, Jeremy Hopkins, David Hahn, Robert Krause, Lauren Kristjansson, Elizabeth Mercer, Shawna Sipe, Teresa Tugwell, Peter Ueffing, Erin Waters, Elizabeth Welch, Vivian TI Complex interventions and their implications for systematic reviews: A pragmatic approach SO INTERNATIONAL JOURNAL OF NURSING STUDIES LA English DT Review DE Systematic reviews; Evaluation; Complex interventions; Complexity; Evidence synthesis; Qualitative research ID HEALTH; EFFICACY; TRIALS AB Complex interventions present unique challenges for systematic reviews. Current debates tend to center around describing complexity, rather than providing guidance on what to do about it. At a series of meetings during 2009-2012, we met to review the challenges and practical steps reviewer could take to incorporate a complexity perspective into systematic reviews. Based on this, we outline a pragmatic approach to dealing with complexity, beginning, as for any review, with clearly defining the research question(s). We argue that reviews of complex interventions can themselves be simple or complex, depending on the question to be answered. In systematic reviews and evaluations of complex interventions, it will be helpful to start by identifying the sources of complexity, then mapping aspects of complexity in the intervention onto the appropriate sources of evidence (such as specific types of quantitative or qualitative study). Although we focus on systematic reviews, the general approach is also applicable to primary research that is aimed at evaluating complex interventions. Although the examples are drawn from health care, the approach may also be applied to other sectors (e.g., social policy or international development). We end by concluding that systematic reviews should follow the principle of Occam's razor: explanations should be as complex as they need to be and no more. (C) 2015 Published by Elsevier Ltd. C1 [Petticrew, Mark] London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, London WC1H 9SH, England. [Anderson, Laurie] Washington State Inst Publ Policy, Olympia, WA USA. [Elder, Randy; Hopkins, David; Hahn, Robert; Mercer, Shawna; Sipe, Teresa] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Grimshaw, Jeremy; Kristjansson, Elizabeth; Tugwell, Peter; Welch, Vivian] Univ Ottawa, Inst Populat Hlth, Ottawa, ON, Canada. [Krause, Lauren] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Ueffing, Erin] Ottawa Hosp Res Inst, Canadian Cochrane Ctr, Ottawa, ON, Canada. [Waters, Elizabeth] Univ Melbourne, McCaughey Ctr, Melbourne Sch Populat Hlth, Melbourne, Vic, Australia. RP Petticrew, M (reprint author), London Sch Hyg & Trop Med, Dept Social & Environm Hlth Res, London WC1H 9SH, England. EM Mark.Petticrew@lshtm.ac.uk OI Tugwell, Peter/0000-0001-5062-0556 FU CIHR FX No relevant conflicts relating to this article. M.P. receives funding from the CIHR funded International Collaboration on Complex Interventions, which supported some of the work reported in this article. NR 27 TC 1 Z9 1 U1 0 U2 8 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0020-7489 EI 1873-491X J9 INT J NURS STUD JI Int. J. Nurs. Stud. PD JUL PY 2015 VL 52 IS 7 BP 1211 EP 1216 DI 10.1016/j.ijnurstu.2015.01.004 PG 6 WC Nursing SC Nursing GA CL0LN UT WOS:000356634300009 PM 25661527 ER PT J AU Holmes, JS Driscoll, AK Heron, M AF Holmes, Julia S. Driscoll, Anne K. Heron, Melonie TI Mortality among US-born and immigrant Hispanics in the US: effects of nativity, duration of residence, and age at immigration SO INTERNATIONAL JOURNAL OF PUBLIC HEALTH LA English DT Article DE Immigration; Age at immigration; Mortality; Health behaviors; Hispanics; Acculturation ID UNITED-STATES; ADULT MORTALITY; EPIDEMIOLOGIC PARADOX; ALLOSTATIC LOAD; HEALTH; ACCULTURATION; ADVANTAGE; MIGRATION; ETHNICITY; PATTERNS AB We examined the effects of duration of residence and age at immigration on mortality among US-born and foreign-born Hispanics aged 25 and older. We analyzed the National Health Interview Survey-National Death Index linked files from 1997-2009 with mortality follow-up through 2011. We used Cox proportional hazard models to examine the effects of duration of US residence and age at immigration on mortality for US-born and foreign-born Hispanics, controlling for various demographic, socioeconomic and health factors. Age at immigration included 4 age groups: < 18, 18-24, 25-34, and 35+ years. Duration of residence was 0-15 and > 15 years. We observed a mortality advantage among Hispanic immigrants compared to US-born Hispanics only for those who had come to the US after age 24 regardless of how long they had lived in the US. Hispanics who immigrated as youths (< 18) did not differ from US-born Hispanics on mortality despite duration of residence. Findings suggest that age at immigration, rather than duration of residence, drives differences in mortality between Hispanic immigrants and the US-born Hispanic population. C1 [Holmes, Julia S.; Driscoll, Anne K.; Heron, Melonie] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Holmes, JS (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 6126, Hyattsville, MD 20782 USA. EM JSHolmes@cdc.gov; ADriscoll1@cdc.gov; mheron@cdc.gov NR 35 TC 4 Z9 4 U1 2 U2 12 PU SPRINGER BASEL AG PI BASEL PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND SN 1661-8556 EI 1661-8564 J9 INT J PUBLIC HEALTH JI Int. J. Public Health PD JUL PY 2015 VL 60 IS 5 BP 609 EP 617 DI 10.1007/s00038-015-0686-7 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL2WX UT WOS:000356809400010 PM 26022191 ER PT J AU Lichtenstein, KA Hart, RLD Wood, KC Bozzette, S Buchacz, K Brooks, JT AF Lichtenstein, Kenneth A. Hart, Rachel L. D. Wood, Kathleen C. Bozzette, Samuel Buchacz, Kate Brooks, John T. CA HIV Outpatient Study Investigators TI Statin Use Is Associated With Incident Diabetes Mellitus Among Patients in the HIV Outpatient Study SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE statin; diabetes; low-density lipoprotein ID HUMAN-IMMUNODEFICIENCY-VIRUS; ACUTE MYOCARDIAL-INFARCTION; RANDOMIZED CONTROLLED-TRIAL; ANTIRETROVIRAL THERAPY; MEDICINE-ASSOCIATION; CLINICAL-TRIALS; RISK; INFECTION; DISEASE; GUIDELINES AB Introduction:Statin therapy is effective in the prevention of cardiovascular disease in the general population but has been shown to modestly increase the risk for incident diabetes mellitus (DM).Methods:We analyzed incident DM in HIV Outpatient Study (HOPS) participants followed at 8 HIV clinic sites during 2002-2011, comparing rates among those who initiated statin therapy during that period with those who did not. Using Cox proportional hazards models, we examined the association between cumulative years of statin exposure and the risk of developing DM, after controlling for age, sex, race/ethnicity, antiretroviral history, prevalent hepatitis C, body mass index, and cumulative exposure to protease inhibitor therapy. We also adjusted for propensity scores to account for residual confounding by indication.Results:Of 4692 patients analyzed, 590 (12.6%) initiated statin therapy and 355 (7.2%) developed DM. Incident DM was independently associated with statin therapy (adjusted hazard ratio, 1.14 per year of statin use), as well as older age, Hispanic/Latino ethnicity, non-Hispanic/Latino black race, antiretroviral-naive status, prevalent hepatitis C, and body mass index 30 kg/m(2) (P < 0.05 for all). The association of statin use with incident DM was similar in the model adjusted for propensity score.Conclusions:Statin use was associated with a modestly increased risk of incident DM in an HIV-infected population, similar to existing data for the general population. HIV-infected patients should be monitored for glucose intolerance, but statins should not be withheld if clinically indicated for cardiovascular disease risk reduction. C1 [Lichtenstein, Kenneth A.] Natl Jewish Hlth Ctr, Dept Med, Denver, CO 80206 USA. [Hart, Rachel L. D.; Wood, Kathleen C.; Bozzette, Samuel] Cerner Corp, Res Dept, Kansas City, MO USA. [Bozzette, Samuel] Univ Calif San Diego, San Diego, CA 92103 USA. [Buchacz, Kate; Brooks, John T.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. RP Lichtenstein, KA (reprint author), Natl Jewish Hlth Ctr, Dept Med, 1400 Jackson St, Denver, CO 80206 USA. EM lichtensteink@njhealth.org FU Centers for Disease Control and Prevention [200-2001-00133, 200-2006-18797, 200-2011-41872]; AbbVie; Gilead Sciences FX Supported by Centers for Disease Control and Prevention (contract nos. 200-2001-00133, 200-2006-18797, and 200-2011-41872).; K.A.L. receives research support from AbbVie and Gilead Sciences. The remaining authors have no conflicts of interest to disclose. NR 35 TC 7 Z9 7 U1 0 U2 3 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUL 1 PY 2015 VL 69 IS 3 BP 306 EP 311 DI 10.1097/QAI.0000000000000581 PG 6 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CL1OY UT WOS:000356714600008 PM 26181706 ER PT J AU Widen, EM Bentley, ME Chasela, CS Kayira, D Flax, VL Kourtis, AP Ellington, SR Kacheche, Z Tegha, G Jamieson, DJ van der Horst, CM Allen, LH Shahab-Ferdows, S Adair, LS AF Widen, Elizabeth M. Bentley, Margaret E. Chasela, Charles S. Kayira, Dumbani Flax, Valerie L. Kourtis, Athena P. Ellington, Sascha R. Kacheche, Zebrone Tegha, Gerald Jamieson, Denise J. van der Horst, Charles M. Allen, Lindsay H. Shahab-Ferdows, Setareh Adair, Linda S. CA BAN Study Team TI Antiretroviral Treatment Is Associated With Iron Deficiency in HIV-Infected Malawian Women That Is Mitigated With Supplementation, but Is Not Associated With Infant Iron Deficiency During 24 Weeks of Exclusive Breastfeeding SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE iron; breastfeeding; lipid-based nutrient supplement; antiretrovirals; maternal; infant ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNINFECTED INFANTS; ANEMIA; TRANSMISSION; PROPHYLAXIS; TANZANIA; ZIDOVUDINE; CHILDREN; MOTHERS; BAN AB Objective:In resource-limited settings without safe alternatives to breastfeeding, the WHO recommends exclusive breastfeeding and antiretroviral (ARV) prophylaxis. Given the high prevalence of anemia among HIV-infected women, mothers and their infants (through fetal iron accretion) may be at risk of iron deficiency. We assessed the effects of maternal micronutrient-fortified lipid-based nutrient supplements (LNS) and maternal ARV treatment or infant ARV prophylaxis on maternal and infant iron status during exclusive breastfeeding from birth to 24 weeks.Methods:The Breastfeeding, Antiretrovirals, and Nutrition study was a randomized controlled trial conducted in Lilongwe, Malawi, from 2004 to 2010. HIV-infected mothers (CD4 >200 cells/L) and their infants were randomly assigned to 28-week interventions: maternal LNS/maternal ARV (n = 424), maternal LNS/infant ARV (n = 426), maternal LNS (n = 334), maternal ARV (n = 425), infant ARV (n = 426), or control (n = 334). Longitudinal models tested intervention effects on hemoglobin (Hb). In a subsample (n = 537) with multiple iron indicators, intervention effects on Hb, transferrin receptors (TfR), and ferritin were tested with linear and Poisson regression.Results:In longitudinal models, LNS effects on maternal and infant Hb were minimal. In subsample mothers, maternal ARVs were associated with tissue iron depletion (TfR >8.3 mg/L) (risk ratio: 3.1, P < 0.01), but not in ARV-treated mothers receiving LNS (P = 0.17). LNS without ARVs was not associated with iron deficiency or anemia (P > 0.1). In subsample infants, interventions were not associated with impaired iron status (all P > 0.1).Conclusions:Maternal ARV treatment with protease inhibitors is associated with maternal tissue iron depletion; but LNS mitigates adverse effects. ARVs do not seem to influence infant iron status; however, extended use needs to be evaluated. C1 [Widen, Elizabeth M.; Bentley, Margaret E.; Flax, Valerie L.; van der Horst, Charles M.; Adair, Linda S.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. [Chasela, Charles S.] Univ Witwatersrand, Dept Nutr, Parktown, South Africa. [Kayira, Dumbani; Kacheche, Zebrone; Tegha, Gerald] UNC Project, Fac Hlth Sci, Lilongwe, Malawi. [Kourtis, Athena P.; Ellington, Sascha R.; Jamieson, Denise J.] US Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. [Allen, Lindsay H.; Shahab-Ferdows, Setareh] ARS, USDA, Western Human Nutr Res Ctr, Davis, CA USA. RP Widen, EM (reprint author), Columbia Univ, Inst Human Nutr, Dept Epidemiol, 630 W 168th St 1512, New York, NY 10032 USA. EM ew2435@cumc.columbia.edu OI Flax, Valerie/0000-0003-0200-3355 FU Abbott Laboratories; GlaxoSmithKline FX The University of North Carolina received grant support from Abbott Laboratories and GlaxoSmithKline. NR 50 TC 3 Z9 3 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUL 1 PY 2015 VL 69 IS 3 BP 319 EP 328 DI 10.1097/QAI.0000000000000588 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CL1OY UT WOS:000356714600010 PM 25723140 ER PT J AU Colomar, M Tong, VT Morello, P Farr, SL Lawsin, C Dietz, PM Aleman, A Berrueta, M Mazzoni, A Becu, A Buekens, P Belizan, J Althabe, F AF Colomar, Mercedes Tong, Van T. Morello, Paola Farr, Sherry L. Lawsin, Catalina Dietz, Patricia M. Aleman, Alicia Berrueta, Mabel Mazzoni, Agustina Becu, Ana Buekens, Pierre Belizan, Jos Althabe, Fernando TI Barriers and Promoters of an Evidenced-Based Smoking Cessation Counseling During Prenatal Care in Argentina and Uruguay SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Qualitative research; Health personnel; Prenatal care; Smoking cessation counseling ID PREGNANT-WOMEN; MATERNAL SMOKING; TOBACCO SMOKING; PROVIDERS; ATTITUDES; PERCEPTIONS; POSTPARTUM; SMOKERS; IMPLEMENTATION; GYNECOLOGISTS AB In Argentina and Uruguay, 10.3 and 18.3 %, respectively, of pregnant women smoked in 2005. Brief cessation counseling, based on the 5A's model, has been effective in different settings. This qualitative study aims to improve the understanding of factors influencing the provision of smoking cessation counseling during pregnancy in Argentina and Uruguay. In 2010, we obtained prenatal care providers', clinic directors', and pregnant smokers' opinions regarding barriers and promoters to brief smoking cessation counseling in publicly-funded prenatal care clinics in Buenos Aires, Argentina and Montevideo, Uruguay. We interviewed six prenatal clinic directors, conducted focus groups with 46 health professionals and 24 pregnant smokers. Themes emerged from three issue areas: health professionals, health system, and patients. Health professional barriers to cessation counseling included inadequate knowledge and motivation, perceived low self-efficacy, and concerns about inadequate time and large workload. They expressed interest in obtaining a counseling script. Health system barriers included low prioritization of smoking cessation and a lack of clinic protocols to implement interventions. Pregnant smokers lacked information on the risks of prenatal smoking and underestimated the difficulty of smoking cessation. Having access to written materials and receiving cessation services during clinic waiting times were mentioned as promoters for the intervention. Women also were receptive to non-physician office staff delivering intervention components. Implementing smoking cessation counseling in publicly-funded prenatal care clinics in Argentina and Uruguay may require integrating counseling into routine prenatal care and educating and training providers on best-practices approaches. C1 [Colomar, Mercedes; Aleman, Alicia] Hosp Clin Montevideo, Unidad Invest Clin & Epidemiol Montevideo, Montevideo, Uruguay. [Tong, Van T.; Farr, Sherry L.; Dietz, Patricia M.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Morello, Paola] Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, Argentina. [Lawsin, Catalina; Berrueta, Mabel; Mazzoni, Agustina; Becu, Ana; Belizan, Jos; Althabe, Fernando] Univ Sydney, Sch Psychol, Sydney, NSW 2006, Australia. [Buekens, Pierre] Tulane Univ, Sch Publ Hlth & Trop Med, New Orleans, LA USA. RP Colomar, M (reprint author), Hosp Clin Montevideo, Unidad Invest Clin & Epidemiol Montevideo, Av Italia S-N, Montevideo, Uruguay. EM mcolomar@unicem-web.org OI Belizan, Jose/0000-0002-8412-3010 FU CDC [5U48DP001948-04 (SIP09-18)] FX We want to thank the institutions who kindly accepted to participate in this research. From Buenos Aires, Argentina: MV de Martinez Maternity Hospital, San Isidro Maternity Hospital, Ramon Carrillo Maternity Hospital, and Tigre Maternity Hospital. From Montevideo, Uruguay: Maternal and Child health Center 2, Badano Repetto Health Center, Jardines del Hipodromo Health Center, and Canzani Hospital. The study was supported through CDC cooperative agreement 5U48DP001948-04 (SIP09-18) to Tulane University. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of CDC. NR 34 TC 3 Z9 3 U1 2 U2 5 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD JUL PY 2015 VL 19 IS 7 BP 1481 EP 1489 DI 10.1007/s10995-014-1652-3 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0DM UT WOS:000356609300007 PM 25500989 ER PT J AU Howland, RE Madsen, AM Toprani, A Gambatese, M Mulready-Ward, C Begier, E AF Howland, Renata E. Madsen, Ann M. Toprani, Amita Gambatese, Melissa Mulready-Ward, Candace Begier, Elizabeth TI How Well Do Birth Records Serve Maternal and Child Health Programs? Birth Registration System Evaluation, New York City, 2008-2011 SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Maternal-child health centers; Public health surveillance; Vital statistics; Evaluation studies ID CERTIFICATE AB National birth registration guidelines were revised in 2003 to improve data quality; however, few studies have evaluated the impact on local jurisdictions and their data users. In New York City (NYC), approximately 125,000 births are registered annually with the NYC Department of Health and Mental Hygiene, and data are used routinely by the department's maternal and child health (MCH) programs. In order to better meet MCH program needs, we used Centers for Disease Control and Prevention guidelines to assess birth data usefulness, simplicity, data quality, timeliness and representativeness. We interviewed birth registration and MCH program staff, reviewed a 2009 survey of birth registrars (n = 39), and analyzed 2008-2011 birth records for timeliness and completeness (n = 502,274). Thirteen MCH programs use birth registration data for eligibility determination, needs assessment, program evaluation, and surveillance. Demographic variables are used frequently, nearly 100 % complete, and considered the gold standard by programs; in contrast, medical variables' use and validity varies widely. Seventy-seven percent of surveyed birth registrars reported a parts per thousand yen1 problematic items in the system; 64.1 % requested further training. During 2008-2011, the median interval between birth and registration was 5 days (range 0-260 days); 11/13 programs were satisfied with timeliness. The NYC birth registration system provides local MCH programs useful, timely, and representative data. However, some medical items are difficult to collect, of low quality, and rarely used. We recommend enhancing training for birth registrars, continuing quality improvement efforts, increasing collaboration with program users, and removing consistently low-quality and low-use variables. C1 [Howland, Renata E.; Madsen, Ann M.; Gambatese, Melissa; Mulready-Ward, Candace; Begier, Elizabeth] New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA. [Toprani, Amita] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. RP Howland, RE (reprint author), New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA. EM rroney@health.nyc.gov FU Applied Epidemiology Fellowship Program; Centers for Disease Control and Prevention (CDC) [5U38HM000414-5] FX This study and paper were supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by the Centers for Disease Control and Prevention (CDC) Cooperative Agreement Number 5U38HM000414-5. The authors thank the programs' representatives at the New York City Department of Health and Mental Hygiene, including the staff in the Bureau of Vital Statistics, for their participation in this project. NR 28 TC 0 Z9 0 U1 2 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD JUL PY 2015 VL 19 IS 7 BP 1559 EP 1566 DI 10.1007/s10995-015-1664-7 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0DM UT WOS:000356609300016 PM 25604629 ER PT J AU Zhu, Y Romitti, PA Conway, KMC Kim, S Zhang, Y Yang, M Mathews, KD AF Zhu, Yong Romitti, Paul A. Conway, Kristin M. Caspers Kim, Sunkyung Zhang, Ying Yang, Michele Mathews, Katherine D. CA Muscular Dystrophy Surveillance Tr TI GENITOURINARY HEALTH IN A POPULATION-BASED COHORT OF MALES WITH DUCHENNE AND BECKER MUSCULAR DYSTROPHIES SO MUSCLE & NERVE LA English DT Article DE Becker muscular dystrophy; Duchenne muscular dystrophy; epidemiology; male urogenital diseases; neuromuscular diseases ID NETWORK MD STARNET; SURVEILLANCE TRACKING; DYSFUNCTION; CORTICOSTEROIDS; IMPACT; ONSET AB Introduction: Genitourinary (GU) health among patients with Duchenne and Becker muscular dystrophies (DBMD) has not been explored using population-based data. Methods: Medical records of 918 males ascertained by the Muscular Dystrophy Surveillance, Tracking, and Research Network were reviewed for documentation of GU-related hospitalizations and prescribed medications. Percentages of males who received these medical interventions were calculated, and hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated for associations with sociodemographics (study site, race/ethnicity), symptoms (early- vs. late-onset, ambulation status, scoliosis), and treatments (respiratory support, steroids). Results: Among the 918 males, 81 (9%) had a GU condition, with voiding dysfunction (n = 40), GU tract infection ( n = 19), and kidney/ureter calculus (n = 9) most frequently seen. The Kaplan-Meier curve produced a cumulative probability of 27%. Cox regression showed GU conditions were more common when males were non-ambulatory (HR 2.7, 95% CI 1.3-5.6). Conclusions: Our findings highlight the need for increased awareness of GU health and multidisciplinary care of DBMD patients. C1 [Zhu, Yong; Romitti, Paul A.; Conway, Kristin M. Caspers] Univ Iowa, Dept Epidemiol, Iowa City, IA 52242 USA. [Kim, Sunkyung] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Zhang, Ying] Indiana Univ, Dept Biostat, Indianapolis, IN 46204 USA. [Yang, Michele] Childrens Hosp Colorado, Dept Pediat, Aurora, CO USA. [Mathews, Katherine D.] Univ Iowa, Dept Pediat, Iowa City, IA 52242 USA. RP Romitti, PA (reprint author), Univ Iowa, Dept Epidemiol, S416 CPHB,145 North Riverside Dr, Iowa City, IA 52242 USA. EM paul-romitti@uiowa.edu FU Centers for Disease Control and Prevention [U01 DD000831] FX This work was supported by a cooperative agreement (U01 DD000831) from the Centers for Disease Control and Prevention. NR 22 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0148-639X EI 1097-4598 J9 MUSCLE NERVE JI Muscle Nerve PD JUL PY 2015 VL 52 IS 1 BP 22 EP 27 DI 10.1002/mus.24486 PG 6 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CK8OQ UT WOS:000356498000004 PM 25297835 ER PT J AU Watson, CV Valentin-Blasini, L Damian, M Watson, CH AF Watson, Christina Vaughan Valentin-Blasini, Liza Damian, Maria Watson, Clifford H. TI Method for the determination of ammonium in cigarette tobacco using ion chromatography SO REGULATORY TOXICOLOGY AND PHARMACOLOGY LA English DT Article DE Ammonia; Cigarettes; Ion chromatography ID TOTAL PARTICULATE MATTER; ORAL-MUCOSA; NICOTINE; ABSORPTION; SMOKE; DEPOSITION; RETENTION; BLOOD AB Ammonia and other alkaline substances have been postulated to be important in cigarette design. The most significant potential contribution of ammonia is a possible interaction with the native, protonated nicotine in the smoke. Ammonia is more alkaline than nicotine and could facilitate a shift in the acid/base equilibrium where a fraction of the total nicotine converts to the more lipophilic, non-protonated form. This non-protonated, or free-base, form of nicotine absorbs more efficiently across membranes, resulting in more rapid delivery to the smoker's bloodstream. Ammonia and other potential ammonia sources, such as additives like diammonium phosphate, could influence the acid-base dynamics in cigarette smoke and ultimately the rate of nicotine delivery. To examine and characterize the ammonia content in modern cigarettes, we developed a fast, simple and reliable ion chromatography based method to measure extractable ammonia levels in cigarette filler. This approach has minimal sample preparation and short run times to achieve high sample throughput. We quantified ammonia levels in tobacco filler from 34 non-mentholated cigarette brands from 3 manufacturers to examine the ranges found across a convenience sampling of popular, commercially available domestic brands and present figures of analytical merit here. Ammonia levels ranged from approximately 0.9 to 2.4 mg per gram of cigarette filler between brands and statistically significance differences were observed between brands and manufacturers. Our findings suggest that ammonia levels vary by brand and manufacturer; thus in domestic cigarettes ammonia could be considered a significant design feature because of the potential influence on smoke chemistry. Published by Elsevier Inc. C1 [Watson, Christina Vaughan; Valentin-Blasini, Liza; Damian, Maria; Watson, Clifford H.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Tobacco & Volatiles Branch, Atlanta, GA 31314 USA. RP Watson, CV (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Tobacco & Volatiles Branch, Mailstop F-47,4770 Buford Highway NE, Atlanta, GA 31314 USA. EM cvaughan@cdc.gov NR 29 TC 1 Z9 1 U1 3 U2 19 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0273-2300 EI 1096-0295 J9 REGUL TOXICOL PHARM JI Regul. Toxicol. Pharmacol. PD JUL PY 2015 VL 72 IS 2 BP 266 EP 270 DI 10.1016/j.yrtph.2015.04.019 PG 5 WC Medicine, Legal; Pharmacology & Pharmacy; Toxicology SC Legal Medicine; Pharmacology & Pharmacy; Toxicology GA CL4DN UT WOS:000356902900013 PM 25934256 ER PT J AU Foster, MC Inker, LA Hsu, CY Eckfeldt, JH Levey, AS Pavkov, ME Myers, BD Bennett, PH Kimmel, PL Vasan, RS Coresh, J Nelson, RG AF Foster, Meredith C. Inker, Lesley A. Hsu, Chi-yuan Eckfeldt, John H. Levey, Andrew S. Pavkov, Meda E. Myers, Bryan D. Bennett, Peter H. Kimmel, Paul L. Vasan, Ramachandran S. Coresh, Josef Nelson, Robert G. CA CKD Biomarkers Consortium TI Filtration Markers as Predictors of ESRD and Mortality in Southwestern American Indians With Type 2 Diabetes SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Beta-trace protein (BTP); beta-2 microglobulin (B2M); end-stage renal disease (ESRD); type 2 diabetes mellitus; diabetic kidney failure; mortality; filtration markers; glomerular filtration rate (GFR); kidney function; Pima Indians; CKD Biomarkers Consortium ID BETA-TRACE PROTEIN; STAGE RENAL-DISEASE; CYSTATIN-C; SERUM CREATININE; AFRICAN-AMERICANS; KIDNEY-FUNCTION; MEASURED GFR; RISK; PROGRESSION; NEPHROPATHY AB Background: A growing number of serum filtration markers are associated with mortality and end-stage renal disease (ESRD) in adults. Whether b-trace protein (BTP) and b2-microglobulin (B2M) are associated with these outcomes in adults with type 2 diabetes is not known. Study Design: Longitudinal cohort study. Setting & Participants: 250 Pima Indians with type 2 diabetes (69% women; mean age, 42 years; mean diabetes duration, 11 years). Predictors: Serum BTP, B2M, and glomerular filtration rate measured by iothalamate clearance (mGFR) or estimated using creatinine (eGFR(cr)) or cystatin C level (eGFR(cys)). Outcomes & Measurements: Incident ESRD and all-cause mortality through December 2013. HRs were reported per interquartile range decrease of the inverse of BTP and B2M (1/BTP and 1/B2M) using Cox regression. Improvement in risk prediction with the addition of BTP or B2M level to established markers (eGFRcys with mGFR or eGFRcr) was evaluated using C statistics, continuous net reclassification improvement, and relative integrated discrimination improvement (RIDI). Results: During a median follow-up of 14 years, 69 participants developed ESRD and 95 died. Both novel markers were associated with ESRD in multivariable models. BTP level remained statistically significant after further adjustment for mGFR (1/BTP, 1.53 [95% CI, 1.01-2.30]; 1/B2M, 1.54 [95% CI, 0.98-2.42]). B2M level was associated with mortality in multivariable models and after further adjustment for mGFR (HR, 2.12; 95% CI, 1.38-3.26). The addition of B2M level to established markers increased the C statistic for mortality but only weakly when assessed by either continuous net reclassification improvement or RIDI; none was improved for ESRD by the addition of these markers. Limitations: Small sample size, single measurements of markers. Conclusions: In Pima Indians with type 2 diabetes, BTP and, to a lesser extent, B2M levels were associated with ESRD. B2M level was associated with mortality after adjustment for traditional risk factors and established filtration markers. Further studies are warranted to confirm whether inclusion of B2M level in a multimarker approach leads to improved risk prediction for mortality in this population. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc. C1 [Foster, Meredith C.; Inker, Lesley A.; Levey, Andrew S.] Tufts Med Ctr, Boston, MA USA. [Hsu, Chi-yuan] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Eckfeldt, John H.] Univ Minnesota, Minneapolis, MN USA. [Pavkov, Meda E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Myers, Bryan D.] Stanford Univ, Stanford, CA 94305 USA. [Bennett, Peter H.; Nelson, Robert G.] NIDDK, NIH, Phoenix, AZ USA. [Kimmel, Paul L.] NIDDK, NIH, Bethesda, MD 20892 USA. [Vasan, Ramachandran S.] Boston Univ, Boston, MA 02215 USA. [Coresh, Josef] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. RP Nelson, RG (reprint author), NIH, 1550 E Indian Sch Rd, Phoenix, AZ 85014 USA. EM rnelson@nih.gov OI Ramachandran, Vasan/0000-0001-7357-5970 FU NIDDK grants [U01DK85649, U01DK085673, U01DK085660, U01DK085688, U01DK085651, U01DK085689]; Intramural Research Program of the NIDDK; National Heart, Lung and Blood Institute grant [T32 HL007024] FX The CKD Biomarkers Consortium is funded by NIDDK grants U01DK85649, U01DK085673, U01DK085660, U01DK085688, U01DK085651, and U01DK085689 and by the Intramural Research Program of the NIDDK. Dr Foster was supported in part by National Heart, Lung and Blood Institute grant T32 HL007024. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. The funders of this study had no role in study design; collection, analysis, and interpretation of data; writing the report; and the decision to submit the report for publication. NR 27 TC 7 Z9 7 U1 0 U2 3 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUL PY 2015 VL 66 IS 1 BP 75 EP 83 DI 10.1053/j.ajkd.2015.01.013 PG 9 WC Urology & Nephrology SC Urology & Nephrology GA CL1UO UT WOS:000356730600016 PM 25773485 ER PT J AU Hoerger, TJ Burrows, NR Pavkov, ME AF Hoerger, Thomas J. Burrows, Nilka Rios Pavkov, Meda E. TI In Reply to 'The Myth of the Future Burden of CKD in United States' SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Letter ID DISEASE C1 [Hoerger, Thomas J.] RTI Int, Res Triangle Pk, NC 27709 USA. [Burrows, Nilka Rios; Pavkov, Meda E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Hoerger, TJ (reprint author), RTI Int, Res Triangle Pk, NC 27709 USA. FU Intramural CDC HHS [CC999999] NR 5 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD JUL PY 2015 VL 66 IS 1 BP 172 EP 172 DI 10.1053/j.ajkd.2015.05.003 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA CL1UO UT WOS:000356730600031 PM 26111907 ER PT J AU Bardenheier, BH Imperatore, G Gilboa, SM Geiss, LS Saydah, SH Devlin, HM Kim, SY Gregg, EW AF Bardenheier, Barbara H. Imperatore, Giuseppina Gilboa, Suzanne M. Geiss, Linda S. Saydah, Sharon H. Devlin, Heather M. Kim, Shin Y. Gregg, Edward W. TI Trends in Gestational Diabetes Among Hospital Deliveries in 19 US States, 2000-2010 SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID UNITED-STATES; CARDIOVASCULAR MORBIDITY; MELLITUS; PREVALENCE; WOMEN; OBESITY; PREECLAMPSIA; HYPERTENSION; POPULATION; PREVENTION AB Introduction: Diabetes is one of the most common and fastest-growing comorbidities of pregnancy. Temporal trends in gestational diabetes mellitus (GDM) have not been examined at the state level. This study examines GDM prevalence trends overall and by age, state, and region for 19 states, and by race/ethnicity for 12 states. Sub-analysis assesses trends among GDM deliveries by insurance type and comorbid hypertension in pregnancy. Methods: Using the Agency for Healthcare Research and Quality's National and State Inpatient Databases, deliveries were identified using diagnosis-related group codes for GDM and comorbidities using ICD-9-CM diagnosis codes among all community hospitals. General linear regression with a log-link and binomial distribution was used in 2014 to assess annual change in GDM prevalence from 2000 through 2010. Results: The age-standardized prevalence of GDM increased from 3.71 in 2000 to 5.77 per 100 deliveries in 2010 (relative increase, 56%). From 2000 through 2010, GDM deliveries increased significantly in all states (p < 0.01), with relative increases ranging from 36% to 88%. GDM among deliveries in 12 states reporting race and ethnicity increased among all groups (p < 0.01), with the highest relative increase in Hispanics (66%). Among GDM deliveries in 19 states, those with pre-pregnancy hypertension increased significantly from 2.5% to 4.1% (relative increase, 64%). The burden of GDM delivery payment shifted from private insurers (absolute decrease of 13.5 percentage points) to Medicaid/Medicare (13.2-percentage point increase). Conclusions: Results suggest that GDM deliveries are increasing. The highest rates of increase are among Hispanics and among GDM deliveries complicated by pre-pregnancy hypertension. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Bardenheier, Barbara H.; Imperatore, Giuseppina; Geiss, Linda S.; Saydah, Sharon H.; Devlin, Heather M.; Gregg, Edward W.] CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Kim, Shin Y.] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Gilboa, Suzanne M.] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. RP Bardenheier, BH (reprint author), CDC, 4770 Buford Hwy NE,MS F-73, Atlanta, GA 30341 USA. EM bfb7@cdc.gov FU Intramural CDC HHS [CC999999] NR 30 TC 12 Z9 12 U1 2 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUL PY 2015 VL 49 IS 1 BP 12 EP 19 DI 10.1016/j.amepre.2015.01.026 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CK6UI UT WOS:000356363400005 PM 26094225 ER PT J AU Suryaprasad, A Basavaraju, SV Hocevar, SN Theodoropoulos, N Zuckerman, RA Hayden, T Forbi, JC Pegues, D Levine, M Martin, SI Kuehnert, MJ Blumberg, EA AF Suryaprasad, A. Basavaraju, S. V. Hocevar, S. N. Theodoropoulos, N. Zuckerman, R. A. Hayden, T. Forbi, J. C. Pegues, D. Levine, M. Martin, S. I. Kuehnert, M. J. Blumberg, E. A. CA Organ Transplantation Hepatitis C TI Transmission of Hepatitis C Virus From Organ Donors Despite Nucleic Acid Test Screening SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; B-VIRUS; TRANSPLANT RECIPIENTS; RESIDUAL RISK; INFECTION; METAANALYSIS; TRANSFUSION; PREVALENCE; GENOTYPES; SURVIVAL AB Nucleic acid testing (NAT) for hepatitis C virus (HCV) is recommended for screening of organ donors, yet not all donor infections may be detected. We describe three US clusters of HCV transmission from donors at increased risk for HCV infection. Donor's and recipients' medical records were reviewed. Newly infected recipients were interviewed. Donor-derived HCV infection was considered when infection was newly detected after transplantation in recipients of organs from increased risk donors. Stored donor sera and tissue samples were tested for HCV RNA with high-sensitivity quantitative PCR. Posttransplant and pretransplant recipient sera were tested for HCV RNA. Quasispecies analysis of hypervariable region-1 was used to establish genetic relatedness of recipient HCV variants. Each donor had evidence of injection drug use preceding death. Of 12 recipients, 8 were HCV-infected6 were newly diagnosed posttransplant. HCV RNA was retrospectively detected in stored samples from donor immunologic tissue collected at organ procurement. Phylogenetic analysis showed two clusters of closely related HCV variants from recipients. These investigations identified the first known HCV transmissions from increased risk organ donors with negative NAT screening, indicating very recent donor infection. Recipient informed consent and posttransplant screening for blood-borne pathogens are essential when considering increased risk donors. C1 [Suryaprasad, A.; Hayden, T.; Forbi, J. C.] US Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Basavaraju, S. V.; Hocevar, S. N.; Kuehnert, M. J.] Ctr Dis Control & Prevent, Div Healthcare Qual & Promot, Off Blood Organ & Other Tissue Safety, Atlanta, GA USA. [Theodoropoulos, N.; Martin, S. I.] Ohio State Univ, Dept Internal Med, Div Infect Dis, Columbus, OH 43210 USA. [Zuckerman, R. A.] Dartmouth Hitchcock Med Ctr, Sect Infect Dis & Int Hlth, Lebanon, NH 03766 USA. [Pegues, D.; Levine, M.; Blumberg, E. A.] Univ Penn Hlth Syst, Perelman Sch Med, Philadelphia, PA USA. RP Suryaprasad, A (reprint author), US Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM asuryaprasad@cdc.gov RI Levine, Matthew/O-4809-2015 OI Levine, Matthew/0000-0003-4525-5827 FU Centers for Disease Control and Prevention FX The Centers for Disease Control and Prevention. NR 34 TC 5 Z9 5 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUL PY 2015 VL 15 IS 7 BP 1827 EP 1835 DI 10.1111/ajt.13283 PG 9 WC Surgery; Transplantation SC Surgery; Transplantation GA CK8NF UT WOS:000356494300018 PM 25943299 ER PT J AU Zlot, A Simckes, M Vines, J Reynolds, L Sullivan, A Scott, MK McLuckie, JM Kromer, D Hill, VR Yoder, JS Hlavsa, MC AF Zlot, Amy Simckes, Maayan Vines, Jennifer Reynolds, Laura Sullivan, Amy Scott, Magdalena Kendall McLuckie, J. Michael Kromer, Dan Hill, Vincent R. Yoder, Jonathan S. Hlavsa, Michele C. TI Norovirus Outbreak Associated With a Natural Lake Used for Recreation-Oregon, 2014 SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Editorial Material ID UNITED-STATES; WATER C1 [Zlot, Amy; Simckes, Maayan; Vines, Jennifer; Reynolds, Laura; Sullivan, Amy; McLuckie, J. Michael] Multnomah Cty Hlth Dept, Fairview, OR 97030 USA. [Simckes, Maayan] CDC, CSTE, Appl Epidemiol Fellowship Program, Fairview, OR USA. [Scott, Magdalena Kendall] Oregon Publ Hlth Div, Fairview, OR USA. [Kromer, Dan] Metro, Blue Lake Reg Pk, Fairview, OR USA. [Hill, Vincent R.; Yoder, Jonathan S.; Hlavsa, Michele C.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Zlot, A (reprint author), Multnomah Cty Hlth Dept, Fairview, OR 97030 USA. EM amy.zlot@multco.us NR 9 TC 0 Z9 0 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD JUL PY 2015 VL 15 IS 7 BP 2001 EP 2005 DI 10.1111/ajt.13404 PG 5 WC Surgery; Transplantation SC Surgery; Transplantation GA CK8NF UT WOS:000356494300037 PM 26086301 ER PT J AU Galloway, RL Hoffmaster, AR AF Galloway, Renee L. Hoffmaster, Alex R. TI Optimization of LipL32 PCR assay for increased sensitivity in diagnosing leptospirosis SO DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE LA English DT Article DE Leptospirosis; Diagnosis; Real time PCR AB Early diagnosis of leptospirosis in humans is critical with regard to initiation of appropriate treatment; however, the gold standard serological test cannot detect antibodies until nearly a week after symptom onset. PCR has been shown to be sensitive and specific in the early phase of leptospirosis. Previously, we developed and validated a TaqMan PCR assay targeting lipL32. We reoptimized and validated this assay using PerfeCfa (R) qPCRToughMix (R), Low ROX (TM) (Quanta Biosciences, Gaithersburg, MD, USA). For optimization with the new mix, the final primer concentrations were increased from 0.5 mu mol/L to 0.9 mu mol/L compared to our previous assay, and the probe concentration increased from 0.1 pmol/L to 0.125 mu mol/L. This newly optimized assay resulted in a lower limit of detection and increased diagnostic sensitivity. Here, we present the performance data of the improved assay and describe several clinical cases that were initially negative but tested positive using the optimized assay. Published by Elsevier Inc. C1 [Galloway, Renee L.; Hoffmaster, Alex R.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Bacterial Special Pathogens Branch, Atlanta, GA 30329 USA. RP Galloway, RL (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Bacterial Special Pathogens Branch, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM rgalloway@cdc.gov NR 5 TC 3 Z9 4 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0732-8893 EI 1879-0070 J9 DIAGN MICR INFEC DIS JI Diagn. Microbiol. Infect. Dis. PD JUL PY 2015 VL 82 IS 3 BP 199 EP 200 DI 10.1016/j.diagmicrobio2015.03.024 PG 2 WC Infectious Diseases; Microbiology SC Infectious Diseases; Microbiology GA CK7FX UT WOS:000356399300004 PM 25912810 ER PT J AU Wang, ZM Rajaraman, P Melin, BS Chung, CC Zhang, WJ McKean-Cowdin, R Michaud, D Yeager, M Ahlbom, A Albanes, D Andersson, U Freeman, LEB Buring, JE Butler, MA Carreon, T Feychting, M Gapstur, SM Gaziano, JM Giles, GG Hallmans, G Henriksson, R Hoffman-Bolton, J Inskip, PD Kitahara, CM Marchand, LL Linet, MS Li, SC Peters, U Purdue, MP Rothman, N Ruder, AM Sesso, HD Severi, G Stampfer, M Stevens, VL Visvanathan, K Wang, SS White, E Zeleniuch-Jacquotte, A Hoover, R Fraumeni, JF Chatterjee, N Hartge, P Chanock, SJ AF Wang, Zhaoming Rajaraman, Preetha Melin, Beatrice S. Chung, Charles C. Zhang, Weijia McKean-Cowdin, Roberta Michaud, Dominique Yeager, Meredith Ahlbom, Anders Albanes, Demetrius Andersson, Ulrika Freeman, Laura E. Beane Buring, Julie E. Butler, Mary Ann Carreon, Tania Feychting, Maria Gapstur, Susan M. Gaziano, J. Michael Giles, Graham G. Hallmans, Goran Henriksson, Roger Hoffman-Bolton, Judith Inskip, Peter D. Kitahara, Cari M. Marchand, Loic Le Linet, Martha S. Li, Shengchao Peters, Ulrike Purdue, Mark P. Rothman, Nathaniel Ruder, Avima M. Sesso, Howard D. Severi, Gianluca Stampfer, Meir Stevens, Victoria L. Visvanathan, Kala Wang, Sophia S. White, Emily Zeleniuch-Jacquotte, Anne Hoover, Robert Fraumeni, Joseph F. Chatterjee, Nilanjan Hartge, Patricia Chanock, Stephen J. TI Further Confirmation of Germline Glioma Risk Variant rs78378222 in TP53 and Its Implication in Tumor Tissues via Integrative Analysis of TCGA Data SO HUMAN MUTATION LA English DT Article DE glioma; TP53; rare SNP; TCGA ID GENOME-WIDE ASSOCIATION; SQUAMOUS-CELL CARCINOMA; NERVOUS-SYSTEM TUMORS; POLYADENYLATION SIGNAL; CANCER SUSCEPTIBILITY; SNPS; RARE AB We confirmed strong association of rs78378222:A>C (per allele odds ratio [OR] = 3.14; P = 6.48 x 10(-11)), a germline rare single-nucleotide polymorphism (SNP) in TP53, via imputation of a genome-wide association study of glioma (1,856 cases and 4,955 controls). We subsequently performed integrative analyses on the Cancer Genome Atlas (TCGA) data for GBM (glioblastoma multiforme) and LUAD (lung adenocarcinoma). Based on SNP data, we imputed genotypes for rs78378222 and selected individuals carrying rare risk allele (C). Using RNA sequencing data, we observed aberrant transcripts with approximate to 3 kb longer than normal for those individuals. Using exome sequencing data, we further showed that loss of haplotype carrying common protective allele (A) occurred somatically in GBM but not in LUAD. Our bioinformatic analysis suggests rare risk allele (C) disrupts mRNA termination, and an allelic loss of a genomic region harboring common protective allele (A) occurs during tumor initiation or progression for glioma. (C) 2015 Wiley Periodicals, Inc. C1 [Wang, Zhaoming; Rajaraman, Preetha; Chung, Charles C.; Yeager, Meredith; Albanes, Demetrius; Freeman, Laura E. Beane; Inskip, Peter D.; Kitahara, Cari M.; Linet, Martha S.; Li, Shengchao; Purdue, Mark P.; Rothman, Nathaniel; Hoover, Robert; Fraumeni, Joseph F.; Chatterjee, Nilanjan; Hartge, Patricia; Chanock, Stephen J.] NCI, Div Canc Epidemiol & Genet, Rockville, MD USA. [Wang, Zhaoming; Chung, Charles C.; Yeager, Meredith; Li, Shengchao] Leidos Biomed Res Inc, Canc Genom Res Lab, Gaithersburg, MD USA. [Melin, Beatrice S.; Andersson, Ulrika; Henriksson, Roger] Umea Univ, Dept Radiat Sci, Oncol, Umea, Sweden. [Zhang, Weijia] Icahn Sch Med Mt Sinai, Dept Med Bioinformat Core, New York, NY 10029 USA. [McKean-Cowdin, Roberta] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Michaud, Dominique] Brown Univ, Dept Epidemiol, Div Biol & Med, Providence, RI 02912 USA. [Michaud, Dominique] Univ London Imperial Coll Sci Technol & Med, Sch Publ Hlth, London, England. [Ahlbom, Anders; Feychting, Maria] Karolinska Inst, Inst Environm Med, Div Epidemiol, S-10401 Stockholm, Sweden. [Buring, Julie E.; Gaziano, J. Michael; Sesso, Howard D.] Brigham & Womens Hosp, Div Prevent Med, Boston, MA 02115 USA. [Buring, Julie E.; Gaziano, J. Michael; Sesso, Howard D.] Harvard Univ, Sch Med, Boston, MA USA. [Butler, Mary Ann; Carreon, Tania; Ruder, Avima M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Gapstur, Susan M.; Stevens, Victoria L.] Amer Canc Soc, Epidemiol Res Program, Atlanta, GA 30329 USA. [Gaziano, J. Michael] VA Boston Healthcare Syst, Ctr Geriatr Res Educ & Clin, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA. [Giles, Graham G.; Severi, Gianluca] Canc Council Victoria, Canc Epidemiol Ctr, Melbourne, Vic, Australia. [Giles, Graham G.; Severi, Gianluca] Univ Melbourne, Ctr Mol Environm Genet & Analyt Epidemiol, Melbourne, Vic, Australia. [Hallmans, Goran] Umea Univ, Dept Publ Hlth & Clin Med Nutr Res, Umea, Sweden. [Hoffman-Bolton, Judith; Visvanathan, Kala] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Marchand, Loic Le] Univ Hawaii, Canc Res Ctr, Honolulu, HI 96813 USA. [Peters, Ulrike; White, Emily] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA. [Peters, Ulrike; White, Emily] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Stampfer, Meir] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Lab, Boston, MA 02115 USA. [Stampfer, Meir] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA. [Stampfer, Meir] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA. [Visvanathan, Kala] Johns Hopkins Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA. [Wang, Sophia S.] City Hope Natl Med Ctr, Dept Populat Sci, Div Canc Etiol, Duarte, CA USA. [Wang, Sophia S.] City Hope Natl Med Ctr, Beckman Res Inst, Duarte, CA 91010 USA. [Zeleniuch-Jacquotte, Anne] NYU Sch Med, Dept Environm Med, Div Epidemiol, New York, NY USA. RP Chanock, SJ (reprint author), NCI, Div Canc Epidemiol & Genet, 9609 Med Ctr Dr Rm 7E412,MSC 9776, Bethesda, MD 20892 USA. EM wangzha@mail.nih.gov; chanocks@mail.nih.gov RI Purdue, Mark/C-9228-2016; Kitahara, Cari/R-8267-2016; OI Purdue, Mark/0000-0003-1177-3108; Giles, Graham/0000-0003-4946-9099; Zeleniuch-Jacquotte, Anne/0000-0001-9350-1303 FU NCI; NIH [N01-CO-12400]; Department of Health and Human Services FX Contract grant sponsors: NCI; NIH; Department of Health and Human Services; NCI; NIH (N01-CO-12400). NR 18 TC 3 Z9 3 U1 1 U2 5 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1059-7794 EI 1098-1004 J9 HUM MUTAT JI Hum. Mutat. PD JUL PY 2015 VL 36 IS 7 BP 684 EP 688 DI 10.1002/humu.22799 PG 5 WC Genetics & Heredity SC Genetics & Heredity GA CK8NT UT WOS:000356495700005 PM 25907361 ER PT J AU Harper, M Weis, C Pleil, JD Blount, BC Miller, A Hoover, MD Jahn, S AF Harper, Martin Weis, Christopher Pleil, Joachim D. Blount, Benjamin C. Miller, Aubrey Hoover, Mark D. Jahn, Steven TI Commentary on the contributions and future role of occupational exposure science in a vision and strategy for the discipline of exposure science SO JOURNAL OF EXPOSURE SCIENCE AND ENVIRONMENTAL EPIDEMIOLOGY LA English DT Review DE education; exposure science; exposure assessment; exposome; risk ID ENVIRONMENTAL EXPOSURE; HEALTH-RISKS; BISPHENOL-A; EXPOSOME; POPULATION; EXPERIENCE; INDUSTRY; EXHAUST; BRITAIN; WORKERS AB Exposure science is a holistic concept without prejudice to exposure source. Traditionally, measurements aimed at mitigating environmental exposures have not included exposures in the workplace, instead considering such exposures to be an internal affair between workers and their employers. Similarly, occupational (or industrial) hygiene has not typically accounted for environmental contributions to poor health at work. Many persons spend a significant amount of their lifetime in the workplace, where they maybe exposed to more numerous chemicals at higher levels than elsewhere in their environment. In addition, workplace chemical exposures and other exogenous stressors may increase epigenetic and germline modifications that are passed on to future generations. We provide a brief history of the development of exposure science from its roots in the assessment of workplace exposures, including an appendix where we detail current resources for education and training in exposure science offered through occupational hygiene organizations. We describe existing successful collaborations between occupational and environmental practitioners in the field of exposure science, which may serve as a model for future interactions. Finally, we provide an integrated vision for the field of exposure science, emphasizing interagency collaboration, the need for complete exposure information in epidemiological studies, and the importance of integrating occupational, environmental, and residential assessments. Our goal is to encourage communication and spur additional collaboration between the fields of occupational and environmental exposure assessment. Providing a more comprehensive approach to exposure science is critical to the study of the "exposome", which conceptualizes the totality of exposures throughout a person's life, not only chemical, but also from diet, stress, drugs, infection, and so on, and the individual response. C1 [Harper, Martin] NIOSH, Exposure Assessment Branch, Hlth Effects Lab Div, Morgantown, WV 26505 USA. [Weis, Christopher; Miller, Aubrey] NIEHS, Off Director, Bethesda, MD USA. [Pleil, Joachim D.] US EPA, Methods Dev & Applicat Branch, Natl Exposure Res Lab, Off Res & Dev, Res Triangle Pk, NC 27711 USA. [Blount, Benjamin C.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, CDC, Atlanta, GA USA. [Hoover, Mark D.] NIOSH, Div Resp Dis Studies, Morgantown, WV 26505 USA. [Jahn, Steven] Jahn Ind Hyg, Aiken, SC USA. RP Harper, M (reprint author), NIOSH, Exposure Assessment Branch, Hlth Effects Lab Div, 1095 Willowdale Rd,MS-3030, Morgantown, WV 26505 USA. EM mharper@cdc.gov FU Intramural CDC HHS [CC999999] NR 51 TC 3 Z9 3 U1 0 U2 14 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1559-0631 EI 1559-064X J9 J EXPO SCI ENV EPID JI J. Expo. Sci. Environ. Epidemiol. PD JUL-AUG PY 2015 VL 25 IS 4 BP 381 EP 387 DI 10.1038/jes.2014.91 PG 7 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CK8TT UT WOS:000356512100003 PM 25670022 ER PT J AU Hamel, MJ Slutsker, L AF Hamel, Mary J. Slutsker, Laurence TI Ebola: the hidden toll SO LANCET INFECTIOUS DISEASES LA English DT Editorial Material C1 [Hamel, Mary J.; Slutsker, Laurence] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. RP Hamel, MJ (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA 30329 USA. EM lms5@cdc.gov NR 4 TC 1 Z9 1 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD JUL PY 2015 VL 15 IS 7 BP 75 EP 757 DI 10.1016/S1473-3099(15)70167-2 PG 2 WC Infectious Diseases SC Infectious Diseases GA CL0HT UT WOS:000356622900007 ER PT J AU Hines, EP Mendola, P von Ehrenstein, OS Ye, XY Calafat, AM Fenton, SE AF Hines, Erin P. Mendola, Pauline von Ehrenstein, Ondine S. Ye, Xiaoyun Calafat, Antonia M. Fenton, Suzanne E. TI Concentrations of environmental phenols and parabens in milk, urine and serum of lactating North Carolina women SO REPRODUCTIVE TOXICOLOGY LA English DT Article DE Biomonitoring; BPA; Breast milk; Lactation; MAMA Study; Parabens phenols; Serum; Urine ID TANDEM MASS-SPECTROMETRY; HPLC-MS/MS METHOD; POLYBROMINATED DIPHENYL ETHERS; NUTRITION EXAMINATION SURVEY; BISPHENOL-A CONCENTRATIONS; MALE REPRODUCTIVE-SYSTEM; PERSONAL CARE PRODUCTS; HUMAN BREAST-MILK; NATIONAL-HEALTH; RISK-ASSESSMENT AB Phenols and parabens show some evidence for endocrine disruption in laboratory animals. The goal of the Methods Advancement for Milk Analysis (MAMA) Study was to develop or adapt methods to measure parabens (methyl, ethyl, butyl, propyl) and phenols (bisphenol A (BPA), 2,4- and 2,5-dichlorophenol, benzophenone-3, triclosan) in urine, milk and serum twice during lactation, to compare concentrations across matrices and with endogenous biomarkers among 34 North Carolina women. These non-persistent chemicals were detected in most urine samples (53-100%) and less frequently in milk or serum; concentrations differed by matrix. Although urinary parabens, triclosan and dichlorophenols concentrations correlated significantly at two time points, those of BPA and benzophenone-3 did not, suggesting considerable variability in those exposures. These pilot data suggest that nursing mothers are exposed to phenols and parabens; urine is the best measurement matrix; and correlations between chemical and endogenous immune-related biomarkers merit further investigation. Published by Elsevier Inc. C1 [Hines, Erin P.] US EPA, Off Res & Dev, Natl Ctr Environm Assessment, Res Triangle Pk, NC 27711 USA. [Mendola, Pauline] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Intramural Populat Hlth Res, Rockville, MD USA. [von Ehrenstein, Ondine S.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Community Hlth Sci, Los Angeles, CA USA. [Ye, Xiaoyun; Calafat, Antonia M.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Fenton, Suzanne E.] NIEHS, Div Natl Toxicol Program, NIH, Res Triangle Pk, NC USA. RP Hines, EP (reprint author), US EPA, Off Res & Dev, Natl Ctr Environm Assessment, Res Triangle Pk, NC 27711 USA. EM hines.erin@epa.gov; pauline.mendola@nih.gov; ovehren@ucla.edu; xay5@cdc.gov; aic7@cdc.gov; fentonse@niehs.nih.gov OI Hines, Erin Pias/0000-0002-2458-6267; Mendola, Pauline/0000-0001-5330-2844 FU National Children's Study Inter-Agency Coordinating Committee; Intramural Research Program of the NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development FX We thank Jack Reidy, Tao Jia, Xiaoliu Zhou, Amber Bishop, Charles Dodson, Pam Olive, and Richard Wang for technical assistance. The authors thank the Westat, Inc. recruiters (Andrea Ware, Bethany Bradford, Brian Karasek), U.S. EPA nursing staff (Deb Levin, Mary Ann Bassett, and Tracey Montilla), and the MAMA study participants, without whom this project would not have been a success. This project received partial extramural funding through the recommendation of the National Children's Study Inter-Agency Coordinating Committee. This research was supported, in part, by the Intramural Research Program of the NIH, Eunice Kennedy Shriver National Institute of Child Health and Human Development. NR 62 TC 16 Z9 16 U1 8 U2 47 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0890-6238 J9 REPROD TOXICOL JI Reprod. Toxicol. PD JUL PY 2015 VL 54 SI SI BP 120 EP 128 DI 10.1016/j.reprotox.2014.11.006 PG 9 WC Reproductive Biology; Toxicology SC Reproductive Biology; Toxicology GA CK7GR UT WOS:000356401300015 PM 25463527 ER PT J AU D'Anna, LH Warner, L Margolis, AD Korosteleva, OA O'Donnell, L Rietmeijer, CA Klausner, JD Malotte, CK AF D'Anna, Laura Hoyt Warner, Lee Margolis, Andrew D. Korosteleva, Olga A. O'Donnell, Lydia Rietmeijer, Cornelis A. Klausner, Jeffrey D. Malotte, C. Kevin CA Safe City Study Grp TI Consistency of Condom Use During Receptive Anal Intercourse Among Women and Men Who Have Sex With Men: Findings From the Safe in the City Behavioral Study SO SEXUALLY TRANSMITTED DISEASES LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED-DISEASES; UNITED-STATES; BISEXUAL MEN; YOUNG-ADULTS; DELAYED APPLICATION; CONTROLLED-TRIAL; RISK BEHAVIORS; HIV RISK; INFECTION AB Background Unprotected receptive anal intercourse poses HIV risk for men who have sex with men (MSM) and heterosexual women. Little is known about differences in consistent condom use during anal intercourse among these populations. Methods Data were analyzed from a nested study conducted from 2004 to 2005 within a behavioral intervention trial of approximately 40,000 urban US sexually transmitted disease clinic patients. Analyses were restricted to women and MSM who reported receptive anal intercourse with at least 1 partner in the prior 3 months at baseline, or 3-month follow-up surveys. Condom use was categorized as consistent (100% of receptive acts) or inconsistent/nonuse (0-99% of receptive acts). Multivariable regression with general estimating equations was used to identify factors associated with consistent condom use within each population. Results Approximately 31% of women and 70% of MSM reported receptive anal intercourse at least once in the past 3 months. Men who have sex with men were significantly more likely to report consistent condom use compared with women. For women, intention to use condoms, partner support for condom use, the belief they could stop having sex when condoms were unavailable, and believing their partner had not given them a sexually transmitted infection (STI) were associated with using condoms consistently. For MSM, intention to use condoms, condom use self-efficacy, perceived partner support for condom use, having a nonmain partner, believing their partner had not given them an STI, and fewer sex acts were associated with consistent condom use. Conclusions Findings confirm the importance of considering anal intercourse when assessing STI/HIV risk in MSM and heterosexual women. C1 [D'Anna, Laura Hoyt; Korosteleva, Olga A.; Malotte, C. Kevin] Calif State Univ Long Beach, Long Beach, CA 90840 USA. [Warner, Lee; Margolis, Andrew D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [O'Donnell, Lydia] Educ Dev Ctr, Boston, MA USA. [Rietmeijer, Cornelis A.] Denver Publ Hlth, Denver, CO USA. [Klausner, Jeffrey D.] Univ Calif Los Angeles, Dept Med & Publ Hlth, Los Angeles, CA 90024 USA. RP D'Anna, LH (reprint author), Calif State Univ Long Beach, Ctr Hlth Equ Res, 1250 Bellflower Blvd,F05-120, Long Beach, CA 90840 USA. EM laura.d'anna@csulb.edu FU United States Centers for Disease Control and Prevention; National Institute on Minority Health and Health Disparities [P20MD003942] FX The Safe in the City Study was funded by the United States Centers for Disease Control and Prevention. The preparation of this manuscript was supported, in part, by Award Number P20MD003942 from the National Institute on Minority Health and Health Disparities. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, the National Institute on Minority Health and Health Disparities, or the National Institutes of Health. NR 30 TC 0 Z9 0 U1 3 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0148-5717 EI 1537-4521 J9 SEX TRANSM DIS JI Sex. Transm. Dis. PD JUL PY 2015 VL 42 IS 7 BP 393 EP 399 DI 10.1097/OLQ.0000000000000306 PG 7 WC Infectious Diseases SC Infectious Diseases GA CK8MH UT WOS:000356491700008 PM 26222753 ER PT J AU Nguyen, KH King, BA Dube, SR AF Nguyen, Kimberly H. King, Brian A. Dube, Shanta R. TI Association between current asthma and secondhand smoke exposure in vehicles among adults living in four US states SO TOBACCO CONTROL LA English DT Article ID POLYCYCLIC AROMATIC-HYDROCARBONS; UNITED-STATES; SYMPTOMS; OUTCOMES; INDOOR; AIR AB Objective Many states have implemented laws prohibiting tobacco smoking in indoor public places. However, private settings remain a major source of secondhand smoke (SHS) exposure for many people. We assessed the association between current asthma and SHS exposure in vehicles among adult never-smokers in Indiana, Kentucky, Louisiana and Mississippi. Methods Data came from the 2011 Behavioral Risk Factor Surveillance System, a state-based telephone survey of US adults aged >= 18 years. Analyses were restricted to states (n=4) that administered an optional SHS module. Prevalence of self-reported asthma and past 7-day SHS exposure in vehicles was calculated by demographics, voluntary smoke-free vehicle rules and SHS exposure in homes, public places and workplaces. Logistic regression was used to assess the adjusted association between asthma and SHS exposure in vehicles. Results Among 17 863 never-smoking adults, 7.4% reported having current asthma, whereas 12.3% reported past 7-day SHS exposure in vehicles. Among adults with asthma, SHS exposure in vehicles was lower among those with voluntary smoke-free rules compared with those without voluntary smoke-free rules (9.5% vs 56.7%, p<0.0001). Following adjustment, adults exposed to SHS in a vehicle had a higher odds of having current asthma compared with unexposed adults (OR=2.01, 95% CI 1.18 to 3.40). Conclusions Never-smoking adults recently exposed to SHS in a vehicle had higher odds of having current asthma compared with unexposed adults. Efforts are warranted to warn about the dangers of SHS and to encourage voluntary smoke-free rules in vehicles, especially among adults with asthma. C1 [Nguyen, Kimberly H.; King, Brian A.; Dube, Shanta R.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Dube, Shanta R.] Georgia State Univ, Sch Publ Hlth, Div Epidemiol & Biostat, Atlanta, GA 30303 USA. RP Nguyen, KH (reprint author), Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,MS F-79, Atlanta, GA 30341 USA. EM Uxp1@cdc.gov NR 23 TC 0 Z9 0 U1 1 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0964-4563 EI 1468-3318 J9 TOB CONTROL JI Tob. Control PD JUL PY 2015 VL 24 IS 4 BP 376 EP 381 DI 10.1136/tobaccocontrol-2013-051526 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0BS UT WOS:000356604100017 PM 24794714 ER PT J AU Wang, DX Krilich, J Baudys, J Barr, JR Kalb, SR AF Wang, Dongxia Krilich, Joan Baudys, Jakub Barr, John R. Kalb, Suzanne R. TI Enhanced detection of type C botulinum neurotoxin by the Endopep-MS assay through optimization of peptide substrates SO BIOORGANIC & MEDICINAL CHEMISTRY LA English DT Article DE Botulinum neurotoxins; Botulism; Peptide synthesis; Mass spectrometry ID MASS-SPECTROMETRY; PROTEOLYSIS; SYNTAXIN; RELEASE; SNAP-25; CLEAVES; INTACT; MOUSE AB It is essential to have a simple, quick and sensitive method for the detection and quantification of botulinum neurotoxins, the most toxic substances and the causative agents of botulism. Type C botulinum neurotoxin (BoNT/C) represents one of the seven members of distinctive BoNT serotypes (A to G) that cause botulism in animals and avians. Here we report the development of optimized peptide substrates for improving the detection of BoNT/C and /CD mosaic toxins using an Endopep-MS assay, a mass spectrometry-based method that is able to rapidly and sensitively detect and differentiate all types of BoNTs by extracting the toxin with specific antibodies and detecting the unique cleavage products of peptide substrates. Based on the sequence of a short SNAP-25 peptide, we conducted optimization through a comprehensive process including length determination, terminal modification, single and multiple amino acid residue substitution, and incorporation of unnatural amino acid residues. Our data demonstrate that an optimal peptide provides a more than 200-fold improvement over the substrate currently used in the Endopep-MS assay for the detection of BoNT/C1 and /CD mosaic. Using the new substrate in a four-hour cleavage reaction, the limit of detection for the BoNT/C1 complex spiked in buffer, serum and milk samples was determined to be 0.5, 0.5 and 1 mouseLD(50)/mL, respectively, representing a similar or higher sensitivity than that obtained by traditional mouse bioassay. Published by Elsevier Ltd. C1 [Wang, Dongxia; Krilich, Joan; Baudys, Jakub; Barr, John R.; Kalb, Suzanne R.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. RP Kalb, SR (reprint author), Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, 4770 Buford Highway, Atlanta, GA 30341 USA. EM SKalb@cdc.gov OI Kalb, Suzanne/0000-0002-8067-136X FU Intramural CDC HHS [CC999999] NR 21 TC 6 Z9 6 U1 2 U2 6 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0968-0896 EI 1464-3391 J9 BIOORGAN MED CHEM JI Bioorg. Med. Chem. PD JUL 1 PY 2015 VL 23 IS 13 BP 3667 EP 3673 DI 10.1016/j.bmc.2015.04.012 PG 7 WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Chemistry, Organic SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Chemistry GA CJ9UO UT WOS:000355848900070 PM 25913863 ER PT J AU Bandini, L Danielson, M Esposito, LE Foley, JT Fox, MH Frey, GC Fleming, RK Krahn, G Must, A Porretta, DL Rodgers, AB Stanish, H Urv, T Vogel, LC Humphries, K AF Bandini, Linda Danielson, Melissa Esposito, Layla E. Foley, John T. Fox, Michael H. Frey, Georgia C. Fleming, Richard K. Krahn, Gloria Must, Aviva Porretta, David L. Rodgers, Anne Brown Stanish, Heidi Urv, Tiina Vogel, Lawrence C. Humphries, Kathleen TI Obesity in children with developmental and/or physical disabilities SO DISABILITY AND HEALTH JOURNAL LA English DT Editorial Material DE Obesity; Children; Physical disability; Developmental disability; Intellectual disability ID AUTISM SPECTRUM DISORDERS; CEREBRAL-PALSY; INTELLECTUAL DISABILITY; ENERGY-EXPENDITURE; MENTAL-RETARDATION; CHILDHOOD OBESITY; BODY-COMPOSITION; DOWN-SYNDROME; CARDIOVASCULAR FITNESS; ADOLESCENT OVERWEIGHT AB Children with developmental or physical disabilities, many of whom face serious health-related conditions, also are affected by the current obesity crisis. Although evidence indicates that children with disabilities have a higher prevalence of obesity than do children without disabilities, little is known of the actual magnitude of the problem in this population. To address this concern, the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) held a conference on obesity in children with intellectual, developmental, or physical disabilities, bringing together scientists and practitioners in the fields of obesity and disability to foster collaboration, identify barriers to healthy weight status in populations with disabilities, propose avenues to solutions through research and practice, and develop a research agenda to address the problem. This article describes current knowledge about prevalence of obesity in this population, discusses factors influencing obesity risk, and summarizes recommendations for research presented at the conference. Published by Elsevier Inc. C1 [Bandini, Linda] Univ Massachusetts, Sch Med, Eunice Kennedy Shriver Ctr, Waltham, MA 02452 USA. [Bandini, Linda] Boston Univ, Dept Hlth Sci, Boston, MA 02215 USA. [Danielson, Melissa; Fox, Michael H.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Human Dev & Disabil, Atlanta, GA 30333 USA. [Esposito, Layla E.] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Child Dev & Behav Branch, NIH, Rockville, MD 20892 USA. [Foley, John T.] SUNY Coll Cortland, Dept Phys Educ, Cortland, NY 13045 USA. [Frey, Georgia C.] Indiana Univ, Dept Kinesiol, Child Dev, Bloomington, IN 47405 USA. [Fleming, Richard K.; Stanish, Heidi] Univ Massachusetts, Dept Exercise & Hlth Sci, Boston, MA 02125 USA. [Krahn, Gloria] Oregon State Univ, Coll Publ Hlth & Human Sci, Barbara E Knudson Endowed Chair Family Policy, External Relat & Econ Dev, Corvallis, OR 97331 USA. [Must, Aviva] Tufts Univ, Sch Med, Dept Publ Hlth & Community Med, Boston, MA 02111 USA. [Porretta, David L.] Ohio State Univ, Kinesiol, Columbus, OH 43210 USA. [Rodgers, Anne Brown] NICHD Consultant, Falls Church, VA 22046 USA. [Urv, Tiina] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Intellectual & Dev Disabil Branch, NIH, Bethesda, MD 20892 USA. [Vogel, Lawrence C.] Shriners Hosp Children, Chicago, IL 60707 USA. [Humphries, Kathleen] Univ Montana, Rural Inst Disabil, Missoula, MT 59812 USA. RP Esposito, LE (reprint author), Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Child Dev & Behav Branch, NIH, 6100 Execut Blvd, Rockville, MD 20892 USA. EM espositl@mail.nih.gov OI Danielson, Melissa/0000-0001-9461-0341 NR 70 TC 4 Z9 4 U1 3 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 EI 1876-7583 J9 DISABIL HEALTH J JI Disabil. Health J. PD JUL PY 2015 VL 8 IS 3 BP 309 EP 316 DI 10.1016/j.dhjo.2015.04.005 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA CJ8QM UT WOS:000355768600003 PM 26058685 ER PT J AU Fox, MH Krahn, GL Sinclair, LB Cahill, A AF Fox, Michael H. Krahn, Gloria L. Sinclair, Lisa B. Cahill, Anthony TI Using the international classification of functioning, disability and health to expand understanding of paralysis in the United States through improved surveillance SO DISABILITY AND HEALTH JOURNAL LA English DT Article DE Paralysis; Functional definition of disability; ICF; Surveillance ID SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; PREVALENCE; ICF; STROKE; DEMENTIA; US AB Background: Surveillance on paralysis prevalence has been conceptually and methodologically challenging. Numerous methods have been used to approximate population-level paralysis prevalence estimates leading to widely divergent prevalence estimates. Objective/hypotheses: To describe three phases in use of the International Classification of Functioning, Disability and Health (ICF) as a framework and planning tool for defining paralysis and developing public health surveillance of this condition. \ Methods: Description of the surveillance methodology covers four steps: an assessment of prior data collection efforts that included a review of existing surveys, registries and other data collection efforts designed to capture both case definitions in use and prevalence of paralysis; use of a consensus conference of experts to develop a case definition of paralysis based on the ICF rather than medical diagnostic criteria; explanation of use of the ICF framework for domains of interest to develop, cognitively test, validate and administer a brief self-report questionnaire for telephone administration on a population; and development and administration of a Paralysis Prevalence and Health Disparities Survey that used content mapping to back code items from existing national surveys to operationalize key domains. Results: ICF coding led to a national population-based survey of paralysis that produced accurate estimates of prevalence and identification of factors related to the health of people in the U.S. living with paralysis. Conclusions: The ICF can be a useful tool for developing valid and reliable surveillance strategies targeting subgroups of individuals with functional disabilities such as people with paralysis and others. Published by Elsevier Inc. C1 [Fox, Michael H.; Sinclair, Lisa B.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Krahn, Gloria L.] Oregon State Univ, Coll Publ Hlth & Human Sci, Corvallis, OR 97331 USA. [Cahill, Anthony] Univ New Mexico, Sch Med, Ctr Dev & Disabil, Albuquerque, NM 87107 USA. RP Fox, MH (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop E88, Atlanta, GA 30333 USA. EM Imv9@cdc.gov FU Administration for Community Living [90PR3001]; Centers for Disease Control and Prevention [HHS1U59DD000838] FX This publication was made possible through grant number 90PR3001 from the Administration for Community Living and prior grant number HHS1U59DD000838 from the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Administration on Community Living. NR 30 TC 2 Z9 2 U1 2 U2 8 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1936-6574 EI 1876-7583 J9 DISABIL HEALTH J JI Disabil. Health J. PD JUL PY 2015 VL 8 IS 3 BP 457 EP 463 DI 10.1016/j.dhjo.2015.03.002 PG 7 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health; Rehabilitation SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Rehabilitation GA CJ8QM UT WOS:000355768600020 PM 25887622 ER PT J AU Li, J Chen, J Yang, G Zheng, YX Mao, SH Zhu, WP Yu, XL Gao, Y Pan, QC Yuan, ZA AF Li, J. Chen, J. Yang, G. Zheng, Y. X. Mao, S. H. Zhu, W. P. Yu, X. L. Gao, Y. Pan, Q. C. Yuan, Z. A. TI Case-control study of risk factors for human infection with avian influenza A(H7N9) virus in Shanghai, China, 2013 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Avian influenza A(H7N9) virus; case-control study; human infection; risk factor ID A H7N9 VIRUS; LIVE POULTRY MARKETS; HONG-KONG; AIRBORNE TRANSMISSION; H5N1; FERRETS AB The first human infection with avian influenza A(H7N9) virus was reported in Shanghai, China in March 2013. An additional 32 cases of human H7N9 infection were identified in the following months from March to April 2013 in Shanghai. Here we conducted a case-control study of the patients with H7N9 infection (n = 25) using controls matched by age, sex, and residence to determine risk factors for H7N9 infection. Our findings suggest that chronic disease and frequency of visiting a live poultry market (>10 times, or 1-9 times during the 2 weeks before illness onset) were likely to be significantly associated with H7N9 infection, with the odds ratios being 4.07 [95% confidence interval (CI) 1.32 12.56], 10.61 (95% CI 1.85 60.74), and 3.76 (95% CI 1.31-10.79), respectively. Effective strategies for live poultry market control should be reinforced and ongoing education of the public is warranted to promote behavioural changes that can help to eliminate direct or indirect contact with influenza A(H7N9) virus. C1 [Li, J.; Chen, J.; Zheng, Y. X.; Mao, S. H.; Pan, Q. C.; Yuan, Z. A.] Shanghai Municipal Ctr Dis Control & Prevent, Dept Acute Infect Dis Control, Shanghai 200336, Peoples R China. [Yang, G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Zhu, W. P.] Pudong New Dist Ctr Dis Control & Prevent, Dept Acute Infect Dis Control, Shanghai 200336, Peoples R China. [Yu, X. L.; Gao, Y.] Shanghai Municipal Ctr Dis Control & Prevent, Dept Microbiol, Shanghai 200336, Peoples R China. RP Yuan, ZA (reprint author), Shanghai Municipal Ctr Dis Control & Prevent, Dept Acute Infect Dis Control, 1380 West Zhongshan Rd, Shanghai 200336, Peoples R China. EM qcpan@scdc.sh.cn; zayuan@scdc.sh.cn FU National Science and Technology Supporting Programme [KJYJ-2013-01-05]; Joint Research Project of Shanghai Municipal Avian Influenza A(H7N9) Prevention and Control [2013QLG008]; Constructing Programme of Shanghai Municipal Public Health Key Discipline [12GWZX0101] FX We thank the Centers for Disease Control and Prevention of Minhang, Pudong, Baoshan, Huangpu, Sonjiang, Fengxian, Zhabei, Putuo, Changning and Yangpu districts in Shanghai for skilful assistance with the field investigations, which ensured timely study conduct and high-quality data collection. We also thank Professor Paul Chan (Chinese University of Hongkong) for critical review of the manuscript. This work was supported by the National Science and Technology Supporting Programme (grant no. KJYJ-2013-01-05); the Joint Research Project of Shanghai Municipal Avian Influenza A(H7N9) Prevention and Control (grant no. 2013QLG008); and the Constructing Programme of Shanghai Municipal Public Health Key Discipline (grant no. 12GWZX0101). NR 21 TC 5 Z9 5 U1 0 U2 10 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JUL PY 2015 VL 143 IS 9 BP 1826 EP 1832 DI 10.1017/S0950268814003264 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CJ8NU UT WOS:000355760600004 PM 25471822 ER PT J AU Mao, B Chheng, K Wannemuehler, K Vynnycky, E Buth, S Soeung, SC Reef, S Weldon, W Quick, L Gregory, CJ AF Mao, B. Chheng, K. Wannemuehler, K. Vynnycky, E. Buth, S. Soeung, S. C. Reef, S. Weldon, W. Quick, L. Gregory, C. J. TI Immunity to polio, measles and rubella in women of child-bearing age and estimated congenital rubella syndrome incidence, Cambodia, 2012 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Congenital (intrauterine) infection; epidemiology; measles (rubeola); polio; rubella ID POPULATION IMMUNITY; DEVELOPING-COUNTRIES; SEROPREVALENCE; VACCINATION; OUTBREAK; POLIOVIRUSES; TRANSMISSION; ELIMINATION; ANTIBODIES; WILD AB Significant gaps in immunity to polio, measles, and rubella may exist in adults in Cambodia and threaten vaccine-preventable disease (VPD) elimination and control goals, despite high childhood vaccination coverage. We conducted a nationwide serological survey during November-December 2012 of 2154 women aged 15-39 years to assess immunity to polio, measles, and rubella and to estimate congenital rubella syndrome (CRS) incidence. Measles and rubella antibodies were detected by IgG ELISA and polio antibodies by microneutralization testing. Age-structured catalytic models were fitted to rubella serological data to predict CRS cases. Overall, 29.8% of women lacked immunity to at least one poliovirus (PV); seroprevalence to PV1, PV2 and PV3 was 85.9%, 93.4% and 83.3%, respectively. Rubella and measles antibody seroprevalence was 73.3% and 95.9%, respectively. In the 15-19 years age group, 48.2% [95% confidence interval (CI) 42.4-54.1] were susceptible to either PV1 or PV3, and 40.3% (95% CI 33.0-47.5) to rubella virus. Based on rubella antibody seroprevalence, we estimate that >600 infants are born with CRS in Cambodia annually. Significant numbers of Cambodian women are still susceptible to polio and rubella, especially those aged 15-19 years, emphasizing the need to include adults in VPD surveillance and a potential role for vaccination strategies targeted at adults. C1 [Mao, B.] Univ Hlth Sci, Phnom Penh, Cambodia. [Chheng, K.; Buth, S.] Natl Inst Publ Hlth, Phnom Penh, Cambodia. [Wannemuehler, K.; Reef, S.; Quick, L.; Gregory, C. J.] CDC, Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. [Vynnycky, E.] Publ Hlth England, Modelling & Econ Unit, London, England. [Vynnycky, E.] London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1, England. [Soeung, S. C.] Minist Hlth, Natl Immunizat Program, Phnom Penh, Cambodia. [Weldon, W.] CDC, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30333 USA. RP Gregory, CJ (reprint author), US Ctr Dis Control & Prevent, CDC Box 68, APO, AP 96546 USA. EM hgk4@cdc.gov FU US Centers for Disease Control and Prevention; National Institute for Public Health, Cambodia [5U2GPS000939-05] FX This work was supported by the US Centers for Disease Control and Prevention through Cooperative Agreement with the National Institute for Public Health, Cambodia (Cooperative Agreement number: 5U2GPS000939-05). NR 39 TC 6 Z9 6 U1 1 U2 4 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JUL PY 2015 VL 143 IS 9 BP 1858 EP 1867 DI 10.1017/S0950268814002817 PG 10 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CJ8NU UT WOS:000355760600008 PM 25373419 ER PT J AU Naser, AM Hossain, MJ Sazzad, HMS Homaira, N Gurley, ES Podder, G Afroj, S Banu, S Rollin, PE Daszak, P Ahmed, BN Rahman, M Luby, SP AF Naser, A. M. Hossain, M. J. Sazzad, H. M. S. Homaira, N. Gurley, E. S. Podder, G. Afroj, S. Banu, S. Rollin, P. E. Daszak, P. Ahmed, B. -N. Rahman, M. Luby, S. P. TI Integrated cluster- and case-based surveillance for detecting stage III zoonotic pathogens: an example of Nipah virus surveillance in Bangladesh SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Cluster; encephalitis; Nipah; outbreak; stage III pathogen; surveillance ID DATE PALM SAP; INFECTIOUS-DISEASES; TRANSMISSION; COMMUNITY; EMERGENCE; EPIDEMIC; OUTBREAK AB This paper explores the utility of cluster-and case-based surveillance established in government hospitals in Bangladesh to detect Nipah virus, a stage III zoonotic pathogen. Physicians listed meningo-encephalitis cases in the 10 surveillance hospitals and identified a cluster when 52 cases who lived within 30 min walking distance of one another developed symptoms within 3 weeks of each other. Physicians collected blood samples from the clustered cases. As part of case-based surveillance, blood was collected from all listed meningo-encephalitis cases in three hospitals during the Nipah season (January-March). An investigation team visited clustered cases' communities to collect epidemiological information and blood from the living cases. We tested serum using Nipah-specific IgM ELISA. Up to September 2011, in 5887 listed cases, we identified 62 clusters comprising 176 encephalitis cases. We collected blood from 127 of these cases. In 10 clusters, we identified a total of 62 Nipah cases: 18 laboratory-confirmed and 34 probable. We identified person-to-person transmission of Nipah virus in four clusters. From case-based surveillance, we identified 23 (4%) Nipah cases. Faced with thousands of encephalitis cases, integrated cluster surveillance allows targeted deployment of investigative resources to detect outbreaks by stage III zoonotic pathogens in resource-limited settings. C1 [Naser, A. M.; Hossain, M. J.; Sazzad, H. M. S.; Homaira, N.; Gurley, E. S.; Podder, G.; Afroj, S.; Banu, S.; Luby, S. P.] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Rollin, P. E.; Luby, S. P.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. [Daszak, P.] EcoHlth Alliance, New York, NY USA. [Ahmed, B. -N.] Minist Hlth & Family Welf, Directorate Gen Hlth Serv, Dhaka, Bangladesh. [Rahman, M.] Inst Epidemiol Dis Control & Res, Dhaka, Bangladesh. [Luby, S. P.] Stanford Univ, Stanford, CA 94305 USA. RP Naser, AM (reprint author), Int Ctr Diarrhoeal Dis Res, GPO Box 128, Dhaka 1000, Bangladesh. EM abunaser@icddrb.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X FU CDC, Atlanta, USA [5U01CI000628-01]; US National Institutes of Health (NIH); Bangladesh-NIH/EID [07-015-0712-52200]; NSF/NIH Ecology and Evolution of Infectious Diseases grant from the Fogarty International Center [2R01-TW005869] FX This research was funded by CDC, Atlanta, USA, cooperative agreement number 5U01CI000628-01, the US National Institutes of Health (NIH), grant no. 07-015-0712-52200 (Bangladesh-NIH/EID), and NSF/NIH Ecology and Evolution of Infectious Diseases grant no. 2R01-TW005869 from the Fogarty International Center. icddr,b acknowledges with gratitude the commitment of EcoHealth Alliance, CDC, NIH and the Government of Bangladesh for their research efforts. We are grateful to the study participants for their valuable time and information. We are also grateful to the Hospital Authorities for their cooperation. We are indebted to Dorothy Southern, Meghan Scott, Carrie Read and James Heffelfinger for their support in reviewing and editing this manuscript. icddr,b is grateful to the Governments of Australia, Bangladesh, Canada, Sweden and the UK for providing core/unrestricted support. NR 31 TC 2 Z9 2 U1 1 U2 9 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JUL PY 2015 VL 143 IS 9 BP 1922 EP 1930 DI 10.1017/S0950268814002635 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CJ8NU UT WOS:000355760600016 PM 25342551 ER PT J AU Laufer, AS Grass, J Holt, K Whichard, JM Griffin, PM Gould, LH AF Laufer, A. S. Grass, J. Holt, K. Whichard, J. M. Griffin, P. M. Gould, L. H. TI Outbreaks of itSalmonella infections attributed to beef-United States,1973-2011 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Antibiotic resistance; food safety; foodborne infections; outbreaks; Salmonella enterica ID FOODBORNE DISEASE OUTBREAKS; GROUND-BEEF; SALMONELLA-TYPHIMURIUM; LYMPH-NODES; STATES; FOOD; SURVEILLANCE; PATHOGENS; ENTERICA; MEAT AB Non-typhoidal Salmonella is estimated to be the most common bacterial cause of foodborne illness in the United States, causing an estimated one million domestically acquired foodborne illnesses annually. Recent, large outbreaks have highlighted the importance of ground beef as an important source of multidrug-resistant Salmonella. We analysed the epidemiology of salmonellosis outbreaks that were attributed to beef in the United States reported to the Centers for Disease Control and Prevention (CDC) from 1973 to 2011. During 1973-2011, of the 1965 outbreaks of Salmonella where a food vehicle was implicated, 96 were attributed to beef, accounting for 3684 illnesses. We observed a shift in the type of beef implicated in salmonellosis outbreaks, from roast to ground beef. Delicatessen-style roast beef cooked in commercial processing establishments was the predominant type during the 1970s and early 1980s; regulations on cooking and processing essentially eliminated this problem by 1987. Ground beef emerged as an important vehicle in the 2000s; it was implicated in 17 (45%) of the 38 beef-attributed outbreaks reported during 2002-2011. Although this emergence was likely due in part to increased participation in CDC's PulseNet, which was established in 1996, and proactive decisions by the United States Department of Agriculture's Food Safety and Inspection Service, stronger measures are needed to decrease contamination of ground beef with Salmonella. C1 [Laufer, A. S.] CDC, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, CSELS, Atlanta, GA 30333 USA. [Laufer, A. S.; Grass, J.; Griffin, P. M.; Gould, L. H.] CDC, Enter Dis Epidemiol Branch, DFWED, NCEZID, Atlanta, GA 30333 USA. [Holt, K.] USDA, Food Safety & Inspect Serv, Washington, DC 20250 USA. [Whichard, J. M.] CDC, Enter Dis Lab Branch, DFWED, NCEZID, Atlanta, GA 30333 USA. RP Laufer, AS (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop A-31, Atlanta, GA 30333 USA. EM ALAUFER@cdc.gov FU Intramural CDC HHS [CC999999] NR 43 TC 7 Z9 7 U1 7 U2 30 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JUL PY 2015 VL 143 IS 9 BP 2003 EP 2013 DI 10.1017/S0950268814003112 PG 11 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CJ8NU UT WOS:000355760600025 PM 25427978 ER PT J AU Nakao, JH Pringle, J Jones, RW Nix, BE Borders, J Heseltine, G Gomez, TM McCluskey, B Roney, CS Brinson, D Erdman, M McDaniel, A Behravesh, CB AF Nakao, J. H. Pringle, J. Jones, R. W. Nix, B. E. Borders, J. Heseltine, G. Gomez, T. M. McCluskey, B. Roney, C. S. Brinson, D. Erdman, M. McDaniel, A. Behravesh, C. Barton TI 'One Health' investigation: outbreak of human Salmonella Braenderup infections traced to a mail-order hatchery - United States, 2012-2013 SO EPIDEMIOLOGY AND INFECTION LA English DT Article DE Outbreaks; poultry; Salmonella; Salmonella enterica; zoonoses ID LIVE POULTRY; CONTACT AB Human salmonellosis linked to contact with live poultry is an increasing public health concern. In 2012, eight unrelated outbreaks of human salmonellosis linked to live poultry contact resulted in 517 illnesses. In July 2012, PulseNet, a national molecular surveillance network, reported a multistate cluster of a rare strain of Salmonella Braenderup infections which we investigated. We defined a case as infection with the outbreak strain, determined by pulsed-field gel electrophoresis, with illness onset from 25 July 2012-27 February 2013. Ill persons and mail-order hatchery (MOH) owners were interviewed using standardized questionnaires. Traceback and environmental investigations were conducted. We identified 48 cases in 24 states. Twenty-six (81%) of 32 ill persons reported live poultry contact in the week before illness; case-patients named 12 different MOHs from eight states. The investigation identified hatchery D as the ultimate poultry source. Sampling at hatchery D yielded the outbreak strain. Hatchery D improved sanitation procedures and pest control; subsequent sampling failed to yield Salmonella. This outbreak highlights the interconnectedness of humans, animals, and the environment and the importance of industry knowledge and involvement in solving complex outbreaks. Preventing these infections requires a 'One Health' approach that leverages expertise in human, animal, and environmental health. C1 [Nakao, J. H.] Ctr Dis Control & Prevent CDC, NCEZID, DFWED, EIS,EDEB, Atlanta, GA USA. [Pringle, J.; Behravesh, C. Barton] CDC, NCEZID, DFWED, ORPB, Atlanta, GA 30333 USA. [Jones, R. W.; Nix, B. E.] Texas Dept State Hlth Serv, Hlth Serv Reg 7, Temple, TX USA. [Heseltine, G.] Texas Dept State Hlth Serv, Foodborne Illness Surveillance, Emerging & Acute Infect Dis Branch, Temple, TX USA. [Gomez, T. M.; McCluskey, B.] USDA, Anim & Plant Hlth Inspect Serv, Vet Serv, Riverdale, MD USA. [Roney, C. S.; Brinson, D.] USDA, APHIS, VS, NPIP, Conyers, GA USA. [Erdman, M.] USDA, Natl Vet Serv Labs, APHIS, VS,Diagnost Bacteriol Lab, Ames, IA 50010 USA. [McDaniel, A.] CDC, NCEZID, DFWED, Enter Dis Lab Branch, Atlanta, GA 30333 USA. RP Nakao, JH (reprint author), Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, CGH DGHP, 4770 Buford Hwy,MSF 57, Atlanta, GA 30341 USA. EM jnakao@cdc.gov FU Epi-Aid [2013-027] FX This work was supported by Epi-Aid 2013-027. NR 20 TC 2 Z9 3 U1 1 U2 8 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0950-2688 EI 1469-4409 J9 EPIDEMIOL INFECT JI Epidemiol. Infect. PD JUL PY 2015 VL 143 IS 10 SI SI BP 2178 EP 2186 DI 10.1017/S0950268815000151 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CK3ZY UT WOS:000356157400016 PM 25703600 ER PT J AU Huang, QS Turner, N Baker, MG Williamson, DA Wong, C Webby, R Widdowson, MA AF Huang, Qiu Sue Turner, Nikki Baker, Michael G. Williamson, Deborah A. Wong, Conroy Webby, Richard Widdowson, Marc-Alain CA SHIVERS Invest Team TI Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Review DE disease burden; epidemiology; immunology; influenza; risk factors; vaccine effectiveness ID RESPIRATORY SYNCYTIAL VIRUS; PANDEMIC H1N1 INFLUENZA; TEST-NEGATIVE DESIGN; NEW-ZEALAND; SEASONAL INFLUENZA; VIRAL-INFECTIONS; A H1N1; UNITED-STATES; HOSPITALIZED CHILDREN; HUMAN-METAPNEUMOVIRUS AB The 2009 influenza A(H1N1)pdm09 pandemic highlighted the need for improved scientific knowledge to support better pandemic preparedness and seasonal influenza control. The Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance (SHIVERS) project, a 5-year (2012-2016) multiagency and multidisciplinary collaboration, aimed to measure disease burden, epidemiology, aetiology, risk factors, immunology, effectiveness of vaccination and other prevention strategies for influenza and other respiratory infectious diseases of public health importance. Two active, prospective, population-based surveillance systems were established for monitoring influenza and other respiratory pathogens among those hospitalized patients with acute respiratory illness and those enrolled patients seeking consultations at sentinel general practices. In 2015, a sero-epidemiological study will use a sample of patients from the same practices. These data will provide a full picture of the disease burden and risk factors from asymptomatic infections to severe hospitalized disease and deaths and related economic burden. The results during the first 2years (2012-2013) provided scientific evidence to (a) support a change to NZ's vaccination policy for young children due to high influenza hospitalizations in these children; (b) contribute to the revision of the World Health Organization's case definition for severe acute respiratory illness for global influenza surveillance; and (c) contribute in part to vaccine strain selection using vaccine effectiveness assessment in the prevention of influenza-related consultations and hospitalizations. In summary, SHIVERS provides valuable international platforms for supporting seasonal influenza control and pandemic preparedness, and responding to other emerging/endemic respiratory-related infections. C1 [Huang, Qiu Sue; Williamson, Deborah A.] Inst Environm Sci & Res, Wellington, New Zealand. [Turner, Nikki] Univ Auckland, Auckland 1, New Zealand. [Baker, Michael G.; Williamson, Deborah A.] Univ Otago, Wellington, New Zealand. [Williamson, Deborah A.] Auckland Dist Hlth Board, Auckland, New Zealand. [Wong, Conroy] Counties Manakau Dist Hlth Board, Auckland, New Zealand. [Webby, Richard] St Jude Childrens Res Hosp, WHO Collaborating Ctr, Memphis, TN USA. [Widdowson, Marc-Alain] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Huang, QS (reprint author), Inst Environm Sci & Res, WHO Natl Influenza Ctr, 66 Ward St, Upper Hutt 5018, New Zealand. EM Sue.Huang@esr.cri.nz OI Grant, Cameron/0000-0002-4032-7230; Thomas, Paul G./0000-0001-7955-0256 FU US Department of Health and Human Services, Centers for Disease Control and Prevention (CDC) [1U01IP000480-01] FX The SHIVERS (Southern Hemisphere Influenza and Vaccine Effectiveness Research and Surveillance) project is funded by US Department of Health and Human Services, Centers for Disease Control and Prevention (CDC) (1U01IP000480-01). The project is a 5-year research cooperative agreement between ESR and US CDC's National Center for Immunization and Respiratory Diseases Influenza Division. NR 82 TC 1 Z9 1 U1 0 U2 6 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD JUL PY 2015 VL 9 IS 4 BP 179 EP 190 DI 10.1111/irv.12315 PG 12 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CK2XE UT WOS:000356077200002 PM 25912617 ER PT J AU McAnerney, JM Treurnicht, F Walaza, S Cohen, AL Tempia, S Mtshali, S Buys, A Blumberg, L Cohen, C AF McAnerney, Johanna M. Treurnicht, Florette Walaza, Sibongile Cohen, Adam L. Tempia, Stefano Mtshali, Senzo Buys, Amelia Blumberg, Lucille Cohen, Cheryl TI Evaluation of influenza vaccine effectiveness and description of circulating strains in outpatient settings in South Africa, 2014 SO INFLUENZA AND OTHER RESPIRATORY VIRUSES LA English DT Article DE Effectiveness; influenza; vaccine ID UNITED-STATES; A VIRUS; SURVEILLANCE; EVOLUTION; SELECTION; A(H1N1); ASSAY AB The effectiveness of the trivalent seasonal influenza vaccine during the 2014 season in South Africa was assessed using a test-negative case-control study design including 472 cases and 362 controls. Influenza A(H3N2) was the dominant strain circulating. The overall vaccine effectiveness estimate, adjusted for age and underlying conditions, was 431% (95% CI: -268-745). 2014 H3N2 viruses from South Africa were mainly in sublineage 3C.3 with accumulation of amino acid changes that differentiate them from the vaccine strain in 3C.1. C1 [McAnerney, Johanna M.; Treurnicht, Florette; Walaza, Sibongile; Tempia, Stefano; Mtshali, Senzo; Buys, Amelia; Blumberg, Lucille; Cohen, Cheryl] NICD, NHLS, Johannesburg, South Africa. [Walaza, Sibongile; Cohen, Cheryl] Univ Witwatersrand, Fac Hlth Sci, Sch Publ Hlth, Johannesburg, South Africa. [Cohen, Adam L.; Tempia, Stefano] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Cohen, Adam L.; Tempia, Stefano] US Ctr Dis Control & Prevent South Africa, Pretoria, South Africa. RP McAnerney, JM (reprint author), Natl Inst Communicable Dis, Private Bag X4, ZA-2131 Johannesburg, South Africa. EM jomca@nicd.ac.za FU NICD/NHLS; United States Centers for Disease Control and Prevention (CDC), Atlanta; Georgia Preparedness and Response to Avian and Pandemic Influenza in South Africa [U51/IP000155-04] FX This study received funding from the NICD/NHLS and was supported in part by funds from the United States Centers for Disease Control and Prevention (CDC), Atlanta, Georgia Preparedness and Response to Avian and Pandemic Influenza in South Africa (Cooperative Agreement Number: U51/IP000155-04). The contents are solely the responsibility of the authors and do not necessarily represent the official views of the CDC. The funders had no role in study design, implementation, manuscript writing or the decision to submit for publication. The corresponding author had full access to all the data in the study and takes final responsibility for the decision to submit for publication. NR 22 TC 5 Z9 5 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1750-2640 EI 1750-2659 J9 INFLUENZA OTHER RESP JI Influenza Other Respir. Viruses PD JUL PY 2015 VL 9 IS 4 BP 209 EP 215 DI 10.1111/irv.12314 PG 7 WC Infectious Diseases; Virology SC Infectious Diseases; Virology GA CK2XE UT WOS:000356077200005 PM 25865249 ER PT J AU Wiesner, M Elliott, MN McLaughlin, KA Banspach, SW Tortolero, S Schuster, MA AF Wiesner, Margit Elliott, Marc N. McLaughlin, Katie A. Banspach, Stephen W. Tortolero, Susan Schuster, Mark A. TI Common Versus Specific Correlates of Fifth-Grade Conduct Disorder and Oppositional Defiant Disorder Symptoms: Comparison of Three Racial/Ethnic Groups SO JOURNAL OF ABNORMAL CHILD PSYCHOLOGY LA English DT Article DE Conduct disorder; Oppositional defiant disorder; Risk factors; Race/ethnicity; Children ID DEFICIT-HYPERACTIVITY DISORDER; PAST 10 YEARS; RISK-FACTORS; DEVELOPMENTAL PATHWAYS; PSYCHIATRIC-DISORDERS; DISRUPTIVE BEHAVIOR; TEMPERAMENT; ADOLESCENTS; COMORBIDITY; CHILDHOOD AB The extent to which risk profiles or correlates of conduct disorder (CD) and oppositional defiant disorder (ODD) symptoms overlap among youth continues to be debated. Cross-sectional data from a large, representative community sample (N = 4,705) of African-American, Latino, and White fifth graders were used to examine overlap in correlates of CD and ODD symptoms. About 49 % of the children were boys. Analyses were conducted using negative binomial regression models, accounting for several confounding factors (e.g., attention deficit/hyperactivity disorder symptoms), sampling weights, stratification, and clustering. Results indicated that CD and ODD symptoms had very similar correlates. In addition to previously established correlates, several social skills dimensions were significantly related to ODD and CD symptoms, even after controlling for other correlates. In contrast, temperamental dimensions were not significantly related to CD and ODD symptoms, possibly because more proximal correlates (e.g., social skills) were also taken into account. Only two factors (gender and household income) were found to be specific correlates of CD, but not ODD, symptoms. The pattern of common and specific correlates of CD and ODD symptoms was replicated fairly consistently across the three racial/ethnic subgroups. Implications of these findings for further research and intervention efforts are discussed. C1 [Wiesner, Margit] Univ Houston, Dept Educ Psychol, Houston, TX 77204 USA. [Elliott, Marc N.] RAND Corp, Santa Monica, CA 90401 USA. [McLaughlin, Katie A.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA. [Banspach, Stephen W.] Ctr Dis Control & Prevent, Div Adolescent & Sch Hlth, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30341 USA. [Tortolero, Susan] Univ Texas Hlth Sci Ctr Houston, Ctr Hlth Promot & Prevent Res, Sch Publ Hlth, Houston, TX 77030 USA. [Schuster, Mark A.] Boston Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA. [Schuster, Mark A.] Harvard Univ, Sch Med, Boston, MA 02115 USA. RP Wiesner, M (reprint author), Univ Houston, Dept Educ Psychol, 491 Farish Hall, Houston, TX 77204 USA. EM mfwiesner@uh.edu; Elliott@rand.org; mclaughk@uw.edu; SBanspach@cdc.gov; Susan.Tortolero@uth.tmc.edu; mark.schuster@childrens.harvard.edu FU Centers for Disease Control and Prevention [CCU409679, CCU609653, CCU915773, U48DP000046, U48DP000057, U48DP000056, U19DP002663, U19DP002664, U19DP002665] FX The Healthy Passages study was funded by the Centers for Disease Control and Prevention (Cooperative Agreements (CCU409679, CCU609653, CCU915773, U48DP000046, U48DP000057, U48DP000056, U19DP002663, U19DP002664, and U19DP002665). The content of this report is solely the responsibility of the authors and does not necessarily represent the official position of the Centers for Disease Control and Prevention. We thank Lionel Santibanez for editorial assistance with the manuscript. NR 66 TC 0 Z9 0 U1 2 U2 10 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0091-0627 EI 1573-2835 J9 J ABNORM CHILD PSYCH JI J. Abnorm. Child Psychol. PD JUL PY 2015 VL 43 IS 5 BP 985 EP 998 DI 10.1007/s10802-014-9955-9 PG 14 WC Psychology, Clinical; Psychology, Developmental SC Psychology GA CK3CN UT WOS:000356093600016 PM 25411125 ER PT J AU Holman, DM Berkowitz, Z Guy, GP Hawkins, NA Saraiya, M Watson, M AF Holman, Dawn M. Berkowitz, Zahava Guy, Gery P., Jr. Hawkins, Nikki A. Saraiya, Mona Watson, Meg TI Patterns of sunscreen use on the face and other exposed skin among US adults SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY LA English DT Article DE broad spectrum; skin cancer prevention; sun protection; sun protection factor; sun safety; sunscreen ID SUN-PROTECTION; BEHAVIORS; PREVENTION; CANCER; SUNBURN; ASSOCIATION; MAGAZINES; AMERICANS; GENDER; HEALTH AB Background: Sunscreen is a common form of sun protection, but little is known about patterns of use. Objective: We sought to assess patterns of sunscreen use on the face and other exposed skin among US adults. Methods: Using cross-sectional data from the 2013 Summer ConsumerStyles survey (N = 4033), we calculated descriptive statistics and adjusted risk ratios to identify characteristics associated with regular sunscreen use (always/most of the time when outside on a warm sunny day for >= 1 hour). Results: Few adults regularly used sunscreen on the face (men: 18.1%, 95% confidence interval [CI] 15.8-20.6; women: 42.6%, 95% CI 39.5-46.7), other exposed skin (men: 19.9%, 95% CI 17.5-22.6; women: 34.4%, 95% CI 31.5-37.5), or both the face and other exposed skin (men: 14.3%, 95% CI 12.3-16.6; women: 29.9%, 95% CI 27.2-32.8). Regular use was associated with sun-sensitive skin, an annual household income >=$ 60,000, and meeting aerobic activity guidelines (Ps < .05). Nearly 40% of users were unsure if their sunscreen provided broad-spectrum protection. Limitations: Reliance on self-report and lack of information on sunscreen reapplication or other sun-safety practices are limitations. Conclusion: Sunscreen use is low, especially among certain demographic groups. These findings can inform sun-safety interventions and the interpretation of surveillance data on sunscreen use. C1 [Holman, Dawn M.; Berkowitz, Zahava; Guy, Gery P., Jr.; Hawkins, Nikki A.; Saraiya, Mona; Watson, Meg] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. RP Holman, DM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Highway,MS F-76 Chamblee, Atlanta, GA 30341 USA. EM dholman@cdc.gov FU Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control FX Funded by the Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion, Division of Cancer Prevention and Control. The findings and conclusions in this report are those of the author(s) and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 33 TC 9 Z9 9 U1 0 U2 10 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0190-9622 J9 J AM ACAD DERMATOL JI J. Am. Acad. Dermatol. PD JUL PY 2015 VL 73 IS 1 BP 83 EP U166 DI 10.1016/j.jaad.2015.02.1112 PG 11 WC Dermatology SC Dermatology GA CK6BZ UT WOS:000356314100028 PM 26002066 ER PT J AU Liu, Y Pleasants, RA Croft, JB Lugogo, N Ohar, J Heidari, K Strange, C Wheaton, AG Mannino, DM Kraft, M AF Liu, Yong Pleasants, Roy A. Croft, Janet B. Lugogo, Njira Ohar, Jill Heidari, Khosrow Strange, Charlie Wheaton, Anne G. Mannino, David M. Kraft, Monica TI Body mass index, respiratory conditions, asthma, and chronic obstructive pulmonary disease SO RESPIRATORY MEDICINE LA English DT Article DE Body mass index; Chronic obstructive pulmonary disease; Asthma; Respiratory conditions; Population-based study ID AIR-FLOW OBSTRUCTION; MORBIDLY OBESE; LUNG-FUNCTION; WEIGHT-LOSS; COPD; DYSPNEA; ADULTS; RISK; MEN; UNDERWEIGHT AB Background: This study aims to assess the relationship of body mass index (BMI) status with respiratory conditions, asthma, and chronic obstructive pulmonary disease (COPD) in a state population. Methods: Self-reported data from 11,868 adults aged >= 18 years in the 2012 South Carolina Behavioral Risk Factor Surveillance System telephone survey were analyzed using multivariable logistic regression that accounted for the complex sampling design and adjusted for sex, age, race/ethnicity, education, smoking status, physical inactivity, and cancer history. Results: The distribution of BMI (kg/m(2)) was 1.5% for underweight (< 18.5), 32.3% for normal weight (18.5-24.9), 34.6% for overweight (25.0-29.9), 26.5% for obese (30.0-39.9), and 5.1% for morbidly obese (>= 40.0). Among respondents, 10.0% had frequent productive cough, 4.3% had frequent shortness of breath (SOB), 7.3% strongly agreed that SOB affected physical activity, 8.4% had current asthma, and 7.4% had COPD. Adults at extremes of body weight were more likely to report having asthma or COPD, and to report respiratory conditions. Age-adjusted U-shaped relationships of BMI categories with current asthma and strongly agreeing that SOB affected physical activity, but not U-shaped relationship with COPD, persisted after controlling for the covariates (p < 0.001). Morbidly obese but not underweight or obese respondents were significantly more likely to have frequent productive cough and frequent SOB than normal weight adults after adjustment. Conclusion: Our data confirm that both underweight and obesity are associated with current asthma and obesity with COPD. Increased emphasis on exercise and nutrition may improve respiratory conditions. Published by Elsevier Ltd. C1 [Liu, Yong; Croft, Janet B.; Wheaton, Anne G.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Populat Hlth, Atlanta, GA 30333 USA. [Pleasants, Roy A.; Lugogo, Njira] Duke Univ, Sch Med, Div Pulm Allergy & Crit Care Med, Durham, NC USA. [Ohar, Jill] Wake Forest Univ, Sch Med, Sect Pulm Crit Care Allergy & Immunol Dis, Winston Salem, NC 27109 USA. [Heidari, Khosrow] S Carolina Dept Hlth & Environm Control, Chron Dis Epidemiol Off, Columbia, SC 29201 USA. [Heidari, Khosrow] Univ S Carolina, Dept Epidemiol & Stat, Columbia, SC 29208 USA. [Strange, Charlie] Med Univ S Carolina, Div Pulm Crit Care Allergy & Sleep Med, Charleston, SC USA. [Mannino, David M.] Univ Kentucky, Div Pulm Crit Care & Sleep Med, Pulm Epidemiol, Res Lab, Lexington, KY USA. [Kraft, Monica] Univ Arizona, Dept Med, Phoenix, AZ USA. RP Liu, Y (reprint author), 4770 Buford Highway NE,Mail Stop F-78, Atlanta, GA 30341 USA. EM ikd8@cdc.gov OI Mannino, David/0000-0003-3646-7828 FU Intramural CDC HHS [CC999999] NR 49 TC 1 Z9 1 U1 0 U2 8 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0954-6111 EI 1532-3064 J9 RESP MED JI Respir. Med. PD JUL PY 2015 VL 109 IS 7 BP 851 EP 859 DI 10.1016/j.rmed.2015.05.006 PG 9 WC Cardiac & Cardiovascular Systems; Respiratory System SC Cardiovascular System & Cardiology; Respiratory System GA CK2QN UT WOS:000356056200008 PM 26006753 ER PT J AU Jayakumar, A Vittinghoff, E Segal, MR MacKenzie, WR Johnson, JL Gitta, P Saukkonen, J Anderson, J Weiner, M Engle, M Yoon, C Kato-Maeda, M Nahid, P AF Jayakumar, A. Vittinghoff, E. Segal, M. R. MacKenzie, W. R. Johnson, J. L. Gitta, P. Saukkonen, J. Anderson, J. Weiner, M. Engle, M. Yoon, C. Kato-Maeda, M. Nahid, P. CA TB Trials Consortium TI Serum biomarkers of treatment response within a randomized clinical trial for pulmonary tuberculosis SO TUBERCULOSIS LA English DT Article DE Biomarkers; Treatment response; Tuberculosis; Pulmonary ID C-REACTIVE PROTEIN; INTERLEUKIN-2 RECEPTOR-ALPHA; CROSS-VALIDATION; NEOPTERIN LEVELS; DISEASE-ACTIVITY; MARKERS; REGRESSION; INFECTION; DIAGNOSIS; THERAPY AB Rationale: Biomarkers for monitoring response to anti-tuberculosis treatment are needed. We explored immune markers previously published as having predictive capability for 8 week culture status in 39 adults enrolled in a clinical trial in Kampala, Uganda. Methods: We consecutively selected 20 HIV-negative pulmonary TB subjects with positive cultures, and 19 subjects with negative cultures at the end of intensive phase therapy. At baseline and after 8 weeks, serum was assayed for nine cytokines and soluble cytokine receptors using multiplexed platforms or ELISA. We evaluated their association with week 8 culture status first using single-variable logistic models, then using cross-validated estimates of the C-statistic, a measure of discrimination, of candidate models including 2 or 3 analytes in addition to age. Results: All but one analyte decreased from baseline to week 8 (all p < 0.01). Individual biomarkers were not associated with 8 week culture status. Logistic models including increasing age, higher baseline soluble tumor necrosis factor receptor alpha 1 (sTNF-R1), and higher week 8 C-reactive protein (CRP) concentration classified subjects by culture status with up to 85% accuracy and acceptable discrimination (cross-validated C-statistic 0.76) and calibration (HosmereLemeshow P > 0.2). Conclusion: Exploratory post-hoc models including sTNF-R1, CRP, and age, classified 8 week culture status with promising accuracy. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Jayakumar, A.; Anderson, J.; Yoon, C.; Kato-Maeda, M.; Nahid, P.] Univ Calif San Francisco, San Francisco, CA 94110 USA. [Vittinghoff, E.; Segal, M. R.] Univ Calif San Francisco, San Francisco, CA 94158 USA. [MacKenzie, W. R.] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA 30329 USA. [Johnson, J. L.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Cleveland, OH 44106 USA. [Johnson, J. L.; Gitta, P.] Uganda Case Western Reserve Univ Res Collaborat, Kampala, Uganda. [Saukkonen, J.] Boston Univ, Sch Med, Jamaica, MA 02130 USA. [Weiner, M.; Engle, M.] Univ Texas San Antonio, Hlth Sci Ctr, San Antonio, TX 78229 USA. RP Jayakumar, A (reprint author), 1001 Potrero Ave,Rm 5K1, San Francisco, CA 94110 USA. EM archana.jayakumar@ucsf.edu; eric.vittinghoff@ucsf.edu; mark.segal@ucsf.edu; wrm0@cdc.gov; jlj@case.edu; pgitta@mucwru.or.ug; jussi.saukkonen@va.gov; jilliananderson@gmail.com; weiner@uthscsa.edu; Englem2@uthscsa.edu; christina.yoon@ucsf.edu; midori.kato-maeda@ucsf.edu; pnahid@ucsf.edu OI Mac Kenzie, William /0000-0001-7723-0339 FU National Institutes of Health through National Institute of Allergy and Infectious Diseases Funding [1R01AI104589]; Centers for Disease Control and Prevention TB Trials Consortium FX Funding for recruitment, enrollment, and clinical and laboratory follow-up of TBTC Study 29 participants was provided by the United States Centers for Disease Control and Prevention. The biomarker assays and PN were supported by the National Institutes of Health through National Institute of Allergy and Infectious Diseases Funding (1R01AI104589), and by the Centers for Disease Control and Prevention TB Trials Consortium. NR 44 TC 4 Z9 4 U1 1 U2 5 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1472-9792 J9 TUBERCULOSIS JI Tuberculosis PD JUL PY 2015 VL 95 IS 4 BP 415 EP 420 DI 10.1016/j.tube.2015.04.011 PG 6 WC Immunology; Microbiology; Respiratory System SC Immunology; Microbiology; Respiratory System GA CK6BC UT WOS:000356311800008 PM 26022314 ER PT J AU Tsai, RJ Luckhaupt, SE Schumacher, P Cress, RD Deapen, DM Calvert, GM AF Tsai, Rebecca J. Luckhaupt, Sara E. Schumacher, Pam Cress, Rosemary D. Deapen, Dennis M. Calvert, Geoffrey M. TI Risk of cancer among firefighters in California, 1988-2007 SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE cancer; firefighters; occupation; registry; risk ID CENTRAL UNITED-STATES; FIRE-FIGHTERS; DEATH CERTIFICATE; SAN-FRANCISCO; MORTALITY; OCCUPATION; HEALTH; COHORT; ADENOCARCINOMA; CHEMICALS AB BackgroundMost studies of firefighter cancer risks were conducted prior to 1990 and do not reflect risk from advances in building materials. MethodsA case-control study using California Cancer Registry data (1988-2007) was conducted to evaluate the risk of cancer among firefighters, stratified by race. ResultsThis study identified 3,996 male firefighters with cancer. Firefighters were found to have a significantly elevated risk for melanoma (odds ratio [OR]=1.8; 95% confidence interval [CI] 1.4-2.1), multiple myeloma (OR 1.4; 95%CI 1.0-1.8), acute myeloid leukemia (OR 1.4; 95%CI 1.0-2.0), and cancers of the esophagus (OR 1.6; 95%CI 1.2-2.1), prostate (OR 1.5; 95%CI 1.3-1.7), brain (OR 1.5; 95%CI 1.2-2.0), and kidney (OR 1.3; 95%CI 1.0-1.6). ConclusionsIn addition to observing cancer findings consistent with previous research, this study generated novel findings for firefighters with race/ethnicity other than white. It provides additional evidence to support the association between firefighting and several specific cancers. Am. J. Ind. Med. 58:715-729, 2015. (c) 2015 This article has been contributed to by US Government employees and their work is in the public domain in the USA. C1 [Tsai, Rebecca J.; Luckhaupt, Sara E.; Schumacher, Pam; Calvert, Geoffrey M.] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. [Cress, Rosemary D.] Canc Registry Greater Calif, Inst Publ Hlth, Sacramento, CA USA. [Cress, Rosemary D.] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA. RP Tsai, RJ (reprint author), NIOSH, 1090 Tusculum Ave,R-17, Cincinnati, OH 45226 USA. EM rtsai@cdc.gov OI Tsai, Rebecca/0000-0001-8656-9836 FU National Cancer Institute's Surveillance, Epidemiology and End Results Program [HHSN261201000140C, HHSN261201000035C, HHSN261201000034C]; Centers for Disease Control and Prevention's National Program of Cancer Registries [U58DP003862-01, 1U58DP000807-3] FX Contract grant sponsor: National Cancer Institute's Surveillance, Epidemiology and End Results Program; Contract grant number: HHSN261201000140C; Contract grant sponsor: National Cancer Institute's Surveillance, Epidemiology and End Results Program; Contract grant number: HHSN261201000035C; Contract grant sponsor: National Cancer Institute's Surveillance, Epidemiology and End Results Program; Contract grant number: HHSN261201000034C; Contract grant sponsor: Centers for Disease Control and Prevention's National Program of Cancer Registries; Contract grant number: U58DP003862-01; Contract grant sponsor: Centers for Disease Control and Prevention's National Program of Cancer Registries; Contract grant number: 1U58DP000807-3. NR 48 TC 6 Z9 7 U1 4 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD JUL PY 2015 VL 58 IS 7 BP 715 EP 729 DI 10.1002/ajim.22466 PG 15 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CK1PM UT WOS:000355979300002 PM 25943908 ER PT J AU Yu, JX Jing, HQ Lai, SJ Xu, WB Li, MF Wu, JG Liu, W Yuan, ZH Chen, Y Zhao, SW Wang, XH Zhao, Z Ran, L Wu, SY Klena, JD Feng, LZ Li, F Ye, XF Qiu, YZ Wang, X Yu, HJ Li, ZJ Yang, WZ AF Yu, Jianxing Jing, Huaiqi Lai, Shengjie Xu, Wenbo Li, Mengfeng Wu, Jianguo Liu, Wei Yuan, Zhenghong Chen, Yu Zhao, Shiwen Wang, Xinhua Zhao, Zhuo Ran, Lu Wu, Shuyu Klena, John D. Feng, Luzhao Li, Fu Ye, Xianfei Qiu, Yanzi Wang, Xin Yu, Hongjie Li, Zhongjie Yang, Weizhong TI Etiology of diarrhea among children under the age five in China: Results from a five-year surveillance SO JOURNAL OF INFECTION LA English DT Article DE Etiology; Diarrhea; Outpatients; Children; Sentinel surveillance; China ID ROTAVIRUS INFECTION; GLOBAL BURDEN; DISEASE; PROTECTION; COUNTRIES AB Objectives: Diarrhea is a leading cause of morbidity and mortality for children, although sparse data is available on the etiology of diarrhea in China. This study was conducted to determine main causes that underlie childhood diarrhea and related diseases. Method: Surveillance data for diarrhea was collected from 213 participating hospitals between 2009 and 2013. These stool specimens, from children aged 0-59 months, were then analyzed for a panel of etiological agents consisting of 5 viruses, 8 bacteria and 3 protozoa. The proportion of children who tested positive for each pathogen was calculated and seasonal patterns for major organisms were determined. Results: Pathogens were identified in 44.6% of the 32,189 samples from children with diarrhea. The most commonly detected pathogens were rotavirus (29.7% of cases), norovirus (11.8%), Diarrheagenic Escherichia coli (DEC; 5.0%), adenovirus (4.8%), non-typhoidal Salmonella (NTS; 4.3%), and Shigella spp. (3.6%). A strong seasonal pattern was observed for these organisms, including rotavirus (winter), norovirus (autumn), and DEC, NTS, and Shigella (summer). Conclusion: A wide range of enteropathogens were detected in this five-year surveillance study; rotavirus and norovirus were most common among children under the age five. These findings should serve as robust evidence for public health entities when planning and developing national intervention programs in China. (C) 2015 The British Infection Association. Published by Elsevier Ltd. All rights reserved. C1 [Yu, Jianxing; Lai, Shengjie; Ran, Lu; Feng, Luzhao; Yu, Hongjie; Li, Zhongjie; Yang, Weizhong] Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Beijing 102206, Peoples R China. [Jing, Huaiqi; Wang, Xin] Chinese Ctr Dis Control & Prevent, Natl Inst Communicable Dis Control & Prevent, Beijing 102206, Peoples R China. [Xu, Wenbo] Chinese Ctr Dis Control & Prevent, Natl Inst Viral Dis Control & Prevent, Beijing 102206, Peoples R China. [Li, Mengfeng] Sun Yat Sen Univ, Minist Educ, Key Lab Trop Dis Control, Guangzhou 510275, Guangdong, Peoples R China. [Wu, Jianguo; Li, Fu; Qiu, Yanzi] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China. [Liu, Wei] Beijing Inst Microbiol & Epidemiol, State Key Lab Pathogen & Biosecur, Beijing, Peoples R China. [Yuan, Zhenghong] Shanghai Publ Hlth Clin Ctr, Shanghai, Peoples R China. [Chen, Yu; Ye, Xianfei] Zhejiang Univ, Sch Med, Affiliated Hosp 1, State Key Lab Diag & Treatment Infect Dis, Hangzhou 310003, Zhejiang, Peoples R China. [Zhao, Shiwen] Yunnan Prov Ctr Dis Control & Prevent, Kunming, Peoples R China. [Wang, Xinhua] Gansu Prov Ctr Dis Control & Prevent, Lanzhou, Peoples R China. [Zhao, Zhuo] Liaoning Prov Ctr Dis Control & Prevent, Shenyang, Peoples R China. [Wu, Shuyu; Klena, John D.] US Ctr Dis Control & Prevent, Int Emerging Infect Program, Beijing, Peoples R China. [Wu, Shuyu; Klena, John D.] Ctr Global Hlth, Ctr Dis Control & Prevent, Div Global Hlth Protect, Global Dis Detect Branch, Atlanta, GA USA. RP Li, ZJ (reprint author), Chinese Ctr Dis Control & Prevent, Div Infect Dis, Key Lab Surveillance & Early Warning Infect Dis, Changbai Rd 155, Beijing 102206, Peoples R China. EM lizj@chinacdc.cn; yangwz@chinacdc.cn OI YU, Jianxing/0000-0002-9696-2460 FU Ministry of Science and Technology of the People's Republic of China program under the National Key Science and Technology Project on Infectious Disease Surveillance Technique Platform of China [2009ZX10004-201, 2009ZX10004-202, 2009ZX10004-203, 2009ZX10004-204, 2009ZX10004-205, 2009ZX10004-207, 2009ZX10004-208]; [2009ZX10004-209]; [2009ZX10004-210]; [2009ZX10004-211]; [2009ZX10004-212]; [2009ZX10004-213]; [2012ZX10004-201]; [2013ZX10004-202]; [2012ZX10004-206]; [2012ZX10004-207]; [2012ZX10004-208]; [2012ZX10004-209]; [2012ZX10004-210]; [2012ZX10004-211]; [2012ZX10004-212]; [2012ZX10004-213] FX This work was a Ministry of Science and Technology of the People's Republic of China funded program under the National Key Science and Technology Project on Infectious Disease Surveillance Technique Platform of China [2009ZX10004-201, 2009ZX10004-202, 2009ZX10004-203, 2009ZX10004-204, 2009ZX10004-205, 2009ZX10004-207, 2009ZX10004-208, 2009ZX10004-209, 2009ZX10004-210, 2009ZX10004-211, 2009ZX10004-212, 2009ZX10004-213, 2012ZX10004-201, 2013ZX10004-202, 2012ZX10004-206, 2012ZX10004-207, 2012ZX10004-208, 2012ZX10004-209, 2012ZX10004-210, 2012ZX10004-211, 2012ZX10004-212, 2012ZX10004-213]. NR 19 TC 17 Z9 18 U1 3 U2 9 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 EI 1532-2742 J9 J INFECTION JI J. Infect. PD JUL PY 2015 VL 71 IS 1 BP 19 EP 27 DI 10.1016/j.jinf.2015.03.001 PG 9 WC Infectious Diseases SC Infectious Diseases GA CJ9NV UT WOS:000355830200003 PM 25753104 ER PT J AU Honeycutt, AA Wile, K Dove, C Hawkins, J Orenstein, D AF Honeycutt, Amanda A. Wile, Kristina Dove, Cassandra Hawkins, Jackie Orenstein, Diane TI Strategic Planning for Chronic Disease Prevention in Rural America: Looking Through a PRISM Lens SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE chronic disease; prevention; strategic planning; systems modeling ID PARTICULATE AIR-POLLUTION; WORKPLACE SMOKING; HEALTH; INTERVENTIONS; MORTALITY; IMPACT AB Context: Community-level strategic planning for chronic disease prevention. Objective: To share the outcomes of the strategic planning process used by Mississippi Delta stakeholders to prevent and reduce the negative impacts of chronic disease in their communities. A key component of strategic planning was participants' use of the Prevention Impacts Simulation Model (PRISM) to project the reduction, compared with the status quo, in deaths and costs from implementing interventions in Mississippi Delta communities. Design: Participants in Mississippi Delta strategic planning meetings used PRISM, a user-friendly, evidence-based simulation tool that includes 22 categories of policy, systems, and environmental change interventions, to pose what-if questions that explore the likely short-and long-term effects of an intervention or any desired combination of the 22 categories of chronic disease intervention programs and policies captured in PRISM. These categories address smoking, air pollution, poor nutrition, and lack of physical activity. Strategic planning participants used PRISM outputs to inform their decisions and actions to implement interventions. Setting: Rural communities in the Mississippi Delta. Participants: A diverse group of 29 to 34 local chronic disease prevention stakeholders, known as the Mississippi Delta Strategic Alliance. Main Outcome Measure(s): Community plans and actions that were developed and implemented as a result of local strategic planning. Results: Existing strategic planning efforts were complemented by the use of PRISM. The Mississippi Delta Strategic Alliance decided to implement new interventions to improve air quality and transportation and to expand existing interventions to reduce tobacco use and increase access to healthy foods. They also collaborated with the Department of Transportation to raise awareness and use of the current transportation network. Conclusions: The Mississippi Delta Strategic Alliance strategic planning process was complemented by the use of PRISM as a tool for strategic planning, which led to the implementation of new and strengthened chronic disease prevention interventions and policies in the Mississippi Delta. C1 [Honeycutt, Amanda A.] RTI Int, Publ Hlth Econ Program, Res Triangle Pk, NC 27709 USA. [Wile, Kristina] Syst Thinking Collaborat, Stow, MA USA. [Dove, Cassandra; Hawkins, Jackie] Mississippi Dept Hlth, Mississippi Delta Hlth Collaborat, Chron Dis Bur, Off Prevent Hlth, Jackson, MS USA. [Orenstein, Diane] Ctr Dis Control & Prevent, Div Community Hlth, Atlanta, GA USA. RP Honeycutt, AA (reprint author), RTI Int, Publ Hlth Econ Program, 3040 Cornwallis Rd,POB 12194, Res Triangle Pk, NC 27709 USA. EM honeycutt@rti.org NR 19 TC 3 Z9 3 U1 2 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD JUL-AUG PY 2015 VL 21 IS 4 BP 392 EP 399 DI 10.1097/PHH.0000000000000062 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ1IV UT WOS:000355238200014 PM 25084535 ER PT J AU Sinclair, LB Tanenhaus, RH Courtney-Long, E Eaton, DK AF Sinclair, Lisa Bundara Tanenhaus, Rachel H. Courtney-Long, Elizabeth Eaton, Danice K. TI Disability Within US Public Health School and Program Curricula SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE curricula; disability; health objectives; Healthy People; public health competencies ID CARE AB Objective: To describe the percentage of US public health schools and programs offering graduate-level courses with disability content as a potential baseline measurement for Healthy People 2020 objective DH-3 and compare the percentage of public health schools that offered disability coursework in 1999 with those in 2011. Design: In 2011, using SurveyMonkey. com, cross-sectional information was collected from the deans, associate deans, directors, or chairpersons of master of public health-granting public health schools and programs that were accredited and listed with the Council on Education for Public Health. Two rounds of follow-up were conducted at 4-month intervals by e-mails and phone calls to program contacts who had not responded. The responses from schools and programs were calculated and compared. Results: There were 78 responses (34 schools and 44 programs) for a response rate of 63%. Fifty percent of public health schools and programs offered some disability content within their graduate-level courses. A greater percentage of schools than programs (71% vs 34%; P = .003) offered some graduate-level disability coursework within their curricula. The percentage of schools that offered disability coursework was similar in 1999 and 2011. Conclusion: This assessment provides a potential baseline measurement for Healthy People 2020 objective DH-3. Future assessments should focus on clarifying disability content within courses and identifying capacity to offering disability training within public health schools and programs. C1 [Sinclair, Lisa Bundara; Courtney-Long, Elizabeth; Eaton, Danice K.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Disabil & Hlth Branch, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Tanenhaus, Rachel H.] Massachusetts Dept Publ Hlth, Off Hlth Equ, Hlth & Disabil Program, Boston, MA USA. RP Sinclair, LB (reprint author), Ctr Dis Control & Prevent, Div Human Dev & Disabil, Disabil & Hlth Branch, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-88, Atlanta, GA 30333 USA. EM lsinclair@cdc.gov FU Centers for Disease Control and Prevention (CDC) [CDC-RFA-DD12-1204, U59/DD000940] FX This project was funded under Centers for Disease Control and Prevention (CDC) Cooperative Agreement CDC-RFA-DD12-1204 (award no. U59/DD000940). Charles Drum and Susan Havercamp participated in the initial planning discussions. Anita Albright (Massachusetts Department of Health), Jacqui Butler, Scott Campbell, and Mary Helen Witten (CDC) provided administrative oversight to this project under the cooperative agreement. Laura Rasa King consulted on the types of Council on Education for Public Health-accredited public health schools and programs and reviewed and commented on the manuscript. Karen Luken, Janet Hess, Ivette Matos, Theresa Paeglow, and Suzanne McDermott assisted with contacting the public health schools and programs. Andy Eaton provided technical support with Microsoft Excel. Georgia Simpson May, Dianna Carroll, Michael Fox, Alissa Stevens, Rudolfo Valdez, and Gloria Krahn reviewed and commented on the manuscript. NR 19 TC 0 Z9 0 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD JUL-AUG PY 2015 VL 21 IS 4 BP 400 EP 405 DI 10.1097/PHH.0000000000000114 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ1IV UT WOS:000355238200015 PM 26010692 ER PT J AU Biggerstaff, GK AF Biggerstaff, Gwen Kathryn CA FoodCORE Team TI Improving Response to Foodborne Disease Outbreaks in the United States: Findings of the Foodborne Disease Centers for Outbreak Response Enhancement (FoodCORE), 2010-2012 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE foodborne disease; outbreak investigations; public health capacity ID PUBLIC-HEALTH; SURVEILLANCE; ILLNESS; NETWORK AB Context: Each year foodborne diseases (FBD) affect approximately 1 in 6 Americans, resulting in 128 000 hospitalizations and 3000 deaths. Decreasing resources impact the ability of public health officials to identify, respond to, and control FBD outbreaks. Geographically dispersed outbreaks necessitate multijurisdictional coordination across all levels of the public health system. Rapid response depends on rapid detection. Objective: Targeted resources were provided to state and local health departments to improve completeness and timeliness of laboratory, epidemiology, and environmental health (EH) activities for FBD surveillance and outbreak response. Design: Foodborne Disease Centers for Outbreak Response Enhancement (FoodCORE) centers, selected through competitive award, implemented work plans designed to make outbreak response more complete and faster in their jurisdiction. Performance metrics were developed and used to evaluate the impact and effectiveness of activities. Participants: Departments of Health in Connecticut, New York City, Ohio, South Carolina, Tennessee, Utah, and Wisconsin. Results: From the first year (Y1) of the program in October 2010 to the end of the second year (Y2) in December 2012, the centers completed molecular subtyping for a higher proportion of Salmonella, Shiga toxin-producing Escherichia coli, and Listeria (SSL) isolates (86% vs 98%) and reduced the average time to complete testing from a median of 8 to 4 days. The centers attempted epidemiologic interviews with more SSL case-patients (93% vs 99%), and the average time to attempt interviews was reduced from a median of 4 to 2 days. During Y2, nearly 200 EH assessments were conducted. FoodCORE centers began documenting model practices such as streamlining and standardizing case-patient interviewing. Conclusion: Centers used targeted resources and process evaluation to implement and document practices that improve the completeness and timeliness of FBD surveillance and outbreak response activities in several public health settings. FoodCORE strategies and model practices could be replicated in other jurisdictions to improve FBD response. C1 [Biggerstaff, Gwen Kathryn; FoodCORE Team] US Ctr Dis Control & Prevent, Outbreak Response & Prevent Branch, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Biggerstaff, GK (reprint author), US Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM fke8@cdc.gov FU Intramural CDC HHS [CC999999] NR 22 TC 0 Z9 0 U1 1 U2 4 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD JUL-AUG PY 2015 VL 21 IS 4 BP E18 EP E26 DI 10.1097/PHH.0000000000000115 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ1IV UT WOS:000355238200003 PM 24983761 ER PT J AU Roberts, H Myles, RL Truman, BI Dean, HD AF Roberts, Henry Myles, Ranell L. Truman, Benedict I. Dean, Hazel D. TI Association of Employee Attributes and Exceptional Performance Rating at a National Center of the US Centers for Disease Control and Prevention, 2011 SO JOURNAL OF PUBLIC HEALTH MANAGEMENT AND PRACTICE LA English DT Article DE employee attributes; exceptional performance; federal employees; performance evaluation AB Context: Employee performance evaluation motivates and rewards exceptional individual performance that advances the achievement of organizational goals. The Centers for Disease Control and Prevention (CDC) and its operating units evaluate employee performance annually and reward exceptional performance with a cash award or quality step increase in pay. A summary performance rating (SPR) of "exceptional" indicated personal achievements in 2011 that were beyond expectations described in the employee's performance plan. Objective: To determine whether personal attributes and job setting of civil service employees were associated with an exceptional SPR in National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (NCHHSTP) in 2011. Design: Data from the CDC 2011 performance management database collected in 2012 were analyzed in 2013 to identify SPR, personal attributes, and job settings of full-time civil service employees. Multivariate logistic regression controlled for confounding and stratified analysis detected effect modifiers of the association between receiving an exceptional SPR in 2011 and gender, race/ethnicity, education, job location, job series, grade level, years in grade, years of federal service, supervisory role, and NCHHSTP division. Results: Among the 1037 employees, exceptional SPR was independently associated with: female gender (adjusted odds ratio: 1.7 [1.3, 2.3]), advanced degrees (doctorate: 1.7 [1.1, 2.5] master's: [1.1, 2.0]), headquarters location (2.8 [1.9, 4.1]), higher pay grade (3.3 [2.4, 4.5]) and years in grade (0-1 years: 1.7 [1.3, 2.4]; 2-4 years: 1.5 [1.1, 2.0]), division level (Division A: 5.0 [2.5, 9.9]; Division B: 5.5 [3.5, 8.8]), and supervisory status (at a lower-pay grade) (odds ratio: 3.7 [1.1, 11.3]). Conclusions: Exceptional SPR is independently associated with personal employee attributes and job settings that are not modifiable by interventions designed to improve employee performance based on accomplishments. C1 [Roberts, Henry] Ctr Dis Control & Prevent, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Myles, Ranell L.; Truman, Benedict I.; Dean, Hazel D.] Ctr Dis Control & Prevent, Off Director, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Roberts, H (reprint author), CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS G37, Atlanta, GA 30333 USA. EM Hroberts@cdc.gov FU Intramural CDC HHS [CC999999] NR 4 TC 0 Z9 0 U1 0 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1078-4659 EI 1550-5022 J9 J PUBLIC HEALTH MAN JI J. Public Health Manag. Pract. PD JUL-AUG PY 2015 VL 21 IS 4 BP E10 EP E17 DI 10.1097/PHH.0000000000000157 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ1IV UT WOS:000355238200002 PM 25271386 ER PT J AU Belser, JA Gustin, KM Katz, JM Maines, TR Tumpey, TM AF Belser, Jessica A. Gustin, Kortney M. Katz, Jacqueline M. Maines, Taronna R. Tumpey, Terrence M. TI Comparison of traditional intranasal and aerosol inhalation inoculation of mice with influenza A viruses SO VIROLOGY LA English DT Article DE Influenza; Animal model; Aerosol; Infectivity ID RESPIRATORY-TRACT; INFECTION; FERRETS; PATHOGENESIS; TRANSMISSION; H5N1; ANESTHESIA; EXPOSURE; IMMUNITY; MODELS AB Intranasal instillation of virus in a liquid suspension (IN) is the most frequently employed method to inoculate small mammalian models with influenza virus, but does not reflect a natural route of exposure. In contrast, inoculation via aerosol inhalation (AR) more closely resembles human exposure to influenza virus. Studies in mice have yielded conflicting results regarding virulence induced by virus inoculated by these routes, and have not controlled for potential strain-specific differences, or examined contemporary influenza viruses and avian viruses with pandemic potential. We used a whole-body AR inoculation method to compare infectivity and disease progression of a highly pathogenic H5N1, a low pathogenic H7N9, and a 2009 H1N1 virus with traditional IN inoculation in the mouse model. Generally comparable levels of morbidity and mortality were observed with all viruses examined using either inoculation route, indicating that both IN and AR delivery are appropriate for murine studies investigating influenza virus pathogenicity. Published by Elsevier Inc. C1 [Belser, Jessica A.; Gustin, Kortney M.; Katz, Jacqueline M.; Maines, Taronna R.; Tumpey, Terrence M.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30333 USA. RP Belser, JA (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM jax6@cdc.gov NR 27 TC 0 Z9 0 U1 2 U2 9 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0042-6822 J9 VIROLOGY JI Virology PD JUL PY 2015 VL 481 BP 107 EP 112 DI 10.1016/j.virol.2015.02.041 PG 6 WC Virology SC Virology GA CI9CW UT WOS:000355069000011 PM 25771498 ER PT J AU Hamner, T Latzman, RD Latzman, NE Elkin, TD Majumdar, S AF Hamner, Taralee Latzman, Robert D. Latzman, Natasha E. Elkin, T. David Majumdar, Suvankar TI Quality of life among pediatric patients with cancer: Contributions of time since diagnosis and parental chronic stress SO PEDIATRIC BLOOD & CANCER LA English DT Article DE chronic stress; parental stress; pediatric cancer; quality of life; time since diagnosis ID CHILDHOOD-CANCER; CHILDREN; SURVIVORS; ADJUSTMENT; ADOLESCENT; EXPERIENCE; SYMPTOMS; FATIGUE AB BackgroundPediatric cancer is associated with a host of negative psychosocial consequences; however, outcomes vary extensively suggesting a need to better understand this variation. Empirical research suggests a positive association between time since diagnosis (TSD) and Quality of Life (QoL). In addition to TSD, family stressors have been found to be particularly important in predicting QoL among children. The current study examined parental chronic stress beyond TSD in explanation of QoL functioning among a sample of pediatric patients with cancer. ProcedureParticipants included 43 pediatric patients aged 5-18 years (M-age=10.23.6) who were undergoing oncological treatment. Parents reported on TSD, child's QoL, and their own chronic stress. ResultsTSD was associated with greater physical functioning (r=0.30, P<0.05). Parental chronic stress was associated with poorer emotional (r=-0.54, P<0.01), physical (r=-0.41, P<0.01), and social functioning (r=-0.44, P<0.01). Further, hierarchal linear regression analyzes indicated parental chronic stress contributed incrementally beyond TSD in the explanation of physical (=-0.37, t=-2.58, P<0.01), emotional (=-0.47, t=-3.51, P<0.00), and social functioning (=-0.38, t=-2.67, P<0.01). ConclusionsParental chronic stress is associated with reduced levels of emotional, physical, and social functioning among pediatric patients. Future research is needed to further investigate the process by which chronic stress within the family interferes with adaptive coping among pediatric patients. In addition, clinical services may benefit from increased consideration of family factors, such as parental chronic stress, during oncological treatment. Pediatr Blood Cancer 2015;62:1232-1236. (c) 2015 Wiley Periodicals, Inc. C1 [Hamner, Taralee; Latzman, Robert D.] Georgia State Univ, Atlanta, GA 30302 USA. [Latzman, Natasha E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Elkin, T. David; Majumdar, Suvankar] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. RP Latzman, RD (reprint author), Georgia State Univ, Dept Psychol, POB 5010, Atlanta, GA 30302 USA. EM rlatzman@gsu.edu NR 26 TC 3 Z9 3 U1 1 U2 9 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1545-5009 EI 1545-5017 J9 PEDIATR BLOOD CANCER JI Pediatr. Blood Cancer PD JUL PY 2015 VL 62 IS 7 BP 1232 EP 1236 DI 10.1002/pbc.25468 PG 5 WC Oncology; Hematology; Pediatrics SC Oncology; Hematology; Pediatrics GA CI1YQ UT WOS:000354541600024 PM 25755193 ER PT J AU Akelo, V McLellan-Lemal, E Toledo, L Girde, S Borkowf, CB Ward, L Ondenge, K Ndivo, R Lecher, SL Mills, LA Thomas, TK AF Akelo, Victor McLellan-Lemal, Eleanor Toledo, Lauren Girde, Sonali Borkowf, Craig B. Ward, Laura Ondenge, Kenneth Ndivo, Richard Lecher, Shirley L. Mills, Lisa A. Thomas, Timothy K. TI Determinants and Experiences of Repeat Pregnancy among HIV-Positive Kenyan Women-A Mixed-Methods Analysis SO PLOS ONE LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; INFECTED WOMEN; FERTILITY INTENTIONS; BIRTH OUTCOMES; UNITED-KINGDOM; UGANDA; PREVALENCE; DESIRE; MEN AB Objective To identify factors associated with repeat pregnancy subsequent to an index pregnancy among women living with HIV (WLWH) in western Kenya who were enrolled in a 24-month phase-II clinical trial of triple-ART prophylaxis for prevention of mother-to-child transmission, and to contextualize social and cultural influences on WLWH's reproductive decision making. Methods A mixed-methods approach was used to examine repeat pregnancy within a 24 month period after birth. Counselor-administered questionnaires were collected from 500 WLWH. Forty women (22 with a repeat pregnancy; 18 with no repeat pregnancy) were purposively selected for a qualitative interview (QI). Simple and multiple logistic regression analyses were performed for quantitative data. Thematic coding and saliency analysis were undertaken for qualitative data. Results Eighty-eight (17.6%) women had a repeat pregnancy. Median maternal age was 23 years (range 15-43 years) and median gestational age at enrollment was 34 weeks. In multiple logistic regression analyses, living in the same compound with a husband (adjusted odds ratio (AOR): 2.33; 95% confidence interval (CI): 1.14, 4.75) was associated with increased odds of repeat pregnancy (p <= 0.05). Being in the 30-43 age group (AOR: 0.25; 95% CI: 0.07, 0.87), having talked to a partner about family planning (FP) use (AOR: 0.53; 95% CI: 0.29, 0.98), and prior usage of FP (AOR: 0.45; 95% CI: 0.25, 0.82) were associated with a decrease in odds of repeat pregnancy. QI findings centered on concerns about modern contraception methods (side effects and views that they 'ruined the womb') and a desire to have the right number of children. Religious leaders, family, and the broader community were viewed as reinforcing cultural expectations for married women to have children. Repeat pregnancy was commonly attributed to contraception failure or to lack of knowledge about post-delivery fertility. Conclusions In addition to cultural context, reproductive health programs for WLWH may need to address issues related to living circumstances and the possibility that reproductive-decision making may extend beyond the woman and her partner. C1 [Akelo, Victor; Ondenge, Kenneth; Ndivo, Richard] Kenya Govt Med Res Ctr, Kisumu, Kenya. [McLellan-Lemal, Eleanor; Toledo, Lauren; Girde, Sonali; Borkowf, Craig B.; Lecher, Shirley L.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Toledo, Lauren; Girde, Sonali] ICF Int, Atlanta, GA USA. [Ward, Laura; Mills, Lisa A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Thomas, Timothy K.] Ctr Dis Control & Prevent, Kisumu, Kenya. RP Akelo, V (reprint author), Kenya Govt Med Res Ctr, Kisumu, Kenya. EM vakelo@kemricdc.org FU Kenya Medical Research Institute (KEMRI); US Centers for Disease Control and Prevention (CDC) FX Funding for the study was provided by the Kenya Medical Research Institute (KEMRI) through a cooperative agreement with the US Centers for Disease Control and Prevention (CDC). The study design, data collection instruments, data collection, data analysis, decision to publish, and preparation of the manuscript were led by CDC and KEMRI staff based in Atlanta and at the KEMRI/CDC Field Station in Kisumu, Kenya. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the CDC. NR 37 TC 1 Z9 1 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 29 PY 2015 VL 10 IS 6 AR e0131163 DI 10.1371/journal.pone.0131163 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1BL UT WOS:000358150400080 PM 26120846 ER PT J AU Henderson, KC Benitez, AJ Ratliff, AE Crabb, DM Sheppard, ES Winchell, JM Dluhy, RA Waites, KB Atkinson, TP Krause, DC AF Henderson, Kelley C. Benitez, Alvaro J. Ratliff, Amy E. Crabb, Donna M. Sheppard, Edward S. Winchell, Jonas M. Dluhy, Richard A. Waites, Ken B. Atkinson, T. Prescott Krause, Duncan C. TI Specificity and Strain-Typing Capabilities of Nanorod Array-Surface Enhanced Raman Spectroscopy for Mycoplasma pneumoniae Detection SO PLOS ONE LA English DT Article ID REAL-TIME PCR; SEQUENCE-ANALYSIS; SILVER SURFACE; P1 ADHESIN; SCATTERING; SUBSTRATE; IDENTIFICATION; GENOME; SERS AB Mycoplasma pneumoniae is a cell wall-less bacterial pathogen of the human respiratory tract that accounts for > 20% of all community-acquired pneumonia (CAP). At present the most effective means for detection and strain-typing is quantitative polymerase chain reaction (qPCR), which can exhibit excellent sensitivity and specificity but requires separate tests for detection and genotyping, lacks standardization between available tests and between labs, and has limited practicality for widespread, point-of-care use. We have developed and previously described a silver nanorod array-surface enhanced Raman Spectroscopy (NA-SERS) biosensing platform capable of detecting M. pneumoniae with statistically significant specificity and sensitivity in simulated and true clinical throat swab samples, and the ability to distinguish between reference strains of the two main genotypes of M. pneumoniae. Furthermore, we have established a qualitative lower endpoint of detection for NA-SERS of < 1 genome equivalent (cell/mu l) and a quantitative multivariate detection limit of 5.3 +/- 1 cells/mu l. Here we demonstrate using partial least squares-discriminatory analysis (PLS-DA) of sample spectra that NA-SERS correctly identified M. pneumoniae clinical isolates from globally diverse origins and distinguished these from a panel of 12 other human commensal and pathogenic mycoplasma species with 100% cross-validated statistical accuracy. Furthermore, PLS-DA correctly classified by strain type all 30 clinical isolates with 96% cross-validated accuracy for type 1 strains, 98% cross-validated accuracy for type 2 strains, and 90% cross-validated accuracy for type 2V strains. C1 [Henderson, Kelley C.; Sheppard, Edward S.; Krause, Duncan C.] Univ Georgia, Dept Microbiol, Athens, GA 30602 USA. [Benitez, Alvaro J.; Winchell, Jonas M.] Ctr Dis Control & Prevent, Pneumonia Response & Surveillance Lab, Atlanta, GA USA. [Ratliff, Amy E.; Crabb, Donna M.; Waites, Ken B.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Atkinson, T. Prescott] Univ Alabama Birmingham, Dept Pediat, Birmingham, AL USA. [Dluhy, Richard A.] Univ Georgia, Dept Chem, Athens, GA 30602 USA. RP Krause, DC (reprint author), Univ Georgia, Dept Microbiol, Athens, GA 30602 USA. EM dkrause@uga.edu FU National Institute of Allergy and Infectious Disease [AI096364]; National Institute of General Medical Sciences [GM102546] FX Funding provided by Public Health Service grants AI096364 to DCK from the National Institute of Allergy and Infectious Disease (www.niaid.nih.gov) and GM102546 to RAD from the National Institute of General Medical Sciences (www.nigms.nih.gov). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 54 TC 4 Z9 4 U1 0 U2 23 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 29 PY 2015 VL 10 IS 6 AR e0131831 DI 10.1371/journal.pone.0131831 PG 24 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CN1BL UT WOS:000358150400164 PM 26121242 ER PT J AU Pfeiffer, CM Sternberg, MR Fazili, Z Lacher, DA Zhang, M Johnson, CL Hamner, HC Bailey, RL Rader, JI Yamini, S Berry, RJ Yetley, EA AF Pfeiffer, Christine M. Sternberg, Maya R. Fazili, Zia Lacher, David A. Zhang, Mindy Johnson, Clifford L. Hamner, Heather C. Bailey, Regan L. Rader, Jeanne I. Yamini, Sedigheh Berry, R. J. Yetley, Elizabeth A. TI Folate status and concentrations of serum folate forms in the US population: National Health and Nutrition Examination Survey 2011-2 SO BRITISH JOURNAL OF NUTRITION LA English DT Article DE National Health and Nutrition Examination Survey; Folate vitamers; 5-Methyltetrahydrofolate; Unmetabolised folic acid; Non-methyl folate; Folate oxidation products; Liquid chromatography-MS/MS ID TANDEM MASS-SPECTROMETRY; UNMETABOLIZED FOLIC-ACID; LIFE-STYLE VARIABLES; NEURAL-TUBE DEFECTS; MICROBIOLOGIC ASSAY; NHANES 1988-2010; RBC FOLATE; LC-MS/MS; BIOMARKERS; RADIOASSAY AB Serum and erythrocyte (RBC) total folate are indicators of folate status. No nationally representative population data exist for folate forms. We measured the serum folate forms (5-methyltetrahydrofolate (5-methylTHF), unmetabolised folic acid (UMFA), non-methyl folate (sum of tetrahydrofolate (THF), 5-formyltetrahydrofolate (5-formylTHF), 5,10-methenyltetrahydrofolate (5,10-methenylTHF)) and MeFox (5-methylTHF oxidation product)) by HPLC-MS/MS and RBC total folate by microbiologic assay in US population >= 1 year (n approximately 7500) participating in the National Health and Nutrition Examination Survey 2011-2. Data analysis for serum total folate was conducted including and excluding MeFox. Concentrations (geometric mean; detection rate) of 5-methylTHF (37.5 nmol/l; 100 %), UMFA (1.21 nmol/l; 99.9 %), MeFox (1.53 nmol/l; 98.8 %), and THF (1.01 nmol/l; 85.2 %) were mostly detectable. 5-FormylTHF (3.6 %) and 5,10-methenylTHF (4.4 %) were rarely detected. The biggest contributor to serum total folate was 5-methylTHF (86.7 %); UMFA (4.0 %), non-methyl folate (4.7 %) and MeFox (4.5 %) contributed smaller amounts. Age was positively related to MeFox, but showed a U-shaped pattern for other folates. We generally noted sex and race/ethnic biomarker differences and weak (Spearman's r < 0.4) but significant (P < 0.05) correlations with physiological and lifestyle variables. Fasting, kidney function, smoking and alcohol intake showed negative associations. BMI and body surface area showed positive associations with MeFox but negative associations with other folates. All biomarkers showed significantly higher concentrations with recent folic acid-containing dietary supplement use. These first-time population data for serum folate forms generally show similar associations with demographic, physiological and lifestyle variables as serum total folate. Patterns observed for MeFox may suggest altered folate metabolism dependent on biological characteristics. C1 [Pfeiffer, Christine M.; Sternberg, Maya R.; Fazili, Zia; Zhang, Mindy] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Lacher, David A.; Johnson, Clifford L.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Hamner, Heather C.; Berry, R. J.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Bailey, Regan L.; Yetley, Elizabeth A.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Rader, Jeanne I.; Yamini, Sedigheh] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD USA. RP Pfeiffer, CM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. EM cpfeiffer@cdc.gov OI Berry, Robert/0000-0002-7162-5046 FU Office of Dietary Supplements, NIH FX Data collection and laboratory analyses of folate supported by funding from the Office of Dietary Supplements, NIH. None of the authors has reported a conflict of interest. NR 45 TC 13 Z9 13 U1 2 U2 13 PU CAMBRIDGE UNIV PRESS PI CAMBRIDGE PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND SN 0007-1145 EI 1475-2662 J9 BRIT J NUTR JI Br. J. Nutr. PD JUN 28 PY 2015 VL 113 IS 12 BP 1965 EP 1977 DI 10.1017/S0007114515001142 PG 13 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CM7PR UT WOS:000357887800014 PM 25917925 ER PT J AU Cali, I Miller, CJ Parisi, JE Geschwind, MD Gambetti, P Schonberger, LB AF Cali, Ignazio Miller, Cathleen J. Parisi, Joseph E. Geschwind, Michael D. Gambetti, Pierluigi Schonberger, Lawrence B. TI Distinct pathological phenotypes of Creutzfeldt-Jakob disease in recipients of prion-contaminated growth hormone SO ACTA NEUROPATHOLOGICA COMMUNICATIONS LA English DT Article DE Iatrogenic Creutzfeldt-Jakob disease; PrPSc; Growth hormone; Dura mater; Pathological phenotype ID DURA-MATER GRAFT; TO-PERSON TRANSMISSION; FLORID PLAQUES; CLASSIFICATION; PROTEIN; CJD; DIAGNOSIS; ANTIBODY AB Introduction: The present study compares the clinical, pathological and molecular features of a United States (US) case of growth hormone (GH)-associated Creutzfeldt-Jakob disease (GH-CJD) (index case) to those of two earlier referred US cases of GH-CJD and one case of dura mater (d)-associated CJD (dCJD). All iatrogenic CJD (iCJD) subjects were methionine (M) homozygous at codon 129 (129MM) of the prion protein (PrP) gene and had scrapie prion protein (PrPSc) type 1 (iCJDMM1). Results: The index subject presented with ataxia, weight loss and changes in the sleep pattern about 38 years after the midpoint of GH treatment. Autopsy examination revealed a neuropathological phenotype reminiscent of both sCJDMV2-K (a sporadic CJD subtype in subjects methionine/valine heterozygous at codon 129 with PrPSc type 2 and the presence of kuru plaques) and variant CJD (vCJD). The two earlier cases of GH-CJDMM1 and the one of dCJDMM1 were associated with neuropathological phenotypes that differed from that of the index case mainly because they lacked PrP plaques. The phenotype of the earlier GH-CJDMM1 cases shared several, but not all, characteristics with sCJDMM1, whereas dCJDMM1 was phenotypically indistinguishable from sCJDMM1. Two distinct groups of dCJDMM1 have also been described in Japan based on clinical features, the presence or absence of PrP plaques and distinct PK-resistant PrPSc (resPrP(Sc)) electrophoretic mobilities. The resPrP(Sc) electrophoretic mobility was, however, identical in our GH-CJDMM1 and dCJDMM1 cases, and matched that of sCJDMM1. Conclusions: Our study shows that receipt of prion-contaminated GH can lead to a prion disease with molecular features (129MM and PrPSc type 2) and phenotypic characteristics that differ from those of sporadic prion disease (sCJDMM1), a difference that may reflect adaptation of "heterologous" prion strains to the 129MM background. C1 [Cali, Ignazio; Gambetti, Pierluigi] Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA. [Cali, Ignazio] Univ Naples 2, Dept Clin & Expt Med, Naples, Italy. [Miller, Cathleen J.] Kaiser Permanente Sunnyside Med Ctr, Dept Neurol, Clackamas, OR USA. [Parisi, Joseph E.] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA. [Parisi, Joseph E.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Geschwind, Michael D.] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA USA. [Schonberger, Lawrence B.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Cali, I (reprint author), Case Western Reserve Univ, Sch Med, Dept Pathol, Cleveland, OH 44106 USA. EM ixc20@case.edu FU NCEZID CDC HHS [1U51CK000100, U51 CK000100]; NIA NIH HHS [R01 AG031189, R01-AG031189]; NIAID NIH HHS [1AI106705-01A1, P01 AI106705]; NINDS NIH HHS [R01 NS062787, NS083687, R01 NS083687] NR 46 TC 4 Z9 4 U1 1 U2 7 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 2051-5960 J9 ACTA NEUROPATHOL COM JI Acta Neuropathol. Commun. PD JUN 25 PY 2015 VL 3 AR 37 DI 10.1186/s40478-015-0214-2 PG 10 WC Neurosciences SC Neurosciences & Neurology GA CP9WO UT WOS:000360246300002 PM 26108478 ER PT J AU Tapley, JL McGwin, G Ashraf, AP MacLennan, PA Callahan, K Searcey, K Witherspoon, CD Saaddine, J Owsley, C AF Tapley, Jeffrey L. McGwin, Gerald, Jr. Ashraf, Ambika P. MacLennan, Paul A. Callahan, Koula Searcey, Karen Witherspoon, C. Douglas Saaddine, Jinan Owsley, Cynthia TI Feasibility and efficacy of diabetic retinopathy screening among youth with diabetes in a pediatric endocrinology clinic: a cross-sectional study SO DIABETOLOGY & METABOLIC SYNDROME LA English DT Article DE Diabetes mellitus; Diabetes complications; Diabetic retinopathy; Pediatrics; Visual acuity ID TYPE-1; AGE; OPHTHALMOSCOPY; PHOTOGRAPHY; PREVALENCE; GUIDELINES; DURATION; MELLITUS; CHILDREN; PROGRAM AB Background: We examined the feasibility and efficacy of using a non-mydriatic camera to screen for diabetic retinopathy (DR) among youth with type 1 or type 2 diabetes seen in a pediatric endocrinology cinic serving Alabama, the state that has the highest diabetes rate in the United States. Methods: 236 youths with type 1 or type 2 diabetes were screened for DR using a non-mydriatic camera Visual acuity was also assessed. A questionnaire asked parents about diabetes arid eye care history. Results: Mean duration since diabetes diagnosis was 5.5 years. 66 % reported receiving an eye examination within the previous year. 97.5 % had images that were gradable. DR was detected in 3.8 9,6 of participants. 9.1 9,6 were visually impaired. Conclusions: Use of a non-mydriatic fundus camera is feasible and efficacious for DR screening in youth with diabetes. DR screening at routine endocrinology visits may be beneficial in managing youth with diabetes and preventing irreversible vision loss, particularly for those in regions where diabetes rates are high. C1 [Tapley, Jeffrey L.; Callahan, Koula; Searcey, Karen; Witherspoon, C. Douglas; Owsley, Cynthia] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA. [McGwin, Gerald, Jr.] Univ Alabama Birmingham, Dept Epidemiol, Birmingham, AL 35294 USA. [Ashraf, Ambika P.] Univ Alabama Birmingham, Dept Pediat, Div Endocrinol, Birmingham, AL 35294 USA. [MacLennan, Paul A.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Saaddine, Jinan] Ctr Dis Control & Prevent, Vis Hlth Initiat, Div Diabet Translat, Atlanta, GA 30329 USA. RP Owsley, C (reprint author), Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA. EM owsley@uab.edu FU Centers for Disease Control and Prevention (CDC) [5U58DP002651]; University of Alabama at Birmingham; Research to Prevent Blindness; EyeSight Foundation of Alabama; Buck Trust FX Funding was provided by Centers for Disease Control and Prevention (CDC) Cooperative Agreement #5U58DP002651 with the University of Alabama at Birmingham. Supplemental funding was provided by Research to Prevent Blindness, the EyeSight Foundation of Alabama, and the Buck Trust. Research to Prevent Blindness, the EyeSight Foundation of Alabama, and the Buck Trust had no role in the design, collection, analysis, and interpretation of the data, in writing the manuscript, and the decision to submit the manuscript for publication. A medical epidemiologist at CDC (JS) participated in the interpretation of the data and writing the manuscript since this study was funded by a cooperative (and thus collaborative) agreement with CDC. NR 34 TC 1 Z9 1 U1 3 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1758-5996 J9 DIABETOL METAB SYNDR JI Diabetol. Metab. Syndr. PD JUN 24 PY 2015 VL 7 AR 56 DI 10.1186/s13098-015-0054-z PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CL6IZ UT WOS:000357072100001 PM 26136849 ER PT J AU Chanda, E Mzilahowa, T Chipwanya, J Mulenga, S Ali, D Troell, P Dodoli, W Govere, JM Gimnig, J AF Chanda, Emmanuel Mzilahowa, Themba Chipwanya, John Mulenga, Shadreck Ali, Doreen Troell, Peter Dodoli, Wilfred Govere, John M. Gimnig, John TI Preventing malaria transmission by indoor residual spraying in Malawi: grappling with the challenge of uncertain sustainability SO MALARIA JOURNAL LA English DT Article DE Malaria vector control; Indoor residual spraying; Integrated vector management; Insecticide resistance management; Vector surveillance; Sustainability; Malawi ID PYRETHROID RESISTANCE; ELIMINATION; ZAMBIA; IMPACT AB Background: In the past decade, there has been rapid scale-up of insecticide-based malaria vector control in the context of integrated vector management (IVM) according to World Health Organization recommendations. Endemic countries have deployed indoor residual spraying (IRS) and long-lasting insecticidal nets as hallmark vector control interventions. This paper discusses the successes and continued challenges and the way forward for the IRS programme in Malawi. Case description: The National Malaria Control Programme in Malawi, with its efforts to implement an integrated approach to malaria vector control, was the 'case' for this study. Information sources included all available data and accessible archived documentary records on IRS in Malawi. A methodical assessment of published and unpublished documents was conducted via a literature search of online electronic databases. Discussion: Malawi has implemented IRS as the main malaria transmission-reducing intervention. However, pyrethroid and carbamate resistance in malaria vectors has been detected extensively across the country and has adversely affected the IRS programme. Additionally, IRS activities have been characterized by substantial inherent logistical and technical challenges culminating into missed targets. As a consequence, programmatic IRS operations have been scaled down from seven districts in 2010 to only one district in 2014. The future of the IRS programme in Malawi is uncertain due to limited funding, high cost of alternative insecticides and technical resource challenges being experienced in the country. Conclusions: The availability of a long-lasting formulation of the organophosphate pirimiphos-methyl makes the re-introduction of IRS a possibility and may be a useful approach for the management of pyrethroid resistance. Implementing the IVM strategy, advocating for sustainable domestic funding, including developing an insecticide resistance monitoring and management plan and vector surveillance guidelines will be pivotal in steering entomologic monitoring and future vector control activities in Malawi. C1 [Chanda, Emmanuel] Malaria Vector Control Consultant, Lusaka, Zambia. [Mzilahowa, Themba] Malaria Alert Ctr, Blantyre, Malawi. [Chipwanya, John; Mulenga, Shadreck; Ali, Doreen] Minist Hlth, Natl Malaria Control Pro Gramme, Lilongwe, Malawi. [Troell, Peter] USAID, PMI, Country Off, Lilongwe, Malawi. [Dodoli, Wilfred] World Hlth Org, Country Off, Lilongwe, Malawi. [Govere, John M.] Malaria Vector Control Consultant, Nelspruit, South Africa. [Gimnig, John] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Chanda, E (reprint author), Malaria Vector Control Consultant, Lusaka, Zambia. EM emmanuel_chanda@yahoo.co.uk FU PMI/CDC in Malawi FX The authors gratefully acknowledge the NMCP and Ministry of Health staff for facilitating the data collection and review. This study was supported by the PMI/CDC in Malawi. NR 33 TC 7 Z9 7 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD JUN 24 PY 2015 VL 14 AR 254 DI 10.1186/s12936-015-0759-3 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CL0TZ UT WOS:000356657300001 PM 26104657 ER PT J AU McMurray, RG Butte, NF Crouter, SE Trost, SG Pfeiffer, KA Bassett, DR Puyau, MR Berrigan, D Watson, KB Fulton, JE AF McMurray, Robert G. Butte, Nancy F. Crouter, Scott E. Trost, Stewart G. Pfeiffer, Karin A. Bassett, David R. Puyau, Maurice R. Berrigan, David Watson, Kathleen B. Fulton, Janet E. CA CDC NCI NCCOR Res Grp Energy Expen TI Exploring Metrics to Express Energy Expenditure of Physical Activity in Youth SO PLOS ONE LA English DT Article ID BODY-SIZE; SUBSTRATE UTILIZATION; AEROBIC POWER; CHILDREN; ADOLESCENTS; EXPLANATION; COMPENDIUM; VARIABLES; EXERCISE; ECONOMY AB Background Several approaches have been used to express energy expenditure in youth, but no consensus exists as to which best normalizes data for the wide range of ages and body sizes across a range of physical activities. This study examined several common metrics for expressing energy expenditure to determine whether one metric can be used for all healthy children. Such a metric could improve our ability to further advance the Compendium of Physical Activities for Youth. Methods A secondary analysis of oxygen uptake (VO2) data obtained from five sites was completed, that included 947 children ages 5 to 18 years, who engaged in 14 different activities. Resting metabolic rate (RMR) was computed based on Schofield Equations [Hum Nutr Clin Nut. 39 (Suppl 1), 1985]. Absolute oxygen uptake (ml.min(-1)), oxygen uptake per kilogram body mass (VO2 in ml. kg(-1).min(-1)), net oxygen uptake (VO2 - resting metabolic rate), allometric scaled oxygen uptake (VO2 in ml. kg(-0.75).min(-1)) and YOUTH-MET (VO2.[resting VO2](-1)) were calculated. These metrics were regressed with age, sex, height, and body mass. Results Net and allometric-scaled VO2, and YOUTH-MET were least associated with age, sex and physical characteristics. For moderate-to-vigorous intensity activities, allometric scaling was least related to age and sex. For sedentary and low-intensity activities, YOUTH-MET was least related to age and sex. Conclusions No energy expenditure metric completely eliminated the influence of age, physical characteristics, and sex. The Adult MET consistently overestimated EE. YOUTH-MET was better for expressing energy expenditure for sedentary and light activities, whereas allometric scaling was better for moderate and vigorous intensity activities. From a practical perspective, The YOUTH-MET may be the more feasible metric for improving of the Compendium of Physical Activities for Youth. C1 [McMurray, Robert G.] Univ N Carolina, Exercise & Sport Sci & Nutr, Chapel Hill, NC 27599 USA. [Butte, Nancy F.; Puyau, Maurice R.] Baylor Coll Med, USDA ARS, Childrens Nutr Res Ctr, Houston, TX 77030 USA. [Crouter, Scott E.; Bassett, David R.] Univ Tennessee, Dept Kinesiol Recreat & Sport Studies, Knoxville, TN USA. [Trost, Stewart G.] Queensland Univ Technol, Inst Hlth & Biomed Innovat, Exercise & Nutr Sci, Brisbane, Qld 4001, Australia. [Pfeiffer, Karin A.] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA. [Berrigan, David] NCI, Ctr Dis Control & Prevent, Natl Collaborat Childhood Obes Res, Washington, DC USA. [Watson, Kathleen B.; Fulton, Janet E.] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. RP McMurray, RG (reprint author), Univ N Carolina, Exercise & Sport Sci & Nutr, Chapel Hill, NC 27599 USA. EM exphys@live.unc.edu RI Crouter, Scott/H-4852-2011; OI Crouter, Scott/0000-0003-1297-9538; Trost, Stewart/0000-0001-9587-3944 FU NHLBI NIH HHS [R21 HL093407]; NICHD NIH HHS [L30 HD066736] NR 32 TC 2 Z9 2 U1 1 U2 6 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 23 PY 2015 VL 10 IS 6 AR e0130869 DI 10.1371/journal.pone.0130869 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CL4DD UT WOS:000356901900064 PM 26102204 ER PT J AU Hibbs, BF Moro, PL Lewis, P Miller, ER Shimabukuro, TT AF Hibbs, Beth F. Moro, Pedro L. Lewis, Paige Miller, Elaine R. Shimabukuro, Tom T. TI Vaccination errors reported to the Vaccine Adverse Event Reporting System, (VAERS) United States, 2000-2013 SO VACCINE LA English DT Article DE Medication errors; Vaccination; Medical errors; Errors; Patient safety; Vaccine safety ID MEDICATION ERRORS; ADMINISTRATION ERRORS; INFLUENZA VACCINE; YOUNG-CHILDREN; DRUG EVENTS; CARE; EXTRAIMMUNIZATION; GUIDELINES; CONFUSION AB Importance: Vaccination errors are preventable events. Errors can have impacts including inadequate immunological protection, possible injury, cost, inconvenience, and reduced confidence in the healthcare delivery system. Objectives: To describe vaccination error reports submitted to the Vaccine Adverse Event Reporting System (VAERS) and identify opportunities for prevention. Methods: We conducted descriptive analyses using data from VAERS, the U.S. spontaneous surveillance system for adverse events following immunization. The VAERS database was searched from 2000 through 2013 for U.S. reports describing vaccination errors and reports were categorized into 11 error groups. We analyzed numbers and types of vaccination error reports, vaccines involved, reporting trends over time, and descriptions of errors for selected reports. Results: We identified 20,585 vaccination error reports documenting 21,843 errors. Annual reports increased from 10 in 2000 to 4324 in 2013. The most common error group was "Inappropriate Schedule" (5947; 27%); human papillomavirus (quadrivalent) (1516) and rotavirus (880) vaccines were most frequently involved. "Storage and Dispensing" errors (4983; 23%) included mostly expired vaccine administered (2746) and incorrect storage of vaccine (2202). "Wrong Vaccine Administered" errors (3372; 15%) included mix-ups between vaccines with similar antigens such as varicella/herpes zoster (shingles), DTaP/Tdap, and pneumococcal conjugate/polysaccharide. For error reports with an adverse health event (5204; 25% of total), 92% were classified as non-serious. We also identified 936 vaccination error clusters (i.e., same error, multiple patients, in a common setting) involving over 6141 patients. The most common error in clusters was incorrect storage of vaccine (582 clusters and more than 1715 patients). Conclusions: Vaccination error reports to VAERS have increased substantially. Contributing factors might include changes in reporting practices, increasing complexity of the immunization schedule, availability of products with similar sounding names or acronyms, and increased attention to storage and temperature lapses. Prevention strategies should be considered. Published by Elsevier Ltd. C1 [Hibbs, Beth F.; Moro, Pedro L.; Lewis, Paige; Miller, Elaine R.; Shimabukuro, Tom T.] Ctr Dis Control & Prevent CDC, Immunizat Safely Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Hibbs, BF (reprint author), Ctr Dis Control & Prevent CDC, Immunizat Safely Off, Div Healthcare Qual Promot, Natl Ctr Emerging & Zoonot Infect Dis, 1600 Clifton Rd,MS D-26, Atlanta, GA USA. EM bhibbs@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX The study was supported by the Centers for Disease Control and Prevention (CDC). This study had no external sponsors. NR 47 TC 3 Z9 3 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUN 22 PY 2015 VL 33 IS 28 BP 3171 EP 3178 DI 10.1016/j.vaccine.2015.05.006 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CL8PC UT WOS:000357235600005 PM 25980429 ER PT J AU D'Angelo, DV Le, B O'Neil, ME Williams, L Ahluwalia, IB Harrison, LL Floyd, RL Grigorescu, V AF D'Angelo, Denise V. Le, Brenda O'Neil, Mary Elizabeth Williams, Letitia Ahluwalia, Indu B. Harrison, Leslie L. Floyd, R. Louise Grigorescu, Violanda TI Patterns of Health Insurance Coverage Around the Time of Pregnancy Among Women with Live-Born Infants - Pregnancy Risk Assessment Monitoring System, 29 States, 2009 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID AFFORDABLE CARE ACT; SERVICES TASK-FORCE; UNITED-STATES; REPRODUCTIVE HEALTH; MEDICAID COVERAGE; REFORM; ADULTS; UNINSURANCE; DISRUPTION; GAINS AB Problem/Condition: In 2009, before passage of the 2010 Patient Protection and Affordable Care Act (ACA), approximately 20% of women aged 18-64 years had no health insurance coverage. In addition, many women experienced transitions in coverage around the time of pregnancy. Having no health insurance coverage or experiencing gaps or shifts in coverage can be a barrier to receiving preventive health services and treatment for health problems that could affect pregnancy and newborn health. With the passage of ACA, women who were previously uninsured or had insurance that provided inadequate coverage might have better access to health services and better coverage, including additional preventive services with no cost sharing. Because certain elements of ACA (e.g., no lifetime dollar limits, dependent coverage to age 26, and provision of preventive services without cost sharing) were implemented as early as September 2010, data from 2009 can be used as a baseline to measure the incremental impact of ACA on the continuity of health care coverage for women around the time of pregnancy. Reporting Period Covered: 2009. Description of System: The Pregnancy Risk Assessment Monitoring System (PRAMS) is an ongoing state- and population-based surveillance system designed to monitor selected maternal behaviors and experiences that occur before, during, and shortly after pregnancy among women who deliver live-born infants in selected U.S. states and New York City, New York. PRAMS uses mixed-mode data collection, in which up to three self-administered surveys are mailed to a sample of mothers, and those who do not respond are contacted for telephone interviews. Self-reported survey data are linked to birth certificate data and weighted for sample design, nonresponse, and noncoverage. Annual PRAMS data sets are created and used to produce statewide estimates of preconception and perinatal health behaviors and experiences in selected states and New York City. This report summarizes data from 29 states that conducted PRAMS in 2009, before the passage of ACA, and achieved an overall weighted response rate of >= 65%. Data on the prevalence of health insurance coverage stability (stable coverage, unstable coverage, and uninsured) across three time periods (the month before pregnancy, during pregnancy, and at the time of delivery) are reported by state and selected maternal characteristics. Women with stable coverage had the same type of health insurance (private or Medicaid) for all three time periods. Women with unstable coverage experienced a change in health insurance coverage between any of the three time periods. This includes movement from having no insurance coverage to gaining coverage, movement from one type of coverage to another, and loss of coverage. Women in the uninsured group had no insurance coverage during any of the three time periods. Estimates for health insurance stability across the three time periods and estimates of coverage during each time period are presented by state. Patterns of movement between the different types of health insurance coverage among women with unstable coverage are described by state and selected maternal characteristics. Results: In 2009, 30.1% of women who had a live birth experienced changes in health insurance coverage in the period between the month before pregnancy and the time of delivery, either because they lacked coverage at some point or because they moved between different types of coverage. Most women had stable coverage across the three time periods, reporting either private coverage (52.8%) or Medicaid coverage (16.1%) throughout. A small percentage of women (1.1%) reported having no health insurance coverage at any point. Overall, Medicaid coverage increased from 16.6% in the month before pregnancy to 43.9% at delivery. Private coverage decreased from 59.9% in the month before pregnancy to 54.6% at delivery. The percentage of women who were uninsured decreased from 23.4% in the month before pregnancy to 1.5% at the time of delivery. Among those who experienced changes in coverage, 74.4% reported having no insurance the month before pregnancy, 23.9% reported having private insurance, and 1.8% reported having Medicaid. Among those who started out uninsured before pregnancy, 70.2% reported Medicaid coverage, and 4.1% reported private coverage at the time of delivery. Among those who started out with private coverage, 21.3% reported Medicaid coverage at delivery, and 1.4% reported being uninsured. As a result of these transitions in health insurance coverage, 92.4% of all women who experienced a change in health insurance around the time of pregnancy reported Medicaid coverage at delivery. No women with unstable coverage who started out without insurance in the month before pregnancy reported being uninsured at the time of delivery. Women who reported unstable coverage were more likely to be young (aged <35 years), be a minority (black, Hispanic, or American Indian/Alaska Native), have a high school education or less, be unmarried, have incomes <= 200% of the federal poverty level (FPL), or have an unintended pregnancy compared with women with stable private coverage. Compared with women with stable Medicaid coverage, women with unstable coverage were more likely to be Hispanic but less likely to be teenagers (aged <= 19 years), be black, have a high school education or less, have incomes <= 200% of the FPL, or have an unintended pregnancy. Women with unstable coverage were more likely than women in either stable coverage group (private or Medicaid) to report entering prenatal care after the first trimester. Interpretation: In 2009, nearly one third of women reported lacking health insurance or transitioning between types of health insurance coverage around the time of pregnancy. The majority of women who changed health insurance status obtained coverage for prenatal care, delivery, or both through Medicaid. Health insurance coverage during pregnancy can help facilitate access to health care and allow for the identification and treatment of health-related issues; however, prenatal coverage might be too late to prevent the consequences of preexisting conditions and preconception exposures that could affect maternal and infant health. Continuous access to health insurance and health care for women of reproductive age could improve maternal and infant health by providing the opportunity to manage or treat conditions that are present before and between pregnancies. Public Health Action: PRAMS data can be used to identify patterns of health insurance coverage among women around the time of pregnancy. Removing barriers to obtaining health insurance for women who lack coverage, particularly before pregnancy, could improve the health of women and their infants. The findings in this report can be used by public health professionals, policy analysts, and others to monitor health insurance coverage for women around the time of pregnancy. In particular, 2009 state-specific data can serve as baseline information to assess and monitor changes in health insurance coverage since the passage of ACA. C1 [D'Angelo, Denise V.; Le, Brenda; Williams, Letitia; Ahluwalia, Indu B.; Harrison, Leslie L.; Grigorescu, Violanda] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [O'Neil, Mary Elizabeth] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Floyd, R. Louise] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP D'Angelo, DV (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30341 USA. EM DDAngelo@cdc.gov NR 61 TC 0 Z9 0 U1 3 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 19 PY 2015 VL 64 IS 4 SU S BP 1 EP 19 PG 19 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN4IU UT WOS:000358394600001 ER PT J AU D'Angelo, DV Le, B O'Neil, ME Williams, L Ahluwalia, IB Harrison, LL Floyd, RL Grigorescu, V AF D'Angelo, Denise V. Le, Brenda O'Neil, Mary Elizabeth Williams, Letitia Ahluwalia, Indu B. Harrison, Leslie L. Floyd, R. Louise Grigorescu, Violanda TI Patterns of Health Insurance Coverage Around the Time of Pregnancy Among Women with Live-Born Infants - Pregnancy Risk Assessment Monitoring System, 29 States, 2009 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID AFFORDABLE CARE ACT; SERVICES TASK-FORCE; UNITED-STATES; PREVENTIVE-SERVICES; REPRODUCTIVE HEALTH; MEDICAID COVERAGE; REFORM; ADULTS; UNINSURANCE; DISRUPTION AB Problem/Condition: In 2009, before passage of the 2010 Patient Protection and Affordable Care Act (ACA), approximately 20% of women aged 18-64 years had no health insurance coverage. In addition, many women experienced transitions in coverage around the time of pregnancy. Having no health insurance coverage or experiencing gaps or shifts in coverage can be a barrier to receiving preventive health services and treatment for health problems that could affect pregnancy and newborn health. With the passage of ACA, women who were previously uninsured or had insurance that provided inadequate coverage might have better access to health services and better coverage, including additional preventive services with no cost sharing. Because certain elements of ACA (e.g., no lifetime dollar limits, dependent coverage to age 26, and provision of preventive services without cost sharing) were implemented as early as September 2010, data from 2009 can be used as a baseline to measure the incremental impact of ACA on the continuity of health care coverage for women around the time of pregnancy. Reporting Period Covered: 2009. Description of System: The Pregnancy Risk Assessment Monitoring System (PRAMS) is an ongoing state-and population-based surveillance system designed to monitor selected maternal behaviors and experiences that occur before, during, and shortly after pregnancy among women who deliver live-born infants in selected U.S. states and New York City, New York. PRAMS uses mixed-mode data collection, in which up to three self-administered surveys are mailed to a sample of mothers, and those who do not respond are contacted for telephone interviews. Self-reported survey data are linked to birth certificate data and weighted for sample design, nonresponse, and noncoverage. Annual PRAMS data sets are created and used to produce statewide estimates of preconception and perinatal health behaviors and experiences in selected states and New York City. This report summarizes data from 29 states that conducted PRAMS in 2009, before the passage of ACA, and achieved an overall weighted response rate of >= 65%. Data on the prevalence of health insurance coverage stability (stable coverage, unstable coverage, and uninsured) across three time periods (the month before pregnancy, during pregnancy, and at the time of delivery) are reported by state and selected maternal characteristics. Women with stable coverage had the same type of health insurance (private or Medicaid) for all three time periods. Women with unstable coverage experienced a change in health insurance coverage between any of the three time periods. This includes movement from having no insurance coverage to gaining coverage, movement from one type of coverage to another, and loss of coverage. Women in the uninsured group had no insurance coverage during any of the three time periods. Estimates for health insurance stability across the three time periods and estimates of coverage during each time period are presented by state. Patterns of movement between the different types of health insurance coverage among women with unstable coverage are described by state and selected maternal characteristics. Results: In 2009, 30.1% of women who had a live birth experienced changes in health insurance coverage in the period between the month before pregnancy and the time of delivery, either because they lacked coverage at some point or because they moved between different types of coverage. Most women had stable coverage across the three time periods, reporting either private coverage (52.8%) or Medicaid coverage (16.1%) throughout. A small percentage of women (1.1%) reported having no health insurance coverage at any point. Overall, Medicaid coverage increased from 16.6% in the month before pregnancy to 43.9% at delivery. Private coverage decreased from 59.9% in the month before pregnancy to 54.6% at delivery. The percentage of women who were uninsured decreased from 23.4% in the month before pregnancy to 1.5% at the time of delivery. Among those who experienced changes in coverage, 74.4% reported having no insurance the month before pregnancy, 23.9% reported having private insurance, and 1.8% reported having Medicaid. Among those who started out uninsured before pregnancy, 70.2% reported Medicaid coverage, and 4.1% reported private coverage at the time of delivery. Among those who started out with private coverage, 21.3% reported Medicaid coverage at delivery, and 1.4% reported being uninsured. As a result of these transitions in health insurance coverage, 92.4% of all women who experienced a change in health insurance around the time of pregnancy reported Medicaid coverage at delivery. No women with unstable coverage who started out without insurance in the month before pregnancy reported being uninsured at the time of delivery. Women who reported unstable coverage were more likely to be young (aged < 35 years), be a minority (black, Hispanic, or American Indian/Alaska Native), have a high school education or less, be unmarried, have incomes <= 200% of the federal poverty level (FPL), or have an unintended pregnancy compared with women with stable private coverage. Compared with women with stable Medicaid coverage, women with unstable coverage were more likely to be Hispanic but less likely to be teenagers (aged <= 19 years), be black, have a high school education or less, have incomes = 200% of the FPL, or have an unintended pregnancy. Women with unstable coverage were more likely than women in either stable coverage group (private or Medicaid) to report entering prenatal care after the first trimester. Interpretation: In 2009, nearly one third of women reported lacking health insurance or transitioning between types of health insurance coverage around the time of pregnancy. The majority of women who changed health insurance status obtained coverage for prenatal care, delivery, or both through Medicaid. Health insurance coverage during pregnancy can help facilitate access to health care and allow for the identification and treatment of health-related issues; however, prenatal coverage might be too late to prevent the consequences of preexisting conditions and preconception exposures that could affect maternal and infant health. Continuous access to health insurance and health care for women of reproductive age could improve maternal and infant health by providing the opportunity to manage or treat conditions that are present before and between pregnancies. Public Health Action: PRAMS data can be used to identify patterns of health insurance coverage among women around the time of pregnancy. Removing barriers to obtaining health insurance for women who lack coverage, particularly before pregnancy, could improve the health of women and their infants. The findings in this report can be used by public health professionals, policy analysts, and others to monitor health insurance coverage for women around the time of pregnancy. In particular, 2009 state-specific data can serve as baseline information to assess and monitor changes in health insurance coverage since the passage of ACA. C1 [D'Angelo, Denise V.; Le, Brenda; Williams, Letitia; Ahluwalia, Indu B.; Harrison, Leslie L.; Grigorescu, Violanda] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [O'Neil, Mary Elizabeth] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA 30333 USA. [Floyd, R. Louise] CDC, Natl Ctr Birth Defects & Dev Disabil, Div Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. RP D'Angelo, DV (reprint author), Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. EM DDAngelo@cdc.gov NR 59 TC 5 Z9 5 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD JUN 19 PY 2015 VL 64 IS 4 BP 1 EP 19 PG 19 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL9ZU UT WOS:000357338800001 ER PT J AU Glidewell, J Olney, RS Hinton, C Pawelski, J Sontag, M Wood, T Kucik, JE Daskalov, R Hudson, J AF Glidewell, Jill Olney, Richard S. Hinton, Cynthia Pawelski, Jim Sontag, Marci Wood, Thalia Kucik, James E. Daskalov, Rachel Hudson, Jeff TI State Legislation, Regulations, and Hospital Guidelines for Newborn Screening for Critical Congenital Heart Defects - United States, 2011-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID DISEASE; CHILDREN C1 [Glidewell, Jill; Olney, Richard S.] CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Hinton, Cynthia] CDC, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Pawelski, Jim; Daskalov, Rachel; Hudson, Jeff] Amer Acad Pediat, Elk Grove Village, IL USA. [Sontag, Marci] Univ Colorado Denver, Denver, CO USA. [Wood, Thalia] Assoc Publ Hlth Labs, Silver Spring, MD USA. [Kucik, James E.] CDC, Off Associate Director Policy, Off Director, Atlanta, GA 30333 USA. RP Glidewell, J (reprint author), CDC, Div Birth Defects & Dev Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. EM mglidewell@cdc.gov NR 6 TC 7 Z9 7 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 19 PY 2015 VL 64 IS 23 BP 625 EP 630 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5BA UT WOS:000356973300001 PM 26086632 ER PT J AU Diop, OM Burns, CC Sutter, RW Wassilak, SG Kew, OM AF Diop, Ousmane M. Burns, Cara C. Sutter, Roland W. Wassilak, Steven G. Kew, Olen M. TI Update on Vaccine-Derived Polioviruses - Worldwide, January 2014-March 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material C1 [Diop, Ousmane M.] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Burns, Cara C.; Kew, Olen M.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Sutter, Roland W.] WHO, Polio Operat & Res Dept, CH-1211 Geneva, Switzerland. [Wassilak, Steven G.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Kew, OM (reprint author), CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM okew@cdc.gov NR 10 TC 23 Z9 24 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 19 PY 2015 VL 64 IS 23 BP 640 EP 646 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5BA UT WOS:000356973300004 PM 26086635 ER PT J AU Staples, JE Bocchini, JA Rubin, L Fischer, M AF Staples, J. Erin Bocchini, Joseph A., Jr. Rubin, Lorry Fischer, Marc TI Yellow Fever Vaccine Booster Doses: Recommendations of the Advisory Committee on Immunization Practices, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Editorial Material ID HIV-INFECTED PATIENTS; PREVENTION; PREGNANCY; IMMUNITY C1 [Staples, J. Erin; Fischer, Marc] CDC, Nat Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA. [Bocchini, Joseph A., Jr.; Rubin, Lorry] Advisory Comm Immunizat Practices, Bangkok, Thailand. [Bocchini, Joseph A., Jr.] Louisiana State Univ, Hlth Sci Ctr, Shreveport, LA 71105 USA. [Rubin, Lorry] North Shore Long Isl Jewish Hlth Syst, New Hyde Pk, NY USA. RP Staples, JE (reprint author), CDC, Nat Ctr Emerging & Zoonot Dis, Atlanta, GA 30333 USA. EM estaples@cdc.gov NR 17 TC 6 Z9 9 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 19 PY 2015 VL 64 IS 23 BP 647 EP 650 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5BA UT WOS:000356973300005 PM 26086636 ER PT J AU Jones, JM Schumacher, M Peoples, M Souders, N Horn, K Fox, L Scott, M Brady, S Weiss, J Komatsu, K Nieto, N AF Jones, Jefferson M. Schumacher, Mare Peoples, Marie Souders, Nina Horn, Kimberly Fox, Lisa Scott, Michele Brady, Shane Weiss, Joli Komatsu, Ken Nieto, Nathan TI Tickborne Relapsing Fever Outbreak at an Outdoor Education Camp - Arizona, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Jones, Jefferson M.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Jones, Jefferson M.] Maricopa Cty Dept Publ Hlth, Phoenix, AZ USA. [Jones, Jefferson M.; Brady, Shane; Weiss, Joli; Komatsu, Ken] Arizona Dept Hlth Serv, Phoenix, AZ USA. [Schumacher, Mare; Peoples, Marie] Coconino Cty Publ Hlth Serv Dist, Flagstaff, AZ USA. [Souders, Nina; Horn, Kimberly] Flagstaff Med Ctr, Flagstaff, AZ USA. [Fox, Lisa; Scott, Michele] Phoenix Childrens Hosp, Phoenix, AZ USA. [Nieto, Nathan] No Arizona Univ, Flagstaff, AZ 86011 USA. RP Jones, JM (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM ioe8@cdc.gov NR 3 TC 1 Z9 1 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 19 PY 2015 VL 64 IS 23 BP 651 EP 652 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5BA UT WOS:000356973300006 PM 26086637 ER PT J AU Mazurek, JM Schleiff, PL Wood, JM Hendricks, SA Weston, A AF Mazurek, Jacek M. Schleiff, Patricia L. Wood, John M. Hendricks, Scott A. Weston, Ainsley TI Update: Silicosis Mortality - United States, 1999-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID RESPIRABLE CRYSTALLINE SILICA; EXPOSURES; TRENDS C1 [Mazurek, Jacek M.; Schleiff, Patricia L.; Wood, John M.; Weston, Ainsley] CDC, Div Resp Dis Studies, NIOSH, Atlanta, GA 30333 USA. [Hendricks, Scott A.] CDC, Div Safety Res, NIOSH, Atlanta, GA 30333 USA. RP Mazurek, JM (reprint author), CDC, Div Resp Dis Studies, NIOSH, Atlanta, GA 30333 USA. EM jmazurek1@cdc.gov NR 7 TC 4 Z9 4 U1 0 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 19 PY 2015 VL 64 IS 23 BP 653 EP 654 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5BA UT WOS:000356973300007 PM 26086638 ER PT J AU Rose, CE Gardner, L Craw, J Girde, S Wawrzyniak, AJ Drainoni, ML Davila, J DeHovitz, J Keruly, JC Westfall, AO Marks, G AF Rose, Charles E. Gardner, Lytt Craw, Jason Girde, Sonali Wawrzyniak, Andrew J. Drainoni, Mari-Lynn Davila, Jessica DeHovitz, Jack Keruly, Jeanne C. Westfall, Andrew O. Marks, Gary TI A Comparison of Methods for Analyzing Viral Load Data in Studies of HIV Patients SO PLOS ONE LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; VIROLOGICAL FAILURE; CARE; SUPPRESSION; RETENTION; PREVENTION; ADHERENCE; VARIABLES; COHORT; TRIAL AB HIV RNA viral load (VL) is a pivotal outcome variable in studies of HIV infected persons. We propose and investigate two frameworks for analyzing VL: (1) a single-measure VL (SMVL) per participant and (2) repeated measures of VL (RMVL) per participant. We compared these frameworks using a cohort of 720 HIV patients in care (4,679 post-enrollment VL measurements). The SMVL framework analyzes a single VL per participant, generally captured within a "window" of time. We analyzed three SMVL methods where the VL binary outcome is defined as suppressed or not suppressed. The omit-participant method uses a 8-month "window" (-6/+2 months) around month 24 to select the participant's VL closest to month 24 and removes participants from the analysis without a VL in the "window". The set-to-failure method expands on the omit-participant method by including participants without a VL within the "window" and analyzes them as not suppressed. The closest-VL method analyzes each participant's VL measurement closest to month 24. We investigated two RMVL methods: (1) repeat-binary classifies each VL measurement as suppressed or not suppressed and estimates the proportion of participants suppressed at month 24, and (2) repeat-continuous analyzes VL as a continuous variable to estimate the change in VL across time, and geometric mean (GM) VL and proportion of participants virally suppressed at month 24. Results indicated the RMVL methods have more precision than the SMVL methods, as evidenced by narrower confidence intervals for estimates of proportion suppressed and risk ratios (RR) comparing demographic strata. The repeat-continuous method had the most precision and provides more information than other considered methods. We generally recommend using the RMVL framework when there are repeated VL measurements per participant because it utilizes all available VL data, provides additional information, has more statistical power, and avoids the subjectivity of defining a "window." C1 [Rose, Charles E.; Gardner, Lytt; Craw, Jason; Marks, Gary] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Girde, Sonali] ICF Macro Int Inc, Atlanta, GA USA. [Wawrzyniak, Andrew J.] Univ Miami, Miller Sch Med, Psychiat & Behav Sci, Miami, FL 33136 USA. [Drainoni, Mari-Lynn] Boston Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA USA. [Drainoni, Mari-Lynn] Boston Univ, Sch Med, Dept Med, Infect Dis Sect, Boston, MA 02118 USA. [Drainoni, Mari-Lynn] ENRM VA Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA. [Davila, Jessica] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [DeHovitz, Jack] Suny Downstate Med Ctr, Dept Med, STAR Clin, Brooklyn, NY 11203 USA. [Keruly, Jeanne C.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Westfall, Andrew O.] Univ Alabama Birmingham, Dept Biostat, Birmingham, AL 35294 USA. RP Rose, CE (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. EM CRose@cdc.gov FU ICF Macro International FX ICF Macro International provided support in the form of a salary for author SG as a contractor to CDC, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of the full authors are articulated in the 'author contributions' section. NR 24 TC 0 Z9 0 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 19 PY 2015 VL 10 IS 6 AR e0130090 DI 10.1371/journal.pone.0130090 PG 16 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CL3FE UT WOS:000356835000087 PM 26090989 ER PT J AU Louzoun, Y Mitchell, R Behar, H Schukken, Y AF Louzoun, Yoram Mitchell, Rebecca Behar, Hilla Schukken, Ynte TI Two state model for a constant disease hazard in paratuberculosis (and other bovine diseases) SO VETERINARY RESEARCH LA English DT Article ID AVIUM SUBSPECIES PARATUBERCULOSIS; HERPES-SIMPLEX-VIRUS; IMMUNE CONTROL; MYCOBACTERIUM-TUBERCULOSIS; STOCHASTIC RESONANCE; PARASITE VIRULENCE; INFECTION; LATENCY; DYNAMICS; ESCAPE AB Many diseases are characterized by a long and varying sub-clinical period. Two main mechanisms can explain such periods: a slow progress toward disease or a sudden transition from a healthy state to a disease state induced by internal or external events. We here survey epidemiological features of the amount of bacteria shed during Mycobacterium Avium Paratuberculosis (MAP) infection to test which of these two models, slow progression or sudden transition (or a combination of the two), better explains the transition from intermittent and low shedding to high shedding. Often, but not always, high shedding is associated with the occurrence of clinical signs. In the case of MAP, the clinical signs include diarrhea, low milk production, poor fertility and eventually emaciation and death. We propose a generic model containing bacterial growth, immune control and fluctuations. This proposed generic model can represent the two hypothesized types of transitions in different parameter regimes. The results show that the sudden transition model provides a simpler explanation of the data, but also suffers from some limitations. We discuss the different immunological mechanism that can explain and support the sudden transition model and the interpretation of each term in the studied model. These conclusions are applicable to a wide variety of diseases, and MAP serves as a good test case based on the large scale measurements of single cow longitudinal profiles in this disease. C1 [Louzoun, Yoram; Behar, Hilla] Bar Ilan Univ, Gonda Brain Res Ctr, Ramat Gan, Israel. [Louzoun, Yoram; Behar, Hilla] Bar Ilan Univ, Dept Math, Ramat Gan, Israel. [Mitchell, Rebecca] Ctr Dis Control & Prevent, Atlanta, GA USA. [Schukken, Ynte] GD Anim Hlth, Deventer, Netherlands. [Schukken, Ynte] Cornell Univ, Dept Populat Med & Diagnost Sci, Ithaca, NY USA. RP Louzoun, Y (reprint author), Bar Ilan Univ, Gonda Brain Res Ctr, Ramat Gan, Israel. EM louzouy@math.biu.ac.il OI Schukken, Ynte/0000-0002-8250-4194 FU Within-host modeling of MAP infections Working Group at the National Institute for Mathematical and Biological Synthesis; National Science Foundation; U.S. Department of Homeland Security; U.S. Department of Agriculture through NSF [DBI-1300426]; University of Tennessee, Knoxville FX The authors acknowledge the support of the Within-host modeling of MAP infections Working Group at the National Institute for Mathematical and Biological Synthesis, sponsored by the National Science Foundation, the U.S. Department of Homeland Security, and the U.S. Department of Agriculture through NSF Award DBI-1300426, with additional support from The University of Tennessee, Knoxville. NR 50 TC 1 Z9 1 U1 2 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 0928-4249 EI 1297-9716 J9 VET RES JI Vet. Res. PD JUN 19 PY 2015 VL 46 AR 67 DI 10.1186/s13567-015-0189-9 PG 11 WC Veterinary Sciences SC Veterinary Sciences GA CK9WH UT WOS:000356589700001 PM 26092587 ER PT J AU Mitchell, RM Schukken, Y Koets, A Weber, M Bakker, D Stabel, J Whitlock, RH Louzoun, Y AF Mitchell, Rebecca M. Schukken, Ynte Koets, Ad Weber, Maarten Bakker, Douwe Stabel, Judy Whitlock, Robert H. Louzoun, Yoram TI Differences in intermittent and continuous fecal shedding patterns between natural and experimental Mycobacterium avium subspecies paratuberculosis infections in cattle SO VETERINARY RESEARCH LA English DT Article ID JOHNES-DISEASE STATUS; VIRUS LATENCY; DAIRY HERDS; COWS; TUBERCULOSIS; CELLS; RESPONSES; FRAILTY; MODELS; TISSUE AB The objective of this paper is to study shedding patterns of cows infected with Mycobacterium avium subsp. paratuberculosis (MAP). While multiple single farm studies of MAP dynamics were reported, there is not large scale meta-analysis of both natural and experimental infections. Large difference in shedding patterns between experimentally and naturally infected cows were observed. Experimental infections are thus probably driven by different pathological mechanisms. For further evaluations of shedding patterns only natural infections were used. Within such infections, the transition to high shedding was studied as a proxy to the development of a clinical disease. The majority of studied cows never developed high shedding levels. Those that do, typically never reduced their shedding level to low or no shedding. Cows that eventually became high shedders showed a pattern of continuous shedding. In contrast, cows with an intermittent shedding pattern had a low probability to ever become high shedders. In addition, cows that start shedding at a younger age (less than three years of age) have a lower hazard of becoming high shedders compared to cows starting to shed at an older age. These data suggest the presence of three categories of immune control. Cows that are intermittent shedders have the infection process under control (no progressive infection). Cows that start shedding persistently at a young age partially control the infection, but eventually will be high shedders (slow progressive infection), while cows that start shedding persistently at an older age cannot effectively control the infection and become high shedders rapidly. C1 [Mitchell, Rebecca M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mitchell, Rebecca M.] Cornell Univ, Dept Populat Med & Diagnost Sci, Ithaca, NY USA. [Schukken, Ynte] Cent Vet Inst, Dept Bacteriol & TSE, Lelystad, Netherlands. [Schukken, Ynte; Koets, Ad; Weber, Maarten] GD Anim Hlth, Deventer, Netherlands. [Koets, Ad; Bakker, Douwe] Cent Inst Anim Dis Control, Lelystad, Netherlands. [Stabel, Judy] Natl Anim Dis Ctr Ames, Ames, IA 50010 USA. [Whitlock, Robert H.] Univ Penn, Dept Clin Studies, Philadelphia, PA 19104 USA. [Louzoun, Yoram] Bar Ilan Univ, Gonda Brain Res Ctr, Ramat Gan, Israel. [Louzoun, Yoram] Bar Ilan Univ, Dept Math, Ramat Gan, Israel. RP Louzoun, Y (reprint author), Bar Ilan Univ, Gonda Brain Res Ctr, Ramat Gan, Israel. EM louzouy@math.biu.ac.il OI Koets, Ad/0000-0001-9809-3679 FU National Institute for Mathematical and Biological Synthesis; National Science Foundation; U.S. Department of Homeland Security; U.S. Department of Agriculture through NSF [EF-0832858]; University of Tennessee, Knoxville; Regional Dairy Quality Management Alliance; USDA agricultural research services FX We acknowledge the dairy farmers that contributed to the collection of data from their farms. This work was conducted with partial funding provided at the National Institute for Mathematical and Biological Synthesis, an institute sponsored by the National Science Foundation, the U.S. Department of Homeland Security, and the U.S. Department of Agriculture through NSF Award #EF-0832858, with additional support from The University of Tennessee, Knoxville. We acknowledge the long term funding of the Regional Dairy Quality Management Alliance through a collaborative contract with the USDA agricultural research services. NR 32 TC 7 Z9 7 U1 1 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 0928-4249 EI 1297-9716 J9 VET RES JI Vet. Res. PD JUN 19 PY 2015 VL 46 AR 66 DI 10.1186/s13567-015-0188-x PG 10 WC Veterinary Sciences SC Veterinary Sciences GA CK8NL UT WOS:000356494900001 PM 26092571 ER PT J AU Mpimbaza, A Filler, S Katureebe, A Quick, L Chandramohan, D Staedke, SG AF Mpimbaza, Arthur Filler, Scott Katureebe, Agaba Quick, Linda Chandramohan, Daniel Staedke, Sarah G. TI Verbal Autopsy: Evaluation of Methods to Certify Causes of Death in Uganda SO PLOS ONE LA English DT Article ID DATA-DERIVED ALGORITHMS; DIAGNOSTIC-ACCURACY; NEONATAL DEATHS; ADULT DEATHS; VALIDATION; COMMUNITY; MORTALITY; VALIDITY; NEPAL; MODEL AB To assess different methods for determining cause of death from verbal autopsy (VA) questionnaire data, the intra-rater reliability of Physician-Certified Verbal Autopsy (PCVA) and the accuracy of PCVA, expert-derived (non-hierarchical) and data-driven (hierarchal) algorithms were assessed for determining common causes of death in Ugandan children. A verbal autopsy validation study was conducted from 2008-2009 in three different sites in Uganda. The dataset included 104 neonatal deaths (0-27 days) and 615 childhood deaths (1-59 months) with the cause(s) of death classified by PCVA and physician review of hospital medical records (the 'reference standard'). Of the original 719 questionnaires, 141 (20%) were selected for a second review by the same physicians; the repeat cause(s) of death were compared to the original, and agreement assessed using the Kappa statistic. Physician reviewers' refined non-hierarchical algorithms for common causes of death from existing expert algorithms, from which, hierarchal algorithms were developed. The accuracy of PCVA, non-hierarchical, and hierarchical algorithms for determining cause(s) of death from all 719 VA questionnaires was determined using the reference standard. Overall, intra-rater repeatability was high (83% agreement, Kappa 0.79 [95% CI 0.76-0.82]). PCVA performed well, with high specificity for determining cause of neonatal (>67%), and childhood (> 83%) deaths, resulting in fairly accurate cause-specific mortality fraction (CSMF) estimates. For most causes of death in children, non-hierarchical algorithms had higher sensitivity, but correspondingly lower specificity, than PCVA and hierarchical algorithms, resulting in inaccurate CSMF estimates. Hierarchical algorithms were specific for most causes of death, and CSMF estimates were comparable to the reference standard and PCVA. Inter-rater reliability of PCVA was high, and overall PCVA performed well. Hierarchical algorithms performed better than non-hierarchical algorithms due to higher specificity and more accurate CSMF estimates. Use of PCVA to determine cause of death from VA questionnaire data is reasonable while automated data-driven algorithms are improved. C1 [Mpimbaza, Arthur] Makerere Univ, Coll Hlth Sci, Child Hlth & Dev Ctr, Kampala, Uganda. [Mpimbaza, Arthur; Katureebe, Agaba; Staedke, Sarah G.] Infect Dis Res Collaborat, Kampala, Uganda. [Filler, Scott] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland. [Quick, Linda] Ctr Dis Control & Prevent, Atlanta, GA USA. [Chandramohan, Daniel; Staedke, Sarah G.] London Sch Hyg & Trop Med, London WC1, England. RP Mpimbaza, A (reprint author), Makerere Univ, Coll Hlth Sci, Child Hlth & Dev Ctr, Kampala, Uganda. EM arthurwakg@yahoo.com FU President's Malaria Initiative via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, United States Agency for International Development; Centers for Disease Control and Prevention FX This research was made possible through support provided by the President's Malaria Initiative via the Office of Health, Infectious Diseases, and Nutrition, Bureau for Global Health, United States Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 47 TC 2 Z9 2 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 18 PY 2015 VL 10 IS 6 AR e0128801 DI 10.1371/journal.pone.0128801 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK9NT UT WOS:000356567500024 PM 26086600 ER PT J AU Park, DJ Dudas, G Wohl, S Goba, A Whitmer, SLM Andersen, KG Sealfon, RS Ladner, JT Kugelman, JR Matranga, CB Winnicki, SM Qu, J Gire, SK Gladden-Young, A Jalloh, S Nosamiefan, D Yozwiak, NL Moses, LM Jiang, PP Lin, AE Schaffner, SF Bird, B Towner, J Mamoh, M Gbakie, M Kanneh, L Kargbo, D Massally, JLB Kamara, FK Konuwa, E Sellu, J Jalloh, AA Mustapha, I Foday, M Yillah, M Erickson, BR Sealy, T Blau, D Paddock, C Brault, A Amman, B Basile, J Bearden, S Belser, J Bergeron, E Campbell, S Chakrabarti, A Dodd, K Flint, M Gibbons, A Goodman, C Klena, J McMullan, L Morgan, L Russell, B Salzer, J Sanchez, A Wang, D Jungreis, I Tomkins-Tinch, C Kislyuk, A Lin, MF Chapman, S MacInnis, B Matthews, A Bochicchio, J Hensley, LE Kuhn, JH Nusbaum, C Schieffelin, JS Birren, BW Forget, M Nichol, ST Palacios, GF Ndiaye, D Happi, C Gevao, SM Vandi, MA Kargbo, B Holmes, EC Bedford, T Gnirke, A Stroher, U Rambaut, A Garry, RF Sabeti, PC AF Park, Daniel J. Dudas, Gytis Wohl, Shirlee Goba, Augustine Whitmer, Shannon L. M. Andersen, Kristian G. Sealfon, Rachel S. Ladner, Jason T. Kugelman, Jeffrey R. Matranga, Christian B. Winnicki, Sarah M. Qu, James Gire, Stephen K. Gladden-Young, Adrianne Jalloh, Simbirie Nosamiefan, Dolo Yozwiak, Nathan L. Moses, Lina M. Jiang, Pan-Pan Lin, Aaron E. Schaffner, Stephen F. Bird, Brian Towner, Jonathan Mamoh, Mambu Gbakie, Michael Kanneh, Lansana Kargbo, David Massally, James L. B. Kamara, Fatima K. Konuwa, Edwin Sellu, Josephine Jalloh, Abdul A. Mustapha, Ibrahim Foday, Momoh Yillah, Mohamed Erickson, Bobbie R. Sealy, Tara Blau, Dianna Paddock, Christopher Brault, Aaron Amman, Brian Basile, Jane Bearden, Scott Belser, Jessica Bergeron, Eric Campbell, Shelley Chakrabarti, Ayan Dodd, Kimberly Flint, Mike Gibbons, Aridth Goodman, Christin Klena, John McMullan, Laura Morgan, Laura Russell, Brandy Salzer, Johanna Sanchez, Angela Wang, David Jungreis, Irwin Tomkins-Tinch, Christopher Kislyuk, Andrey Lin, Michael F. Chapman, Sinead MacInnis, Bronwyn Matthews, Ashley Bochicchio, James Hensley, Lisa E. Kuhn, Jens H. Nusbaum, Chad Schieffelin, John S. Birren, Bruce W. Forget, Marc Nichol, Stuart T. Palacios, Gustavo F. Ndiaye, Daouda Happi, Christian Gevao, Sahr M. Vandi, Mohamed A. Kargbo, Brima Holmes, Edward C. Bedford, Trevor Gnirke, Andreas Stroeher, Ute Rambaut, Andrew Garry, Robert F. Sabeti, Pardis C. TI Ebola Virus Epidemiology, Transmission, and Evolution during Seven Months in Sierra Leone SO CELL LA English DT Article ID RNA VIRUSES; SELECTION; OUTBREAK; DATABASE AB The 2013-2015 Ebola virus disease (EVD) epidemic is caused by the Makona variant of Ebola virus (EBOV). Early in the epidemic, genome sequencing provided insights into virus evolution and transmission and offered important information for outbreak response. Here, we analyze sequences from 232 patients sampled over 7 months in Sierra Leone, along with 86 previously released genomes from earlier in the epidemic. We confirm sustained human-to-human transmission within Sierra Leone and find no evidence for import or export of EBOV across national borders after its initial introduction. Using high-depth replicate sequencing, we observe both host-to-host transmission and recurrent emergence of intrahost genetic variants. We trace the increasing impact of purifying selection in suppressing the accumulation of nonsynonymous mutations over time. Finally, we note changes in the mucin-like domain of EBOV glycoprotein that merit further investigation. These findings clarify the movement of EBOV within the region and describe viral evolution during prolonged human-to-human transmission. C1 [Park, Daniel J.; Wohl, Shirlee; Sealfon, Rachel S.; Matranga, Christian B.; Winnicki, Sarah M.; Qu, James; Gire, Stephen K.; Gladden-Young, Adrianne; Nosamiefan, Dolo; Yozwiak, Nathan L.; Jiang, Pan-Pan; Lin, Aaron E.; Schaffner, Stephen F.; Tomkins-Tinch, Christopher; Chapman, Sinead; MacInnis, Bronwyn; Matthews, Ashley; Bochicchio, James; Nusbaum, Chad; Birren, Bruce W.; Gnirke, Andreas; Sabeti, Pardis C.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA. [Dudas, Gytis; Rambaut, Andrew] Univ Edinburgh, Inst Evolutionary Biol, Ashworth Labs, Edinburgh EH9 3FL, Midlothian, Scotland. [Wohl, Shirlee; Winnicki, Sarah M.; Gire, Stephen K.; Yozwiak, Nathan L.; Jiang, Pan-Pan; Lin, Aaron E.; Schaffner, Stephen F.; Matthews, Ashley] Harvard Univ, Cambridge, MA 02138 USA. [Goba, Augustine; Jalloh, Simbirie; Mamoh, Mambu; Gbakie, Michael; Kanneh, Lansana; Kargbo, David; Massally, James L. B.; Kamara, Fatima K.; Konuwa, Edwin; Sellu, Josephine; Jalloh, Abdul A.; Mustapha, Ibrahim; Foday, Momoh; Yillah, Mohamed] Kenema Govt Hosp, Kenema, Sierra Leone. [Whitmer, Shannon L. M.; Bird, Brian; Towner, Jonathan; Erickson, Bobbie R.; Sealy, Tara; Blau, Dianna; Paddock, Christopher; Brault, Aaron; Amman, Brian; Basile, Jane; Bearden, Scott; Belser, Jessica; Bergeron, Eric; Campbell, Shelley; Chakrabarti, Ayan; Dodd, Kimberly; Flint, Mike; Gibbons, Aridth; Goodman, Christin; Klena, John; McMullan, Laura; Morgan, Laura; Russell, Brandy; Salzer, Johanna; Sanchez, Angela; Wang, David; Nichol, Stuart T.; Stroeher, Ute] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Whitmer, Shannon L. M.; Bird, Brian; Towner, Jonathan; Erickson, Bobbie R.; Sealy, Tara; Blau, Dianna; Paddock, Christopher; Brault, Aaron; Amman, Brian; Basile, Jane; Bearden, Scott; Belser, Jessica; Bergeron, Eric; Campbell, Shelley; Chakrabarti, Ayan; Dodd, Kimberly; Flint, Mike; Gibbons, Aridth; Goodman, Christin; Klena, John; McMullan, Laura; Morgan, Laura; Russell, Brandy; Salzer, Johanna; Sanchez, Angela; Wang, David; Nichol, Stuart T.; Stroeher, Ute] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Andersen, Kristian G.] Scripps Res Inst, Scripps Translat Sci Inst, La Jolla, CA 92037 USA. [Sealfon, Rachel S.; Jungreis, Irwin] MIT, Cambridge, MA 02139 USA. [Ladner, Jason T.; Kugelman, Jeffrey R.; Palacios, Gustavo F.] US Army, Med Res Inst Infect Dis, Frederick, MD 21702 USA. [Moses, Lina M.; Schieffelin, John S.; Garry, Robert F.] Tulane Univ, New Orleans, LA 70112 USA. [Kislyuk, Andrey; Lin, Michael F.] DNAnexus, Mountain View, CA 94040 USA. [Hensley, Lisa E.; Kuhn, Jens H.] NIAID, Integrated Res Facil Ft Detrick, Div Clin Res, NIH, Frederick, MD 21702 USA. [Forget, Marc] Med Sans Frontieres, B-1050 Brussels, Belgium. [Ndiaye, Daouda] Univ Cheikh Anta Diop, Dakar, Senegal. [Happi, Christian] Redeemers Univ Nigeria, Redemption City, Ogun State, Nigeria. [Gevao, Sahr M.] Univ Sierra Leone, Freetown, Sierra Leone. [Vandi, Mohamed A.; Kargbo, Brima] Sierra Leone Minist Hlth & Sanitat, Freetown, Sierra Leone. [Holmes, Edward C.] Univ Sydney, Johns Hopkins Dr, Camperdown, NSW 2050, Australia. [Bedford, Trevor] Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA. [Rambaut, Andrew] Univ Edinburgh, Ctr Immunol Infect & Evolut, Ashworth Labs, Edinburgh EH9 3FL, Midlothian, Scotland. [Rambaut, Andrew] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. RP Park, DJ (reprint author), Broad Inst Harvard & MIT, 75 Ames St, Cambridge, MA 02142 USA. EM dpark@broadinstitute.org; a.rambaut@ed.ac.uk; pardis@broadinstitute.org RI Palacios, Gustavo/I-7773-2015; Schaffner, Stephen/D-1189-2011; OI Palacios, Gustavo/0000-0001-5062-1938; Flint, Michael/0000-0002-5373-787X; Dudas, Gytis/0000-0002-0227-4158; Tomkins-Tinch, Christopher/0000-0002-9114-6421; Holmes, Edward/0000-0001-9596-3552 FU European Union grant FP7 [278433-PREDEMICS]; European Research Council [260864]; Natural Environment Research Council [D76739X]; NIH [U54 GM111274, GM080177, 1U01HG007480-01]; National Science Foundation Graduate Research Fellowship [DGE 1144152]; National Health and Medical Research Council, Australia; Defense Threat Reduction Agency (USAMRIID); NIH/NIAID (Broad Institute) [U19AI110818]; Bill and Melinda Gates Foundation (Broad Institute) [OPP1123407]; US National Institute of Allergy and Infectious Diseases (NIAID) [HHSN272200700016I]; National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services [HHSN272201400028C]; NIAID (Harvard/Tulane) [HHSN272200900049C]; Zalgen Labs FX This work was supported by European Union grant FP7/2007-2013 278433-PREDEMICS and European Research Council grant 260864 (A.R.); Natural Environment Research Council grant D76739X (G.D.); NIH U54 GM111274 (T.B.); NIH grant GM080177 (S.W.); NIH grant 1U01HG007480-01 (C.H.); National Science Foundation Graduate Research Fellowship Grant No. DGE 1144152 (A.E.L.); the National Health and Medical Research Council, Australia (E.C.H.); the Defense Threat Reduction Agency (USAMRIID); NIH/NIAID U19AI110818 (Broad Institute); the Bill and Melinda Gates Foundation OPP1123407 (Broad Institute); and NIAID HHSN272200900049C (Harvard/Tulane). This work was funded, in part, through Battelle Memorial Institute's prime contract with the US National Institute of Allergy and Infectious Diseases (NIAID) under contract number HHSN272200700016I. Subcontractors to Battelle Memorial Institute who performed this work are: J.H.K., an employee of Tunnell Government Services, Inc. R.F.G. is co-founder of Zalgen Labs.; The Virus Pathogen Database and Analysis Resource (ViPR) has been wholly funded with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, under contract number HHSN272201400028C. NR 30 TC 65 Z9 67 U1 7 U2 75 PU CELL PRESS PI CAMBRIDGE PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA SN 0092-8674 EI 1097-4172 J9 CELL JI Cell PD JUN 18 PY 2015 VL 161 IS 7 BP 1516 EP 1526 DI 10.1016/j.cell.2015.06.007 PG 11 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA CL0GG UT WOS:000356618200010 PM 26091036 ER PT J AU Briet, OJT Huho, BJ Gimnig, JE Bayoh, N Seyoum, A Sikaala, CH Govella, N Diallo, DA Abdullah, S Smith, TA Killeen, GF AF Briet, Olivier J. T. Huho, Bernadette J. Gimnig, John E. Bayoh, Nabie Seyoum, Aklilu Sikaala, Chadwick H. Govella, Nicodem Diallo, Diadier A. Abdullah, Salim Smith, Thomas A. Killeen, Gerry F. TI Applications and limitations of Centers for Disease Control and Prevention miniature light traps for measuring biting densities of African malaria vector populations: a pooled-analysis of 13 comparisons with human landing catches SO MALARIA JOURNAL LA English DT Article DE Human landing catch; CDC light traps; Anopheles gambiae; Anopheles funestus ID PLASMODIUM-FALCIPARUM PARASITEMIA; SAMPLING ANOPHELINE MOSQUITOS; PAPUA-NEW-GUINEA; WESTERN KENYA; DIFFERENTIAL ATTRACTIVENESS; TRANSMISSION INTENSITY; INOCULATION RATES; MBITA TRAP; SHIFT WORK; BED NET AB Background: Measurement of densities of host-seeking malaria vectors is important for estimating levels of disease transmission, for appropriately allocating interventions, and for quantifying their impact. The gold standard for estimating mosquito-human contact rates is the human landing catch (HLC), where human volunteers catch mosquitoes that land on their exposed body parts. This approach necessitates exposure to potentially infectious mosquitoes, and is very labour intensive. There are several safer and less labour-intensive methods, with Centers for Disease Control light traps (LT) placed indoors near occupied bed nets being the most widely used. Methods: This paper presents analyses of 13 studies with paired mosquito collections of LT and HLC to evaluate these methods for their consistency in sampling indoor-feeding mosquitoes belonging to the two major taxa of malaria vectors across Africa, the Anopheles gambiae sensu lato complex and the Anopheles funestus s.l. group. Both overall and study-specific sampling efficiencies of LT compared with HLC were computed, and regression methods that allow for the substantial variations in mosquito counts made by either method were used to test whether the sampling efficacy varies with mosquito density. Results: Generally, LT were able to collect similar numbers of mosquitoes to the HLC indoors, although the relative sampling efficacy, measured by the ratio of LT: HLC varied considerably between studies. The overall best estimate for An. gambiae s.l. was 1.06 (95% credible interval: 0.68-1.64) and for An. funestus s.l. was 1.37 (0.70-2.68). Local calibration exercises are not reproducible, since only in a few studies did LT sample proportionally to HLC, and there was no geographical pattern or consistent trend with average density in the tendency for LT to either under- or over-sample. Conclusions: LT are a crude tool at best, but are relatively easy to deploy on a large scale. Spatial and temporal variation in mosquito densities and human malaria transmission exposure span several orders of magnitude, compared to which the inconsistencies of LT are relatively small. LT, therefore, remain an invaluable and safe alternative to HLC for measuring indoor malaria transmission exposure in Africa. C1 [Briet, Olivier J. T.; Huho, Bernadette J.; Smith, Thomas A.] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, CH-4002 Basel, Switzerland. [Briet, Olivier J. T.; Huho, Bernadette J.; Smith, Thomas A.] Univ Basel, CH-4003 Basel, Switzerland. [Huho, Bernadette J.; Govella, Nicodem; Abdullah, Salim; Killeen, Gerry F.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Gimnig, John E.; Bayoh, Nabie] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Gimnig, John E.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA 30341 USA. [Bayoh, Nabie] Ctr Dis Control & Prevent, Kisumu, Kenya. [Seyoum, Aklilu; Sikaala, Chadwick H.; Killeen, Gerry F.] Univ Liverpool, Liverpool Sch Trop Med, Vector Biol Dept, Liverpool L3 5QA, Merseyside, England. [Sikaala, Chadwick H.] Chainama Hosp, Coll Grounds, Natl Malaria Control Ctr, Lusaka, Zambia. [Diallo, Diadier A.] CNRFP, Ouagadougou, Burkina Faso. RP Briet, OJT (reprint author), Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Socinstr 57, CH-4002 Basel, Switzerland. EM olivier.briet@unibas.ch RI Briet, Olivier/K-1917-2015; Smith, Thomas/B-5569-2015 OI Briet, Olivier/0000-0003-1186-2688; Smith, Thomas/0000-0002-3650-9381 FU Multinational Initiative for Malaria/The Special Programme for Research and Training in Tropical Diseases Research; Roll Back Malaria Programme; Bill and Melinda Gates Foundation [45114]; Stipendienkommission fur Nachwuchs-Krafte aus Entwicklungslandern, Basel, Switzerland; Malaria Modelling Project - Bill and Melinda Gates Foundation [OPP1032350] FX The MTIMBA project was initiated by the International Network for the Demographic Evaluation of Populations and Their Health (INDEPTH) and was financed by the Multinational Initiative for Malaria/The Special Programme for Research and Training in Tropical Diseases Research and the Roll Back Malaria Programme. The MTC project was funded by the Bill and Melinda Gates Foundation (Award 45114, coordinated by Professor Frank Collins and Dr Neil Lobo at Notre Dame University, South Bend, IN, USA). Studentship for BH was financed by the Stipendienkommission fur Nachwuchs-Krafte aus Entwicklungslandern, Basel, Switzerland. The authors thank Japhet Kihonda for help with the field studies. OJTB was supported through the Malaria Modelling Project #OPP1032350, funded by the Bill and Melinda Gates Foundation. This manuscript has been published with permission from the director, KEMRI. The findings and conclusions in this study are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 74 TC 7 Z9 7 U1 1 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD JUN 18 PY 2015 VL 14 AR 247 DI 10.1186/s12936-015-0761-9 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CK7KP UT WOS:000356411600003 PM 26082036 ER PT J AU Varkey, JB Shantha, JG Crozier, I Kraft, CS Lyon, GM Mehta, AK Kumar, G Smith, JR Kainulainen, MH Whitmer, S Stroher, U Uyeki, TM Ribner, BS Yeh, S AF Varkey, Jay B. Shantha, Jessica G. Crozier, Ian Kraft, Colleen S. Lyon, G. Marshall Mehta, Aneesh K. Kumar, Gokul Smith, Justine R. Kainulainen, Markus H. Whitmer, Shannon Stroeher, Ute Uyeki, Timothy M. Ribner, Bruce S. Yeh, Steven TI Persistence of Ebola Virus in Ocular Fluid during Convalescence SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Article ID OUTBREAK; DISEASE; KIKWIT; CONGO AB Among the survivors of Ebola virus disease (EVD), complications that include uveitis can develop during convalescence, although the incidence and pathogenesis of EVD-associated uveitis are unknown. We describe a patient who recovered from EVD and was subsequently found to have severe unilateral uveitis during convalescence. Viable Zaire ebolavirus (EBOV) was detected in aqueous humor 14 weeks after the onset of EVD and 9 weeks after the clearance of viremia. C1 [Varkey, Jay B.; Kraft, Colleen S.; Lyon, G. Marshall; Mehta, Aneesh K.; Ribner, Bruce S.] Emory Univ, Sch Med, Dept Med, Div Infect Dis, Atlanta, GA 30322 USA. [Shantha, Jessica G.; Kumar, Gokul; Yeh, Steven] Emory Univ, Sch Med, Dept Ophthalmol, Atlanta, GA 30322 USA. [Kraft, Colleen S.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA. [Kainulainen, Markus H.; Whitmer, Shannon; Stroeher, Ute; Uyeki, Timothy M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Crozier, Ian] Mulago Hosp Complex, Infect Dis Inst, Kampala, Uganda. [Smith, Justine R.] Flinders Univ S Australia, Adelaide, SA 5001, Australia. RP Yeh, S (reprint author), Emory Univ, Sch Med, Dept Ophthalmol, 1365B Clifton Rd NE, Atlanta, GA 30322 USA. EM steven.yeh@emory.edu RI Mehta, Aneesh/B-8054-2012 OI Mehta, Aneesh/0000-0002-6552-9162 FU National Center for Advancing Translational Sciences of the National Institutes of Health [UL1TR000454]; Research to Prevent Blindness; National Eye Institute [P30-EY06360]; Australian Research Council [FT130101648] FX Supported by a grant from the National Center for Advancing Translational Sciences of the National Institutes of Health (UL1TR000454, to the Atlanta Clinical and Translational Science Institute), an unrestricted grant from Research to Prevent Blindness and a grant from the National Eye Institute (P30-EY06360, to the Department of Ophthalmology, Emory University School of Medicine), and a fellowship grant from the Australian Research Council (FT130101648, to Dr. Smith). Favipiravir was provided by the Department of Defense Joint Project Manager Medical Countermeasure Systems. NR 17 TC 105 Z9 105 U1 3 U2 16 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 18 PY 2015 VL 372 IS 25 BP 2423 EP 2427 DI 10.1056/NEJMoa1500306 PG 5 WC Medicine, General & Internal SC General & Internal Medicine GA CK6RF UT WOS:000356354600008 PM 25950269 ER PT J AU Krauss, S Stucker, KM Schobel, SA Danner, A Friedman, K Knowles, JP Kayali, G Niles, LJ Dey, AD Raven, G Pryor, P Lin, X Das, SR Stockwell, TB Wentworth, DE Webster, RG AF Krauss, Scott Stucker, Karla M. Schobel, Seth A. Danner, Angela Friedman, Kimberly Knowles, James P. Kayali, Ghazi Niles, Lawrence J. Dey, Amanda D. Raven, Garnet Pryor, Paul Lin, Xudong Das, Suman R. Stockwell, Timothy B. Wentworth, David E. Webster, Robert G. TI Long-term surveillance of H7 influenza viruses in American wild aquatic birds: are the H7N3 influenza viruses in wild birds the precursors of highly pathogenic strains in domestic poultry? SO EMERGING MICROBES & INFECTIONS LA English DT Article DE American wild birds; Anseriforme; avian influenza; Charadriiforme; H7; highly pathogenic avian influenza; surveillance ID AVIAN INFLUENZA; A VIRUSES; BRITISH-COLUMBIA; OUTBREAK; MAFFT; CONJUNCTIVITIS; RECOMBINATION; AMPLIFICATION; PENNSYLVANIA; INFECTION AB The emergence of influenza A virus (IAV) in domestic avian species and associated transmissions to mammals is unpredictable. In the Americas, the H7 IAVs are of particular concern, and there have been four separate outbreaks of highly pathogenic (HP) H7N3 in domestic poultry in North and South America between 2002 and 2012, with occasional spillover into humans. Here, we use long-term IAV surveillance in North American shorebirds at Delaware Bay, USA, from 1985 to 2012 and in ducks in Alberta, Canada, from 1976 to 2012 to determine which hemagglutinin (HA)-neuraminidase (NA) combinations predominated in Anseriformes (ducks) and Charadriiformes (shorebirds) and whether there is concordance between peaks of H7 prevalence and transmission in wild aquatic birds and the emergence of H7 IAVs in poultry and humans. Whole-genome sequencing supported phylogenetic and genomic constellation analyses to determine whether HP IAVs emerge in the context of specific internal gene segment sequences. Phylogenetic analysis of whole-genome sequences of the H7N3 influenza viruses from wild birds and HP H7N3 outbreaks in the Americas indicate that each HP outbreak was an independent emergence event and that the low pathogenic (LP) avian influenza precursors were most likely from dabbling ducks. The different polybasic cleavage sites in the four HP outbreaks support independent origins. At the 95% nucleotide percent identity-level phylogenetic analysis showed that the wild duck HA, PB1, and M sequences clustered with the poultry and human outbreak sequences. The genomic constellation analysis strongly suggests that gene segments/virus flow from wild birds to domestic poultry. C1 [Krauss, Scott; Danner, Angela; Friedman, Kimberly; Knowles, James P.; Kayali, Ghazi; Webster, Robert G.] St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA. [Niles, Lawrence J.] Conserve Wildlife Fdn New Jersey, Bordentown, NJ 08505 USA. [Dey, Amanda D.] New Jersey Div Fish & Wildlife, Endangered & Nongame Species, Trenton, NJ 08332 USA. [Raven, Garnet; Pryor, Paul] Canadian Wildlife Serv, Environm Canada, Edmonton, AB T6B 1K5, Canada. [Stucker, Karla M.; Schobel, Seth A.; Lin, Xudong; Das, Suman R.; Stockwell, Timothy B.; Wentworth, David E.] J Craig Venter Inst, Rockville, MD 20850 USA. [Schobel, Seth A.] Univ Maryland, Ctr Bioinformat & Computat Biol, College Pk, MD 20742 USA. RP Wentworth, DE (reprint author), Ctr Dis Control & Prevent, Virol Surveillance & Diag Branch, Influenza Div, Atlanta, GA 30333 USA. EM dwentworth@cdc.gov; robert.webster@stjude.org FU National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, USA [HHSN272200900007C, HHSN266200700005C, HHSN2720140006C]; American Lebanese Syrian Associated Charities FX The authors thank the JCVI team of researchers that provided technical expertise in support of the viral sequencing and assembly pipeline for this project, especially Rebecca A Halpin, Nadia Fedorova, and Susmita Shrivastava. This project was funded in part with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Department of Health and Human Services, USA under contract numbers HHSN272200900007C (Genome Sequencing Center for Infectious Diseases), HHSN266200700005C and HHSN2720140006C, and by American Lebanese Syrian Associated Charities. The data for this manuscript and its preparation were generated while David E Wentworth was employed at JCVI. The opinions expressed in this article are the authors' own and do not reflect the views of the Centers for Disease Control, the Department of Health and Human Services, or the United States Government. NR 48 TC 4 Z9 4 U1 0 U2 9 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2222-1751 J9 EMERG MICROBES INFEC JI Emerg. Microbes Infect. PD JUN 17 PY 2015 VL 4 AR e35 DI 10.1038/emi.2015.35 PG 9 WC Immunology; Microbiology SC Immunology; Microbiology GA CM5NR UT WOS:000357735500001 PM 26954883 ER PT J AU Datwani, H Moro, PL Harrington, T Broder, KR AF Datwani, Hema Moro, Pedro L. Harrington, Theresa Broder, Karen R. TI Chorioamnionitis following vaccination in the Vaccine Adverse Event Reporting System SO VACCINE LA English DT Article DE Adverse event; Chorioamnionitis; Pregnancy; Vaccine safety; Surveillance; Tdap; HPV4; 2009 H1N1 inactivated influenza vaccine ID OBSTETRIC EVENTS; INFLUENZA VACCINE; PREGNANT-WOMEN; SAFETY; VAERS AB Background: In October 2012, the Advisory Committee on Immunization Practices (ACIP) recommended a dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) during each pregnancy, irrespective of the woman's prior history of receiving Tdap. A retrospective cohort study to assess the safety of Tdap vaccination in pregnant women in two Vaccine Safety Datalink (VSD) sites during 2010-2012 found a small but statistically significant increased risk of chorioamnionitis. Objective: We conducted a review of the VAERS database to describe reports of chorioamnionitis following receipt of any vaccines. Methods: We searched the VAERS database for reports of chorioamnionitis after any vaccine in the United States during the period from July 1, 1990 through February 2, 2014. Results: VAERS received 31 reports of chorioamnionitis out of 3389 pregnancy reports in 24 years. The three most common vaccines in these reports were 2009 H1N1 inactivated influenza, quadrivalent human papillomavirus (HPV4), and Tdap vaccines in 32%, 29% and 26% of reports, respectively. Fifty-eight percent of reports had at least one reported risk factor for chorioamnionitis. Chorioamnionitis was identified in 3 reports of spontaneous abortions and 6 stillbirths, 6 reports of preterm birth (two of whom died) and 16 reports of term birth; maternal outcomes included two reports of postpartum hemorrhage and one report of maternal admission to the intensive care unit. No maternal deaths were reported. Conclusion: Chorioamnionitis was found to be uncommonly reported, representing 1% of pregnancy reports to VAERS. A majority of reports had at least one risk factor for chorioamnionitis. Published by Elsevier Ltd. C1 [Datwani, Hema; Moro, Pedro L.; Harrington, Theresa; Broder, Karen R.] Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, NCZEID, Atlanta, GA 30333 USA. RP Moro, PL (reprint author), Ctr Dis Control & Prevent, Immunizat Safety Off, Div Healthcare Qual Promot, 1600 Clifton Rd,MS D26, Atlanta, GA 30333 USA. EM pmoro@cdc.gov NR 22 TC 6 Z9 6 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUN 17 PY 2015 VL 33 IS 27 BP 3110 EP 3113 DI 10.1016/j.vaccine.2015.04.097 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CL8PB UT WOS:000357235500007 PM 25976546 ER PT J AU Srivastav, A Zhai, YS Santibanez, TA Kahn, KE Smith, PJ Singleton, JA AF Srivastav, Anup Zhai, Yusheng Santibanez, Tammy A. Kahn, Katherine E. Smith, Philip J. Singleton, James A. TI Influenza vaccination coverage of Vaccine for Children (VFC)-entitled versus privately insured children, United States, 2011-2013 SO VACCINE LA English DT Article DE Influenza; Vaccination coverage; VFC; Children; Private insurance; NIS-Flu ID PROGRAM; H1N1; CARE AB Background: The Vaccines for Children (VFC) program provides vaccines at no cost to children who are Medicaid-eligible, uninsured, American Indian or Alaska Native (AI/AN), or underinsured and vaccinated at Federally Qualified Health Centers or Rural Health Clinics. The objective of this study was to compare influenza vaccination coverage of VFC-entitled to privately insured children in the United States, nationally, by state, and by selected socio-demographic variables. Methods: Data from the National Immunization Survey-Flu (NIS-Flu) surveys were analyzed for the 2011-2012 and 2012-2013 influenza seasons for households with children 6 months-17 years. VFC-entitlement and private insurance status were defined based upon questions asked of the parent during the telephone interview. Influenza vaccination coverage estimates of children VFC-entitled versus privately insured were compared by t-tests, both nationally and within state, and within selected socio-demographic variables. Results: For both seasons studied, influenza coverage for VFC-entitled children did not significantly differ from coverage for privately insured children (2011-2012: 52.0% +/- 1.9% versus 50.7% +/- 1.2%; 2012-2013: 56.0% +/- 1.6% versus 57.2% +/- 1.2%). Among VFC-entitled children, uninsured children had lower coverage (2011-2012: 38.9% +/- 4.7%; 2012-2013: 44.8% +/- 3.5%) than Medicaid-eligible (2011-2012: 55.2% +/- 2.1%; 2012-2013: 58.6% +/- 1.9%) and AI/AN children (2011-2012: 54.4% +/- 11.3%; 2012-2013: 54.6% +/- 7.0%). Significant differences in vaccination coverage among VFC-entitled and privately insured children were observed within some subgroups of race/ethnicity, income, age, region, and living in a metropolitan statistical area principle city. Conclusions: Although finding few differences in influenza vaccination coverage among VFC-entitled versus privately insured children was encouraging, nearly half of all children were not vaccinated for influenza and coverage was particularly low among uninsured children. Additional public health interventions are needed to ensure that more children are vaccinated such as a strong recommendation from health care providers, utilization of immunization information systems, provider reminders, standing orders, and community-based interventions such as educational activities and expanded access to vaccination services. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Srivastav, Anup; Zhai, Yusheng; Kahn, Katherine E.] Leidos Inc, Atlanta, GA USA. [Srivastav, Anup; Zhai, Yusheng; Santibanez, Tammy A.; Kahn, Katherine E.; Smith, Philip J.; Singleton, James A.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Srivastav, A (reprint author), Ctr Dis Control & Prevent, NCIRD, CDC, 1600 Clifton Rd NE,Mail Stop A-19, Atlanta, GA 30333 USA. EM xbs2@cdc.gov FU Intramural CDC HHS [CC999999] NR 25 TC 2 Z9 2 U1 1 U2 6 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUN 17 PY 2015 VL 33 IS 27 BP 3114 EP 3121 DI 10.1016/j.vaccine.2015.04.098 PG 8 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CL8PB UT WOS:000357235500008 PM 25979804 ER PT J AU Wallace, WT Gazda, DB Limero, TF Minton, JM Macatangay, AV Dwivedi, P Fernandez, FM AF Wallace, William T. Gazda, Daniel B. Limero, Thomas F. Minton, John M. Macatangay, Ariel V. Dwivedi, Prabha Fernandez, Facundo M. TI Electrothermal Vaporization Sample Introduction for Spaceflight Water Quality Monitoring via Gas Chromatography-Differential Mobility Spectrometry SO ANALYTICAL CHEMISTRY LA English DT Article ID MASS-SPECTROMETRY; DIMETHYLSILANEDIOL AB In the history of manned spaceflight, environmental monitoring has relied heavily on archival sampling. However, with the construction of the International Space Station (ISS) and the subsequent extension in mission duration up to one year, an enhanced, real-time method for environmental monitoring is necessary. The station air is currently monitored for trace volatile organic compounds (VOCs) using gas chromatography-differential mobility spectrometry (GC-DMS) via the Air Quality Monitor (AQM), while water is analyzed to measure total organic carbon and biocide concentrations using the Total Organic Carbon Analyzer (TOCA) and the Colorimetric Water Quality Monitoring Kit (CWQMK), respectively. As mission scenarios extend beyond low Earth orbit, a convergence in analytical instrumentation to analyze both air and water samples is highly desirable. Since the AQM currently provides quantitative, compound-specific information for air samples and many of the targets in air are also common to water, this platform is a logical starting point for developing a multimatrix monitor. Here, we report on the interfacing of an electrothermal vaporization (ETV) sample introduction unit with a ground-based AQM for monitoring target analytes in water. The results show that each of the compounds tested from water have similar GC-DMS parameters as the compounds tested in air. Moreover, the ETV enabled AQM detection of dimethlsilanediol (DMSD), a compound whose analysis had proven challenging using other sample introduction methods. Analysis of authentic ISS water samples using the ETV-AQM showed that DMSD could be successfully quantified, while the concentrations obtained for the other compounds also agreed well with laboratory results. C1 [Wallace, William T.; Gazda, Daniel B.; Limero, Thomas F.] Wyle Sci Technol & Engn Grp, Houston, TX 77058 USA. [Minton, John M.] Univ Arkansas, Little Rock, AR 72204 USA. [Macatangay, Ariel V.] NASA Johnson Space Ctr, Houston, TX 77058 USA. [Dwivedi, Prabha] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. RP Wallace, WT (reprint author), Wyle Sci Technol & Engn Grp, Houston, TX 77058 USA. EM william.wallace-1@nasa.gov; facundo.fernandez@chemistry.gatech.edu FU NASA [NAS 9-02078, NNX13AF51G S02]; Arkansas Space Grant Consortium FX W.T.W., D.B.G., and T.F.L. acknowledge funding under NASA contract # NAS 9-02078. The work of J.M.M. was supported through the Arkansas Space Grant Consortium. W.T.W. would like to thank Sarah Castro (NASA Johnson Space Center) for critical editing and Zachary Pickett for his work on our early DMSD studies. F.M.F. thanks NASA for award number NNX13AF51G S02. NR 30 TC 2 Z9 2 U1 9 U2 22 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD JUN 16 PY 2015 VL 87 IS 12 BP 5981 EP 5988 DI 10.1021/acs.analchem.5b00055 PG 8 WC Chemistry, Analytical SC Chemistry GA CL2DZ UT WOS:000356755100019 PM 25971650 ER PT J AU Murphy, JL Arrowood, MJ Lu, X Hlavsa, MC Beach, MJ Hill, VR AF Murphy, Jennifer L. Arrowood, Michael J. Lu, Xin Hlavsa, Michele C. Beach, Michael J. Hill, Vincent R. TI Effect of Cyanuric Acid on the Inactivation of Cryptosporidium parvum under Hyperchlorination Conditions SO ENVIRONMENTAL SCIENCE & TECHNOLOGY LA English DT Article ID SWIMMING POOL DISINFECTION; WATER; CHLORINE AB Cyanuric acid (CYA) is a chlorine stabilizer used in swimming pools to limit UV degradation of chlorine, thus reducing chlorine use and cost. However, CYA has been shown to decrease the efficacy of chlorine disinfection. In the event of a diarrheal incident, CDC recommends implementing 3-log(10) inactivation conditions for Cryptosporidium (CT value = 15 300 mg.min/L) to remediate pools. Currently, CYAs impact on Cryptosporidium inactivation is not fully determined. We investigated the impact of multiple concentrations of CYA on C. parvum inactivation (at 20 and 40 mg/L free chlorine; average pH 7.6; 25 degrees C). At 20 mg/L free chlorine, average estimated 3-log(10) CT values were 17 800 and 31 500 mg.min/L with 8 and 16 mg/L CYA, respectively, and the average estimated 1-log(10) CT value was 76?500 mg.min/L with 48 mg/L CYA. At 40 mg/L free chlorine, 3-log10 CT values were lower than those at 20 mg/L, but still higher than those of free chlorine-only controls. In the presence of similar to 100 mg/L CYA, average 0.8- and 1.4-log(10) reductions were achieved by 72 h at 20 and 40 mg/L free chlorine, respectively. This study demonstrates CYA significantly delays chlorine inactivation of Cryptosporidium oocysts, emphasizing the need for additional pool remediation options following fecal incidents. C1 [Murphy, Jennifer L.; Arrowood, Michael J.; Lu, Xin; Hlavsa, Michele C.; Beach, Michael J.; Hill, Vincent R.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Murphy, JL (reprint author), Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. EM iod7@cdc.gov FU Lonza Group Ltd FX The authors wish to thank Gordana Derado for assistance with statistical analyses. This study was supported in part by funding provided by Arch Chemicals, Inc (now Lonza Group Ltd). The use of trade names and names of commercial sources is for identification only and does not imply endorsement by the CDC or the U.S. Department of Health and Human Services. The findings and conclusions in this report are those of the authors and do not necessarily represent those of the CDC. NR 23 TC 8 Z9 8 U1 4 U2 10 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0013-936X EI 1520-5851 J9 ENVIRON SCI TECHNOL JI Environ. Sci. Technol. PD JUN 16 PY 2015 VL 49 IS 12 BP 7348 EP 7355 DI 10.1021/acs.est.5b00962 PG 8 WC Engineering, Environmental; Environmental Sciences SC Engineering; Environmental Sciences & Ecology GA CL2EA UT WOS:000356755200029 PM 26042636 ER PT J AU Molins, CR Ashton, LV Wormser, GP Hess, AM Delorey, MJ Mahapatra, S Schriefer, ME Belisle, JT AF Molins, Claudia R. Ashton, Laura V. Wormser, Gary P. Hess, Ann M. Delorey, Mark J. Mahapatra, Sebabrata Schriefer, Martin E. Belisle, John T. TI Development of a Metabolic Biosignature for Detection of Early Lyme Disease SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Lyme disease; Borrelia burgdorferi; metabolomics; diagnostics; infectious diseases ID BORRELIA-BURGDORFERI; MASS-SPECTROMETRY; CLASSIFICATION; IMPLEMENTATION; CHROMATOGRAPHY; PERFORMANCE; DISCOVERY; DIAGNOSIS; ANTIBODY; BIOLOGY AB Background. Early Lyme disease patients often present to the clinic prior to developing a detectable antibody response to Borrelia burgdorferi, the etiologic agent. Thus, existing 2-tier serology-based assays yield low sensitivities (29%-40%) for early infection. The lack of an accurate laboratory test for early Lyme disease contributes to misconceptions about diagnosis and treatment, and underscores the need for new diagnostic approaches. Methods. Retrospective serum samples from patients with early Lyme disease, other diseases, and healthy controls were analyzed for small molecule metabolites by liquid chromatography-mass spectrometry (LC-MS). A metabolomics data workflow was applied to select a biosignature for classifying early Lyme disease and non-Lyme disease patients. A statistical model of the biosignature was trained using the patients' LC-MS data, and subsequently applied as an experimental diagnostic tool with LC-MS data from additional patient sera. The accuracy of this method was compared with standard 2-tier serology. Results. Metabolic biosignature development selected 95 molecular features that distinguished early Lyme disease patients from healthy controls. Statistical modeling reduced the biosignature to 44 molecular features, and correctly classified early Lyme disease patients and healthy controls with a sensitivity of 88% (84%-95%), and a specificity of 95% (90%-100%). Importantly, the metabolic biosignature correctly classified 77%-95% of the of serology negative Lyme disease patients. Conclusions. The data provide proof-of-concept that metabolic profiling for early Lyme disease can achieve significantly greater (P < .0001) diagnostic sensitivity than current 2-tier serology, while retaining high specificity. C1 [Molins, Claudia R.; Delorey, Mark J.; Schriefer, Martin E.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Ashton, Laura V.; Mahapatra, Sebabrata; Belisle, John T.] Colorado State Univ, Microbiol Immunol & Pathol Dept, Ft Collins, CO 80523 USA. [Wormser, Gary P.] New York Med Coll, Div Infect Dis, Dept Med, Valhalla, NY 10595 USA. [Hess, Ann M.] Colorado State Univ, Dept Stat, Ft Collins, CO 80523 USA. RP Belisle, JT (reprint author), Colorado State Univ, Microbiol Immunol & Pathol Dept, Ft Collins, CO 80523 USA. EM john.belisle@colostate.edu RI Belisle, John/B-8944-2017 OI Belisle, John/0000-0002-2539-2798 FU National Institute of Allergy and Infectious Diseases at the National Institutes of Health [R21/R33 AI100228]; CDC FX This work was supported by the National Institute of Allergy and Infectious Diseases at the National Institutes of Health [R21/R33 AI100228] and the CDC. NR 40 TC 11 Z9 11 U1 1 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 15 PY 2015 VL 60 IS 12 BP 1767 EP 1775 DI 10.1093/cid/civ185 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CN0BC UT WOS:000358075800007 PM 25761869 ER PT J AU Kotzen, M Sell, J Mathes, RW Dentinger, C Lee, L Schiff, C Weiss, D AF Kotzen, Mollie Sell, Jessica Mathes, Robert W. Dentinger, Catherine Lee, Lillian Schiff, Corinne Weiss, Don TI Using Syndromic Surveillance to Investigate Tattoo-Related Skin Infections in New leYork City SO PLOS ONE LA English DT Article AB In response to two isolated cases of Mycobacterium chelonae infections in tattoo recipients where tap water was used to dilute ink, the New York City (NYC) Department of Health and Mental Hygiene conducted an investigation using Emergency Department (ED) syndromic surveillance to assess whether an outbreak was occuring. ED visits with chief complaints containing the key word "tattoo" from November 1, 2012 to March 18, 2013 were selected for study. NYC laboratories were also contacted and asked to report skin or soft tissue cultures in tattoo recipients that were positive for non-tuberculosis mycobacterial infection (NTM). Thirty-one TREDV were identified and 14 (45%) were interviewed to determine if a NTM was the cause for the visit. One ED visit met the case definition and was referred to a dermatologist. This individual was negative for NTM. No tattoo-associated NTM cases were reported by NYC laboratories. ED syndromic surveillance was utilized to investigate a non-reportable condition for which no other data source existed. The results were reassuring that an outbreak of NTM in tattoo recipients was not occurring. In response to concerns about potential NTM infections, the department sent a letter to all licensed tattoo artists advising them not to dilute tattoo ink with tap water. C1 [Kotzen, Mollie; Sell, Jessica; Mathes, Robert W.; Dentinger, Catherine; Lee, Lillian; Schiff, Corinne; Weiss, Don] New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. [Dentinger, Catherine] Ctr Dis Control & Prevent, Atlanta, GA USA. [Kotzen, Mollie] NYU, New York, NY USA. RP Mathes, RW (reprint author), New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. EM rmathes@health.nyc.gov NR 7 TC 1 Z9 1 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 15 PY 2015 VL 10 IS 6 AR e0130468 DI 10.1371/journal.pone.0130468 PG 7 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK6HU UT WOS:000356329900175 PM 26076006 ER PT J AU Ullmann, AJ Russell, TM Dolan, MC Williams, M Hojgaard, A Weiner, ZP Johnson, BJB AF Ullmann, Amy J. Russell, Theresa M. Dolan, Marc C. Williams, Martin Hojgaard, Andrias Weiner, Zachary P. Johnson, Barbara J. B. TI Evaluation of Borrelia burgdorferi BbHtrA Protease as a Vaccine Candidate for Lyme Borreliosis in Mice SO PLOS ONE LA English DT Article ID ORIENTIA-TSUTSUGAMUSHI; 47-KILODALTON ANTIGEN; DISEASE; ADJUVANT; PROTEINS; TICKS AB Borrelia burgdorferi synthesizes an HtrA protease (BbHtrA) which is a surface-exposed, conserved protein within Lyme disease spirochetes with activity toward CheX and BmpD of Borrelia spp, as well as aggrecan, fibronectin and proteoglycans found in skin, joints and neural tissues of vertebrates. An antibody response against BbHtrA is observed in Lyme disease patients and in experimentally infected laboratory mice and rabbits. Given the surface location of BbHtrA on B. burgdorferi and its ability to elicit an antibody response in infected hosts, we explored recombinant BbHtrA as a potential vaccine candidate in a mouse model of tick-transmitted Lyme disease. We immunized mice with two forms of BbHtrA: the proteolytically active native form and BbHtrA ablated of activity by a serine to alanine mutation at amino acid 226 (BbHtrA(S226A)). Although inoculation with either BbHtrA or BbHtrA(S226A) produced high-titer antibody responses in C3H/HeJ mice, neither antigen was successful in protecting mice from B. burgdorferi challenge. These results indicate that the search for novel vaccine candidates against Lyme borreliosis remains a challenge. C1 [Ullmann, Amy J.; Russell, Theresa M.; Dolan, Marc C.; Williams, Martin; Hojgaard, Andrias; Weiner, Zachary P.; Johnson, Barbara J. B.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO 80521 USA. RP Ullmann, AJ (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, Bacterial Dis Branch, Ft Collins, CO 80521 USA. EM aff1@cdc.gov FU federal government FX All authors are government employees and the research was funded by the federal government. NR 27 TC 1 Z9 1 U1 0 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 15 PY 2015 VL 10 IS 6 AR e0128868 DI 10.1371/journal.pone.0128868 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK6HU UT WOS:000356329900034 PM 26076465 ER PT J AU Walaza, S Cohen, C Nanoo, A Cohen, AL McAnerney, J von Mollendorf, C Moyes, J Tempia, S AF Walaza, Sibongile Cohen, Cheryl Nanoo, Ananta Cohen, Adam L. McAnerney, Johanna von Mollendorf, Claire Moyes, Jocelyn Tempia, Stefano TI Excess Mortality Associated with Influenza among Tuberculosis Deaths in South Africa, 1999-2009 SO PLOS ONE LA English DT Article ID RESPIRATORY SYNCYTIAL VIRUS; UNITED-STATES; HIV; INFECTION; AGE; COHORT AB Background Published data on the interaction between influenza and pulmonary tuberculosis (PTB) are limited. We aimed to estimate the influenza-associated mortality among individuals with PTB in South Africa from 1999-2009. Methods We modelled the excess influenza-associated mortality by applying Poisson regression models to monthly PTB and non-tuberculosis respiratory deaths, using laboratory-confirmed influenza as a covariate. Results PTB deaths increased each winter, coinciding with influenza virus circulation. Among individuals of any age, mean annual influenza-associated PTB mortality rate was 164/100,000 person-years (n = 439). The rate of non-tuberculosis respiratory deaths was 27/100,000 (n = 1125) for HIV-infected and 5/100,000 (n = 2367) for HIV-uninfected individuals of all ages. Among individuals aged <65 years, influenza-associated PTB mortality risk was elevated compared to influenza-associated non-tuberculosis respiratory deaths in HIV-infected (relative risk (RR): 5.2; 95% CI: 4.6-5.9) and HIV-uninfected individuals (RR: 61.0; CI: 41.4-91.0). Among individuals aged >= 65 years, influenza-associated PTB mortality risk was elevated compared to influenza-associated non-tuberculosis respiratory deaths in HIV-uninfected individuals (RR: 13.0; 95% CI: 12.0-14.0). Conclusion We observed an increased risk of influenza-associated mortality in persons with PTB compared to non-tuberculosis respiratory deaths. If confirmed in other settings, our findings may support recommendations for active inclusion of patients with TB for influenza vaccination and empiric influenza anti-viral treatment of patients with TB during influenza epidemics. C1 [Walaza, Sibongile; Cohen, Cheryl; Nanoo, Ananta; McAnerney, Johanna; von Mollendorf, Claire; Moyes, Jocelyn; Tempia, Stefano] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa. [Cohen, Adam L.; Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Cohen, Adam L.; Tempia, Stefano] Ctr Dis Control & Prevent, Influenza Div, Pretoria, South Africa. [Walaza, Sibongile; Cohen, Cheryl; von Mollendorf, Claire; Moyes, Jocelyn] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. RP Walaza, S (reprint author), Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa. EM sibongilew@nicd.ac.za; stefanot@nicd.ac.za NR 37 TC 3 Z9 3 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 15 PY 2015 VL 10 IS 6 AR e0129173 DI 10.1371/journal.pone.0129173 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK6HU UT WOS:000356329900050 PM 26076197 ER PT J AU Ye, JB Xiao, LH Wang, YF Guo, YQ Roellig, DM Feng, YY AF Ye, Jianbin Xiao, Lihua Wang, Yuanfei Guo, Yaqiong Roellig, Dawn M. Feng, Yaoyu TI Dominance of Giardia duodenalis assemblage A and Enterocytozoon bieneusi genotype BEB6 in sheep in Inner Mongolia, China SO VETERINARY PARASITOLOGY LA English DT Article DE Giardia duodenalis; Enterocytozoon bieneusi; Sheep; Zoonosis; Genotype; Molecular epidemiology ID MOLECULAR CHARACTERIZATION; CRYPTOSPORIDIUM; LAMBS; MICROSPORIDIA; PREVALENCE; AUSTRALIA; GOATS; SPP. AB To examine the occurrence and genotype distribution of Giardia duodenalis and Enterocytozoon bieneusi in sheep, fecal specimens were collected from 162 lambs and 213 ewes on seven farms in the Hulunbeier Prairie in Inner Mongolia, China. By PCR analysis of the triosephosphate isomerase gene, 16 of the 375 (4.3%) specimens were positive for G. duodenalis, with 13 sequenced successfully belonging to assemblage A. Lambs had a significantly higher infection rate than ewes (8.6% versus 0.9%, respectively). The dominance of assemblage A in sheep was supported by PCR analysis of the beta-giardin and glutamate dehydrogenase genes; 4 of 7 beta-giardin-positive specimens and 3 of 5 glutamate dehydrogenase-positive specimens were identified as assemblage A. A much higher occurrence of E. bieneusi was detected by PCR analysis of the ribosomal internal transcribed spacer; 77.8% of lambs and 62.9% of ewes were positive for the pathogen. Two genotypes of E. bieneusi were found: BEB6 and CM7. Genotype BEB6 was seen in 237 animals and on all seven farms, whereas genotype CM7 was detected in 23 animals from six farms. These data indicate that sheep in Inner Mongolia are commonly infected with G. duodenalis assemblage A and E. bieneusi genotype BEB6, two zoonotic pathogens in China. (C) 2015 Elsevier B.V. All rights reserved. C1 [Ye, Jianbin; Wang, Yuanfei; Guo, Yaqiong; Feng, Yaoyu] E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. [Xiao, Lihua; Guo, Yaqiong; Roellig, Dawn M.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Feng, YY (reprint author), E China Univ Sci & Technol, Sch Resources & Environm Engn, State Key Lab Bioreactor Engn, Shanghai 200237, Peoples R China. EM yyfeng@ecust.edu.cn RI Yaqiong, Guo/N-4927-2015; Xiao, Lihua/B-1704-2013; Feng, Yaoyu/B-3076-2014 OI Xiao, Lihua/0000-0001-8532-2727; FU National Natural Science Foundation of China [31229005, 31110103901]; National Special Fund for State Key Laboratory of Bioreactor Engineering, China [2060204]; Fundamental Research Funds for the Central Universities, China; Centers for Disease Control and Prevention FX This work was supported by the National Natural Science Foundation of China (31229005 and 31110103901), National Special Fund for State Key Laboratory of Bioreactor Engineering, China (No. 2060204), Fundamental Research Funds for the Central Universities, China, and Centers for Disease Control and Prevention. NR 23 TC 8 Z9 8 U1 0 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-4017 EI 1873-2550 J9 VET PARASITOL JI Vet. Parasitol. PD JUN 15 PY 2015 VL 210 IS 3-4 BP 235 EP 239 DI 10.1016/j.vetpar.2015.04.011 PG 5 WC Parasitology; Veterinary Sciences SC Parasitology; Veterinary Sciences GA CK9IL UT WOS:000356553700014 PM 25944405 ER PT J AU Moore, LV Dodd, KW Thompson, FE Grimm, KA Kim, SA Scanlon, KS AF Moore, Latetia V. Dodd, Kevin W. Thompson, Frances E. Grimm, Kirsten A. Kim, Sonia A. Scanlon, Kelley S. TI Using Behavioral Risk Factor Surveillance System Data to Estimate the Percentage of the Population Meeting US Department of Agriculture Food Patterns Fruit and Vegetable Intake Recommendations SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE fruits; recommended intake; states; vegetables ID TELL US; CONSUMPTION; METAANALYSIS; FREQUENCY; WEIGHT; ISSUES; COHORT AB Most Americans do not eat enough fruits and vegetables with significant variation by state. State-level self-reported frequency of fruit and vegetable consumption is available from the Centers for Disease Control and Prevention's Behavioral Risk Factor Surveillance System (BRFSS). However, BRFSS cannot be used to directly compare states' progress toward national goals because of incongruence in units used to measure intake and because distributions from frequency data are not reflective of usual intake. To help states track progress, we developed scoring algorithms from external data and applied them to BRFSS 2011 data to estimate the percentage of each state's adult population meeting US Department of Agriculture Food Patterns fruit and vegetable intake recommendations. We used 24-hour dietary recall data from the National Health and Nutrition Examination Survey, 2007-2010, to fit sex-and age-specific models that estimate probabilities of meeting recommendations as functions of reported consumption frequency, race/ethnicity, and poverty-income ratio adjusting for intraindividual variation. Regression parameters derived from these models were applied to BRFSS to estimate the percentage meeting recommendations. We estimate that 7%-18% of state populations met fruit recommendations and 5%-12% met vegetable recommendations. Our method provides a new tool for states to track progress toward meeting dietary recommendations. C1 [Moore, Latetia V.; Grimm, Kirsten A.; Kim, Sonia A.; Scanlon, Kelley S.] Ctr Dis Control & Prevent, Nutr Branch, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Dodd, Kevin W.] NCI, Biometry Res Grp, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Thompson, Frances E.] NCI, Appl Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Moore, LV (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE,Mailstop F77, Atlanta, GA 30341 USA. EM lvmoore@cdc.gov FU Intramural CDC HHS [CC999999] NR 35 TC 8 Z9 8 U1 2 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 15 PY 2015 VL 181 IS 12 BP 979 EP 988 DI 10.1093/aje/kwu461 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CK4GE UT WOS:000356180600007 PM 25935424 ER PT J AU Lindley, MC Bridges, CB AF Lindley, Megan C. Bridges, Carolyn B. TI Multifaceted Strategies Needed for Influenza Prevention in Long-term Care SO JOURNAL OF INFECTIOUS DISEASES LA English DT Editorial Material DE influenza; long-term care; vaccination; randomized controlled trial; outbreak control measures ID NURSING-HOME; OLDER-ADULTS; VACCINATION COVERAGE; UNITED-STATES; INFECTION; PERSONNEL; EFFICACY; OUTBREAK C1 [Lindley, Megan C.; Bridges, Carolyn B.] Ctr Dis Control & Prevent, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Lindley, MC (reprint author), Ctr Dis Control & Prevent, Immunizat Serv Div, 1600 Clifton Rd NE,Mailstop A-19, Atlanta, GA 30333 USA. EM cvx9@cdc.gov FU Intramural CDC HHS [CC999999] NR 12 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUN 15 PY 2015 VL 211 IS 12 BP 1860 EP 1861 DI 10.1093/infdis/jiu623 PG 2 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CJ7LC UT WOS:000355675600002 PM 25525052 ER PT J AU Wang, X Shutt, KA Vuong, JT Cohn, A MacNeil, J Schmink, S Plikaytis, B Messonnier, NE Harrison, LH Clark, TA Mayer, LW AF Wang, Xin Shutt, Kathleen A. Vuong, Jeni T. Cohn, Amanda MacNeil, Jessica Schmink, Susanna Plikaytis, Brian Messonnier, Nancy E. Harrison, Lee H. Clark, Thomas A. Mayer, Leonard W. TI Changes in the Population Structure of Invasive Neisseria meningitidis in the United States After Quadrivalent Meningococcal Conjugate Vaccine Licensure SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE meningococcal disease; molecular epidemiology; vaccine impact ID SEROGROUP-B; DISEASE; DIVERSITY; IDENTIFICATION; EPIDEMIOLOGY; REPLACEMENT; VIRULENCE; EMERGENCE; ANTIGENS; ENGLAND AB Background. Meningococcal conjugate vaccines against serogroups A, C, W, and Y (MenACWY) are recommended for routine use in adolescents aged 11-18 years. The impact of these vaccines on the meningococcal population structure in the United States have yet to be evaluated. Methods. Meningococcal isolates recovered during 2006-2010 (ie, after introduction of MenACWY) collected through Active Bacterial Core surveillance (ABCs) were characterized; serogroup distribution and molecular features of these isolates were compared to previously published data on ABCs isolates recovered from 2000 to 2005 (ie, before introduction of MenACWY). P values were generated using chi(2) statistics and exact methods. Results.aEuro integral There was a significant change (P < .05) in serogroup distribution among all age groups between the 2 periods. A small proportion of isolates showed evidence of capsular switching in both periods. Between the 2 periods, significant changes were observed in the distribution of porin A, ferric enterobactin transport, and strain genotypes among vaccine and nonvaccine serogroups. Conclusions.aEuro integral The population structure of US meningococcal isolates is dynamic; some changes occurred over time, but the basic structure remained. Vaccine-induced serogroup replacement was not observed, although a small proportion of isolates had undergone capsule switching, possibly driven by non-vaccine-mediated selection. Changes in the distribution of molecular features are likely due to horizontal gene transfer and changes in serogroup distribution. C1 [Wang, Xin; Vuong, Jeni T.; Cohn, Amanda; MacNeil, Jessica; Schmink, Susanna; Plikaytis, Brian; Messonnier, Nancy E.; Clark, Thomas A.; Mayer, Leonard W.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Shutt, Kathleen A.; Harrison, Lee H.] Univ Pittsburgh, Sch Med, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15260 USA. [Shutt, Kathleen A.; Harrison, Lee H.] Grad Sch Publ Hlth, Pittsburgh, PA USA. RP Wang, X (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mail Stop D11, Atlanta, GA 30333 USA. EM xwang2@cdc.gov OI Shutt, Kathleen/0000-0003-3376-6152 FU Centers for Disease Control and Prevention FX Financial support. This work was supported by the Centers for Disease Control and Prevention. NR 31 TC 8 Z9 8 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUN 15 PY 2015 VL 211 IS 12 BP 1887 EP 1894 DI 10.1093/infdis/jiu842 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CJ7LC UT WOS:000355675600006 PM 25556253 ER PT J AU Gutman, J Kalilani, L Taylor, S Zhou, ZY Wiegand, RE Thwai, KL Mwandama, D Khairallah, C Madanitsa, M Chaluluka, E Dzinjalamala, F Ali, D Mathanga, DP Skarbinski, J Shi, YP Meshnick, S ter Kuile, FO AF Gutman, Julie Kalilani, Linda Taylor, Steve Zhou, Zhiyong Wiegand, Ryan E. Thwai, Kyaw L. Mwandama, Dyson Khairallah, Carole Madanitsa, Mwayi Chaluluka, Ebbie Dzinjalamala, Fraction Ali, Doreen Mathanga, Don P. Skarbinski, Jacek Shi, Ya Ping Meshnick, Steve ter Kuile, Feiko O. TI The A581G Mutation in the Gene Encoding Plasmodium falciparum Dihydropteroate Synthetase Reduces the Effectiveness of Sulfadoxine-Pyrimethamine Preventive Therapy in Malawian Pregnant Women SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE malaria; Plasmodium falciparum; pregnancy; sulfadoxine-pyrimethamine; intermittent preventive therapy; Malawi; dihydropteroate synthase ID BIRTH-WEIGHT; PLACENTAL MALARIA; INFECTION; EFFICACY; OUTCOMES; AFRICA; METAANALYSIS; ASSOCIATION; PARASITES; QUEERPAM AB Background. The A581G mutation in the gene encoding Plasmodium falciparum dihydropteroate synthase (dhps), in combination with the quintuple mutant involving mutations in both dhps and the gene encoding dihydrofolate reductase (dhfr), the so-called sextuple mutant, has been associated with increased placental inflammation and decreased infant birth weight among women receiving intermittent preventive treatment with sulfadoxine-pyrimethamine (IPTp-SP) during pregnancy. Methods.aEuro integral Between 2009 and 2011, delivering women without human immunodeficiency virus infection were enrolled in an observational study of IPTp-SP effectiveness in Malawi. Parasites were detected by polymerase chain reaction (PCR); positive samples were sequenced to genotype the dhfr and dhps loci. The presence of K540E in dhps was used as a marker for the quintuple mutant. Results.aEuro integral Samples from 1809 women were analyzed by PCR; 220 (12%) were positive for P. falciparum. A total of 202 specimens were genotyped at codon 581 of dhps; 17 (8.4%) harbored the sextuple mutant. The sextuple mutant was associated with higher risks of patent infection in peripheral blood (adjusted prevalence ratio [aPR], 2.76; 95% confidence interval [CI], 1.82-4.18) and placental blood (aPR 3.28; 95% CI, 1.88-5.78) and higher parasite densities. Recent SP use was not associated with increased parasite densities or placental pathology overall and among women with parasites carrying dhps A581G. Conclusions.aEuro integral IPTp-SP failed to inhibit parasite growth but did not exacerbate pathology among women infected with sextuple-mutant parasites. New interventions to prevent malaria during pregnancy are needed urgently. C1 [Gutman, Julie; Zhou, Zhiyong; Wiegand, Ryan E.; Skarbinski, Jacek; Shi, Ya Ping] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30322 USA. [Taylor, Steve; Thwai, Kyaw L.; Meshnick, Steve] Duke Univ, Med Ctr, Durham, NC 27706 USA. [Taylor, Steve] Univ N Carolina, Chapel Hill, NC USA. [Kalilani, Linda; Madanitsa, Mwayi; Chaluluka, Ebbie; Dzinjalamala, Fraction] Univ Malawi, Coll Med, Blantyre, Malawi. [Mwandama, Dyson; Dzinjalamala, Fraction; Mathanga, Don P.] Univ Malawi, Coll Med, Malaria Alert Ctr, Blantyre, Malawi. [Kalilani, Linda; Madanitsa, Mwayi; Chaluluka, Ebbie; Mathanga, Don P.] Coll Med, Dept Community Hlth, Blantyre, Malawi. [Ali, Doreen] Natl Malaria Control Program, Lilongwe, Malawi. [Khairallah, Carole; ter Kuile, Feiko O.] Univ Liverpool Liverpool Sch Trop Med, Liverpool, Merseyside, England. RP Gutman, J (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd NE,Mailstop A06, Atlanta, GA 30322 USA. EM jgutman@cdc.gov OI ter Kuile, Feiko/0000-0003-3663-5617 FU US President's Malaria Initiative; US Agency for International Development, under CDC [5 U01 CI000189]; European Developing Countries Clinical Trials Partnership; Malaria in Pregnancy Consortium; Bill and Melinda Gates Foundation FX Financial support. This work was supported by the US President's Malaria Initiative; the US Agency for International Development, under the terms of an interagency agreement with the CDC and through a cooperative agreement (5 U01 CI000189) between the CDC and the University of Malawi College of Medicine Malaria Alert Centre; the European Developing Countries Clinical Trials Partnership; and the Malaria in Pregnancy Consortium, which is funded through a grant from the Bill and Melinda Gates Foundation to the Liverpool School of Tropical Medicine (to F. O. t. K.). NR 29 TC 15 Z9 15 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUN 15 PY 2015 VL 211 IS 12 BP 1997 EP 2005 DI 10.1093/infdis/jiu836 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CJ7LC UT WOS:000355675600018 PM 25564249 ER PT J AU Dietrich, EA Bowen, RA Brault, AC AF Dietrich, Elizabeth A. Bowen, Richard A. Brault, Aaron C. TI An ex vivo avian leukocyte culture model for West Nile virus infection SO JOURNAL OF VIROLOGICAL METHODS LA English DT Article DE West Nile virus; American crow; Peripheral blood mononuclear cells; Leukocytes; Avian ID NEW-YORK; AMERICAN CROWS; BIRDS; REPLICATION; VIRULENCE; STRAIN AB West Nile virus (WNV) replicates in a wide variety of avian species, which act as amplification hosts. In particular, WNV generates high titers and elicits severe pathology in American crows (AMCRs; Corvus brachyrhynchos), a species that has been used as a sentinel for WNV transmission. Although the specific cellular targets of WNV replication in AMCRs are not well defined, preliminary evidence suggests that leukocytes may be an important target of early replication. Therefore, development of a protocol for ex vivo culture of AMCR leukocytes as a model for assessing differential avian host susceptibility is described herein. WNV growth in these cultures mirrored in vivo viremia profiles. These data indicate that ex vivo leukocyte cultures can be used for preliminary pathological assessment of novel WNV strains and potentially of other flaviviruses that use avian reservoir hosts. Published by Elsevier B.V. C1 [Dietrich, Elizabeth A.; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80521 USA. [Bowen, Richard A.] Colorado State Univ, Dept Biomed Sci, Ft Collins, CO 80523 USA. RP Brault, AC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM abrault@cdc.gov FU U.S. Centers for Disease Control and Prevention; American Society for Microbiology/CDC postdoctoral fellowship FX We thank the Colorado Department of Fish and Game and private landowners in Bellvue, Colorado for allowing AMCR trapping on their respective grounds. Angela Bosco-Lauth, Nisha Duggal, and Hannah Romo assisted with bird trapping and care. Todd Felix (USDA) assisted with trapping. Funding for this study was provided by the U.S. Centers for Disease Control and Prevention. E.A.D. was supported by an American Society for Microbiology/CDC postdoctoral fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 19 TC 1 Z9 1 U1 1 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0166-0934 EI 1879-0984 J9 J VIROL METHODS JI J. Virol. Methods PD JUN 15 PY 2015 VL 218 BP 19 EP 22 DI 10.1016/j.jviromet.2015.03.004 PG 4 WC Biochemical Research Methods; Biotechnology & Applied Microbiology; Virology SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology; Virology GA CI1KG UT WOS:000354502500004 PM 25783683 ER PT J AU Henning, TR McNicholl, JM Vishwanathan, SA Kersh, EN AF Henning, Tara R. McNicholl, Janet M. Vishwanathan, Sundaram A. Kersh, Ellen N. TI Macaque models of enhanced susceptibility to HIV SO VIROLOGY JOURNAL LA English DT Review DE SIV; SHIV; HIV; Susceptibility; Risk; Nonhuman primate model; Coinfection model ID SIMIAN IMMUNODEFICIENCY VIRUS; SEXUALLY-TRANSMITTED-DISEASES; CHRONIC ALCOHOL-CONSUMPTION; REGULATORY T-CELLS; CLADE-C INFECTION; RHESUS MACAQUES; MENSTRUAL-CYCLE; PERSONAL LUBRICANTS; PROTECTS MACAQUES; PIGTAIL MACAQUES AB There are few nonhuman primate models of enhanced HIV susceptibility. Such models can improve comprehension of HIV acquisition risk factors and provide rigorous testing platforms for preclinical prevention strategies. This paper reviews past, current, and proposed research on macaque HIV acquisition risk models and identifies areas where modeling is significantly lacking. We compare different experimental approaches and provide practical considerations for designing macaque susceptibility studies. Modifiable (mucosal and systemic coinfections, hormonal contraception, and rectal lubricants) and non-modifiable (hormonal fluctuations) risk factors are highlighted. Risk acquisition models via vaginal, rectal, and penile challenge routes are discussed. There is no consensus on the best statistical model for evaluating increased susceptibility, and additional research is required. The use of enhanced susceptibility macaque models would benefit multiple facets of the HIV research field, including basic acquisition and pathogenesis studies as well as the vaccine and other biomedical preventions pipeline. C1 [Henning, Tara R.; McNicholl, Janet M.; Vishwanathan, Sundaram A.; Kersh, Ellen N.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. RP Kersh, EN (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd NE,MS A-25, Atlanta, GA 30333 USA. EM ekersh@cdc.gov FU CDC [Y1-A1-0681-02]; NIH [Y1-A1-0681-02] FX The authors thank Katherine Butler, Dr. Walid Heneine, and Dr. Angela Amedee for insightful comments during the preparation of this manuscript. Funded by CDC and partially by an interagency agreement (Y1-A1-0681-02) between CDC and NIH. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 47 TC 2 Z9 2 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1743-422X J9 VIROL J JI Virol. J. PD JUN 14 PY 2015 VL 12 AR 90 DI 10.1186/s12985-015-0320-6 PG 9 WC Virology SC Virology GA CL2GX UT WOS:000356762700001 PM 26070461 ER PT J AU Anderson, AR AF Anderson, Ayana R. TI Health Effects of Cut Gas Lines and Other Petroleum Product Release Incidents - Seven States, 2010-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30333 USA. RP Anderson, AR (reprint author), Agcy Tox Subst & Dis Registry, Div Toxicol & Human Hlth Sci, Atlanta, GA 30333 USA. EM aranderson@cdc.gov NR 8 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 12 PY 2015 VL 64 IS 22 BP 601 EP 605 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5AW UT WOS:000356972700001 PM 26068562 ER PT J AU Soeters, HM McNamara, LA Whaley, M Wang, X Alexander-Scott, N Kanadanian, KV Kelleher, CM MacNeil, J Martin, SW Raines, N Sears, S Vanner, C Vuong, J Bandy, U Sicard, K Patel, M AF Soeters, Heidi M. McNamara, Lucy A. Whaley, Melissa Wang, Xin Alexander-Scott, Nicole Kanadanian, Koren V. Kelleher, Catherine M. MacNeil, Jessica Martin, Stacey W. Raines, Nathan Sears, Steven Vanner, Cynthia Vuong, Jeni Bandy, Utpala Sicard, Kenneth Patel, Manisha TI Serogroup B Meningococcal Disease Outbreak and Carriage Evaluation at a College - Rhode Island, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID NEISSERIA-MENINGITIDIS; VACCINE C1 [Soeters, Heidi M.; McNamara, Lucy A.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Soeters, Heidi M.; McNamara, Lucy A.; Whaley, Melissa; Wang, Xin; MacNeil, Jessica; Martin, Stacey W.; Vuong, Jeni; Patel, Manisha] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Alexander-Scott, Nicole; Vanner, Cynthia; Bandy, Utpala] Rhode Isl Dept Hlth, Providence, RI 02908 USA. [Kanadanian, Koren V.; Kelleher, Catherine M.; Sears, Steven; Sicard, Kenneth] Providence Coll, Providence, RI 02918 USA. [Raines, Nathan] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. RP Soeters, HM (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM hzx8@cdc.gov NR 10 TC 13 Z9 13 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 12 PY 2015 VL 64 IS 22 BP 606 EP 607 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5AW UT WOS:000356972700002 PM 26068563 ER PT J AU Folaranmi, T Rubin, L Martin, SW Patel, M MacNeil, JR AF Folaranmi, Temitope Rubin, Lorry Martin, Stacey W. Patel, Manisha MacNeil, Jessica R. TI Use of Serogroup B Meningococcal Vaccines in Persons Aged >= 10 Years at Increased Risk for Serogroup B Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEALTHY ADOLESCENTS; OBSERVER-BLIND; IMMUNOGENICITY; TRIAL; TOLERABILITY; SAFETY; 4CMENB C1 [Folaranmi, Temitope] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Rubin, Lorry] New York & Hofstra North Shore LIJ Sch Med, Advisory Comm Immunizat Practices Meningococcal V, Steven & Alexandra Cohen Childrens Med Ctr New Yo, Hempstead, NY USA. [Martin, Stacey W.; Patel, Manisha; MacNeil, Jessica R.] CDC, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Folaranmi, T (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. NR 19 TC 50 Z9 50 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 12 PY 2015 VL 64 IS 22 BP 608 EP 612 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5AW UT WOS:000356972700003 PM 26068564 ER PT J AU Thapa, A Khanal, S Sharapov, U Swezy, V Sedai, T Dabbagh, A Rota, P Goodson, JL McFarland, J AF Thapa, Arun Khanal, Sudhir Sharapov, Umid Swezy, Virginia Sedai, Tika Dabbagh, Alya Rota, Paul Goodson, James L. McFarland, Jeffrey TI Progress Toward Measles Elimination - South-East Asia Region, 2003-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Thapa, Arun; Khanal, Sudhir; Swezy, Virginia; Sedai, Tika; McFarland, Jeffrey] WHO, Expanded Programme Immunizat, South East Asia Reg Off, Delhi, India. [Sharapov, Umid; Goodson, James L.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Dabbagh, Alya] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Rota, Paul] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP McFarland, J (reprint author), WHO, Expanded Programme Immunizat, South East Asia Reg Off, Delhi, India. EM mcfarlandj@who.int NR 9 TC 2 Z9 2 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 12 PY 2015 VL 64 IS 22 BP 613 EP 617 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5AW UT WOS:000356972700004 PM 26068565 ER PT J AU Law, R Schier, J Martin, C Chang, A Wolkin, A AF Law, Royal Schier, Josh Martin, Colleen Chang, Arthur Wolkin, Amy TI Increase in Reported Adverse Health Effects Related to Synthetic Cannabinoid Use - United States, January-May 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Law, Royal; Schier, Josh; Martin, Colleen; Chang, Arthur; Wolkin, Amy] CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. RP Law, R (reprint author), CDC, Div Environm Hazards & Hlth Effects, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. EM hua1@cdc.gov NR 4 TC 26 Z9 26 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 12 PY 2015 VL 64 IS 22 BP 618 EP 619 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL5AW UT WOS:000356972700005 PM 26068566 ER PT J AU Akogbeto, MC Aikpon, RY Azondekon, R Padonou, GG Osse, RA Agossa, FR Beach, R Sezonlin, M AF Akogbeto, Martin C. Aikpon, Rock Y. Azondekon, Roseric Padonou, Gil G. Osse, Razaki A. Agossa, Fiacre R. Beach, Raymond Sezonlin, Michel TI Six years of experience in entomological surveillance of indoor residual spraying against malaria transmission in Benin: lessons learned, challenges and outlooks SO MALARIA JOURNAL LA English DT Article DE Indoor residual spraying; Lessons learned; Benin ID INSECTICIDAL MOSQUITO NETS; GAMBIAE-S.L. POPULATIONS; ANOPHELES-GAMBIAE; WEST-AFRICA; PYRETHROID RESISTANCE; VECTOR CONTROL; BENDIOCARB; MANAGEMENT; CARBAMATE; EFFICACY AB Background: From 2008 to 2013, a prevention intervention against malaria based on indoor residual spraying (IRS) was implemented in Benin. From 2008 to 2012, Ficam M(R), a bendiocarb-containing product was used for house spraying, in association with pirimiphos methyl EC (Actellic EC) in 2013. This operation aimed to strengthen the effectiveness of treated nets so as to expedite the achievement of Millennium Development Goals (MDGs): the reduction of morbidity and mortality due to malaria by 75 % from 2000 to 2015. Methods: Monitoring and evaluation (M&E) was implemented in order to evaluate the impact of IRS intervention on malaria transmission. Anopheles gambiae s.l. populations were sampled by human landing catch. In addition, window exit traps and pyrethrum spray catches were performed to assess exophagic behaviour of Anopheles vectors the main malaria vector in the treated areas. The residual activity of insecticide in the treated walls was also assessed using WHO bioassay test. Results: The purpose of this project was to draw attention to new challenges and future prospects for the success of IRS in Benin. The main strength of the intervention was a large-scale operation in which more than 80 % of the houses were treated due to the strong adhesion of population. In addition, a significant reduction of the EIR in areas under IRS were observed. However, there were many challenges including the high cost of IRS implementation and the identification of suitable areas to implement IRS. This was because of the low and short residual effect of the insecticides recommended for IRS and the management strategy for vector resistance to insecticides. This indicated that challenges are accompanied by suggested solutions. For the cost of IRS to be accessible to states, then local organizations need to be created in partnership with the National Malaria Control Programme (NMCP) in order to ensure relevant planning and implementation of IRS. Conclusion: As an anticipatory measure against vector resistance, this paper proposes various methods, such as periodic IRS based on a combination of two or three insecticides of different classes used in rotation every two or three years. C1 [Akogbeto, Martin C.; Aikpon, Rock Y.; Azondekon, Roseric; Padonou, Gil G.; Osse, Razaki A.; Agossa, Fiacre R.] CREC, Cotonou, Benin. [Akogbeto, Martin C.; Aikpon, Rock Y.; Padonou, Gil G.; Agossa, Fiacre R.; Sezonlin, Michel] Univ dAbomey Calavi, Fac Sci & Tech, Cotonou, Benin. [Azondekon, Roseric] Univ Massachusetts, Amherst, MA 01003 USA. [Osse, Razaki A.] Univ Agr Ketou, Ketou, Benin. [Beach, Raymond] Ctr Dis Control, Atlanta, GA 30333 USA. RP Aikpon, RY (reprint author), CREC, 06 BP 2604, Cotonou, Benin. EM rockypremier@yahoo.fr FU President's Malaria Initiative of the US Government FX The research leading to these results was financially supported by The President's Malaria Initiative of the US Government. We acknowledge The President's Malaria Initiative through USAID Cotonou, Benin NR 30 TC 1 Z9 1 U1 2 U2 9 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD JUN 12 PY 2015 VL 14 AR 242 DI 10.1186/s12936-015-0757-5 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CK4VH UT WOS:000356220900001 PM 26063497 ER PT J AU Bhattacharjee, M Rajeevan, MS Sillanpaa, MJ AF Bhattacharjee, Madhuchhanda Rajeevan, Mangalathu S. Sillanpaa, Mikko J. TI Prediction of complex human diseases from pathway-focused candidate markers by joint estimation of marker effects: case of chronic fatigue syndrome SO HUMAN GENOMICS LA English DT Article DE Chronic fatigue syndrome; Phenotype prediction; Cross-validation; SNP; Bayesian analysis ID GENOME-WIDE ASSOCIATION; GENETIC-ASSOCIATION; QUANTITATIVE TRAITS; LINKAGE DISEQUILIBRIUM; MISSING HERITABILITY; REGRESSION METHODS; MODELS; POLYMORPHISMS; SELECTION; SNPS AB Background: The current practice of using only a few strongly associated genetic markers in regression models results in generally low power in prediction or accounting for heritability of complex human traits. Purpose: We illustrate here a Bayesian joint estimation of single nucleotide polymorphism (SNP) effects principle to improve prediction of phenotype status from pathway-focused sets of SNPs. Chronic fatigue syndrome (CFS), a complex disease of unknown etiology with no laboratory methods for diagnosis, was chosen to demonstrate the power of this Bayesian method. For CFS, such a genetic predictive model in combination with clinical evidence might lead to an earlier diagnosis than one based solely on clinical findings. Methods: One of our goals is to model disease status using Bayesian statistics which perform variable selection and parameter estimation simultaneously and which can induce the sparseness and smoothness of the SNP effects. Smoothness of the SNP effects is obtained by explicit modeling of the covariance structure of the SNP effects. Results: The Bayesian model achieved perfect goodness of fit when tested within the sampled data. Tenfold cross-validation resulted in 80 % accuracy, one of the best so far for CFS in comparison to previous prediction models. Model reduction aspects were investigated in a computationally feasible manner. Additionally, genetic variation estimates provided by the model identified specific genetic markers for their biological role in the disease pathophysiology. Conclusions: This proof-of-principle study provides a powerful approach combining Bayesian methods, SNPs representing multiple pathways and rigorous case ascertainment for accurate genetic risk prediction modeling of complex diseases like CFS and other chronic diseases. C1 [Bhattacharjee, Madhuchhanda] Univ Hyderabad, Sch Math & Stat, Hyderabad 500046, Andhra Pradesh, India. [Rajeevan, Mangalathu S.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA 30333 USA. [Sillanpaa, Mikko J.] Univ Oulu, Bioctr Oulu, Dept Math Sci, FIN-90014 Oulu, Finland. RP Bhattacharjee, M (reprint author), Univ Hyderabad, Sch Math & Stat, Hyderabad 500046, Andhra Pradesh, India. EM mbsm@uohyd.ernet.in FU Academy of Finland [127076]; University of Helsinki's research funds FX This work was supported by a research grant (Decision No. 127076) from the Academy of Finland and the University of Helsinki's research funds. NR 66 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1473-9542 EI 1479-7364 J9 HUM GENOMICS JI Hum. Genomics PD JUN 11 PY 2015 VL 9 AR 8 DI 10.1186/s40246-015-0030-6 PG 12 WC Genetics & Heredity SC Genetics & Heredity GA CL0RP UT WOS:000356651100001 PM 26063326 ER PT J AU Basile, KC AF Basile, Kathleen C. TI A Comprehensive Approach to Sexual Violence Prevention SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID PROGRAM; ALCOHOL C1 Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. RP Basile, KC (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30333 USA. FU Intramural CDC HHS [CC999999] NR 12 TC 2 Z9 2 U1 1 U2 5 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 11 PY 2015 VL 372 IS 24 BP 2350 EP 2352 DI 10.1056/NEJMe1503952 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CK2DB UT WOS:000356019200014 PM 26061841 ER PT J AU Lessa, FC Winston, LG McDonald, LC AF Lessa, Fernanda C. Winston, Lisa G. McDonald, L. Clifford CA Emerging Infect Program C Difficil TI Burden of Clostridium difficile Infection in the United States REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter C1 [Lessa, Fernanda C.; McDonald, L. Clifford] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Winston, Lisa G.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA. RP Lessa, FC (reprint author), Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. EM flessa@cdc.gov NR 3 TC 25 Z9 25 U1 1 U2 3 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD JUN 11 PY 2015 VL 372 IS 24 BP 2369 EP 2370 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CK2DB UT WOS:000356019200027 PM 26061850 ER PT J AU Cohen, AL McMorrow, M Walaza, S Cohen, C Tempia, S Alexander-Scott, M Widdowson, MA AF Cohen, Adam L. McMorrow, Meredith Walaza, Sibongile Cohen, Cheryl Tempia, Stefano Alexander-Scott, Marissa Widdowson, Marc-Alain TI Potential Impact of Co-Infections and Co-Morbidities Prevalent in Africa on Influenza Severity and Frequency: A Systematic Review SO PLOS ONE LA English DT Article ID SICKLE-CELL-DISEASE; RANDOMIZED CONTROLLED-TRIAL; RESPIRATORY-TRACT INFECTIONS; HUMAN-IMMUNODEFICIENCY-VIRUS; TIME-SERIES ANALYSIS; MENINGOCOCCAL DISEASE; IMMUNE-RESPONSE; SEASONAL INFLUENZA; PANDEMIC H1N1; DENGUE VIRUS AB Infectious diseases and underlying medical conditions common to Africa may affect influenza frequency and severity. We conducted a systematic review of published studies on influenza and the following co-infections or co-morbidities that are prevalent in Africa: dengue, malaria, measles, meningococcus, Pneumocystis jirovecii pneumonia (PCP), hemoglobinopathies, and malnutrition. Articles were identified except for influenza and PCP. Very few studies were from Africa. Sickle cell disease, dengue, and measles co-infection were found to increase the severity of influenza disease, though this is based on few studies of dengue and measles and the measles study was of low quality. The frequency of influenza was increased among patients with sickle cell disease. Influenza infection increased the frequency of meningococcal disease. Studies on malaria and malnutrition found mixed results. Age-adjusted morbidity and mortality from influenza may be more common in Africa because infections and diseases common in the region lead to more severe outcomes and increase the influenza burden. However, gaps exist in our knowledge about these interactions. C1 [Cohen, Adam L.; McMorrow, Meredith; Tempia, Stefano; Widdowson, Marc-Alain] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. [Cohen, Adam L.; Tempia, Stefano] Ctr Dis Control & Prevent South Africa, Influenza Program, Pretoria, South Africa. [Cohen, Adam L.; McMorrow, Meredith] US PHS, Rockville, MD USA. [Walaza, Sibongile; Cohen, Cheryl; Tempia, Stefano] Natl Inst Communicable Dis, Ctr Resp Dis & Meningitis, Johannesburg, South Africa. [Walaza, Sibongile; Cohen, Cheryl] Univ Witwatersrand, Sch Publ Hlth, Johannesburg, South Africa. [Walaza, Sibongile; Cohen, Cheryl] Univ Witwatersrand, Fac Hlth Sci, Johannesburg, South Africa. [Alexander-Scott, Marissa] NIOSH, Ctr Dis Control & Prevent, DART, Cincinnati, OH 45226 USA. [Alexander-Scott, Marissa] Univ Illinois, Springfield, IL USA. RP Cohen, AL (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. EM DVJ1@cdc.gov FU Centers for Disease Control and Prevention, Atlanta, Georgia, USA FX This work is supported by the Centers for Disease Control and Prevention, Atlanta, Georgia, USA. NR 108 TC 4 Z9 4 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 11 PY 2015 VL 10 IS 6 AR UNSP e0128580 DI 10.1371/journal.pone.0128580 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK3FB UT WOS:000356100900026 PM 26068416 ER PT J AU Johnson, A Chen, LM Winne, E Santana, W Metcalfe, MG Mateu-Petit, G Ridenour, C Hossain, MJ Villanueva, J Zaki, SR Williams, TL Cox, NJ Barr, JR Donis, RO AF Johnson, Adam Chen, Li-Mei Winne, Emily Santana, Wanda Metcalfe, Maureen G. Mateu-Petit, Guaniri Ridenour, Callie Hossain, M. Jaber Villanueva, Julie Zaki, Sherif R. Williams, Tracie L. Cox, Nancy J. Barr, John R. Donis, Ruben O. TI Identification of Influenza A/PR/8/34 Donor Viruses Imparting High Hemagglutinin Yields to Candidate Vaccine Viruses in Eggs SO PLOS ONE LA English DT Article ID A VIRUS; PANDEMIC INFLUENZA; MASS-SPECTROMETRY; REVERSE GENETICS; ANTIGEN YIELD; SEED VIRUSES; M2 PROTEIN; PB1 GENE; NEURAMINIDASE; STRAINS AB One of the important lessons learned from the 2009 H1N1 pandemic is that a high yield influenza vaccine virus is essential for efficient and timely production of pandemic vaccines in eggs. The current seasonal and pre-pandemic vaccine viruses are generated either by classical reassortment or reverse genetics. Both approaches utilize a high growth virus, generally A/Puerto Rico/8/1934 (PR8), as the donor of all or most of the internal genes, and the wild type virus recommended for inclusion in the vaccine to contribute the hemagglutinin (HA) and neuraminidase (NA) genes encoding the surface glycoproteins. As a result of extensive adaptation through sequential egg passaging, PR8 viruses with different gene sequences and high growth properties have been selected at different laboratories in past decades. The effect of these related but distinct internal PR8 genes on the growth of vaccine viruses in eggs has not been examined previously. Here, we use reverse genetics to analyze systematically the growth and HA antigen yield of reassortant viruses with 3 different PR8 backbones. A panel of 9 different HA/NA gene pairs in combination with each of the 3 different lineages of PR8 internal genes (27 reassortant viruses) was generated to evaluate their performance. Virus and HA yield assays showed that the PR8 internal genes influence HA yields in most subtypes. Although no single PR8 internal gene set outperformed the others in all candidate vaccine viruses, a combination of specific PR8 backbone with individual HA/NA pairs demonstrated improved HA yield and consequently the speed of vaccine production. These findings may be important both for production of seasonal vaccines and for a rapid global vaccine response during a pandemic. C1 [Johnson, Adam; Chen, Li-Mei; Mateu-Petit, Guaniri; Ridenour, Callie; Hossain, M. Jaber; Villanueva, Julie; Cox, Nancy J.; Donis, Ruben O.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30329 USA. [Winne, Emily; Santana, Wanda; Williams, Tracie L.; Barr, John R.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA. [Metcalfe, Maureen G.; Zaki, Sherif R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Chen, LM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Influenza Div, Atlanta, GA 30329 USA. EM bpr5@cdc.gov; rvd6@cdc.gov FU US Department of Health and Human Services FX The study was funded by the US Department of Health and Human Services. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 61 TC 1 Z9 3 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 11 PY 2015 VL 10 IS 6 AR e0128982 DI 10.1371/journal.pone.0128982 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK3FB UT WOS:000356100900038 PM 26068666 ER PT J AU Ram, PK DiVita, MA Khatun-e-Jannat, K Islam, M Krytus, K Cercone, E Sohel, BM Ahmed, M Rahman, AMQ Rahman, M Yu, J Brooks, WA Azziz-Baumgartner, E Fry, AM Luby, SP AF Ram, Pavani K. DiVita, Margaret A. Khatun-e-Jannat, Kaniz Islam, Manoshi Krytus, Kimberly Cercone, Emily Sohel, Badrul Munir Ahmed, Makhdum Rahman, Abid Mahmud Quaiyum Rahman, Mustafizur Yu, Jihnhee Brooks, W. Abdullah Azziz-Baumgartner, Eduardo Fry, Alicia M. Luby, Stephen P. TI Impact of Intensive Handwashing Promotion on Secondary Household Influenza-Like Illness in Rural Bangladesh: Findings from a Randomized Controlled Trial SO PLOS ONE LA English DT Article ID NONPHARMACEUTICAL INTERVENTIONS; PANDEMIC INFLUENZA; SEASONAL INFLUENZA; HEALTHY-CHILDREN; GLOBAL BURDEN; HAND HYGIENE; TRANSMISSION; URBAN AB Rationale There is little evidence for the efficacy of handwashing for prevention of influenza transmission in resource-poor settings. We tested the impact of intensive handwashing promotion on household transmission of influenza-like illness and influenza in rural Bangladesh. Methods In 2009-10, we identified index case-patients with influenza-like illness (fever with cough or sore throat) who were the only symptomatic person in their household. Household compounds of index case-patients were randomized to control or intervention (soap and daily handwashing promotion). We conducted daily surveillance and collected oropharyngeal specimens. Secondary attack ratios (SAR) were calculated for influenza and ILI in each arm. Among controls, we investigated individual risk factors for ILI among household contacts of index case-patients. Results Among 377 index case-patients, the mean number of days between fever onset and study enrollment was 2.1 (SD 1.7) among the 184 controls and 2.6 (SD 2.9) among 193 intervention case-patients. Influenza infection was confirmed in 20% of controls and 12% of intervention index case-patients. The SAR for influenza-like illness among household contacts was 9.5% among intervention (158/1661) and 7.7% among control households (115/1498) SAR ratio 1.24, 95% CI 0.92-1.65). The SAR ratio for influenza was 2.40 (95% CI 0.68-8.47). In the control arm, susceptible contacts < 2 years old (RRadj 5.51, 95% CI 3.43-8.85), those living with an index case-patient enrolled <= 24 hours after symptom onset (RRadj 1.91, 95% CI 1.18-3.10), and those who reported multiple daily interactions with the index case-patient (RRadj 1.94, 95% CI 1.71-3.26) were at increased risk of influenza-like illness. Discussion Handwashing promotion initiated after illness onset in a household member did not protect against influenza-like illness or influenza. Behavior may not have changed rapidly enough to curb transmission between household members. A reactive approach to reduce household influenza transmission through handwashing promotion may be ineffective in the context of rural Bangladesh. C1 [Ram, Pavani K.; DiVita, Margaret A.; Krytus, Kimberly; Cercone, Emily] SUNY Buffalo, Dept Epidemiol & Environm Hlth, Buffalo, NY 14260 USA. [Khatun-e-Jannat, Kaniz; Islam, Manoshi; Sohel, Badrul Munir; Ahmed, Makhdum; Rahman, Abid Mahmud Quaiyum; Rahman, Mustafizur; Brooks, W. Abdullah; Azziz-Baumgartner, Eduardo; Luby, Stephen P.] Int Ctr Diarrhoeal Dis Res, Ctr Communicable Dis, Dhaka 1000, Bangladesh. [Yu, Jihnhee] SUNY Buffalo, Dept Biostat, Buffalo, NY 14260 USA. [Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Ram, PK (reprint author), SUNY Buffalo, Dept Epidemiol & Environm Hlth, Buffalo, NY 14260 USA. EM pkram@buffalo.edu RI Ahmed, Makhdum/D-2615-2012; OI Ahmed, Makhdum/0000-0002-0772-8710; DiVita, Margaret/0000-0002-4878-2959; Luby, Stephen/0000-0001-5385-899X FU US Centers for Disease Control and Prevention through a cooperative agreement with ICDDR, B [3U01CI000628] FX Funding for this project was provided by the US Centers for Disease Control and Prevention through a cooperative agreement with ICDDR, B (Grant number 3U01CI000628). CDC staff were collaborators on this project. Colleagues from the funder, the US Centers for Disease Control and Prevention (EAB, AMF, SPL), were involved in study design, oversight of data collection, interpretation of data, and reviews of manuscript drafts. NR 26 TC 4 Z9 4 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 11 PY 2015 VL 10 IS 6 AR e0125200 DI 10.1371/journal.pone.0125200 PG 18 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK3FB UT WOS:000356100900004 PM 26066651 ER PT J AU Tebbens, RJD Pallansch, MA Wassilak, SGF Cochi, SL Thompson, KM AF Tebbens, Radboud J. Duintjer Pallansch, Mark A. Wassilak, Steven G. F. Cochi, Stephen L. Thompson, Kimberly M. TI Combinations of Quality and Frequency of Immunization Activities to Stop and Prevent Poliovirus Transmission in the High-Risk Area of Northwest Nigeria SO PLOS ONE LA English DT Article ID VACCINE-DERIVED POLIOVIRUS; POPULATION IMMUNITY; WILD POLIOVIRUS; PARALYTIC POLIOMYELITIS; ERADICATION; DISEASE; EPIDEMIOLOGY; CIRCULATION; STRATEGIES; EMERGENCE AB Background Frequent supplemental immunization activities (SIAs) with the oral poliovirus vaccine (OPV) represent the primary strategy to interrupt poliovirus transmission in the last endemic areas. Materials and Methods Using a differential-equation based poliovirus transmission model tailored to high-risk areas in Nigeria, we perform one-way and multi-way sensitivity analyses to demonstrate the impact of different assumptions about routine immunization (RI) and the frequency and quality of SIAs on population immunity to transmission and persistence or emergence of circulating vaccine-derived polioviruses (cVDPVs) after OPV cessation. Results More trivalent OPV use remains critical to avoid serotype 2 cVDPVs. RI schedules with or without inactivated polio vaccine (IPV) could significantly improve population immunity if coverage increases well above current levels in under-vaccinated subpopulations. Similarly, the impact of SIAs on overall population immunity and cVDPV risks depends on their ability to reach under-vaccinated groups (i.e., SIA quality). Lower SIA coverage in the under-vaccinated subpopulation results in a higher frequency of SIAs needed to maintain high enough population immunity to avoid cVDPVs after OPV cessation. Conclusions National immunization program managers in northwest Nigeria should recognize the benefits of increasing RI and SIA quality. Sufficiently improving RI coverage and improving SIA quality will reduce the frequency of SIAs required to stop and prevent future poliovirus transmission. Better information about the incremental costs to identify and reach under-vaccinated children would help determine the optimal balance between spending to increase SIA and RI quality and spending to increase SIA frequency. C1 [Tebbens, Radboud J. Duintjer; Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Wassilak, Steven G. F.; Cochi, Stephen L.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. RP Tebbens, RJD (reprint author), Kid Risk Inc, Orlando, FL 32832 USA. EM rdt@kidrisk.org FU US Centers for Disease Control and Prevention [U66IP000519] FX RJDT and KMT acknowledge support for this work from the US Centers for Disease Control and Prevention under Contract U66IP000519. The contents of this article are solely the responsibility of the authors and do not represent the official views of the US Centers for Disease Control and Prevention. NR 45 TC 5 Z9 5 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 11 PY 2015 VL 10 IS 6 AR e0130123 DI 10.1371/journal.pone.0130123 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK3FB UT WOS:000356100900100 ER PT J AU Craig, AS Muleba, M Smith, SC Katebe-Sakala, C Chongwe, G Hamainza, B Walusiku, B Tremblay, M Oscadal, M Wirtz, R Tan, KR AF Craig, Allen S. Muleba, Mbanga Smith, Stephen C. Katebe-Sakala, Cecilia Chongwe, Gershom Hamainza, Busiku Walusiku, Batuke Tremblay, Megan Oscadal, Maureen Wirtz, Robert Tan, Kathrine R. TI Long-lasting insecticidal nets in Zambia: a cross-sectional analysis of net integrity and insecticide content SO MALARIA JOURNAL LA English DT Article DE Insecticide-treated net; Malaria; Vector control ID TREATED BED NETS; PERENNIAL MALARIA TRANSMISSION; WESTERN KENYA; PHYSICAL DURABILITY; CHILD-MORTALITY; MOSQUITO NET; AREA; ETHIOPIA; BEDNETS; IMPACT AB Background: Long-lasting insecticidal nets (LLINs) are a mainstay of malaria prevention in Africa. More LLINs are available now than in any time previously due to increases in funding for malaria control. LLINs are expected to last three to five years before they need to be replaced. Reports of nets lasting less than three years are frequent in Zambia, which, if true, will increase the number of LLINs needed to maintain universal coverage. Methods: This study collected nets distributed during mass distribution campaigns. One net was collected from each participating home in 12 districts in 2010 and all nets were examined for holes. One household member was surveyed about net use and care. Results: The study collected 713 polyester nets with a median age of 31 months (range 27-44 months, interquartile (IQR) range: 29-36 months), median number of holes was 17 (IQR: 5-33), and median total hole size was 88.3 sq cm (IQR: 14.5-360.4). The median total number of holes did differ by age of the net, from 27-44 months, but not in a linear fashion. The difference in the number of holes in the newest and oldest nets was not statistically significant. The mean deltamethrin level for all nets was 23 mg/sq m (>= 8 mg/sq m is considered effective). There was a larger total hole area in the lower half of the nets (repeat measures ANOVA, F = 228.43, df = 2, p < 0.0001) compared to the upper half and roof of the net. Only 8.7 % of nets had evidence of repairs. Conclusions: At 27 - 30 months, LLINs already had a large total hole surface area that was equivalent to the oldest nets observed. Nets were often tucked under reed mats which may explain the finding that the largest hole area was found in the lower half of the net. Studies need to be conducted prospectively to determine when physical deterioration occurs and why nets are discarded. Re-enforcing the lower half of the sides of LLINs may help decrease holes. C1 [Craig, Allen S.] Ctr Dis Control & Prevent CDC, Global Immunizat Div, Atlanta, GA 30333 USA. [Craig, Allen S.; Chongwe, Gershom] Trop Dis Res Ctr, Ndola, Zambia. [Smith, Stephen C.; Tan, Kathrine R.] Ctr Dis Control & Prevent CDC, Div Parasit Dis & Malaria, Atlanta, GA USA. [Katebe-Sakala, Cecilia] Bayer Ltd, Islando, South Africa. [Hamainza, Busiku] Natl Malaria Control Ctr, Lusaka, Zambia. [Walusiku, Batuke] Catholic Med Miss Board, Lusaka, Zambia. [Tremblay, Megan] STD HIV Program, Louisiana Dept Publ Hlth, New Orleans, LA USA. [Oscadal, Maureen] Neighborcare Hlth Pike Market Med Clin, Seattle, WA USA. RP Craig, AS (reprint author), Ctr Dis Control & Prevent CDC, Global Immunizat Div, Atlanta, GA 30333 USA. EM acraig@cdc.gov NR 25 TC 2 Z9 2 U1 1 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD JUN 10 PY 2015 VL 14 AR 239 DI 10.1186/s12936-015-0754-8 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CK7KK UT WOS:000356411000001 PM 26054336 ER PT J AU Leshem, E Tate, JE Steiner, CA Curns, AT Lopman, BA Parashar, UD AF Leshem, Eyal Tate, Jacqueline E. Steiner, Claudia A. Curns, Aaron T. Lopman, Ben A. Parashar, Umesh D. TI Acute Gastroenteritis Hospitalizations Among US Children Following Implementation of the Rotavirus Vaccine SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Letter ID HEALTH-CARE UTILIZATION; UNITED-STATES; DIARRHEA C1 [Leshem, Eyal; Tate, Jacqueline E.; Curns, Aaron T.; Lopman, Ben A.; Parashar, Umesh D.] US Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Steiner, Claudia A.] Agcy Healthcare Res & Qual, Healthcare Cost & Utilizat Project, Rockville, MD USA. RP Leshem, E (reprint author), US Ctr Dis Control & Prevent, Div Viral Dis, 1600 Clifton Rd NE,Mail Stop A-34, Atlanta, GA 30333 USA. EM eleshem@cdc.gov OI Leshem, Eyal/0000-0003-1267-6131 NR 6 TC 11 Z9 11 U1 0 U2 4 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUN 9 PY 2015 VL 313 IS 22 BP 2282 EP 2284 DI 10.1001/jama.2015.5571 PG 3 WC Medicine, General & Internal SC General & Internal Medicine GA CK1VH UT WOS:000355995300024 PM 26057291 ER PT J AU Fu, CX Xu, JX Lin, JY Wang, M Li, KB Ge, J Thompson, MG AF Fu, Chuanxi Xu, Jianxiong Lin, Jinyan Wang, Ming Li, Kuibiao Ge, Jing Thompson, Mark G. TI Concurrent and cross-season protection of inactivated influenza vaccine against A(H1N1)pdm09 illness among young children: 2012-2013 case-control evaluation of influenza vaccine effectiveness SO VACCINE LA English DT Article DE A(H1N1)pdm09 influenza; Influenza vaccines; Vaccine effectiveness; Children; Prior vaccination ID 6-TO 23-MONTH-OLD CHILDREN; VIRUS AB In 2012-2013, we examined 1729 laboratory-confirmed A(H1N1)pdm09 influenza cases matched 1:1 with healthy controls and estimated influenza vaccine effectiveness (VE) for trivalent inactivated influenza vaccine (IIV3) to be 67% (95% confidence interval = 58-74%) for ages 8 months to 6 years old. Among children aged 8-35 months old, VE for fully vaccinated children (73%, 60-81%) was significantly higher than VE for partially vaccinated children (55%, 33-70%). Significant cross-season protection from prior IIV3 was noted, including VE of 31% (8-48%) from IIV3 received in 2010-2011 against influenza illness in 2012--2013 without subsequent boosting doses. Published by Elsevier Ltd. C1 [Fu, Chuanxi; Xu, Jianxiong; Wang, Ming; Li, Kuibiao] Guangzhou Ctr Dis Control & Prevent, Guangzhou 510440, Guangdong, Peoples R China. [Lin, Jinyan; Ge, Jing] Southern Med Univ, Nanfang Hosp, Hlth Management Ctr, Guangzhou, Guangdong, Peoples R China. [Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. RP Thompson, MG (reprint author), Ctr Dis Control & Prevent, Influenza Div, 1600 Clifton Rd NE,MS A-32, Atlanta, GA 30333 USA. EM fuchuanxi@gmail.com; isq8@cdc.gov FU Guangdong Provincial Department of Science and Technology [2012B091100045] FX This work was supported by grant from the Guangdong Provincial Department of Science and Technology (2012B091100045). NR 16 TC 3 Z9 3 U1 0 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUN 9 PY 2015 VL 33 IS 25 BP 2917 EP 2921 DI 10.1016/j.vaccine.2015.04.063 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CK4JN UT WOS:000356190200009 PM 25921713 ER PT J AU Spaulding, AC MacGowan, RJ Copeland, B Shrestha, RK Bowden, CJ Kim, MJ Margolis, A Mustaafaa, G Reid, LC Heilpern, KL Shah, BB AF Spaulding, Anne C. MacGowan, Robin J. Copeland, Brittney Shrestha, Ram K. Bowden, Chava J. Kim, Min J. Margolis, Andrew Mustaafaa, Genetha Reid, Laurie C. Heilpern, Katherine L. Shah, Bijal B. TI Costs of Rapid HIV Screening in an Urban Emergency Department and a Nearby County Jail in the Southeastern United States SO PLOS ONE LA English DT Article ID ADULTS; CARE AB Emergency departments and jails provide medical services to persons at risk for HIV infection and are recommended venues for HIV screening. Our main objective in this study was to analyze the cost per new HIV diagnosis associated with the HIV screening program in these two venues. The emergency department's parallel testing program was conducted at Grady Memorial Hospital in Atlanta, Georgia starting in 2008; the jail's integrated testing program began at the Fulton County (GA) Jail in 2011. The two sites, four miles apart from one another, employed the same rapid HIV test. Ascertainment that cases were new differed by site; only the jail systematically checked identities against health department HIV registries. The program in the emergency department used dedicated HIV test counselors and made 242 diagnoses over a 40-month period at a cost of $2,981 per diagnosis. The jail program used staff nurses, and found 41 new HIV cases over 10.5 months at a cost of $6,688 per new diagnosis. Differences in methods for ascertainment of new diagnoses, previously undiagnosed HIV sero-positivity, and methodologies used for assessing program costs prevent concluding that one program was more economical than the other. Nonetheless, our findings show that testing in both venues yielded many new diagnoses, with the costs within the range reported in the literature. C1 [Spaulding, Anne C.; Bowden, Chava J.; Kim, Min J.; Mustaafaa, Genetha] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. [MacGowan, Robin J.; Shrestha, Ram K.; Margolis, Andrew; Reid, Laurie C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Copeland, Brittney; Heilpern, Katherine L.; Shah, Bijal B.] Emory Sch Med, Dept Emergency Med, Atlanta, GA USA. RP Spaulding, AC (reprint author), Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA 30322 USA. EM ASpauld@emory.edu FU ACS BBS; [P30 AI050409]; [1H62PS003187-01] FX Funding was provided by www.cdc.gov; P30 AI050409 and 1H62PS003187-01; and ACS BBS. Under this collaborative project, CDC project officers contributed to the study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 22 TC 0 Z9 0 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 8 PY 2015 VL 10 IS 6 AR UNSP e0128408 DI 10.1371/journal.pone.0128408 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK1GM UT WOS:000355955300035 PM 26053140 ER PT J AU Lambert, N Strebel, P Orenstein, W Icenogle, J Poland, GA AF Lambert, Nathaniel Strebel, Peter Orenstein, Walter Icenogle, Joseph Poland, Gregory A. TI Rubella SO LANCET LA English DT Article ID IMMUNE-RESPONSE; VIRUS VACCINE; T-CELL; DEVELOPING-COUNTRIES; CYTOKINE RESPONSES; MATERNAL RUBELLA; FUCHS UVEITIS; SYNDROME CRS; ORAL FLUID; PCR ASSAY AB Rubella remains an important pathogen worldwide, with roughly 100 000 cases of congenital rubella syndrome estimated to occur every year. Rubella-containing vaccine is highly effective and safe and, as a result, endemic rubella transmission has been interrupted in the Americas since 2009. Incomplete rubella vaccination programmes result in continued disease transmission, as evidenced by recent large outbreaks in Japan and elsewhere. In this Seminar, we provide present results regarding rubella control, elimination, and eradication policies, and a brief review of new laboratory diagnostics. Additionally, we provide novel information about rubella-containing vaccine immunogenetics and review the emerging evidence of interindividual variability in humoral and cell-mediated innate and adaptive immune responses to rubella-containing vaccine and their association with haplotypes and single-nucleotide polymorphisms across the human genome. C1 [Lambert, Nathaniel; Poland, Gregory A.] Mayo Clin, Mayo Clin Vaccine Res Grp, Rochester, MN 55902 USA. [Poland, Gregory A.] Mayo Clin, Program Translat Immunovirol & Biodef, Rochester, MN USA. [Strebel, Peter] WHO, Dept Immunizat Vaccines & Biol, CH-1211 Geneva, Switzerland. [Orenstein, Walter] Emory Univ, Emory Vaccine Ctr, Atlanta, GA 30322 USA. [Icenogle, Joseph] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Poland, GA (reprint author), Mayo Clin, Mayo Clin Vaccine Res Grp, Rochester, MN 55902 USA. EM poland.gregory@mayo.edu FU National Institute of Allergy and Infectious Diseases of the National Institutes of Health [R37AI48793] FX Research reported in this Seminar was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under award number R37AI48793 (which recently received a MERIT Award). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The findings and conclusions in this Seminar are those of the authors and do not necessarily represent the views of the US Department of Health and Human Services. PS is a staff member of the World Health Organization. PS is responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy, or views of the World Health Organization. We thank Caroline L Vitse for her editorial assistance. NR 111 TC 17 Z9 17 U1 2 U2 14 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD JUN 6 PY 2015 VL 385 IS 9984 BP 2297 EP 2307 DI 10.1016/S0140-6736(14)60539-0 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA CK1CR UT WOS:000355943500033 PM 25576992 ER PT J AU Takumi, K Caccio, SM van der Giessen, J Xiao, LH Sprong, H AF Takumi, Katsuhisa Caccio, Simone M. van der Giessen, Joke Xiao, Lihua Sprong, Hein TI Hypothesis: Cryptosporidium genetic diversity mirrors national disease notification rate SO PARASITES & VECTORS LA English DT Article DE Cryptosporidium hominis; Cryptosporidium parvum; GP60; Population genetics; Molecular epidemiology ID PARVUM; GLYCOPROTEIN; NETHERLANDS; CHILDREN AB Background: Cryptosporidiosis is a gastrointestinal disease affecting many people worldwide. Disease incidence is often unknown and surveillance of human cryptosporidiosis is installed in only a handful of developed countries. A genetic marker that mirrors disease incidence is potentially a powerful tool for monitoring the two primary human infected species of Cryptosporidium. Methods: We used the molecular epidemiological database with Cryptosporidium isolates from ZoopNet, which currently contains more than 1400 records with their sampling nations, and the names of the host species from which the isolates were obtained. Based on 296 Cryptosporidium hominis and 195 Cryptosporidium parvum GP60 sequences from human origin, the genetic diversities of Cryptosporidium was estimated for several nations. Notified cases of human cryptosporidiosis were collected from statistics databases for only four nations. Results: Genetic diversities of Cryptosporidium hominis were estimated in 10 nations in 5 continents, and that of Cryptosporidium parvum of human origin were estimated in 15 nations. Correlation with reported incidence of human cryptosporidiosis in four nations (the Netherlands, United States, United Kingdom and Australia) was positive and significant. A linear model for testing the relationship between the genetic diversity and incidence produced a significantly positive estimate for the slope (P-value < 0.05). Conclusions: The hypothesis that genetic diversity at GP60 locus mirrors notification rates of human cryptosporidiosis was not rejected based on the data presented. Genetic diversity of Cryptosporidium hominis and Cryptosporidium parvum may therefore be an independent and complementary measure for quantifying disease incidence, for which only a moderate number of stool samples from each nation are sufficient data input. C1 [Takumi, Katsuhisa; van der Giessen, Joke; Sprong, Hein] Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, NL-3720 Bilthoven, Netherlands. [Caccio, Simone M.] Ist Super Sanita, Dept Infect Parasit & Immunomediated Dis, I-00161 Rome, Italy. [Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Takumi, K (reprint author), Natl Inst Publ Hlth & Environm RIVM, Ctr Infect Dis Control, POB 1, NL-3720 Bilthoven, Netherlands. EM katsuhisa.takumi@rivm.nl RI Caccio, Simone/K-9278-2015; Xiao, Lihua/B-1704-2013; OI Xiao, Lihua/0000-0001-8532-2727; Sprong, Hein/0000-0002-0218-4320 NR 19 TC 1 Z9 1 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-3305 J9 PARASITE VECTOR JI Parasites Vectors PD JUN 6 PY 2015 VL 8 AR 308 DI 10.1186/s13071-015-0921-3 PG 7 WC Parasitology SC Parasitology GA CK6NI UT WOS:000356344400001 PM 26048280 ER PT J AU Sumner, SA Mercy, JA Saul, J Motsa-Nzuza, N Kwesigabo, G Buluma, R Marcelin, LH Lina, H Shawa, M Moloney-Kitts, M Kilbane, T Sommarin, C Ligiero, DP Brookmeyer, K Chiang, L Lea, V Lee, J Kress, H Hillis, SD AF Sumner, Steven A. Mercy, James A. Saul, Janet Motsa-Nzuza, Nozipho Kwesigabo, Gideon Buluma, Robert Marcelin, Louis H. Lina, Hang Shawa, Mary Moloney-Kitts, Michele Kilbane, Theresa Sommarin, Clara Ligiero, Daniela P. Brookmeyer, Kathryn Chiang, Laura Lea, Veronica Lee, Juliette Kress, Howard Hillis, Susan D. TI Prevalence of Sexual Violence Against Children and Use of Social Services Seven Countries, 2007-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID ABUSE; PERPETRATION; PREVENTION; RISK C1 [Sumner, Steven A.; Mercy, James A.; Chiang, Laura; Lea, Veronica; Lee, Juliette; Kress, Howard; Hillis, Susan D.] CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Sumner, Steven A.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Saul, Janet] CDC, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. [Motsa-Nzuza, Nozipho] Minist Hlth, Zurich, Switzerland. [Kwesigabo, Gideon] Muhimbili Univ Hlth & Allied Sci, Sch Publ Hlth & Social Sci, Dar Es Salaam, Tanzania. [Buluma, Robert] Kenya Natl Bur Stat, Nairobi, Kenya. [Marcelin, Louis H.] Interuniv Inst Res & Dev, Port Au Prince, Haiti. [Lina, Hang] Cambodia Minist Planning, Natl Inst Stat, Phnom Penh, Cambodia. [Shawa, Mary] Malawi Minist Gender Children & Social Welf, Lilongwe, Malawi. [Moloney-Kitts, Michele] Together Girls, Washington, DC USA. [Kilbane, Theresa; Sommarin, Clara] United Nations Childrens Fund, Child Protect Programme Div, New York, NY USA. [Ligiero, Daniela P.] US Dept State, Off Global AIDS Coordinator, Houston, TX USA. [Brookmeyer, Kathryn] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div STD Prevent, Atlanta, GA USA. RP Sumner, SA (reprint author), CDC, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. EM SSumner@cdc.gov NR 10 TC 10 Z9 10 U1 1 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 5 PY 2015 VL 64 IS 21 BP 565 EP 569 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0NC UT WOS:000356638400001 PM 26042646 ER PT J AU Scott, KC Taylor, EM Mamo, B Herr, ND Cronkright, PJ Yun, K Altshuler, M Shetty, S AF Scott, Kevin C. Taylor, Eboni M. Mamo, Blain Herr, Nathaniel D. Cronkright, Peter J. Yun, Katherine Altshuler, Marc Shetty, Sharmila TI Hepatitis B Screening and Prevalence Among Resettled Refugees - United States, 2006-2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID IRAQI REFUGEES; HEALTH C1 [Scott, Kevin C.; Altshuler, Marc] Thomas Jefferson Univ, Philadelphia, PA 19107 USA. [Taylor, Eboni M.; Shetty, Sharmila] CDC, Div Global Migrat & Quarantine, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Mamo, Blain] Minnesota Dept Hlth, St Paul, MN USA. [Herr, Nathaniel D.] Univ Minnesota, Minneapolis, MN USA. [Cronkright, Peter J.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Yun, Katherine] Childrens Hosp Philadelphia, Philadelphia, PA USA. RP Scott, KC (reprint author), Thomas Jefferson Univ, Philadelphia, PA 19107 USA. EM Kevin.Scott@jefferson.edu NR 10 TC 2 Z9 2 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 5 PY 2015 VL 64 IS 21 BP 570 EP 573 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0NC UT WOS:000356638400002 PM 26042647 ER PT J AU Qin, J Theis, KA Barbour, KE Helmick, CG Baker, NA Brady, TJ AF Qin, Jin Theis, Kristina A. Barbour, Karnil E. Helmick, Charles G. Baker, Nancy A. Brady, Teresa J. TI Impact of Arthritis and Multiple Chronic Conditions on Selected Life Domains - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DISABILITY; PREVALENCE; ADULTS C1 [Qin, Jin; Theis, Kristina A.; Barbour, Karnil E.; Helmick, Charles G.; Baker, Nancy A.; Brady, Teresa J.] CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Qin, Jin] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. RP Qin, J (reprint author), CDC, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM jqin@cdc.gov NR 10 TC 6 Z9 6 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 5 PY 2015 VL 64 IS 21 BP 578 EP 582 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0NC UT WOS:000356638400004 PM 26042649 ER PT J AU Appiah, GD Blanton, L D'Mello, T Kniss, K Smith, S Mustaquim, D Steffens, C Dhara, R Cohen, J Chaves, SS Bresee, J Wallis, T Xu, XY Abd Elal, AI Gubareva, L Wentworth, DE Katz, J Jernigan, D Brammer, L AF Appiah, Grace D. Blanton, Lenee D'Mello, Tiffany Kniss, Krista Smith, Sophie Mustaquim, Desiree Steffens, Craig Dhara, Rosaline Cohen, Jessica Chaves, Sandra S. Bresee, Joseph Wallis, Teresa Xu, Xiyan Abd Elal, Anwar Isa Gubareva, Larisa Wentworth, David E. Katz, Jacqueline Jernigan, Daniel Brammer, Lynnette TI Influenza Activity - United States, 2014-15 Season and Composition of the 2015-16 Influenza Vaccine SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Appiah, Grace D.; Blanton, Lenee; D'Mello, Tiffany; Kniss, Krista; Smith, Sophie; Mustaquim, Desiree; Steffens, Craig; Dhara, Rosaline; Cohen, Jessica; Chaves, Sandra S.; Bresee, Joseph; Wallis, Teresa; Xu, Xiyan; Abd Elal, Anwar Isa; Gubareva, Larisa; Wentworth, David E.; Katz, Jacqueline; Jernigan, Daniel; Brammer, Lynnette] CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Appiah, GD (reprint author), CDC, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM ydg3@cdc.gov OI Wentworth, David/0000-0002-5190-980X NR 9 TC 30 Z9 30 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 5 PY 2015 VL 64 IS 21 BP 583 EP 590 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0NC UT WOS:000356638400005 PM 26042650 ER PT J AU Guy, GP Thomas, CC Thompson, T Watson, M Massetti, GM Richardson, LC AF Guy, Gery P., Jr. Thomas, Cheryll C. Thompson, Trevor Watson, Meg Massetti, Greta M. Richardson, Lisa C. TI Vital Signs: Melanoma Incidence and Mortality Trends and Projections - United States, 1982-2030 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CUTANEOUS MELANOMA; SKIN-CANCER; ADULTS; METAANALYSIS; ASSOCIATION; BEHAVIORS; SUNBURN; COSTS; US AB Background: Melanoma incidence rates have continued to increase in the United States, and risk behaviors remain high. Melanoma is responsible for the most skin cancer deaths, with about 9,000 persons dying from it each year. Methods: CDC analyzed current (2011) melanoma incidence and mortality data, and projected melanoma incidence, mortality, and the cost of treating newly diagnosed melanomas through 2030. Finally, CDC estimated the potential melanoma cases and costs averted through 2030 if a comprehensive skin cancer prevention program was implemented in the United States. Results: In 2011, the melanoma incidence rate was 19.7 per 100,000, and the death rate was 2.7 per 100,000. Incidence rates are projected to increase for white males and females through 2019. Death rates are projected to remain stable. The annual cost of treating newly diagnosed melanomas was estimated to increase from $457 million in 2011 to $1.6 billion in 2030. Implementation of a comprehensive skin cancer prevention program was estimated to avert 230,000 melanoma cases and $2.7 billion in initial year treatment costs from 2020 through 2030. Conclusions: If additional prevention efforts are not undertaken, the number of melanoma cases is projected to increase over the next 15 years, with accompanying increases in health care costs. Much of this morbidity, mortality, and health care cost can be prevented. Implications for Public Health Practice: Substantial reductions in melanoma incidence, mortality, and cost can be achieved if evidence-based comprehensive interventions that reduce ultraviolet (UV) radiation exposure and increase sun protection are fully implemented and sustained. C1 [Guy, Gery P., Jr.; Thomas, Cheryll C.; Thompson, Trevor; Watson, Meg; Massetti, Greta M.; Richardson, Lisa C.] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. RP Guy, GP (reprint author), CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA. EM gguy@cdc.gov NR 22 TC 28 Z9 28 U1 5 U2 13 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 5 PY 2015 VL 64 IS 21 BP 591 EP 596 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0NC UT WOS:000356638400006 PM 26042651 ER PT J AU Bowen, A Eikmeier, D Talley, P Siston, A Smith, S Hurd, J Smith, K Leano, F Bicknese, A Norton, JC Campbell, D AF Bowen, Anna Eikmeier, Dana Talley, Pamela Siston, Alicia Smith, Shamika Hurd, Jacqueline Smith, Kirk Leano, Fe Bicknese, Amelia Norton, J. Corbin Campbell, Davina TI Outbreaks of Shigella sonnei Infection with Decreased Susceptibility to Azithromycin Among Men Who Have Sex with Men - Chicago and Metropolitan Minneapolis-St. Paul, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; CANADA C1 [Bowen, Anna; Hurd, Jacqueline; Bicknese, Amelia; Norton, J. Corbin; Campbell, Davina] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. [Eikmeier, Dana; Talley, Pamela; Smith, Kirk; Leano, Fe] Minnesota Dept Hlth, Minneapolis, MN 55414 USA. [Talley, Pamela] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Siston, Alicia; Smith, Shamika] Chicago Dept Publ Hlth, Chicago, IL USA. RP Bowen, A (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging Zoonot & Infect Dis, Atlanta, GA 30333 USA. EM abowen@cdc.gov NR 10 TC 6 Z9 6 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD JUN 5 PY 2015 VL 64 IS 21 BP 597 EP 598 PG 2 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0NC UT WOS:000356638400007 PM 26042652 ER PT J AU Eng, JLV Chan, A Ablio, AP Wolkon, A de Leon, GP Gimnig, J Morgan, J AF Eng, Jodi L. Vanden Chan, Adeline Ablio, Ana Paula Wolkon, Adam de Leon, Gabriel Ponce Gimnig, John Morgan, Juliette TI Bed Net Durability Assessments: Exploring a Composite Measure of Net Damage SO PLOS ONE LA English DT Article ID INSECTICIDE-TREATED NETS; CULEX-QUINQUEFASCIATUS MOSQUITOS; PYRETHROID-RESISTANT MOSQUITOS; EXPERIMENTAL HUT EVALUATION; PHYSICAL CONDITION; ANOPHELES-GAMBIAE; WESTERN KENYA; MALARIA VECTORS; OLYSET(R) NETS; HOUSEHOLD USE AB Background The durability of Long Lasting Insecticidal Nets (LLINs) in field conditions is of great importance for malaria prevention and control efforts; however, the physical integrity of the net fabric is not well understood making it challenging to determine overall effectiveness of nets as they age. The 2011 World Health Organization Pesticide Evaluation Scheme (WHOPES) guidelines provide a simple, standardized method using a proportional hole index (PHI) for assessing net damage with the intent to provide national malaria control programs with guidelines to assess the useful life of LLINS and estimate the rate of replacement. Methods We evaluated the utility of the PHI measure using 409 LLINs collected over three years in Nampula Province, Mozambique following a mass distribution campaign in 2008. For each LLIN the diameter and distance from the bottom of the net were recorded for every hole. Holes were classified into four size categories and a PHI was calculated following WHOPES guidelines. We investigate how the size, shape, and location of holes influence the PHI. The areas of the WHOPES defined categories were compared to circular and elliptical areas based on approximate shape and actual measured axes of each hole and the PHI was compared to cumulative damaged surface area of the LLIN. Results The damaged area of small, medium, large, and extra-large holes was overestimated using the WHOPES categories compared to elliptical areas using the actual measured axes. Similar results were found when comparing to circular areas except for extra-large holes which were underestimated. (Wilcoxon signed rank test of differences p < 0.0001 for all sizes). Approximating holes as circular overestimated hole surface area by 1.5 to 2 times or more. There was a significant difference in the mean number of holes < 0.5 cm by brand and there were more holes of all sizes on the bottom of nets than the top. For a range of hypothetical PHI thresholds used to designate a "failed LLIN", roughly 75 to 80% of failed LLINs were detected by considering large and extra-large holes alone, but sensitivity varied by brand. Conclusions Future studies may refine the PHI to better approximate overall damaged surface area. Furthermore, research is needed to identify whether or not appropriate PHI thresholds can be used to deem a net no longer protective. Once a cutoff is selected, simpler methods of determining the effective lifespan of LLINs can help guide replacement strategies for malaria control programs. C1 [Eng, Jodi L. Vanden; Wolkon, Adam; de Leon, Gabriel Ponce; Morgan, Juliette] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30333 USA. [Chan, Adeline; Gimnig, John] Ctr Dis Control & Prevent, Entomol Branch, Div Parasit Dis & Malaria, Atlanta, GA USA. [Ablio, Ana Paula] Minist Saude, Inst Nacl Saude, Maputo, Mozambique. [de Leon, Gabriel Ponce; Morgan, Juliette] Ctr Dis Control & Prevent, US Presidents Malaria Initiat, Atlanta, GA USA. RP Eng, JLV (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30333 USA. EM JEV8@cdc.gov FU U.S. President's Malaria Initiative through the U.S. Agency for International Development FX This study was funded by the U.S. President's Malaria Initiative through the U.S. Agency for International Development. Two co-authors are affiliated with the President's Malaria Initiative. The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 54 TC 1 Z9 1 U1 2 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 5 PY 2015 VL 10 IS 6 AR e0128499 DI 10.1371/journal.pone.0128499 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ7CR UT WOS:000355652200071 ER PT J AU Saxton-Shaw, KD Ledermann, JP Kenney, JL Berl, E Graham, AC Russo, JM Powers, AM Mutebi, JP AF Saxton-Shaw, Kali D. Ledermann, Jeremy P. Kenney, Joan L. Berl, Erica Graham, Alan C. Russo, Joel M. Powers, Ann M. Mutebi, John-Paul TI The First Outbreak of Eastern Equine Encephalitis in Vermont: Outbreak Description and Phylogenetic Relationships of the Virus Isolate SO PLOS ONE LA English DT Article ID ENCEPHALOMYELITIS VIRUS; ARBOVIRUS ISOLATIONS; MOSQUITOS DIPTERA; CULICIDAE; STRAINS AB The first known outbreak of eastern equine encephalitis (EEE) in Vermont occurred on an emu farm in Rutland County in 2011. The first isolation of EEE virus (EEEV) in Vermont (VT11) was during this outbreak. Phylogenetic analysis revealed that VT11 was most closely related to FL01, a strain from Florida isolated in 2001, which is both geographically and temporally distinct from VT11. EEEV RNA was not detected in any of the 3,905 mosquito specimens tested, and the specific vectors associated with this outbreak are undetermined. C1 [Saxton-Shaw, Kali D.; Ledermann, Jeremy P.; Kenney, Joan L.; Powers, Ann M.; Mutebi, John-Paul] Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80521 USA. [Berl, Erica] Vermont Dept Hlth, Burlington, VT 05402 USA. [Graham, Alan C.] Vermont Agcy Agr Food & Markets, Waterbury, VT USA. [Russo, Joel M.] USDA, APHIS VS, Montpelier, VT USA. RP Mutebi, JP (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Ft Collins, CO 80521 USA. EM grv0@cdc.gov NR 32 TC 3 Z9 3 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 4 PY 2015 VL 10 IS 6 AR e0128712 DI 10.1371/journal.pone.0128712 PG 9 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ7TC UT WOS:000355701600062 PM 26043136 ER PT J AU Dinh, TH Delaney, KP Goga, A Jackson, D Lombard, C Woldesenbet, S Mogashoa, M Pillay, Y Shaffer, N AF Thu-Ha Dinh Delaney, Kevin P. Goga, Ameena Jackson, Debra Lombard, Carl Woldesenbet, Selamawit Mogashoa, Mary Pillay, Yogan Shaffer, Nathan TI Impact of Maternal HIV Seroconversion during Pregnancy on Early Mother to Child Transmission of HIV (MTCT) Measured at 4-8 Weeks Postpartum in South Africa 2011-2012: A National Population-Based Evaluation (vol 10, e0125525, 2015) SO PLOS ONE LA English DT Correction C1 [Thu-Ha Dinh] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30329 USA. [Thu-Ha Dinh] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Goga, Ameena] MRC, Pretoria, South Africa. [Goga, Ameena] Univ Pretoria, Dept Paediat & Child Hlth, Kalafong Hosp, ZA-0002 Pretoria, South Africa. [Jackson, Debra] Univ Western Cape, Sch Publ Hlth, ZA-7535 Bellville, South Africa. [Jackson, Debra] United Nations Childrens Fund, New York, NY USA. [Lombard, Carl; Woldesenbet, Selamawit] MRC, Cape Town, South Africa. [Mogashoa, Mary] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Pretoria, South Africa. [Pillay, Yogan] Natl Dept Hlth, Pretoria, South Africa. [Shaffer, Nathan] WHO, CH-1211 Geneva, Switzerland. RP Dinh, TH (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30329 USA. NR 1 TC 0 Z9 0 U1 0 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 4 PY 2015 VL 10 IS 6 AR e0130321 DI 10.1371/journal.pone.0130321 PG 1 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ7TC UT WOS:000355701600111 PM 26043225 ER PT J AU Nowak, GJ Sheedy, K Bursey, K Smith, TM Basket, M AF Nowak, Glen J. Sheedy, Kristine Bursey, Kelli Smith, Teresa M. Basket, Michelle TI Promoting influenza vaccination: Insights from a qualitative meta-analysis of 14 years of influenza-related communications research by US Centers for Disease Control and Prevention (CDC) SO VACCINE LA English DT Review DE Influenza; Health communication; Influenza vaccination; Influenza knowledge, Attitudes and beliefs (KABs); Communication research; Vaccine promotion ID SEASONAL INFLUENZA; UNITED-STATES; PARENTS; STRATEGY; RATES AB Introduction: A primary mission of the U.S. Centers for Disease Control and Prevention's (CDC) is promoting immunization against seasonal influenza. As with most education efforts, CDC's influenza-related communications are often informed by formative research. Methods:. A qualitative meta-analysis of 29 unpublished, primarily qualitative CDC-sponsored studies related to flu and flu vaccination knowledge, attitudes and beliefs (KABs). The studies, undertaken between 2000 and 2013, involved focus groups, in-depth interviews, message testing and surveys. Some involved health care professionals, while others involved members of the public, including sub-populations at risk for severe illness. Findings: The themes that emerged suggested progress in terms of KABs related to influenza and influenza vaccination, but also the persistence of many barriers to vaccine acceptance. With respect to the public, recurring themes included limited understanding of influenza and immunization recommendations, indications of greater sub-group recognition of the value of flu vaccination, continued resistance to vaccination among many, and overestimation of the effectiveness of non-vaccine measures. Seven cognitive facilitators of vaccination were identified in the studies along with six cognitive barriers. For health care providers, the analysis suggests greater knowledge and more favorable beliefs, but many misperceptions persist and are similar to those held by the public. KABs often differed by type or category of health care provider. Conclusions: The themes identified in this qualitative analysis illustrate the difficulty in changing KABs related to influenza and influenza vaccine, particularly on the scope and scale needed to greatly improve uptake. Even with an influenza pandemic and more vaccine options available, public and some health care provider perceptions and beliefs are difficult and slow to change. This meta-analysis does, however, provide important insights from previously unpublished information that can help those who are promoting influenza vaccination to health care providers, the general public and specific populations within the general population. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Nowak, Glen J.] Univ Georgia, Grady Coll Journalism & Mass Commun, Ctr Hlth & Risk Commun, Athens, GA 30602 USA. [Sheedy, Kristine; Smith, Teresa M.; Basket, Michelle] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Bursey, Kelli] Oakridge Inst Sci & Educ, Oak Ridge, TN 37831 USA. RP Nowak, GJ (reprint author), Univ Georgia, Grady Coll Journalism & Mass Commun, Ctr Hlth & Risk Commun, 120 Hooper St, Athens, GA 30602 USA. EM gnowak@uga.edu FU Health Communication Science Office, National Center for Influenza and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, Atlanta, GA; ORISE Inter Agency [13FED1310076] FX Funding for this study was provided by the Health Communication Science Office, National Center for Influenza and Respiratory Diseases, U.S. Centers for Disease Control and Prevention, Atlanta, GA. ORISE Inter Agency Agreement 13FED1310076 supported data analysis and report writing. NR 33 TC 10 Z9 10 U1 4 U2 24 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUN 4 PY 2015 VL 33 IS 24 BP 2741 EP 2756 DI 10.1016/j.vaccine.2015.04.064 PG 16 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CJ7UO UT WOS:000355705700005 PM 25936726 ER PT J AU Saleem, AF Mach, O Quadri, F Khan, A Bhatti, Z Rehman, NU Zaidi, S Weldon, WC Oberste, SM Salama, M Sutter, RW Zaidi, AKM AF Saleem, Ali Faisal Mach, Ondrej Quadri, Farheen Khan, Asia Bhatti, Zaid Rehman, Najeeb Ur Zaidi, Sohail Weldon, William C. Oberste, Steven M. Salama, Maha Sutter, Roland W. Zaidi, Anita K. M. TI Immunogenicity of poliovirus vaccines in chronically malnourished infants: A randomized controlled trial in Pakistan SO VACCINE LA English DT Article DE Chronic malnutrition; Polio vaccine immunity; Seroconversion; Polio vaccine trial ID EFFICACY; CHILDREN; ERADICATION; IMMUNITY; INDIA AB Reaching high population immunity against polioviruses (PV) is essential to achieving global polio eradication. Efficacy of oral poliovirus vaccine (OPV) varies and is lower among children living in tropical areas with impoverished environments. Malnutrition found as a risk factor for lower serological protection against PV. We compared whether inactivated polio vaccine (IPV) can be used to rapidly close the immunity gap among chronically malnourished (stunted) infants in Pakistan who will not be eligible for the 14 week IPV dose in routine EPI schedule. A phase 3, multicenter 4-arm randomized controlled trial conducted at five Primary Health Care (PHC) centers in Karachi, Pakistan. Infants, 9-12 months were stratified by length for age Z score into chronically malnourished and normally nourished. Infants were randomized to receive one dose of either bivalent OPV (bOPV) alone or bOPV + IPV. Baseline seroprevalence of PV antibodies and serum immune response to study vaccine dose were assessed by neutralization assay. Vaccine PV shedding in stool was evaluated 7 days after a bOPV challenge dose. Sera and stool were analyzed from 852/928(92%) enrolled children. At baseline, the seroprevalence was 85.6% (n=386), 73.6% (n = 332), and 70.7% (n=319) in malnourished children against PV types 1,2 and 3 respectively; and 94.1% (n = 448), 87.0% (n=441) and 83.6% (n=397) in the normally nourished group (p < 0.05). Children had previously received 9-10 doses of bOPV (80%) or tOPV (20%). One dose of IPV + bOPV given to malnourished children increased their serological protection (PVI, n = 201, 97.6%; PV2, n=198, 96.1% and PV3, n = 189, 91.7%) to parity with normally nourished children who had not received IPV (p = <0.001). Seroconversion and boosting for all three serotypes was significantly more frequent in children who received IPV + bOPV than in those with bOPV only (p <0.001) in both strata. Shedding of polioviruses in stool did not differ between study groups and ranged from 2.4% (n=5) to 7.1% (n=15). In malnourished children the shedding was reduced after bOPV + IPV compared to bOPV only. Chronically malnourished infants were more likely to be unprotected against polioviruses than normal infants. bOPV + IPV helped close the immunity gap better than bOPV alone. (C) 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). C1 [Saleem, Ali Faisal; Quadri, Farheen; Khan, Asia; Bhatti, Zaid; Rehman, Najeeb Ur; Zaidi, Anita K. M.] Aga Khan Univ, Dept Pediat & Child Hlth, Karachi 74800, Pakistan. [Mach, Ondrej; Sutter, Roland W.] WHO, Polio Eradicat Dept, CH-1211 Geneva, Switzerland. [Zaidi, Sohail] Natl Inst Hlth, Dept Virol, Islamabad, Pakistan. [Oberste, Steven M.] Ctr Dis Control & Prevent, Polio & Picornavirus Lab Branch, Atlanta, GA USA. [Weldon, William C.] Ctr Dis Control & Prevent, Polio & Picornavirus Lab Branch, Populat Immun Lab, Atlanta, GA USA. [Salama, Maha] VACSERA Holding Co, Cairo, Egypt. RP Zaidi, AKM (reprint author), Aga Khan Univ, Dept Pediat & Child Hlth, Stadium Rd,POB 3500, Karachi 74800, Pakistan. EM anita.zaidi@aku.edu FU World Health Organization FX The World Health Organization. NR 22 TC 5 Z9 5 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUN 4 PY 2015 VL 33 IS 24 BP 2757 EP 2763 DI 10.1016/j.vaccine.2015.04.055 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CJ7UO UT WOS:000355705700006 PM 25917673 ER PT J AU Collier, MG Drobeniuc, J Cuevas-Mota, J Garfein, RS Kamili, S Teshale, EH AF Collier, Melissa G. Drobeniuc, Jan Cuevas-Mota, Jazmine Garfein, Richard S. Kamili, Saleem Teshale, Eyasu H. TI Hepatitis A and B among young persons who inject drugs-Vaccination, past, and present infection SO VACCINE LA English DT Article DE Hepatitis C virus; Persons who inject drugs; Self-report ID HCV INFECTION; SAN-DIEGO; USERS; PREVALENCE; VIRUSES; ABUSERS; HEALTH AB Background: Our study aims were to assess hepatitis A virus (HAV) and hepatitis B virus (HBV) susceptibility and infection among young persons who inject drugs (PWID) who may have been vaccinated as children and to evaluate self-report of HAV and HBV vaccination. Methods: We recruited PWID aged 18-40 years-old in San Diego during 2009 and 2010 and collected demographic, socioeconomic, health, and behavioral factors. Participants were asked if they had been vaccinated against HAV and HBV, and serum samples were collected for HAV and HBV serologic testing. Results: Of 519 participants, 365 (72%) were male, 252 (49%) were white non-Hispanic, 38 (7%) were Black non-Hispanic, 138 (27%) were White Hispanic, and 22 (4%) were born outside the U.S. Of the total participants, 245 (47%) had surface hepatitis B antibody (anti-HBs) titers <10 mIU/ml (i.e., HBV susceptible) and 325 (63%) had no detectable HAV antibodies (HAV susceptible). Hepatitis B surface antigen was detected in 7 (I%) of total participants; and 135 (26%) were anti-HCV-antibody positive. Compared to serologic findings, self-report of HBV and HAV vaccination was 71% and 41% sensitive, and 58% and 73% specific, respectively. Conclusion: HAV and HBV antibodies in half or more of this young PWID population did not have levels indicative of protection, and about a quarter had HCV infection, putting them at risk for complications resulting from co-infection with HAV or HBV. Programs serving this population should vaccinate PWIDs against HAV and HBV and not rely on self-report of vaccination. Published by Elsevier Ltd. C1 [Collier, Melissa G.; Drobeniuc, Jan; Kamili, Saleem; Teshale, Eyasu H.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Cuevas-Mota, Jazmine; Garfein, Richard S.] Univ Calif San Diego, Sch Med, Div Global Publ Hlth, San Diego, CA 92103 USA. RP Collier, MG (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM mgcollier@cdc.gov FU Centers for Disease Control and Prevention [200 2007 21016] FX This study was funded by the Centers for Disease Control and Prevention grant number 200 2007 21016. NR 22 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUN 4 PY 2015 VL 33 IS 24 BP 2808 EP 2812 DI 10.1016/j.vaccine.2015.04.019 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CJ7UO UT WOS:000355705700013 PM 25889161 ER PT J AU Broderick, MP Oberste, MS Moore, D Romero-Steiner, S Hansen, CJ Faix, DJ AF Broderick, Michael P. Oberste, M. Steven Moore, Deborah Romero-Steiner, Sandra Hansen, Christian J. Faix, Dennis J. TI Effect of multiple, simultaneous vaccines on polio seroresponse and associated health outcomes SO VACCINE LA English DT Article DE Polio vaccine; IPV; Simultaneous vaccination; Multiple vaccinations; Td; Tdap ID TETANUS-ACELLULAR PERTUSSIS; RANDOMIZED CONTROLLED-TRIAL; T-CELL RESPONSES; GULF-WAR; CONJUGATE VACCINE; CHILDHOOD ASTHMA; ATOPIC DISEASE; RISK-FACTORS; B VACCINE; DIPHTHERIA AB Background: Administration of multiple simultaneous vaccines to infants, children, and military recruits is not uncommon. However, little research exists to examine associated serological and health effects, especially in adults. Method: We retrospectively examined 416 paired serum specimens from U.S. military subjects who had received the inactivated polio vaccine (IPV) alone or in combination with either 1 other vaccine (<3 group) or 4 other vaccines (>4 group). Each of the 2 groups was subdivided into 2 subgroups in which Tdap was present or absent. Results: The >4 group was associated with a higher proportion of polio seroconversions than the <3 group (95% vs. 58%, respectively, p<0.01). Analysis of the <3 subgroup that excluded Tdap vs. the >4 subgroup that excluded Tdap showed no difference between them (p>0.1). However, the >4 subgroup that included Tdap had significantly more seroconversions than either the <3 subgroup that excluded Tdap or the >4 subgroup that excluded Tdap (p<0.01). Overall, at least 98% of subjects were at or above the putative level of seroprotection both pre- and post-vaccination, yet at least 81% of subjects seroconverted. In an analysis of 400 of the subjects in which clinic in- and outpatient encounters were counted over the course of 1 year following vaccinations, there was no significant difference between the 2 groups (p>0.1). Conclusion: A combination of >4 vaccines including IPV appeared to have an immunopotentiation effect on polio seroconversion, and Tdap in particular was a strong candidate for an important role. The dose of IPV we studied in our subjects, who already had a high level of seroprotection, acted as a booster. In addition, there appear to be no negative health consequences from receiving few versus more multiple simultaneous vaccinations. Published by Elsevier Ltd. C1 [Broderick, Michael P.; Hansen, Christian J.; Faix, Dennis J.] Naval Hlth Res Ctr, Operat Infect Dis Dept, San Diego, CA 92106 USA. [Oberste, M. Steven; Moore, Deborah; Romero-Steiner, Sandra] Ctr Dis Control & Prevent, PPLB DVD NCIRD, Atlanta, GA 30333 USA. RP Broderick, MP (reprint author), Naval Hlth Res Ctr, Operat Infect Dis Dept, McClelland & Patterson Rd,Gate 4 Bldg 315, San Diego, CA 92106 USA. EM michael.broderick@med.navy.mil OI Romero-Steiner, Sandra/0000-0003-4128-7768 FU Military Vaccine Agency (MILVAX); Bureau of Medicine and Surgery [60501] FX This study was funded by the Military Vaccine Agency (MILVAX) and by the Bureau of Medicine and Surgery under work unit number 60501. The views expressed in this work are those of the authors and do not reflect the official policy of the Department of the Navy, Department of Defense, Centers for Disease Control and Prevention, or the U.S. Government. Approved for public release; distribution is unlimited. This research has been conducted in compliance with all applicable federal regulations governing the protection of human subjects in research (protocol NHRC.2011.0015). We thank Jennifer Radin for consultation on the statistical analyses. NR 35 TC 2 Z9 2 U1 1 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUN 4 PY 2015 VL 33 IS 24 BP 2842 EP 2848 DI 10.1016/j.vaccine.2014.07.088 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CJ7UO UT WOS:000355705700017 PM 25131729 ER PT J AU Pan, Q Pais, R Ohandjo, A He, C He, Q Omosun, Y Igietseme, JU Eko, FO AF Pan, Qing Pais, Roshan Ohandjo, Adaugo He, Cheng He, Qing Omosun, Yusuf Igietseme, J. U. Eko, F. O. TI Comparative evaluation of the protective efficacy of two formulations of a recombinant Chlamydia abortus subunit candidate vaccine in a mouse model (vol 33, pg 1865, 2015) SO VACCINE LA English DT Correction C1 [Pan, Qing; Pais, Roshan; Ohandjo, Adaugo; He, Qing; Omosun, Yusuf; Eko, F. O.] Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. [He, Cheng] China Agr Univ, Coll Vet Med, Beijing 100094, Peoples R China. [Igietseme, J. U.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Eko, FO (reprint author), Morehouse Sch Med, Dept Microbiol Biochem & Immunol, Atlanta, GA 30310 USA. EM feko@msm.edu NR 1 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD JUN 4 PY 2015 VL 33 IS 24 BP 2849 EP 2849 DI 10.1016/j.vaccine.2015.04.075 PG 1 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CJ7UO UT WOS:000355705700018 ER PT J AU Perez, JW Pantazides, BG Watson, CM Thomas, JD Blake, TA Johnson, RC AF Perez, Jonas W. Pantazides, Brooke G. Watson, Caroline M. Thomas, Jerry D. Blake, Thomas A. Johnson, Rudolph C. TI Enhanced Stability of Blood Matrices Using a Dried Sample Spot Assay To Measure Human Butyrylcholinesterase Activity and Nerve Agent Adducts SO ANALYTICAL CHEMISTRY LA English DT Article ID ACETYLCHOLINESTERASE ACTIVITY; QUANTITATIVE BIOANALYSIS; QUALITY-CONTROL; FILTER-PAPER; WHOLE-BLOOD; CHOLINESTERASES; REACTIVATION; HEMATOCRIT; INFANTS; BIAS AB Dried matrix spots are safer to handle and easier to store than wet blood products, but factors such as intraspot variability and unknown sample volumes have limited their appeal as a sampling format for quantitative analyses. In this work, we introduce a dried spot activity assay for quantifying butyrylcholinesterase (BChE) specific activity which is BChE activity normalized to the total protein content in a sample spot. The method was demonstrated with blood, serum, and plasma spotted on specimen collection devices (cards) which were extracted to measure total protein and BChE activity using a modified Ellman assay. Activity recovered from dried spots was similar to 80% of the initial spotted activity for blood and >90% for plasma and serum. Measuring total protein in the sample and calculating specific activity substantially improved quantification and reduced intraspot variability. Analyte stability of nerve agent adducts was also evaluated, and the results obtained via BChE-specific activity measurements were confirmed by quantification of BChE adducts using a previously established LC-MS/MS method. The spotted samples were up to 10 times more resistant to degradation compared to unspotted control samples when measuring BChE inhibition by the nerve agents sarin and VX. Using this method, both BChE activity and adducts can be accurately measured from a dried sample spot. This use of a dried sample spot with normalization to total protein is robust, demonstrates decreased intraspot variability without the need to control for initial sample volume, and enhances analyte stability. C1 [Perez, Jonas W.; Pantazides, Brooke G.; Thomas, Jerry D.; Blake, Thomas A.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30341 USA. [Watson, Caroline M.] Ctr Dis Control & Prevent, Oak Ridge Inst Sci & Educ Fellowship, Atlanta, GA 30341 USA. RP Perez, JW (reprint author), Ctr Dis Control & Prevent, Div Lab Sci, Natl Ctr Environm Hlth, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM xfx0@cdc.gov OI Blake, Thomas/0000-0001-8536-9998 FU Centers for Disease Control and Prevention; Defense Threat and Reduction Agency [11-005-12430]; Oak Ridge Institute for Science and Education FX This work was supported by the Centers for Disease Control and Prevention, the Defense Threat and Reduction Agency (11-005-12430), and the Oak Ridge Institute for Science and Education. The findings and conclusions in this article are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. Use of trade names is for identification only and does not imply endorsement by the Centers for Disease Control and Prevention, the Public Health Service, or the U.S. Department of Health and Human Services. NR 29 TC 2 Z9 2 U1 8 U2 20 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 0003-2700 EI 1520-6882 J9 ANAL CHEM JI Anal. Chem. PD JUN 2 PY 2015 VL 87 IS 11 BP 5723 EP 5729 DI 10.1021/acs.analchem.5b00893 PG 7 WC Chemistry, Analytical SC Chemistry GA CJ8UR UT WOS:000355779500040 PM 25955132 ER PT J AU Ali, A Kazi, AM Cortese, MM Fleming, JA Moon, S Parashar, UD Jiang, BM McNeal, MM Steele, D Bhutta, Z Zaidi, AKM AF Ali, Asad Kazi, Abdul Momin Cortese, Margaret M. Fleming, Jessica A. Moon, SungSil Parashar, Umesh D. Jiang, Baoming McNeal, Monica M. Steele, Duncan Bhutta, Zulfiqar Zaidi, Anita K. M. TI Impact of Withholding Breastfeeding at the Time of Vaccination on the Immunogenicity of Oral Rotavirus Vaccine-A Randomized Trial SO PLOS ONE LA English DT Article ID MILK; LIVE; COUNTRIES; INFANTS AB Background Breast milk contains anti-rotavirus IgA antibodies and other innate immune factors that inhibit rotavirus replication in vitro. These factors could diminish the immunogenicity of oral rotavirus vaccines, particularly if breastfeeding occurs close to the time of vaccine administration. Methods Between April 2011 and November 2012, we conducted an open label, randomized trial to compare the immunogenicity of Rotarix (RV1) in infants whose breastfeeding was withheld one hour before through one hour after vaccination with that in infants breastfed at the time of vaccination. The trial was conducted in the peri-urban area of Ibrahim Hyderi in Karachi, Pakistan. Both groups received three doses of RV1 at 6, 10 and 14 weeks of age. Seroconversion (anti-rotavirus IgA antibodies >= 20 U/mL in subjects seronegative at 6 weeks of age) following three vaccine doses (6, 10 and 14 weeks) was determined at 18 weeks of age (primary objective) and seroconversion following two doses (6 and 10 weeks) was determined at 14 weeks of age (secondary objective). Results Four hundred eligible infants were randomly assigned in a 1: 1 ratio between the withholding breastfeeding and immediate breastfeeding arms. Overall, 353 (88.3%) infants completed the study according to protocol; 181 in the withholding breastfeeding group and 172 in the immediate breastfeeding group. After three RV1 doses, anti-rotavirus IgA antibody seroconversion was 28.2%(95% CI: 22.1; 35.1) in the withholding arm and 37.8%(95% CI: 30.9; 45.2) in the immediate breastfeeding arm (difference: -9.6% [95% CI: -19.2; 0.2] p = 0.07). After two doses of RV1, seroconversion was 16.6%(95% CI: 11.9; 22.7) in the withholding arm and 29.1%(95% CI: 22.8, 36.3) in the immediate breastfeeding arm (difference: -12.5% [95% CI: -21.2,-3.8] p = 0.005). Conclusions Withholding breastfeeding around the time of RV1 vaccine administration did not lead to increased anti-rotavirus IgA seroconversion compared with that seen with a breastfeed at the time of vaccination. On the contrary, IgA seroconversion in infants immediately breastfed tended to be higher than in those withheld from a feeding. Our findings suggest that breastfeeding should be continued adlib around the time of rotavirus vaccination and withholding breastfeeding at that time is unlikely to improve the vaccine immunogenicity. C1 [Ali, Asad; Kazi, Abdul Momin; Bhutta, Zulfiqar; Zaidi, Anita K. M.] Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, Pakistan. [Cortese, Margaret M.; Moon, SungSil; Parashar, Umesh D.; Jiang, Baoming] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. [Fleming, Jessica A.; Steele, Duncan] PATH, Vaccine Access & Delivery, Seattle, WA USA. [McNeal, Monica M.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Infect Dis, Cincinnati, OH 45229 USA. RP Ali, A (reprint author), Aga Khan Univ, Dept Pediat & Child Hlth, Karachi, Pakistan. EM asad.ali@aku.edu FU PATH from Gavi; Vaccine Alliance FX Support for this project was provided by PATH through funding from Gavi, the Vaccine Alliance. The views expressed by the authors do not necessarily reflect the views of Gavi and/or PATH. Investigators from PATH participated in study design, monitoring, data analysis and manuscript preparation. NR 13 TC 8 Z9 8 U1 2 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD JUN 2 PY 2015 VL 10 IS 6 AR e0127622 DI 10.1371/journal.pone.0127622 PG 12 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ7SJ UT WOS:000355699100016 PM 26035743 ER PT J AU Boggild, AK Esposito, DH Kozarsky, PE Ansdell, V Beeching, NJ Campion, D Castelli, F Caumes, E Chappuis, F Cramer, JP Gkrania-Klotsas, E Grobusch, MP Hagmann, SHF Hynes, NA Lim, PL Lopez-Velez, R Malvy, DJM Mendelson, M Parola, P Sotir, MJ Wu, HM Hamer, DH AF Boggild, Andrea K. Esposito, Douglas H. Kozarsky, Phyllis E. Ansdell, Vernon Beeching, Nicholas J. Campion, Daniel Castelli, Francesco Caumes, Eric Chappuis, Francois Cramer, Jakob P. Gkrania-Klotsas, Effrossyni Grobusch, Martin P. Hagmann, Stefan H. F. Hynes, Noreen A. Lim, Poh Lian Lopez-Velez, Rogelio Malvy, Denis J. M. Mendelson, Marc Parola, Philippe Sotir, Mark J. Wu, Henry M. Hamer, Davidson H. CA GeoSentinel Surveillance Network TI Differential Diagnosis of Illness in Travelers Arriving From Sierra Leone, Liberia, or Guinea: A Cross-sectional Study From the GeoSentinel Surveillance Network SO ANNALS OF INTERNAL MEDICINE LA English DT Article ID EBOLA-VIRUS DISEASE; MARBURG HEMORRHAGIC-FEVER; RETURNED TRAVELERS; WEST-AFRICA; VACCINE; MANAGEMENT AB Background: The largest-ever outbreak of Ebola virus disease (EVD), ongoing in West Africa since late 2013, has led to export of cases to Europe and North America. Clinicians encountering ill travelers arriving from countries with widespread Ebola virus transmission must be aware of alternate diagnoses associated with fever and other nonspecific symptoms. Objective: To define the spectrum of illness observed in persons returning from areas of West Africa where EVD transmission has been widespread. Design: Descriptive, using GeoSentinel records. Setting: 57 travel or tropical medicine clinics in 25 countries. Patients: 805 ill returned travelers and new immigrants from Sierra Leone, Liberia, or Guinea seen between September 2009 and August 2014. Measurements: Frequencies of demographic and travel-related characteristics and illnesses reported. Results: The most common specific diagnosis among 770 non-immigrant travelers was malaria (n = 310 [40.3%]), with Plasmodium falciparum or severe malaria in 267 (86%) and non-P. falciparum malaria in 43 (14%). Acute diarrhea was the second most common diagnosis among nonimmigrant travelers (n = 95 [12.3%]). Such common diagnoses as upper respiratory tract infection, urinary tract infection, and influenza-like illness occurred in only 26, 9, and 7 returning travelers, respectively. Few instances of typhoid fever (n = 8), acute HIV infection (n = 5), and dengue (n = 2) were encountered. Limitation: Surveillance data collected by specialist clinics may not be representative of all ill returned travelers. Conclusion: Although EVD may currently drive clinical evaluation of ill travelers arriving from Sierra Leone, Liberia, and Guinea, clinicians must be aware of other more common, potentially fatal diseases. Malaria remains a common diagnosis among travelers seen at GeoSentinel sites. Prompt exclusion of malaria and other life-threatening conditions is critical to limiting morbidity and mortality. C1 Univ Toronto, Toronto Gen Hosp, Trop Dis Unit, Toronto, ON M5G 1L7, Canada. Publ Hlth Ontario Lab, Toronto, ON, Canada. Ctr Dis Control & Prevent, Atlanta, GA USA. Emory Univ, Atlanta, GA 30322 USA. Univ Hawaii, Honolulu, HI 96822 USA. Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. Natl Inst Hlth Res, Hlth Protect Res Unit Emerging & Zoonot Infect, Liverpool, Merseyside, England. InterHlth Worldwide, London, England. Univ Brescia, Brescia, Italy. Univ Paris 06, Pitie Salpetriere Hosp, Paris, France. Univ Hosp Geneva, Geneva, Switzerland. Bernhard Nocht Inst Trop Med, D-20359 Hamburg, Germany. Univ Cambridge, Cambridge, England. Univ Amsterdam, Amsterdam, Netherlands. Bronx Lebanon Hosp Ctr, Bronx, NY 10456 USA. Albert Einstein Coll Med, Bronx, NY 10467 USA. Johns Hopkins Univ, Sch Med, Baltimore, MD USA. Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. Tan Tock Seng Hosp, Singapore, Singapore. Lee Kong Chian Sch Med, Singapore, Singapore. Hosp Ramon & Cajal, E-28034 Madrid, Spain. Univ Bordeaux, Bordeaux, France. Univ Cape Town, ZA-7925 Cape Town, South Africa. Groote Schuur Hosp, ZA-7925 Cape Town, South Africa. Aix Marseille Univ, Marseille, France. Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA. Boston Univ, Sch Med, Boston, MA 02118 USA. RP Hamer, DH (reprint author), Boston Univ, Ctr Global Hlth & Dev, Crosstown 3rd Floor,801 Massachusetts Ave, Boston, MA 02118 USA. EM dhamer@bu.edu OI McCarthy, Anne/0000-0001-7195-6366; Gkrania-Klotsas, Effrossyni/0000-0002-0930-8330 FU Centers for Disease Control and Prevention; CDC [U50/CCU412347]; National Institute for Health Research Cambridge Biomedical Research Centre; National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections; University of Liverpool; Liverpool School of Tropical Medicine; Public Health England FX Centers for Disease Control and Prevention.; GeoSentinel, the Global Surveillance Network of the International Society of Travel Medicine, is supported by cooperative agreement U50/CCU412347 from the CDC. Dr. Gkrania-Klotsas was supported by the National Institute for Health Research Cambridge Biomedical Research Centre. Dr. Beeching was funded in part by the National Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, a partnership among the University of Liverpool, the Liverpool School of Tropical Medicine, and Public Health England. NR 40 TC 10 Z9 10 U1 4 U2 9 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD JUN 2 PY 2015 VL 162 IS 11 BP 757 EP 764 DI 10.7326/M15-0074 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CJ5ZH UT WOS:000355572300003 PM 25961811 ER PT J AU Khoury, MJ Evans, JP AF Khoury, Muin J. Evans, James P. TI A Public Health Perspective on a National Precision Medicine Cohort Balancing Long-term Knowledge Generation With Early Health Benefit SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material C1 [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA 30333 USA. [Evans, James P.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA. [Evans, James P.] Univ N Carolina, Dept Med, Chapel Hill, NC USA. RP Khoury, MJ (reprint author), Ctr Dis Control & Prevent, Off Publ Hlth Genom, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM muk1@cdc.gov FU Intramural CDC HHS [CC999999] NR 8 TC 15 Z9 19 U1 1 U2 12 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD JUN 2 PY 2015 VL 313 IS 21 BP 2117 EP 2118 DI 10.1001/jama.2015.3382 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CJ4CC UT WOS:000355430900005 PM 26034952 ER PT J AU Hill, VR Narayanan, J Gallen, RR Ferdinand, KL Cromeans, T Vinje, J AF Hill, Vincent R. Narayanan, Jothikumar Gallen, Rachel R. Ferdinand, Karen L. Cromeans, Theresa Vinje, Jan TI Development of a Nucleic Acid Extraction Procedure for Simultaneous Recovery of DNA and RNA from Diverse Microbes in Water SO PATHOGENS LA English DT Article DE drinking water; water testing; nucleic acid; DNA; RNA; extraction; purification; PCR facilitators ID POLYMERASE-CHAIN-REACTION; REAL-TIME PCR; CRYPTOSPORIDIUM-PARVUM; DRINKING-WATER; RAPID METHOD; RT-PCR; SAMPLES; ASSAYS; PURIFICATION; VIRUS AB Drinking and environmental water samples contain a diverse array of constituents that can interfere with molecular testing techniques, especially when large volumes of water are concentrated to the small volumes needed for effective molecular analysis. In this study, a suite of enteric viruses, bacteria, and protozoan parasites were seeded into concentrated source water and finished drinking water samples, in order to investigate the relative performance of nucleic acid extraction techniques for molecular testing. Real-time PCR and reverse transcription-PCR crossing threshold (CT) values were used as the metrics for evaluating relative performance. Experimental results were used to develop a guanidinium isothiocyanate-based lysis buffer (UNEX buffer) that enabled effective simultaneous extraction and recovery of DNA and RNA from the suite of study microbes. Procedures for bead beating, nucleic acid purification, and PCR facilitation were also developed and integrated in the protocol. The final lysis buffer and sample preparation procedure was found to be effective for a panel of drinking water and source water concentrates when compared to commercial nucleic acid extraction kits. The UNEX buffer-based extraction protocol enabled PCR detection of six study microbes, in 100 L finished water samples from four drinking water treatment facilities, within three CT values (i.e., within 90% difference) of the reagent-grade water control. The results from this study indicate that this newly formulated lysis buffer and sample preparation procedure can be useful for standardized molecular testing of drinking and environmental waters. C1 [Hill, Vincent R.; Narayanan, Jothikumar; Gallen, Rachel R.] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE,Mailstop D-66, Atlanta, GA 30329 USA. [Ferdinand, Karen L.; Cromeans, Theresa; Vinje, Jan] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA 30329 USA. RP Hill, VR (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd NE,Mailstop D-66, Atlanta, GA 30329 USA. EM vhill@cdc.gov; jin2@cdc.gov; rrgallen@gmail.com; karen.ferdinand@abbott.com; trc1@cdc.gov; ahx8@cdc.gov NR 41 TC 2 Z9 2 U1 2 U2 8 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2076-0817 J9 PATHOGENS JI Pathogens PD JUN PY 2015 VL 4 IS 2 BP 335 EP 354 DI 10.3390/pathogens4020335 PG 20 WC Microbiology SC Microbiology GA DG0YS UT WOS:000371792700010 PM 26016775 ER PT J AU Pastor, PN Reuben, CA AF Pastor, Patricia N. Reuben, Cynthia A. TI Trends in Parent-Reported Emotional and Behavioral Problems Among Children Using Special Education Services SO PSYCHIATRIC SERVICES LA English DT Article ID STUDENTS; DISABILITY AB Objective: This report describes trends in health conditions reported by parents as the limitations leading to special education services for their children. Methods: Data are reported for children ages 6-17 (N=182,998) surveyed in households in the 2001-2012 National Health Interview Survey. Results: Between 2001 and 2012, the overall percentage of U.S. children ages 6-17 who were receiving special education services increased from 7.2% to 8.7%. Between 2001 and 2012, the leading causes of activity limitations among children receiving special education services included emotional or behavioral problems, which increased from 36% to 43%; speech problems, which increased from 16% to 22%; and learning disability, which decreased from 41% to 27%. There were no significant trends in any of the other conditions considered as possible sources of activity limitations. Conclusions: Emotional and behavioral problems have become the most frequently reported source of activity limitations among children receiving special education services. C1 [Pastor, Patricia N.; Reuben, Cynthia A.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Hyattsville, MD 20782 USA. RP Pastor, PN (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Off Anal & Epidemiol, Hyattsville, MD 20782 USA. EM php3@cdc.gov NR 15 TC 1 Z9 1 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD JUN PY 2015 VL 66 IS 6 BP 656 EP 659 DI 10.1176/appi.ps.201400254 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA DE5RL UT WOS:000370689100020 PM 25726981 ER PT J AU Hall, HI Song, RG Szwarcwald, CL Green, T AF Hall, H. Irene Song, Ruiguang Szwarcwald, Celia Landmann Green, Timothy TI Time From Infection With the Human Immunodeficiency Virus to Diagnosis, United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; diagnosis; CD4 cell counts; delayed diagnosis ID CELL COUNT AB HIV testing efforts increased in recent years to reduce the percentage of persons with HIV unaware of their infection and to detect HIV early. An analysis of CD4 data from national HIV surveillance indicates that diagnosis delays decreased during 2003-2011; on average, persons diagnosed in 2011 had been infected 5.6 years before their diagnosis compared with 7.0 years among those diagnosed in 2003. Diagnosis delays were longer among females, blacks, Hispanics/Latinos, and older persons, but shorter among men who have sex with men, compared with their counterparts. Continued efforts to implement routine testing can help reduce diagnosis delays. C1 [Hall, H. Irene; Song, Ruiguang; Green, Timothy] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Szwarcwald, Celia Landmann] Fundacao Oswaldo Cruz, Inst Commun & Informat Sci & Technol Hlth, Minist Hlth, Rio De Janeiro, Brazil. RP Hall, HI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. EM ixh1@cdc.gov FU US Government FX Supported by the US Government. NR 15 TC 6 Z9 6 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUN 1 PY 2015 VL 69 IS 2 BP 248 EP 251 DI 10.1097/QAI.0000000000000589 PG 4 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DC5GW UT WOS:000369250500023 PM 25714245 ER PT J AU Hall, HI Espinoza, L Harris, S Tang, T Mermin, J AF Hall, H. Irene Espinoza, Lorena Harris, Shericka Tang, Tian Mermin, Jonathan TI Using Surveillance Data to Assess the HIV Tipping Point in the United States SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Letter ID TRANSMISSION RISK; INFECTION C1 [Hall, H. Irene; Espinoza, Lorena; Mermin, Jonathan] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Harris, Shericka; Tang, Tian] ICF Int, Atlanta, GA USA. [Mermin, Jonathan] Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. RP Hall, HI (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. NR 14 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUN 1 PY 2015 VL 69 IS 2 BP E82 EP E84 DI 10.1097/QAI.0000000000000564 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA DC5GW UT WOS:000369250500006 PM 25647526 ER PT J AU Badell, ML Meaney-Delman, D Tuuli, MG Rasmussen, SA Petersen, BW Sheffield, JS Beigi, RH Damon, IK Jamieson, DJ AF Badell, Martina L. Meaney-Delman, Dana Tuuli, Methodius G. Rasmussen, Sonja A. Petersen, Brett W. Sheffield, Jeanne S. Beigi, Richard H. Damon, Inger K. Jamieson, Denise J. TI Risks Associated With Smallpox Vaccination in Pregnancy A Systematic Review and Meta-analysis SO OBSTETRICS AND GYNECOLOGY LA English DT Review ID PRENATAL VACCINIA; BIRTH-DEFECTS; METAANALYSIS; INFANTS; FETUS; PREVENTION; OUTCOMES; TRIALS; VIRUS; WOMEN AB OBJECTIVE: To estimate the maternal and fetal risks of smallpox vaccination during pregnancy. DATA SOURCES: MEDLINE, Web of Science, EMBASE, Global Health, ClinicalTrials.gov, and CINHAL from inception to September 2014. METHODS OF STUDY SELECTION: We included published articles containing primary data regarding smallpox vaccination during pregnancy that reported maternal or fetal outcomes (spontaneous abortion, congenital defect, stillbirth, preterm birth, or fetal vaccinia). TABULATIONS, INTEGRATION, AND RESULTS: The primary search yielded 887 articles. After hand-searching, 37 articles were included: 18 articles with fetal outcome data and 19 case reports of fetal vaccinia. Outcomes of smallpox vaccination in 12,201 pregnant women were included. Smallpox vaccination was not associated with an increased risk of spontaneous abortion (pooled relative risk [RR] 1.03, confidence interval [CI] 0.76-1.41), stillbirth (pooled RR 1.03, CI 0.75-1.40), or preterm birth (pooled RR 0.84, CI 0.62-1.15). When vaccination in any trimester was considered, smallpox vaccination was not associated with an increased risk of congenital defects (pooled RR 1.25, CI 0.99-1.56); however, first-trimester exposure was associated with an increased risk of congenital defects (2.4% compared with 1.5%, pooled RR 1.34, CI 1.02-1.77). No cases of fetal vaccinia were reported in the studies examining fetal outcomes; 21 cases of fetal vaccinia were identified in the literature, of which three neonates survived. CONCLUSION: The overall risk associated with maternal smallpox vaccination appears low. No association between smallpox vaccination and spontaneous abortion, preterm birth, or stillbirth was identified. First-trimester vaccination was associated with a small increase in congenital defects, but the effect size was small and based on limited data. Fetal vaccinia appears to be a rare consequence of maternal smallpox vaccination but is associated with a high rate of fetal loss. C1 Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Maternal Fetal Med, Atlanta, GA USA. Natl Ctr Emerging & Zoonot Infect Dis, Off Publ Hlth Preparedness & Response, Atlanta, GA USA. Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA USA. Washington Univ, Sch Med, Dept Obstet, Div Maternal Fetal Med, St Louis, MO USA. Washington Univ, Sch Med, Dept Gynecol, St Louis, MO USA. Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA. Univ Pittsburgh, Med Ctr, Div Reprod Infect Dis & Obstetr Specialties, Dept Obstet Gynecol & Reprod Sci,Magee Womens Hos, Pittsburgh, PA USA. RP Badell, ML (reprint author), Emory Univ Hosp Midtown, 550 Peachtree St,8th Floor Perinatal Ctr, Atlanta, GA 30308 USA. EM mbadell@emory.edu FU Intramural CDC HHS [CC999999] NR 56 TC 2 Z9 2 U1 0 U2 5 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD JUN PY 2015 VL 125 IS 6 BP 1439 EP 1451 DI 10.1097/AOG.0000000000000857 PG 13 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA DD0VA UT WOS:000369637100024 PM 26000516 ER PT J AU Scallan, E Crim, SM Runkle, A Henao, OL Mahon, BE Hoekstra, RM Griffin, PM AF Scallan, Elaine Crim, Stacy M. Runkle, Arthur Henao, Olga L. Mahon, Barbara E. Hoekstra, Robert M. Griffin, Patricia M. TI Bacterial Enteric Infections Among Older Adults in the United States: Foodborne Diseases Active Surveillance Network, 1996-2012 SO FOODBORNE PATHOGENS AND DISEASE LA English DT Article ID 5 FOODNET SITES; RISK-FACTORS; SALMONELLA; SEROTYPE; TRENDS; EPIDEMIOLOGY; CONSUMPTION; PATHOGENS; COMMUNITY; ILLNESS AB Background: A growing segment of the populationadults aged 65 yearsis more susceptible than younger adults to certain enteric (including foodborne) infections and experience more severe disease. Materials and Methods: Using data on laboratory-confirmed infections from the Foodborne Diseases Active Surveillance Network (FoodNet), we describe trends in the incidence of Campylobacter spp., Escherichia coli O157, Listeria monocytogenes, and nontyphoidal Salmonella infections in adults aged 65 years over time and by age group and sex. We used data from FoodNet and other sources to estimate the total number of illnesses, hospitalizations, and deaths in the United States caused by these infections each year using a statistical model to adjust for underdiagnosis (taking into account medical care-seeking, stool sample submission, laboratory practices, and test sensitivity). Results: From 1996 to 2012, 4 pathogens caused 21,405 laboratory-confirmed infections among older adults residing in the FoodNet surveillance area; 49.3% were hospitalized, and 2.6% died. The average annual rate of infection was highest for Salmonella (12.8/100,000) and Campylobacter (12.1/100,000). Salmonella and Listeria led as causes of death. Among older adults, rates of laboratory-confirmed infection and the percentage of patients who were hospitalized and who died generally increased with age. A notable exception was the rate of Campylobacter infections, which decreased with increasing age. Adjusting for underdiagnosis, we estimated that these pathogens caused about 226,000 illnesses (approximate to 600/100,000) annually among U.S. adults aged 65 years, resulting in approximate to 9700 hospitalizations and approximate to 500 deaths. Conclusions:Campylobacter, E. coli O157, Listeria, and Salmonella are major contributors to illness in older adults, highlighting the value of effective and targeted intervention. C1 [Scallan, Elaine; Runkle, Arthur] Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, 13001 East 17th Pl Bldg 500,Room W3146,Mail Stop, Aurora, CO 80045 USA. [Crim, Stacy M.; Henao, Olga L.; Mahon, Barbara E.; Griffin, Patricia M.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Atlanta, GA USA. [Hoekstra, Robert M.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Biostat & Informat Management Off, Atlanta, GA USA. RP Scallan, E (reprint author), Univ Colorado Denver, Colorado Sch Publ Hlth, Dept Epidemiol, 13001 East 17th Pl Bldg 500,Room W3146,Mail Stop, Aurora, CO 80045 USA. EM Elaine.Scallan@ucdenver.edu FU Association of Public Health Laboratories; Centers for Disease Control and Prevention (CDC) [1U60HM000803] FX This article was supported in part by the Association of Public Health Laboratories and Cooperative Agreement Number #1U60HM000803 from Centers for Disease Control and Prevention (CDC). NR 29 TC 5 Z9 5 U1 3 U2 4 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1535-3141 EI 1556-7125 J9 FOODBORNE PATHOG DIS JI Foodborne Pathog. Dis. PD JUN 1 PY 2015 VL 12 IS 6 BP 492 EP 499 DI 10.1089/fpd.2014.1915 PG 8 WC Food Science & Technology SC Food Science & Technology GA DB7GD UT WOS:000368681900004 PM 26067228 ER PT J AU Kuiper, N Zhang, L Lee, J Babb, SD Anderson, CM Shannon, C Welton, M Lew, R Zhu, SH AF Kuiper, Nicole Zhang, Lei Lee, Joann Babb, Stephen D. Anderson, Christopher M. Shannon, Curt Welton, MaryBeth Lew, Rod Zhu, Shu-Hong TI A National Asian-Language Smokers' Quitline - United States, 2012-2014 SO PREVENTING CHRONIC DISEASE LA English DT Article ID SMOKING PREVALENCE; TOBACCO QUITLINE; CALIFORNIA; AMERICANS AB Introduction Until recently, in-language telephone quitline services for smokers who speak Asian languages were available only in California. In 2012, the Centers for Disease Control and Prevention (CDC) funded the national Asian Smokers' Quitline (ASQ) to expand this service to all states. The objective of this study was to examine characteristics of ASQ callers, how they heard about the quitline, and their use of the service. Methods Characteristics of callers from August 2012 through July 2014 were examined by using descriptive statistics. We examined demographics, cigarette smoking status, time to first cigarette, how callers heard about the quitline, and service use (receipt of counseling and medication) by using ASQ intake and administrative data. We analyzed these data by language and state. Results In 2 years, 5,771 callers from 48 states completed intake; 31% were Chinese (Cantonese or Mandarin), 38% were Korean, and 31% were Vietnamese. More than 95% of all callers who used tobacco were current daily cigarette smokers at intake. About 87% of ASQ callers were male, 57% were aged 45 to 64 years, 48% were uninsured, and educational attainment varied. Most callers (54%) were referred by newspapers or magazines. Nearly all eligible callers (99%) received nicotine patches. About 85% of smokers enrolled in counseling; counseled smokers completed an average of 4 sessions. Conclusion ASQ reached Chinese, Korean, and Vietnamese speakers nationwide. Callers were referred by the promotional avenues employed by ASQ, and most received services (medication, counseling, or both). State quitlines and local organizations should consider transferring callers and promoting ASQ to increase access to cessation services. C1 [Kuiper, Nicole; Zhang, Lei; Babb, Stephen D.; Shannon, Curt; Welton, MaryBeth] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Lee, Joann; Lew, Rod] APPEAL, Oakland, CA USA. [Lee, Joann; Anderson, Christopher M.; Zhu, Shu-Hong] Univ Calif San Diego, San Diego, CA 92103 USA. RP Kuiper, N (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F79, Atlanta, GA 30341 USA. EM NKuiper@cdc.gov OI Zhu, Shu-Hong/0000-0002-4149-3441 FU Centers for Disease Control and Prevention [1U58DP004038] FX The authors thank Joseph Chu (UCSD) for administrative support and both him and Caroline Chen (UCSD) for reviews of the manuscript; Shiushing Wong (UCSD) for statistical analysis support; and Karen Debrot and LaTisha Marshall (CDC/OSH) for pre-clearance manuscript review. Funding for implementation of the Asian Smokers' Quitline was provided by the Centers for Disease Control and Prevention through grant no. 1U58DP004038. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 23 TC 0 Z9 0 U1 2 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-1151 J9 PREV CHRONIC DIS JI Prev. Chronic Dis. PD JUN PY 2015 VL 12 AR 140584 DI 10.5888/pcd12.140584 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DB6ZG UT WOS:000368663600002 ER PT J AU Dantes, R Mu, Y Hicks, LA Cohen, J Bamberg, W Beldavs, ZG Dumyati, G Farley, MM Holzbauer, S Meek, J Phipps, E Wilson, L Winston, LG McDonald, LC Lessa, FC AF Dantes, Raymund Mu, Yi Hicks, Lauri A. Cohen, Jessica Bamberg, Wendy Beldavs, Zintars G. Dumyati, Ghinwa Farley, Monica M. Holzbauer, Stacy Meek, James Phipps, Erin Wilson, Lucy Winston, Lisa G. McDonald, L. Clifford Lessa, Fernanda C. TI Association Between Outpatient Antibiotic Prescribing Practices and Community-Associated Clostridium difficile Infection SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE antibacterial agents; Clostridium difficile; epidemiology; outpatients; public health surveillance ID UNITED-STATES; PRIMARY-CARE; TRACT-INFECTION; GUIDELINES; DIARRHEA; ADULTS; EPIDEMIOLOGY; SURVEILLANCE; PREVENTION; SETTINGS AB Background. Antibiotic use predisposes patients to Clostridium difficile infections (CDI), and approximately 32% of these infections are community-associated (CA) CDI. The population-level impact of antibiotic use on adult CA-CDI rates is not well described. Methods. We used 2011 active population-and laboratory-based surveillance data from 9 US geographic locations to identify adult CA-CDI cases, defined as C difficile-positive stool specimens (by toxin or molecular assay) collected from outpatients or from patients <= 3 days after hospital admission. All patients were surveillance area residents and aged >= 20 years with no positive test <= 8 weeks prior and no overnight stay in a healthcare facility <= 12 weeks prior. Outpatient oral antibiotic prescriptions dispensed in 2010 were obtained from the IMS Health Xponent database. Regression models examined the association between outpatient antibiotic prescribing and adult CA-CDI rates. Results. Healthcare providers prescribed 5.2 million courses of antibiotics among adults in the surveillance population in 2010, for an average of 0.73 per person. Across surveillance sites, antibiotic prescription rates (0.50-0.88 prescriptions per capita) and unadjusted CA-CDI rates (40.7-139.3 cases per 100 000 persons) varied. In regression modeling, reducing antibiotic prescribing rates by 10% among persons >= 20 years old was associated with a 17% (95% confidence interval, 6.0%-26.3%; P =.032) decrease in CA-CDI rates after adjusting for age, gender, race, and type of diagnostic assay. Reductions in prescribing penicillins and amoxicillin/clavulanic acid were associated with the greatest decreases in CA-CDI rates. Conclusions. Community-associated CDI prevention should include reducing unnecessary outpatient antibiotic use. A modest reduction of 10% in outpatient antibiotic prescribing can have a disproportionate impact on reducing CA-CDI rates. C1 [Dantes, Raymund; Mu, Yi; Hicks, Lauri A.; Cohen, Jessica; McDonald, L. Clifford; Lessa, Fernanda C.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Cohen, Jessica] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Bamberg, Wendy] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Beldavs, Zintars G.] Oregon Hlth Author, Portland, OR USA. [Dumyati, Ghinwa] Univ Rochester, Med Ctr, New York, NY USA. [Farley, Monica M.] Emory Univ, Atlanta, GA 30322 USA. [Farley, Monica M.] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Holzbauer, Stacy] Minnesota Dept Hlth, St Paul, MN USA. [Meek, James] Connecticut Emerging Infect Program, New Haven, CT USA. [Phipps, Erin] Univ New Mexico, Albuquerque, NM 87131 USA. [Wilson, Lucy] Maryland Emerging Infect Program Baltimore, Baltimore, MD USA. [Wilson, Lucy] Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Winston, Lisa G.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Winston, Lisa G.] San Francisco Gen Hosp, San Francisco, CA USA. RP Dantes, R (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,Mailstop A-31, Atlanta, GA 30333 USA. EM vic5@cdc.gov NR 39 TC 4 Z9 4 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SUM PY 2015 VL 2 IS 3 DI 10.1093/ofid/ofv113 PG 7 WC Infectious Diseases SC Infectious Diseases GA CX6BP UT WOS:000365786500006 ER PT J AU Diaz, MH Benitez, AJ Cross, KE Hicks, LA Kutty, P Bramley, AM Chappell, JD Hymas, W Patel, A Qi, C Williams, DJ Arnold, SR Ampofo, K Self, WH Grijalva, CG Anderson, EJ McCullers, JA Pavia, AT Wunderink, RG Edwards, KM Jain, S Winchell, JM AF Diaz, Maureen H. Benitez, Alvaro J. Cross, Kristen E. Hicks, Lauri A. Kutty, Preeta Bramley, Anna M. Chappell, James D. Hymas, Weston Patel, Anami Qi, Chao Williams, Derek J. Arnold, Sandra R. Ampofo, Krow Self, Wesley H. Grijalva, Carlos G. Anderson, Evan J. McCullers, Jonathan A. Pavia, Andrew T. Wunderink, Richard G. Edwards, Kathryn M. Jain, Seema Winchell, Jonas M. TI Molecular Detection and Characterization of Mycoplasma pneumoniae Among Patients Hospitalized With Community-Acquired Pneumonia in the United States SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE community-acquired pneumonia; macrolide resistance; molecular epidemiology; Mycoplasma pneumonia ID TANDEM-REPEAT ANALYSIS; REAL-TIME PCR; MACROLIDE-RESISTANT STRAINS; RESOLUTION MELT ANALYSIS; CHLAMYDIA-PNEUMONIAE; PEDIATRIC-PATIENTS; INFECTIONS; CHINA; CHILDREN; OUTBREAK AB Background. Mycoplasma pneumoniae is a common cause of community-acquired pneumonia (CAP). The molecular characteristics of M pneumoniae detected in patients hospitalized with CAP in the United States are poorly described. Methods. We performed molecular characterization of M pneumoniae in nasopharyngeal/ oropharyngeal swabs from children and adults hospitalized with CAP in the Centers for Disease Control and Prevention Etiology of Pneumonia in the Community (EPIC) study, including P1 typing, multilocus variable-number tandem-repeat analysis (MLVA), and macrolide susceptibility genotyping. Results. Of 216 M pneumoniae polymerase chain reaction-positive specimens, 40 (18.5%) were obtained from adults and 176 (81.5%) from children. P1 type distribution differed between adults (64% type 1 and 36% type 2) and children (84% type 1, 13% type 2, and 3% variant) (P <.05) and among sites (P <.01). Significant differences in the proportions of MLVA types 4/5/7/2 and 3/5/6/2 were also observed by age group (P <.01) and site (P <.01). A macrolide-resistant genotype was identified in 7 (3.5%) specimens, 5 of which were from patients who had recently received macrolide therapy. No significant differences in clinical characteristics were identified among patients with various strain types or between macrolide-resistant and -sensitive M pneumoniae infections. Conclusions. The P1 type 1 genotype and MLVA type 4/5/7/2 predominated, but there were differences between children and adults and among sites. Macrolide resistance was rare. Differences in strain types did not appear to be associated with differences in clinical outcomes. Whole genome sequencing of M pneumoniae may help identify better ways to characterize strains. C1 [Diaz, Maureen H.; Benitez, Alvaro J.; Cross, Kristen E.; Hicks, Lauri A.; Kutty, Preeta; Winchell, Jonas M.] Ctr Dis Control & Prevent, Div Bacterial Dis, Atlanta, GA 30333 USA. [Bramley, Anna M.; Jain, Seema] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Qi, Chao; Wunderink, Richard G.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Chappell, James D.; Williams, Derek J.; Self, Wesley H.; Grijalva, Carlos G.; Edwards, Kathryn M.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Williams, Derek J.; Edwards, Kathryn M.] Vanderbilt Vaccine Res Program, Nashville, TN USA. [Patel, Anami; Arnold, Sandra R.; McCullers, Jonathan A.] Le Bonheur Childrens Hosp, Salt Lake City, UT USA. [Ampofo, Krow; Pavia, Andrew T.] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA. [McCullers, Jonathan A.] St Jude Childrens Res Hosp, Memphis, TN 38105 USA. [Anderson, Evan J.] Emory Univ, Sch Med, Atlanta, GA USA. RP Winchell, JM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS G-03, Atlanta, GA 30333 USA. EM jwinchell@cdc.gov NR 40 TC 4 Z9 4 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SUM PY 2015 VL 2 IS 3 DI 10.1093/ofid/ofv106 PG 9 WC Infectious Diseases SC Infectious Diseases GA CX6BP UT WOS:000365786500007 ER PT J AU Harcourt, BH Anderson, RD Wu, HM Cohn, AC MacNeil, JR Taylor, TH Wang, X Clark, TA Messonnier, NE Mayer, LW AF Harcourt, Brian H. Anderson, Raydel D. Wu, Henry M. Cohn, Amanda C. MacNeil, Jessica R. Taylor, Thomas H. Wang, Xin Clark, Thomas A. Messonnier, Nancy E. Mayer, Leonard W. CA Act Bacterial Core Surveillance TI Population-Based Surveillance of Neisseria meningitidis Antimicrobial Resistance in the United States SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE broth microdilution; ciprofloxacin; Neisseria meningitidis; penicillin G; susceptibility testing ID INVASIVE MENINGOCOCCAL DISEASE; REAL-TIME PCR; DECREASED SUSCEPTIBILITY; ANTIBIOTIC SUSCEPTIBILITY; PENICILLIN RESISTANCE; GENETIC DIVERSITY; CIPROFLOXACIN; EMERGENCE; EPIDEMIOLOGY; PREVALENCE AB Background. Antimicrobial treatment and chemoprophylaxis of patients and their close contacts is critical to reduce the morbidity and mortality and prevent secondary cases of meningococcal disease. Through the 1990's, the prevalence of antimicrobial resistance to commonly used antimicrobials among Neisseria meningitidis was low in the United States. Susceptibility testing was performed to ascertain whether the proportions of isolates with reduced susceptibility to antimicrobials commonly used for N meningitidis have increased since 2004 in the United States. Methods. Antimicrobial susceptibility testing was performed by broth microdilution on 466 isolates of N meningitidis collected in 2004, 2008, 2010, and 2011 from an active, population-based surveillance system for susceptibility to ceftriaxone, ciprofloxacin, penicillin G, rifampin, and azithromycin. The molecular mechanism of reduced susceptibility was investigated for isolates with intermediate or resistant phenotypes. Results. All isolates were susceptible to ceftriaxone and azithromycin, 10.3% were penicillin G intermediate (range, 8% in 2008-16.7% in 2010), and < 1% were ciprofloxacin, rifampin, or penicillin G resistant. Of the penicillin G intermediate or resistant isolates, 63% contained mutations in the penA gene associated with reduced susceptibility to penicillin G. All ciprofloxacin-resistant isolates contained mutations in the gyrA gene associated with reduced susceptibility. Conclusions. Resistance of N meningitidis to antimicrobials used for empirical treatment of meningitis in the United States has not been detected, and resistance to penicillin G and chemoprophylaxis agents remains uncommon. Therapeutic agent recommendations remain valid. Although periodic surveillance is warranted to monitor trends in susceptibility, routine clinical testing may be of little use. C1 [Harcourt, Brian H.; Anderson, Raydel D.; Wu, Henry M.; Cohn, Amanda C.; MacNeil, Jessica R.; Taylor, Thomas H.; Wang, Xin; Clark, Thomas A.; Messonnier, Nancy E.; Mayer, Leonard W.] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Atlanta, GA 30329 USA. [Act Bacterial Core Surveillance] Emerging Infect Program, Atlanta, GA USA. RP Harcourt, BH (reprint author), Ctr Dis Control & Prevent, Meningitis Lab, 1600 Clifton Rd NE,MS D-11, Atlanta, GA 30329 USA. EM beh0@cdc.gov NR 40 TC 4 Z9 4 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SUM PY 2015 VL 2 IS 3 DI 10.1093/ofid/ofv117 PG 6 WC Infectious Diseases SC Infectious Diseases GA CX6BP UT WOS:000365786500015 ER PT J AU McLean, HQ Belongia, EA Kieke, BA Meece, JK Fry, AM AF McLean, Huong Q. Belongia, Edward A. Kieke, Burney A. Meece, Jennifer K. Fry, Alicia M. TI Impact of Late Oseltamivir Treatment on Influenza Symptoms in the Outpatient Setting: Results of a Randomized Trial SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE influenza; oseltamivir ID EFFICACY; CHILDREN; SAFETY AB We conducted a double-blind, randomized trial of 134 outpatients with polymerase chain reaction-confirmed influenza to assess the effects of oseltamivir initiated 48-119 hours after illness onset. Oseltamivir treatment did not reduce illness duration, severity, or duration of virus detection. However, the power of this study was limited due to lower than expected enrollment. C1 [McLean, Huong Q.; Belongia, Edward A.; Kieke, Burney A.] Marshfield Clin Res Fdn, Ctr Clin Epidemiol & Populat Hlth, Marshfield, WI USA. [Meece, Jennifer K.] Marshfield Clin Res Fdn, Integrated Res & Dev Lab, Marshfield, WI USA. [Fry, Alicia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP McLean, HQ (reprint author), Marshfield Clin Res Fdn ML2, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM mclean.huong@marshfieldclinic.org NR 10 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SUM PY 2015 VL 2 IS 3 DI 10.1093/ofid/ofv100 PG 3 WC Infectious Diseases SC Infectious Diseases GA CX6BP UT WOS:000365786500026 ER PT J AU Polgreen, PM Santibanez, S Koonin, LM Rupp, ME Beekmann, SE del Rio, C AF Polgreen, Philip M. Santibanez, Scott Koonin, Lisa M. Rupp, Mark E. Beekmann, Susan E. del Rio, Carlos TI Infectious Disease Physician Assessment of Hospital Preparedness for Ebola Virus Disease SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE Ebola; healthcare facilities; preparedness ID HEALTH-CARE WORKERS; LIBERIA; EPIDEMIC; AFRICA; FEVER AB Background. The first case of Ebola diagnosed in the United States and subsequent cases among 2 healthcare workers caring for that patient highlighted the importance of hospital preparedness in caring for Ebola patients. Methods. From October 21, 2014 to November 11, 2014, infectious disease physicians who are part of the Emerging Infections Network (EIN) were surveyed about current Ebola preparedness at their institutions. Results. Of 1566 EIN physician members, 869 (55.5%) responded to this survey. Almost all institutions represented in this survey showed a substantial degree of preparation for the management of patients with suspected and confirmed Ebola virus disease. Despite concerns regarding shortages of personal protective equipment, approximately two thirds of all respondents reported that their facilities had sufficient and ready availability of hoods, full body coveralls, and fluid-resistant or impermeable aprons. The majority of respondents indicated preference for transfer of Ebola patients to specialized treatment centers rather than caring for them locally. In general, we found that larger hospitals and teaching hospitals reported higher levels of preparedness. Conclusions. Prior to the Centers for Disease Control and Prevention-s plan for a tiered approach that identified specific roles for frontline, assessment, and designated treatment facilities, our query of infectious disease physicians suggested that healthcare facilities across the United States were making preparations for screening, diagnosis, and treatment of Ebola patients. Nevertheless, respondents from some hospitals indicated that they were relatively unprepared. C1 [Polgreen, Philip M.; Beekmann, Susan E.] Univ Iowa, Emerging Infect Network, Carver Coll Med, Iowa City, IA 52242 USA. [Santibanez, Scott; Koonin, Lisa M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Santibanez, Scott; del Rio, Carlos] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Santibanez, Scott; del Rio, Carlos] Emory Univ, Sch Med, Atlanta, GA USA. [Rupp, Mark E.] Univ Nebraska Med Ctr, Dept Internal Med, Omaha, NE USA. RP Polgreen, PM (reprint author), Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA. EM philip-polgreen@uiowa.edu RI del Rio, Carlos/B-3763-2012 OI del Rio, Carlos/0000-0002-0153-3517 NR 18 TC 1 Z9 1 U1 0 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SUM PY 2015 VL 2 IS 3 DI 10.1093/ofid/ofv087 PG 6 WC Infectious Diseases SC Infectious Diseases GA CX6BP UT WOS:000365786500028 ER PT J AU Rhee, C Klompas, M Tamburini, FB Fremin, BJ Chea, N Epstein, L Halpin, AL Guh, A Gallen, R Coulliette, A Gee, J Hsieh, C Desjardins, CA Pedamullu, CS DeAngelo, DJ Manzo, VE Folkerth, RD Milner, DA Pecora, N Osborne, M Chalifoux-Judge, D Bhatt, AS Yokoe, DS AF Rhee, Chanu Klompas, Michael Tamburini, Fiona B. Fremin, Brayon J. Chea, Nora Epstein, Lauren Halpin, Alison Laufer Guh, Alice Gallen, Rachel Coulliette, Angela Gee, Jay Hsieh, Candace Desjardins, Christopher A. Pedamullu, Chandra Sekhar DeAngelo, Daniel J. Manzo, Veronica E. Folkerth, Rebecca Dunn Milner, Danny A., Jr. Pecora, Nicole Osborne, Matthew Chalifoux-Judge, Diane Bhatt, Ami S. Yokoe, Deborah S. TI Epidemiologic Investigation of a Cluster of Neuroinvasive Bacillus cereus Infections in 5 Patients With Acute Myelogenous Leukemia SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE acute myelogenous leukemia; Bacillus cereus; central nervous system infection; infection control investigation ID MULTIPLE BRAIN ABSCESSES; INFLAMMATORY REACTION; MENINGITIS; BACTEREMIA; TRANSPLANTATION; MALIGNANCIES; CHILDREN AB Background. Five neuroinvasive Bacillus cereus infections (4 fatal) occurred in hospitalized patients with acute myelogenous leukemia (AML) during a 9-month period, prompting an investigation by infection control and public health officials. Methods. Medical records of case-patients were reviewed and a matched case-control study was performed. Infection control practices were observed. Multiple environmental, food, and medication samples common to AML patients were cultured. Multilocus sequence typing was performed for case and environmental B cereus isolates. Results. All 5 case-patients received chemotherapy and had early-onset neutropenic fevers that resolved with empiric antibiotics. Fever recurred at a median of 17 days (range, 9-20) with headaches and abrupt neurological deterioration. Case-patients had B cereus identified in central nervous system (CNS) samples by (1) polymerase chain reaction or culture or (2) bacilli seen on CNS pathology stains with high-grade B cereus bacteremia. Two case-patients also had colonic ulcers with abundant bacilli on autopsy. No infection control breaches were observed. On case-control analysis, bananas were the only significant exposure shared by all 5 case-patients (odds ratio, 9.3; P =.04). Five environmental or food isolates tested positive for B cereus, including a homogenized banana peel isolate and the shelf of a kitchen cart where bananas were stored. Multilocus sequence typing confirmed that all case and environmental strains were genetically distinct. Multilocus sequence typing-based phylogenetic analysis revealed that the organisms clustered in 2 separate clades. Conclusions. The investigation of this neuroinvasive B cereus cluster did not identify a single point source but was suggestive of a possible dietary exposure. Our experience underscores the potential virulence of B cereus in immunocompromised hosts. C1 [Rhee, Chanu; Klompas, Michael] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Rhee, Chanu; Klompas, Michael] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Rhee, Chanu; Klompas, Michael; Yokoe, Deborah S.] Brigham & Womens Hosp, Infect Control Dept, Boston, MA 02115 USA. [Folkerth, Rebecca Dunn; Milner, Danny A., Jr.; Pecora, Nicole] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA. [Tamburini, Fiona B.; Fremin, Brayon J.; Manzo, Veronica E.; Bhatt, Ami S.] Stanford Univ, Sch Med, Stanford, CA 94305 USA. [Chea, Nora; Epstein, Lauren; Halpin, Alison Laufer; Guh, Alice; Coulliette, Angela] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Gallen, Rachel] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. [Gee, Jay] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Atlanta, GA USA. [Chea, Nora; Epstein, Lauren; Coulliette, Angela] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Atlanta, GA USA. [Desjardins, Christopher A.; Pedamullu, Chandra Sekhar] Broad Inst, Cambridge, MA USA. [Pedamullu, Chandra Sekhar; DeAngelo, Daniel J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA. [Osborne, Matthew] Massachusetts Dept Publ Hlth, Div Epidemiol & Immunizat, Jamaica Plain, MA USA. [Chalifoux-Judge, Diane] Boston Inspect Serv Dept, Boston, MA USA. RP Bhatt, AS (reprint author), Stanford Univ, Med & Genet, 269 Campus Dr,CCSR1155b, Stanford, CA 94305 USA. EM asbhatt@stanford.edu RI Laufer Halpin, Alison/E-5453-2015 OI Laufer Halpin, Alison/0000-0003-1643-1617 NR 27 TC 1 Z9 1 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SUM PY 2015 VL 2 IS 3 DI 10.1093/ofid/ofv096 PG 7 WC Infectious Diseases SC Infectious Diseases GA CX6BP UT WOS:000365786500029 ER PT J AU Viazis, S Beal, JK Monahan, C Lanier, WA Kreil, KR Melka, DC Boden, WD Dion, JL Miller, ZA Nguyen, TA Gieraltowski, LB Zink, DL AF Viazis, Stelios Beal, Jennifer K. Monahan, Caitlin Lanier, William A. Kreil, Katherine R. Melka, David C. Boden, William D. Dion, Jamie L. Miller, Zachary A. Thai-An Nguyen Gieraltowski, Laura B. Zink, Donald L. TI Laboratory, Environmental, and Epidemiologic Investigation and Regulatory Enforcement Actions in Response to an Outbreak of Salmonella Bredeney Infections Linked to Peanut Butter SO OPEN FORUM INFECTIOUS DISEASES LA English DT Article DE food safety; outbreak; peanut butter; Salmonella ID UNITED-STATES AB Background. In September 2012, the Centers for Disease Control and Prevention (CDC), U.S. Food and Drug Administration (FDA), and state and local partners investigated an outbreak of Salmonella enterica serovar Bredeney linked to peanut butter (PB). Methods. A case was defined as infection with the outbreak strain of Salmonella Bredeney between June 1, 2012 and October 31, 2012. Food exposure questionnaires were analyzed by the CDC to determine the food vehicle. The FDA reviewed production information from Retail Chain A's sole supplier of PB, Company A. The PB samples collected from case-patients and Company A were tested for Salmonella. Results. Forty-two case-patients from 20 states were identified. Of 33 case-patients from whom food exposure information was obtained, 25 (76%) shopped at Retail Chain A and 25 (100%) purchased Company A PB. Three state health departments isolated the outbreak strain from opened jars of PB collected from case-patients. The FDA investigators identified multiple deficiencies in current Good Manufacturing Practices (cGMPs) in Company A's manufacturing facility and determined that internal controls were insufficient to prevent shipment of contaminated product. The FDA isolated the outbreak strain of Salmonella Bredeney from implicated product collected at the firm and the environment of the firm's food production facility. Conclusions. Timely laboratory, investigational, and epidemiologic data led to the voluntary recall of PB by Company A. The FDA suspended Company A's food facility registration, prohibiting the firm from introducing food into interstate commerce. This outbreak underscores the need for effective preventive controls, including robust internal environmental monitoring programs, appropriate action in response to contamination findings, and an improved understanding of food safety at the managerial and corporate levels. C1 [Viazis, Stelios; Beal, Jennifer K.; Monahan, Caitlin; Lanier, William A.; Kreil, Katherine R.] US FDA, Coordinated Outbreak Response & Evaluat Network, College Pk, MD 20740 USA. [Melka, David C.; Zink, Donald L.] US FDA, Ctr Food Safety & Appl Nutr, College Pk, MD 20740 USA. [Boden, William D.; Dion, Jamie L.] US FDA, Denver Dist Off, Denver, CO USA. [Miller, Zachary A.] US FDA, Denver Lab, Denver, CO USA. [Thai-An Nguyen; Gieraltowski, Laura B.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Viazis, S (reprint author), US FDA, Coordinated Outbreak Response & Evaluat Network, 4300 River Rd, College Pk, MD 20740 USA. EM stelios.viazis@fda.hhs.gov NR 20 TC 1 Z9 1 U1 0 U2 4 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 2328-8957 J9 OPEN FORUM INFECT DI JI Open Forum Infect. Dis. PD SUM PY 2015 VL 2 IS 3 DI 10.1093/ofid/ofv114 PG 8 WC Infectious Diseases SC Infectious Diseases GA CX6BP UT WOS:000365786500038 ER PT J AU Rhodes, LA Huisingh, CE McGwin, G Mennemeyer, S Crews, J Girkin, CA Owsley, C AF Rhodes, Lindsay Anne Huisingh, Carrie E. McGwin, Gerald Mennemeyer, Stephen Crews, John Girkin, Christopher A. Owsley, Cynthia TI The EQUALITY Program: Evaluating Change in Patient Attitudes and Knowledge about Glaucoma SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Rhodes, Lindsay Anne; Huisingh, Carrie E.; McGwin, Gerald; Mennemeyer, Stephen; Girkin, Christopher A.; Owsley, Cynthia] Univ Alabama Birmingham, Ophthalmol, Birmingham, AL USA. [Crews, John] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 3705 PG 2 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891101330 ER PT J AU West, SK Munoz, BE Weaver, J Mrango, Z Dize, L Gaydos, C Quinn, T Martin, D Zambrano, A AF West, Sheila K. Munoz, Beatriz E. Weaver, Jerusha Mrango, Zakayo Dize, Laura Gaydos, Charlotte Quinn, Thomas Martin, Diana Zambrano, Andrea TI Once Trachoma is gone, what tools can we use for surveillance? SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [West, Sheila K.; Munoz, Beatriz E.; Weaver, Jerusha; Zambrano, Andrea] Johns Hopkins Univ, Wilmer Eye Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD 21218 USA. [Mrango, Zakayo] Natl Inst Med Res, Kilosa, Tanzania. [Dize, Laura; Gaydos, Charlotte; Quinn, Thomas] Johns Hopkins Univ, Div Infect Dis, Int Chlamydia Lab, Baltimore, MD USA. [Quinn, Thomas] NIAID, Bethesda, MD 20892 USA. [Martin, Diana] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 6204 PG 3 WC Ophthalmology SC Ophthalmology GA CT5ZY UT WOS:000362891107272 ER PT J AU Asfar, T Lee, DJ Owsley, C McGwin, G Gower, EW Friedman, DS Murchison, AP Mayro, EL Saaddine, J AF Asfar, Taghrid Lee, David J. Owsley, Cynthia McGwin, Gerald Gower, Emily W. Friedman, David S. Murchison, Ann P. Mayro, Eileen L. Saaddine, Jinan TI Training Eye-care Providers to Deliver Smoking Cessation Counseling to Their Patients SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Asfar, Taghrid; Lee, David J.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA. [Owsley, Cynthia; McGwin, Gerald] Univ Alabama Birmingham, Ophthalmol, Birmingham, AL USA. [Gower, Emily W.] Wake Forest Sch Med, Publ Hlth Sci & Ophthalmol, Winston Salem, NC USA. [Friedman, David S.] Johns Hopkins Univ, Ophthalmol, Baltimore, MD USA. [Murchison, Ann P.; Mayro, Eileen L.] Wills Eye Inst, Philadelphia, PA USA. [Saaddine, Jinan] Ctr Dis Control & Prevent, Div Diabet Translat, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 125 PG 3 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882200115 ER PT J AU Russ, R Rothschild, M Saaddine, J Collin, L Haddad, D AF Russ, Rebecca Rothschild, Michael Saaddine, Jinan Collin, Lindsay Haddad, Danny TI Eye health and access to eye care among migrant farmworkers in Georgia SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE LA English DT Meeting Abstract CT Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO) CY MAY 03-07, 2015 CL Denver, CO SP Assoc Res Vis & Ophthalmol C1 [Russ, Rebecca; Rothschild, Michael; Haddad, Danny] Emory Univ, Sch Med, Ophthalmol, Atlanta, GA USA. [Saaddine, Jinan] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Collin, Lindsay] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC PI ROCKVILLE PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA SN 0146-0404 EI 1552-5783 J9 INVEST OPHTH VIS SCI JI Invest. Ophthalmol. Vis. Sci. PD JUN PY 2015 VL 56 IS 7 MA 1380 PG 2 WC Ophthalmology SC Ophthalmology GA CT5WQ UT WOS:000362882203271 ER PT J AU Saydah, SH Imperatore, G Henkin, L D'Agostino, R Divers, J Mayer-Davis, EJ Dabelea, D Klingensmith, G Pihoker, C Lawrence, JM AF Saydah, Sharon H. Imperatore, Giuseppina Henkin, Leora D'Agostino, Ralph, Jr. Divers, Jasmin Mayer-Davis, Elizabeth J. Dabelea, Dana Klingensmith, Georgeanna Pihoker, Catherine Lawrence, Jean M. TI Trends and Characteristics of Self-reported Case Presentation of Diabetes Diagnosis Among Youth From 2002 to 2010: Findings From the SEARCH for Diabetes in Youth Study SO DIABETES CARE LA English DT Editorial Material ID PREVALENCE; TYPE-1 C1 [Saydah, Sharon H.; Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30322 USA. [Henkin, Leora; D'Agostino, Ralph, Jr.; Divers, Jasmin] Wake Forest Sch Med, Winston Salem, NC USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Chapel Hill, NC USA. [Dabelea, Dana] Univ Colorado Denver, Colorado Sch Publ Hlth, Aurora, CO USA. [Klingensmith, Georgeanna] Univ Colorado, Barbara Davis Ctr Diabet, Sch Med, Aurora, CO USA. [Klingensmith, Georgeanna] Univ Colorado, Dept Pediat, Sch Med, Aurora, CO USA. [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Lawrence, Jean M.] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. RP Saydah, SH (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30322 USA. EM ssaydah@cdc.gov FU HSRD VA [HIR 10-001]; NCATS NIH HHS [8 UL1 TR000077, UL1 TR000077, UL1 TR000154, UL1 TR000423, UL1 TR001082, UL1 TR00423]; NCCDPHP CDC HHS [U01 DP000244, 1U18DP002709, DP-05-069, DP-10-001, U01 DP000245, U01 DP000246, U01 DP000247, U01 DP000248, U01 DP000250, U01 DP000254, U18 DP002708, U18 DP002709, U18 DP002710, U18 DP002714, U18DP000247-06A1, U18DP002708, U18DP002710-01, U18DP002714]; NCRR NIH HHS [UL1 RR029882, UL1RR029882]; NIDDK NIH HHS [P30 DK017047, P30 DK057516, P30 DK57516]; PHS HHS [00097, 200-2010-35171, U48/CCU419249, U48/CCU519239, U48/CCU819241-3, U48/CCU919219, U58/CCU019235-4, U58CCU919256] NR 5 TC 1 Z9 1 U1 0 U2 0 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0149-5992 EI 1935-5548 J9 DIABETES CARE JI Diabetes Care PD JUN PY 2015 VL 38 IS 6 BP E84 EP E85 DI 10.2337/dc15-0157 PG 2 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CT7BV UT WOS:000362969000001 PM 25998301 ER PT J AU Denny, CH Orozco, AM Yeung, L Ahluwalia, IB AF Denny, C. H. Orozco, A. M. Yeung, L. Ahluwalia, I. B. TI MATERNAL REPORT OF PRENATAL DISCUSSION OF THE EFFECTS OF ALCOHOL USE DURING PREGNANCY ON THE BABY SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Denny, C. H.; Orozco, A. M.; Yeung, L.; Ahluwalia, I. B.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 624 BP 167A EP 167A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101147 ER PT J AU Tan, CH Denny, CH Cheal, N Sniezek, JE AF Tan, C. H. Denny, C. H. Cheal, N. Sniezek, J. E. TI ALCOHOL USE AMONG WOMEN OF CHILDBEARING AGE - UNITED STATES, 2011-2013 SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Meeting Abstract CT 38th Annual Scientific Meeting of the Research-Society-on-Alcoholism CY JUN 20-24, 2015 CL San Antonio, TX SP Res Soc Alcoholism C1 [Tan, C. H.; Denny, C. H.; Cheal, N.; Sniezek, J. E.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD JUN PY 2015 VL 39 SU 1 SI SI MA 743 BP 196A EP 196A PG 1 WC Substance Abuse SC Substance Abuse GA CR8XG UT WOS:000361637101265 ER PT J AU Haider, N Rahman, MS Khan, SU Mikolon, A Osmani, MG Gurley, ES Shanta, IS Paul, SK Macfarlane-Berry, L Islam, A Islam, A Desmond, J Epstein, JH Priestley, RA Kersh, GJ Rahman, MZ Daszak, P Luby, SP Massung, RF Zeidner, N AF Haider, Najmul Rahman, Md. Shafiqur Khan, Salah Uddin Mikolon, Andrea Osmani, Muzaffor G. Gurley, Emily S. Shanta, Ireen Sultana Paul, Suman Kumer Macfarlane-Berry, Laura Islam, Ariful Islam, Ausraful Desmond, James Epstein, Jonathan H. Priestley, Rachael A. Kersh, Gilbert J. Rahman, Mohammed Ziaur Daszak, Peter Luby, Stephen P. Massung, Robert F. Zeidner, Nord TI Serological Evidence of Coxiella burnetii Infection in Cattle and Goats in Bangladesh SO ECOHEALTH LA English DT Article DE seroprevalence; C. burnetii; Q fever; cattle; goat; Bangladesh ID Q-FEVER; PREVALENCE; ANTIBODIES; ANIMALS AB We tested 1149 ruminant sera conveniently collected from three districts of Bangladesh to identify the serological evidence of Coxiella burnetii infection in cattle and goats by enzyme-linked immunosorbent assay. We found that 0.7% (8/1149) of ruminants had detectable immunoglobulin G for C. burnetii: 0.65% (4/620) in cattle and 0.76% (4/529) in goats. A sub-set of ruminant samples was retested and confirmed by immunofluorescence assay (18/112). Although we cannot rule out false-positive reactions, our study suggests the presence of C. burnetii in cattle and goats in Bangladesh. Further studies are required to estimate disease burden at the population level and identify risk factors for Q fever in ruminants in Bangladesh. C1 [Haider, Najmul; Rahman, Md. Shafiqur; Khan, Salah Uddin; Gurley, Emily S.; Shanta, Ireen Sultana; Paul, Suman Kumer; Macfarlane-Berry, Laura; Islam, Ausraful; Rahman, Mohammed Ziaur; Luby, Stephen P.; Zeidner, Nord] Int Ctr Diarrheal Dis Res Bangladesh Icddr B, Ctr Communicable Dis, Zoonot Dis Res Grp, Dhaka, Bangladesh. [Mikolon, Andrea] USDA, Hawthorne, CA USA. [Osmani, Muzaffor G.] Minist Fisheries & Livestock, Dept Livestock Serv, Dhaka, Bangladesh. [Islam, Ariful; Desmond, James; Epstein, Jonathan H.; Daszak, Peter] EcoHlth Alliance, New York, NY USA. [Priestley, Rachael A.; Kersh, Gilbert J.; Massung, Robert F.; Zeidner, Nord] Ctr Dis Control & Prevent, Atlanta, GA USA. [Luby, Stephen P.] Stanford Univ, Woods Inst Environm, Stanford, CA 94305 USA. RP Haider, N (reprint author), Int Ctr Diarrheal Dis Res Bangladesh Icddr B, Ctr Communicable Dis, Zoonot Dis Res Grp, Dhaka, Bangladesh. EM nazmulh@icddrb.org RI Gurley, Emily/B-7903-2010; OI Gurley, Emily/0000-0002-8648-9403; Luby, Stephen/0000-0001-5385-899X; Haider, Najmul/0000-0002-5980-3460 FU Google; Rockefeller foundation through EcoHealth Alliance FX This research was funded by Google and the Rockefeller foundation through EcoHealth Alliance. icddr,b acknowledges with gratitude the commitment of Google and the Rockefeller foundation to its research efforts. We acknowledge the veterinarians of Department of Livestock Services of Bangladesh as well as Chittagong Veterinary and Animal Sciences University who assisted with various aspects of this project. We are grateful to Ms. Diana DiazGranados, icddr,b, for her constructive support in editing this manuscript. NR 19 TC 0 Z9 0 U1 0 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1612-9202 EI 1612-9210 J9 ECOHEALTH JI EcoHealth PD JUN PY 2015 VL 12 IS 2 BP 354 EP 358 DI 10.1007/s10393-015-1011-x PG 5 WC Biodiversity Conservation; Ecology; Environmental Sciences SC Biodiversity & Conservation; Environmental Sciences & Ecology GA CS0JZ UT WOS:000361746600020 PM 25649716 ER PT J AU Demers, LM Hankinson, SE Haymond, S Key, T Rosner, W Santen, RJ Stanczyk, FZ Vesper, HW Ziegler, RG AF Demers, L. M. Hankinson, S. E. Haymond, S. Key, T. Rosner, W. Santen, R. J. Stanczyk, F. Z. Vesper, H. W. Ziegler, R. G. TI Measuring Estrogen Exposure and Metabolism: Workshop Recommendations on Clinical Issues SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM LA English DT Article ID POSTMENOPAUSAL WOMEN; ESTRADIOL LEVELS; SERUM ESTRADIOL; STATEMENT C1 [Demers, L. M.] Penn State Univ, Sch Med, Dept Pathol, Hershey, PA 17003 USA. [Demers, L. M.] Penn State Univ, Sch Med, Dept Med, Hershey, PA 17003 USA. [Hankinson, S. E.] Univ Massachusetts, Div Biostat & Epidemiol, Amherst, MA 01003 USA. [Haymond, S.] Ann & Robert H Lurie Childrens Hosp Chicago, Chicago, IL 60611 USA. [Key, T.] Univ Oxford, Nuffield Dept Populat Hlth, Oxford OX3 7LF, England. [Rosner, W.] Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA. [Santen, R. J.] Univ Virginia Hlth Sci Syst, Div Endocrinol & Metab, Charlottesville, VA 22903 USA. [Stanczyk, F. Z.] Univ So Calif, Keck Sch Med, Dept Obstet Gynecol, Los Angeles, CA 90033 USA. [Stanczyk, F. Z.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Vesper, H. W.] Ctr Dis Control & Prevent, Div Sci Lab, Atlanta, GA 30333 USA. [Ziegler, R. G.] NCI, Div Canc Epidemiol & Genet, Bethesda, MD 20892 USA. RP Demers, LM (reprint author), Penn State Univ Pathol, 1175 Stonegate Rd, Hummelstown, PA 17036 USA. EM lmd4@psu.edu FU Intramural Program of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, the National Institutes of Health; CDC Foundation; American Association for Clinical Chemistry; Endocrine Society; ARUP Laboratories; Beckman Coulter, Inc; inVentiv Health; Quest Diagnostics FX Appreciation is expressed for financial support for the meeting provided by the Intramural Program of the Division of Cancer Epidemiology and Genetics of the National Cancer Institute, the National Institutes of Health; the CDC Foundation; the American Association for Clinical Chemistry; The Endocrine Society; ARUP Laboratories; Beckman Coulter, Inc; inVentiv Health; and Quest Diagnostics. NR 14 TC 5 Z9 5 U1 0 U2 3 PU ENDOCRINE SOC PI WASHINGTON PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA SN 0021-972X EI 1945-7197 J9 J CLIN ENDOCR METAB JI J. Clin. Endocrinol. Metab. PD JUN PY 2015 VL 100 IS 6 BP 2165 EP 2170 DI 10.1210/jc.2015-1040 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA CQ8ET UT WOS:000360840000027 PM 25850026 ER PT J AU Vanichseni, S Martin, M Suntharasamai, P Sangkum, U Mock, PA Gvetadze, RJ Curlin, ME Leethochawalit, M Chiamwongpaet, S Chaipung, B McNicholl, JM Paxton, LA Kittimunkong, S Choopanya, K AF Vanichseni, Suphak Martin, Michael Suntharasamai, Pravan Sangkum, Udomsak Mock, Philip A. Gvetadze, Roman J. Curlin, Marcel E. Leethochawalit, Manoj Chiamwongpaet, Sithisat Chaipung, Benjamaporn McNicholl, Janet M. Paxton, Lynn A. Kittimunkong, Somyot Choopanya, Kachit TI High Mortality Among Non-HIV-Infected People Who Inject Drugs in Bangkok, Thailand, 2005-2012 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID USERS; COHORT; METAANALYSIS; HEPATITIS; TRIAL; RISK AB Objectives. We examined the causes of hospitalization and death of people who inject drugs participating in the Bangkok Tenofovir Study, an HIV pre-exposure prophylaxis trial. Methods. The Bangkok Tenofovir Study was a randomized, double-blind, placebo-controlled trial conducted during 2005 to 2012 among 2413 people who inject drugs. We reviewed medical records to define the causes of hospitalization and death, examined participant characteristics and risk behaviors to determine predictors of death, and compared the participant mortality rate with the rate of the general population of Bangkok, Thailand. Results. Participants were followed an average of 4 years; 107 died: 22 (20.6%) from overdose, 13 (12.2%) from traffic accidents, and 12 (11.2%) from sepsis. In multivariable analysis, older age (40-59 years; P = .001), injecting drugs (P = .03), and injecting midazolam (P < .001) were associated with death. The standardized mortality ratio was 2.9. Conclusions. People who injected drugs were nearly 3 times as likely to die as were those in the general population of Bangkok and injecting midazolam was independently associated with death. Drug overdose and traffic accidents were the most common causes of death, and their prevention should be public health priorities. C1 [Vanichseni, Suphak; Suntharasamai, Pravan; Sangkum, Udomsak; Choopanya, Kachit] Bangkok Tenofovir Study Grp, Bangkok, Thailand. [Martin, Michael; Mock, Philip A.; Curlin, Marcel E.; Chaipung, Benjamaporn] Thailand Minist Publ Hlth, US Ctr Dis Control & Prevent Collaborat, Nonthaburi, Thailand. [Kittimunkong, Somyot] Thailand Minist Publ Hlth, Nonthaburi, Thailand. [McNicholl, Janet M.; Paxton, Lynn A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Leethochawalit, Manoj; Chiamwongpaet, Sithisat] Bangkok Metropol Adm, Bangkok, Thailand. RP Martin, M (reprint author), Minist Publ Hlth, 7 Bldg,4th Floor, Nonthaburi 11000, Thailand. EM Znd9@cdc.gov FU US Centers for Disease Control and Prevention; Bangkok Metropolitan Administration FX This work was supported by the US Centers for Disease Control and Prevention and the Bangkok Metropolitan Administration. Gilead Sciences donated study medication but was not involved in conducting the study, analysis, or article preparation. NR 35 TC 2 Z9 2 U1 0 U2 0 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2015 VL 105 IS 6 BP 1136 EP 1141 DI 10.2105/AJPH.2014.302473 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ2XW UT WOS:000360466800028 PM 25880964 ER PT J AU Chou, CF Beckles, GLA Zhang, XZ Saaddine, JB AF Chou, Chiu-Fang Beckles, Gloria L. A. Zhang, Xinzhi Saaddine, Jinan B. TI Association of Socioeconomic Position With Sensory Impairment Among US Working-Aged Adults SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NUTRITION EXAMINATION SURVEY; HEALTH INTERVIEW SURVEY; QUALITY-OF-LIFE; VISUAL IMPAIRMENT; NATIONAL-HEALTH; UNITED-STATES; HEARING-LOSS; OLDER-ADULTS; SOCIAL-CLASS; MIDDLE-AGE AB Objectives. We examined the relationship between socioeconomic position (SEP) and sensory impairment. Methods. We used data from the 2007 to 2010 National Health Interview Surveys (n = 69 845 adults). Multivariable logistic regressions estimated odds ratios (ORs) for associations of educational attainment, occupational class, and poverty-income ratio with impaired vision or hearing. Results. Nearly 20% of respondents reported sensory impairment. Each SEP indicator was negatively associated with sensory impairment. Adjusted odds of vision impairment were significantly higher for farm workers (OR = 1.41; 95% confidence interval [CI] = 1.01, 2.02), people with some college (OR = 1.29; 95% CI = 1.16, 1.44) or less than a high school diploma (OR = 1.36; 95% CI = 1.19, 1.55), and people from poor (OR = 1.35; 95% CI = 1.20, 1.52), low-income (OR = 1.28; 95% CI = 1.14, 1.43), or middle-income (OR = 1.19; 95% CI = 1.07, 1.31) families than for the highest-SEP group. Odds of hearing impairment were significantly higher for people with some college or less education than for those with a college degree or more; for service groups, farmers, and blue-collar workers than for white-collar workers; and for people in poor families. Conclusions. More research is needed to understand the SEP-sensory impairment association. C1 [Chou, Chiu-Fang; Beckles, Gloria L. A.; Zhang, Xinzhi; Saaddine, Jinan B.] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Beckles, GLA (reprint author), Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy,NE F-73, Atlanta, GA 30341 USA. EM glb4@cdc.gov FU Intramural CDC HHS [CC999999] NR 42 TC 0 Z9 0 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2015 VL 105 IS 6 BP 1262 EP 1268 DI 10.2105/AJPH.2014.302475 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ2XW UT WOS:000360466800045 PM 25880957 ER PT J AU Cono, J Jaffe, H AF Cono, Joanne Jaffe, Harold TI THE CDC CLEARANCE PROCESS: SUPPORTING QUALITY SCIENCE SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Letter C1 [Cono, Joanne] Off Associate Director Sci, Off Sci Qual, Atlanta, GA 30329 USA. [Jaffe, Harold] Ctr Dis Control & Prevent, Sci, Atlanta, GA USA. RP Cono, J (reprint author), Off Associate Director Sci, Off Sci Qual, 1600 Clifton Rd NE,MS-D-72, Atlanta, GA 30329 USA. EM jcono@cdc.gov NR 3 TC 0 Z9 0 U1 0 U2 1 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2015 VL 105 IS 6 BP E1 EP E2 DI 10.2105/AJPH.2015.302691 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ2XW UT WOS:000360466800002 PM 25879144 ER PT J AU Mehta, P AF Mehta, Paul TI Prevalence of Amyotrophic Lateral Sclerosis - United States, 2010-2011 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article C1 CDC, Div Toxicol & Human Hlth Sci, ATSDR, Atlanta, GA 30333 USA. RP Mehta, P (reprint author), CDC, Div Toxicol & Human Hlth Sci, ATSDR, Atlanta, GA 30333 USA. EM pum4@cdc.gov NR 1 TC 1 Z9 2 U1 3 U2 5 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2015 VL 105 IS 6 BP E7 EP E9 DI 10.2105/AJPH.2014.302321 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ2XW UT WOS:000360466800008 ER PT J AU Shenson, D Moore, RT Benson, W Anderson, LA AF Shenson, Douglas Moore, Ryan T. Benson, William Anderson, Lynda A. TI Polling Places, Pharmacies, and Public Health: Vote & Vax 2012 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID SEASONAL INFLUENZA; UNITED-STATES; INTEGRATION AB US national elections, which draw sizable numbers of older voters, take place during flu-shot season and represent an untapped opportunity for large-scale delivery of vaccinations. In 2012, Vote & Vax deployed a total of 1585 clinics in 48 states; Washington, DC; Guam; Puerto Rico; and the US Virgin Islands. Approximately 934 clinics were located in pharmacies, and 651 were near polling places. Polling place clinics delivered significantly more vaccines than did pharmacies (5710 vs 3669). The delivery of vaccines was estimated at 9379, and approximately 45% of the recipients identified their race/ethnicity as African American or Hispanic. More than half of the White Vote & Vax recipients and more than two thirds of the non-White recipients were not regular flu shot recipients. C1 [Shenson, Douglas] SPARC, Newton, MA USA. [Shenson, Douglas] Yale Univ, Sch Med, New Haven, CT USA. [Moore, Ryan T.] Amer Univ, Dept Govt, Washington, DC 20016 USA. [Benson, William] Hlth Benefits ABCs, Silver Spring, MD USA. [Anderson, Lynda A.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Anderson, Lynda A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Shenson, D (reprint author), 76 Prince St, Newton, MA 02465 USA. EM douglas.shenson@yale.edu FU Centers for Disease Control and Prevention (CDC) FX All funding for this initiative was provided by the Centers for Disease Control and Prevention (CDC). NR 12 TC 0 Z9 0 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD JUN PY 2015 VL 105 IS 6 BP E12 EP E15 DI 10.2105/AJPH.2015.302628 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CQ2XW UT WOS:000360466800009 PM 25879150 ER PT J AU Mancuso, A Boulet, S Duran, H Munch, E Kissin, D Van Voorhis, B AF Mancuso, A. Boulet, S. Duran, H. Munch, E. Kissin, D. Van Voorhis, B. TI Elective single embryo transfer (eSET) in United States IVF clinics SO HUMAN REPRODUCTION LA English DT Meeting Abstract CT 31st Annual Meeting of the European-Society-of-Human-Reproduction-and-Embryology (ESHRE) CY JUN 14-17, 2015 CL Lisbon, PORTUGAL SP European Soc Human Reprod & Embryol DE in vitro fertilization; multiple gestation; pregnancy rate; single embryo transfer C1 [Mancuso, A.; Duran, H.; Munch, E.; Van Voorhis, B.] Univ Iowa, Carver Coll Med, Obstet & Gynecol, Iowa City, IA USA. [Boulet, S.; Kissin, D.] Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1161 EI 1460-2350 J9 HUM REPROD JI Hum. Reprod. PD JUN PY 2015 VL 30 SU 1 MA P-586 BP 372 EP 372 PG 1 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CP2XF UT WOS:000359740302252 ER PT J AU McNeil, CS Nagy, S Moonan, C Wallace, RM Vora, NM Dyer, JL Blanton, JD Dorado, T Heinrich, ML Sankey, R Uhrig, S Cary, A Houghton, W Ettestad, P AF McNeil, Carrie S. Nagy, Samantha Moonan, Catherine Wallace, Ryan M. Vora, Neil M. Dyer, Jessie L. Blanton, Jesse D. Dorado, Tina Heinrich, Mark L. Sankey, Robin Uhrig, Samantha Cary, Angela Houghton, Woods Ettestad, Paul TI Community rabies knowledge and pet vaccination practices after a skunk rabies outbreak in Eddy County, New Mexico SO JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION LA English DT Article AB Objective-To determine percentages of domestic cats and dogs vaccinated against rabies, identify barriers to vaccination, and assess knowledge about rabies in a semirural New Mexico community after a skunk rabies outbreak. Design-Cross-sectional, door-to-door, bilingual, community-based participatory survey. Sample-366 residential properties in Eddy County, NM. Procedures-The New Mexico Department of Health and CDC administered surveys and analyzed data. Results-Individuals at 247 of the 366 residential properties participated in the survey. One hundred eighty of the 247 (73%) households owned a dog (n = 292) or cat (163). Cats were more likely than dogs to not have an up-to-date rabies vaccination status (prevalence ratio, 3.2; 95% confidence interval, 2.3 to 4.4). Cost and time or scheduling were the most frequently identified barriers to vaccination. One hundred sixty (65%) respondents did not know livestock can transmit rabies, 78 (32%) did not know rabies is fatal, and 89 (36%) did not know a bat scratching a person can be an exposure. Only 187 (76%) respondents indicated they would contact animal control if they saw a sick skunk, and only 166 (67%) indicated they would contact animal control if bitten by a dog they did not own. Conclusions and Clinical Relevance-Findings indicated that rabies vaccination prevalence among pet dogs and cats was low, despite the fact that the region had experienced a skunk rabies outbreak during the previous 2 years. In addition, substantial percentages of respondents did not have correct knowledge of rabies or rabies exposure. C1 [McNeil, Carrie S.; Wallace, Ryan M.; Vora, Neil M.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Nagy, Samantha; Moonan, Catherine] CDC, Publ Hlth Associate Program, Atlanta, GA 30333 USA. [Dyer, Jessie L.; Blanton, Jesse D.] CDC, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. [Dorado, Tina] City Carlsbad Anim Control, Carlsbad, NM 88220 USA. [Heinrich, Mark L.] Carlsbad Anim Clin, Carlsbad, NM 88220 USA. [Sankey, Robin] Anim Care Ctr, Carlsbad, NM 88220 USA. [Uhrig, Samantha] Desert Willow Vet Serv, Carlsbad, NM 88220 USA. [Cary, Angela] Noahs Ark Anim Shelter, Carlsbad, NM 88220 USA. [Ettestad, Paul] New Mexico Dept Hlth, Santa Fe, NM 87505 USA. RP McNeil, CS (reprint author), CDC, Epidem Intelligence Serv, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM mcneilca@yahoo.com NR 4 TC 0 Z9 0 U1 3 U2 8 PU AMER VETERINARY MEDICAL ASSOC PI SCHAUMBURG PA 1931 N MEACHAM RD SUITE 100, SCHAUMBURG, IL 60173-4360 USA SN 0003-1488 EI 1943-569X J9 JAVMA-J AM VET MED A JI JAVMA-J. Am. Vet. Med. Assoc. PD JUN 1 PY 2015 VL 246 IS 11 BP 1242 EP 1247 PG 6 WC Veterinary Sciences SC Veterinary Sciences GA CP4KH UT WOS:000359849900062 PM 25970222 ER PT J AU Pappas, RS Martone, N Gonzalez-Jimenez, N Fresquez, MR Watson, CH AF Pappas, R. Steven Martone, Naudia Gonzalez-Jimenez, Nathalie Fresquez, Mark R. Watson, Clifford H. TI Determination of Toxic Metals in Little Cigar Tobacco with 'Triple Quad' ICP-MS SO JOURNAL OF ANALYTICAL TOXICOLOGY LA English DT Article ID SMOKE PARTICULATE; UNITED-STATES; CADMIUM; CONSTITUENTS; THALLIUM; SLUDGE; ADULTS; LEAD AB Smoking remains the leading cause of preventable death in the USA. Much of the focus on harmful and potentially harmful constituents (HPHCs) in tobacco products has been on cigarettes. Little cigars gained popularity over the last decade until tobacco taxes made cigarettes more expensive in the USA. Many little cigar brands are similar in size with cigarettes and may be smoked in a similar manner. Scant data are available on HPHC concentrations in little cigars, therefore we developed and applied a new analytical method to determine concentrations of 10 toxic metals in little cigar tobacco. The method utilizes 'triple quadrupole' ICP-MS. By optimizing octapole bias, energy discrimination and cell gas flow settings, we were able to accurately quantify a range of elements including those for which the cell gas reactions were endothermic. All standard modes (Single Quad No Gas, MS-MS NH3/He and MS-MS O-2) were utilized for the quantitation of 10 toxic metals in little cigar tobacco, including uranium, which was added as an analyte in the new method. Because of the elimination of interfering ions at 'shifted analyte masses', detection limits were lower compared with a previous method. Tobacco selenium concentrations were below the limit of detection in the previous method, but the new technology made it possible to report all selenium concentrations. C1 [Pappas, R. Steven; Martone, Naudia; Gonzalez-Jimenez, Nathalie; Watson, Clifford H.] Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, Atlanta, GA 30341 USA. [Fresquez, Mark R.] Battelle Analyt Serv, Atlanta, GA USA. RP Pappas, RS (reprint author), Ctr Dis Control & Prevent, Tobacco & Volatiles Branch, 4770 Buford Highway,MS F-44, Atlanta, GA 30341 USA. EM rpappas@cdc.gov FU U.S. Food and Drug Administration, Center for Tobacco Products FX This study was funded by an interagency agreement by the U.S. Food and Drug Administration, Center for Tobacco Products. NR 25 TC 3 Z9 3 U1 3 U2 15 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0146-4760 EI 1945-2403 J9 J ANAL TOXICOL JI J. Anal. Toxicol. PD JUN PY 2015 VL 39 IS 5 BP 347 EP 352 DI 10.1093/jat/bkv016 PG 6 WC Chemistry, Analytical; Toxicology SC Chemistry; Toxicology GA CP2TE UT WOS:000359729200002 PM 25724197 ER PT J AU Sgaier, SK Baer, J Rutz, DC Njeuhmeli, E Seifert-Ahanda, K Basinga, P Parkyn, R Laube, C AF Sgaier, Sema K. Baer, James Rutz, Daniel C. Njeuhmeli, Emmanuel Seifert-Ahanda, Kim Basinga, Paulin Parkyn, Rosie Laube, Catharine TI Toward a Systematic Approach to Generating Demand for Voluntary Medical Male Circumcision: Insights and Results From Field Studies SO GLOBAL HEALTH-SCIENCE AND PRACTICE LA English DT Article ID HEALTH PROMOTION PROGRAMS; ADULT MALE CIRCUMCISION; HIV PREVENTION; MEN; ACCEPTABILITY; CAMPAIGNS; SOUTH; COMMUNICATION; BEHAVIOR; AFRICA AB By the end of 2014, an estimated 8.5 million men had undergone voluntary medical male circumcision (VMMC) for HIV prevention in 14 priority countries in eastern and southern Africa, representing more than 40% of the global target. However, demand, especially among men most at risk for HIV infection, remains a barrier to realizing the program's full scale and potential impact. We analyzed current demand generation interventions for VMMC by reviewing the available literature and reporting on field visits to programs in 7 priority countries. We present our findings and recommendations using a framework with 4 components: insight development; intervention design; implementation and coordination to achieve scale; and measurement, learning, and evaluation. Most program strategies lacked comprehensive insight development; formative research usually comprised general acceptability studies. Demand generation interventions varied across the countries, from advocacy with community leaders and community mobilization to use of interpersonal communication, mid-and mass media, and new technologies. Some shortcomings in intervention design included using general instead of tailored messaging, focusing solely on the HIV preventive benefits of VMMC, and rolling out individual interventions to address specific barriers rather than a holistic package. Interventions have often been scaled-up without first being evaluated for effectiveness and cost-effectiveness. We recommend national programs create coordinated demand generation interventions, based on insights from multiple disciplines, tailored to the needs and aspirations of defined subsets of the target population, rather than focused exclusively on HIV prevention goals. Programs should implement a comprehensive intervention package with multiple messages and channels, strengthened through continuous monitoring. These insights may be broadly applicable to other programs where voluntary behavior change is essential to achieving public health benefits. C1 [Sgaier, Sema K.; Basinga, Paulin] Bill & Melinda Gates Fdn, Global Dev Program, Integrated Delivery, Seattle, WA USA. [Sgaier, Sema K.] Univ Washington, Dept Global Hlth, Seattle, WA 98195 USA. [Sgaier, Sema K.] Harvard Univ, TH Chan Sch Publ Hlth, Boston, MA 02115 USA. [Baer, James; Seifert-Ahanda, Kim] Bill & Melinda Gates Fdn, London, England. [Rutz, Daniel C.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Njeuhmeli, Emmanuel] US Agcy Int Dev, Div Global HIV AIDS, Washington, DC 20523 USA. [Parkyn, Rosie] BBC Media Act, London, England. [Laube, Catharine] US Dept State, Off US Global AIDS Coordinator, Washington, DC 20520 USA. RP Sgaier, SK (reprint author), Surgo Fdn, Seattle, WA 98122 USA. EM semasgaier@surgofoundation.org NR 80 TC 6 Z9 6 U1 0 U2 8 PU US AGENCY INT DEVELOPMENT-USAID PI BALTIMORE PA US AGENCY INT DEVELOPMENT-USAID, BALTIMORE, MD 00000 USA SN 2169-575X J9 GLOB HEALTH-SCI PRAC JI Glob. Health PD JUN PY 2015 VL 3 IS 2 BP 209 EP 229 DI 10.9745/GHSP-D-15-00020 PG 21 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2SR UT WOS:000359007400008 PM 26085019 ER PT J AU Solomon, AW Pavluck, AL Courtright, P Aboe, A Adamu, L Alemayehu, W Alemu, M Alexander, NDE Kello, AB Bero, B Brooker, SJ Chu, BK Dejene, M Emerson, PM Flueckiger, RM Gadisa, S Gass, K Gebre, T Habtamu, Z Harvey, E Haslam, D King, JD Le Mesurier, R Lewallen, S Lietman, TM MacArthur, C Mariotti, SP Massey, A Mathieu, E Mekasha, A Millar, T Mpyet, C Munoz, BE Ngondi, J Ogden, S Pearce, J Sarah, V Sisay, A Smith, JL Taylor, HR Thomson, J West, SK Willis, R Bush, S Haddad, D Foster, A AF Solomon, Anthony W. Pavluck, Alexandre L. Courtright, Paul Aboe, Agatha Adamu, Liknaw Alemayehu, Wondu Alemu, Menbere Alexander, Neal D. E. Kello, Amir Bedri Bero, Berhanu Brooker, Simon J. Chu, Brian K. Dejene, Michael Emerson, Paul M. Flueckiger, Rebecca M. Gadisa, Solomon Gass, Katherine Gebre, Teshome Habtamu, Zelalem Harvey, Erik Haslam, Dominic King, Jonathan D. Le Mesurier, Richard Lewallen, Susan Lietman, Thomas M. MacArthur, Chad Mariotti, Silvio P. Massey, Anna Mathieu, Els Mekasha, Addis Millar, Tom Mpyet, Caleb Munoz, Beatriz E. Ngondi, Jeremiah Ogden, Stephanie Pearce, Joseph Sarah, Virginia Sisay, Alemayehu Smith, Jennifer L. Taylor, Hugh R. Thomson, Jo West, Sheila K. Willis, Rebecca Bush, Simon Haddad, Danny Foster, Allen TI The Global Trachoma Mapping Project: Methodology of a 34-Country Population-Based Study SO OPHTHALMIC EPIDEMIOLOGY LA English DT Article DE Blindness; mHealth; prevalence study; trachoma; trichiasis ID NEGLECTED TROPICAL DISEASES; CENTRAL TANZANIA; CONTROL PROGRAMS; MUSCA-SORBENS; EPIDEMIOLOGY; ECOLOGY; VECTOR; SYSTEM; FACE AB Purpose: To complete the baseline trachoma map worldwide by conducting population-based surveys in an estimated 1238 suspected endemic districts of 34 countries. Methods: A series of national and sub-national projects owned, managed and staffed by ministries of health, conduct house-to-house cluster random sample surveys in evaluation units, which generally correspond to "health district" size: populations of 100,000-250,000 people. In each evaluation unit, we invite all residents aged 1 year and older from h households in each of c clusters to be examined for clinical signs of trachoma, where h is the number of households that can be seen by 1 team in 1 day, and the product h x c is calculated to facilitate recruitment of 1019 children aged 1-9 years. In addition to individual-level demographic and clinical data, household-level water, sanitation and hygiene data are entered into the purpose-built LINKS application on Android smartphones, transmitted to the Cloud, and cleaned, analyzed and ministry-of-health-approved via a secure web-based portal. The main outcome measures are the evaluation unit-level prevalence of follicular trachoma in children aged 1-9 years, prevalence of trachomatous trichiasis in adults aged 15+ years, percentage of households using safe methods for disposal of human feces, and percentage of households with proximate access to water for personal hygiene purposes. Results: In the first year of fieldwork, 347 field teams commenced work in 21 projects in 7 countries. Conclusion: With an approach that is innovative in design and scale, we aim to complete baseline mapping of trachoma throughout the world in 2015. C1 [Solomon, Anthony W.; Brooker, Simon J.; Smith, Jennifer L.; Foster, Allen] Univ London London Sch Hyg & Trop Med, Fac Infect & Trop Dis, London WC1E 7HT, England. [Solomon, Anthony W.; Brooker, Simon J.; Smith, Jennifer L.] London Ctr Neglected Trop Dis Res, London, England. [Pavluck, Alexandre L.; Chu, Brian K.; Flueckiger, Rebecca M.; Gass, Katherine; Ogden, Stephanie; Willis, Rebecca; Haddad, Danny] Int Trachoma Initiat, Task Force Global Hlth, Decatur, GA USA. [Courtright, Paul; Lewallen, Susan] Univ Cape Town, Div Ophthalmol, Kilimanjaro Ctr Community Ophthalmol, ZA-7925 Cape Town, South Africa. [Aboe, Agatha; Bush, Simon] Sightsavers, Airport Residential Area, Accra, Ghana. [Adamu, Liknaw] Community Eye Hlth Consultancy, Addis Ababa, Ethiopia. [Alemayehu, Wondu] Fred Hollows Fdn Ethiopia, Addis Ababa, Ethiopia. [Alemayehu, Wondu] Berhan Publ Hlth & Eye Care Consultancy, Addis Adaba, Ethiopia. [Alemu, Menbere; Bero, Berhanu] Int Trachoma Initiat, Ethiopia Off, Addis Ababa, Ethiopia. [Alexander, Neal D. E.] Univ London London Sch Hyg & Trop Med, MRC Trop Epidemiol Grp, London WC1E 7HT, England. [Kello, Amir Bedri] Light World, Addis Ababa, Ethiopia. [Dejene, Michael] Michael Dejene Publ Hlth Consultancy Serv, Addis Ababa, Ethiopia. [Emerson, Paul M.; King, Jonathan D.; Ngondi, Jeremiah] Emory Univ, Carter Ctr, Atlanta, GA 30322 USA. [Gadisa, Solomon; Habtamu, Zelalem; Mekasha, Addis] Oromia Reg Hlth Bur, Addis Ababa, Ethiopia. [Gebre, Teshome] Int Trachoma Initiat, Reg Off Africa, Addis Ababa, Ethiopia. [Harvey, Erik; Pearce, Joseph] Water Aid, London, England. [Haslam, Dominic; Massey, Anna; Millar, Tom] Sightsavers, Haywards Heath, W Sussex, England. [Le Mesurier, Richard; Sarah, Virginia; Thomson, Jo] Fred Hollows Fdn, Rosebery, NSW, Australia. [Lietman, Thomas M.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA. [MacArthur, Chad] Helen Keller Int, New York, NY USA. [Mariotti, Silvio P.] World Hlth Org, Prevent Blindness & Deafness, Geneva, Switzerland. [Mathieu, Els] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mpyet, Caleb] Sightsavers Nigeria, Kaduna, Nigeria. [Mpyet, Caleb] Univ Jos, Dept Ophthalmol, Jos, Nigeria. [Munoz, Beatriz E.; West, Sheila K.] Johns Hopkins Sch Med, Wilmer Inst, Dana Ctr Prevent Ophthalmol, Baltimore, MD USA. [Sisay, Alemayehu] ORBIS Int Ethiopia, Addis Ababa, Ethiopia. [Taylor, Hugh R.] Univ Melbourne, Melbourne Sch Populat & Global Hlth, Melbourne, Vic 3010, Australia. [Haddad, Danny] Emory Eye Ctr, Atlanta, GA USA. RP Solomon, AW (reprint author), Univ London London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London WC1E 7HT, England. EM anthony.solomon@lshtm.ac.uk OI Taylor, Hugh/0000-0002-9437-784X; Solomon, Anthony/0000-0001-7101-6649 FU United Kingdom's Department for International Development (DFID) [ARIES: 203145]; United States Agency for International Development through its END in Asia grant [FHI 360]; ENVISION grant; Pfizer FX The GTMP is funded by a grant from the United Kingdom's Department for International Development (DFID)(ARIES: 203145) to Sightsavers, who is leading a consortium of non-governmental organizations and academic institutions to complete the work described. Additional funding for fieldwork is provided by the United States Agency for International Development through its END in Asia grant to FHI 360; and its ENVISION grant to Sightsavers. The Committee established in March 2012 to examine issues surrounding completion of global trachoma mapping was initially supported by the International Trachoma Initiative, who receive funding from Pfizer. AWS was a Wellcome Trust Intermediate Clinical Fellow (098521) and SJB a Wellcome Trust Senior Research Fellow (098045) at the London School of Hygiene & Tropical Medicine. None of the funders had any role in study design, in study implementation or analysis or interpretation of data, in the decisions on where, how or when to publish in the peer reviewed press, or in preparation of the manuscript. NR 38 TC 32 Z9 32 U1 2 U2 13 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 0928-6586 EI 1744-5086 J9 OPHTHAL EPIDEMIOL JI Ophthalmic Epidemiol. PD JUN PY 2015 VL 22 IS 3 SI SI BP 214 EP 225 DI 10.3109/09286586.2015.1037401 PG 12 WC Ophthalmology SC Ophthalmology GA CO6QC UT WOS:000359280200012 PM 26158580 ER PT J AU Alexiev, I Shankar, A Wensing, AMJ Beshkov, D Elenkov, I Stoycheva, M Nikolova, D Nikolova, M Switzer, WM AF Alexiev, Ivailo Shankar, Anupama Wensing, A. M. J. Beshkov, Danail Elenkov, Ivaylo Stoycheva, Mariyana Nikolova, Daniela Nikolova, Maria Switzer, William M. TI Low HIV-1 transmitted drug resistance in Bulgaria against a background of high clade diversity SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE antiretroviral mutations; surveillance; viral heterogeneity; eastern Europe ID MOLECULAR EPIDEMIOLOGY; PREVALENCE; MUTATIONS; INFECTION; SUBTYPES; RECOMBINATION; SURVEILLANCE; STRAINS; SERBIA; NAIVE AB Objectives: To determine transmitted drug resistance (TDR) and HIV-1 genetic diversity in Bulgaria. Methods: The prevalence of TDR and HIV-1 subtypes was determined in 305/1446 (21.1%) persons newly diagnosed with HIV/AIDS from 1988 to 2011. TDR mutations (TDRMs) in protease and reverse transcriptase were defined using the WHO HIV drug mutation list. Phylogenetic analysis was used to infer polymerase (pol) genotype. Results: TDRMs were found in 16/305 (5.2%) persons, 11 (3.6%) with resistance to NRTIs, 5 (1.6%) with resistance to NNRTIs and 3 (0.9%) with resistance to PIs. Dual-class TDRMs were found in three (1.0%) patients and one statistically supported cluster of TDRMs comprising two individuals with subtype B infection. TDRMs were found in 10 heterosexuals, 4 MSM and two intravenous drug users. Phylogenetic analyses identified high HIV-1 diversity consisting of mostly subtype B (44.6%), subtype C (3.3%), sub-subtype A1 (2.6%), sub-subtype F1 (2.3%), sub-subtype A-like (3.6%), subtype G (0.3%), CRF14_BG (1.6%), CRF05_DF (1.3%), CRF03_AB (0.3%) and unique recombinant forms (1.3%). Conclusions: We found a low prevalence of TDR against a background of high HIV-1 genetic diversity among anti-retroviral-naive patients in Bulgaria. Our results provide baseline data on TDR and support continued surveillance of high-risk populations in Bulgaria to better target treatment and prevention efforts. C1 [Alexiev, Ivailo; Beshkov, Danail] Natl Ctr Infect & Parasit Dis, Natl Reference Lab HIV, Sofia, Bulgaria. [Shankar, Anupama; Switzer, William M.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Wensing, A. M. J.] Univ Med Ctr Utrecht, Virol, Utrecht, Netherlands. [Elenkov, Ivaylo] Hosp Infect & Parasit Dis, Sofia, Bulgaria. [Stoycheva, Mariyana] Med Univ, Dept Infect Dis, Plovdiv, Bulgaria. [Nikolova, Daniela] Med Univ, Clin Infect Dis, Varna, Bulgaria. [Nikolova, Maria] Natl Ctr Infect & Parasit Dis, Natl Reference Lab Immunol, Sofia, Bulgaria. RP Alexiev, I (reprint author), Natl Ctr Infect & Parasit Dis, Natl Reference Lab HIV, Sofia, Bulgaria. EM ivoalexiev@yahoo.com FU Bulgarian Ministry of Education and Science [BG051PO001-3.3.05-0001]; European Commission [LSHPCT-2006-518211]; Bulgarian Ministry of Health Directorate 'Management of Specialized Donor-funded Programs' FX This study was funded in part by the Bulgarian Ministry of Education and Science, Project 'Science and Business' (grant number BG051PO001-3.3.05-0001), by the European Commission sixth framework supported programs EuropeHIVResistance, grant LSHPCT-2006-518211 and by the Bulgarian Ministry of Health Directorate 'Management of Specialized Donor-funded Programs'. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 27 TC 3 Z9 3 U1 0 U2 3 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD JUN PY 2015 VL 70 IS 6 BP 1874 EP 1880 DI 10.1093/jac/dkv011 PG 7 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA CN5YP UT WOS:000358510300035 PM 25652746 ER PT J AU Talih, M AF Talih, Makram TI EXAMINING SOCIOECONOMIC HEALTH DISPARITIES USING A RANK-DEPENDENT RENYI INDEX SO ANNALS OF APPLIED STATISTICS LA English DT Article DE Social welfare function; concentration curve; Renyi divergence; statistical inference; complex survey data; health surveillance data ID SOCIAL-CLASS INEQUALITY; COMPLEX SURVEY DATA; MULTIDIMENSIONAL INEQUALITY; GENERALIZED ENTROPY; VARIANCE-ESTIMATION; CANCER INCIDENCE; UNITED-STATES; US; DISTRIBUTIONS; DETERMINANTS AB The Renyi index (RI) is a one-parameter class of indices that summarize health disparities among population groups by measuring divergence between the distributions of disease burden and population shares of these groups. The rank-dependent RI introduced in this paper is a two-parameter class of health disparity indices that also accounts for the association between socioeconomic rank and health; it may be derived from a rank-dependent social welfare function. Two competing classes are discussed and the rank-dependent RI is shown to be more robust to changes in the distribution of either socioeconomic rank or health. The standard error and sampling distribution of the rank-dependent RI are evaluated using linearization and resampling techniques, and the methodology is illustrated using health survey data from the U.S. National Health and Nutrition Examination Survey and registry data from the U.S. Surveillance, Epidemiology and End Results Program. Such data underlie many population-based objectives within the U.S. Healthy People 2020 initiative. The rank-dependent RI provides a unified mathematical framework for eliciting various societal positions with regards to the policies that are tied to such wide-reaching public health initiatives. For example, if population groups with lower socioeconomic position were ascertained to be more likely to utilize costly public programs, then the parameters of the RI could be selected to reflect prioritizing those population groups for intervention or treatment. C1 Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Talih, M (reprint author), Ctr Dis Control & Prevent, Off Anal & Epidemiol, Natl Ctr Hlth Stat, 3311 Toledo Rd, Hyattsville, MD 20782 USA. EM mtalih@cdc.gov FU Intramural CDC HHS [CC999999] NR 82 TC 1 Z9 1 U1 4 U2 7 PU INST MATHEMATICAL STATISTICS PI CLEVELAND PA 3163 SOMERSET DR, CLEVELAND, OH 44122 USA SN 1932-6157 J9 ANN APPL STAT JI Ann. Appl. Stat. PD JUN PY 2015 VL 9 IS 2 BP 992 EP 1023 DI 10.1214/15-AOAS822 PG 32 WC Statistics & Probability SC Mathematics GA CN3ZR UT WOS:000358368000021 PM 26566419 ER PT J AU Demirjian, A Lucas, CE Garrison, LE Kozak-Muiznieks, NA States, S Brown, EW Wortham, JM Beaudoin, A Casey, ML Marriott, C Ludwig, AM Sonel, AF Muder, RR Hicks, LA AF Demirjian, Alicia Lucas, Claressa E. Garrison, Laurel E. Kozak-Muiznieks, Natalia A. States, Stanley Brown, Ellen W. Wortham, Jonathan M. Beaudoin, Amanda Casey, Megan L. Marriott, Chandra Ludwig, Alison M. Sonel, Ali F. Muder, Robert R. Hicks, Lauri A. TI The Importance of Clinical Surveillance in Detecting Legionnaires' Disease Outbreaks: A Large Outbreak in a Hospital With a Legionella Disinfection System-Pennsylvania, 2011-2012 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Legionnaires' disease; Legionella pneumophila; healthcare-acquired infection; disinfectants; infection control ID COPPER-SILVER IONIZATION; SEQUENCE-BASED SCHEME; WATER; PNEUMOPHILA; CONSTRUCTION; EXPERIENCE; PNEUMONIA; FOUNTAIN; IONS; GENE AB Background. Healthcare-associated Legionnaires' disease (LD) is a preventable pneumonia with a 30% case fatality rate. The Centers for Disease Control and Prevention guidelines recommend a high index of suspicion for the diagnosis of healthcare-associated LD. We characterized an outbreak and evaluated contributing factors in a hospital using copper-silver ionization for prevention of Legionella growth in water. Methods. Through medical records review at a large, urban tertiary care hospital in November 2012, we identified patients diagnosed with LD during 2011-2012. Laboratory-confirmed cases were categorized as definite, probable, and not healthcare associated based on time spent in the hospital during the incubation period. We performed an environmental assessment of the hospital, including collection of samples for Legionella culture. Clinical and environmental isolates were compared by genotyping. Copper and silver ion concentrations were measured in 11 water samples. Results. We identified 5 definite and 17 probable healthcare-associated LD cases; 6 case patients died. Of 25 locations (mostly potable water) where environmental samples were obtained for Legionella-specific culture, all but 2 showed Legionella growth; 11 isolates were identical to 3 clinical isolates by sequence-based typing. Mean copper and silver concentrations were at or above the manufacturer's recommended target for Legionella control. Despite this, all samples where copper and silver concentrations were tested showed Legionella growth. Conclusions. This outbreak was linked to the hospital's potable water system and highlights the importance of maintaining a high index of suspicion for healthcare-associated LD, even in the setting of a long-term disinfection program. C1 [Demirjian, Alicia; Wortham, Jonathan M.; Beaudoin, Amanda; Ludwig, Alison M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA 30309 USA. [Demirjian, Alicia; Lucas, Claressa E.; Garrison, Laurel E.; Kozak-Muiznieks, Natalia A.; Brown, Ellen W.; Wortham, Jonathan M.; Hicks, Lauri A.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30309 USA. [States, Stanley] Pittsburgh Water & Sewer Author, Pittsburgh, PA USA. [Beaudoin, Amanda] Penn Dept Hlth, Harrisburg, PA 17108 USA. [Casey, Megan L.] Allegheny Cty Hlth Dept, Pittsburgh, PA USA. [Marriott, Chandra] Penn Dept Hlth, Pittsburgh, PA USA. [Ludwig, Alison M.] VA Off Publ Hlth Surveillance & Res, Palo Alto, CA USA. [Sonel, Ali F.; Muder, Robert R.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA 15260 USA. [Sonel, Ali F.; Muder, Robert R.] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. RP Demirjian, A (reprint author), Ctr Dis Control & Prevent, Epidem Intelligence Serv, 1600 Clifton Rd NE,MS C-25, Atlanta, GA 30309 USA. EM alicia.demirjian@post.harvard.edu NR 32 TC 16 Z9 16 U1 3 U2 8 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 IS 11 BP 1596 EP 1602 DI 10.1093/cid/civ153 PG 7 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZP UT WOS:000358070500007 PM 25722201 ER PT J AU Currier, RL Payne, DC Staat, MA Selvarangan, R Shirley, SH Halasa, N Boom, JA Englund, JA Szilagyi, PG Harrison, CJ Klein, EJ Weinberg, GA Wikswo, ME Parashar, U Vinje, J Morrow, AL AF Currier, Rebecca L. Payne, Daniel C. Staat, Mary A. Selvarangan, Rangaraj Shirley, S. Hannah Halasa, Natasha Boom, Julie A. Englund, Janet A. Szilagyi, Peter G. Harrison, Christopher J. Klein, Eileen J. Weinberg, Geoffrey A. Wikswo, Mary E. Parashar, Umesh Vinje, Jan Morrow, Ardythe L. TI Innate Susceptibility to Norovirus Infections Influenced by FUT2 Genotype in a United States Pediatric Population SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE norovirus; FUT2; gastroenteritis; diarrhea; histo-blood group antigens ID BLOOD-GROUP ANTIGENS; HUMAN-MILK; GENETIC SUSCEPTIBILITY; NORWALK VIRUS; GASTROENTERITIS; BINDING; ROTAVIRUS; DISEASE; GII.4; POLYMORPHISM AB Background. Norovirus is a leading cause of acute gastroenteritis (AGE). Noroviruses bind to gut histo-blood group antigens (HBGAs), but only 70%-80% of individuals have a functional copy of the FUT2 ("secretor") gene required for gut HBGA expression; these individuals are known as "secretors." Susceptibility to some noroviruses depends on FUT2 secretor status, but the population impact of this association is not established. Methods. From December 2011 to November 2012, active AGE surveillance was performed at 6 geographically diverse pediatric sites in the United States. Case patients aged <5 years were recruited from emergency departments and inpatient units; age-matched healthy controls were recruited at well-child visits. Salivary DNA was collected to determine secretor status and genetic ancestry. Stool was tested for norovirus by real-time reverse transcription polymerase chain reaction. Norovirus genotype was then determined by sequencing. Results. Norovirus was detected in 302 of 1465 (21%) AGE cases and 52 of 826 (6%) healthy controls. Norovirus AGE cases were 2.8-fold more likely than norovirus-negative controls to be secretors (P < .001) in a logistic regression model adjusted for ancestry, age, site, and health insurance. Secretors comprised all 155 cases and 21 asymptomatic infections with the most prevalent norovirus, GII.4. Control children of Meso-American ancestry were more likely than children of European or African ancestry to be secretors (96% vs 74%; P < .001). Conclusions. FUT2 status is associated with norovirus infection and varies by ancestry. GII.4 norovirus exclusively infected secretors. These findings are important to norovirus vaccine trials and design of agents that may block norovirus-HBGA binding. C1 [Currier, Rebecca L.; Staat, Mary A.; Morrow, Ardythe L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45236 USA. [Currier, Rebecca L.] Univ Cincinnati, Med Scientist Training Program, Cincinnati, OH 45221 USA. [Currier, Rebecca L.] Univ Cincinnati, Mol Epidemiol Childrens Environm Hlth Training Pr, Cincinnati, OH 45221 USA. [Payne, Daniel C.; Shirley, S. Hannah; Wikswo, Mary E.; Parashar, Umesh; Vinje, Jan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Selvarangan, Rangaraj; Harrison, Christopher J.] Childrens Mercy Hosp & Clin, Kansas City, MO USA. [Selvarangan, Rangaraj; Harrison, Christopher J.] Univ Missouri, Sch Med, Kansas City, MO 64108 USA. [Shirley, S. Hannah] Atlanta Res & Educ Fdn, Decatur, GA USA. [Halasa, Natasha] Vanderbilt Univ, Med Ctr, Nashville, TN USA. [Boom, Julie A.] Baylor Coll Med, Houston, TX 77030 USA. [Englund, Janet A.; Klein, Eileen J.] Seattle Childrens Res Inst, Seattle, WA USA. [Szilagyi, Peter G.; Weinberg, Geoffrey A.] Univ Rochester, Sch Med, Rochester, NY 14627 USA. RP Morrow, AL (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 7009, Cincinnati, OH 45236 USA. EM ardythe.morrow@cchmc.org FU CDC; National Institutes of Health [P01 HD013021, F30 AI109893, T32 GM063483, T32 ES010957] FX This work was supported by the CDC and the National Institutes of Health (grant numbers P01 HD013021 to A. L. M., F30 AI109893 to R. L. C., T32 GM063483, and T32 ES010957). NR 35 TC 17 Z9 18 U1 0 U2 9 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 IS 11 BP 1631 EP 1638 DI 10.1093/cid/civ165 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZP UT WOS:000358070500012 PM 25744498 ER PT J AU Traeger, MS Regan, JJ Humpherys, D Mahoney, DL Martinez, M Emerson, GL Tack, DM Geissler, A Yasmin, S Lawson, R Hamilton, C Williams, V Levy, C Komatsu, K McQuiston, JH Yost, DA AF Traeger, Marc S. Regan, Joanna J. Humpherys, Dwight Mahoney, Dianna L. Martinez, Michelle Emerson, Ginny L. Tack, Danielle M. Geissler, Aimee Yasmin, Seema Lawson, Regina Hamilton, Charlene Williams, Velda Levy, Craig Komatsu, Kenneth McQuiston, Jennifer H. Yost, David A. TI Rocky Mountain Spotted Fever Characterization and Comparison to Similar Illnesses in a Highly Endemic Area-Arizona, 2002-2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Rocky Mountain spotted fever; American Indians; AIAN; tick-borne; Rhipicephalus sanguineus ID RHIPICEPHALUS-SANGUINEUS TICKS; RICKETTSIA-RICKETTSII; RISK-FACTORS; UNITED-STATES; SURVEILLANCE; MANAGEMENT; MASSILIAE; FEATURES; VECTOR AB Background. Rocky Mountain spotted fever (RMSF) has emerged as a significant cause of morbidity and mortality since 2002 on tribal lands in Arizona. The explosive nature of this outbreak and the recognition of an unexpected tick vector, Rhipicephalus sanguineus, prompted an investigation to characterize RMSF in this unique setting and compare RMSF cases to similar illnesses. Methods. We compared medical records of 205 patients with RMSF and 175 with non-RMSF illnesses that prompted RMSF testing during 2002-2011 from 2 Indian reservations in Arizona. Results. RMSF cases in Arizona occurred year-round and peaked later (July-September) than RMSF cases reported from other US regions. Cases were younger (median age, 11 years) and reported fever and rash less frequently, compared to cases from other US regions. Fever was present in 81% of cases but not significantly different from that in patients with non-RMSF illnesses. Classic laboratory abnormalities such as low sodium and platelet counts had small and subtle differences between cases and patients with non-RMSF illnesses. Imaging studies reflected the variability and complexity of the illness but proved unhelpful in clarifying the early diagnosis. Conclusions. RMSF epidemiology in this region appears different than RMSF elsewhere in the United States. No specific pattern of signs, symptoms, or laboratory findings occurred with enough frequency to consistently differentiate RMSF from other illnesses. Due to the nonspecific and variable nature of RMSF presentations, clinicians in this region should aggressively treat febrile illnesses and sepsis with doxycycline for suspected RMSF. C1 [Traeger, Marc S.; Humpherys, Dwight; Mahoney, Dianna L.; Martinez, Michelle; Yost, David A.] Indian Hlth Serv Hosp, Whiteriver, AZ 85941 USA. [Regan, Joanna J.; McQuiston, Jennifer H.] Ctr Dis Control & Prevent CDC, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis NCEZID, Atlanta, GA USA. [Emerson, Ginny L.; Tack, Danielle M.] Ctr Dis Control & Prevent CDC, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathogen, NCEZID, Atlanta, GA USA. [Tack, Danielle M.; Yasmin, Seema] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA USA. [Geissler, Aimee] CDC, Bacterial Dis Branch, Div Vector Borne Dis, NCEZID, Ft Collins, CO USA. [Lawson, Regina] N Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC USA. [Hamilton, Charlene] Arizona Dept Hlth Serv, Div Hlth Programs, Community A, Phoenix, AZ 85007 USA. [Williams, Velda] Arizona Dept Hlth Serv, Dept Hlth & Human Serv, Community B, Phoenix, AZ 85007 USA. [Levy, Craig; Komatsu, Kenneth] Arizona Dept Hlth Serv, Bur Epidemiol & Dis Control, Div Publ Hlth Serv, Phoenix, AZ 85007 USA. RP Traeger, MS (reprint author), Indian Hlth Serv Hosp, 200 W Hosp Dr, Whiteriver, AZ 85941 USA. EM marc.traeger@ihs.gov OI Regan, Joanna/0000-0002-9179-6694 FU Intramural CDC HHS [CC999999] NR 32 TC 4 Z9 4 U1 4 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 IS 11 BP 1650 EP 1658 DI 10.1093/cid/civ115 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZP UT WOS:000358070500015 PM 25697743 ER PT J AU Regan, JJ Traeger, MS Humpherys, D Mahoney, DL Martinez, M Emerson, GL Tack, DM Geissler, A Yasmin, S Lawson, R Williams, V Hamilton, C Levy, C Komatsu, K Yost, DA McQuiston, JH AF Regan, Joanna J. Traeger, Marc S. Humpherys, Dwight Mahoney, Dianna L. Martinez, Michelle Emerson, Ginny L. Tack, Danielle M. Geissler, Aimee Yasmin, Seema Lawson, Regina Williams, Velda Hamilton, Charlene Levy, Craig Komatsu, Ken Yost, David A. McQuiston, Jennifer H. TI Risk Factors for Fatal Outcome From Rocky Mountain Spotted Fever in a Highly Endemic Area-Arizona, 2002-2011 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Rocky Mountain spotted fever; American Indians; tick-borne; fatalities; Rhipicephalus sanguineus ID RICKETTSIA-RICKETTSII; SPOTLESS FEVER; UNITED-STATES; SURVEILLANCE; MORTALITY AB Background. Rocky Mountain spotted fever (RMSF) is a disease that now causes significant morbidity and mortality on several American Indian reservations in Arizona. Although the disease is treatable, reported RMSF case fatality rates from this region are high (7%) compared to the rest of the nation (<1%), suggesting a need to identify clinical points for intervention. Methods. The first 205 cases from this region were reviewed and fatal RMSF cases were compared to nonfatal cases to determine clinical risk factors for fatal outcome. Results. Doxycycline was initiated significantly later in fatal cases (median, day 7) than nonfatal cases (median, day 3), although both groups of case patients presented for care early (median, day 2). Multiple factors increased the risk of doxycycline delay and fatal outcome, such as early symptoms of nausea and diarrhea, history of alcoholism or chronic lung disease, and abnormal laboratory results such as elevated liver aminotransferases. Rash, history of tick bite, thrombocytopenia, and hyponatremia were often absent at initial presentation. Conclusions. Earlier treatment with doxycycline can decrease morbidity and mortality from RMSF in this region. Recognition of risk factors associated with doxycycline delay and fatal outcome, such as early gastrointestinal symptoms and a history of alcoholism or chronic lung disease, may be useful in guiding early treatment decisions. Healthcare providers should have a low threshold for initiating doxycycline whenever treating febrile or potentially septic patients from tribal lands in Arizona, even if an alternative diagnosis seems more likely and classic findings of RMSF are absent. C1 [Regan, Joanna J.; McQuiston, Jennifer H.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis NCEZID, Atlanta, GA 30329 USA. [Traeger, Marc S.; Humpherys, Dwight; Mahoney, Dianna L.; Martinez, Michelle; Yost, David A.] Indian Hlth Serv Hosp, Phoenix, AZ USA. [Emerson, Ginny L.] CDC, Poxvirus & Rabies Branch, Div High Consequence Pathogens & Pathogen, NCEZID, Atlanta, GA 30333 USA. [Tack, Danielle M.; Yasmin, Seema] CDC, Epidem Intelligence Serv, Div Appl Publ Hlth Training, Epidemiol Program Off, Atlanta, GA 30333 USA. [Geissler, Aimee] CDC, Bacterial Dis Branch, Div Vector Borne Dis, NCEZID, Ft Collins, CO USA. [Lawson, Regina] N Carolina State Univ, Coll Vet Med, Dept Populat Hlth & Pathobiol, Raleigh, NC USA. [Williams, Velda] Arizona Dept Hlth Serv, Dept Hlth & Human Serv, Community B, Phoenix, AZ 85007 USA. [Hamilton, Charlene] Arizona Dept Hlth Serv, Div Hlth Programs, Community A, Phoenix, AZ 85007 USA. [Levy, Craig; Komatsu, Ken] Arizona Dept Hlth Serv, Bur Epidemiol & Dis Control, Div Publ Hlth Serv, Phoenix, AZ 85007 USA. RP Regan, JJ (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS C01, Atlanta, GA 30329 USA. EM jregan@cdc.gov OI Regan, Joanna/0000-0002-9179-6694 FU CDC FX This work was supported by the CDC. NR 27 TC 6 Z9 6 U1 2 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 IS 11 BP 1659 EP 1666 DI 10.1093/cid/civ116 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZP UT WOS:000358070500016 PM 25697742 ER PT J AU Havers, F Flannery, B Clippard, JR Gaglani, M Zimmerman, RK Jackson, LA Petrie, JG McLean, HQ Nowalk, MP Jackson, ML Monto, AS Belongia, EA Eng, HF Lamerato, L Campbell, AP Fry, AM AF Havers, Fiona Flannery, Brendan Clippard, Jessie R. Gaglani, Manjusha Zimmerman, Richard K. Jackson, Lisa A. Petrie, Joshua G. McLean, Huong Q. Nowalk, Mary Patricia Jackson, Michael L. Monto, Arnold S. Belongia, Edward A. Eng, Heather F. Lamerato, Lois Campbell, Angela P. Fry, Alicia M. TI Use of Influenza Antiviral Medications Among Outpatients at High Risk for Influenza-Associated Complications During the 2013-2014 Influenza Season SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE influenza; antiviral treatment; ambulatory care; neuraminidase inhibitors ID RESPIRATORY-TRACT COMPLICATIONS; UNITED-STATES; OSELTAMIVIR; CHEMOPROPHYLAXIS; METAANALYSIS; AGENTS; TRIAL AB During the 2013-2014 influenza season, we analyzed data from 6004 outpatients aged >= 6 months with acute respiratory illness (ARI). Among the 2786 ARI patients at higher risk for influenza complications, 835 (30%) presented to care <= 2 days from symptom onset; among those, 126 (15%) were prescribed an antiviral medication. C1 [Havers, Fiona; Flannery, Brendan; Clippard, Jessie R.; Campbell, Angela P.; Fry, Alicia M.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30333 USA. [Gaglani, Manjusha] Texas A&M Univ, Coll Med, Hlth Sci Ctr, Baylor Scott & White Hlth, Temple, TX 76508 USA. [Zimmerman, Richard K.; Nowalk, Mary Patricia] Univ Pittsburgh, Dept Family Med, Pittsburgh, PA 15260 USA. [Jackson, Lisa A.; Jackson, Michael L.] Grp Hlth Res Inst, Seattle, WA USA. [Petrie, Joshua G.; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [McLean, Huong Q.; Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Eng, Heather F.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Lamerato, Lois] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA. RP Havers, F (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A-32, Atlanta, GA 30333 USA. EM fhavers@cdc.gov OI Zimmerman, Richard/0000-0001-5941-6092 FU CDC; University of Michigan [U01 IP000474]; Group Health Research Institute [U01 IP000466]; Marshfield Clinic Research Foundation [U01 IP000471]; University of Pittsburgh [U01 IP000467]; Scott and White Healthcare [U01 IP000473)]; National Institutes of Health [UL1 RR024153, UL1TR000005] FX This work was supported by the CDC through cooperative agreements with the University of Michigan (U01 IP000474), Group Health Research Institute (U01 IP000466), Marshfield Clinic Research Foundation (U01 IP000471), University of Pittsburgh (U01 IP000467), and Scott and White Healthcare (U01 IP000473). At the University of Pittsburgh, the project was also supported by the National Institutes of Health through grants UL1 RR024153 and UL1TR000005. NR 12 TC 2 Z9 2 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 IS 11 BP 1677 EP 1680 DI 10.1093/cid/civ146 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZP UT WOS:000358070500018 PM 25722198 ER PT J AU Rasmussen, SA Gerber, SI Swerdlow, DL AF Rasmussen, Sonja A. Gerber, Susan I. Swerdlow, David L. TI Middle East Respiratory Syndrome Coronavirus: Update for Clinicians SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE Middle East respiratory syndrome coronavirus; MERS-CoV; infection control; coronavirus ID PUBLIC-HEALTH AUTHORITIES; MERS-COV INFECTION; SAUDI-ARABIA; DROMEDARY CAMELS; UNITED-STATES; EPIDEMIOLOGY; GUIDANCE; OUTBREAK; OUTCOMES AB Although much recent focus has been on the recognition of Ebola virus disease among travelers from West Africa, cases of Middle East respiratory syndrome coronavirus (MERS-CoV), including travel-associated cases, continue to be reported. US clinicians need to be familiar with recommendations regarding when to suspect MERS-CoV, how to make a diagnosis, and what infection control measures need to be instituted when a case is suspected. Infection control is especially critical, given that most cases have been healthcare-associated. Two cases of MERS-CoV were identified in the United States in May 2014; because these cases were detected promptly and appropriate control measures were put in place quickly, no secondary cases occurred. This paper summarizes information that US clinicians need to know to prevent secondary cases of MERS-CoV from occurring in the United States. C1 [Rasmussen, Sonja A.; Gerber, Susan I.; Swerdlow, David L.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Rasmussen, SA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E-69, Atlanta, GA 30333 USA. EM skr9@cdc.gov NR 26 TC 8 Z9 8 U1 1 U2 19 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 IS 11 BP 1686 EP 1689 DI 10.1093/cid/civ118 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZP UT WOS:000358070500021 PM 25701855 ER PT J AU Stensvold, CR Elwin, K Winiecka-Krusnell, J Chalmers, RM Xiao, L Lebbad, M AF Stensvold, C. R. Elwin, K. Winiecka-Krusnell, J. Chalmers, R. M. Xiao, L. Lebbad, M. TI Development and Application of a gp60-Based Typing Assay for Cryptosporidium viatorum SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID CHIPMUNK GENOTYPE I; CLINICAL-MANIFESTATIONS; HUMANS; CHILDREN; SUBTYPES; HOMINIS; PARVUM AB The apicomplexan intestinal parasites of the genus Cryptosporidium take a major toll on human and animal health and are frequent causes of waterborne outbreaks. Several species and genotypes can infect humans, including Cryptosporidium viatorum, which, to date, has only been found in humans. Molecular characterization of Cryptosporidium spp., critical to epidemiological analyses, is commonly based on gp60 gene analysis, which appears to require bespoke species- or group-specific PCR primers due to extensive genetic diversity across the genus. In this study, we amplified, sequenced, and characterized the gp60 gene of C. viatorum for the first time. Moreover, we developed and validated a gp60 typing assay for this species and applied it to 27 isolates originating from Asia, Africa, and Central America. A single subtype family, XVa, was identified containing multiple alleles. C1 [Stensvold, C. R.] Statens Serum Inst, Dept Microbiol & Infect Control, DK-2300 Copenhagen, Denmark. [Elwin, K.; Chalmers, R. M.] Singleton Hosp, Publ Hlth Wales Microbiol, Cryptosporidium Reference Unit, Swansea SA2 8QA, W Glam, Wales. [Winiecka-Krusnell, J.; Lebbad, M.] Publ Hlth Agcy Sweden, Dept Microbiol, Solna, Sweden. [Xiao, L.] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Stensvold, CR (reprint author), Statens Serum Inst, Dept Microbiol & Infect Control, DK-2300 Copenhagen, Denmark. EM run@ssi.dk RI Stensvold, Rune/H-3718-2011; Xiao, Lihua/B-1704-2013 OI Stensvold, Rune/0000-0002-1417-7048; Xiao, Lihua/0000-0001-8532-2727 NR 21 TC 4 Z9 5 U1 1 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUN PY 2015 VL 53 IS 6 BP 1891 EP 1897 DI 10.1128/JCM.00313-15 PG 7 WC Microbiology SC Microbiology GA CN2WZ UT WOS:000358284600015 PM 25832304 ER PT J AU Bennett, A Bar-Zeev, N Jere, KC Tate, JE Parashar, UD Nakagomi, O Heyderman, RS French, N Iturriza-Gomara, M Cunliffe, NA AF Bennett, A. Bar-Zeev, N. Jere, K. C. Tate, J. E. Parashar, U. D. Nakagomi, O. Heyderman, R. S. French, N. Iturriza-Gomara, M. Cunliffe, N. A. TI Determination of a Viral Load Threshold To Distinguish Symptomatic versus Asymptomatic Rotavirus Infection in a High-Disease-Burden African Population SO JOURNAL OF CLINICAL MICROBIOLOGY LA English DT Article ID DIAGNOSING ROTAVIRUS; INTESTINAL DISEASE; CHILDREN; VACCINE; GASTROENTERITIS; PCR; CUTOFF; MALAWI; PLOTS AB We evaluated quantitative real-time PCR to establish the diagnosis of rotavirus gastroenteritis in a high-disease-burden population in Malawi using enzyme immunoassay as the gold standard diagnostic test. In 146 children with acute gastroenteritis and 65 asymptomatic children, we defined a cutoff point in the threshold cycle value (26.7) that predicts rotavirus-attributable gastroenteritis in this population. These data will inform the evaluation of direct and indirect rotavirus vaccine effects in Africa. C1 [Bennett, A.; Bar-Zeev, N.; Jere, K. C.; Heyderman, R. S.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi. [Bennett, A.; Bar-Zeev, N.; Jere, K. C.; French, N.; Iturriza-Gomara, M.; Cunliffe, N. A.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Tate, J. E.; Parashar, U. D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Nakagomi, O.] Nagasaki Univ, Dept Mol Microbiol & Immunol, Nagasaki 852, Japan. [Heyderman, R. S.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. RP Cunliffe, NA (reprint author), Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. EM n.a.cunliffe@liv.ac.uk OI Cunliffe, Nigel/0000-0002-5449-4988; Jere, Khuzwayo/0000-0003-3376-8529 FU Wellcome Trust program grant [091909/Z/10/Z]; Malawi-Liverpool Wellcome Trust clinical research program core award; Wellcome Trust clinical Ph.D. fellowship [102466/Z/13/A]; GlaxoSmithKline Biologicals; Sanofi Pasteur MSD; Japan Vaccine; Merck Sharp Dohme FX This work was supported by a Wellcome Trust program grant (no. 091909/Z/10/Z) and the Malawi-Liverpool Wellcome Trust clinical research program core award. A.B. was supported by a Wellcome Trust clinical Ph.D. fellowship (grant no. 102466/Z/13/A).; N.B.-Z. and N.F. have received research grant support from GlaxoSmithKline Biologicals for work on rotavirus vaccines. M.I.-G. has received research grant support from GlaxoSmithKline Biologicals and Sanofi Pasteur MSD for work on rotavirus. O.N. has received research grant support and honoraria from Japan Vaccine and Merck Sharp & Dohme for lectures on rotavirus vaccines. N.A.C. has received research grant support and honoraria for participation in rotavirus vaccine advisory board meetings from GlaxoSmithKline Biologicals. The other authors declare no conflicts of interest. NR 20 TC 7 Z9 7 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0095-1137 EI 1098-660X J9 J CLIN MICROBIOL JI J. Clin. Microbiol. PD JUN PY 2015 VL 53 IS 6 BP 1951 EP 1954 DI 10.1128/JCM.00875-15 PG 4 WC Microbiology SC Microbiology GA CN2WZ UT WOS:000358284600027 PM 25854480 ER PT J AU Reback, CJ Fletcher, JB Shoptaw, S Mansergh, G AF Reback, Cathy J. Fletcher, Jesse B. Shoptaw, Steven Mansergh, Gordon TI Exposure to Theory-Driven Text Messages is Associated with HIV Risk Reduction Among Methamphetamine-Using Men Who have Sex with Men SO AIDS AND BEHAVIOR LA English DT Article DE Men who have sex with men (MSM); HIV/AIDS; Methamphetamine; Text messaging (SMS); Mobile technology; mHealth; Theory ID HEALTH BELIEF MODEL; BEHAVIOR-CHANGE INTERVENTIONS; SOCIAL SUPPORT; ANTIRETROVIRAL THERAPY; MEDICATION ADHERENCE; SUBSTANCE USE; PREVENTION; COMMUNICATION; METAANALYSIS; MANAGEMENT AB Fifty-two non-treatment-seeking methamphet-amine-using men who have sex with men were enrolled in Project Tech Support, an open-label pilot study to evaluate whether exposure to theory-based [social support theory (SST), social cognitive theory (SCT), and health belief model (HBM)] text messages could promote reductions in HIV sexual risk behaviors and/or methamphetamine use. Multivariable analyses revealed that increased relative exposure to HBM or SCT (vs. SST) text messages was associated with significant reductions in the number of HIV serodiscordant unprotected (i.e., without a condom) anal sex partners, engagement in sex for money and/or drugs, and frequency of recent methamphetamine use; additionally, increased relative exposure to HBM (vs. SCT or SST) messages was uniquely associated with reductions in the overall number of non-primary anal sex partners (all p <= 0.05, two-tailed). Pilot data demonstrated that text messages based on the principles of HBM and SCT reduced sentinel HIV risk and drug use behaviors in active methamphetamine users. C1 [Reback, Cathy J.; Fletcher, Jesse B.] Friends Res Inst Inc, Los Angeles, CA 90028 USA. [Reback, Cathy J.] Univ Calif Los Angeles, David Geffen Sch Med, Integrated Subst Abuse Programs, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90095 USA. [Shoptaw, Steven] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med, Los Angeles, CA 90095 USA. [Mansergh, Gordon] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, NCHHSTP, Atlanta, GA USA. RP Reback, CJ (reprint author), Friends Res Inst Inc, 1419 La Brea Ave, Los Angeles, CA 90028 USA. EM reback@friendsresearch.org FU Centers for Disease Control and Prevention [UR6PS000312]; National Institute of Mental Health [P30 MH58107] FX This study was supported by the Centers for Disease Control and Prevention, cooperative agreement #UR6PS000312. Drs. Reback and Shoptaw acknowledge additional support from the National Institute of Mental Health (P30 MH58107). The authors would also like to thank Catherine M. Branson, Joshua Rusow, and Kimberly Kisler, MPH, Ph.D. for their contributions to the development of this manuscript, and Deborah Ling Grant Ph.D., MPH, MBA for her work as Project director during the implementation of the study. NR 69 TC 1 Z9 1 U1 4 U2 12 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD JUN PY 2015 VL 19 SU 2 BP S130 EP S141 DI 10.1007/s10461-014-0985-7 PG 12 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CM4IA UT WOS:000357646800008 ER PT J AU Kaplan, JE Dominguez, K Jobarteh, K Spira, TJ AF Kaplan, Jonathan E. Dominguez, Kenneth Jobarteh, Kebba Spira, Thomas J. TI Postexposure Prophylaxis Against Human Immunodeficiency Virus (HIV): New Guidelines From the WHO: A Perspective SO CLINICAL INFECTIOUS DISEASES LA English DT Article ID HEALTH-CARE WORKERS; TRANSMISSION; PREVENTION; MACAQUES; ZIDOVUDINE; EXPOSURES; EFFICACY C1 [Kaplan, Jonathan E.; Jobarteh, Kebba; Spira, Thomas J.] Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA USA. [Dominguez, Kenneth] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. RP Kaplan, JE (reprint author), Ctr Dis Control & Prevent, Div Global HIV AIDS, Mailstop E-04,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM jxk2@cdc.gov FU World Health Organization FX This article appears as part of the supplement "HIV Postexposure Prophylaxis," sponsored by the World Health Organization. NR 24 TC 2 Z9 3 U1 1 U2 2 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 SU 3 BP S196 EP S199 DI 10.1093/cid/civ087 PG 4 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZZ UT WOS:000358072500009 PM 25972504 ER PT J AU Penazzato, M Dominguez, K Cotton, M Barlow-Mosha, L Ford, N AF Penazzato, Martina Dominguez, Ken Cotton, Mark Barlow-Mosha, Linda Ford, Nathan TI Choice of Antiretroviral Drugs for Postexposure Prophylaxis for Children: A Systematic Review SO CLINICAL INFECTIOUS DISEASES LA English DT Review DE antiretroviral; children; postexposure prophylaxis; tolerability; safety ID REVERSE-TRANSCRIPTASE INHIBITOR; HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-INFECTED CHILDREN; OPEN-LABEL; TRIAL; RISK; NEVIRAPINE; INJURIES; EXPOSURE; THERAPY AB Background. This systematic review aimed to assess the safety and efficacy of antiretroviral options for postexposure prophylaxis (PEP). Recognizing the limited data on the safety and efficacy of antiretroviral drugs for PEP in children, this review was extended to include consideration of data on the use of antiretroviral drugs for treatment of infants and children living with human immunodeficiency virus. Methods. The PEP literature was assessed to identify studies reporting safety and completion rates for children given PEP, and this information was complemented by safety and efficacy data for drugs used in antiretroviral therapy. The proportion of patients experiencing each outcome was calculated and data were pooled using randomeffects meta-analysis. Results. Three prospective cohort studies reported outcomes of children given zidovudine (ZDV) plus lamivudine (3TC) as a 2-drug PEP regimen. The proportion of children completing the full 28-day course of PEP was 64.0% (95% confidence interval [CI], 41.2%-86.8%), whereas the proportion discontinuing due to adverse events was 4.5% (95% CI,.4%-8.6%). One randomized trial compared abacavir (ABC) plus lamivudine (3TC) and ZDV+3TC as part of a dual or triple first-line antiretroviral therapy regimen; this study showed better efficacy in the ABC-containing combinations and no difference in the time to first serious adverse event. Three randomized trials compared lopinavir/ritonavir (LPV/r) to nevirapine (NVP) for antiretroviral therapy and showed a lower risk of treatment discontinuations associated with LPV/r vs NVP (hazard ratio, 0.56 [95% CI, .41-.75]) but no difference in drug-related adverse events. The overall quality of the evidence was rated as very low. Conclusions. This review supports ZDV+3TC+LPV/r as the preferred 3-drug regimen for PEP in children. C1 [Penazzato, Martina; Ford, Nathan] WHO, Dept HIV AIDS, CH-1211 Geneva, Switzerland. [Dominguez, Ken] US Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Cotton, Mark] Univ Stellenbosch, Dept Pediat & Child Hlth, Div Paediat Infect Dis, Cape Town, South Africa. [Cotton, Mark] Tygerberg Childrens Hosp, Cape Town, South Africa. [Barlow-Mosha, Linda] Makerere Univ Johns Hopkins Univ Res Collaborat, Kampala, Uganda. RP Penazzato, M (reprint author), WHO, Dept HIV AIDS, 20 Ave Appia, CH-1211 Geneva, Switzerland. EM penazzatom@who.int FU Bill & Melinda Gates Foundation FX This work was in part supported by funds from the Bill & Melinda Gates Foundation. NR 25 TC 2 Z9 3 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD JUN 1 PY 2015 VL 60 SU 3 BP S177 EP S181 DI 10.1093/cid/civ110 PG 5 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CM9ZZ UT WOS:000358072500005 PM 25972500 ER PT J AU Nduba, V Van't Hoog, AH Mitchell, E Onyango, P Laserson, K Borgdorff, M AF Nduba, Videlis Van't Hoog, Anna H. Mitchell, Ellen Onyango, Peter Laserson, Kayla Borgdorff, Martien TI Prevalence of tuberculosis in adolescents, western Kenya: implications for control programs SO INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Tuberculosis; Pulmonary; Diagnosis; Epidemiology; Mantoux ID CHILDHOOD PULMONARY TUBERCULOSIS; VACCINE; DISEASE; INFECTION; BURDEN; SYSTEM; TB AB Objective: The aim of this study was to determine the prevalence of tuberculosis (TB) in adolescents in western Kenya. Methods: A cohort study of 5004 adolescents aged 12-18 years was conducted. Adolescents were screened for prevalent TB using clinical criteria, history of TB contact, and a Mantoux test. Cases of suspected TB were investigated through two sputum examinations (microscopy and liquid culture) and chest radiography. Results: Out of 5004 adolescents enrolled, 1960 (39.2%) were identified with suspected TB, including 1544 with a positive Mantoux (prevalence 1544/4808, 32.1%), 515 with symptoms suggestive of TB (10.3%), and 144 (2.9%) with household TB contact. Sixteen culture-confirmed (definite) and 18 probable pulmonary TB (PTB) cases were identified, reflecting a prevalence estimate of 3.2/1000 (definite) and 6.8/1000 all PTB, respectively. Only one smear-positive case was detected. The case notification rate among 12-18-year-old adolescents for all TB was 101/100 000, yielding a patient diagnostic rate of 0.13 (95% confidence interval 0.03-3.7) cases detected per person-year for all TB. Conclusion: The prevalence of PTB among adolescents is high, with the majority of cases not detected routinely. Innovative active case finding including the wider use of Xpert MTB/RIF is needed to detect smear-negative TB among adolescents. (C) 2015 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. C1 [Nduba, Videlis; Van't Hoog, Anna H.; Onyango, Peter; Laserson, Kayla; Borgdorff, Martien] Kenya Med Res Inst KEMRI, CGHR Res & Publ Hlth Collaborat, TB Res Branch, Kisumu, Kenya. [Nduba, Videlis; Van't Hoog, Anna H.; Mitchell, Ellen; Borgdorff, Martien] Univ Amsterdam, Acad Med Ctr, NL-1012 WX Amsterdam, Netherlands. [Nduba, Videlis] Ctr Resp Dis Res CRDR, Kenya Med Res Inst, Nairobi, Kenya. [Van't Hoog, Anna H.] Univ Amsterdam, Amsterdam Inst Global Hlth & Dev, NL-1012 WX Amsterdam, Netherlands. [Mitchell, Ellen] KNCV TB Fdn, The Hague, Netherlands. [Laserson, Kayla; Borgdorff, Martien] CDC, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Nduba, V (reprint author), Kenya Med Res Inst KEMRI, CGHR Res & Publ Hlth Collaborat, TB Res Branch, POB 1578, Kisumu, Kenya. EM vnduba@kemricdc.org FU European and Developing Countries Clinical Trials Partnership [IP_07_32080_003]; Aeras Global TB Vaccine Foundation; KNCV TB Foundation; NACCAP; Vienna School of Clinical Research; San Rafaele Laboratory, Milan, Italy FX This study was supported by grants from The European and Developing Countries Clinical Trials Partnership (grant number: IP_07_32080_003), Aeras Global TB Vaccine Foundation, KNCV TB Foundation, NACCAP, Vienna School of Clinical Research, and San Rafaele Laboratory, Milan, Italy. NR 27 TC 3 Z9 3 U1 1 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1201-9712 EI 1878-3511 J9 INT J INFECT DIS JI Int. J. Infect. Dis. PD JUN PY 2015 VL 35 BP 11 EP 17 DI 10.1016/j.ijid.2015.03.008 PG 7 WC Infectious Diseases SC Infectious Diseases GA CM9CO UT WOS:000358004000003 PM 25770911 ER PT J AU Kennedy, SM Davis, SP Thorne, SL AF Kennedy, Sara M. Davis, Shane P. Thorne, Stacy L. TI Smoke-Free Policies in US Prisons and Jails: A Review of the Literature SO NICOTINE & TOBACCO RESEARCH LA English DT Review ID UNITED-STATES; CIGARETTE-SMOKING; CORRECTIONAL FACILITIES; QUITTING SMOKING; SECONDHAND SMOKE; TOBACCO BAN; EXPOSURE; INMATES; HEALTH; CESSATION AB Introduction: Despite progress in limiting exposure to secondhand smoke (SHS) in the United States, little is known about the impact of smoke-free polices in prisons and jails. SHS exposure in this setting may be great, as smoking prevalence among inmates is more than three times higher than among non-incarcerated adults. To inform the implementation of smoke-free policies, this article reviews the literature on the extent, nature, and impact of smoke-free policies in U.S. prisons and jails. Methods: We systematically searched PubMed, Embase, EconLit, and Social Services Abstracts databases. We examined studies published prior to January 2014 that described policies prohibiting smoking tobacco in adult U.S. correctional facilities. Results: Twenty-seven studies met inclusion criteria. Smoke-free policies in prisons were rare in the 1980s but, by 2007, 87% prohibited smoking indoors. Policies reduced SHS exposure and a small body of evidence suggests they are associated with health benefits. We did not identify any studies documenting economic outcomes. Non-compliance with policies was documented in a small number of prisons and jails, with 20%-76% of inmates reporting smoking in violation of a policy. Despite barriers, policies were implemented successfully when access to contraband tobacco was limited and penalties were enforced. Conclusion: Smoke-free policies have become increasingly common in prisons and jails, but evidence suggests they are not consistently implemented. Future studies should examine the health and economic outcomes of smoke-free policies in prisons and jails. By implementing smoke-free policies, prisons and jails have an opportunity to improve the health of staff and inmates. C1 [Kennedy, Sara M.] RTI Int, Biostat & Epidemiol, Atlanta, GA 30341 USA. [Davis, Shane P.; Thorne, Stacy L.] Ctr Dis Control & Prevent, Epidemiol Branch, Off Smoking & Hlth, Atlanta, GA USA. RP Kennedy, SM (reprint author), RTI Int, 2951 Flowers Rd South,Suite 119, Atlanta, GA 30341 USA. EM vnd2@cdc.gov FU U.S. Department of Energy; CDC FX This research was supported in part by an appointment to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 58 TC 5 Z9 5 U1 1 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1462-2203 EI 1469-994X J9 NICOTINE TOB RES JI Nicotine Tob. Res. PD JUN PY 2015 VL 17 IS 6 BP 629 EP 635 DI 10.1093/ntr/ntu225 PG 7 WC Substance Abuse; Public, Environmental & Occupational Health SC Substance Abuse; Public, Environmental & Occupational Health GA CM7PS UT WOS:000357887900001 PM 25475088 ER PT J AU Deziel, NC Friesen, MC Hoppin, JA Hines, CJ Thomas, K Freeman, LEB AF Deziel, Nicole C. Friesen, Melissa C. Hoppin, Jane A. Hines, Cynthia J. Thomas, Kent Freeman, Laura E. Beane TI A Review of Nonoccupational Pathways for Pesticide Exposure in Women Living in Agricultural Areas SO ENVIRONMENTAL HEALTH PERSPECTIVES LA English DT Review ID URINARY METABOLITE LEVELS; FARM FAMILY EXPOSURE; HERBICIDE EXPOSURE; CHILDRENS EXPOSURE; PREGNANT-WOMEN; ONTARIO FARMS; UNITED-STATES; COMMUNITY; PROXIMITY; HOMES AB BACKGROUND: Women living in agricultural areas may experience high pesticide exposures compared with women in urban or suburban areas because of their proximity to farm activities. OBJECTIVE: Our objective was to review the evidence in the published literature for the contribution of nonoccupational pathways of pesticide exposure in women living in North American agricultural areas. METHODS: We evaluated the following nonoccupational exposure pathways: para-occupational (i.e., take-home or bystander exposure), agricultural drift, residential pesticide use, and dietary ingestion. We also evaluated the role of hygiene factors (e.g., house cleaning, shoe removal). RESULTS: Among 35 publications identified (published 1995-2013), several reported significant or suggestive (p < 0.1) associations between para-occupational (n = 19) and agricultural drift (n = 10) pathways and pesticide dust or biomarker levels, and 3 observed that residential use was associated with pesticide concentrations in dust. The 4 studies related to ingestion reported low detection rates of most pesticides in water; additional studies are needed to draw conclusions about the importance of this pathway. Hygiene factors were not consistently linked to exposure among the 18 relevant publications identified. CONCLUSIONS: Evidence supported the importance of para-occupational, drift, and residential use pathways. Disentangling exposure pathways was difficult because agricultural populations are concurrently exposed to pesticides via multiple pathways. Most evidence was based on measurements of pesticides in residential dust, which are applicable to any household member and are not specific to women. An improved understanding of nonoccupational pesticide exposure pathways in women living in agricultural areas is critical for studying health effects in women and for designing effective exposure-reduction strategies. C1 [Deziel, Nicole C.; Friesen, Melissa C.; Freeman, Laura E. Beane] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Deziel, Nicole C.] Yale Univ, Sch Publ Hlth, Dept Environm Hlth Sci, New Haven, CT 06510 USA. [Hoppin, Jane A.] N Carolina State Univ, Dept Biol Sci, Raleigh, NC 27695 USA. [Hines, Cynthia J.] Ctr Dis Control & Prevent, Natl Inst Occupat Safety & Hlth, Div Surveillance Hazard Evaluat & Field Studie, Cincinnati, OH USA. [Thomas, Kent] US EPA, Natl Exposure Res Lab, Res Triangle Pk, NC 27711 USA. RP Deziel, NC (reprint author), Yale Univ, Sch Publ Hlth, 60 Coll St, New Haven, CT 06510 USA. EM nicole.deziel@yale.edu RI Friesen, Melissa/A-5362-2009; Beane Freeman, Laura/C-4468-2015 OI Beane Freeman, Laura/0000-0003-1294-4124 FU National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics [Z01CP010119] FX This work was supported by the Intramural Research Program of the National Institutes of Health, National Cancer Institute, Division of Cancer Epidemiology and Genetics (Z01CP010119). NR 52 TC 9 Z9 10 U1 4 U2 23 PU US DEPT HEALTH HUMAN SCIENCES PUBLIC HEALTH SCIENCE PI RES TRIANGLE PK PA NATL INST HEALTH, NATL INST ENVIRONMENTAL HEALTH SCIENCES, PO BOX 12233, RES TRIANGLE PK, NC 27709-2233 USA SN 0091-6765 EI 1552-9924 J9 ENVIRON HEALTH PERSP JI Environ. Health Perspect. PD JUN PY 2015 VL 123 IS 6 BP 515 EP 524 DI 10.1289/ehp.1408273 PG 10 WC Environmental Sciences; Public, Environmental & Occupational Health; Toxicology SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health; Toxicology GA CL9KD UT WOS:000357296200011 PM 25636067 ER PT J AU Page, K Tsui, J Maher, L Choopanya, K Vanichseni, S Mock, PA Celum, C Martin, M AF Page, Kimberly Tsui, Judith Maher, Lisa Choopanya, Kachit Vanichseni, Suphak Mock, Philip A. Celum, Connie Martin, Michael TI Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article ID MEDICATION-ASSISTED TREATMENT; RANDOMIZED-CONTROLLED-TRIAL; FEMALE SEX WORKERS; GENDER-DIFFERENCES; MAINTENANCE THERAPY; OPIOID DEPENDENCE; INTERIM GUIDANCE; RISK BEHAVIORS; AFRICAN WOMEN; USERS AB Women who inject drugs (WWID) are at higher risk of HIV compared with their male counterparts as a result of multiple factors, including biological, behavioral, and sociostructural factors, yet comparatively little effort has been invested in testing and delivering prevention methods that directly target this group. In this article, we discuss the need for expanded prevention interventions for WWID, focusing on 2 safe, effective, and approved, yet underutilized biomedical prevention methods: opiate agonist therapy (OAT) and oral pre-exposure prophylaxis (PrEP). Although both interventions are well researched, they have not been well examined in the context of gender. We discuss the drivers of women injectors' higher HIV risk, review the effectiveness of OAT and PrEP interventions among women, and explain why these new HIV prevention tools should be prioritized for WWID. There is substantial potential for impact of OAT and PrEP programs for WWID in the context of broader gender-responsive HIV prevention initiatives. Although awaiting efficacy data on other biomedical approaches in the HIV prevention research "pipeline," we propose that the scale-up and implementation of these proven, safe, and effective interventions are needed now. C1 [Page, Kimberly] Univ New Mexico, Hlth Sci Ctr, Dept Internal Med Epidemiol Biostat & Prevent Med, Albuquerque, NM 87131 USA. [Tsui, Judith] Univ Washington, Dept Med, Seattle, WA USA. [Maher, Lisa] UNSW Australia, Kirby Inst Infect & Immun, Sydney, NSW, Australia. [Choopanya, Kachit; Vanichseni, Suphak] Taksin Hosp, Bangkok Tenofovir Study Grp, Bangkok, Thailand. [Mock, Philip A.; Martin, Michael] US Ctr Dis Control & Prevent Collaborat, Thailand MOPH, HIV Clin Res, Nonthaburi, Thailand. [Celum, Connie] Univ Washington, Dept Global Hlth & Med, Seattle, WA 98195 USA. [Martin, Michael] Ctr Dis Control & Prevent, HIV Clin Res, Div HIV AIDS Prevent, Atlanta, GA USA. RP Page, K (reprint author), Univ New Mexico, Hlth Sci Ctr, Dept Internal Med, Epidemiol Biostat & Prevent Med, MSC10 5550,1 Univ New Mexico, Albuquerque, NM 87131 USA. EM pagek@salud.unm.edu FU U.S. Centers for Disease Control and Prevention; Bangkok Metropolitan Administration FX The Bangkok Tenofovir Study was supported by the U.S. Centers for Disease Control and Prevention and the Bangkok Metropolitan Administration. Study drug was donated by Gilead Sciences. NR 78 TC 2 Z9 2 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD JUN 1 PY 2015 VL 69 SU 2 BP S169 EP S175 DI 10.1097/QAI.0000000000000641 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CL9TK UT WOS:000357320800013 PM 25978484 ER PT J AU Suaza-Vasco, J Lopez-Rubio, A Galeano, J Uribe, S Velez, I Porter, C AF Suaza-Vasco, Juan Lopez-Rubio, Andres Galeano, Juan Uribe, Sandra Velez, Ivan Porter, Charles TI THE SABETHINES OF NORTHERN ANDEAN COFFEE-GROWING REGIONS OF COLOMBIA SO JOURNAL OF THE AMERICAN MOSQUITO CONTROL ASSOCIATION LA English DT Article DE Sabethini; arbovirus; phytotelmata; Andean region ID ARTHROPOD-BORNE VIRUSES; MOSQUITOS DIPTERA; CULICIDAE DIPTERA; YELLOW-FEVER; PHYLOGENY; CLASSIFICATION; TRINIDAD; BRAZIL AB Sampling for sabethine mosquitoes occurred intermittently from September 2007 to April 2013 in 17 municipalities, located in 5 departments (divisions) in the northern Andean coffee-growing regions of Colombia. Of the 9 genera within the Sabethini tribe known to occur in the Neotropical region, 6 were encountered including 15 species: Jonhhelkinia ulopus, Limatus durhamii, Sobethes ignotus, Sa,. luxodens, So. undosus, Shannoniana fluviatilis, Trichoprosopon compressum, Tr. digitatum, Tr. evansae, Tr. pallidiventer s.l., Tr. pallidiventer s.s., Wyeomyia arthrostigma, Wy. oblita, Wy. ulocoma, and Wy. undulata. The species So. luxodens and Wy. undulata constitute new records for Colombia. These records broaden the knowledge of this important group that includes some important species related to the arbovirus transmission. Records are from the northern Colombian Andes, a region noted for coffee cultivation and ecotourism. C1 [Suaza-Vasco, Juan; Lopez-Rubio, Andres; Galeano, Juan; Uribe, Sandra] Univ Nacl Colombia, Fac Ciencias, Grp Invest Sistemat Mol, Medellin, Colombia. [Lopez-Rubio, Andres] Inst Univ, Direcc Invest, Tecnol Antioquia, Medellin, Colombia. [Lopez-Rubio, Andres; Velez, Ivan] Univ Antioquia, Programa Estudio & Control Enfermedades, Fac Med, Medellin, Colombia. [Porter, Charles] Ctr Dis Control & Prevent CDC, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Suaza-Vasco, J (reprint author), Univ Nacl Colombia, Fac Ciencias, Grp Invest Sistemat Mol, Calle 59A 63-20 Bloque 16,Lab 102, Medellin, Colombia. FU COL-CIENCIAS [1423-521-28794, 567]; Universidad de Antioquia-CODI [E01551]; Tecnologico de Antioquia-CODEI [104458] FX Special thanks to the Medical Entomology and Vector Control Program personnel of Chinchina, Cordoba, Pueblo Rico, Quimbaya, and Salento municipalities, the Federacion Nacional de Cafeteros committee at Alcala, Anserma, Ciudad Bolivar, Filandia, Fredonia, Hispania, Jardin, Jerico, Tamesis, Valparaiso, and Venecia, and CENICAFE, which helped with the collection, localities selection, and specimen-sampling efforts. This work received funding from COL-CIENCIAS (contract 1423-521-28794, 567, doctoral funding), Universidad de Antioquia-CODI (contract E01551), and Tecnologico de Antioquia-CODEI (project funding 104458). Thanks to Jovany Barajas, Libertad Ochoa, and everyone from the Entomology Unit at PECET-Universidad de Antioquia for their collaboration in field and laboratory work. We also thank Richard Hoyos and other members of GSMUN-Universidad Nacional de Colombia, for their help with field work. NR 63 TC 1 Z9 1 U1 1 U2 5 PU AMER MOSQUITO CONTROL ASSOC PI MOUNT LAUREL PA 15000 COMMERCE PARKWAY, SUITE C, MOUNT LAUREL, NJ 08054 USA SN 8756-971X EI 1943-6270 J9 J AM MOSQUITO CONTR JI J. Am. Mosq. Control Assoc. PD JUN PY 2015 VL 31 IS 2 BP 125 EP 134 PG 10 WC Entomology SC Entomology GA CM5DM UT WOS:000357707000001 PM 26181687 ER PT J AU Marks, M Katz, S Chi, KH Vahi, V Sun, YC Mabey, DC Solomon, AW Chen, CY Pillay, A AF Marks, Michael Katz, Samantha Chi, Kai-Hua Vahi, Ventis Sun, Yongcheng Mabey, David C. Solomon, Anthony W. Chen, Cheng Y. Pillay, Allan TI Failure of PCR to Detect Treponema pallidum ssp pertenue DNA in Blood in Latent Yaws SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID TIME MULTIPLEX PCR; SOLOMON-ISLANDS; AZITHROMYCIN RESISTANCE; HAEMOPHILUS-DUCREYI; SKIN ULCERS; SYPHILIS; CHILDREN; GENE AB Yaws, caused by Treponema pallidum ssp. pertenue, is a neglected tropical disease closely related to venereal syphilis and is targeted for eradication by 2020. Latent yaws represents a diagnostic challenge, and current tools cannot adequately distinguish between individuals with true latent infection and individuals who are serofast following successful treatment. PCR on blood has previously been shown to detect T. pallidum DNA in patients with syphilis, suggesting that this approach may be of value in yaws. We performed real-time PCR for Treponema pallidum ssp. pertenue on blood samples from 140 children with positive T. pallidum Particle Agglutination (TPPA) and Rapid Plasma Reagin (RPR) tests and 7 controls (negative serology), all collected as part of a prospective study of yaws in the Solomon Islands. All samples were also tested by a nested PCR for T. pallidum. 12 patients had clinical evidence of active yaws whilst 128 were considered to have latent yaws. 43 children had high titre rapid plasma reagins (RPRs) of >= 1:32. PCR testing with both assays gave negative results in all cases. It is possible that the failure to detect T. pallidum ssp. pertenue in blood reflects lower loads of organism in latent yaws compared to those in latent infection with T. pallidum ssp. pertenue, and/or a lower propensity for haematogenous dissemination in yaws than in syphilis. As the goal of the yaws control programme is eradication, a tool that can differentiate true latent infection from individuals who are serofast would be of value; however, PCR of blood is not that tool. C1 [Marks, Michael; Mabey, David C.; Solomon, Anthony W.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England. [Marks, Michael; Mabey, David C.; Solomon, Anthony W.] Hosp Trop Dis, London NW1 0PE, England. [Katz, Samantha; Chi, Kai-Hua; Sun, Yongcheng; Chen, Cheng Y.; Pillay, Allan] Ctr Dis Control & Prevent, Lab Reference & Res Branch, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Vahi, Ventis] Minist Hlth & Med Serv, Honiara, Solomon Islands. RP Marks, M (reprint author), London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England. EM Michael.marks@lshtm.ac.uk OI Mabey, David/0000-0002-0031-8276; Marks, Michael/0000-0002-7585-4743; Solomon, Anthony/0000-0001-7101-6649 FU United Kingdom's Department for International Development, though the Global Trachoma Mapping; Wellcome Trust Clinical Research Fellowship [102807]; Wellcome Trust Intermediate Clinical Fellowship [098521] FX The fieldwork for this study was supported by the United Kingdom's Department for International Development, though the Global Trachoma Mapping grant to Sightsavers. MM was supported by a Wellcome Trust Clinical Research Fellowship - 102807. AWS was supported by a Wellcome Trust Intermediate Clinical Fellowship - 098521. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 19 TC 1 Z9 1 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD JUN PY 2015 VL 9 IS 6 AR e0003905 DI 10.1371/journal.pntd.0003905 PG 7 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CM0VX UT WOS:000357398100067 PM 26125585 ER PT J AU Millien, MF Pierre-Louis, JB Wallace, R Caldas, E Rwangabgoba, JM Poncelet, JL Cosivi, O Vilas, VJD AF Millien, Max F. Pierre-Louis, Jocelyne B. Wallace, Ryan Caldas, Eduardo Rwangabgoba, Jean M. Poncelet, Jean L. Cosivi, Ottorino Vilas, Victor J. Del Rio TI Control of Dog Mediated Human Rabies in Haiti: No Time to Spare SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Review ID ELIMINATION; AMERICA; HEALTH; BITES AB The American region has pledged to eliminate dog-mediated human rabies by 2015. As part of these efforts, we describe the findings of a desk and field mission review of Haiti's rabies situation by the end of 2013. While government officials recognize the importance of dog-mediated rabies control, and the national rabies plan adequately contemplates the basic capacities to that effect, regular and sufficient implementation, for example, of dog vaccination, is hampered by limited funding. Compounding insufficient funding and human resources, official surveillance figures do not accurately reflect the risk to the population, as evidenced by the large number of rabid dogs detected by focalized and enhanced surveillance activities conducted by the Ministry of Agriculture, Natural Resources and Rural Development (MARNDR) and the Health and Population Ministry (MSPP) with the technical assistance of the United States Centers for Disease Control and Prevention. Although international support is common, either in the form of on-the-ground technical support or donations of immunobiologicals, it is not comprehensive. In addition, there is limited coordination with MARNDR/MSPP and with other actors at the strategic or operational level due to human resources limitations. Given these findings, the 2015 elimination goal in the region is compromised by the situation in Haiti where control of the disease is not yet in sight despite the best efforts of the resolute national officials. More importantly, dog-mediated rabies is still a threat to the Haitian population. C1 [Millien, Max F.] Minist Agr Nat Resources & Rural Dev, Port Au Prince, Haiti. [Pierre-Louis, Jocelyne B.] Minist Publ Hlth & Populat, Port Au Prince, Haiti. [Wallace, Ryan] Ctr Dis Control & Prevent, Atlanta, GA USA. [Caldas, Eduardo] Minist Hlth, Serv Vigilancia Saude, Brasilia, DF, Brazil. [Rwangabgoba, Jean M.; Poncelet, Jean L.] Pan Amer Hlth Org, Port Au Prince, Haiti. [Cosivi, Ottorino; Vilas, Victor J. Del Rio] Pan Amer Hlth Org, Pan Amer Ctr Foot and Mouth Dis PANAFTOSA, Rio De Janeiro, Brazil. RP Millien, MF (reprint author), Minist Agr Nat Resources & Rural Dev, Port Au Prince, Haiti. EM vdelrio@paho.org NR 12 TC 1 Z9 1 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD JUN PY 2015 VL 9 IS 6 AR e0003806 DI 10.1371/journal.pntd.0003806 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CM0VX UT WOS:000357398100020 PM 26110845 ER PT J AU Harder, T Abu Sin, M Bosch-Capblanch, X Coignard, B Gomes, HDC Duclos, P Eckmanns, T Elder, R Ellis, S Forland, F Garner, P James, R Jansen, A Krause, G Levy-Bruhl, D Morgan, A Meerpohl, JJ Norris, S Rehfuess, E Sanchez-Vivar, A Schunemann, H Takla, A Wichmann, O Zingg, W Zuiderent-Jerak, T AF Harder, Thomas Abu Sin, Muna Bosch-Capblanch, Xavier Coignard, Bruno Gomes, Helena de Carvalho Duclos, Phillippe Eckmanns, Tim Elder, Randy Ellis, Simon Forland, Frode Garner, Paul James, Roberta Jansen, Andreas Krause, Gerard Levy-Bruhl, Daniel Morgan, Antony Meerpohl, Joerg J. Norris, Susan Rehfuess, Eva Sanchez-Vivar, Alex Schuenemann, Holger Takla, Anja Wichmann, Ole Zingg, Walter Zuiderent-Jerak, Teun TI Towards a framework for evaluating and grading evidence in public health SO HEALTH POLICY LA English DT Article DE Evidence-based health care; Public health; Infectious diseases; GRADE; PRECEPT ID VACCINATION; QUALITY; RECOMMENDATIONS AB The Project on a Framework for Rating Evidence in Public Health (PRECEPT) is an international collaboration of public health institutes and universities which has been funded by the European Centre for Disease Prevention and Control (ECDC) since 2012. Main objective is to define a framework for evaluating and grading evidence in the field of public health, with particular focus on infectious disease prevention and control. As part of the peer review process, an international expert meeting was held on 13-1 4 June 2013 in Berlin. Participants were members of the PRECEPT team and selected experts from national public health institutes, World Health Organization (WHO), and academic institutions. The aim of the meeting was to discuss the draft framework and its application to two examples from infectious disease prevention and control. This article introduces the draft PRECEPT framework and reports on the meeting, its structure, most relevant discussions and major conclusions. (C) 2015 Elsevier Ireland Ltd. All rights reserved. C1 [Harder, Thomas] Robert Koch Inst, Dept Infect Dis Epidemiol, Immunizat Unit, D-13353 Berlin, Germany. [Abu Sin, Muna; Eckmanns, Tim; Takla, Anja; Wichmann, Ole] Robert Koch Inst, D-13353 Berlin, Germany. [Bosch-Capblanch, Xavier] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Coignard, Bruno; Levy-Bruhl, Daniel] Inst Veille Sanitaire, Paris, France. [Gomes, Helena de Carvalho; Jansen, Andreas] European Ctr Dis Prevent & Control ECDC, Stockholm, Sweden. [Duclos, Phillippe; Norris, Susan] WHO, CH-1211 Geneva, Switzerland. [Elder, Randy] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ellis, Simon; Morgan, Antony] Natl Inst Hlth & Care Excellence NICE, London, England. [Forland, Frode] Norwegian Inst Publ Hlth, Oslo, Norway. [Garner, Paul] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [James, Roberta] SIGN, Edinburgh, Midlothian, Scotland. [Krause, Gerard] Helmholtz Ctr Infect Res, Braunschweig, Germany. [Meerpohl, Joerg J.] German Cochrane Ctr, Freiburg, Germany. [Rehfuess, Eva] Univ Munich, Inst Med Informat Biometry & Epidemiol, D-81377 Munich, Germany. [Sanchez-Vivar, Alex] HPS, Glasgow, Lanark, Scotland. [Sanchez-Vivar, Alex] Scottish Hlth Protect Network HPN, Glasgow, Lanark, Scotland. [Schuenemann, Holger] McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat & Med, Hamilton, ON, Canada. [Zingg, Walter] Hop Cantonal Univ Geneva, Geneva, Switzerland. [Zuiderent-Jerak, Teun] Linkoping Univ, Dept Themat Studies Technol & Social Change, S-58183 Linkoping, Sweden. RP Harder, T (reprint author), Robert Koch Inst, Dept Infect Dis Epidemiol, Immunizat Unit, Seestr 10, D-13353 Berlin, Germany. EM HarderT@rki.de OI Krause, Gerard/0000-0003-3328-8808; Garner, Paul/0000-0002-0607-6941 FU World Health Organization [001] NR 16 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0168-8510 EI 1872-6054 J9 HEALTH POLICY JI Health Policy PD JUN PY 2015 VL 119 IS 6 BP 732 EP 736 DI 10.1016/j.healthpol.2015.02.010 PG 5 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CL0LE UT WOS:000356633400004 PM 25863647 ER PT J AU Braekkan, S Grosse, S Okoroh, EM Tsai, J Cannegieter, SC Naess, IA Krokstad, S Hansen, JB Skjeldestad, FE AF Braekkan, S. Grosse, S. Okoroh, E. M. Tsai, J. Cannegieter, S. C. Naess, I. A. Krokstad, S. Hansen, J-B Skjeldestad, F-E TI Unprovoked deep vein thrombosis is associated with future risk of disability pension SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Braekkan, S.; Hansen, J-B] Uit, Dept Clin Med, TREC, Tromso, Norway. [Braekkan, S.; Hansen, J-B] Univ Hosp North Norway, Div Internal Med, Tromso, Norway. [Grosse, S.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Okoroh, E. M.; Tsai, J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Cannegieter, S. C.] Leiden Univ, Med Ctr, Dept Clin Epidemiol, Leiden, Netherlands. [Naess, I. A.] Univ Trondheim Hosp, Dept Hematol, Trondheim, Norway. [Krokstad, S.] Norwegian Univ Sci & Technol, Dept Publ Hlth & Gen Practice, HUNT Res Ctr, Levanger, Norway. [Skjeldestad, F-E] Uit, Dept Community Med, Res Grp Epidemiol Chron Dis, Tromso, Norway. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA OR134 BP 145 EP 145 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426901384 ER PT J AU Soucie, M Monahan, PE Mazepa, M Kulkarni, R Konkle, BA AF Soucie, M. Monahan, P. E. Mazepa, M. Kulkarni, R. Konkle, B. A. CA US Hemophilia Treatment Ctr Networ TI Relations between factor activity level and joint bleeding in a large cohort of males with mild and moderate hemophilia in the United States SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Soucie, M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Monahan, P. E.; Mazepa, M.] Univ N Carolina, Chapel Hill, NC USA. [Kulkarni, R.] Michigan State Univ, E Lansing, MI 48824 USA. [Konkle, B. A.] Puget Sound Blood Ctr, Seattle, WA 98104 USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA OR162 BP 157 EP 157 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426901412 ER PT J AU Manco-Johnson, M Byams, V Cooke, B Recht, M Aschman, D Dudley, B Voutsis, M Oakley, M AF Manco-Johnson, M. Byams, V Cooke, B. Recht, M. Aschman, D. Dudley, B. Voutsis, M. Oakley, M. CA US Hemophilia Treatment Ctr TI US surveillance of prophylaxis use among persons with hemophilia a receiving care at hemophilia treatment centers (HTCS) SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Manco-Johnson, M.] Univ Colorado Denver Anschutz, Pediat, Aurora, CO USA. [Byams, V; Cooke, B.; Oakley, M.] CDC, Div Blood Disorders, NCBDDD, Atlanta, GA 30333 USA. [Recht, M.] Oregon Hlth & Sci Univ, Pediat, Portland, OR 97201 USA. [Aschman, D.; Dudley, B.] Amer Thrombosis & Hemostasis Network, Riverwoods, IL USA. [Voutsis, M.] Icahn Sch Med Mt Sinai, Med, New York, NY 10029 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA PO285-MON BP 366 EP 366 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426902442 ER PT J AU Sword-Buster, A Wendelboe, A Campbell, J Beckman, M Reyes, N Raskob, GE AF Sword-Buster, A. Wendelboe, A. Campbell, J. Beckman, M. Reyes, N. Raskob, G. E. TI Developing a case definition for venous thromboembolism-related deaths using death certificates SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS LA English DT Meeting Abstract C1 [Sword-Buster, A.; Wendelboe, A.; Campbell, J.; Raskob, G. E.] Univ Oklahoma, Coll Publ Hlth, Oklahoma City, OK USA. [Beckman, M.; Reyes, N.] Ctr Dis Control & Prevent, Div Blood Disorders, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1538-7933 EI 1538-7836 J9 J THROMB HAEMOST JI J. Thromb. Haemost. PD JUN PY 2015 VL 13 SU 2 SI SI MA PO637-WED BP 982 EP 982 PG 1 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA CK7QJ UT WOS:000356426905473 ER PT J AU Olmstead, AD Montoya, V Joy, J Poon, AF Jacka, B Lamoury, F Applegate, T Monaner, J Khudyakov, Y Grebely, J Cook, D Harrigan, PR Krajden, M AF Olmstead, A. D. Montoya, V. Joy, J. Poon, A. F. Jacka, B. Lamoury, F. Applegate, T. Monaner, J. Khudyakov, Y. Grebely, J. Cook, D. Harrigan, P. R. Krajden, M. TI Characterizing hepatitis C virus transmission dynamics using molecular phylogenetic-based methods SO JOURNAL OF VIRAL HEPATITIS LA English DT Meeting Abstract CT 15th International Symposium on Viral Hepatitis and Liver Diseases (ISVHLD) CY JUN 26-28, 2015 CL Berlin, GERMANY C1 [Olmstead, A. D.; Montoya, V.; Cook, D.; Krajden, M.] BC Ctr Dis Control, Vancouver, BC, Canada. [Olmstead, A. D.; Montoya, V.; Krajden, M.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. [Joy, J.; Poon, A. F.; Monaner, J.; Harrigan, P. R.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada. [Jacka, B.; Lamoury, F.; Applegate, T.; Grebely, J.] Univ New S Wales, Sydney, NSW, Australia. [Khudyakov, Y.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 1 Z9 1 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1352-0504 EI 1365-2893 J9 J VIRAL HEPATITIS JI J. Viral Hepatitis PD JUN PY 2015 VL 22 SU 2 SI SI MA P080 BP 60 EP 60 DI 10.1111/jvh.76_12425 PG 1 WC Gastroenterology & Hepatology; Infectious Diseases; Virology SC Gastroenterology & Hepatology; Infectious Diseases; Virology GA CL3XB UT WOS:000356884200108 ER PT J AU MacGowan, RJ Lifshay, J Mizuno, Y Johnson, WD McCormick, L Zack, B AF MacGowan, Robin J. Lifshay, Julie Mizuno, Yuko Johnson, Wayne D. McCormick, Lyle Zack, Barry TI Positive Transitions (POST): Evaluation of an HIV Prevention Intervention for HIV-Positive Persons Releasing from Correctional Facilities SO AIDS AND BEHAVIOR LA English DT Article DE HIV prevention; Prison; Jail; Reentry ID IMMUNODEFICIENCY-VIRUS-INFECTION; INTAKE MEDICAL EVALUATION; ANTIRETROVIRAL THERAPY; PRISON-INMATES; RISK BEHAVIOR; UNITED-STATES; JAIL; CARE; REINCARCERATION; INDIVIDUALS AB People with HIV who are released from custody frequently do not maintain the viral suppression and other health benefits achieved while incarcerated. This study was conducted to provide preliminary evidence of efficacy of an intervention to reduce HIV risk behaviors and increase use of HIV medical services following release from custody. People with HIV were recruited from San Francisco County jails, San Quentin State Prison and the California Medical Facility (Vacaville, CA), and randomly assigned to the "standard of care'' or POST intervention. POST consisted of 4 sessions pre-release and 2 sessions post-release, focusing on HIV prevention and access to care. Behavioral data were obtained for the 3 months before incarceration and 3 months after release. Although POST participants reported a statistically significant increase in receiving health care at HIV clinics (62.5-84.4 %), there were no significant differences between the POST and control participants with respect to any primary outcomes. C1 [MacGowan, Robin J.; Mizuno, Yuko; Johnson, Wayne D.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Lifshay, Julie] Centerforce, San Quentin, CA USA. [McCormick, Lyle] ICF Int, Atlanta, GA USA. [Zack, Barry] Bridging Grp, Oakland, CA USA. RP MacGowan, RJ (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd,MS E-37, Atlanta, GA 30333 USA. EM rmacgowan@cdc.gov FU [UR6/PS000364] FX We acknowledge the contributions of Joseph Bick M.D., Chief Medical Executive, California Medical Facility,Vacaville, California, Joe Goldenson, MD, Director/Medical Director Jail Health Services, San Francisco Department of Public Health, Kate Monico Klein, Director, FAP, San Francisco Department of Public Health, Kathleen Morrow, PhD, Associate Professor of Psychiatry & Human Behavior, The Miriam Hospital and Alpert Medical School of Brown University, Elena Tootell, MD, Chief Medical Executive, California State Prison, San Quentin, TCM program personnel and the study participants. This study was funded by Cooperative Agreement UR6/PS000364 awarded to Centerforce. NR 38 TC 1 Z9 1 U1 1 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD JUN PY 2015 VL 19 IS 6 BP 1061 EP 1069 DI 10.1007/s10461-014-0879-8 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CK8WF UT WOS:000356519600014 PM 25190222 ER PT J AU Tinker, SC Hamner, HC Qi, YP Crider, KS AF Tinker, Sarah C. Hamner, Heather C. Qi, Yan Ping Crider, Krista S. TI US women of childbearing age who are at possible increased risk of a neural tube defect-affected pregnancy due to suboptimal red blood cell folate concentrations, National Health and Nutrition Examination Survey 2007 to 2012 SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Article DE neural tube defects; optimal RBC folate concentration; folic acid; fortification; NHANES ID FOLIC-ACID FORTIFICATION; UNITED-STATES; BIRTH-DEFECTS; SPINA-BIFIDA; PREVENTION; POPULATION; PREVALENCE; SERUM; VITAMIN; DECLINE AB BackgroundRed blood cell (RBC) folate concentrations are a potential biomarker of folate-sensitive neural tube defect (NTD) risk in the population. The purpose of this analysis was to describe women in the U.S. population with RBC folate concentrations below those associated with optimal NTD prevention. MethodsWe used data from the 2007 to 2012 National Health and Nutrition Examination Survey (NHANES) to assess the RBC folate status of U.S. women of childbearing age relative to risk categories for NTD risk based on RBC folate concentrations. We defined suboptimal RBC folate concentrations as those associated with a prevalence of 9 NTDs per 10,000 live births. ResultsAmong nonpregnant women age 12 to 49 years, 22.8% (95% Confidence Interval: 21.1, 24.6) had suboptimal RBC folate concentrations. Women had greater odds of having a suboptimal RBC folate concentration if they did not use dietary supplements containing folic acid; had mandatorily fortified enriched cereal grain products as their only source of folic acid; were non-Hispanic black or Hispanic; or were current smokers. ConclusionBased on RBC folate concentrations, we would predict that the majority of U.S. women of reproductive age are not at increased risk for folate sensitive NTDs in the presence of mandatory folic acid fortification. Prevention policies and programs can be aimed at population subgroups identified as having higher predicted risk for folate-sensitive NTDs based on RBC folate concentrations. Birth Defects Research (Part A) 103:517-526, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Tinker, Sarah C.; Qi, Yan Ping; Crider, Krista S.] Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30333 USA. [Hamner, Heather C.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Tinker, SC (reprint author), Ctr Dis Control & Prevent CDC, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd,Mail Stop E-86, Atlanta, GA 30333 USA. EM zzu9@cdc.gov FU Intramural CDC HHS [CC999999] NR 37 TC 6 Z9 6 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD JUN PY 2015 VL 103 IS 6 BP 517 EP 526 DI 10.1002/bdra.23378 PG 10 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CL1AO UT WOS:000356674800007 PM 25884850 ER PT J AU Janda, JM Newton, AE Bopp, CA AF Janda, J. Michael Newton, Anna E. Bopp, Cheryl A. TI Vibriosis SO CLINICS IN LABORATORY MEDICINE LA English DT Article DE Vibriosis; Vibrio; Cholera; Marine; Aquatic; V vulnificus; Seafood ID FLIGHT MASS-SPECTROMETRY; CHOLERA-LIKE DIARRHEA; UNITED-STATES; RAPID IDENTIFICATION; VULNIFICUS INFECTION; PCR ASSAY; FLUVIALIS; BACTERIA; DIAGNOSIS; KOLKATA AB Vibriosis is a group of intestinal and extraintestinal infections caused by marine-dwelling bacteria of the genus Vibrio. Infections range from indolent illnesses to fulminant diseases, including cholera and necrotizing fasciitis. Most illnesses result from direct contact with the marine environment or consumption of shellfish, especially oysters. In the United States vibrio infections are increasing but are underreported because of lack of clinical recognition and appropriate detection in the microbiology laboratory. Recent advances to aid in the detection and identification of vibrio illnesses in the laboratory include rapid identification tests, new media, and molecular identification systems. C1 [Janda, J. Michael] Alameda Cty Publ Hlth Lab, Dept Publ Hlth, Oakland, CA 94607 USA. [Newton, Anna E.] Ctr Dis Control & Prevent, Enter Dis Epidemiol Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. [Bopp, Cheryl A.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Bopp, CA (reprint author), Ctr Dis Control & Prevent, Enter Dis Lab Branch, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM cherylbopp@gmail.com NR 54 TC 4 Z9 5 U1 3 U2 12 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-2712 EI 1557-9832 J9 CLIN LAB MED JI Clin. Lab. Med. PD JUN PY 2015 VL 35 IS 2 BP 273 EP + DI 10.1016/j.cll.2015.02.007 PG 17 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CK9EV UT WOS:000356544300004 PM 26004642 ER PT J AU Fitzgerald, C AF Fitzgerald, Collette TI Campylobacter SO CLINICS IN LABORATORY MEDICINE LA English DT Article DE Campylobacter; Campylobacter jejuni; Gastroenteritis; Campylobacteriosis ID ACTIVE SURVEILLANCE NETWORK; FLIGHT MASS-SPECTROMETRY; STOOL SPECIMENS; ENZYME-IMMUNOASSAY; ENTERIC INFECTIONS; RAPID DETECTION; UNITED-STATES; PCR ASSAYS; JEJUNI; IDENTIFICATION AB Campylobacter continues to be one of the most common bacterial causes of diarrheal illness in the United States and worldwide. Infection with Campylobacter causes a spectrum of diseases including acute enteritis, extraintestinal infections, and postinfectious complications. The most common species of Campylobacter associated with human illness is Campylobacter jejuni, but other Campylobacter species can also cause human infections. This comprehensive review includes discussion of the taxonomy, clinical manifestations of infection, epidemiology and the different methods of laboratory detection of Campylobacter. C1 Ctr Dis Control & Prevent, Enter Dis Lab Branch, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. RP Fitzgerald, C (reprint author), Ctr Dis Control & Prevent, Enter Dis Lab Branch, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM chf3@cdc.gov NR 49 TC 4 Z9 4 U1 7 U2 32 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-2712 EI 1557-9832 J9 CLIN LAB MED JI Clin. Lab. Med. PD JUN PY 2015 VL 35 IS 2 BP 289 EP + DI 10.1016/j.cll.2015.03.001 PG 11 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CK9EV UT WOS:000356544300005 PM 26004643 ER PT J AU Esona, MD Gautam, R AF Esona, Mathew D. Gautam, Rashi TI Rotavirus SO CLINICS IN LABORATORY MEDICINE LA English DT Article DE Rotavirus; Acute gastroenteritis; Rotavirus vaccines; Rotarix (R); RotaTeq (R); qRT-PCR; Multiplex assays; Next-generation sequencing ID GROUP-A ROTAVIRUS; POLYMERASE-CHAIN-REACTION; REVERSE TRANSCRIPTION-PCR; LINKED-IMMUNOSORBENT-ASSAY; QUANTITATIVE RT-PCR; STOOL SPECIMENS; MONOCLONAL-ANTIBODIES; LATEX AGGLUTINATION; ENZYME-IMMUNOASSAY; ACUTE GASTROENTERITIS AB Group A rotavirus (RVA) is the major cause of acute gastroenteritis (AGE) in young children worldwide. Introduction of two live, attenuated rotavirus vaccines, Rotarix (R) and RotaTeq (R), has dramatically reduced RVA-associated AGE and mortality. High-throughput, sensitive and specific techniques are required to rapidly diagnose and characterize rotavirus strains in stool samples for proper patient treatment and to monitor circulating vaccine and wild-type rotavirus strains. New molecular assays are rapidly developed that are more sensitive and specific than the conventional assays for detection, genotyping and full genome characterization of circulating rotavirus wild-type and vaccine (Rotarix (R) and RotaTeq (R)) strains causing AGE. C1 [Esona, Mathew D.; Gautam, Rashi] Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, Atlanta, GA 30333 USA. RP Gautam, R (reprint author), Ctr Dis Control & Prevent, Gastroenteritis & Resp Viruses Lab Branch, Div Viral Dis, 1600 Clifton Rd, Atlanta, GA 30333 USA. EM ijs0@cdc.gov NR 154 TC 4 Z9 4 U1 4 U2 14 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-2712 EI 1557-9832 J9 CLIN LAB MED JI Clin. Lab. Med. PD JUN PY 2015 VL 35 IS 2 BP 363 EP + DI 10.1016/j.cll.2015.02.012 PG 30 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CK9EV UT WOS:000356544300010 PM 26004648 ER PT J AU Ali, IKM AF Ali, Ibne Karim M. TI Intestinal Amebae SO CLINICS IN LABORATORY MEDICINE LA English DT Article DE Amebiasis laboratory diagnosis; Entamoeba histolytica; Entamoeba dispar; Entamoeba moshkovskii; Entamoeba Bangladeshi; Serology; Antigen detection; Molecular detection ID POLYMERASE-CHAIN-REACTION; REAL-TIME PCR; MEDIATED ISOTHERMAL AMPLIFICATION; ENTAMOEBA-MOSHKOVSKII INFECTIONS; CLINICAL STOOL SAMPLES; YEAST-SCFV PROBES; LIVER-ABSCESS; FECAL SAMPLES; DIFFERENTIAL DETECTION; CRYPTOSPORIDIUM SPP. AB Among the Entamoeba species that infect humans, Entamoeba histolytica causes diseases, Entamoeba dispar is a harmless commensal, Entamoeba moshkovskii seems to be a pathogen, and the pathogenicity of Entamoeba bangladeshi remains to be investigated. Species-specific detection needed for treatment decisions and for understanding the epidemiology and pathogenicity of these amebae. Antigen-based detection methods are needed for E dispar, E moshkovskii, and E bangladeshi; and molecular diagnostic test capable of detecting E histolytica, E dispar, E moshkovskii, and E bangladeshi simultaneously in clinical samples. Next-generation sequencing of DNA from stool is needed to identify novel species of Entamoeba. C1 Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. RP Ali, IKM (reprint author), Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, 1600 Clifton Rd Northeast, Atlanta, GA 30329 USA. EM xzn5@cdc.gov NR 104 TC 5 Z9 5 U1 2 U2 20 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-2712 EI 1557-9832 J9 CLIN LAB MED JI Clin. Lab. Med. PD JUN PY 2015 VL 35 IS 2 BP 393 EP + DI 10.1016/j.cll.2015.02.009 PG 31 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CK9EV UT WOS:000356544300011 PM 26004649 ER PT J AU Cama, VA Mathison, BA AF Cama, Vitaliano A. Mathison, Blaine A. TI Infections by Intestinal Coccidia and Giardia duodenalis SO CLINICS IN LABORATORY MEDICINE LA English DT Article DE Cryptosporidium; Cyclospora cayetanensis; Giardia duodenalis; Cystoisospora belli; Human enteric coccidian ID ACQUIRED-IMMUNODEFICIENCY-SYNDROME; HUMAN FECAL SPECIMENS; CRYPTOSPORIDIUM-PARVUM; UNITED-STATES; CYCLOSPORA-CAYETANENSIS; CLINICAL-MANIFESTATIONS; TAXONOMIC REVISION; LIFE-CYCLE; SURVEILLANCE; HUMANS AB The coccidians Cryptosporidium spp, Cyclospora cayetanensis, and Cystoisospora belli and the flagellate Giardia duodenalis are pathogenic protozoa associated with gastrointestinal manifestations. Diagnosis relies heavily on microscopy, and although ova-and-parasite examinations can detect Giardia and Cystoisospora, Cryptosporidium and Cyclospora often require specific diagnostic requests. Approved non-microscopy methods are available for Giardia and Cryptosporidium, although negative results are frequently followed by microscopic assays. Polymerase chain reaction-based methods are not frequently used for diagnosis of Giardia and Cryptosporidium and have been used primarily for epidemiologic or outbreak investigations of Giardia and Cryptosporidium. C1 [Cama, Vitaliano A.; Mathison, Blaine A.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30341 USA. RP Cama, VA (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, MSD-65, Atlanta, GA 30341 USA. EM VCama@cdc.gov FU Intramural CDC HHS [CC999999] NR 97 TC 1 Z9 1 U1 0 U2 8 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-2712 EI 1557-9832 J9 CLIN LAB MED JI Clin. Lab. Med. PD JUN PY 2015 VL 35 IS 2 BP 423 EP + DI 10.1016/j.cll.2015.02.010 PG 24 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CK9EV UT WOS:000356544300012 PM 26004650 ER PT J AU Wang, BH He, MF Chao, A Engelgau, MM Saraiya, M Wang, LM Wang, LH AF Wang, Baohua He, Minfu Chao, Ann Engelgau, Michael M. Saraiya, Mona Wang, Limin Wang, Linhong TI Cervical Cancer Screening Among Adult Women in China, 2010 SO ONCOLOGIST LA English DT Article DE Cervical cancer; Papanicolaou test; Women; China; Epidemiology ID RANDOMIZED CONTROLLED-TRIAL; RURAL CHINA; HEALTH; PREVENTION; BEHAVIOR; INDIA; AGE AB Introduction. Cervical cancer is one of the most commonly diagnosed cancers among women in China. The World Health Organization ( WHO) recommends routine screening for cervical cancer, and the WHO Global Monitoring Framework suggests that every nation monitors cervical cancer screening. However, little information is available on cervical cancer screening behavior among women in China. Methods. We used data from the 2010 China Chronic Disease and Risk Factor Surveillance System that included 51,989 women aged 18 years and older. We report the proportion of women who reported ever having had a Papanicolaou ( Pap) test, stratified by sociodemographic characteristics and geographic region. Multivariable logistic regression modeling was performed to adjust for potential confounders. Results. Overall, 21% of 51,989 women reported having ever had a Pap test. The highest proportion was reported among women aged 30-39 years (30.1%, 95% confidence interval, 26.8%-33.4%). In all geographic regions, women in rural areas were consistently less likely than women in urban areas to report having had a Pap test. Among women who reported ever having a Pap test, 82% reported having the most recent test in the past 3 years. Factors associated with reporting ever having a test were being aged 30-49 years, higher education, being married, and having urban health insurance. Conclusion. Our results indicate that screening programs need to be strengthened along with a more intense focus on specific demographic groups. National cervical cancer screening guidelines and comprehensive implementation strategies are needed to make screening services available and accessible to all women. C1 [Wang, Baohua; He, Minfu; Wang, Limin; Wang, Linhong] Chinese Ctr Dis Control & Prevent, Natl Ctr Chron & Noncommunicable Dis Control & Pr, Beijing, Peoples R China. [Chao, Ann] NCI, Ctr Global Hlth, Rockville, MD USA. [Engelgau, Michael M.] Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Saraiya, Mona] Ctr Dis Control & Prevent, Ctr Chron Dis Prevent & Hlth Promot, Div Canc Control & Prevent, Atlanta, GA USA. RP Wang, LH (reprint author), 27 Nanwei Rd, Beijing 100050, Peoples R China. EM linhong@chinawch.org.cn FU National Health and Family Planning Commission of the People's Republic of China FX This study was funded by the National Health and Family Planning Commission of the People's Republic of China. We thank all study participants for taking part in this study. We are grateful to all staff members of the provincial and local health administrative departments and the provincial and county Centers for Disease Control and Prevention and the more than 2,000 field interviewers for their support and hard work. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 33 TC 6 Z9 9 U1 1 U2 4 PU ALPHAMED PRESS PI DURHAM PA 318 BLACKWELL ST, STE 260, DURHAM, NC 27701-2884 USA SN 1083-7159 EI 1549-490X J9 ONCOLOGIST JI Oncologist PD JUN PY 2015 VL 20 IS 6 BP 627 EP 634 DI 10.1634/theoncologist.2014-0303 PG 8 WC Oncology SC Oncology GA CL1EC UT WOS:000356684400013 PM 25956407 ER PT J AU Phan, TG Desnues, C Switzer, WM Djoko, CF Schneider, BS Deng, XT Delwart, E AF Phan, Tung Gia Desnues, Christelle Switzer, William M. Djoko, Cyrille F. Schneider, Bradley S. Deng, Xutao Delwart, Eric TI Absence of giant blood Marseille-like virus DNA detection by polymerase chain reaction in plasma from healthy US blood donors and serum from multiply transfused patients from Cameroon SO TRANSFUSION LA English DT Article ID NO EVIDENCE; LAUSANNEVIRUS; RECIPIENTS; DISCOVERY; HUMANS; ORIGIN AB BACKGROUNDA new Marseilleviridae virus family member, giant blood Marseille-like (GBM) virus, was recently reported in persons from France in the serum of an infant with adenitis, in the blood of 4% of healthy blood donors, and in 9% of multiply transfused thalassemia patients. These results suggested the presence of a nucleocytoplasmic large DNA virus potentially transmissible by blood product transfusion. STUDY DESIGN AND METHODSTo investigate this possibility we tested the plasma from 113 US blood donors and 74 multiply transfused Cameroon patients for GBM viral DNA using highly sensitive polymerase chain reaction (PCR) assays. RESULTSGBM DNA was not detected by nested PCR in any of these 187 human specimens. CONCLUSIONSFurther testing is required to confirm the occurrence of human GBM virus infections. C1 [Phan, Tung Gia; Deng, Xutao; Delwart, Eric] Univ Calif San Francisco, Blood Syst Res Inst, San Francisco, CA 94143 USA. [Phan, Tung Gia; Deng, Xutao; Delwart, Eric] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA. [Desnues, Christelle] Aix Marseille Univ, URMITE, Inserm 1095, CNRS 7278,IRD 198,UM63, Marseille, France. [Switzer, William M.] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA USA. [Djoko, Cyrille F.] Global Viral Cameroon, Yaounde, Cameroon. [Schneider, Bradley S.] Metabiota, San Francisco, CA USA. RP Delwart, E (reprint author), Blood Syst Res Inst, San Francisco, CA 94118 USA. EM del-warte@medicine.ucsf.edu RI Desnues, Christelle/B-1383-2010 OI Desnues, Christelle/0000-0002-2178-0355 FU NIH [R01 HL105770] FX We acknowledge Sonia Monteil and Sarah Temmam for their technical assistance. Funding from NIH R01 HL105770 to Eric Delwart. Use of trade names is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services, the Public Health Service, or the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. NR 21 TC 6 Z9 6 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0041-1132 EI 1537-2995 J9 TRANSFUSION JI Transfusion PD JUN PY 2015 VL 55 IS 6 BP 1256 EP 1262 DI 10.1111/trf.12997 PG 7 WC Hematology SC Hematology GA CK6VJ UT WOS:000356366300034 PM 25645088 ER PT J AU Shoemaker, ML Holman, DM Henley, J White, MC AF Shoemaker, Meredith L. Holman, Dawn M. Henley, Jane White, Mary C. TI News from CDC: applying a life course approach to primary cancer prevention SO TRANSLATIONAL BEHAVIORAL MEDICINE LA English DT News Item DE Cancer; Primary prevention; Knowledge translation; Public health practice ID HUMAN-PAPILLOMAVIRUS VACCINATION; OPPORTUNITIES; PREADOLESCENCE; ADOLESCENCE; HIGHLIGHTS; MIDLIFE; ADULTS; RISK; USA C1 [Shoemaker, Meredith L.; Holman, Dawn M.; Henley, Jane; White, Mary C.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Shoemaker, ML (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM xhr1@cdc.gov FU Centers for Disease Control and Prevention FX This research was supported in part by an appointment (MLS) to the Research Participation Program at the Centers for Disease Control and Prevention administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. The members of the Cancer Prevention Across the Lifespan (CPAL) workgroup were instrumental in the activities described in this report. Workgroup members included Jennifer E. Boehm, Natasha Buchanan, Donatus Ekwueme, T'Ronda Flagg, Kristi Fultz-Butts, Gery Guy, Nikki Hawkins, Jane Henley, Dawn Holman, Chunyu Li, Jun Li, Greta M. Massetti, Mary Elizabeth O'Neil, Lucy Peipins, Mary Puckett, Juan Rodriguez, Meredith L. Shoemaker, Katrina F. Trivers, Meg Watson, Mary C. White, and Susan White. Additionally, we would like to thank Katherine B. Roland for her constructive contributions to this report. NR 19 TC 2 Z9 2 U1 0 U2 1 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1869-6716 EI 1613-9860 J9 TRANSL BEHAV MED JI Transl. Behav. Med. PD JUN PY 2015 VL 5 IS 2 BP 131 EP 133 DI 10.1007/s13142-015-0309-0 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL2QI UT WOS:000356788700002 PM 26029275 ER PT J AU Ondenge, K McLellan-Lemal, E Awuonda, E Angira, F Mills, LA Thomas, T AF Ondenge, K. McLellan-Lemal, E. Awuonda, E. Angira, F. Mills, L. A. Thomas, T. TI Disseminating results: community response and input on Kisumu breastfeeding study SO TRANSLATIONAL BEHAVIORAL MEDICINE LA English DT Article DE Study results; Dissemination; Community feedback; KiBS; FGDs; Clinical trials ID DEVELOPING-COUNTRIES; CLINICAL-RESEARCH; GLOBAL HEALTH; SOCIAL VALUE; TRIAL; ENGAGEMENT; ETHICS; KENYA; RECRUITMENT; PREVENTION AB Communicating findings to study participants and their communities is a practice that often gets overlooked or receives low prioritization by research investigators, but is crucially important. The purpose of this study was to describe the process and community response to the dissemination of results from the Kisumu Breastfeeding Study (KiBS), specifically in terms of (1) community research knowledge and expectations and (2) impressions of result dissemination efforts. A qualitative evaluation was completed for 10 result dissemination events using focus group discussions (FGDs) (n= 10; total number of participants= 98). An inductive, thematic qualitative data analysis was completed in NVivo 8.0. Overall, FGD participants expressed great appreciation for being given information on the study results. Participants had a good understanding of what research entails and had specific expectations for the process, including that the community receive information about the study, not only at the end of the study but also at regular intervals throughout the study's conduct. They also wanted to receive the communications from a credible source, the principal investigator preferably. Other expectations centered on better community and research interactions and development and the use of community collaborators. Impressions of KiBS result dissemination events were positive, but suggestions for the future included having the event in a larger area, inviting more people, having more written materials, and putting the information in an entertaining format such as skits or movies. Sharing study findings with local community members is essential and beneficial to the researchers' long-term engagement with communities and importantly, the successful implementation of study findings when appropriate. It is imperative that dissemination of results be embedded as an integral part of research project planning and development. C1 [Ondenge, K.; Awuonda, E.; Angira, F.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu 40100, Kenya. [McLellan-Lemal, E.; Thomas, T.] Ctr Dis Control & Prevent, Off Infect Dis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Div HIV AIDS Prevent, Atlanta, GA USA. [Mills, L. A.] Ctr Dis Control & Prevent, Kisumu, Kenya. RP Ondenge, K (reprint author), Kenya Govt Med Res Ctr, Ctr Global Hlth Res, POB 1578, Kisumu 40100, Kenya. EM kondenge@kemricdc.org FU Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA FX Funding for this study was provided by the Centers for Disease Control and Prevention (CDC), Atlanta, GA, USA. NR 33 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER INTERNATIONAL PUBLISHING AG PI CHAM PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND SN 1869-6716 EI 1613-9860 J9 TRANSL BEHAV MED JI Transl. Behav. Med. PD JUN PY 2015 VL 5 IS 2 BP 207 EP 215 DI 10.1007/s13142-014-0303-y PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL2QI UT WOS:000356788700010 PM 26029283 ER PT J AU Mwangi, MW Kellogg, TA Brookmeyer, K Buluma, R Chiang, L Otieno-Nyunya, B Chesang, K AF Mwangi, Mary W. Kellogg, Timothy A. Brookmeyer, Kathryn Buluma, Robert Chiang, Laura Otieno-Nyunya, Boaz Chesang, Kipruto CA Kenya 2010 Violence Children TI Perpetrators and context of child sexual abuse in Kenya SO CHILD ABUSE & NEGLECT LA English DT Article DE Children; Child sexual abuse; Sexual violence; Perpetrators; Violence against children survey; Kenya ID VIOLENCE; AFRICA; EXPERIENCE; BEHAVIOR; COERCION AB Child sexual abuse (CSA) interventions draw from a better understanding of the context of CSA. A survey on violence before age 18 was conducted among respondents aged 13-17 and 18-24 years. Among females (13-17), the key perpetrators of unwanted sexual touching (UST) were friends/classmates (27.0%) and among males, intimate partners (IP) (35.9%). The first incident of UST among females occurred while traveling on foot (33.0%) and among males, in the respondent's home (29.1%). Among females (13-17), the key perpetrators of unwanted attempted sex (UAS) were relatives (28.9%) and among males, friends/classmates (31.0%). Among females, UAS occurred mainly while traveling on foot (42.2%) and among males, in school (40.8%). Among females and males (18-24 years), the main perpetrators of UST were IP (32.1% and 43.9%) and the first incident occurred mainly in school (24.9% and 26.0%), respectively. The main perpetrators of UAS among females and males (18-24 years) were IP (33.3% and 40.6%, respectively). Among females, UAS occurred while traveling on foot (32.7%), and among males, in the respondent's home (38.8%); UAS occurred mostly in the evening (females 60.7%; males 41.4%) or afternoon (females 27.8%; males 37.9%). Among females (18-24 years), the main perpetrators of pressured/forced sex were IP and the first incidents occurred in the perpetrator's home. Prevention interventions need to consider perpetrators and context of CSA to increase their effectiveness. In Kenya, effective CSA prevention interventions that target intimate relationships among young people, the home and school settings are needed. Published by Elsevier Ltd. C1 [Mwangi, Mary W.; Otieno-Nyunya, Boaz; Chesang, Kipruto] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Nairobi, Kenya. [Kellogg, Timothy A.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Brookmeyer, Kathryn] US Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA USA. [Buluma, Robert] Kenya Natl Bur Stat, Nairobi, Kenya. [Chiang, Laura] US Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA USA. RP Mwangi, MW (reprint author), US Ctr Dis Control & Prevent, Div Global HIV AIDS, Nairobi, Kenya. FU UNICEF Kenya Country Office FX The Kenya Violence against Children Survey was funded by UNICEF Kenya Country Office and received in-kind technical support by the CDC, Division of Violence Prevention in Atlanta and the CDC Division of Global HIV/AIDS in Kenya. We acknowledge Jonna Carlsson for providing leadership in all aspects of the survey; the Kenya National Bureau of Statistics who implemented the survey, and the Kenya VACS Technical Working Group for guidance and support in the survey development process. We acknowledge the Kenya VAC 2010 survey teams who administered the survey and team leads who took great care in ensuring the privacy and safety of the respondents. We are greatly indebted to all the households and participants who responded to the survey questions. NR 22 TC 0 Z9 0 U1 1 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0145-2134 EI 1873-7757 J9 CHILD ABUSE NEGLECT JI Child Abuse Negl. PD JUN PY 2015 VL 44 BP 46 EP 55 DI 10.1016/j.chiabu.2015.03.011 PG 10 WC Family Studies; Psychology, Social; Social Work SC Family Studies; Psychology; Social Work GA CL0PK UT WOS:000356644400007 PM 25882669 ER PT J AU Mead, PS AF Mead, Paul S. TI Epidemiology of Lyme Disease SO INFECTIOUS DISEASE CLINICS OF NORTH AMERICA LA English DT Article DE Lyme disease; Epidemiology; Incidence; Borrelia burgdorferi; Tick-borne diseases; Human; Zoonosis; Ixodes ID BURGDORFERI-SENSU-LATO; ERYTHEMA CHRONICUM MIGRANS; POLYMERASE-CHAIN-REACTION; IXODES-SCAPULARIS NYMPHS; BORRELIA-BURGDORFERI; UNITED-STATES; ENDEMIC AREA; RISK-FACTORS; CEREBROSPINAL-FLUID; WESTCHESTER-COUNTY AB Lyme disease is the most common vector-borne illness in North America and Europe. The etiologic agent, Borrelia burgdorferi sensu lato, is transmitted to humans by certain species of Ixodes ticks, which are found widely in temperate regions of the Northern hemisphere. Clinical features are diverse, but death is rare. The risk of human infection is determined by the geographic distribution of vector tick species, ecologic factors that influence tick infection rates, and human behaviors that promote tick bite. Rates of infection are highest among children 5 to 15 years old and adults older than 50 years. C1 Ctr Dis Control & Prevent CDC, Epidemiol & Surveillance Act, Bacterial Dis Branch,Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, Ft Collins, CO 80521 USA. RP Mead, PS (reprint author), Ctr Dis Control & Prevent CDC, Epidemiol & Surveillance Act, Bacterial Dis Branch,Div Vector Borne Dis, Natl Ctr Emerging & Zoonot Infect Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM pfm0@CDC.GOV NR 148 TC 52 Z9 52 U1 11 U2 43 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0891-5520 EI 1557-9824 J9 INFECT DIS CLIN N AM JI Infect. Dis. Clin. North Am. PD JUN PY 2015 VL 29 IS 2 BP 187 EP + DI 10.1016/j.idc.2015.02.010 PG 25 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CL0LT UT WOS:000356634900002 PM 25999219 ER PT J AU Kohler, BA Sherman, RL Howlader, N Jemal, A Ryerson, AB Henry, KA Boscoe, FP Cronin, KA Lake, A Noone, AM Henley, SJ Eheman, CR Anderson, RN Penberthy, L AF Kohler, Betsy A. Sherman, Recinda L. Howlader, Nadia Jemal, Ahmedin Ryerson, A. Blythe Henry, Kevin A. Boscoe, Francis P. Cronin, Kathleen A. Lake, Andrew Noone, Anne-Michelle Henley, S. Jane Eheman, Christie R. Anderson, Robert N. Penberthy, Lynne TI Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID AFRICAN-AMERICAN WOMEN; AGE-SPECIFIC INCIDENCE; DISPARITIES GEOCODING PROJECT; BLACK-WHITE CROSSOVER; UNITED-STATES; INCIDENCE RATES; SOCIOECONOMIC-STATUS; COLORECTAL-CANCER; SURVEILLANCE DATA; PROSTATE-CANCER AB Background: The American Cancer Society (ACS), Centers for Disease Control and Prevention (CDC), National Cancer Institute (NCI), and North American Association of Central Cancer Registries (NAACCR) collaborate annually to produce updated, national cancer statistics. This Annual Report includes a focus on breast cancer incidence by subtype using new, national-level data. Methods: Population-based cancer trends and breast cancer incidence by molecular subtype were calculated. Breast cancer subtypes were classified using tumor biomarkers for hormone receptor (HR) and human growth factor-neu receptor (HER2) expression. Results: Overall cancer incidence decreased for men by 1.8% annually from 2007 to 2011. Rates for women were stable from 1998 to 2011. Within these trends there was racial/ethnic variation, and some sites have increasing rates. Among children, incidence rates continued to increase by 0.8% per year over the past decade while, like adults, mortality declined. Overall mortality has been declining for both men and women since the early 1990's and for children since the 1970's. HR+/HER2-breast cancers, the subtype with the best prognosis, were the most common for all races/ethnicities with highest rates among non-Hispanic white women, local stage cases, and low poverty areas (92.7, 63.51, and 98.69 per 100 000 non-Hispanic white women, respectively). HR+/HER2-breast cancer incidence rates were strongly, positively correlated with mammography use, particularly for non-Hispanic white women (Pearson 0.57, two-sided P <.001). Triple-negative breast cancers, the subtype with the worst prognosis, were highest among non-Hispanic black women (27.2 per 100 000 non-Hispanic black women), which is reflected in high rates in southeastern states. Conclusions: Progress continues in reducing the burden of cancer in the United States. There are unique racial/ethnic-specific incidence patterns for breast cancer subtypes; likely because of both biologic and social risk factors, including variation in mammography use. Breast cancer subtype analysis confirms the capacity of cancer registries to adjust national collection standards to produce clinically relevant data based on evolving medical knowledge. C1 [Kohler, Betsy A.; Sherman, Recinda L.; Henry, Kevin A.; Boscoe, Francis P.] North Amer Assoc Cent Canc Registries, Springfield, IL 62704 USA. [Howlader, Nadia; Cronin, Kathleen A.; Noone, Anne-Michelle; Penberthy, Lynne] NCI, Bethesda, MD 20892 USA. [Jemal, Ahmedin] Amer Canc Soc, Atlanta, GA 30329 USA. [Ryerson, A. Blythe; Henley, S. Jane; Eheman, Christie R.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Henry, Kevin A.] Temple Univ, Dept Geog, Philadelphia, PA 19122 USA. [Boscoe, Francis P.] New York State Canc Registry, New York, NY USA. [Lake, Andrew] Information Management Serv Inc, Rockville, MD USA. [Anderson, Robert N.] Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Kohler, BA (reprint author), North Amer Assoc Cent Canc Registries, 2121 West White Oaks Dr,Suite B, Springfield, IL 62704 USA. EM bkohler@naaccr.org FU American Cancer Society; Centers for Disease Control and Prevention; National Cancer Institute; North American Association of Central Cancer Registries FX This work was supported by the American Cancer Society, the Centers for Disease Control and Prevention, the National Cancer Institute, and the North American Association of Central Cancer Registries. NR 105 TC 87 Z9 89 U1 11 U2 30 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JUN PY 2015 VL 107 IS 6 AR djv048 DI 10.1093/jnci/djv048 PG 25 WC Oncology SC Oncology GA CK5EG UT WOS:000356244500002 PM 25825511 ER PT J AU Saraiya, M Unger, ER Thompson, TD Lynch, CF Hernandez, BY Lyu, CW Steinau, M Watson, M Wilkinson, EJ Hopenhayn, C Copeland, G Cozen, W Peters, ES Huang, YJ Saber, MS Altekruse, S Goodman, MT AF Saraiya, Mona Unger, Elizabeth R. Thompson, Trevor D. Lynch, Charles F. Hernandez, Brenda Y. Lyu, Christopher W. Steinau, Martin Watson, Meg Wilkinson, Edward J. Hopenhayn, Claudia Copeland, Glenn Cozen, Wendy Peters, Edward S. Huang, Youjie Saber, Maria Sibug Altekruse, Sean Goodman, Marc T. CA HPV Typing Canc Workgrp TI US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE LA English DT Article ID HUMAN-PAPILLOMAVIRUS TYPES; INVASIVE CERVICAL-CANCER; UNITED-STATES; INTRAEPITHELIAL NEOPLASIA; VACCINATION COVERAGE; PREVALENCE; INFECTION; WORLDWIDE; IMPACT; ATTRIBUTION AB Background: This study sought to determine the prevaccine type-specific prevalence of human papillomavirus (HPV)-associated cancers in the United States to evaluate the potential impact of the HPV types in the current and newly approved 9-valent HPV vaccines. Methods: The Centers for Disease Control and Prevention partnered with seven US population-based cancer registries to obtain archival tissue for cancers diagnosed from 1993 to 2005. HPV testing was performed on 2670 case patients that were fairly representative of all participating cancer registry cases by age and sex. Demographic and clinical data were evaluated by anatomic site and HPV status. Current US cancer registry data and the detection of HPV types were used to estimate the number of cancers potentially preventable through vaccination. Results: HPV DNA was detected in 90.6% of cervical, 91.1% of anal, 75.0% of vaginal, 70.1% of oropharyngeal, 68.8% of vulvar, 63.3% of penile, 32.0% of oral cavity, and 20.9% of laryngeal cancers, as well as in 98.8% of cervical cancer in situ (CCIS). A vaccine targeting HPV 16/18 potentially prevents the majority of invasive cervical (66.2%), anal (79.4%), oropharyngeal (60.2%), and vaginal (55.1%) cancers, as well as many penile (47.9%), vulvar (48.6%) cancers: 24 858 cases annually. The 9-valent vaccine also targeting HPV 31/33/45/52/58 may prevent an additional 4.2% to 18.3% of cancers: 3944 cases annually. For most cancers, younger age at diagnosis was associated with higher HPV 16/18 prevalence. With the exception of oropharyngeal cancers and CCIS, HPV 16/18 prevalence was similar across racial/ethnic groups. Conclusions: In the United States, current vaccines will reduce most HPV-associated cancers; a smaller additional reduction would be contributed by the new 9-valent vaccine. C1 [Saraiya, Mona; Thompson, Trevor D.; Watson, Meg] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Unger, Elizabeth R.; Steinau, Martin] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30341 USA. [Hernandez, Brenda Y.; Goodman, Marc T.] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA. [Lynch, Charles F.] Univ Iowa, Coll Publ Hlth, Dept Epidemiol, Iowa City, IA USA. [Cozen, Wendy] Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA. [Cozen, Wendy; Saber, Maria Sibug] Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA. [Peters, Edward S.] Louisiana State Univ, Hlth Sci Ctr, Sch Publ Hlth, Dept Epidemiol, New Orleans, LA USA. [Wilkinson, Edward J.] Univ Florida, Coll Med, Dept Pathol Immunol & Lab Med, Gainesville, FL USA. [Copeland, Glenn] Michigan Dept Community Hlth, Lansing, MI USA. [Hopenhayn, Claudia] Univ Kentucky, Coll Publ Hlth, Dept Epidemiol, Lexington, KY USA. [Huang, Youjie] Florida Dept Hlth, Tallahassee, FL USA. [Altekruse, Sean] NCI, Div Canc Control & Populat Sci, Rockville, MD USA. [Lyu, Christopher W.] Battelle Mem Inst, Durham, NC USA. [Altekruse, Sean] NCI, Bethesda, MD 20892 USA. RP Saraiya, M (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,MS F-76, Atlanta, GA 30341 USA. EM msaraiya@cdc.gov OI /0000-0003-4928-6532 FU National Program of Cancer Registries and Surveillance, Epidemiology, and End Results (SEER); Centers for Disease Control and Prevention via in-kind funds [200-2002-00573]; California Department of Health Services; National Cancer Institute, National Institutes of Health, Department of Health and Human Services [N01-PC-2010-00035, 1U58DP000807-3]; SEER Program, National Institutes of Health, Department of Health and Human Services [N01-PC-35139, N01-PC-35143, N01-PC-35137] FX The support for collection of original specimens from non-repositories (Kentucky, Florida, Michigan, Louisiana); coordination of genotyping data from registries funded, in part, by the National Program of Cancer Registries and Surveillance, Epidemiology, and End Results (SEER); and genotyping was largely supported by the Centers for Disease Control and Prevention (CDC).; This project was largely supported by the Centers for Disease Control and Prevention via in-kind funds, intramural funds to CDC human papillomavirus (HPV) lab, and contract (# 200-2002-00573, Task Order 0018). The support for coordination of genotyping data and genotyping was largely supported by CDC intramural funds via a contract. The collection of routine cancer registry data from California was supported by the California Department of Health Services as part of the statewide cancer reporting program mandated by California Health and Safety Code Section 103885; by the National Cancer Institute, National Institutes of Health, Department of Health and Human Services under Contract N01-PC-2010-00035, and cooperative agreement number 1U58DP000807-3. The support of the repositories and staff came from the SEER Program, National Institutes of Health, Department of Health and Human Services, under Contracts N01-PC-35139 (Los Angeles), N01-PC-35143 (Iowa), and N01-PC-35137 (Hawaii). NR 46 TC 29 Z9 30 U1 8 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0027-8874 EI 1460-2105 J9 JNCI-J NATL CANCER I JI JNCI-J. Natl. Cancer Inst. PD JUN PY 2015 VL 107 IS 6 AR djv086 DI 10.1093/jnci/djv086 PG 12 WC Oncology SC Oncology GA CK5EG UT WOS:000356244500013 PM 25925419 ER PT J AU Yi, SH Baggs, J Culler, SD Berrios-Torres, SI Jernigan, JA AF Yi, Sarah H. Baggs, James Culler, Steven D. Berrios-Torres, Sandra I. Jernigan, John A. TI Medicare Reimbursement Attributable to Periprosthetic Joint Infection Following Primary Hip and Knee Arthroplasty SO JOURNAL OF ARTHROPLASTY LA English DT Article DE arthroplasty; periprosthetic joint infection; Medicare reimbursement; healthcare-associated infection; healthcare costs ID SURGICAL SITE INFECTIONS; UNITED-STATES; MORTALITY; SURVEILLANCE; COSTS; OUTCOMES; DIAGNOSIS; SURGERY; BURDEN; IMPACT AB This study estimated Medicare reimbursement attributable to periprosthetic joint infection (PJI) across the continuum of covered services four years following hip or knee arthroplasty. Using 2001-2008 Medicare claims data, total and annual attributable reimbursements were assessed using generalized linear regression, adjusting for potential confounders. Within one year following arthroplasty, 109 (1.04%) of 10,418 beneficiaries were diagnosed with PJI. Cumulative Medicare reimbursement in the PJI arm was 2.2-fold (1.9-2.6, P < .0001) or $53,470 ($39,575-$68,221) higher than that of the non-PJI arm. The largest difference in reimbursement occurred the first year (3.2-fold); differences persisted the second (2.3-fold) and third (1.9-fold) follow up years. PJI following hip or knee arthroplasty appears costly to Medicare, with cost traversing several years and health care service areas. Published by Elsevier Inc. C1 [Yi, Sarah H.; Baggs, James; Culler, Steven D.; Berrios-Torres, Sandra I.; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. [Culler, Steven D.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Yi, SH (reprint author), 1600 Clifton Rd,MS A-31, Atlanta, GA 30333 USA. OI Baggs, James/0000-0003-0757-4683 NR 46 TC 1 Z9 1 U1 1 U2 1 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 0883-5403 EI 1532-8406 J9 J ARTHROPLASTY JI J. Arthroplast. PD JUN PY 2015 VL 30 IS 6 BP 931 EP + DI 10.1016/j.arth.2015.01.017 PG 10 WC Orthopedics SC Orthopedics GA CK4GY UT WOS:000356183500007 PM 25727999 ER PT J AU Tomer, Y Dolan, LM Kahaly, G Divers, J D'Agostino, RB Imperatore, G Dabelea, D Marcovina, S Black, MH Pihoker, C Hasham, A Hammerstad, SS Greenberg, DA Lotay, V Zhang, WJ Monti, MC Matheis, N AF Tomer, Yaron Dolan, Lawrence M. Kahaly, George Divers, Jasmin D'Agostino, Ralph B., Jr. Imperatore, Giuseppina Dabelea, Dana Marcovina, Santica Black, Mary Helen Pihoker, Catherine Hasham, Alia Hammerstad, Sara Salehi Greenberg, David A. Lotay, Vaneet Zhang, Weijia Monti, Maria Cristina Matheis, Nina CA SEARCH Diabet Youth Study TI Genome wide identification of new genes and pathways in patients with both autoimmune thyroiditis and type 1 diabetes SO JOURNAL OF AUTOIMMUNITY LA English DT Article DE Type 1 diabetes; Graves' disease; Hashimoto's thyroiditis; Gene; HLA ID HASHIMOTOS-THYROIDITIS; RISK LOCI; SUSCEPTIBILITY; DISEASE; ASSOCIATION; FAMILIES; GENETICS; CHILDREN; MELLITUS; COMMON AB Autoimmune thyroid diseases (AITD) and Type 1 diabetes (T1D) frequently occur in the same individual pointing to a strong shared genetic susceptibility. Indeed, the co-occurrence of T1D and AITD in the same individual is classified as a variant of the autoimmune polyglandular syndrome type 3 (designated APS3v). Our aim was to identify new genes and mechanisms causing the co-occurrence of T1D AITD (APS3v) in the same individual using a genome-wide approach. For our discovery set we analyzed 346 Caucasian APS3v patients and 727 gender and ethnicity matched healthy controls. Genotyping was performed using the Illumina Human660W-Quad.v1. The replication set included 185 APS3v patients and 340 controls. Association analyses were performed using the PLINK program, and pathway analyses were performed using the MAGENTA software. We identified multiple signals within the HLA region and conditioning studies suggested that a few of them contributed independently to the strong association of the HLA locus with APS3v. Outside the HLA region, variants in GPR103, a gene not suggested by previous studies of APS3v, T1D, or AITD, showed genolne-wide significance (p < 5 x 10(-8)). In addition, a locus on 1p13 containing the PTPN22 gene showed genome-wide significant associations. Pathway analysis demonstrated that cell cycle, B-cell development, CD40, and CTLA-4 signaling were the major pathways contributing to the pathogenesis of APS3v. These findings suggest that complex mechanisms involving T-cell and B-cell pathways are involved in the strong genetic association between AITD and T1D. Published by Elsevier Ltd. C1 [Tomer, Yaron; Hasham, Alia; Hammerstad, Sara Salehi] Icahn Sch Med Mt Sinai, Div Endocrinol, New York, NY 10029 USA. [Tomer, Yaron] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Dolan, Lawrence M.] Cincinnati Childrens Hosp Med Ctr, Div Pediat Endocrinol, Cincinnati, OH 45229 USA. [Kahaly, George; Matheis, Nina] Johannes Gutenberg Univ Mainz, Med Ctr, Thyroid Res Lab, D-55122 Mainz, Germany. [Divers, Jasmin; D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Dept Biostat Sci, Winston Salem, NC USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Dabelea, Dana] Univ Colorado, Colorado Sch Publ Hlth, Denver, CO 80202 USA. [Marcovina, Santica] Univ Washington, Northwest Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Black, Mary Helen] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Pihoker, Catherine] Univ Washington, Dept Pediat, Seattle, WA 98195 USA. [Greenberg, David A.] Nationwide Childrens Hosp, Battelle Ctr Math Med, Columbus, OH USA. [Lotay, Vaneet; Zhang, Weijia] Icahn Sch Med Mt Sinai, Dept Med Bioinformat Core, Charles Bronfman Inst Personalized Med, New York, NY 10029 USA. [Monti, Maria Cristina] Univ Pavia, Dept Publ Hlth Neurosci Expt & Forens Med, I-27100 Pavia, Italy. RP Tomer, Y (reprint author), Mt Sinai Med Ctr, Div Endocrinol, Box 1055,One Gustave L Levy Pl, New York, NY 10029 USA. EM Yaron.Tomer@mssm.edu RI Dagostino Jr, Ralph/C-4060-2017; OI Dagostino Jr, Ralph/0000-0002-3550-8395; Monti, Maria Cristina/0000-0003-1586-527X FU NIH-NIDDK [DK61659, DK067555, DK073681]; Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai; Andrea and Charles Bronfman Philanthropies; Centers for Disease Control and Prevention [00097, DP-05-069, DP-10-001]; National Institute of Diabetes and Digestive and Kidney Diseases; Kaiser Permanente Southern California [U48/CCU919219, U01 DP000246, U18DP002714]; University of Colorado Denver [U48/CCU819241-3, U01 DP000247, U18DP000247-06A1]; Kuakini Medical Center [U58CCU919256, U01 DP000245]; Children's Hospital Medical Center (Cincinnati) [U48/CCU519239, U01 DP000248, 1U18DP002709]; University of North Carolina at Chapel Hill [U48/CCU419249, U01 DP000254, U18DP002708]; University of Washington School of Medicine [U58/CCU019235-4, U01 DP000244, U18DP002710-01]; Wake Forest University School of Medicine [U48/CCU919219, U01 DP000250, 200-2010-35171]; General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR) [UL1RR029882]; Seattle Children's Hospital (NIH CTSA) of the University of Washington [UL1 TR00423]; University of Colorado Pediatric Clinical and Translational Research Center (CTRC) [UL1 TR000154]; Barbara Davis Center at the University of Colorado at Denver [DERC NIH P30 DK57516]; National Center for Research Resources; National Center for Advancing Translational Sciences, National Institutes of Health [8 UL1 TR000077] FX We thank the Human Biological Data Interchange (Philadelphia, PA) for assisting with the recruitment of the replication set. This work was supported in part by grants DK61659, DK067555 & DK073681 from NIH-NIDDK (to YT). This study was also supported in part by the Charles Bronfman Institute for Personalized Medicine at the Icahn School of Medicine at Mount Sinai with funding provided by the Andrea and Charles Bronfman Philanthropies.; Grant Support: SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA numbers 00097, DP-05-069, and DP-10-001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases.; Site Contract Numbers: Kaiser Permanente Southern California (U48/CCU919219, U01 DP000246, and U18DP002714), University of Colorado Denver (U48/CCU819241-3, U01 DP000247, and U18DP000247-06A1), Kuakini Medical Center (U58CCU919256 and U01 DP000245), Children's Hospital Medical Center (Cincinnati) (U48/CCU519239, U01 DP000248, and 1U18DP002709), University of North Carolina at Chapel Hill (U48/CCU419249, U01 DP000254, and U18DP002708), University of Washington School of Medicine (U58/CCU019235-4, U01 DP000244, and U18DP002710-01), Wake Forest University School of Medicine (U48/CCU919219, U01 DP000250, and 200-2010-35171).; The authors wish to acknowledge the involvement of General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR Grant number UL1RR029882); Seattle Children's Hospital (NIH CTSA Grant UL1 TR00423 of the University of Washington); University of Colorado Pediatric Clinical and Translational Research Center (CTRC) (Grant Number UL1 TR000154) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516); and the National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant 8 UL1 TR000077; and the Children with Medical Handicaps program managed by the Ohio Department of Health. NR 40 TC 12 Z9 13 U1 1 U2 9 PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD PI LONDON PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND SN 0896-8411 EI 1095-9157 J9 J AUTOIMMUN JI J. Autoimmun. PD JUN PY 2015 VL 60 BP 32 EP 39 DI 10.1016/j.jaut.2015.03.006 PG 8 WC Immunology SC Immunology GA CK9JX UT WOS:000356557500004 PM 25936594 ER PT J AU Young, HS Dirzo, R McCauley, DJ Agwanda, B Cattaneo, L Dittmarjj, K Eckerlin, RP Fleischer, RC Helgen, LE Hintz, A Montinieri, J Zhao, S Helgen, KM AF Young, Hillary S. Dirzo, Rodolfo McCauley, Douglas J. Agwanda, Bernard Cattaneo, Lia Dittmarjj, Katharina Eckerlin, Ralph P. Fleischer, Robert C. Helgen, Lauren E. Hintz, Ashley Montinieri, John Zhao, Serena Helgen, Kristofer M. TI DRIVERS OF INTENSITY AND PREVALENCE OF FLEA PARASITISM ON SMALL MAMMALS IN EAST AFRICAN SAVANNA ECOSYSTEMS SO JOURNAL OF PARASITOLOGY LA English DT Article ID SEXUAL SIZE DIMORPHISM; DISEASE RISK; BIASED PARASITISM; INFECTIOUS-DISEASE; SPECIES-DIVERSITY; PATHOGEN TRANSMISSION; MAXIMUM-LIKELIHOOD; GROUND-SQUIRRELS; AIR-TEMPERATURE; HOST DIVERSITY AB The relative importance of environmental factors and host factors in explaining variation in prevalence and intensity of flea parasitism in small mammal communities is poorly established. We examined these relationships in an East African savanna landscape, considering multiple host levels: across individuals within a local population, across populations within species, and across species within a landscape. We sampled fleas from 2,672 small mammals of 27 species. This included a total of 8,283 fleas, with 5 genera and 12 species identified. Across individual hosts within a site, both rodent body mass and season affected total intensity of flea infestation, although the explanatory power of these factors was generally modest (<10%). Across host populations in the landscape, we found consistently positive effects of host density and negative effects of vegetation cover on the intensity of flea infestation. Other factors explored (host diversity, annual rainfall, anthropogenic disturbance, and soil properties) tended to have lower and less consistent explanatory power. Across host species in the landscape, we found that host body mass was strongly positively correlated with both prevalence and intensity of flea parasitism, while average robustness of a host species to disturbance was not correlated with flea parasitism. Cumulatively, these results provide insight into the intricate roles of both host and environmental factors in explaining complex patterns of flea parasitism across landscape mosaics. C1 [Young, Hillary S.; McCauley, Douglas J.] Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA. [Young, Hillary S.; Dirzo, Rodolfo] Stanford Univ, Dept Biol, Stanford, CA 94305 USA. [Young, Hillary S.; Cattaneo, Lia; Helgen, Lauren E.; Hintz, Ashley; Zhao, Serena; Helgen, Kristofer M.] Natl Museum Nat Hist, Smithsonian Inst, Div Mammals, Washington, DC 20013 USA. [Agwanda, Bernard; Hintz, Ashley; Zhao, Serena; Helgen, Kristofer M.] Natl Museums Kenya, Mammal Sect, Nairobi, Kenya. [Dittmarjj, Katharina] SUNY Buffalo, Dept Biol Sci, Buffalo, NY 14260 USA. [Eckerlin, Ralph P.] No Virginia Community Coll, Div Nat Sci, Annandale, VA 22003 USA. [Fleischer, Robert C.] Smithsonian Conservat Biol Inst, Natl Zool Pk, Ctr Conservat & Evolutionary Genet, Washington, DC 20008 USA. [Montinieri, John] Ctr Dis Control & Prevent, Natl Ctr Infect Dis, Div Vector Borne Infect Dis, Ft Collins, CO 80521 USA. RP Young, HS (reprint author), Univ Calif Santa Barbara, Dept Ecol Evolut & Marine Biol, Santa Barbara, CA 93106 USA. EM hillary.young@lifesci.ucsb.edu FU James Smithson Fund of the Smithsonian Institution; National Geographic Society [4691-91, 8846-10, 9106-12]; National Science Foundation [DEB-09-09670]; Smithsonian Barcode Network; Stanford's Woods Institute for the Environment; Smithsonian Institution Women's Committee [SWC 22, 44] FX We thank Jack Silanje, Peter Lokeny, Everlyn Ndinda, Stephen Nyaga, Anne Adelson, Benjamin Boyce, Cara Brook, Jacy Hyde, Lacey Hughey, Jennifer Guyton, and Pasha Feinberg for their assistance throughout this project. We also thank the Kenyan government, Kenya Wildlife Service, National Museums Kenya, Mpala Research Centre, Ol Jogi Ranch, Ol Pejeta Ranch, Segera Ranch, Ol Maisor Ranch, and the Lekiji, Il Motiok, Koija, Lododo, Narok, Il Polei, Thome, Marura, and Kimugandura communities for their assistance in facilitating this research. Financial support for this project came from the James Smithson Fund of the Smithsonian Institution, the National Geographic Society (grants 4691-91, 8846-10, 9106-12), National Science Foundation (DEB-09-09670), Smithsonian Barcode Network, Stanford's Woods Institute for the Environment, and Smithsonian Institution Women's Committee (SWC 22 and 44). All small mammal trapping and sampling was conducted in accordance with institutional animal care and use permits (Smithsonian Institution IACUC permit 2009-04) and the guidelines of the American Society of Mammalogists for the use of wild mammals in research. We thank S. Miller, A. Bergman, A. Driskell, D. Lunde, and J. Ososky for assistance at the Smithsonian Institution. NR 87 TC 2 Z9 2 U1 3 U2 11 PU AMER SOC PARASITOLOGISTS PI LAWRENCE PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA SN 0022-3395 EI 1937-2345 J9 J PARASITOL JI J. Parasitol. PD JUN PY 2015 VL 101 IS 3 BP 327 EP 335 DI 10.1645/14-684.1 PG 9 WC Parasitology SC Parasitology GA CK9DA UT WOS:000356539600009 PM 25634599 ER PT J AU Schubauer-Berigan, MK Daniels, RD Bertke, SJ Tseng, CY Richardson, DB AF Schubauer-Berigan, Mary K. Daniels, Robert D. Bertke, Stephen J. Tseng, Chih-Yu Richardson, David B. TI Cancer Mortality through 2005 among a Pooled Cohort of US Nuclear Workers Exposed to External Ionizing Radiation SO RADIATION RESEARCH LA English DT Article ID PORTSMOUTH-NAVAL-SHIPYARD; CHRONIC LYMPHOCYTIC-LEUKEMIA; TABLE ANALYSIS SYSTEM; LUNG-CANCER; OAK-RIDGE; OCCUPATIONAL COHORT; MULTIPLE-MYELOMA; RISK; INDUSTRY; FACILITIES AB Nuclear workers worldwide have been studied for decades to estimate associations between their exposure to ionizing radiation and cancer. The low-level exposure of these workers requires pooling of large cohorts studied over many years to obtain risk estimates with appropriate latency and good precision. We assembled a pooled cohort of 119,195 U.S. nuclear workers at four Department of Energy nuclear weapons facilities (Hanford site, Idaho National Laboratory, Oak Ridge National Laboratory and Savannah River site) and at the Portsmouth Naval Shipyard. The cohort was followed at the start of the workers beginning their radiation work (at earliest, between 1944 and 1952) through 2005, and we compared its mortality to that of the U.S. population. We also conducted regression-modeling analysis to evaluate dose-response associations for external radiation exposure and outcomes: all cancers, smoking-and nonsmoking-related cancers, all lymphatic and hematopoietic cancers, leukemia (excluding chronic lymphocytic), multiple myeloma, cardiovascular disease and others. The mean dose observed among the cohort was 20 mSv. For most outcomes, mortality was below expectation compared to the general population, but mesothelioma and pleura cancers were highly elevated. We found an excess relative risk (ERR) per 10 mSv of 0.14% [95% confidence interval (CI): -0.17%, 0.48%] for all cancers excluding leukemia. Estimates were higher for nonsmoking-related cancers (0.70%, 95% CI: 0.058%, 1.5%) and lower for smoking-related cancers (-0.079%, 95% CI: -0.43%, 0.32%). The ERR per 10 mSv was 1.7% (95% CI: -0.22%, 4.7%) for leukemia, which was similar to the estimate of 1.8% (95% CI: 0.027%, 4.4%) for all lymphatic and hematopoietic cancers. The ERR per 10 mSv for multiple myeloma was 3.9% (95% CI: 0.60%, 9.5%). The ERR per 10 mSv for cardiovascular disease was 0.026% (-0.25%, 0.32%). Little evidence of heterogeneity was seen by facility, birth cohort or sex for most outcomes. The estimates observed here are similar to those found in previous large pooled nuclear worker studies and also (with the exception of multiple myeloma) to those conducted in the Life Span Study of Japanese atomic bomb survivors. The tendency of observed risks to persist many years after exposure for most outcomes illustrates the importance of continued follow-up of nuclear worker cohorts. (C) 2015 by Radiation Research Society C1 [Schubauer-Berigan, Mary K.; Daniels, Robert D.; Bertke, Stephen J.; Tseng, Chih-Yu] NIOSH, Div Surveillance Hazard Evaluat & Field Studies, Cincinnati, OH 45226 USA. [Richardson, David B.] Univ N Carolina, Sch Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. RP Schubauer-Berigan, MK (reprint author), NIOSH, 1090 Tusculum Ave,MS-R15, Cincinnati, OH 45226 USA. EM zcg3@cdc.gov FU U.S. Department of Energy; U.S. Department of Health and Human Services; University of North Carolina from the National Institute for Occupational Safety and Health [R03.OH-010056] FX Funding for this study was provided, in part, by the U.S. Department of Energy through an agreement with the U.S. Department of Health and Human Services and through a grant received by the University of North Carolina from the National Institute for Occupational Safety and Health (R03.OH-010056). We acknowledge the NDI and state vital statistics offices for providing updated mortality information for cohort members. The authors are grateful to Kathleen Waters, Patricia Laber, Lisa Thomas and Christine Gersic for help in processing study data. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 45 TC 9 Z9 10 U1 1 U2 8 PU RADIATION RESEARCH SOC PI LAWRENCE PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA SN 0033-7587 EI 1938-5404 J9 RADIAT RES JI Radiat. Res. PD JUN PY 2015 VL 183 IS 6 BP 620 EP 631 DI 10.1667/RR13988.1 PG 12 WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology, Nuclear Medicine & Medical Imaging GA CK7YI UT WOS:000356452600004 PM 26010709 ER PT J AU Thierry-Chef, I Richardson, DB Daniels, RD Gillies, M Hamra, GB Haylock, R Kesminiene, A Laurier, D Leuraud, K Moissonnier, M O'Hagan, J Schubauer-Berigan, MK Cardis, E AF Thierry-Chef, I. Richardson, D. B. Daniels, R. D. Gillies, M. Hamra, G. B. Haylock, R. Kesminiene, A. Laurier, D. Leuraud, K. Moissonnier, M. O'Hagan, J. Schubauer-Berigan, M. K. Cardis, E. CA INWORKS Consortium TI Dose Estimation for a Study of Nuclear Workers in France, the United Kingdom and the United States of America: Methods for the International Nuclear Workers Study (INWORKS) SO RADIATION RESEARCH LA English DT Article ID EXTERNAL RADIATION-EXPOSURE; IONIZING-RADIATION; CANCER-RISK; RADIOLOGICAL PROTECTION; INDUSTRY WORKERS; MORTALITY; 15-COUNTRY; COHORT; LEUKEMIA; DOSIMETRY AB In the framework of the International Nuclear Workers Study conducted in France, the UK and the U.S. (INWORKS), updated and expanded methods were developed to convert recorded doses of ionizing radiation to estimates of organ doses or individual personal dose equivalent [H-p (10)] for a total number of 308,297 workers, including 40,035 women. This approach accounts for differences in dosimeter response to predominant workplace energy and geometry of exposure and for the recently published ICRP report on dose coefficients for men and women separately. The overall mean annual individual personal dose equivalent, including zero doses, is 1.73 mSv [median = 0.42; interquartile range (IQR): 0.07, 1.59]. Associated individual organ doses were estimated. INWORKS includes workers who had potential for exposure to neutrons. Therefore, we analyzed neutron dosimetry data to identify workers potentially exposed to neutrons. We created a time-varying indicator for each worker, classifying them according to whether they had a positive recorded neutron dose and if so, whether their neutron dose ever exceeded 10% of their total external penetrating radiation dose. The number of workers flagged as being exposed to neutrons was 13% for the full cohort, with 15% of the cohort in France, 12% of the cohort in the UK and 14% in the U.S. We also used available information on in vivo and bioassay monitoring to identify workers with known depositions or suspected internal contaminations. As a result of this work, information is now available that will allow various types of sensitivity analyses. (C) 2015 by Radiation Research Society C1 [Thierry-Chef, I.; Kesminiene, A.; Moissonnier, M.] Int Agcy Res Canc, F-69372 Lyon, France. [Richardson, D. B.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA. [Daniels, R. D.; Schubauer-Berigan, M. K.] NIOSH, Cincinnati, OH 45226 USA. [Gillies, M.] Publ Hlth England, Ctr Radiat Chem & Environm Hazards PHE CRCE, Didcot, Oxon, England. [Hamra, G. B.] Drexel Univ, Sch Publ Hlth, Dept Environm & Occupat Hlth, Philadelphia, PA 19104 USA. [Haylock, R.] Publ Hlth England, Ctr Radiat Chem & Environm Hazards PHE CRCE, Moor Row, Cumbria, England. [Laurier, D.; Leuraud, K.] IRSN, PRP HOM SRBE LEPID, Fontenay Aux Roses, France. [Cardis, E.] Ctr Res Environm Epidemiol CREAL, Barcelona, Spain. [Cardis, E.] UPF, Barcelona, Spain. [Cardis, E.] CIBER Epidemiol & Salud Publ CIBERESP, Madrid, Spain. RP Thierry-Chef, I (reprint author), 150 Cours Albert Thomas, F-69372 Lyon 08, France. EM thierrychefi@iarc.fr RI Cardis, Elisabeth/C-3904-2017 FU National Institute for Occupational Safety and Health; U.S. Department of Energy; U.S. Department of Health and Human Services; University of North Carolina from the National Institute for Occupational Safety and Health [R03.OH-010056]; Ministry of Health, Labour and Welfare of Japan (GA) [2012-02-21-01]; AREVA Nuclear Cycle (AREVA NC); Electricite de France (EDF) FX The authors would like to thank the participants at the February 2013 meeting held in Lyon, France: Franc, ois Trompier (France, IRSN); Guenther Dietze (Germany); David Bartlett (UK), Timothy Taulbee (U.S., NIOSH) and Rick Tanner (UK, PHE) for the very fruitful discussion on neutron monitoring and associated impact on dose estimates. The authors are also very grateful to Drs. Mike Marshall, Ethel S. Gilbert, Celia Hacker and Francis Bermann for their support and careful reading of the manuscript. This work was funded by the National Institute for Occupational Safety and Health, U.S. Department of Energy through an agreement with the U.S. Department of Health and Human Services, and through a grant received by the University of North Carolina from the National Institute for Occupational Safety and Health (R03.OH-010056) and by the Ministry of Health, Labour and Welfare of Japan (GA No 2012-02-21-01). The construction of the French cohort was realized by the Institut de Radioprotection et de Surete Nucleaire (IRSN), with partial funding from AREVA Nuclear Cycle (AREVA NC) and Electricite de France (EDF). The construction of the UK cohort was undertaken by Public Health England (PHE), who operates the UK National Registry for Radiation Workers (NRRW). PHE thanks all organizations and individuals participating in the NRRW for their cooperation, as well as the NRRW Steering Group for their continued support. NR 30 TC 6 Z9 6 U1 0 U2 7 PU RADIATION RESEARCH SOC PI LAWRENCE PA 810 E TENTH STREET, LAWRENCE, KS 66044 USA SN 0033-7587 EI 1938-5404 J9 RADIAT RES JI Radiat. Res. PD JUN PY 2015 VL 183 IS 6 BP 632 EP 642 DI 10.1667/RR14006.1 PG 11 WC Biology; Biophysics; Radiology, Nuclear Medicine & Medical Imaging SC Life Sciences & Biomedicine - Other Topics; Biophysics; Radiology, Nuclear Medicine & Medical Imaging GA CK7YI UT WOS:000356452600005 PM 26010707 ER PT J AU Vora, NM Orciari, LA Niezgoda, M Selvaggi, G Stosor, V Lyon, GM Wallace, RM Gabel, J Stanek, DR Jenkins, P Shiferaw, M Yager, P Jackson, F Hanlon, CA Damon, I Blanton, JD Recuenco, S Franka, R AF Vora, N. M. Orciari, L. A. Niezgoda, M. Selvaggi, G. Stosor, V. Lyon, G. M., III Wallace, R. M. Gabel, J. Stanek, D. R. Jenkins, P. Shiferaw, M. Yager, P. Jackson, F. Hanlon, C. A. Damon, I. Blanton, J. D. Recuenco, S. Franka, R. TI Clinical management and humoral immune responses to rabies post-exposure prophylaxis among three patients who received solid organs from a donor with rabies SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE rabies; solid organ transplantation; post-exposure prophylaxis ID HUMAN-IMMUNODEFICIENCY-VIRUS; UNITED-STATES; IMMUNIZATION PRACTICES; ADVISORY-COMMITTEE; ANTIBODY-RESPONSE; LOCAL TREATMENT; VACCINATION; RECOMMENDATIONS; EPIDEMIOLOGY; PREVENTION AB BackgroundThe rabies virus causes a fatal encephalitis and can be transmitted through organ transplantation. In 2013, a man developed rabies 18months after receiving a kidney from a donor with rabies, who was not known to have been infected when the organs were procured. Three additional persons who received organs from the same donor (liver, kidney, heart), all of whom were not vaccinated for rabies before transplantation, received rabies post-exposure prophylaxis (PEP) with rabies immune globulin and 5 doses of rabies vaccine as soon as the diagnosis of rabies was made in the donor (18months after their transplant surgeries). We describe their clinical management. MethodsAs the 3 recipients were all on immunosuppressive medications, post-vaccination serologic testing was performed using the rapid fluorescent focus inhibition test to measure rabies virus neutralizing antibodies (RVNAs). An acceptable antibody response to administration of rabies vaccine was defined as detection of RVNAs at a concentration 0.1IU/mL from a serum specimen collected 7days after the fifth vaccine dose. ResultsAll 3 recipients demonstrated an acceptable antibody response despite their immunosuppressed states. More than 36months have passed since their transplant surgeries, and all 3 recipients have no evidence of rabies. ConclusionsThe survival of 3 previously unvaccinated recipients of solid organs from a donor with rabies is unexpected. Although the precise factors that led to their survival remain unclear, our data suggest that PEP can possibly enhance transplant safety in settings in which donors are retrospectively diagnosed with rabies. C1 [Vora, N. M.; Wallace, R. M.] Ctr Dis Control & Prevent CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Vora, N. M.; Orciari, L. A.; Niezgoda, M.; Wallace, R. M.; Shiferaw, M.; Yager, P.; Jackson, F.; Hanlon, C. A.; Damon, I.; Blanton, J. D.; Recuenco, S.; Franka, R.] CDC, Poxvirus & Rabies Branch, Atlanta, GA 30333 USA. [Selvaggi, G.] Univ Miami, Miller Sch Med, Miami Transplant Inst, Miami, FL 33136 USA. [Stosor, V.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA. [Lyon, G. M., III] Emory Univ, Sch Med, Atlanta, GA USA. [Gabel, J.] Georgia Dept Publ Hlth, Atlanta, GA USA. [Stanek, D. R.; Jenkins, P.] Florida Dept Hlth, Tallahassee, FL USA. RP Vora, NM (reprint author), 1600 Clifton Rd NE,Mailstop G33, Atlanta, GA 30333 USA. EM nvora@cdc.gov OI Recuenco-Cabrera, Sergio/0000-0002-8446-7411 FU Intramural CDC HHS [CC999999] NR 26 TC 3 Z9 3 U1 0 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD JUN PY 2015 VL 17 IS 3 BP 389 EP 395 DI 10.1111/tid.12393 PG 7 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA CK2YW UT WOS:000356082600008 PM 25851103 ER PT J AU Forrest, GN Bhalla, P DeBess, EE Winthrop, KL Lockhart, SR Mohammadi, J Cieslak, PR AF Forrest, G. N. Bhalla, P. DeBess, E. E. Winthrop, K. L. Lockhart, S. R. Mohammadi, J. Cieslak, P. R. TI Cryptococcus gattii infection in solid organ transplant recipients: description of Oregon outbreak cases SO TRANSPLANT INFECTIOUS DISEASE LA English DT Article DE Cryptococcus gattii; organ transplantation; antifungals; immunosuppression ID CALCINEURIN-INHIBITOR AGENTS; INVASIVE FUNGAL-INFECTIONS; PACIFIC-NORTHWEST; PRACTICE GUIDELINES; BRITISH-COLUMBIA; UNITED-STATES; IN-VITRO; NEOFORMANS; MANAGEMENT; DISEASE AB Cryptococcus gattii was recognized as an emerging infection in the Pacific Northwest in 2004. Out of 62 total infections in Oregon since the outbreak, 11 were in solid organ transplant (SOT) recipients. SOT recipients were more likely to have disseminated disease and higher mortality than normal hosts, who mostly had isolated mass lesions. The median time from transplantation to C.gattii diagnosis was 17.8months. The primary sites of infection were lung (n=4), central nervous system (n=3), or both (n=4). The Oregon-endemic strain, VGII (subtypes IIa and IIc) was present in 10 of 11 patients; the median fluconazole minimum inhibitory concentration (MIC) was 12g/mL (range 2-32g/mL) for this strain. We found C.gattii infection among organ transplant recipients was disseminated at diagnosis, had low cerebrospinal fluid cryptococcal antigen titers, and was associated with an elevated fluconazole MIC and high attributable mortality. C1 [Forrest, G. N.; Mohammadi, J.] Portland VA Med Ctr, Div Infect Dis, Portland, OR 97239 USA. [Bhalla, P.; Winthrop, K. L.] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA. [Bhalla, P.; DeBess, E. E.; Cieslak, P. R.] Oregon Hlth Author, Publ Hlth Div, Acute & Communicable Dis Prevent, Portland, OR USA. [Lockhart, S. R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. RP Forrest, GN (reprint author), Portland VA Med Ctr, Div Infect Dis, 3710 SW US Vet Hosp Rd,P3ID, Portland, OR 97239 USA. EM forrestg@ohsu.edu FU Oregon Health Authority; Epidemiology and Laboratory Capacity Cooperative Agreement [5U50CK000218]; Centers for Disease Control and Prevention (CDC) FX The study was conducted under the auspices of the Oregon Health Authority. This publication was supported by the Epidemiology and Laboratory Capacity Cooperative Agreement (number 5U50CK000218) with the Centers for Disease Control and Prevention (CDC). NR 25 TC 2 Z9 2 U1 0 U2 2 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1398-2273 EI 1399-3062 J9 TRANSPL INFECT DIS JI Transpl. Infect. Dis. PD JUN PY 2015 VL 17 IS 3 BP 467 EP 476 DI 10.1111/tid.12370 PG 10 WC Immunology; Infectious Diseases; Transplantation SC Immunology; Infectious Diseases; Transplantation GA CK2YW UT WOS:000356082600021 PM 25677448 ER PT J AU Aschebrook-Kilfoy, B DellaValle, CT Purdue, M Kim, C Zhang, YW Sjodin, A Ward, MH AF Aschebrook-Kilfoy, Briseis DellaValle, Curt T. Purdue, Mark Kim, Christopher Zhang, Yawei Sjodin, Andreas Ward, Mary H. TI Polybrominated Diphenyl Ethers and Thyroid Cancer Risk in the Prostate, Colorectal, Lung, and Ovarian Cancer Screening Trial Cohort SO AMERICAN JOURNAL OF EPIDEMIOLOGY LA English DT Article DE brominated diphenyl ethers; flame retardants; thyroid cancer risk ID BROMINATED FLAME RETARDANTS; IN-HOUSE DUST; HORMONE-LEVELS; POLYCHLORINATED-BIPHENYLS; ASSOCIATIONS; PREGNANCY; EXPOSURE; TRENDS; GLAND; SERUM AB Polybrominated diphenyl ethers (PBDEs) alter thyroid hormone homeostasis, but their relationship with thyroid cancer is unknown. To investigate whether serum concentrations of PBDE were associated with thyroid cancer, we conducted a nested, case-control study in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, a large multicenter clinical trial in the United States. Cases with thyroid cancer (n = 104) were recruited from 1992 to 2001 and diagnosed through 2009, and controls (n = 208) were individually matched (2: 1) to cases by race, sex, birth date (within 1 year), center, and blood collection date (within 15 days). We used gas chromatography isotope dilution high-resolution mass spectrometry to measure 10 tri-to heptabrominated diphenyl eithers in serum samples. Odds ratios and 95% confidence intervals were calculated using conditional logistic regression for lipid-adjusted PBDE levels detected in more than 50% of controls and for the sum of these BDEs (Sigma PBDEs). We observed no significant differences between cases and controls in lipid-adjusted concentrations of Sigma PBDEs (for cases, median = 12.8 ng/g lipid (interquartile range, 6.2-42.1); for controls, median = 19.4 ng/g lipid (interquartile range, 7.6-50.2)) or for individual congeners. Increasing quartiles of Sigma PBDEs and 4 BDE congeners were not associated with risk of thyroid cancer (for the fourth vs. first quartile of Sigma PBDEs, adjusted odd ratio = 0.62, 95% confidence interval: 0.29, 1.30; P for trend = 0.56). Our study does not support an association between exposure to PBDEs and thyroid cancer. C1 [Aschebrook-Kilfoy, Briseis] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA. [Aschebrook-Kilfoy, Briseis; DellaValle, Curt T.; Purdue, Mark; Kim, Christopher; Ward, Mary H.] NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,US Dept HHS, Bethesda, MD 20892 USA. [Zhang, Yawei] Yale Univ, Sch Epidemiol & Publ Hlth, New Haven, CT USA. [Sjodin, Andreas] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Ward, MH (reprint author), NCI, Occupat & Environm Epidemiol Branch, Div Canc Epidemiol & Genet, NIH DHHS, 9609 Med Ctr Dr,6E-138,MSC 9771, Rockville, MD 20850 USA. EM wardm@mail.nih.gov FU Intramural Research Program of the National Cancer Institute, National Institutes of Health FX This work was funded by the Intramural Research Program of the National Cancer Institute, National Institutes of Health. NR 24 TC 2 Z9 2 U1 5 U2 23 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0002-9262 EI 1476-6256 J9 AM J EPIDEMIOL JI Am. J. Epidemiol. PD JUN 1 PY 2015 VL 181 IS 11 BP 883 EP 888 DI 10.1093/aje/kwu358 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CK4GC UT WOS:000356180300007 PM 25939348 ER PT J AU Green, MD Hostetler, DM Nettey, H Swamidoss, I Ranieri, N Newton, PN AF Green, Michael D. Hostetler, Dana M. Nettey, Henry Swamidoss, Isabel Ranieri, Nicola Newton, Paul N. TI Integration of Novel Low-Cost Colorimetric, Laser Photometric, and Visual Fluorescent Techniques for Rapid Identification of Falsified Medicines in Resource-Poor Areas: Application to Artemether-Lumefantrine SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID COUNTERFEIT ANTIMALARIAL TABLETS; SOUTHEAST-ASIA; ARTESUNATE; QUALITY; DRUGS; SPECTROSCOPY; AFRICA; SOLD AB The availability of falsified antimalarial drugs can be reduced with effective drug regulatory agencies and proper enforcement. Fundamental to these agencies taking action, rapid identification must be made as soon as they appear in the market place. Since falsified antimalarials occur mostly in developing countries, performing drug analysis presents itself with unique challenges. A fundamental factor in choosing a useful technique is affordability and simplicity. Therefore, we suggest a three-tiered drug evaluation strategy for identifying a falsified drug in resource-poor areas. Tier I is a simple comparison of a tablet's weight and dimensions with official specifications. Tier II uses inexpensive photometric devices (laser and fluorescence) to evaluate a tablet. Suspicious samples from Tier I and II assessments are then subjected to a colorimetric assay for active ingredients identification and quantification. In this article, we evaluate a novel colorimetric assay for the simultaneous assessment of both lumefantrine and artemether in co-formulated Coartem (TM) tablets, and integrate the method with two novel, low-cost, fluorescence and laser photometric devices. Image analysis software is used for the assessments. Although artemether-lumefantrine is used as an example, the strategy may be adapted to other medicines. C1 [Green, Michael D.; Hostetler, Dana M.; Swamidoss, Isabel] CDC, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Nettey, Henry] Univ Ghana, Coll Hlth Sci, Sch Pharm, Dept Pharmaceut & Microbiol, Legon, Ghana. [Ranieri, Nicola] US FDA, Forens Chem Ctr, Cincinnati, OH USA. [Newton, Paul N.] Mahosot Hosp, Microbiol Lab, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit, Viangchan, Laos. [Newton, Paul N.] Univ Oxford, Churchill Hosp, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England. RP Green, MD (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,Mailstop F12, Atlanta, GA 30333 USA. EM mgreen@cdc.gov; danahostetler@gmail.com; hnettey@msn.com; gtz8@cdc.gov; nicola.ranieri@fda.hhs.gov; paul.newton@tropmedres.ac NR 29 TC 7 Z9 7 U1 2 U2 10 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 SU S BP 8 EP 16 DI 10.4269/ajtmh.14-0832 PG 9 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8XA UT WOS:000355785600003 PM 25897066 ER PT J AU Yeung, S Lawford, HLS Tabemero, P Nguon, C van Wyk, A Malik, N DeSousa, M Rada, O Boravann, M Dwivedi, P Hostetler, DM Swamidoss, I Green, MD Fernandez, FM Kaur, H AF Yeung, Shunmay Lawford, Harriet L. S. Tabemero, Patricia Nguon, Chea van Wyk, Albert Malik, Naiela DeSousa, Mikhael Rada, Ouk Boravann, Mam Dwivedi, Prabha Hostetler, Dana M. Swamidoss, Isabel Green, Michael D. Fernandez, Facundo M. Kaur, Harparkash TI Quality of Antimalarials at the Epicenter of Antimalarial Drug Resistance: Results from an Overt and Mystery Client Survey in Cambodia SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SEVERE FALCIPARUM-MALARIA; POOR-QUALITY; SOUTHEAST-ASIA; ARTEMISININ RESISTANCE; PLASMODIUM-FALCIPARUM; RANDOMIZED-TRIAL; FAKE ARTESUNATE; MEDICINES; COUNTERFEIT; COUNTRIES AB Widespread availability of monotherapies and falsified antimalarials is thought to have contributed to the historical development of multidrug-resistant malaria in Cambodia. This study aimed to document the quality of artemisinin-containing antimalarials (ACAs) and to compare two methods of collecting antimalarials from drug outlets: through open surveyors and mystery clients (MCs). Few oral artemisinin-based monotherapies and no suspected falsified medicines were found. All 291 samples contained the stated active pharmaceutical ingredient (API) of which 69% were considered good quality by chemical analysis. Overall, medicine quality did not differ by collection method, although open surveyors were less likely to obtain oral artemisinin-based monotherapies than MCs. The results are an encouraging indication of the positive impact of the country's efforts to tackle falsified antimalarials and artemisinin-based monotherapies. However, poor-quality medicines remain an ongoing challenge that demands sustained political will and investment of human and financial resources. C1 [Yeung, Shunmay; Lawford, Harriet L. S.; Tabemero, Patricia] LSHTM, Dept Global Hlth & Dev, Fac Publ Hlth & Policy, London WC1H 9SH, England. [Tabemero, Patricia] Univ Oxford, Ctr Trop Med, Worldwide Antimalarial Resistance Network WWARN, Oxford OX1 2JD, England. [Nguon, Chea; Rada, Ouk; Boravann, Mam] Natl Ctr Parasitol Entomol & Malaria Control, Phnom Penh, Cambodia. [DeSousa, Mikhael] LSHTM, Dept Global Hlth & Dev, Fac Publ Hlth & Policy, Med Sans Frontieres, London WC1H 9SH, England. [van Wyk, Albert; Malik, Naiela; Kaur, Harparkash] LSHTM, Fac Infect & Trop Dis, Dept Clin Res, London WC1H 9SH, England. [Dwivedi, Prabha; Hostetler, Dana M.; Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Swamidoss, Isabel; Green, Michael D.] Ctr Dis Control & Prevent, Div Parasit Dis, Atlanta, GA USA. RP Yeung, S (reprint author), LSHTM, Dept Global Hlth & Dev, Fac Publ Hlth & Policy, 15-17 Tavistock Pl, London WC1H 9SH, England. EM shunmay.yeung@ishtm.ac.uk; harrietlawford@gmail.com; patricia.tabernero@wwarn.org; cheanguoncnm@gmail.com; albert.vanwyk@gmail.com; naiela-begum.malik@lshtm.ac.uk; milchael_desouza@yahoo.com; oukrada@gmail.com; boravann@gmail.com; prabha.dwivedi@chemistry.gatech.edu; danahostetler@gmail.com; iswamidoss@cdc.gov; mdg4@cdc.gov; facundo.fernandez@chemistry.gatech.edu; harparkash.Kaur@lshtm.ac.uk FU U.K. Department for International Development (DfID) through the Tracking Resistance to Artemisinins Collaboration; Clinton Health Access Initiative; ACT Consortium by Bill and Melinda Gates Foundation; DFID FX This study was supported by funds from U.K. Department for International Development (DfID) through the Tracking Resistance to Artemisinins Collaboration; the Clinton Health Access Initiative; and the ACT Consortium which is supported by a grant from the Bill and Melinda Gates Foundation. This document is an output from a project funded by DFID for the benefit of developing countries. However the views expressed and information contained in it are not necessarily those of or endorsed by DFID, which can accept no responsibility for such views or for any reliance place on them. NR 59 TC 10 Z9 10 U1 0 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 SU S BP 39 EP 50 DI 10.4269/ajtmh.14-0391 PG 12 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8XA UT WOS:000355785600007 PM 25897063 ER PT J AU Kaur, H van Wyk, A Malik, N Lynch, C Fadeyi, I Long, J Schellenberg, D Swamidoss, I Green, MD Dwivedi, P Kachur, SP Fernandez, FM Yeung, S Thomson, R Bruxvoort, K Goodman, C Johanes, B Festo, C Kalolella, A Taylor, M AF Kaur, Harparkash van Wyk, Albert Malik, Naiela Lynch, Caroline Fadeyi, Ifeyinwa Long, Jamie Schellenberg, David Swamidoss, Isabel Green, Michael D. Dwivedi, Prabha Kachur, S. Patrick Fernandez, Facundo M. Yeung, Shunmay Thomson, Rebecca Bruxvoort, Katia Goodman, Catherine Johanes, Boniface Festo, Charles Kalolella, Admirabilis Taylor, Mark CA ACT Consortium Drug Quality Projec IMPACT2 Study Team TI Quality of Artemisinin-Containing Antimalarials in Tanzania's Private Sector-Results from a Nationally Representative Outlet Survey SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID SULPHADOXINE/PYRIMETHAMINE TABLETS SOLD; PLASMODIUM-FALCIPARUM; CHLOROQUINE RESISTANCE; COMBINATION THERAPIES; SOUTHEAST-ASIA; ANTI-MALARIALS; MARKET SHARE; MEDICINES; AFRICA; COUNTRIES AB Ensuring that artemisinin-containing antimalarials (ACAs) are of good quality is a key component of effective malaria treatment. There are concerns that a high proportion of ACAs are falsified or substandard, though estimates are rarely based on representative data. During a nationally representative survey in Tanzania, ACAs were purchased from private retail drug outlets, and the active pharmaceutical ingredient (API) was measured. All 1,737 ACAs contained the labeled artemisinin derivative, with 4.1% being outside the 857115% artemisinin API range defined as acceptable quality. World Health Organization (WHO) prequalified drugs had 0.1 times the odds of being poor quality compared with non-prequalified ACAs for the artemisinin component. When partner components of combination therapies were also considered, 12.1% were outside the acceptable API range, and WHO prequalified ACAs had 0.04 times the odds of being poor quality. Although the prevalence of poor quality ACAs was lower than reported elsewhere, the minority of samples found to be substandard is a cause for concern. Improvements in quality could be achieved by increasing the predominance of WHO prequalified products in the market. Continued monitoring of quality standards is essential. C1 London Sch Hyg & Trop Med, Dept Clin Res, London WC1E 7HT, England. London Sch Hyg & Trop Med, Dept Dis Control, London WC1E 7HT, England. London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London WC1E 7HT, England. London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, London WC1E 7HT, England. [Swamidoss, Isabel; Green, Michael D.; Dwivedi, Prabha; Kachur, S. Patrick] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Festo, Charles; Kalolella, Admirabilis] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. RP Kaur, H (reprint author), London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England. EM harparkash.kaur@lshtm.ac.uk; albert.vanwyk@gmail.com; naiela-begum.malik@lshtm.ac.uk; caroline.lynch@lshtm.ac.uk; ifeyinwa.fadeyi@lshtm.ac.uk; gtz8@cdc.gov; mdg4@cdc.gov; yed9@cdc.gov; spk0@cdc.gov; facundo.fernandez@chemistry.gatech.edu; shunmay.yeung@lshtm.ac.uk; rebecca.thomson@lshtm.ac.uk; katia.bruxvoort@lshtm.ac.uk; catherine.goodman@lshtm.ac.uk; bjohanes14@gmail.com; cfesto@ihi.or.tz; akalolella@ihi.or.tz; mark.taylor@lshtm.ac.uk OI Taylor, Mark/0000-0002-7646-7905 FU Bill and Melinda Gates Foundation; ACT Consortium [PHGB VG0410, ITGBVG 17-10]; Global Fund to Fight AIDS, Tuberculosis and Malaria FX The study was funded by the Bill and Melinda Gates Foundation (www.gatesfoundation.org), through a grant with the ACT Consortium (actconsortium.org), project code PHGB VG0410 and project code ITGBVG 17-10 for all drug quality work. The outlet survey was conducted as part of the Independent Evaluation of the Affordable Medicines Facility-malaria (AMFm) and funded by the Global Fund to Fight AIDS, Tuberculosis and Malaria. NR 50 TC 0 Z9 0 U1 1 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 SU S BP 75 EP 86 DI 10.4269/ajtmh.14-0544 PG 12 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8XA UT WOS:000355785600011 ER PT J AU Tabernero, P Mayxay, M Culzoni, MJ Dwivedi, P Swamidoss, I Allan, EL Khanthavong, M Phonlavong, C Vilayhong, C Yeuchaixiong, S Sichanh, C Sengaloundeth, S Kaur, H Fernandez, FM Green, MD Newton, PN AF Tabernero, Patricia Mayxay, Mayfong Julia Culzoni, Maria Dwivedi, Prabha Swamidoss, Isabel Allan, Elizabeth Louise Khanthavong, Maniphone Phonlavong, Chindaphone Vilayhong, Chantala Yeuchaixiong, Sengchanh Sichanh, Chanvilay Sengaloundeth, Sivong Kaur, Harparkash Fernandez, Facundo M. Green, Michael D. Newton, Paul N. TI A Repeat Random Survey of the Prevalence of Falsified and Substandard Antimalarials in the Lao PDR: A Change for the Better SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID UNCOMPLICATED FALCIPARUM-MALARIA; PLASMODIUM-FALCIPARUM; POOR-QUALITY; ARTEMISININ RESISTANCE; SAVANNAKHET PROVINCE; DRUG-RESISTANCE; FAKE ARTESUNATE; SOUTHEAST-ASIA; PUBLIC-HEALTH; MEDICINE AB In 2003, a stratified random sample survey was conducted in the Lao People's Democratic Republic (Laos) to study the availability and quality of antimalarials in the private sector. In 2012, this survey was repeated to allow a statistically valid analysis of change through time. The counterfeit detection device 3 (CD-3) was used to assess packaging quality in the field and HPLC and mass spectroscopy analysis chemical analysis performed. The availability of oral artesunate monotherapies had significantly decreased from 22.9% (22) of 96 outlets in southern Laos in 2003 to 4.8% (7) of 144 outlets in 2012 (P < 0.0001). All the samples collected in the 2012 survey contained the correct active pharmaceutical ingredients (APIs) in contrast to the 21 (84%) falsified artesunate samples found in the 2003 survey. Although none of the medicines found in 2012 survey had evidence for falsification, 25.4% (37) of the samples were outside the 90-110% pharmacopeial limits of the label claim, suggesting that they were substandard or degraded. Results obtained from this survey show that patients are still exposed to poorly manufactured drugs or to ineffective medicines such as chloroquine. The quality of artemisinin-based combination therapies (ACTs) used in Laos needs to be monitored, since falsified ACTs would have devastating consequences in public health. C1 [Tabernero, Patricia; Vilayhong, Chantala; Yeuchaixiong, Sengchanh; Sichanh, Chanvilay; Newton, Paul N.] Mahosot Hosp, Microbiol Lab, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit, Viangchan, Laos. [Tabernero, Patricia; Mayxay, Mayfong; Sichanh, Chanvilay; Newton, Paul N.] Univ Oxford, Nuffield Dept Clin Med, Worldwide Antimalarial Resistance Network WWARN, Oxford OX3 7FZ, England. [Mayxay, Mayfong; Newton, Paul N.] Univ Oxford, Ctr Trop Med & Global Hlth, Nuffield Dept Clin Med, Oxford OX3 7FZ, England. [Mayxay, Mayfong] Univ Hlth Sci, Fac Postgrad Studies, Viangchan, Laos. [Julia Culzoni, Maria; Dwivedi, Prabha] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Julia Culzoni, Maria] Univ Nacl Litoral, CONICET, Fac Bioquim & Ciencias Biol, Santa Fe, NM, Argentina. [Swamidoss, Isabel; Fernandez, Facundo M.; Green, Michael D.] CDC, Div Parasit Dis & Malaria, US Centers Dis Control & Prevent, Atlanta, GA 30333 USA. [Allan, Elizabeth Louise; Kaur, Harparkash; Newton, Paul N.] London Sch Hyg & Trop Med, London WC1, England. [Khanthavong, Maniphone] Ctr Malariol Parasitol & Entomol, Viangchan, Laos. [Phonlavong, Chindaphone; Sengaloundeth, Sivong] Govt Lao PDR, Minist Hlth, Bur Food & Drug Inspect, Viangchan, Laos. Govt Lao PDR, Minist Hlth, Food & Drug Dept, Viangchan, Laos. RP Tabernero, P (reprint author), Univ Oxford, Ctr Trop Med & Global Hlth, Roosevelt Dr, Oxford OX3 7FZ, England. EM patricia.tabernero@wwarn.org; mayfong@tropmedres.ac; juliaculzoni@gmail.com; yed9@cdc.gov; gtz8@cdc.gov; louise.allan@lshtm.ac.uk; kv.maniphone@gmail.com; bfdi_chindaphone@yahoo.com; vchanthala@yahoo.com; chanvilay.sing@wwarn.org; sengaloundeth.sivong@gmail.com; harparkash.kaur@lshtm.ac.uk; facundo.fermandez@chemistry.gatech.edu; mdg4@cdc.gov; paul.newton@tropmedres.ac FU Projet FSP Mekong; French Ministry of Foreign Affairs and International Development; Wellcome Trust of Great Britain; Artemisinin Combination Therapy Consortium (ACTc) via Bill and Melinda Gates Foundation FX The study was funded by the Projet FSP Mekong, with finance from the French Ministry of Foreign Affairs and International Development and the Wellcome Trust of Great Britain and the Artemisinin Combination Therapy Consortium (ACTc) via an award from the Bill and Melinda Gates Foundation to the London School of Hygiene and Tropical Medicine (LSHTM). NR 58 TC 5 Z9 5 U1 1 U2 8 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 SU S BP 95 EP 104 DI 10.4269/ajtmh.15-0057 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8XA UT WOS:000355785600013 PM 25897062 ER PT J AU Yong, YL Plancon, A Lau, YH Hostetler, DM Fernandez, FM Green, MD Sounvoravong, S Nara, S Boravann, M Dumrong, T Bangsawan, N Low, MY Lim, CC Ai, RLC Newton, PN AF Yong, Yuk Lin Plancon, Aline Lau, Yen Hui Hostetler, Dana M. Fernandez, Facundo M. Green, Michael D. Sounvoravong, Sourisak Nara, Suon Boravann, Mam Dumrong, Thitikornkovit Bangsawan, Nurjaya Low, Min Yong Lim, Chin-Chin Ai, Ruth Lee Choo Newton, Paul N. TI Collaborative Health and Enforcement Operations on the Quality of Antimalarials and Antibiotics in Southeast Asia SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID PLASMODIUM-FALCIPARUM MALARIA; POOR-QUALITY; SUBSTANDARD MEDICINES; FAKE ARTESUNATE; PUBLIC-HEALTH; DRUG QUALITY; COUNTERFEIT; RESISTANCE; THAILAND; CAMBODIA AB Counterfeit (or falsified) and substandard medicines pose a major public health risk. We describe the findings of Operation Storm I and II conducted in 2008-2009 to combat counterfeit medicines through partnership between national customs, Drug Regulatory Agencies (DRAs), and police in Cambodia, Indonesia, Laos, Myanmar, Singapore, Thailand, and Vietnam. Samples were obtained from seizures and market surveillance by national DRAs. Laboratory analysis using spectroscopic and chromatographic techniques and examination of packaging were performed. Ninety-three suspect antibiotics and 95 antimalarial samples were collected. Of the 93 antibiotics, 29 (31%) had % active pharmaceutical ingredient content (%API) < 85% or > 115% (including one counterfeit). Of the 95 antimalarials, 30 (32%) had %API < 85 > 115% API (including one counterfeit). A significant minority of samples, antimalarials (13%) and antibiotics (15%), were collected in plastic bags with minimal or no labeling. Of 20 ampicillin samples, 13 (65%) contained < 85% API (with one counterfeit containing additional amoxicillin). Of 34 oral artesunate samples, 7 (21%) contained %API out of the 85-115% range. Coordinated and synergistic partnership adopted by the participating countries, International Criminal Police Organization (INTERPOL), World Health Organization (WHO), and laboratories facilitated a platform for discussions and intelligence sharing, helping to improve each participating country's capacity to combat poor-quality medicines. C1 [Yong, Yuk Lin; Lau, Yen Hui; Low, Min Yong; Lim, Chin-Chin; Ai, Ruth Lee Choo] Hlth Sci Author, Singapore, Singapore. [Plancon, Aline] INTERPOL, Med Prod Counterfeiting & Pharmaceut Crime Sub Di, Lyon, France. [Hostetler, Dana M.; Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. [Green, Michael D.] CDC, Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. [Sounvoravong, Sourisak] Govt Lao PDR, Minist Hlth, Food & Drug Dept, Viangchan, Laos. [Nara, Suon; Boravann, Mam] Royal Govt Cambodia, Antiecon Crime Dept, Cambodian Natl Police, Southeastern Asia, Cambodia. [Nara, Suon; Boravann, Mam] Royal Govt Cambodia, Dept Drugs & Food, Minist Hlth, Southeastern Asia, Cambodia. [Dumrong, Thitikornkovit] Food & Drug Adm, Bangkok, Thailand. [Bangsawan, Nurjaya] Food & Drug Adm, Jakarta, Indonesia. [Newton, Paul N.] Mahosot Hosp, Lao Oxford Mahosot Hosp Wellcome Trust Res Unit, Microbiol Lab, Viangchan, Laos. [Newton, Paul N.] Univ Oxford, Nuffield Dept Med, Churchill Hosp, Ctr Trop Med & Global Hlth, Oxford OX1 2JD, England. [Newton, Paul N.] Univ Oxford, Nuffield Dept Med, Worldwide Antimalarial Resistance Network, Oxford OX1 2JD, England. [Newton, Paul N.] London Sch Hyg & Trop Med, London WC1, England. RP Plancon, A (reprint author), INTERPOL, Med Prod Counterfeiting & Pharmaceut Crime Sub Di, Lyon, France. EM yyuklin@yahoo.com; a.plancon@interpol.int; lau_yen_hui@hsa.gov.sg; danahostetler@gatech.edu; facundo.fernandez@chemistry.gatech.edu; mdg4@cdc.gov; ssourisak@hotmail.com; suon_nara@hotmail.com; boravann@gmail.com; dthitikornkovit@gmail.com; nnnurjayabangsawan@yahoo.com; low_min_yong@hsa.gov.sg; chinchin@forensicexperts.com.sg; ruth_lee@hsa.gov.sg; paul@tropmedres.ac FU Bill and Melinda Gates Foundation; Wellcome Trust of Great Britain; Ministry of Health, Singapore FX The chemical analysis in Atlanta was supported by the ACT Consortium funded by the Bill and Melinda Gates Foundation. Paul Newton is supported by the Wellcome Trust of Great Britain. The chemical and packaging analysis in HSA was supported by the Regulatory Reinvestment Fund from the Ministry of Health, Singapore. NR 37 TC 5 Z9 5 U1 0 U2 7 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 SU S BP 105 EP 112 DI 10.4269/ajtmh.14-0574 PG 8 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8XA UT WOS:000355785600014 PM 25897069 ER PT J AU Shin, HU Stefaniak, AB Stojilovic, N Chase, GG AF Shin, Hyeon Ung Stefaniak, Aleksandr B. Stojilovic, Nenad Chase, George G. TI Comparative dissolution of electrospun Al2O3 nanofibres in artificial human lung fluids SO ENVIRONMENTAL SCIENCE-NANO LA English DT Article ID SYNTHETIC VITREOUS FIBERS; IN-VITRO DISSOLUTION; VIBRATIONAL FREQUENCIES; GAMMA-ALUMINA; GRAIN-GROWTH; HEATING RATE; NANOMATERIALS; PARTICLES; BIOPERSISTENCE; DENSIFICATION AB Sub-micron sized alumina fibres were fabricated by electrospinning and calcination of a polymer template fibre. In the calcination step, different controlled temperature heating cycles were conducted to obtain fibres of different crystalline structures. Their biodurabilities were tested at pH 7.4 with lung airway epithelial lining fluid or serum ultrafiltrate (SUF) and at pH 4.5 with macrophage phagolysosomal simulant fluid (PSF). Potential to generate free radicals was tested in vitro. Through the variation in the soak temperature from 650 degrees C to 950 degrees C (experiments S650-S950), the heating protocol affected the morphological characteristics, crystal structure, surface area, and density of the alumina fibres while their dissolution half-times were not significantly affected in SUF or PSF. Fibre samples formed at different heating ramp rates (experiments R93-R600) showed significant variation in the dissolution rates with the highest ramp rate corresponding to the highest dissolution rate. Thus, by increasing the calcination temperature ramp rate the alumina fibres may be produced that have reduced biodurability and lower inflammogenic potential. The fibres with the highest dissolution rated had the least aluminium content. The solubility half-times of the alumina fibres were shortest for fibres calcined at the fastest temperature ramp rate (though soak temperature did not have an effect). The ramp rates also affected the aluminium content of the fibres suggesting that the content may affect the structural strength of the fibres and control the dissolution. C1 [Shin, Hyeon Ung; Chase, George G.] Univ Akron, Dept Chem & Biomol Engn, Akron, OH 44325 USA. [Stefaniak, Aleksandr B.] Natl Inst Occupat Safety & Hlth, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Stojilovic, Nenad] Univ Wisconsin, Dept Phys & Astron, Oshkosh, WI 54901 USA. RP Chase, GG (reprint author), Univ Akron, Dept Chem & Biomol Engn, Akron, OH 44325 USA. EM gchase@uakron.edu FU Donaldson; Ahlstrom; Parker Hannifin; Cummins Filtration; Bekaert; Hollingsworth and Vose; SNS Nanofibre Technology; UWO [FDR859] FX This work was financially supported by the Coalescence Filtration Nanofibres Consortium: Donaldson, Ahlstrom, Parker Hannifin, Cummins Filtration, Bekaert, Hollingsworth and Vose, and SNS Nanofibre Technology to fabricate the fibres. H. U. Shin specially thanks Youlee Hong, Jeongwoo lee and Sangyoup Hwang for their technical assistance with TEM and FT-IR analysis. A. B. Stefaniak wishes to acknowledge M. G. Duling and R. B. Lawrence for their technical support with the dissolution studies and Dr. M. A. Virji for guidance on statistics. Mention of a specific product or company does not constitute endorsement by the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of NIOSH. N.S. was supported by UWO FDR859 grant. NR 50 TC 6 Z9 6 U1 2 U2 22 PU ROYAL SOC CHEMISTRY PI CAMBRIDGE PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS, ENGLAND SN 2051-8153 EI 2051-8161 J9 ENVIRON SCI-NANO JI Environ.-Sci. Nano PD JUN PY 2015 VL 2 IS 3 BP 251 EP 261 DI 10.1039/c5en00033e PG 11 WC Chemistry, Multidisciplinary; Environmental Sciences; Nanoscience & Nanotechnology SC Chemistry; Environmental Sciences & Ecology; Science & Technology - Other Topics GA CK1SF UT WOS:000355986900004 PM 26807259 ER PT J AU Harrison, LH Shutt, KA Arnold, KE Stern, EJ Pondo, T Kiehlbauch, JA Myers, RA Hollick, RA Schmink, S Vello, M Stephens, DS Messonnier, NE Mayer, LW Clark, TA AF Harrison, Lee H. Shutt, Kathleen A. Arnold, Kathryn E. Stern, Eric J. Pondo, Tracy Kiehlbauch, Julia A. Myers, Robert A. Hollick, Rosemary A. Schmink, Susanna Vello, Marianne Stephens, David S. Messonnier, Nancy E. Mayer, Leonard W. Clark, Thomas A. TI Meningococcal Carriage Among Georgia and Maryland High School Students SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE Neisseria meningitidis; meningococcus; meningococcal; meningococcal conjugate vaccine; oropharyngeal carriage; high school students ID AGED 13-17 YEARS; CONJUGATE VACCINE; NEISSERIA-MENINGITIDIS; HERD-IMMUNITY; UNITED-STATES; UNIVERSITY-STUDENTS; COLLEGE-STUDENTS; RISK-FACTORS; SEROGROUP; ADOLESCENTS AB Background. Meningococcal disease incidence in the United States is at an all-time low. In a previous study of Georgia high school students, meningococcal carriage prevalence was 7%. The purpose of this study was to measure the impact of a meningococcal conjugate vaccine on serogroup Y meningococcal carriage and to define the dynamics of carriage in high school students. Methods.aEuro integral This was a prospective cohort study at 8 high schools, 4 each in Maryland and Georgia, during a school year. Students at participating schools received quadrivalent meningococcal conjugate vaccine that uses diphtheria toxoid as the protein carrier (MCV4-DT). In each state, 2 high schools were randomly assigned for MCV4-DT receipt by students at the beginning of the study, and 2 were randomly assigned for MCV4-DT receipt at the end. Oropharyngeal swab cultures for meningococcal carriage were performed 3 times during the school year. Results.aEuro integral Among 3311 students, the prevalence of meningococcal carriage was 3.21%-4.01%. Phenotypically nongroupable strains accounted for 88% of carriage isolates. There were only 5 observed acquisitions of serogroup Y strains during the study; therefore, the impact of MCV4-DT on meningococcal carriage could not be determined. Conclusions.aEuro integral Meningococcal carriage rates in US high school students were lower than expected, and the vast majority of strains did not express capsule. These findings may help explain the historically low incidence of meningococcal disease in the United States. C1 [Harrison, Lee H.; Hollick, Rosemary A.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA. [Kiehlbauch, Julia A.; Myers, Robert A.] Maryland Dept Hlth & Mental Hyg, Baltimore, MD USA. [Harrison, Lee H.; Shutt, Kathleen A.] Univ Pittsburgh, Infect Dis Epidemiol Res Unit, Pittsburgh, PA 15260 USA. [Arnold, Kathryn E.; Vello, Marianne; Stephens, David S.] Georgia Dept Human Resources, Georgia Emerging Infect Program, Atlanta, GA USA. [Arnold, Kathryn E.; Vello, Marianne] Georgia Dept Human Resources, Div Publ Hlth, Atlanta, GA USA. [Stern, Eric J.; Pondo, Tracy; Schmink, Susanna; Messonnier, Nancy E.; Mayer, Leonard W.; Clark, Thomas A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Stern, Eric J.] Ctr Dis Control & Prevent, Epidem Intelligence Serv Program, Atlanta, GA USA. [Stephens, David S.] Emory Univ, Sch Med, Atlanta, GA USA. [Stephens, David S.] VA Med Ctr, Atlanta, GA USA. RP Harrison, LH (reprint author), 521 Parran Hall,130 DeSoto St, Pittsburgh, PA 15261 USA. EM lharriso@edc.pitt.edu OI Shutt, Kathleen/0000-0003-3376-6152 FU Sanofi Pasteur FX This work was supported by Sanofi Pasteur (grant to the Centers for Disease Control and Prevention Foundation). NR 33 TC 6 Z9 6 U1 1 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUN 1 PY 2015 VL 211 IS 11 BP 1761 EP 1768 DI 10.1093/infdis/jiu679 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CJ7KY UT WOS:000355675100010 PM 25505298 ER PT J AU Kalkowska, DA Tebbens, RJD Grotto, I Shulman, LM Anis, E Wassilak, SGF Pallansch, MA Thompson, KM AF Kalkowska, Dominika A. Tebbens, Radboud J. Duintjer Grotto, Itamar Shulman, Lester M. Anis, Emilia Wassilak, Steven G. F. Pallansch, Mark A. Thompson, Kimberly M. TI Modeling Options to Manage Type 1 Wild Poliovirus Imported Into Israel in 2013 SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE polio; eradication; population immunity; vaccine; OPV; IPV ID POPULATION IMMUNITY; TRANSMISSION; VACCINE; POLIOMYELITIS; RISKS; ERADICATION; STRATEGIES; CESSATION; OUTBREAKS; EVOLUTION AB Background. After 25 years without poliomyelitis cases caused by circulating wild poliovirus (WPV) in Israel, sewage sampling detected WPV type 1 (WPV1) in April 2013, despite high vaccination coverage with only inactivated poliovirus vaccine (IPV) since 2005. Methods.aEuro integral We used a differential equation-based model to simulate the dynamics of poliovirus transmission and population immunity in Israel due to past exposure to WPV and use of oral poliovirus vaccine (OPV) in addition to IPV. We explored the influences of various immunization options to stop imported WPV1 circulation in Israel. Results.aEuro integral We successfully modeled the potential for WPVs to circulate without detected cases in Israel. Maintaining a sequential IPV/OPV schedule instead of switching to an IPV-only schedule in 2005 would have kept population immunity high enough in Israel to prevent WPV1 circulation. The Israeli response to WPV1 detection prevented paralytic cases; a more rapid response might have interrupted transmission more quickly. Conclusions.aEuro integral IPV-based protection alone might not provide sufficient population immunity to prevent poliovirus transmission after an importation. As countries transition to IPV in immunization schedules, they may need to actively manage population immunity and consider continued use of OPV, to avoid the potential circulation of imported live polioviruses before globally coordinated cessation of OPV use. C1 [Kalkowska, Dominika A.; Tebbens, Radboud J. Duintjer; Thompson, Kimberly M.] Kid Risk Inc, Orlando, FL 32832 USA. [Thompson, Kimberly M.] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA. [Wassilak, Steven G. F.] Ctr Dis Control & Prevent, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA USA. [Pallansch, Mark A.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Kalkowska, Dominika A.] Delft Univ Technol, NL-2600 AA Delft, Netherlands. [Grotto, Itamar; Shulman, Lester M.] Minist Hlth, Publ Hlth Serv, Jerusalem, Israel. [Anis, Emilia] Minist Hlth, Div Epidemiol, Jerusalem, Israel. [Grotto, Itamar] Ben Gurion Univ Negev, Fac Hlth Sci, Beer Sheva, Israel. [Shulman, Lester M.] Tel Aviv Univ, Sackler Fac Med, Ramat Aviv, Israel. RP Thompson, KM (reprint author), Kid Risk Inc, 10524 Moss Pk Rd,Ste 204-364, Orlando, FL 32832 USA. EM kimt@kidrisk.org FU CDC [U66IP000519] FX This work was supported by the CDC (to D. A. K., R. J. D. T., and K. M. T., under cooperative agreement U66IP000519). NR 31 TC 16 Z9 16 U1 1 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUN 1 PY 2015 VL 211 IS 11 BP 1800 EP 1812 DI 10.1093/infdis/jiu674 PG 13 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CJ7KY UT WOS:000355675100015 PM 25505296 ER PT J AU Lopman, BA Trivedi, T Vicuna, Y Costantini, V Collins, N Gregoricus, N Parashar, U Sandoval, C Broncano, N Vaca, M Chico, ME Vinje, J Cooper, PJ AF Lopman, Ben A. Trivedi, Tarak Vicuna, Yosselin Costantini, Veronica Collins, Nikail Gregoricus, Nicole Parashar, Umesh Sandoval, Carlos Broncano, Nely Vaca, Maritza Chico, Martha E. Vinje, Jan Cooper, Philip J. TI Norovirus Infection and Disease in an Ecuadorian Birth Cohort: Association of Certain Norovirus Genotypes With Host FUT2 Secretor Status SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE norovirus; immunity; histo-blood group antigen; cohort study; incidence ID BLOOD GROUP ANTIGENS; NORWALK VIRUS-INFECTION; NONSENSE MUTATION; ROTAVIRUS INFECTION; GASTROENTERITIS; SUSCEPTIBILITY; RESISTANCE; CHALLENGE; PREVALENCE; PROTECTION AB Background. Although norovirus is the most common cause of gastroenteritis, there are few data on the community incidence of infection/disease or the patterns of acquired immunity or innate resistance to norovirus. Methods.aEuro integral We followed a community-based birth cohort of 194 children in Ecuador with the aim to estimate (1) the incidence of norovirus gastroenteritis from birth to age 3 years, (2) the protective effect of norovirus infection against subsequent infection/disease, and (3) the association of infection and disease with FUT2 secretor status. Results.aEuro integral Over the 3-year period, we detected a mean of 2.26 diarrheal episodes per child (range, 0-12 episodes). Norovirus was detected in 260 samples (18%) but was not found more frequently in diarrheal samples (79 of 438 [18%]), compared with diarrhea-free samples (181 of 1016 [18%]; P = .919). A total of 66% of children had at least 1 norovirus infection during the first 3 years of life, and 40% of children had 2 infections. Previous norovirus infections were not associated with the risk of subsequent infection. All genogroup II, genotype 4 (GII.4) infections were among secretor-positive children (P < .001), but higher rates of non-GII.4 infections were found in secretor-negative children (relative risk, 0.56; P = .029). Conclusions.aEuro integral GII.4 infections were uniquely detected in secretor-positive children, while non-GII.4 infections were more often found in secretor-negative children. C1 [Lopman, Ben A.; Trivedi, Tarak; Costantini, Veronica; Collins, Nikail; Gregoricus, Nicole; Parashar, Umesh; Vinje, Jan] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Costantini, Veronica] Emory Univ, Dept Pediat, Atlanta, GA 30322 USA. [Vicuna, Yosselin; Sandoval, Carlos; Broncano, Nely; Vaca, Maritza; Chico, Martha E.; Cooper, Philip J.] Lab Invest FEPIS, Quininde, Ecuador. [Vicuna, Yosselin; Sandoval, Carlos; Broncano, Nely; Vaca, Maritza; Chico, Martha E.; Cooper, Philip J.] Pontificia Univ Catolica Ecuador, Ctr Invest Enfermedades Infecciosas, Quito, Ecuador. [Cooper, Philip J.] St Georges Univ London, Inst Infect & Immun, London, England. RP Lopman, BA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-34, Atlanta, GA 30333 USA. EM blopman@cdc.gov OI Costantini, Veronica/0000-0002-1532-4345 FU Wellcome Trust [088862/Z/09/Z]; CDC; American Society of Tropical Medicine and Hygiene FX This work was supported by the Wellcome Trust (grant 088862/Z/09/Z), the CDC; and the American Society of Tropical Medicine and Hygiene (Benjamin H. Kean Travel Fellowship in Tropical Medicine to T. T.). NR 34 TC 11 Z9 11 U1 0 U2 5 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD JUN 1 PY 2015 VL 211 IS 11 BP 1813 EP 1821 DI 10.1093/infdis/jiu672 PG 9 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CJ7KY UT WOS:000355675100016 PM 25505295 ER PT J AU McCarty, TP Baddley, JW Walsh, TJ Alexander, BD Kontoyiannis, DP Perl, TM Walker, R Patterson, TF Schuster, MG Lyon, GM Wingard, JR Andes, DR Park, BJ Brandt, ME Pappas, PG AF McCarty, Todd P. Baddley, John W. Walsh, Thomas J. Alexander, Barbara D. Kontoyiannis, Dimitrios P. Perl, Trish M. Walker, Randall Patterson, Thomas F. Schuster, Mindy G. Lyon, G. Marshall Wingard, John R. Andes, David R. Park, Benjamin J. Brandt, Mary E. Pappas, Peter G. CA TRANSNET Investigators TI Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET) SO MEDICAL MYCOLOGY LA English DT Article DE phaeohyphomycosis; dematiaceous mold; Alternaria; Exserohilum ID VITRO ANTIFUNGAL SUSCEPTIBILITY; INVASIVE FUNGAL-INFECTIONS; METHYLPREDNISOLONE INJECTIONS; CEREBRAL PHEOHYPHOMYCOSIS; VORICONAZOLE; DIAGNOSIS AB Transplant recipients are at a high risk for developing invasive fungal infections. The agents of phaeohyphomycosis are environmental molds found worldwide, and they cause a broad spectrum of disease including skin and subcutaneous lesions, pneumonia, central nervous system disease, fungemia, and disseminated disease. Using data from the Transplant Associated Infection Surveillance Network (TRANSNET), we evaluated patients with proven and probable phaeohyphomycosis. Centers collected data on demographics, co-morbid conditions, clinical features, treatment, and three-month mortality. Fifty-six patients with phaeohyphomycosis were identified from 15 centers, comprising 26 stem cell transplant (SCT) and 30 solid organ transplant (SOT) recipients. Median time to diagnosis post-transplant was 358 days (SCT 100 days; SOT 685 days; P = <.001). The most frequent pathogen was Alternaria species (32%). Disseminated disease was found in 55.4%. Cutaneous infection was more common in SOT (53.3% vs 23.1%; P = .021), while pulmonary disease was more common in SCT (57.7 vs. 26.7; P = .019). Voriconazole (44.6%) and amphotericin B preparations (37.5%) were the most common antifungal therapies. Overall mortality was 25% and was higher in SCT than in SOT (42% vs 10%; P = <.001). A wide variety of organisms encompass phaeohyphomycosis contributing to varying types of infection in transplant recipients. Site of infection, time to disease, and mortality varies significantly between SCT and SOT recipients. Lipid formulations of amphotericin B and voriconazole were the most common antifungals used to treat this disorder. C1 [McCarty, Todd P.; Baddley, John W.; Pappas, Peter G.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [Walsh, Thomas J.] Weill Cornell Med Ctr, New York Presbyterian Hosp, Dept Med, New York, NY USA. [Walsh, Thomas J.] Weill Cornell Med Ctr, New York Presbyterian Hosp, Dept Pediat, New York, NY USA. [Walsh, Thomas J.] Weill Cornell Med Ctr, New York Presbyterian Hosp, Dept Microbiol & Immunol, New York, NY USA. [Alexander, Barbara D.] Duke Univ, Sch Med, Dept Med, Durham, NC 27706 USA. [Kontoyiannis, Dimitrios P.] Univ Texas MD Anderson Canc Ctr, Dept Med, Houston, TX 77030 USA. [Perl, Trish M.] Johns Hopkins Univ Hosp, Dept Med, Baltimore, MD 21287 USA. [Perl, Trish M.] Johns Hopkins Univ Hosp, Dept Pathol, Baltimore, MD 21287 USA. [Perl, Trish M.] Johns Hopkins Univ Hosp, Dept Epidemiol, Baltimore, MD 21287 USA. [Walker, Randall] Mayo Clin, Dept Med, Rochester, MN USA. [Patterson, Thomas F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Patterson, Thomas F.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Schuster, Mindy G.] Univ Penn, Med Ctr, Dept Med, Philadelphia, PA 19104 USA. [Lyon, G. Marshall] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Wingard, John R.] Univ Florida, Dept Med, Gainesville, FL USA. [Andes, David R.] Univ Wisconsin, Dept Med, Madison, WI 53706 USA. [Park, Benjamin J.; Brandt, Mary E.] Ctr Dis Control & Prevent, Atlanta, GA USA. RP McCarty, TP (reprint author), Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. EM tmccarty@uabmc.edu FU Centers for Disease Control and Prevention [5U01CI000286-05]; Merck Co., Inc.; Astellas US, Inc.; Pfizer, Inc.; Enzon Pharmaceuticals, Inc.; Vicuron Pharmaceuticals FX Funding was provided by the Centers for Disease Control and Prevention (Grant 5U01CI000286-05) and grants from Merck & Co., Inc.; Astellas US, Inc.; Pfizer, Inc.; Enzon Pharmaceuticals, Inc.; and Vicuron Pharmaceuticals. NR 22 TC 7 Z9 7 U1 0 U2 1 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1369-3786 EI 1460-2709 J9 MED MYCOL JI Med. Mycol. PD JUN PY 2015 VL 53 IS 5 BP 440 EP 446 DI 10.1093/mmy/myv018 PG 7 WC Infectious Diseases; Mycology; Veterinary Sciences SC Infectious Diseases; Mycology; Veterinary Sciences GA CK5GA UT WOS:000356249800002 PM 25908651 ER PT J AU Amaya, A Leclere, F Carris, K Liao, YL AF Amaya, Ashley Leclere, Felicia Carris, Kari Liao, Youlian TI WHERE TO START AN EVALUATION OF PRIMARY DATA-COLLECTION MODES IN AN ADDRESS-BASED SAMPLING DESIGN SO PUBLIC OPINION QUARTERLY LA English DT Article ID INTERNET; MAIL AB As address-based sampling becomes increasingly popular for multimode surveys, researchers continue to refine data-collection best practices. While much work has been conducted to improve efficiency within a given mode, additional research is needed on how multimode designs can be optimized across modes. Previous research has not evaluated the consequences of mode sequencing on multimode mail and phone surveys, nor has significant research been conducted to evaluate mode sequencing on a variety of indicators beyond response rates. We conducted an experiment within the Racial and Ethnic Approaches to Community Health across the U.S. Risk Factor Survey (REACH U.S.) to evaluate two multimode case-flow designs: (1) phone followed by mail (phone-first) and (2) mail followed by phone (mail-first). We compared response rates, cost, timeliness, and data quality to identify differences across case-flow design. Because surveys often differ on the rarity of the target population, we also examined whether changes in the eligibility rate altered the choice of optimal case flow. Our results suggested that, on most metrics, the mail-first design was superior to the phone-first design. Compared with phone-first, mail-first achieved a higher yield rate at a lower cost with equivalent data quality. While the phone-first design initially achieved more interviews compared to the mail-first design, over time the mail-first design surpassed it and obtained the greatest number of interviews. C1 [Amaya, Ashley] Univ Maryland, Joint Program Survey Methodol, College Pk, MD 20742 USA. [Amaya, Ashley] Univ Chicago, Publ Hlth Res Dept, NORC, Chicago, IL 60637 USA. [Leclere, Felicia] Univ Chicago, Hlth Care Dept, NORC, Chicago, IL 60637 USA. [Carris, Kari] Univ Chicago, Dept Hlth Sci, NORC, Chicago, IL 60637 USA. [Liao, Youlian] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Amaya, A (reprint author), Univ Maryland, Joint Program Survey Methodol, 1218 LeFrak Hall, College Pk, MD 20742 USA. EM aamaya@umd.edu FU Intramural CDC HHS [CC999999] NR 25 TC 0 Z9 0 U1 6 U2 13 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0033-362X EI 1537-5331 J9 PUBLIC OPIN QUART JI Public Opin. Q. PD SUM PY 2015 VL 79 IS 2 BP 420 EP 442 DI 10.1093/poq/nfv012 PG 23 WC Communication; Political Science; Social Sciences, Interdisciplinary SC Communication; Government & Law; Social Sciences - Other Topics GA CK4GZ UT WOS:000356183600002 PM 26120203 ER PT J AU Noyd, DH Sharp, TM AF Noyd, David H. Sharp, Tyler M. TI Recent Advances in Dengue: Relevance to Puerto Rico SO PUERTO RICO HEALTH SCIENCES JOURNAL LA English DT Review DE Dengue; Epidemiology; Public Health ID LABORATORY FEATURES; CASE CLASSIFICATION; FEBRILE ILLNESSES; VIRUS-INFECTION; SHOCK SYNDROME; SURVEILLANCE; EPIDEMIC; CLIMATE; DISEASE; VACCINE AB Dengue represents an increasingly important public health challenge in Puerto Rico, with recent epidemics in 2007, 2010, and 2012-2013. Although recent advances in dengue vaccine development offer hope for primary prevention, the role of health professionals in the diagnosis and management of dengue patients is paramount. Case definitions for dengue, dengue with warning signs, and severe dengue provide a framework to guide clinical decision-making. Furthermore, the differentiation between dengue and other acute febrile illnesses, such as leptospirosis and chikungunya, is necessary for the appropriate diagnosis and management of cases. An understanding of dengue epidemiology and surveillance in Puerto; Rico provides context for clinicians in epidemic and non-epidemic periods. This review aims to improve health professionals' ability to diagnose dengue, and as highlight the relevance of recent advances in dengue prevention and management in Puerto Rico. C1 [Noyd, David H.] Oregon Hlth & Sci Univ, Dengue Branch, Div Vector Borne Dis, Ctr Dis Control & Prevent, San Juan, PR USA. [Sharp, Tyler M.] Ctr Dis Control & Prevent, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA. RP Sharp, TM (reprint author), Ctr Dis Control & Prevent, Dengue Branch, 1324 Calle Canada, San Juan, PR 00920 USA. EM tsharp@cdc.gov FU Centers for Disease Control and Prevention (CDC); Oregon Clinical and Translational Research Institute (OCTRI) from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH) [TL1TR000129] FX This publication was supported by the Centers for Disease Control and Prevention (CDC) and the Oregon Clinical and Translational Research Institute (OCTRI) under grant number TL1TR000129 from the National Center for Advancing Translational Sciences (NCATS) at the National Institutes of Health (NIH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or CDC. NR 50 TC 4 Z9 4 U1 1 U2 4 PU UNIV PUERTO RICO MEDICAL SCIENCES CAMPUS PI SAN JUAN PA OFFICE DEAN ACADEMIC AFFAIRS BOX 365067, SAN JUAN, PR 00936-5067 USA SN 0738-0658 J9 P R HEALTH SCI J JI P. R. Health Sci. J. PD JUN PY 2015 VL 34 IS 2 BP 65 EP 70 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CK2FX UT WOS:000356027300003 PM 26061055 ER PT J AU Tsang, BL Devine, OJ Cordero, AM Marchetta, CM Mulinare, J Mersereau, P Guo, J Qi, YP Berry, RJ Rosenthal, J Crider, KS Hamner, HC AF Tsang, Becky L. Devine, Owen J. Cordero, Amy M. Marchetta, Claire M. Mulinare, Joseph Mersereau, Patricia Guo, Jing Qi, Yan Ping Berry, Robert J. Rosenthal, Jorge Crider, Krista S. Hamner, Heather C. TI Assessing the association between the methylenetetrahydrofolate reductase (MTHFR) 677C > T polymorphism and blood folate concentrations: a systematic review and meta-analysis of trials and observational studies SO AMERICAN JOURNAL OF CLINICAL NUTRITION LA English DT Review DE MTHFR; serum folate; plasma folate; red blood cell folate; neural tube defects ID NEURAL-TUBE DEFECTS; FOLIC-ACID SUPPLEMENTATION; PLASMA HOMOCYSTEINE LEVELS; 5,10-METHYLENETETRAHYDROFOLATE REDUCTASE; YOUNG-WOMEN; MICROBIOLOGICAL ASSAY; HEALTHY-SUBJECTS; THERMOLABILE VARIANT; ERYTHROCYTE FOLATE; STATUS RESPONSE AB Background: The methylenetetrahydrofolate reductase (MTHFR) 677C>T polymorphism is a risk factor for neural tube defects. The T allele produces an enzyme with reduced folate-processing capacity, which has been associated with lower blood folate concentrations. Objective: We assessed the association between MTHFR C677T genotypes and blood folate concentrations among healthy women aged 12-49 y. Design: We conducted a systematic review of the literature published from January 1992 to March 2014 to identify trials and observational studies that reported serum, plasma, or red blood cell (RBC) folate concentrations and MTHFR C677T genotype. We conducted a meta-analysis for estimates of percentage differences in blood folate concentrations between genotypes. Results: Forty studies met the inclusion criteria. Of the 6 studies that used the microbiologic assay (MA) to measure serum or plasma (SIP) and RBC folate concentrations, the percentage difference between genotypes showed a clear pattern of CC > CT > IT The percentage difference was greatest for CC > IT [S/P: 13%; 95% credible interval (CrI): 7%, 18%; RBC: 16%; 95% CrI: 12%, 20%] followed by CC > CT (S/P: 7%; 95% CrI: 1%, 12%; RBC: 8%; 95% CrI: 4%, 12%) and CT > IT (S/P: 6%; 95% CrI: 1%, 11%; RBC: 9%; 95% CrI: 5%, 13%). S/P folate concentrations measured by using protein-binding assays (PBAs) also showed this pattern but to a greater extent (e.g., CC > 171 20%; 95% CrI: 17%, 22%). In contrast, RBC folate concentrations measured by using PBAs did not show the same pattern and are presented in the Supplemental Material only. Conclusions: Meta-analysis results (limited to the MA, the recommended population assessment method) indicated a consistent percentage difference in SIP and RBC folate concentrations across MTHFR C677T genotypes. Lower blood folate concentrations associated with this polymorphism could have implications for a population-level risk of neural tube defects. C1 [Cordero, Amy M.; Berry, Robert J.; Rosenthal, Jorge; Crider, Krista S.] CDC, Div Birth Defects & Dev Disabil, NCBDDD, Atlanta, GA 30341 USA. [Hamner, Heather C.] CDC, Div Nutr Phys Activiti & Obes, Natl Ctr Chron Dis Prevent & Hlth Prmot, Atlanta, GA 30341 USA. [Guo, Jing] Acentia, Falls Church, VA USA. [Devine, Owen J.; Mulinare, Joseph; Qi, Yan Ping] Carter Consulting Inc, Atlanta, GA USA. [Tsang, Becky L.; Marchetta, Claire M.; Qi, Yan Ping] Oak Ridge Inst Sci & Educ, Oak Ridge, TN USA. [Mersereau, Patricia] SciMetrika LLC, Atlanta, GA USA. RP Hamner, HC (reprint author), CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway,NE,MS F-76, Atlanta, GA 30341 USA. EM hfc2@cdc.gov FU CDC FX BLT, CMM, and YPQ were supported by the CDC and in part by an appointment to the Research Participation Program at CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department of Energy and CDC. NR 68 TC 17 Z9 19 U1 3 U2 10 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0002-9165 EI 1938-3207 J9 AM J CLIN NUTR JI Am. J. Clin. Nutr. PD JUN PY 2015 VL 101 IS 6 BP 1286 EP 1294 DI 10.3945/ajcn.114.099994 PG 9 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CJ6YU UT WOS:000355641900023 PM 25788000 ER PT J AU Sanchez, JF Halsey, ES Bayer, AM Beltran, M Razuri, HR Velasquez, DE Cama, VA Graf, PCF Quispe, AM Mayes, RC Montgomery, JM Sanders, JW Lescano, AG AF Sanchez, Juan F. Halsey, Eric S. Bayer, Angela M. Beltran, Martin Razuri, Hugo R. Velasquez, Daniel E. Cama, Vitaliano A. Graf, Paul C. F. Quispe, Antonio M. Mayes, Ryan C. Montgomery, Joel M. Sanders, John W. Lescano, Andres G. TI Needs, Acceptability, and Value of Humanitarian Medical Assistance in Remote Peruvian Amazon Riverine Communities SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID INTESTINAL PARASITIC INFECTIONS; HELMINTH INFECTION; SOCIOECONOMIC-STATUS; IMPACT ASSESSMENT; AID PROGRAMS; RISK-FACTORS; ACRE STATE; PREVALENCE; CHILDREN; POPULATION AB Much debate exists regarding the need, acceptability, and value of humanitarian medical assistance. We conducted a cross-sectional study on 457 children under 5 years from four remote riverine communities in the Peruvian Amazon and collected anthropometric measures, blood samples (1-4 years), and stool samples. Focus groups and key informant interviews assessed perspectives regarding medical aid delivered by foreigners. The prevalence of stunting, anemia, and intestinal parasites was 20%, 37%, and 62%, respectively. Infection with multiple parasites, usually geohelminths, was detected in 41% of children. The prevalence of intestinal parasites both individual and polyparasitism increased with age. Participants from smaller communities less exposed to foreigners expressed lack of trust and fear of them. However, participants from all communities were positive about foreigners visiting to provide health support. Prevalent health needs such as parasitic infections and anemia may be addressed by short-term medical interventions. There is a perceived openness to and acceptability of medical assistance delivered by foreign personnel. C1 US Naval Med Res Unit 6 NAMRU 6, Lima 02, Peru. [Bayer, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Bayer, Angela M.] Univ Peruana Cayetano Heredia, Sch Publ Hlth & Management, Lima, Peru. [Beltran, Martin] Peruvian Minist Hlth, Alto Amazonas Hlth Network, Yurimaguas, Peru. [Halsey, Eric S.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Mayes, Ryan C.] Naval Med Ctr, San Diego, CA USA. [Sanchez, Juan F.] US Naval Med Res Unit 6 NAMRU 6, Dept Parasitol, Lima 02, Peru. [Halsey, Eric S.] Paul Naval Med Res Unit NAMRU 6, Dept Virol, Lima, Peru. [Halsey, Eric S.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Bayer, Angela M.; Lescano, Andres G.] Univ Peruana Cayetano Heredia, Sch Publ Hlth & Management, Lima, Peru. [Beltran, Martin] Peruvian Minist Hlth, Alto Amazonas Hlth Network, Yurimaguas, Peru. [Razuri, Hugo R.; Montgomery, Joel M.] US Naval Med Res Unit 6 NAMRU 6, Dept Emerging Infect, Lima, Peru. [Velasquez, Daniel E.; Cama, Vitaliano A.] Ctr Dis Control & Prevent CDC, Div Parasit Dis & Malaria, Atlanta, GA USA. [Graf, Paul C. F.] Naval Med Ctr, Div Infect Dis, San Diego, CA USA. [Mayes, Ryan C.] US Naval Med Res Unit 6 NAMRU 6, Dept Bacteriol, Lima, Peru. [Sanders, John W.] US Naval Med Res Unit 6 NAMRU 6, Lima, Peru. RP Lescano, AG (reprint author), US Naval Med Res Unit 6 NAMRU 6, Dept Parasitol, Ctr Med Naval, Ave Venezuela Cdra 36 S-N, Lima 02, Peru. EM juan.f.sanchez@med.navy.mil; ycw8@cdc.gov; angelabayerx@gmail.com; mjbeltran72@hotmail.es; hugorazuri@gmail.com; iqm6@cdc.gov; vec5@cdc.gov; paul.graf@med.navy.mil; aquispe@jhu.edu; ryan.maves@med.navy.mil; ztq9@cdc.gov; john.w.sanders38.mil@mail.mil; willy.lescano@med.navy.mil RI Lescano, Andres/B-8479-2008; OI Lescano, Andres/0000-0001-9779-633X; Quispe, Antonio/0000-0003-2100-7423 FU U.S. Southern Command (SOUTHCOM) [847705 82000 25GB B0016]; National Institutes of Health/Fogarty International Center (NIH/FIC) [2D43 TW007393] FX This study was supported by the U.S. Southern Command (SOUTHCOM) under work unit 847705 82000 25GB B0016 and the National Institutes of Health/Fogarty International Center (NIH/FIC) under Training Grant 2D43 TW007393. NR 47 TC 0 Z9 0 U1 0 U2 4 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 BP 1090 EP 1099 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8WY UT WOS:000355785400003 PM 25846293 ER PT J AU Bosco-Lauth, AM Panella, NA Root, JJ Gidlewski, T Lash, RR Harmon, JR Burkhalter, KL Godsey, MS Savage, HM Nicholson, WL Komar, N Brault, AC AF Bosco-Lauth, Angela M. Panella, Nicholas A. Root, J. Jeffrey Gidlewski, Tom Lash, R. Ryan Harmon, Jessica R. Burkhalter, Kristen L. Godsey, Marvin S. Savage, Harry M. Nicholson, William L. Komar, Nicholas Brault, Aaron C. TI Serological Investigation of Heartland Virus (Bunyaviridae: Phlebovirus) Exposure in Wild and Domestic Animals Adjacent to Human Case Sites in Missouri 2012-2013 SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID THROMBOCYTOPENIA SYNDROME VIRUS; SEVERE FEVER; AMBLYOMMA-AMERICANUM; SHANDONG PROVINCE; UNITED-STATES; RIO-GRANDE; CHINA; TICK; IDENTIFICATION; TRANSMISSION AB Heartland virus (HRTV; Bunyaviridae: Phlebovirus) has recently emerged as a causative agent of human disease characterized by thrombocytopenia and leukopenia in the United States. The lone star tick (Amblyomma americanum L.) has been implicated as a vector. To identify candidate vertebrate amplification hosts associated with enzootic maintenance of the virus, sera and ticks were sampled from 160 mammals (8 species) and 139 birds (26 species) captured near 2 human case residences in Andrew and Nodaway Counties in northwest Missouri. HRTV-specific neutralizing antibodies were identified in northern raccoons (42.6%), horses (17.4%), white-tailed deer (14.3%), dogs (7.7%), and Virginia opossums (3.8%), but not in birds. Virus isolation attempts from sera and ticks failed to detect HRTV. The high antibody prevalence coupled with local abundance of white-tailed deer and raccoons identifies these species as candidate amplification hosts. C1 [Bosco-Lauth, Angela M.; Panella, Nicholas A.; Burkhalter, Kristen L.; Godsey, Marvin S.; Savage, Harry M.; Komar, Nicholas; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Arboviral Dis Branch, Ft Collins, CO 80521 USA. [Root, J. Jeffrey; Gidlewski, Tom] Wildlife Serv, USDA, Natl Wildlife Res Ctr, Ft Collins, CO USA. [Lash, R. Ryan; Harmon, Jessica R.; Nicholson, William L.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Rickettsial Dis Branch, Ft Collins, CO 80521 USA. RP Brault, AC (reprint author), Ctr Dis Control & Prevent, Div Vector Borne Dis, 3156 Rampart Rd, Ft Collins, CO 80521 USA. EM mopargal@rams.colostate.edu; nap4@cdc.gov; Jeff.Root@aphis.usda.gov; Thomas.Gidlewski@aphis.usda.gov; rlash@cdc.gov; jharmon@cdc.gov; ktb3@cdc.gov; mjg9@cdc.gov; hms1@cdc.gov; wnicholson@cdc.gov; nck6@cdc.gov; abrault@cdc.gov FU American Society of Microbiology (ASM) FX Funding for Angela Bosco-Lauth was provided by a fellowship from the American Society of Microbiology (ASM). NR 27 TC 8 Z9 8 U1 2 U2 9 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 BP 1163 EP 1167 DI 10.4269/mtmh.14-0702 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8WY UT WOS:000355785400014 PM 25870419 ER PT J AU Segel, MJ Rozenman, J Lindsley, MD Lachish, T Berkman, N Neuberger, A Schwartz, E AF Segel, Michael J. Rozenman, Judith Lindsley, Mark D. Lachish, Tamar Berkman, Neville Neuberger, Ami Schwartz, Eli TI Histoplasmosis in Israeli Travelers SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID MIDDLE-EAST; OUTBREAK AB Histoplasmosis is a common endemic human mycoses acquired mostly in the Americas. We reviewed 23 cases of histoplasmosis in Israeli travelers; 22 had traveled to Central or South America and one to North America. Fourteen cases had been exposed to bat habitats and were symptomatic, presenting 3 months after their return. Asymptomatic patients (N = 9) were diagnosed during the evaluation of incidental radiological findings or because a travel partner had been suspected of Histoplasrna infection, 16-120 months after their return. Serological testing was positive in 75% of symptomatic cases but only 22% of asymptomatic cases. Histoplasmosis should be considered in travelers returning from the Americas with respiratory or febrile illness within weeks of return, particularly if exposed to bat habitats. Travel history is essential in patients presenting with pulmonary nodules, even years after travel to endemic countries. C1 Chaim Sheba Med Ctr, Internal Med C, Dept Imaging, Inst Pulmonol, IL-52621 Ramat Gan, Israel. Chaim Sheba Med Ctr, Ctr Geog Med, IL-52621 Ramat Gan, Israel. [Segel, Michael J.; Rozenman, Judith; Schwartz, Eli] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel. [Lindsley, Mark D.] Ctr Dis Control & Prevent, Mycot Dis Branch, Atlanta, GA USA. [Lachish, Tamar] Shaare Zedek Med Ctr, Infect Dis Unit, Jerusalem, Israel. [Berkman, Neville] Hadassah Hebrew Univ, Med Ctr, Inst Pulmonol, Jerusalem, Israel. [Neuberger, Ami] Technion Israel Inst Technol, Rappaport Fac Med, Haifa, Israel. [Neuberger, Ami] Rambam Med Ctr, Internal Med B, Infect Dis Unit, Haifa, Israel. [Segel, Michael J.] Chaim Sheba Med Ctr, Inst Pulmonol, IL-52621 Ramat Gan, Israel. [Rozenman, Judith] Chaim Sheba Med Ctr, Dept Imaging, IL-52621 Ramat Gan, Israel. [Schwartz, Eli] Chaim Sheba Med Ctr, Internal Med C, IL-52621 Ramat Gan, Israel. [Schwartz, Eli] Chaim Sheba Med Ctr, Ctr Geog Med, IL-52621 Ramat Gan, Israel. RP Schwartz, E (reprint author), Chaim Sheba Med Ctr, Internal Med C, IL-52621 Ramat Gan, Israel. EM Michael.Segel@gmail.com; Yehudit.Rozenman@Sheba.health.gov.il; mil6@cdc.gov; LachishT@yahoo.com; Neville@Hadassah.org.il; A_Neuberger@Rambam.health.gov.il; elischwa@post.tau.ac.il NR 25 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 BP 1168 EP 1172 DI 10.4269/ajtmh.14-0509 PG 5 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8WY UT WOS:000355785400015 PM 25918200 ER PT J AU Foo, KT Blackstock, AJ Ochola, EA Matete, DO Mwinzi, PNM Montgomery, SP Karanja, DMS Secor, WE AF Foo, Karen T. Blackstock, Anna J. Ochola, Elizabeth A. Matete, Daniel O. Mwinzi, Pauline N. M. Montgomery, Susan P. Karanja, Diana M. S. Secor, W. Evan TI Evaluation of Point-of-Contact Circulating Cathodic Antigen Assays for the Detection of Schistosoma mansoni Infection in Low-, Moderate-, and High-Prevalence Schools in Western Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID INTESTINAL SCHISTOSOMIASIS; DIAGNOSIS; SENSITIVITY; DIPSTICKS; SETTINGS; ACCURACY; CHILDREN; UGANDA; TESTS AB We evaluated the performance of a point-of-contact circulating cathodic antigen assay (POC-CCA) to detect schistosome infections in primary school children (N = 1,801) living in areas with low, moderate, and high Schistosoma mansoni prevalence in western Kenya. The commercially available assay (CCA-1) and a second, experimental formulation (CCA-2) were compared against Kato-Katz stool examinations and an anti-schistosome enzyme-linked immunosorbent assay (ELISA). A latent class model based on the four tests was used to establish "true infection status" in three different zones based on their distance from Lake Victoria. As a screening tool for community treatment according to World Health Organization (WHO) guidelines, the Kato-Katz examination was in closest agreement with the latent class model, followed by the experimental CCA-2, soluble adult worm antigen preparation (SWAP) ELISA, and CCA-1, which had high sensitivity compared with the other tests but was consistently the least specific. Our experience suggests that POC-CCA tests offer a field-friendly alternative to Kato-Katz, but need further interpretation for appropriate field use. C1 Karolinska Inst, Dept Publ Hlth Sci, Div Global Hlth IHCAR, Stockholm, Sweden. [Foo, Karen T.; Blackstock, Anna J.; Montgomery, Susan P.; Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. [Ochola, Elizabeth A.; Matete, Daniel O.; Mwinzi, Pauline N. M.; Karanja, Diana M. S.] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Neglected Trop Dis Unit, Kisumu, Kenya. RP Secor, WE (reprint author), Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, 1600 Clifton Rd,MS D-65, Atlanta, GA 30329 USA. EM karen.t.foo@gmail.com; hyp9@cdc.gov; eakinyi@kemricdc.org; dmatete@kemricdc.org; pmwinzi@kemricdc.org; zqu6@cdc.gov; dkaranja@kemricdc.org; was4@cdc.gov FU University of Georgia Research Foundation, Inc - Bill and Melinda Gates Foundation; Division of Parasitic Diseases and Malaria/CDC; United States Agency for International Development (USAID) FX This project was funded by the University of Georgia Research Foundation, Inc, which is funded by the Bill and Melinda Gates Foundation for this SCORE project, the Division of Parasitic Diseases and Malaria/CDC and the United States Agency for International Development (USAID). NR 32 TC 6 Z9 6 U1 1 U2 3 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 BP 1227 EP 1232 DI 10.4269/ajtmh.14-0643 PG 6 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8WY UT WOS:000355785400024 PM 25870418 ER PT J AU Worrell, CM Bartoces, M Karanja, DMS Ochola, EA Matete, DO Mwinzi, PNM Montgomery, SP Secor, WE AF Worrell, Caitlin M. Bartoces, Monina Karanja, Diana M. S. Ochola, Elizabeth A. Matete, Daniel O. Mwinzi, Pauline N. M. Montgomery, Susan P. Secor, W. Evan TI Cost Analysis of Tests for the Detection of Schistosoma mansoni Infection in Children in Western Kenya SO AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE LA English DT Article ID CIRCULATING-CATHODIC-ANTIGEN; NEGLECTED TROPICAL DISEASES; KATO-KATZ; URINARY SCHISTOSOMIASIS; REAGENT STRIP; CCA STRIP; DIAGNOSIS; TRANSMISSION; CHEMOTHERAPY; PREVALENCE AB Financial resources tend to be limited in schistosomiasis endemic areas, forcing program managers to balance financial and scientific considerations when selecting detection assays. Therefore, we compared the costs of using single stool Kato-Katz, triplicate stool Kato-Katz, and point-of-contact circulating cathodic antigen (POC-CCA) assays for the detection of Schistosoma mansoni infection. Economic and financial costs were estimated from the viewpoint of a schistosomiasis control program using the ingredients approach. Costs related to specimen collection, sample processing and analysis, and treatment delivery were considered. Analysis inputs and assumptions were tested using one-way and two-way sensitivity analysis. The total per-person cost of performing the single Kato-Katz, triplicate Kato-Katz, and POC-CCA was US$6.89, US$17.54, and US$7.26, respectively. Major cost drivers included labor, transportation, and supplies. In addition, we provide a costing tool to guide program managers in evaluating detection costs in specific settings, as costs may vary temporally and spatially. C1 [Worrell, Caitlin M.; Montgomery, Susan P.; Secor, W. Evan] Ctr Dis Control & Prevent, Parasit Dis Branch, Atlanta, GA USA. [Bartoces, Monina] Ctr Dis Control & Prevent, Data Management Act, Div Parasit Dis & Malaria, Atlanta, GA USA. [Karanja, Diana M. S.; Ochola, Elizabeth A.; Matete, Daniel O.; Mwinzi, Pauline N. M.] Kenya Govt Med Res Ctr, Ctr Global Hlth Res, Kisumu, Kenya. RP Secor, WE (reprint author), 1600 Clifton Rd,MS D-65, Atlanta, GA 30329 USA. EM cworrell@cdc.gov; jze8@cdc.gov; dkaranja@kemricdc.org; eakinyi@kemricdc.org; dmatete@kemricdc.org; pmwinzi@kemricdc.org; zqu6@cdc.gov; was4@cdc.gov FU University of Georgia Research foundation - Bill and Melinda Gates Foundation; USAID FX This study received financial support from The University of Georgia Research foundation that is funded by the Bill and Melinda Gates Foundation and also by USAID-supported NTD control activities at the Centers for Disease Control and Prevention, Atlanta, GA. NR 30 TC 4 Z9 4 U1 1 U2 2 PU AMER SOC TROP MED & HYGIENE PI MCLEAN PA 8000 WESTPARK DR, STE 130, MCLEAN, VA 22101 USA SN 0002-9637 EI 1476-1645 J9 AM J TROP MED HYG JI Am. J. Trop. Med. Hyg. PD JUN PY 2015 VL 92 IS 6 BP 1233 EP 1239 DI 10.4269/ajtmh.14-0644 PG 7 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ8WY UT WOS:000355785400025 PM 25870422 ER PT J AU Smith, RM Derado, G Wise, M Harris, JR Chiller, T Meltzer, MI Park, BJ AF Smith, Rachel M. Derado, Gordana Wise, Matthew Harris, Julie R. Chiller, Tom Meltzer, Martin I. Park, Benjamin J. TI Estimated Deaths and Illnesses Averted During Fungal Meningitis Outbreak Associated with Contaminated Steroid Injections, United States, 2012-2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID METHYLPREDNISOLONE AB During 2012-2013, the US Centers for Disease Control and Prevention and partners responded to a multistate outbreak of fungal infections linked to methylpreclnisolone acetate (MPA) injections produced by a compounding pharmacy. We evaluated the effects of public health actions on the scope of this outbreak. A comparison of 60-day case-fatality rates and clinical characteristics of patients given a diagnosis on or before October 4, the date the outbreak was widely publicized, with those of patients given a diagnosis after October 4 showed that an estimated 3,150 MPA injections, 153 cases of meningitis or stroke, and 124 deaths were averted. Compared with diagnosis after October 4, diagnosis on or before October 4 was significantly associated with a higher 60-day casefatality rate (28% vs. 5%; p<0.0001). Aggressive public health action resulted in a substantially reduced estimated number of persons affected by this outbreak and improved survival of affected patients. C1 [Smith, Rachel M.; Derado, Gordana; Wise, Matthew; Harris, Julie R.; Chiller, Tom; Meltzer, Martin I.; Park, Benjamin J.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Smith, RM (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30329 USA. EM vih9@cdc.gov FU US Department of Health and Human Services FX All funding and material support for this work was provided by the US Department of Health and Human Services and state and local health departments. NR 12 TC 4 Z9 4 U1 1 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 933 EP 940 DI 10.3201/eid2106.141558 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900002 PM 25989264 ER PT J AU Ao, TT Feasey, NA Gordon, MA Keddy, KH Angulo, FJ Crump, JA AF Ao, Trong T. Feasey, Nicholas A. Gordon, Melita A. Keddy, Karen H. Angulo, Frederick J. Crump, John A. TI Global Burden of Invasive Nontyphoidal Salmonella Disease, 2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID BLOOD-STREAM INFECTIONS; SUB-SAHARAN AFRICA; SYSTEMATIC ANALYSIS; TYPHOID-FEVER; CHILDREN; BACTEREMIA; TRANSMISSION; MORTALITY; EPIDEMIOLOGY; POPULATION AB Nontyphoidal Salmonella is a major cause of bloodstream infections worldwide, and HIV-infected persons and malaria-infected and malnourished children are at increased risk for the disease. We conducted a systematic literature review to obtain age group specific, population-based invasive nontyphoidal Salmonella (iNTS) incidence data. Data were categorized by HIV and malaria prevalence and then extrapolated by using 2010 population data. The case-fatality ratio (CFR) was determined by expert opinion consensus. We estimated that 3.4 (range 2.1-6.5) million cases of iNTS disease occur annually (overall incidence 49 cases [range 30-94] per 100,000 population). Africa, where infants, young children, and young adults are most affected, had the highest incidence (227 cases [range 152-341] per 100,000 population) and number of cases (1.9 [range 1.3-2.9] million cases). An iNTS CFR of 20% yielded 681,316 (range 415,164-1,301,520) deaths annually. iNTS disease is a major cause of illness and death globally, particularly in Africa. Improved understanding of the epidemiology of iNTS is needed. C1 [Ao, Trong T.; Angulo, Frederick J.; Crump, John A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Feasey, Nicholas A.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Feasey, Nicholas A.; Gordon, Melita A.] Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi. [Gordon, Melita A.] Univ Liverpool, Liverpool L69 3BX, Merseyside, England. [Keddy, Karen H.] Natl Hlth Lab Serv, Johannesburg, South Africa. [Crump, John A.] Univ Otego, Dunedin 9054, New Zealand. RP Crump, JA (reprint author), Univ Otego, Ctr Int Hlth, POB 56, Dunedin 9054, New Zealand. EM john.crump@otago.ac.nz FU US Centers for Disease Control and Prevention; US National Institutes of Health-National Science Foundation Ecology and Evolution of Infectious Disease program [R01 TW009237]; UK Biotechnology and Biological Sciences Research Council (BBSRC) [BB/J010367/1]; UK BBSRC Zoonoses in Emerging Livestock Systems awards [BB/L017679, BB/L018926, BB/L018845] FX This work was commissioned by the World Health Organization (WHO) Foodborne Diseases Epidemiology Reference Group, and support was provided in-kind by the US Centers for Disease Control and Prevention. Copyright of the original work on which this article is based belongs to WHO. The authors have been given permission to publish this article.; J.A.C. is supported by the joint US National Institutes of Health-National Science Foundation Ecology and Evolution of Infectious Disease program (R01 TW009237); the UK Biotechnology and Biological Sciences Research Council (BBSRC) (BB/J010367/1); and the UK BBSRC Zoonoses in Emerging Livestock Systems awards BB/L017679, BB/L018926, and BB/L018845. NR 39 TC 45 Z9 45 U1 3 U2 21 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 941 EP 949 DI 10.3201/eid2106.140999 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900003 ER PT J AU Owusu-Edusei, K Chesson, HW Gift, TL Brunham, RC Bolan, G AF Owusu-Edusei, Kwame, Jr. Chesson, Harrell W. Gift, Thomas L. Brunham, Robert C. Bolan, Gail TI Cost-effectiveness of Chlamydia Vaccination Programs for Young Women SO EMERGING INFECTIOUS DISEASES LA English DT Article ID SEXUALLY-TRANSMITTED INFECTIONS; PELVIC-INFLAMMATORY-DISEASE; HUMAN-PAPILLOMAVIRUS VACCINATION; TRACHOMATIS INFECTION; UNITED-STATES; HPV VACCINATION; US WOMEN; HEALTH; MODEL; RISK AB We explored potential cost-effectiveness of a chlamydia vaccine for young women in the United States by using a compartmental heterosexual transmission model. We tracked health outcomes (acute infections and sequelae measured in quality-adjusted life-years [QALYs]) and determined incremental cost-effectiveness ratios (ICERs) over a 50-year analytic horizon. We assessed vaccination of 14-year-old girls and catch-up vaccination for 15-24-year-old women in the context of an existing chlamydia screening program and assumed 2 prevaccination prevalences of 3.2% by main analysis and 3.7% by additional analysis. Estimated ICERs of vaccinating 14-year-old girls were $35,300/QALY by main analysis and $16,200/QALY by additional analysis compared with only screening. Catch-up vaccination for 15-24-year-old women resulted in estimated ICERs of $53,200/QALY by main analysis and $26,300/QALY by additional analysis. The ICER was most sensitive to prevaccination prevalence for women, followed by cost of vaccination, duration of vaccine-conferred immunity, and vaccine efficacy. Our results suggest that a successful chlamydia vaccine could be cost-effective. C1 [Owusu-Edusei, Kwame, Jr.; Chesson, Harrell W.; Gift, Thomas L.; Bolan, Gail] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Brunham, Robert C.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada. RP Owusu-Edusei, K (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E80, Atlanta, GA 30329 USA. EM kowusuedusei@cdc.gov RI Barley, Kamal/F-9579-2011 OI Barley, Kamal/0000-0003-1874-9813 NR 39 TC 6 Z9 6 U1 1 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 960 EP 968 DI 10.3201/eid2106.141270 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900005 PM 25989525 ER PT J AU Kurbatova, EV Dalton, T Ershova, J Tupasi, T Caoili, JC Van Der Walt, M Kvasnovsky, C Yagui, M Bayona, J Contreras, C Leimane, V Via, LE Kim, H Akksilp, S Kazennyy, BY Volchenkov, GV Jou, R Kliiman, K Demikhova, OV Cegielski, JP AF Kurbatova, Ekaterina V. Dalton, Tracy Ershova, Julia Tupasi, Thelma Caoili, Janice Campos Van Der Walt, Martie Kvasnovsky, Charlotte Yagui, Martin Bayona, Jaime Contreras, Carmen Leimane, Vaira Via, Laura E. Kim, HeeJin Akksilp, Somsak Kazennyy, Boris Y. Volchenkov, Grigory V. Jou, Ruwen Kliiman, Kai Demikhova, Olga V. Cegielski, J. Peter TI Additional Drug Resistance of Multidrug-Resistant Tuberculosis in Patients in 9 Countries SO EMERGING INFECTIOUS DISEASES LA English DT Article ID TREATMENT OUTCOMES; PNCA MUTATIONS; SURVEILLANCE; METAANALYSIS AB Data from a large multicenter observational study of patients with multidrug-resistant tuberculosis (MDR TB) were analyzed to simulate the possible use of 2 new approaches to treatment of MDR TB: a short (9-month) regimen and a bedaquiline-containing regimen. Of 1,254 patients, 952 (75.9%) had no resistance to fluoroquinolones and second-line injectable drugs and thus would qualify as candidates for the 9-month regimen; 302 (24.1%) patients with resistance to a fluoroquinolone or second-line injectable drug would qualify as candidates for a bedaquiline-containing regimen in accordance with published guidelines. Among candidates for the 9-month regimen, standardized drug-susceptibility tests demonstrated susceptibility to a median of 5 (interquartile range 5-6) drugs. Among candidates for bedaquiline, drug-susceptibility tests demonstrated susceptibility to a median of 3 (interquartile range 2-4) drugs; 26% retained susceptibility to <= 2 drugs. These data may assist national TB programs in planning to implement new drugs and drug regimens. C1 [Kurbatova, Ekaterina V.; Dalton, Tracy; Ershova, Julia; Caoili, Janice Campos; Kvasnovsky, Charlotte; Cegielski, J. Peter] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Tupasi, Thelma; Caoili, Janice Campos] Trop Dis Fdn, Manila, Philippines. [Van Der Walt, Martie; Kvasnovsky, Charlotte] MRC, Pretoria, South Africa. [Yagui, Martin] Natl Inst Hlth, Lima, Peru. [Bayona, Jaime; Contreras, Carmen] Socios Salud Sucursal Peru, Lima, Peru. [Leimane, Vaira] Riga East Univ Hosp, Ctr TB & Lung Dis, Riga, Latvia. [Via, Laura E.] NIAID, NIH, Bethesda, MD 20892 USA. [Via, Laura E.] Univ Cape Town, ZA-7925 Cape Town, South Africa. [Kim, HeeJin] Korean Inst TB, Seoul, South Korea. [Akksilp, Somsak] Minist Publ Hlth, Bangkok, Thailand. [Kazennyy, Boris Y.] Orel Oblast TB Dispensary, Oryol, Russia. [Volchenkov, Grigory V.] Vladimir Oblast TB Dispensary, Vladimir, Russia. [Jou, Ruwen] Taiwan Ctr Dis Control, Taipei, Taiwan. [Kliiman, Kai] Tartu Univ Hosp, Tartu, Estonia. [Demikhova, Olga V.] Russian Acad Med Sci, Moscow, Russia. RP Kurbatova, EV (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E10, Atlanta, GA 30329 USA. EM ies3@cdc.gov FU US Agency for International Development; CDC; National Institutes of Health's National Institute of Allergy and Infectious Diseases, Division of Intramural Research and South Korea's Center for Disease Control FX This work was supported by the US Agency for International Development; CDC; and, in part, by the National Institutes of Health's National Institute of Allergy and Infectious Diseases, Division of Intramural Research and South Korea's Center for Disease Control support of the sites in South Korea. NR 21 TC 6 Z9 6 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 977 EP 983 DI 10.3201/eid2106.141329 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900007 PM 25988299 ER PT J AU Tohme, RA Francois, J Wannemuehler, K Lyengar, P Dismer, A Adrien, P Hyde, TB Marston, BJ Date, K Mintz, E Katz, MA AF Tohme, Rania A. Francois, Jeannot Wannemuehler, Kathleen Lyengar, Preetha Dismer, Amber Adrien, Paul Hyde, Terri B. Marston, Barbara J. Date, Kashmira Mintz, Eric Katz, Mark A. TI Oral Cholera Vaccine Coverage, Barriers to Vaccination, and Adverse Events following Vaccination, Haiti, 2013 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MASS VACCINATION; RUBELLA ELIMINATION; CAMPAIGN; INDIA; OUTBREAK; KOLKATA; MEASLES AB In 2013, the first government-led oral cholera vaccination (OCV) campaign in Haiti was implemented in Petite Anse and Cerca Carvajal. To evaluate vaccination coverage, barriers to vaccination, and adverse events following vaccination, we conducted a cluster survey. We enrolled 1,121 persons from Petite Anse and 809 persons from Cerca Carvajal, categorized by 3 age groups (1-4, 5-14, >= 15 years). Two-dose OCV coverage was 62.5% in Petite Anse and 76.8% in Cerca Carvajal. Two-dose coverage was lowest among persons >= 15 years of age. In Cerca Carvajal, coverage was significantly lower for male than female respondents (69% vs. 85%; p<0.001). No major adverse events were reported. The main reason for nonvaccination was absence during the campaign. Vaccination coverage after this campaign was acceptable and comparable, to that resulting from campaigns implemented by nongovernmental organizations. Future campaigns should be tailored to reach adults who are not available during daytime hours. C1 [Tohme, Rania A.; Wannemuehler, Kathleen; Lyengar, Preetha; Dismer, Amber; Hyde, Terri B.; Marston, Barbara J.; Date, Kashmira; Mintz, Eric] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Francois, Jeannot; Adrien, Paul] Minist Publ Hlth & Populat, Port Au Prince, Haiti. [Katz, Mark A.] Ctr Dis Control & Prevent, Port Au Prince, Haiti. RP Tohme, RA (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop A04, Atlanta, GA 30329 USA. EM rtohme@cdc.gov NR 33 TC 4 Z9 4 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 984 EP 991 DI 10.3201/eid2106.141797 PG 8 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900008 PM 25988350 ER PT J AU Smith, SE Ershova, J Vlasova, N Nikishova, E Tarasova, I Eliseev, P Maryandyshev, AO Shemyakin, IG Kurbatova, E Cegielski, JP AF Smith, Sarah E. Ershova, Julia Vlasova, Natalia Nikishova, Elena Tarasova, Irina Eliseev, Platon Maryandyshev, Andrey O. Shemyakin, Igor G. Kurbatova, Ekaterina Cegielski, J. Peter TI Risk Factors for Acquisition of Drug Resistance during Multidrug-Resistant Tuberculosis Treatment, Arkhangelsk Oblast, Russia, 2005-2010 SO EMERGING INFECTIOUS DISEASES LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; PULMONARY TUBERCULOSIS; 2ND-LINE DRUGS; CAPREOMYCIN; EMERGENCE; KANAMYCIN; REGIMENS; OUTCOMES; THERAPY AB Acquired resistance to antituberculosis drugs decreases effective treatment options and the likelihood of treatment success. We identified risk factors for acquisition of drug resistance during treatment for multidrug-resistant tuberculosis (MDR TB) and evaluated the effect on treatment outcomes. Data were collected prospectively from adults from Arkhangelsk Oblast, Russia, who had pulmonary MDR TB during 2005-2008. Acquisition of resistance to capreomycin and of extensively drug-resistant TB were more likely among patients who received <3 effective drugs than among patients who received >= 3 effective drugs (9.4% vs. 0% and 8.6% vs. 0.8%, respectively). Poor outcomes were more likely among patients with acquired capreomycin resistance (100% vs. 25.9%), acquired ofloxacin resistance (83.6% vs. 22.7%), or acquired extensive drug resistance (100% vs. 24.4%). To prevent acquired drug resistance and poor outcomes, baseline susceptibility to first- and second-line drugs should be determined quickly, and treatment should be adjusted to contain >= 3 effective drugs. C1 [Smith, Sarah E.; Ershova, Julia; Kurbatova, Ekaterina; Cegielski, J. Peter] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Vlasova, Natalia; Nikishova, Elena; Tarasova, Irina; Eliseev, Platon; Maryandyshev, Andrey O.] Arkhangelsk Reg TB Dispensary, Arkhangelsk, Russia. [Maryandyshev, Andrey O.] Northern State Med Univ, Arkhangelsk, Russia. [Shemyakin, Igor G.] State Res Ctr Appl Microbiol & Biotechnol, Obolensk, Russia. RP Smith, SE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop E10, Atlanta, GA 30329 USA. EM uyi7@cdc.gov FU US Agency for International Development Mission in Russia; US CDC FX This study was supported by the US Agency for International Development Mission in Russia and the US CDC. NR 38 TC 2 Z9 2 U1 4 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 1002 EP 1011 DI 10.3201/eid2106.141907 PG 10 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900010 PM 25988954 ER PT J AU de Perio, MA Niemeier, RT Burr, GA AF de Perio, Marie A. Niemeier, R. Todd Burr, Gregory A. TI Coccidioides Exposure and Coccidioidomycosis among Prison Employees, California, United States SO EMERGING INFECTIOUS DISEASES LA English DT Article AB Responding to a request by corrections agency management, we investigated coccidioidomycosis in prison employees in central California, a coccidioidonnycosis-endemic area. We identified 103 cases of coccidioidomycosis that occurred over 4.5 years. As a result, we recommended training-and other steps to reduce dust exposure among employees and thus potential exposure to Coccidioides. C1 [de Perio, Marie A.; Niemeier, R. Todd; Burr, Gregory A.] Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP de Perio, MA (reprint author), Ctr Dis Control & Prevent, 1090 Tusculum Ave,R-10, Cincinnati, OH 45226 USA. EM mdeperio@cdc.gov NR 8 TC 1 Z9 1 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 1031 EP 1033 DI 10.3201/eid2106.141201 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900015 PM 25989420 ER PT J AU Nett, RJ Skillman, D Riek, L Davis, B Blue, SR Sundberg, EE Merriman, JR Hahn, CG Park, BJ AF Nett, Randall J. Skillman, Donald Riek, Laurel Davis, Brian Blue, Sky R. Sundberg, Elizabeth E. Merriman, Joel R. Hahn, Christine G. Park, Benjamin J. TI Histoplasmosis in Idaho and Montana, USA, 2012-2013 SO EMERGING INFECTIOUS DISEASES LA English DT Letter ID FUNGAL-INFECTIONS; ENDEMIC MYCOSES; UNITED-STATES; UPDATE C1 [Nett, Randall J.; Merriman, Joel R.] Montana Dept Publ Hlth & Human Serv, Helena, MT 59620 USA. [Nett, Randall J.; Park, Benjamin J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Skillman, Donald] St Peters Med Grp, Helena, MT USA. [Riek, Laurel] Lewis & Clark City Cty Hlth Dept, Helena, MT USA. [Davis, Brian] Billings Clin, Billings, MT USA. [Blue, Sky R.] Sawtooth Infect Dis, Boise, ID USA. [Sundberg, Elizabeth E.] Holy Rosary Healthcare, Miles City, MT USA. [Hahn, Christine G.] Idaho Dept Hlth & Welf, Boise, ID USA. RP Nett, RJ (reprint author), Montana Dept Publ Hlth & Human Serv, 1400 Broadway,Cogswell Bldg,Rm B201, Helena, MT 59620 USA. EM gge5@cdc.gov NR 10 TC 3 Z9 3 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 1071 EP 1072 DI 10.3201/eid2106.141367 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900028 PM 25989199 ER PT J AU Judd, MC Grass, JE Mintz, ED Bicknese, A Mahon, BE AF Judd, Michael C. Grass, Julian E. Mintz, Eric D. Bicknese, Amelia Mahon, Barbara E. TI Salmonella enterica Paratyphi A Infections in Travelers Returning from Cambodia, United States SO EMERGING INFECTIOUS DISEASES LA English DT Letter C1 [Judd, Michael C.; Grass, Julian E.; Mintz, Eric D.; Bicknese, Amelia; Mahon, Barbara E.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Judd, Michael C.] Atlanta Res & Educ Fdn, Atlanta, GA USA. RP Judd, MC (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C09, Atlanta, GA 30329 USA. EM mjudd@cdc.gov NR 7 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 1089 EP 1091 DI 10.3201/eid2106.150088 PG 3 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900039 PM 25988984 ER PT J AU Breedlove, B AF Breedlove, Byron TI Light, Reflection, Illumination SO EMERGING INFECTIOUS DISEASES LA English DT Editorial Material C1 Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. RP Breedlove, B (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,Mailstop C17, Atlanta, GA 30329 USA. EM wbb1@cdc.gov OI Breedlove, Byron/0000-0002-1026-1963 NR 7 TC 0 Z9 0 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1080-6040 EI 1080-6059 J9 EMERG INFECT DIS JI Emerg. Infect. Dis PD JUN PY 2015 VL 21 IS 6 BP 1094 EP 1095 DI 10.3201/eid2106.AC2106 PG 2 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA CJ3MA UT WOS:000355386900041 ER PT J AU Kawwass, JF Crawford, S Session, DR Kissin, DM Jamieson, DJ AF Kawwass, Jennifer F. Crawford, Sara Session, Donna R. Kissin, Dmitry M. Jamieson, Denise J. CA Natl ART Surveillance Syst Grp TI Endometriosis and Assisted Reproductive Technology: United States Trends and Outcomes 2000-2011 SO FERTILITY AND STERILITY LA English DT Article DE Endometriosis; outcomes; ART; cancellation; hyperstimulation ID IN-VITRO FERTILIZATION; OVARIAN RESERVE; METAANALYSIS; INFERTILITY; SURGERY; RATES; WOMEN AB Objective: To assess endometriosis-associated infertility trends among assisted reproductive technology (ART) cycles, and to compare cancellation and hyperstimulation risks and pregnancy and live birth rates among women using ART for endometriosis-associated vs. male factor infertility. Design: Descriptive and multivariable analyses of Centers for Disease Control and Prevention (CDC) National ART Surveillance System data. Setting: Fertility centers. Patient(s): All reported fresh autologous ART cycles in the United States between 2000 and 2011 (n = 1,589,079). Intervention(s): None. Main Outcome Measure(s): Oocyte yield, hyperstimulation, cancellation, implantation, pregnancy, live birth. Result(s): The absolute number of ART cycles with an endometriosis diagnosis fell in recent years, from 16,751 (2000) to 15,311 (2011); the percentage fell over time, from 17.0% (2000) to 9.6% (2011) of all cycles. Compared with male factor (n = 375,557), endometriosis-associated cycles (n = 112,475) yielded fewer oocytes (50.5% vs. 42.5% of cycles with only 0-10 oocytes retrieved), lower risk of hyperstimulation (1.1% vs. 1.3%, adjusted risk ratio [aRR] 0.82, 95% confidence interval [CI] 0.74-0.91), and an increased risk of cancellation (12.9% vs. 10.1%, aRR 1.30, 95% CI 1.25-1.35). Endometriosis was associated with a statistically decreased but likely clinically insignificant difference in the following outcomes: chance of pregnancy per transfer (43.7% vs. 44.8%, aRR 0.96, 95% CI 0.95-0.98) among couples who did not also have tubal factor infertility and live birth per transfer (37.2% vs. 37.6%, aRR 0.96, 95% CI 0.94-0.98). Conclusion(s): The percentage of endometriosis-associated ART cycles has decreased over time. As compared with male factor infertility, endometriosis is associated with increased cancellation and decreased hyperstimulation risks. Despite decreased oocyte yield and higher medication dose, the difference in pregnancy and live birth rates may be of limited clinical significance, suggesting comparable pregnancy outcomes per transfer. (C) 2015 by American Society for Reproductive Medicine. C1 [Kawwass, Jennifer F.; Session, Donna R.; Kissin, Dmitry M.; Jamieson, Denise J.] Emory Univ, Sch Med, Dept Gynecol & Obstet, Div Reprod Endocrinol & Infertil, Atlanta, GA 30308 USA. [Kawwass, Jennifer F.; Crawford, Sara; Kissin, Dmitry M.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. RP Kawwass, JF (reprint author), Emory Univ, Sch Med, Reprod Endocrinol & Infertil, 550 Peachtree St,Suite 1800, Atlanta, GA 30308 USA. EM jennifer.kawwass@emory.edu NR 17 TC 3 Z9 3 U1 1 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0015-0282 EI 1556-5653 J9 FERTIL STERIL JI Fertil. Steril. PD JUN PY 2015 VL 103 IS 6 BP 1537 EP 1543 DI 10.1016/j.fertnstert.2015.03.003 PG 7 WC Obstetrics & Gynecology; Reproductive Biology SC Obstetrics & Gynecology; Reproductive Biology GA CJ5TM UT WOS:000355552600027 PM 25881877 ER PT J AU Chang, CQ Tingle, SR Filipski, KK Khoury, MJ Lam, TK Schully, SD Ioannidis, JPA AF Chang, Christine Q. Tingle, Sharna R. Filipski, Kelly K. Khoury, Muin J. Lam, Tram Kim Schully, Sheri D. Ioannidis, John P. A. TI An overview of recommendations and translational milestones for genomic tests in cancer SO GENETICS IN MEDICINE LA English DT Review DE cancer; genomics; genetic testing; recommendations and guidelines; translational research ID PERSONALIZED MEDICINE; PROGNOSTIC MARKERS AB Purpose: To understand the translational trajectory of genomic tests in cancer screening, diagnosis, prognosis, and treatment, we reviewed tests that have been assessed by recommendation and guideline developers. Methods: For each test, we marked translational milestones by determining when the genomic association with cancer was first discovered and studied in patients, and when a health application for a specified clinical use was successfully demonstrated and approved or cleared by the US Food and Drug Administration. To identify recommendations and guidelines, we reviewed the websites of cancer, genomic, and general guideline developers and professional organizations. We searched the in vitro diagnostics database of the US Food and Drug Administration for information, and we searched PubMed for translational milestones. Milestones were examined against type of recommendation, Food and Drug Administration approval or clearance, disease rarity, and test purpose. Results: Of the 45 tests we identified, 9 received strong recommendations for their usage in clinical settings, 14 received positive but moderate recommendations, and 22 were not currently recommended. For 18 tests, two or more different sources had issued recommendations, with 67% concordance. Only five tests had Food and Drug Administration approval, and an additional five had clearance. The median time from discovery to recommendation statement was 14.7 years. Conclusion: In general, there were no associations found between translational trajectory and recommendation category. C1 [Chang, Christine Q.; Tingle, Sharna R.; Filipski, Kelly K.; Khoury, Muin J.; Lam, Tram Kim; Schully, Sheri D.; Ioannidis, John P. A.] NCI, Epidemiol & Genom Res Program, Rockville, MD 20852 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Gen, Atlanta, GA USA. [Ioannidis, John P. A.] Stanford Univ, Stanford Prevent Res Ctr, Sch Med, Dept Med, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA. [Ioannidis, John P. A.] Stanford Univ, Sch Humanities & Sci, Dept Stat, Stanford, CA 94305 USA. RP Chang, CQ (reprint author), NCI, Epidemiol & Genom Res Program, Rockville, MD 20852 USA. EM christine.chang2@nih.gov OI Chang, Christine/0000-0002-4624-898X FU Intramural CDC HHS [CC999999] NR 30 TC 1 Z9 1 U1 0 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD JUN PY 2015 VL 17 IS 6 BP 431 EP 440 DI 10.1038/gim.2014.133 PG 10 WC Genetics & Heredity SC Genetics & Heredity GA CJ5WS UT WOS:000355564200001 PM 25341115 ER PT J AU Wang, Y Liu, G Caggana, M Kennedy, J Zimmerman, R Oyeku, SO Werner, EM Grant, AM Green, NS Grosse, SD AF Wang, Ying Liu, Gang Caggana, Michele Kennedy, Joseph Zimmerman, Regina Oyeku, Suzette O. Werner, Ellen M. Grant, Althea M. Green, Nancy S. Grosse, Scott D. TI Mortality of New York children with sickle cell disease identified through newborn screening SO GENETICS IN MEDICINE LA English DT Article DE long-term follow-up; maternal race/ethnicity; mortality; newborn screening; sickle cell disease ID TERM-FOLLOW-UP; UNITED-STATES; BIRTH OUTCOMES; 1ST DECADE; ANEMIA; HYDROXYUREA; LIFE; US; ADOLESCENTS; DISORDERS AB Purpose: Long-term follow-up of newborn screening for conditions such as sickle cell disease can be conducted using linkages to population-based data. We sought to estimate childhood sickle cell disease mortality and risk factors among a statewide birth cohort with sickle cell disease identified through newborn screening. Methods: Children with sickle cell disease identified by newborn screening and born to New York residents in 2000-2008 were matched to birth and death certificates. Mortality rates were calculated (using numbers of deaths and observed person-years at risk) and compared with mortality rates for all New York children by maternal race/ethnicity. Stratified analyses were conducted to examine associations between selected factors and mortality. Results: Among 1,911 infants with sickle cell disease matched to birth certificates, 21 deaths were identified. All-cause mortality following diagnosis was 3.8 per 1,000 person-years in the first 2 years of life and 1.0 per 1,000 person-years at ages 2-9 years. The mortality rate was significantly lower among children of foreign-born mothers and was significantly higher among preterm infants with low birth weight. The mortality rates were not significantly higher for infants after 28 days with sickle cell disease than for all New York births, but they were 2.7-8.4 times higher for children 1 through 9 years old with homozygous sickle cell disease than for those of all non-Hispanic black or Hispanic children born to New York residents. Conclusion: Estimated mortality risk in children with homozygous sickle cell disease remains elevated even after adjustment for maternal race/ethnicity. These results provide evidence regarding the current burden of child mortality among children with sickle cell disease despite newborn screening. C1 [Wang, Ying; Liu, Gang; Caggana, Michele] SUNY Albany, Sch Publ Hlth, Albany, NY 12222 USA. [Wang, Ying] New York State Dept Hlth, Div Data Management & Res, Off Primary Care & Hlth Management Syst, Albany, NY USA. [Caggana, Michele] New York State Dept Hlth, Wadsworth Ctr, Newborn Screening Program, Albany, NY USA. [Zimmerman, Regina] New York City Dept Hlth & Mental Hyg, Off Vital Stat, New York, NY USA. [Oyeku, Suzette O.] Childrens Hosp Montefiore, Albert Einstein Coll Med, Dept Pediat, New York, NY USA. [Werner, Ellen M.] NHLBI, Div Blood Dis & Resources, Bethesda, MD 20892 USA. [Grant, Althea M.; Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Div Blood Disorders, Atlanta, GA USA. [Green, Nancy S.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY USA. RP Wang, Y (reprint author), SUNY Albany, Sch Publ Hlth, Albany, NY 12222 USA. EM wxy01@health.state.ny.us OI Green, Nancy/0000-0002-9877-1561 FU US Centers for Disease Control and Prevention; National Heart, Lung and Blood Institute [U50DD000722] FX This project was supported by the US Centers for Disease Control and Prevention and the National Heart, Lung and Blood Institute (grant U50DD000722). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 40 TC 2 Z9 3 U1 1 U2 6 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD JUN PY 2015 VL 17 IS 6 BP 452 EP 459 DI 10.1038/gim.2014.123 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA CJ5WS UT WOS:000355564200004 PM 25255366 ER PT J AU Grosse, SD Palomaki, GE Mvundura, M Hampel, H AF Grosse, Scott D. Palomaki, Glenn E. Mvundura, Mercy Hampel, Heather TI The cost-effectiveness of routine testing for Lynch syndrome in newly diagnosed patients with colorectal cancer in the United States: corrected estimates SO GENETICS IN MEDICINE LA English DT Letter C1 [Grosse, Scott D.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. [Palomaki, Glenn E.] Brown Univ, Dept Pathol & Lab Med, Women & Infants Hosp, Alpert Med Sch, Providence, RI 02912 USA. [Mvundura, Mercy] Program Appropriate Technol Hlth, Seattle, WA USA. [Hampel, Heather] Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA. RP Grosse, SD (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. EM sgrosse@cdc.gov OI Mvundura, Mercy/0000-0002-7711-9558 FU Intramural CDC HHS [CC999999] NR 4 TC 7 Z9 7 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1098-3600 EI 1530-0366 J9 GENET MED JI Genet. Med. PD JUN PY 2015 VL 17 IS 6 BP 510 EP 511 DI 10.1038/gim.2015.53 PG 2 WC Genetics & Heredity SC Genetics & Heredity GA CJ5WS UT WOS:000355564200014 PM 26035801 ER PT J AU Wolf, RB Edwards, K Grijalva, CG Self, WH Zhu, YW Chappell, J Bramley, AM Jain, S Williams, DJ AF Wolf, Rachel B. Edwards, Kathryn Grijalva, Carlos G. Self, Wesley H. Zhu, Yuwei Chappell, James Bramley, Anna M. Jain, Seema Williams, Derek J. TI Time to clinical stability among children hospitalized with pneumonia SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID COMMUNITY-ACQUIRED PNEUMONIA; GUIDELINES; SEVERITY; HEART AB We evaluated the performance of time to clinical stability (TCS), a longitudinal outcome measure using 4 physiologic parameters (temperature, heart rate, respiratory rate, and use of supplemental oxygen), among children enrolled in a prospective study of pneumonia hospitalizations. We calculated the time from admission to normalization for each of the 4 parameters individually along with various combinations of these parameters (2 parameters). We assessed for agreement between the combined TCS measures and both hospital length of stay and an ordinal severity scale (nonsevere, severe, and very severe). Overall, 323 (96.7%) of 334 included children had 1 parameter abnormal on admission; 70 (21%) children had 1 parameter abnormal at discharge. For the 4 combined measures, median TCS decreased with increasing age. Increasing TCS was associated with both longer length of stay and increasing disease severity. The simplest combined measure incorporating only respiratory rate and need for supplemental oxygen performed similarly to more complex measures including additional parameters. Our study demonstrates that longitudinal TCS measures may be useful in children with pneumonia, both in clinical settings to assess recovery and readiness for discharge, and as an outcome measure in research and quality assessments. Additional study is needed to further validate our findings. Journal of Hospital Medicine 2015;10:380-383. (c) 2015 Society of Hospital Medicine C1 [Wolf, Rachel B.; Edwards, Kathryn; Williams, Derek J.] Vanderbilt Univ, Sch Med, Dept Pediat, Monroe Carell Jr Childrens Hosp Vanderbilt, Nashville, TN 37232 USA. [Grijalva, Carlos G.] Vanderbilt Univ, Sch Med, Dept Hlth Policy, Nashville, TN 37232 USA. [Self, Wesley H.] Vanderbilt Univ, Sch Med, Dept Emergency Med, Nashville, TN 37232 USA. [Zhu, Yuwei] Vanderbilt Univ, Sch Med, Dept Biostat, Nashville, TN 37232 USA. [Chappell, James] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37232 USA. [Bramley, Anna M.; Jain, Seema] Ctr Dis Control & Prevent, Atlanta, GA USA. RP Williams, DJ (reprint author), Vanderbilt Univ, Sch Med, 1161 21st Ave S,Med Ctr North S2323, Nashville, TN 37232 USA. EM derek.williams@vanderbilt.edu FU National Institute of Allergy and Infectious Diseases of the National Institutes of Health [K23AI104779]; Influenza Division in the National Center for Immunizations and Respiratory Diseases at the Centers for Disease Control and Prevention; Novartis; BioFire Diagnostics; Venaxis, Inc; CareFusion; BioMerieux; Affinium Pharmaceuticals; Astute Medical; Crucell Holland BV; BRAHMS GmbH; Pfizer; Rapid Pathogen Screening; Venaxis, Bio-Aegis Inc.; Sphingotec GmbH; Cempra Pharmaceuticals FX This work was supported by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number K23AI104779 to Dr. Williams. The EPIC study was supported by the Influenza Division in the National Center for Immunizations and Respiratory Diseases at the Centers for Disease Control and Prevention through cooperative agreements with each study site and was based on a competitive research funding opportunity. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention or the National Institutes of Health. Dr. Grijalva serves as a consultant to Glaxo-Smith-Kline and Pfizer outside of the scope of this article. Dr. Edwards is supported through grants from Novartis for the conduction of a Group B strep vaccine study and serves as the Chair of the Data Safety and Monitoring Data Committee for Influenza Study outside the scope of this article. Dr. Self reports grants from CareFusion, BioMerieux, Affinium Pharmaceuticals, Astute Medical, Crucell Holland BV, BRAHMS GmbH, Pfizer, Rapid Pathogen Screening, Venaxis, Bio-Aegis Inc., Sphingotec GmbH, and Cempra Pharmaceuticals; personal fees from BioFire Diagnostics and Venaxis, Inc; and patent 13/632,874 (Sterile Blood Culture Collection System) pending; all outside the scope of this article. NR 12 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD JUN PY 2015 VL 10 IS 6 BP 380 EP 383 DI 10.1002/jhm.2370 PG 4 WC Medicine, General & Internal SC General & Internal Medicine GA CJ8GU UT WOS:000355739000006 PM 25919391 ER PT J AU Toprani, A AF Toprani, Amita TI Repeat Abortions in New York City, 2010 SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Article DE Abortion; Induced; Pregnancy outcome; Pregnancy; Unplanned ID PUBLIC-HEALTH; UNITED-STATES; PREGNANCY; WOMEN; RATES; RISK AB This study aims to describe factors associated with the number of past abortions obtained by New York City (NYC) abortion patients in 2010. We calculated rates of first and repeat abortion by age, race/ethnicity, and neighborhood-level poverty and the mean number of self-reported past abortions by age, race/ethnicity, neighborhood-level poverty, number of living children, education, payment method, marital status, and nativity. We used negative binomial regression to predict number of past abortions by patient characteristics. Of the 76,614 abortions reported for NYC residents in 2010, 57 % were repeat abortions. Repeat abortions comprised > 50 % of total abortions among the majority of sociodemographic groups we examined. Overall, mean number of past abortions was 1.3. Mean number of past abortions was higher for women aged 30-34 years (1.77), women with a parts per thousand yen5 children (2.50), and black non-Hispanic women (1.52). After multivariable regression, age, race/ethnicity, and number of children were the strongest predictors of number of past abortions. This analysis demonstrates that, although socioeconomic disparities exist, all abortion patients are at high risk for repeat unintended pregnancy and abortion. C1 [Toprani, Amita] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Toprani, Amita] New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA. RP Toprani, A (reprint author), New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA. EM atoprani@health.nyc.gov NR 35 TC 1 Z9 2 U1 2 U2 8 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 EI 1468-2869 J9 J URBAN HEALTH JI J. Urban Health PD JUN PY 2015 VL 92 IS 3 BP 593 EP 603 DI 10.1007/s11524-015-9946-3 PG 11 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CJ6SR UT WOS:000355624400015 PM 25779755 ER PT J AU Toprani, A Cadwell, BL Li, WH Sackoff, J Greene, C Begier, E AF Toprani, Amita Cadwell, Betsy L. Li, Wenhui Sackoff, Judith Greene, Carolyn Begier, Elizabeth TI Repeat Abortions in New York City, 2010 (vol 92, pg 593, 2015) SO JOURNAL OF URBAN HEALTH-BULLETIN OF THE NEW YORK ACADEMY OF MEDICINE LA English DT Correction C1 [Toprani, Amita; Li, Wenhui; Sackoff, Judith; Greene, Carolyn; Begier, Elizabeth] New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA. [Toprani, Amita] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Cadwell, Betsy L.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. RP Toprani, A (reprint author), New York City Dept Hlth & Mental Hyg, New York, NY 10013 USA. EM atoprani@health.nyc.gov NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1099-3460 EI 1468-2869 J9 J URBAN HEALTH JI J. Urban Health PD JUN PY 2015 VL 92 IS 3 BP 604 EP 604 DI 10.1007/s11524-015-9960-5 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CJ6SR UT WOS:000355624400016 PM 25947221 ER PT J AU Samson, DM Archer, RS Alimi, TO Arheart, KL Impoinvil, DE Oscar, R Fuller, DO Qualls, WA AF Samson, Dayana M. Archer, Reginald S. Alimi, Temitope O. Arheart, Kristopher L. Impoinvil, Daniel E. Oscar, Roland Fuller, Douglas O. Qualls, Whitney A. TI New baseline environmental assessment of mosquito ecology in northern Haiti during increased urbanization SO JOURNAL OF VECTOR ECOLOGY LA English DT Article DE Remote sensing; rapid urbanization; mosquitoes; Aedes albopictus; Haiti; earthquake ID PLASMODIUM-FALCIPARUM MALARIA; AEDES-AEGYPTI DIPTERA; UP LAND FEATURES; IMPERVIOUS SURFACE; MAXIMUM-ENTROPY; BUILT-UP; CULEX-QUINQUEFASCIATUS; LYMPHATIC FILARIASIS; DISTRIBUTION MODELS; SATELLITE IMAGERY AB The catastrophic 2010 earthquake in Port-au-Prince, Haiti, led to the large-scale displacement of over 2.3 million people, resulting in rapid and unplanned urbanization in northern Haiti. This study evaluated the impact of this unplanned urbanization on mosquito ecology and vector-borne diseases by assessing land use and change patterns. Land-use classification and change detection were carried out on remotely sensed images of the area for 2010 and 2013. Change detection identified areas that went from agricultural, forest, or bare-land pre-earthquake to newly developed and urbanized areas post-earthquake. Areas to be sampled for mosquito larvae were subsequently identified. Mosquito collections comprised five genera and ten species, with the most abundant species being Culex quinquefasciatus 35% (304/876), Aedes albopictus 27% (238/876), and Aedes aegypti 20% (174/876). All three species were more prevalent in urbanized and newly urbanized areas. Anopheles albimanus, the predominate malaria vector, accounted for less than 1% (8/876) of the collection. A set of spectral indices derived from the recently launched Landsat 8 satellite was used as covariates in a species distribution model. The indices were used to produce probability surfaces maps depicting the likelihood of presence of the three most abundant species within 30 m pixels. Our findings suggest that the rapid urbanization following the 2010 earthquake has increased the amount of area with suitable habitats for urban mosquitoes, likely influencing mosquito ecology and posing a major risk of introducing and establishing emerging vector-borne diseases. C1 [Samson, Dayana M.; Arheart, Kristopher L.; Qualls, Whitney A.] Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA. [Archer, Reginald S.; Fuller, Douglas O.] Univ Miami, Dept Geog & Reg Studies, Miami, FL 33124 USA. [Alimi, Temitope O.] Leonard & Jayne Abess Ctr Ecosyst Sci & Policy, Miami, FL 33124 USA. [Impoinvil, Daniel E.] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Entomol Branch, Atlanta, GA USA. [Oscar, Roland] Minist Publ Hlth & Populat, Natl Malaria Control Program, Port Au Prince, Haiti. RP Samson, DM (reprint author), Univ Miami, Miller Sch Med, Dept Publ Hlth Sci, Miami, FL 33136 USA. EM DSamson@med.miami.edu OI Alimi, Temitope/0000-0002-7161-6190 FU National Institutes of Health [R01AI100968, R01GM093345] FX The authors thank CSTARS/ University of Miami and Mr. Raymond Turner for helping us acquire the RapidEye imagery of northern Haiti. Additionally, we thank the following organizations for their support: Haitian Ministry of Public Health and Population, Directors of Hospital Justinien, the Directors of the North and Northeast Department, the Department of Sanitation, as well as the Caracol Industrial Park. Thank you to Stanley Rigaud for his assistance in the field. This research was supported by the National Institutes of Health under Award Numbers R01AI100968 and R01GM093345.The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 69 TC 6 Z9 6 U1 2 U2 37 PU SOC VECTOR ECOLOGY PI CORONA PA 1966 COMPTON AVE, CORONA, CA 92881 USA SN 1081-1710 EI 1948-7134 J9 J VECTOR ECOL JI J. Vector Ecol. PD JUN PY 2015 VL 40 IS 1 BP 46 EP 58 DI 10.1111/jvec.12131 PG 13 WC Entomology SC Entomology GA CJ9VN UT WOS:000355851400006 PM 26047183 ER PT J AU Feldman, KA Connally, NP Hojgaard, A Jones, EH White, JL Hinckley, AF AF Feldman, Katherine A. Connally, Neeta P. Hojgaard, Andrias Jones, Erin H. White, Jennifer L. Hinckley, Alison F. TI Abundance and infection rates of Ixodes scapularis nymphs collected from residential properties in Lyme disease-endemic areas of Connecticut, Maryland, and New York SO JOURNAL OF VECTOR ECOLOGY LA English DT Article ID EASTERN UNITED-STATES; BORRELIA-BURGDORFERI; ANAPLASMA-PHAGOCYTOPHILUM; WESTCHESTER-COUNTY; HUMAN RISK; PREVALENCE; MIYAMOTOI; IXODIDAE; ACARI C1 [Feldman, Katherine A.; Jones, Erin H.] Maryland Dept Hlth & Mental Hyg, Emerging Infect Program, Baltimore, MD 21201 USA. [Connally, Neeta P.] Western Connecticut State Univ, Connecticut Emerging Infect Program, Danbury, CT USA. [Hojgaard, Andrias; Hinckley, Alison F.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Atlanta, GA USA. [White, Jennifer L.] New York State Dept Hlth, Emerging Infect Program, Albany, NY 12237 USA. RP Feldman, KA (reprint author), Maryland Dept Hlth & Mental Hyg, Emerging Infect Program, Baltimore, MD 21201 USA. EM Katherine.Feldman@maryland.gov FU Intramural CDC HHS [CC999999] NR 18 TC 2 Z9 2 U1 2 U2 11 PU SOC VECTOR ECOLOGY PI CORONA PA 1966 COMPTON AVE, CORONA, CA 92881 USA SN 1081-1710 EI 1948-7134 J9 J VECTOR ECOL JI J. Vector Ecol. PD JUN PY 2015 VL 40 IS 1 BP 198 EP 201 DI 10.1111/jvec.12153 PG 4 WC Entomology SC Entomology GA CJ9VN UT WOS:000355851400027 PM 26047204 ER PT J AU Acosta, AM DeBolt, C Tasslimi, A Lewis, M Stewart, LK Misegades, LK Messonnier, NE Clark, TA Martin, SW Patel, M AF Acosta, Anna M. DeBolt, Chas Tasslimi, Azadeh Lewis, Melissa Stewart, Laurie K. Misegades, Lara K. Messonnier, Nancy E. Clark, Thomas A. Martin, Stacey W. Patel, Manisha TI Tdap Vaccine Effectiveness in Adolescents During the 2012 Washington State Pertussis Epidemic SO PEDIATRICS LA English DT Article ID IMMUNIZATION PRACTICES ACIP; AGED 13-17 YEARS; UNITED-STATES; BORDETELLA-PERTUSSIS; ADVISORY-COMMITTEE; WANING IMMUNITY; WHOLE-CELL; DIPHTHERIA; TETANUS; ADULTS AB BACKGROUND: Acellular pertussis vaccines replaced whole-cell vaccines for the 5-dose childhood vaccination series in 1997. A sixth dose of pertussis-containing vaccine, tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis, adsorbed (Tdap), was recommended in 2005 for adolescents and adults. Studies examining Tdap vaccine effectiveness (VE) among adolescents who have received all acellular vaccines are limited. METHODS: To assess Tdap VE and duration of protection, we conducted a matched case-control study during the 2012 pertussis epidemic in Washington among adolescents born during 1993-2000. All pertussis cases reported from January 1 through June 30, 2012, in 7 counties were included; 3 controls were matched by primary provider clinic and birth year to each case. Vaccination histories were obtained through medical records, the state immunization registry, and parent interviews. Participants were classified by type of pertussis vaccine received on the basis of birth year: a mix of whole-cell and acellular vaccines (1993-1997) or all acellular vaccines (1998-2000). We used conditional logistic regression to calculate odds ratios comparing Tdap receipt between cases and controls. RESULTS: Among adolescents who received all acellular vaccines (450 cases, 1246 controls), overall Tdap VE was 63.9% (95% confidence interval [CI]: 50% to 74%). VE within 1 year of vaccination was 73% (95% CI: 60% to 82%). At 2 to 4 years postvaccination, VE declined to 34% (95% CI: -0.03% to 58%). CONCLUSIONS: Tdap protection wanes within 2 to 4 years. Lack of long-term protection after vaccination is likely contributing to increases in pertussis among adolescents. C1 [Acosta, Anna M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [Acosta, Anna M.; Misegades, Lara K.; Messonnier, Nancy E.; Clark, Thomas A.; Martin, Stacey W.; Patel, Manisha] Ctr Dis Control & Prevent, Meningitis & Vaccine Preventable Dis Branch, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Lewis, Melissa] Ctr Dis Control & Prevent, Biostat Off, Div Bacterial Dis, Atlanta, GA USA. [DeBolt, Chas; Tasslimi, Azadeh; Stewart, Laurie K.] Washington State Dept Hlth, Communicable Dis Epidemiol, Shoreline, WA USA. RP Acosta, AM (reprint author), 1600 Clifton Rd NE,Mailstop C-25, Atlanta, GA 30329 USA. EM amacosta@cdc.gov NR 34 TC 24 Z9 24 U1 0 U2 7 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUN PY 2015 VL 135 IS 6 BP 981 EP 989 DI 10.1542/peds.2014-4118 PG 9 WC Pediatrics SC Pediatrics GA CJ5UR UT WOS:000355557400035 PM 25941309 ER PT J AU Tiwari, TSP Baughman, AL Clark, TA AF Tiwari, Tejpratap S. P. Baughman, Andrew L. Clark, Thomas A. TI First Pertussis Vaccine Dose and Prevention of Infant Mortality SO PEDIATRICS LA English DT Article ID EXTRACORPOREAL MEMBRANE-OXYGENATION; IMMUNIZATION PRACTICES ACIP; NONHUMAN PRIMATE MODEL; BORDETELLA-PERTUSSIS; UNITED-STATES; NEONATAL VACCINATION; ADVISORY-COMMITTEE; ACELLULAR VACCINES; INFECTION; SURVEILLANCE AB BACKGROUND: American infants are at highest risk of severe pertussis and death. We investigated the role of >= 1 pertussis vaccinations in preventing pertussis-related deaths and risk markers for death among infants aged < 42 days. METHODS: We analyzed characteristics of fatal and nonfatal infant pertussis cases reported nationally during 1991-2008. Infants were categorized into 2 age groups on the basis of eligibility to receive a first pertussis vaccine dose at age 6 weeks; dose 1 was considered valid if given >= 14 days before illness onset. Multivariable logistic regression was used to estimate the effect of >= 1 pertussis vaccine doses on outcome and risk markers. RESULTS: Pertussis-related deaths occurred among 258 of 45 404 cases. Fatal and nonfatal cases were confirmed by culture (54% vs 49%) and polymerase chain reaction (31% vs 27%). All deaths occurred before age 34 weeks at illness onset; 64% occurred before age 6 weeks. Among infants aged >= 42 days, receiving >= 1 doses of vaccine protected against death (adjusted odds ratio [aOR]: 0.28; 95% confidence interval [CI]: 0.11-0.74), hospitalization (aOR: 0.69; 95% CI: 0.63-0.77), and pneumonia (aOR: 0.80; 95% CI: 0.68-0.95). Risk was elevated for Hispanic ethnicity (aOR: 2.28; 95% CI: 1.36-3.83) and American Indian/Alaska Native race (aOR: 5.15; 95% CI: 2.37-11.2) and lower for recommended antibiotic treatment (aOR: 0.28; 95% CI: 0.16-0.47). Among infants aged,42 days, risk was elevated for Hispanic ethnicity and lower with recommended antibiotic use. CONCLUSIONS: The first pertussis vaccine dose and antibiotic treatment protect against death, hospitalization, and pneumonia. C1 [Tiwari, Tejpratap S. P.; Clark, Thomas A.] Ctr Dis Control & Prevent, Meningitis & Bacterial Vaccine Preventable Dis Br, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Baughman, Andrew L.] Ctr Dis Control & Prevent, Div Global HIV AIDS, Ctr Global Hlth, Atlanta, GA 30333 USA. RP Tiwari, TSP (reprint author), Ctr Dis Control & Prevent, NCIRD DBD MVPD Branch, Mail Stop C-25,1600 Clifton Rd NE, Atlanta, GA 30333 USA. EM tit2@cdc.gov FU Centers for Disease Control and Prevention (CDC) FX The study was supported by the Centers for Disease Control and Prevention (CDC) and was determined to be exempt from CDC institutional review board review. NR 47 TC 11 Z9 11 U1 0 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUN PY 2015 VL 135 IS 6 BP 990 EP 999 DI 10.1542/peds.2014-2291 PG 10 WC Pediatrics SC Pediatrics GA CJ5UR UT WOS:000355557400036 PM 25941302 ER PT J AU Ailes, EC Gilboa, SM Honein, MA Oster, ME AF Ailes, Elizabeth C. Gilboa, Suzanne M. Honein, Margaret A. Oster, Matthew E. TI Estimated Number of Infants Detected and Missed by Critical Congenital Heart Defect Screening SO PEDIATRICS LA English DT Article ID PULSE OXIMETRY; PRENATAL DETECTION; DISEASE; NEWBORNS; DIAGNOSIS; ACCURACY; PROGRAM; TRENDS AB BACKGROUND AND OBJECTIVES: In 2011, the US Secretary of Health and Human Services recommended universal screening of newborns for critical congenital heart defects (CCHDs), yet few estimates of the number of infants with CCHDs likely to be detected through universal screening exist. Our objective was to estimate the number of infants with nonsyndromic CCHDs in the United States likely to be detected (true positives) and missed (false negatives) through universal newborn CCHD screening. METHODS: We developed a simulation model based on estimates of birth prevalence, prenatal diagnosis, late detection, and sensitivity of newborn CCHD screening through pulse oximetry to estimate the number of true-positive and false-negative nonsyndromic cases of the 7 primary and 5 secondary CCHD screening targets identified through screening. RESULTS: We estimated that 875 (95% uncertainty interval [UI]: 705-1060) US infants with nonsyndromic CCHDs, including 470 (95% UI: 360-585) infants with primary CCHD screening targets, will be detected annually through newborn CCHD screening. An additional 880 (UI: 700-1080) false-negative screenings, including 280 (95% UI: 195-385) among primary screening targets, are expected. We estimated that similar numbers of CCHDs would be detected under scenarios comparing "lower" (similar to 19%) and "higher" (similar to 41%) than current prenatal detection prevalences. CONCLUSIONS: A substantial number of nonsyndromic CCHD cases are likely to be detected through universal CCHD screening; however, an equal number of false-negative screenings, primarily among secondary targets of screening, are likely to occur. Future efforts should document the true impact of CCHD screening in practice. C1 [Ailes, Elizabeth C.; Gilboa, Suzanne M.; Honein, Margaret A.; Oster, Matthew E.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30329 USA. [Oster, Matthew E.] Childrens Healthcare Atlanta, Sibley Heart Ctr, Atlanta, GA USA. [Oster, Matthew E.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. RP Ailes, EC (reprint author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, 1600 Clifton Rd NE,MS E-86, Atlanta, GA 30329 USA. EM eailes@cdc.gov FU Centers for Disease Control and Prevention [PA 96043, PA 02081, FOA DD09-001] FX This work was partially supported through cooperative agreements under PA 96043, PA 02081, and FOA DD09-001 from the Centers for Disease Control and Prevention. NR 26 TC 8 Z9 8 U1 1 U2 3 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUN PY 2015 VL 135 IS 6 BP 1000 EP 1008 DI 10.1542/peds.2014-3662 PG 9 WC Pediatrics SC Pediatrics GA CJ5UR UT WOS:000355557400037 PM 25963011 ER PT J AU Nelson, JM Li, RW Perrine, CG AF Nelson, Jennifer M. Li, Ruowei Perrine, Cria G. TI Trends of US Hospitals Distributing Infant Formula Packs to Breastfeeding Mothers, 2007 to 2013 SO PEDIATRICS LA English DT Article ID CARE MPINC SURVEY; MATERNITY PRACTICES; DISCHARGE BAGS; SAMPLE PACKS; NUTRITION; POLICY AB OBJECTIVE: To examine trends in the prevalence of hospitals and birth centers (hereafter, hospitals) distributing infant formula discharge packs to breastfeeding mothers in the United States from 2007 to 2013. METHODS: The Maternity Practices in Infant Nutrition and Care survey is administered every 2 years to all hospitals with registered maternity beds in the United States. A Web- or paper-based questionnaire was distributed and completed by the people most knowledgeable about breastfeeding-related hospital practices. We examined the distribution of infant formula discharge packs to breastfeeding mothers from 2007 to 2013 by state and hospital characteristics. RESULTS: The percentage of hospitals distributing infant formula discharge packs to breastfeeding mothers was 72.6% in 2007 and 31.6% in 2013, a decrease of 41 percentage points. In 2007, there was only 1 state (Rhode Island) in which <25% of hospitals distributed infant formula discharge packs to breastfeeding mothers, whereas in 2013 there were 24 such states and territories. Distribution declined across all hospital characteristics examined, including facility type, teaching versus nonteaching, and size (annual number of births). CONCLUSIONS: The distribution of infant formula discharge packs to breastfeeding mothers declined markedly from 2007 to 2013. Discontinuing the practice of distributing infant formula discharge packs is a part of optimal, evidence-based maternity care to support mothers who want to breastfeed. C1 [Nelson, Jennifer M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Div Sci Educ & Profess Dev, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30341 USA. [Nelson, Jennifer M.; Li, Ruowei; Perrine, Cria G.] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Nelson, JM (reprint author), Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, 4770 Buford Hwy NE,Mailstop F-77, Atlanta, GA 30341 USA. EM jmnelson@cdc.gov FU Intramural CDC HHS [CC999999] NR 27 TC 1 Z9 1 U1 1 U2 2 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUN PY 2015 VL 135 IS 6 BP 1051 EP 1056 DI 10.1542/peds.2015-0093 PG 6 WC Pediatrics SC Pediatrics GA CJ5UR UT WOS:000355557400043 PM 26009631 ER PT J AU Osterman, MJK Kochanek, KD MacDorman, MF Strobino, DM Guyer, B AF Osterman, Michelle J. K. Kochanek, Kenneth D. MacDorman, Marian F. Strobino, Donna M. Guyer, Bernard TI Annual Summary of Vital Statistics: 2012-2013 SO PEDIATRICS LA English DT Article ID INFANT-MORTALITY; EUROPE AB The number of births in the United States declined by 1% between 2012 and abstract 2013, to a total of 3 932 181. The general fertility rate also declined 1% to 62.5 births per 1000 women, the lowest rate ever reported. The total fertility rate was down by 1% in 2013 (to 1857.5 births per 1000 women). The teenage birth rate fell to another historic low in 2013, 26.5 births per 1000 women. Birth rates also declined for women 20 to 29 years, but the rates rose for women 30 to 39 and were unchanged for women 40 to 44. The percentage of all births that were to unmarried women declined slightly to 40.6% in 2013, from 40.7% in 2012. In 2013, the cesarean delivery rate declined to 32.7% from 32.8% for 2012. The preterm birth rate declined for the seventh straight year in 2013 to 11.39%; the low birth weight (LBW) rate was essentially unchanged at 8.02%. The infant mortality rate was 5.96 infant deaths per 1000 live births in 2013, down 13% from 2005 (6.86). The age-adjusted death rate for 2013 was 7.3 deaths per 1000 population, unchanged from 2012. Crude death rates for children aged 1 to 19 years declined to 24.0 per 100 000 population in 2013, from 24.8 in 2012. Unintentional injuries and suicide were, respectively, the first and second leading causes of death in this age group. These 2 causes of death jointly accounted for 45.7% of all deaths to children and adolescents in 2013. C1 [Osterman, Michelle J. K.; Kochanek, Kenneth D.; MacDorman, Marian F.] Ctr Dis Control & Prevent, Div Vital Stat, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Strobino, Donna M.; Guyer, Bernard] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Family & Reprod Hlth, Baltimore, MD USA. RP Osterman, MJK (reprint author), Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, 3311 Toledo Rd,Rm 7414, Hyattsville, MD 20782 USA. EM ibx6@cdc.gov FU Intramural CDC HHS [CC999999]; NICHD NIH HHS [R24 HD042854] NR 30 TC 20 Z9 21 U1 4 U2 15 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD JUN PY 2015 VL 135 IS 6 BP 1115 EP 1125 DI 10.1542/peds.2015-0434 PG 11 WC Pediatrics SC Pediatrics GA CJ5UR UT WOS:000355557400050 PM 25941306 ER PT J AU Cummings, KJ Kreiss, K AF Cummings, Kristin J. Kreiss, Kathleen TI Occupational and Environmental Bronchiolar Disorders SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE bronchiolitis; BOOP; exposure; lung function; biopsy ID WORLD-TRADE-CENTER; INTERSTITIAL LUNG-DISEASE; SILO-FILLERS DISEASE; OBLITERANS ORGANIZING PNEUMONIA; FLOCK WORKERS LUNG; RESOLUTION COMPUTED-TOMOGRAPHY; HYDROGEN-SULFIDE EXPOSURE; SPRAGUE-DAWLEY RATS; HOME HUMIDIFIER USE; BHOPAL GAS TRAGEDY AB Occupational and environmental causes of bronchiolar disorders are recognized on the basis of case reports, case series, and, less commonly, epidemiologic investigations. Pathology may be limited to the bronchioles or also involve other components of the respiratory tract, including the alveoli. A range of clinical, functional, and radiographic findings, including symptomatic disease lacking abnormalities on noninvasive testing, poses a diagnostic challenge and highlights the value of surgical biopsy, Disease clusters in workplaces and communities have identified new etiologies, drawn attention to indolent disease that may Otherwise have been categorized as idiopathic, and expanded the spectrum of histopathologic responses to an exposure. More sensitive noninvasive diagnostic tools, evidence-based therapies, and ongoing epidemiologic investigation of at-risk populations are needed to identify, treat, and prevent exposure-related bronchiolar disorders. C1 [Cummings, Kristin J.; Kreiss, Kathleen] NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. RP Cummings, KJ (reprint author), NIOSH, Div Resp Dis Studies, Ctr Dis Control & Prevent, 1095 Willowdale Rd,MS 2800, Morgantown, WV 26505 USA. EM cvx5@cdc.gov FU National Institute for Occupational Safety and Health (NIOSH) FX This work was supported by intramural funding from the National Institute for Occupational Safety and Health (NIOSH). The findings and conclusions in this report are those of the authors and do not necessarily represent the views of NIOSH. The authors thank Dr. Ann Hubbs and Tia McClelland of NIOSH and Dr. Victor Roggli and Steven Conlon of Duke University School of Medicine for their invaluable contributions. NR 147 TC 3 Z9 3 U1 1 U2 5 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD JUN PY 2015 VL 36 IS 3 BP 366 EP 378 DI 10.1055/s-0035-1549452 PG 13 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CJ3CX UT WOS:000355362100006 PM 26024345 ER PT J AU Antao, VC Pinheiro, GA AF Antao, Vinicius C. Pinheiro, Germania A. TI Surveillance for Occupational Respiratory Diseases in Developing Countries SO SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Review DE surveillance; occupational diseases; respiratory diseases; epidemiology; public health ID DENIM SANDBLASTERS; GLOBAL BURDEN; EVENTS SABRE; SILICOSIS; WORKERS; INDIA; MESOTHELIOMA; MORTALITY; EXPOSURE; BRAZIL AB The burden of chronic diseases, including occupational respiratory diseases (ORDs), is increasing worldwide. Nevertheless, epidemiological data on these conditions are scarce in most countries. Therefore, it is important to conduct surveillance to monitor ORDs, particularly in developing countries, where the working population is especially vulnerable and the health system infrastructure is usually weak. This article provides a general framework for the implementation of ORD surveillance in developing countries. The main objectives of surveillance are to describe incidence and prevalence of ORDs, as well as to identify sentinel events and new associations between occupational exposures and health outcomes. Diseases with high morbidity and mortality and those in which early diagnosis with standardized tests are available are especially suitable for surveillance activities. Simple strategies, preferably using existing resources and technology, are the best option for surveillance in developing countries. This article offers examples of specific surveillance systems that are in place in Brazil, China, Cuba, India, and South Africa. C1 [Antao, Vinicius C.; Pinheiro, Germania A.] Ctr Dis Control & Prevent CDC, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry ATSDR, Atlanta, GA 30341 USA. RP Antao, VC (reprint author), Ctr Dis Control & Prevent CDC, Div Toxicol & Human Hlth Sci, Agcy Tox Subst & Dis Registry ATSDR, 4770 Buford Highway NE,MS F58, Atlanta, GA 30341 USA. EM VAntao@cdc.gov FU Intramural CDC HHS [CC999999] NR 43 TC 0 Z9 0 U1 1 U2 2 PU THIEME MEDICAL PUBL INC PI NEW YORK PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA SN 1069-3424 EI 1098-9048 J9 SEMIN RESP CRIT CARE JI Semin. Respir. Crit. Care Med. PD JUN PY 2015 VL 36 IS 3 BP 449 EP 454 DI 10.1055/s-0035-1549456 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CJ3CX UT WOS:000355362100012 PM 26024351 ER PT J AU Watson, NF Badr, MS Belenky, G Bliwise, DL Buxton, OM Buysse, D Dinges, DF Gangwisch, J Grandner, MA Kushida, C Malhotra, RK Martin, JL Patel, SR Quan, SF Tasali, E Twery, M Croft, JB Maher, E Barrett, JA Thomas, SM Heald, JL AF Watson, Nathaniel F. Badr, M. Safwan Belenky, Gregory Bliwise, Donald L. Buxton, Orfeu M. Buysse, Daniel Dinges, David F. Gangwisch, James Grandner, Michael A. Kushida, Clete Malhotra, Raman K. Martin, Jennifer L. Patel, Sanjay R. Quan, Stuart F. Tasali, Esra Twery, Michael Croft, Janet B. Maher, Elise Barrett, Jerome A. Thomas, Sherene M. Heald, Jonathan L. TI Recommended Amount of Sleep for a Healthy Adult: A Joint Consensus Statement of the American Academy of Sleep Medicine and Sleep Research Society SO SLEEP LA English DT Editorial Material AB Sleep is essential for optimal health. The American Academy of Sleep Medicine (AASM) and Sleep Research Society (SRS) developed a consensus recommendation for the amount of sleep needed to promote optimal health in adults, using a modified RAND Appropriateness Method process. The recommendation is summarized here. A manuscript detailing the conference proceedings and evidence supporting the final recommendation statement will be published in SLEEP and the Journal of Clinical Sleep Medicine. C1 Univ Washington, Seattle, WA 98195 USA. [Badr, M. Safwan] Wayne State Univ, Detroit, MI USA. [Belenky, Gregory] Washington State Univ, Spokane, WA USA. [Bliwise, Donald L.] Emory Univ, Atlanta, GA 30322 USA. [Buxton, Orfeu M.] Penn State Univ, University Pk, PA 16802 USA. [Buysse, Daniel] Univ Pittsburgh, Pittsburgh, PA USA. [Dinges, David F.; Grandner, Michael A.] Univ Penn, Philadelphia, PA 19104 USA. [Gangwisch, James] Columbia Univ, New York, NY USA. [Kushida, Clete] Stanford Univ, Stanford, CA 94305 USA. [Malhotra, Raman K.] St Louis Univ, St Louis, MO 63103 USA. [Martin, Jennifer L.] Univ Calif Los Angeles, Los Angeles, CA USA. [Patel, Sanjay R.; Quan, Stuart F.] Harvard Univ, Sch Med, Boston, MA USA. [Tasali, Esra] Univ Chicago, Chicago, IL 60637 USA. [Twery, Michael] NHLBI, NIH, Bethesda, MD 20892 USA. [Croft, Janet B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Maher, Elise] Sleep Disorders Inst, New York, NY USA. [Barrett, Jerome A.; Thomas, Sherene M.; Heald, Jonathan L.] Amer Acad Sleep Med, Darien, IL USA. RP Watson, NF (reprint author), 2510 Frontage Rd, Darien, IL 60561 USA. EM research@aasmnet.org OI Patel, Sanjay/0000-0002-9142-5172 FU NCATS NIH HHS [UL1 TR000430]; NCCDPHP CDC HHS [1U50DP004930-01] NR 3 TC 42 Z9 43 U1 4 U2 9 PU AMER ACAD SLEEP MEDICINE PI WESTCHESTER PA ONE WESTBROOK CORPORATE CTR, STE 920, WESTCHESTER, IL 60154 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD JUN 1 PY 2015 VL 38 IS 6 BP 843 EP 844 AR PII sp-00231-15 DI 10.5665/sleep.4716 PG 2 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CJ6PY UT WOS:000355617000001 PM 26039963 ER PT J AU Johnson, JL Farr, SL Dietz, PM Sharma, AJ Barfield, WD Robbins, CL AF Johnson, Jonetta L. Farr, Sherry L. Dietz, Patricia M. Sharma, Andrea J. Barfield, Wanda D. Robbins, Cheryl L. TI Trends in gestational weight gain: the Pregnancy Risk Assessment Monitoring System, 2000-2009 SO AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY LA English DT Article DE gestational weight gain; Institute of Medicine gestational weight gain recommendations; Pregnancy Risk Assessment Monitoring System; prepregnancy body mass index; trend ID PREPREGNANCY OBESITY TRENDS; LONG-TERM OBESITY; BODY-MASS INDEX; GUIDELINES; OUTCOMES; STATES; RECOMMENDATIONS; INTERVENTIONS; MANAGEMENT; OVERWEIGHT AB OBJECTIVE: Achieving adequate gestational weight gain (GWG) is important for optimal health of the infant and mother. We estimate current population-based trends of GWG. STUDY DESIGN: We analyzed data from the Pregnancy Risk Assessment Monitoring System for 124,348 women who delivered live infants in 14 states during 2000 through 2009. We examined prevalence and trends in GWG in pounds as a continuous variable, and within 1990 Institute of Medicine (IOM) recommendations (yes/no) as a dichotomous variable. We examined adjusted trends in mean GWG using multivariable linear regression and GWG within recommendations using multivariable multinomial logistic regression. RESULTS: During 2000 through 2009, 35.8% of women gained within IOM GWG recommendations, 44.4% gained above, and 19.8% gained below. From 2000 through 2009, there was a biennial 1.0 percentage point decrease in women gaining within IOM GWG recommendations (P trend < .01) and a biennial 0.8 percentage point increase in women gaining above IOM recommendations (P trend < .01). The percentage of women gaining weight below IOM recommendations remained relatively constant from 2000 through 2009 (P trend = .14). The adjusted odds of gaining within IOM recommendations were lower in 2006 through 2007 (adjusted odds ratio, 0.90; 95% confidence interval, 0.85-0.96) and 2008 through 2009 (adjusted odds ratio, 0.90; 95% confidence interval, 0.85-0.96) relative to 2000 through 2001. CONCLUSION: Overall, from 2000 through 2009 the percentage of women gaining within IOM recommendations slightly decreased while mean GWG slightly increased. Efforts are needed to develop and implement strategies to ensure that women achieve GWG within recommendations. C1 [Johnson, Jonetta L.; Farr, Sherry L.; Sharma, Andrea J.; Barfield, Wanda D.; Robbins, Cheryl L.] Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. [Johnson, Jonetta L.] Off Publ Hlth Sci Serv, Div Sci Educ & Profess Dev, Epidem Intelligence Serv, Atlanta, GA USA. [Dietz, Patricia M.] Natl Ctr HIV AIDS Viral Hepatitis Sexually Transm, Div HIV AIDS Prevent, Atlanta, GA USA. [Johnson, Jonetta L.; Sharma, Andrea J.; Barfield, Wanda D.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Johnson, Jonetta L.; Sharma, Andrea J.; Barfield, Wanda D.] US Publ Hlth Serv Commissioned Corps, Atlanta, GA USA. RP Johnson, JL (reprint author), Ctr Dis Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Reprod Hlth, Atlanta, GA 30333 USA. EM jljohnson1@cdc.gov OI Sharma, Andrea/0000-0003-0385-0011 FU Centers for Disease Control and Prevention (CDC) FX Funding was provided by the Centers for Disease Control and Prevention (CDC). NR 30 TC 5 Z9 5 U1 0 U2 3 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9378 EI 1097-6868 J9 AM J OBSTET GYNECOL JI Am. J. Obstet. Gynecol. PD JUN PY 2015 VL 212 IS 6 AR 806.e1 DI 10.1016/j.ajog.2015.01.030 PG 8 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CJ1RN UT WOS:000355262000032 PM 25637844 ER PT J AU Arantes, TEF Silveira, C Holland, GN Muccioli, C Yu, F Jones, JL Goldhardt, R Lewis, KG Belfort, R AF Arantes, Tiago E. F. Silveira, Claudio Holland, Gary N. Muccioli, Cristina Yu, Fei Jones, Jeffrey L. Goldhardt, Raquel Lewis, Kevan G. Belfort, Rubens, Jr. TI Ocular Involvement Following Postnatally Acquired Toxoplasma gondii Infection in Southern Brazil: A 28-Year Experience SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID UNITED-STATES; RETINOCHOROIDITIS; OUTBREAK; DIAGNOSIS; PATTERNS; DECADE; IGM AB PURPOSE: To determine the incidence of, and risk factors for, ocular involvement among people known to have postnatally acquired Toxoplasma gondii infection in a region of southern Brazil where there is a high prevalence of endemic disease. DESIGN: Retrospective longitudinal cohort study. METHODS: Records of 302 patients with serologic evidence of recent T gondii infection (a positive anti-T gondii IgM antibody test) from Erechim, Rio Grande do Sul state, Brazil (1974-2002) were analyzed. The incidence of ocular involvement was calculated in terms of person-years (PY) of follow-up. Risk factors for ocular involvement were analyzed using log-rank and Fisher exact tests. RESULTS: At initial ocular examination (baseline), 30 patients (9.9%) had intraocular inflammation only (anterior chamber cells and flare, vitreous inflammatory reactions, retinal whitening), without clinically apparent necrotizing retinochoroiditis. At baseline, men were more likely to have ocular involvement (P =.043) and antiparasitic treatment was associated with less ocular involvement (P =.015). Follow-up examinations were performed on 255 patients (median follow-up, 13.7 months [range 0.4-261.9 months]). Among those without ocular involvement at baseline, the incidence of necrotizing retinochoroiditis was 6.4/100 PY. Patients >40 years of age at first IgM test had a greater risk of incident necrotizing retinochoroiditis (hazard ratio = 4.47, 95% CI = 1.67-11.93, P =.003) than younger patients. The incidence of recurrent necrotizing retinochoroiditis was 10.5/100 PY. CONCLUSION: Isolated intraocular inflammatory reactions can be an initial manifestation of T gondii infection, with necrotizing retinochoroiditis occurring months or years later. Male sex and older age are risk factors for toxoplasmic retinochoroiditis. Antitoxoplasmic treatment may protect against early ocular involvement. (C) 2015 by Elsevier Inc. All rights reserved. C1 [Arantes, Tiago E. F.; Holland, Gary N.; Yu, Fei; Goldhardt, Raquel; Lewis, Kevan G.] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Ocular Inflammatory Dis Ctr, Los Angeles, CA 90095 USA. [Arantes, Tiago E. F.; Holland, Gary N.; Yu, Fei; Goldhardt, Raquel; Lewis, Kevan G.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Silveira, Claudio] Clin Silveira, Erechim, RS, Brazil. [Arantes, Tiago E. F.; Silveira, Claudio; Muccioli, Cristina; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil. [Jones, Jeffrey L.] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Holland, GN (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM uveitis@jsei.ucla.edu RI Arantes, Tiago/I-3093-2013 OI Arantes, Tiago/0000-0002-8122-3446 FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (CNPq/FAPESP), Sao Paulo, Brazil; Research to Prevent Blindness (RPB), Inc, New York, New York; Skirball Foundation, New York, New York; Centers for Disease Control and Prevention; RPB Physician-Scientist Award FX Funding: Supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico and the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (CNPq/FAPESP), Sao Paulo, Brazil (Drs Silveira, Muccioli, Belfort); Research to Prevent Blindness (RPB), Inc, New York, New York (Dr Holland), the Skirball Foundation, New York, New York (Dr Holland), and the Centers for Disease Control and Prevention (Dr Jones). Dr Holland is recipient of an RPB Physician-Scientist Award. Funding entities had no rote in the reporting of study data and the interpretation of the data. All authors attest that they meet the current ICMJE requirements to qualify as authors. NR 41 TC 5 Z9 5 U1 0 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD JUN PY 2015 VL 159 IS 6 BP 1002 EP 1012 DI 10.1016/j.ajo.2015.02.015 PG 11 WC Ophthalmology SC Ophthalmology GA CI9DL UT WOS:000355070500002 PM 25743338 ER PT J AU Silveira, C Muccioli, C Holland, GN Jones, JL Yu, F de Paulo, A Belfort, R AF Silveira, Claudio Muccioli, Cristina Holland, Gary N. Jones, Jeffrey L. Yu, Fei de Paulo, Adam Belfort, Rubens, Jr. TI Ocular Involvement Following an Epidemic of Toxoplasma gondii Infection in Santa Isabel do Ivai, Brazil SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID ACQUIRED TOXOPLASMOSIS; SOUTHERN BRAZIL; OUTBREAK; RETINOCHOROIDITIS; DISEASE; WATER; CATS AB PURPOSE: To investigate ocular involvement (prevalence, incidence, lesion characteristics) following postnatally. acquired infection with an "atypical" genotype of Toxoplasma gondii during a well-characterized 2001 outbreak in Santa Isabel do Ivai, Brazil, attributed to a contaminated municipal reservoir. DESIGN: Prospective longitudinal cohort study. METHODS: We performed ophthalmic examinations on 290 of 454 individuals with serologic evidence of T gondii infection during the epidemic (positive IgM antibody tests). Prevalence of ophthalmic findings (intraocular inflammatory reactions [including transient, isolated retinal whitening without clinically apparent retinal necrosis] and necrotizing retinochoroiditis) at initial examination (baseline) and incidence of new findings during 10.5 months of follow-up were calculated. Cumulative risks of ophthalmic events were determined (Kaplan-Meier technique). " RESULTS: Ocular involvement was present in 33 of 288 IgM individuals (11.5%) at baseline, including 17 with focal retinal whitening only and 13 with necrotizing retinochoroiditis. Incidence of new ocular involvement was estimated to be 1.73 events per 100 person-months (PM); cumulative risk at 10.5 months was 30.1%. Incident necrotizing retinochoroiditis was more common among those with focal retinal whitening at baseline (6.7/100 PM) than among those with no ocular involvement at baseline (1.11/100 PM; hazard ratio 6.07 [1.94-19.01]; P <.0001). CONCLUSIONS: Waterborne infection with an atypical genotype of T gondii is associated with substantial risk of ocular involvement. Lesions may continue to develop during the first year after infection. The increased risk of late necrotizing retinochoroiditis associated with isolated focal retinal whitening at presentation suggests the early presence of parasites in the retina, despite initial lack of observable retinal necrosis. (C) 2015 by Elsevier Inc. All rights reserved. C1 [Silveira, Claudio; Muccioli, Cristina; de Paulo, Adam; Belfort, Rubens, Jr.] Univ Fed Sao Paulo, Dept Ophthalmol, Sao Paulo, Brazil. [Silveira, Claudio] Clin Silveira, Erechim, RS, Brazil. [Holland, Gary N.; Yu, Fei] Univ Calif Los Angeles, Jules Stein Eye Inst, David Geffen Sch Med, Ocular Inflammatory Dis Ctr, Los Angeles, CA 90095 USA. [Holland, Gary N.; Yu, Fei] Univ Calif Los Angeles, David Geffen Sch Med, Dept Ophthalmol, Los Angeles, CA 90095 USA. [Jones, Jeffrey L.] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Holland, GN (reprint author), Univ Calif Los Angeles, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM uveitis@jsei.ucla.edu FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico; Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (CNPq/FAPESP), Sao Paulo, Brazil; Research to Prevent Blindness (RPB), Inc, New York, New York; Skirball Foundation, New York, New York; Centers for Disease Control and Prevention, Atlanta, Georgia; RPB Physician-Scientist Award FX Funding: Supported by the Conselho Nacional de Desenvolvimento Cientifico e Tecnologico and the Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (CNPq/FAPESP), Sao Paulo, Brazil (Drs Silveira, Muccioli, Belfort); Research to Prevent Blindness (RPB), Inc, New York, New York (Dr Holland); the Skirball Foundation, New York, New York (Dr Holland); and the Centers for Disease Control and Prevention, Atlanta, Georgia (Dr Jones). Dr Holland is recipient of an RPB Physician-Scientist Award. Funding entities had no role in the reporting of study data and the interpretation of the data. All authors attest that they meet the current ICMJE requirements to qualify as authors. NR 28 TC 9 Z9 9 U1 0 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD JUN PY 2015 VL 159 IS 6 BP 1013 EP 1021 DI 10.1016/j.ajo.2015.02.017 PG 9 WC Ophthalmology SC Ophthalmology GA CI9DL UT WOS:000355070500003 PM 25743340 ER PT J AU Breiding, MJ Armour, BS AF Breiding, Matthew J. Armour, Brian S. TI The association between disability and intimate partner violence in the United States SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Intimate partner violence; Domestic violence; Sexual violence; Disability ID WOMEN; ABUSE; STRATEGIES; RISK AB Purpose: Prior research has shown that people with disabilities are at greater risk of intimate partner violence (IPV) victimization. This study seeks to examine the link between disability and IPV in a nationally representative sample of U.S. women and men. Also, by establishing that disability preceded recent IPV victimization, this study allows for a more thorough understanding of whether people with disabilities are at greater risk of victimization subsequent to having a disability. Methods: Data were analyzed from the 2010 National Intimate Partner and Sexual Violence Survey, an ongoing, national random digit dial telephone survey of U.S. adults. Estimates of age-adjusted 12-month IPV prevalence by disability status were calculated. Results: Compared to women without a disability, women with a disability were significantly more likely to report experiencing each form of IPV measured, which includes rape, sexual violence other than rape, physical violence, stalking, psychological aggression, and control of reproductive or sexual health. For men, significant associations were found with respect to stalking and psychological aggression by an intimate partner. Conclusions: The results suggest that people with a disability are at greater risk of victimization and that primary and secondary prevention efforts might be targeted to those with a disability. Published by Elsevier Inc. C1 [Breiding, Matthew J.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30341 USA. [Armour, Brian S.] Ctr Dis Control & Prevent, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA. RP Breiding, MJ (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,Mailstop F-64, Atlanta, GA 30341 USA. EM dvi8@cdc.gov FU Intramural CDC HHS [CC999999] NR 16 TC 2 Z9 2 U1 2 U2 16 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD JUN PY 2015 VL 25 IS 6 BP 455 EP 457 DI 10.1016/j.annepidem.2015.03.017 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI8KM UT WOS:000355021200011 PM 25976023 ER PT J AU Brownson, RC Samet, JM Chavez, GF Davies, MM Galea, S Hiatt, RA Hornung, CA Khoury, MJ Koo, D Mays, VM Remington, P Yarber, L AF Brownson, Ross C. Samet, Jonathan M. Chavez, Gilbert F. Davies, Megan M. Galea, Sandro Hiatt, Robert A. Hornung, Carlton A. Khoury, Muin J. Koo, Denise Mays, Vickie M. Remington, Patrick Yarber, Laura TI Charting a future for epidemiologic training SO ANNALS OF EPIDEMIOLOGY LA English DT Article DE Epidemiology; Genomics; Globalization; Medicine; Public health; Translational research ID PUBLIC-HEALTH; TRANSLATIONAL RESEARCH; CANCER-EPIDEMIOLOGY; POPULATION HEALTH; BIG DATA; 21ST-CENTURY; OPPORTUNITIES; COMPETENCES; SCIENCE; GLOBALIZATION AB Purpose: To identify macro-level trends that are changing the needs of epidemiologic research and practice and to develop and disseminate a set of competencies and recommendations for epidemiologic training that will be responsive to these changing needs. Methods: There were three stages to the project: (1) assembling of a working group of senior epidemiologists from multiple sectors, (2) identifying relevant literature, and (3) conducting key informant interviews with 15 experienced epidemiologists. Results: Twelve macro trends were identified along with associated actions for the field and educational competencies. The macro trends include the following: (1) "Big Data" or informatics, (2) the changing health communication environment, (3) the Affordable Care Act or health care system reform, (4) shifting demographics, (5) globalization, (6) emerging high-throughput technologies (omics), (7) a greater focus on accountability, (8) privacy changes, (9) a greater focus on "upstream" causes of disease, (10) the emergence of translational sciences, (11) the growing centrality of team and transdisciplinary science, and (12) the evolving funding environment. Conclusions: Addressing these issues through curricular change is needed to allow the field of epidemiology to more fully reach and sustain its full potential to benefit population health and remain a scientific discipline that makes critical contributions toward ensuring clinical, social, and population health. (C) 2015 Elsevier Inc. All rights reserved. C1 [Brownson, Ross C.] Washington Univ, Brown Sch, Prevent Res Ctr St Louis, St Louis, MO 63130 USA. [Brownson, Ross C.] Washington Univ, Sch Med, Div Publ Hlth Sci, St Louis, MO 63130 USA. [Brownson, Ross C.] Washington Univ, Sch Med, Alvin J Siteman Canc Ctr, St Louis, MO 63130 USA. [Samet, Jonathan M.] Univ So Calif, Keck Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA. [Chavez, Gilbert F.] Calif Dept Publ Hlth, Ctr Infect Dis, Sacramento, CA USA. [Davies, Megan M.] North Carolina Dept Hlth & Human Serv, Div Publ Hlth, Raleigh, NC USA. [Davies, Megan M.] Council State & Terr Epidemiologists, Atlanta, GA USA. [Galea, Sandro] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Hiatt, Robert A.] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Hornung, Carlton A.] Univ Louisville, Sch Med, Dept Med, Louisville, KY 40292 USA. [Khoury, Muin J.] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. [Khoury, Muin J.] NCI, Epidemiol & Genom Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. [Koo, Denise] Ctr Dis Control & Prevent, Off Publ Hlth Sci Serv, Atlanta, GA USA. [Mays, Vickie M.] Univ Calif Los Angeles, Dept Psychol, Fielding Sch Publ Hlth, Los Angeles, CA 90024 USA. [Mays, Vickie M.] Univ Calif Los Angeles, BRITE Ctr Sci Res & Policy, Los Angeles, CA USA. [Mays, Vickie M.] Univ Calif Los Angeles, Dept Hlth Policy & Management, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Remington, Patrick] Univ Wisconsin, Sch Med & Publ Hlth, Dept Populat Hlth Sci, Madison, WI 53706 USA. [Yarber, Laura] St Louis Univ, Coll Publ Hlth & Social Justice, Prevent Res Ctr St Louis, St Louis, MO 63103 USA. RP Brownson, RC (reprint author), Washington Univ, Brown Sch, Prevent Res Ctr St Louis, 621 N Skinker Blvd, St Louis, MO 63130 USA. EM rbrownson@wustl.edu FU Intramural CDC HHS [CC999999]; NCCDPHP CDC HHS [U48 DP000060]; NCI NIH HHS [P50 CA095815]; NIDDK NIH HHS [P30 DK092950]; NIMHD NIH HHS [P60 MD006923] NR 58 TC 6 Z9 6 U1 1 U2 13 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1047-2797 EI 1873-2585 J9 ANN EPIDEMIOL JI Ann. Epidemiol. PD JUN PY 2015 VL 25 IS 6 BP 458 EP 465 DI 10.1016/j.annepidem.2015.03.002 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI8KM UT WOS:000355021200012 PM 25976024 ER PT J AU Lee, N Leo, YS Cao, B Chan, PKS Kyaw, WM Uyeki, TM Tam, WWS Cheung, CSK Yung, IMH Li, H Gu, L Liu, YM Liu, ZJ Qu, JX Hui, DSC AF Lee, Nelson Leo, Yee-Sin Cao, Bin Chan, Paul K. S. Kyaw, W. M. Uyeki, Timothy M. Tam, Wilson W. S. Cheung, Catherine S. K. Yung, Irene M. H. Li, Hui Gu, Li Liu, Yingmei Liu, Zhenjia Qu, Jiuxin Hui, David S. C. TI Neuraminidase inhibitors, superinfection and corticosteroids affect survival of influenza patients SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article ID H1N1 VIRUS-INFECTION; IMMUNOMODULATORY AGENTS; HOSPITALIZED ADULTS; ANTIVIRAL TREATMENT; SEASONAL INFLUENZA; A(H1N1) VIRUS; OSELTAMIVIR; PNEUMONIA; OUTCOMES; STATINS AB We aimed to study factors influencing outcomes of adults hospitalised for seasonal and pandemic influenza. Individual-patient data from three Asian cohorts (Hong Kong, Singapore and Beijing; N=2649) were analysed. Adults hospitalised for laboratory-confirmed influenza (prospectively diagnosed) during 20082011 were studied. The primary outcome measure was 30-day survival. Multivariate Cox regression models (time-fixed and time-dependent) were used. Patients had high morbidity (respiratory/nonrespiratory complications in 68.4%, respiratory failure in 48.6%, pneumonia in 40.8% and bacterial superinfections in 10.8%) and mortality (5.9% at 30 days and 6.9% at 60 days). 75.2% received neuraminidase inhibitors (NAI) (73.8% received oseltamivir and 1.4% received peramivir/zanamivir; 44.5% of patients received NAI <= 2 days and 65.5% <= 5 days after onset of illness); 23.1% received systemic corticosteroids. There were fewer deaths among NAI-treated patients (5.3% versus 7.6%; p=0.032). NAI treatment was independently associated with survival (adjusted hazard ratio (HR) 0.28, 95% CI 0.19-0.43), adjusted for treatment-propensity score and patient characteristics. Superinfections increased (adjusted HR 2.18, 95% CI 1.52-3.11) and chronic statin use decreased (adjusted HR 0.44, 95% CI 0.23-0.84) death risks. Best survival was shown when treatment started within <= 2 days (adjusted HR 0.20, 95% CI 0.12-0.32), but there was benefit with treatment within 3-5 days (adjusted HR 0.35, 95% CI 0.21-0.58). Time-dependent analysis showed consistent results of NAI treatment (adjusted HR 0.39, 95% CI 0.27-0.57). Corticosteroids increased superinfection (9.7% versus 2.7%) and deaths when controlled for indications (adjusted HR 1.73, 95% CI 1.14-2.62). Early NAI treatment was associated with shorter length of stay in a subanalysis. NAI treatment may improve survival of hospitalised influenza patients; benefit is greatest from, but not limited to, treatment started within 2 days of illness. Superinfections and corticosteroids increase mortality. Antiviral and non-antiviral management strategies should be considered. C1 [Lee, Nelson; Cheung, Catherine S. K.; Yung, Irene M. H.; Hui, David S. C.] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, Hong Kong, Peoples R China. [Lee, Nelson; Chan, Paul K. S.; Hui, David S. C.] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China. [Leo, Yee-Sin; Kyaw, W. M.] Natl Univ Singapore, Yong Loo Lin Sch Med, Tan Tock Seng Hosp, Communicable Dis Ctr,Inst Infect Dis & Epidemiol, Singapore 117595, Singapore. [Cao, Bin; Li, Hui; Gu, Li; Liu, Yingmei; Liu, Zhenjia; Qu, Jiuxin] Capital Med Univ, Dept Infect Dis & Clin Microbiol, Beijing Chao Yang Hosp, Beijing Inst Resp Med, Beijing, Peoples R China. [Chan, Paul K. S.] Chinese Univ Hong Kong, Dept Microbiol, Shatin, Hong Kong, Peoples R China. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. [Tam, Wilson W. S.] Chinese Univ Hong Kong, Sch Publ Hlth & Primary Care, Shatin, Hong Kong, Peoples R China. RP Lee, N (reprint author), Chinese Univ Hong Kong, Prince Wales Hosp, Fac Med, Dept Med & Therapeut,Div Infect Dis, 9-F Lui Che Woo Clin Sci Bldg, Shatin, Hong Kong, Peoples R China. EM leelsn@cuhk.edu.hk RI Hui, David/O-2754-2015; Lee, Nelson/B-6418-2008; Chan, Paul/J-9360-2013; OI Tam, Wilson/0000-0003-0641-3060; Cheung, Siu King/0000-0002-3486-489X FU Research Fund for the Control of Infectious Diseases, Food and Health Bureau of the Hong Kong Special Administrative Region Government [CU-11-01-01]; departmental research fund, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong; National Natural Science Foundation of China, Beijing [81070005/H0104, 81030032/H19, 81271840] FX This project is jointly supported by the Research Fund for the Control of Infectious Diseases (grant CU-11-01-01), Food and Health Bureau of the Hong Kong Special Administrative Region Government; a departmental research fund, Faculty of Medicine, The Chinese University of Hong Kong, Hong Kong; and research grants from the National Natural Science Foundation of China (grants 81070005/H0104, 81030032/H19 and 81271840), Beijing. Funding information for this article has been deposited with FundRef. NR 44 TC 12 Z9 14 U1 1 U2 6 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD JUN PY 2015 VL 45 IS 6 BP 1642 EP 1652 DI 10.1183/09031936.00169714 PG 11 WC Respiratory System SC Respiratory System GA CJ2QN UT WOS:000355329700018 PM 25573405 ER PT J AU Jemmott, JB Jemmott, LS O'Leary, A Ngwane, Z Lewis, DA Bellamy, SL Icard, LD Carty, C Heeren, GA Tyler, JC Makiwane, MB Teitelman, A AF Jemmott, John B., III Jemmott, Loretta S. O'Leary, Ann Ngwane, Zolani Lewis, David A. Bellamy, Scarlett L. Icard, Larry D. Carty, Craig Heeren, G. Anita Tyler, Joanne C. Makiwane, Monde B. Teitelman, Anne TI HIV/STI Risk-Reduction Intervention Efficacy With South African Adolescents Over 54 Months SO HEALTH PSYCHOLOGY LA English DT Article DE South Africa; adolescents; HIV; intervention trial; sexually transmitted infections ID RANDOMIZED-CONTROLLED-TRIAL; SUB-SAHARAN AFRICA; PLANNED BEHAVIOR; HIV PREVENTION; SEXUAL RISK; YOUTH; ABSTINENCE; AMERICAN; BURDEN; IMPACT AB Objective: Little research has tested HIV/sexually transmitted infection (STI) risk-reduction interventions' effects on early adolescents as they age into middle and late adolescence. This study tested whether intervention-induced reductions in unprotected intercourse during a 12-month period endured over a 54-month period and whether the intervention reduced the prevalence of STIs, which increase risk for HIV. Method: Grade 6 learners (mean age = 12.4 years) participated in a 12-month trial in Eastern Cape Province, South Africa, in which 9 matched pairs of schools were randomly selected and within pairs randomized to a theory-based HIV/STI risk-reduction intervention or an attention-control intervention. They completed 42- and 54-month postintervention measures of unprotected intercourse (the primary outcome), other sexual behaviors, theoretical constructs, and, at 42- and 54-month follow-up only, biologically confirmed curable STIs (chlamydial infection, gonorrhea, and trichomoniasis) and herpes simplex virus 2. Results: The HIV/STI risk-reduction intervention reduced unprotected intercourse averaged over the entire follow-up period (OR = 0.42, 95% CI [0.22, 0.84]), an effect not significantly reduced at 42- and 54-month follow-up compared with 3-, 6-, and 12-month follow-ups. The intervention caused positive changes on theoretical constructs averaged over the 5 follow-ups, although most effects weakened at long-term follow-up. Although the intervention's main effect on STIs was nonsignificant, an Intervention Condition x Time interaction revealed that it significantly reduced curable STIs at 42-month follow-up in adolescents who reported sexual experience. Conclusion: These results suggest that theory-based behavioral interventions with early adolescents can have long-lived effects in the context of a generalized severe HIV epidemic. C1 [Jemmott, John B., III] Univ Penn, Annenberg Sch Commun, Philadelphia, PA 19104 USA. [Jemmott, John B., III; Carty, Craig; Heeren, G. Anita] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Jemmott, Loretta S.; Teitelman, Anne] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [O'Leary, Ann] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ngwane, Zolani] Haverford Coll, Dept Anthropol, Haverford, PA 19041 USA. [Lewis, David A.] Natl Inst Communicable Dis, Johannesburg, South Africa. [Lewis, David A.] Univ Witwatersrand, Fac Hlth Sci, ZA-2050 Johannesburg, South Africa. [Bellamy, Scarlett L.] Univ Penn, Dept Biostat & Epidemiol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Icard, Larry D.] Temple Univ, Coll Hlth Profess & Social Work, Philadelphia, PA 19122 USA. [Tyler, Joanne C.] Univ Ft Hare, Dept Stat, Alice, South Africa. [Makiwane, Monde B.] Human Resources Res Council, Pretoria, South Africa. RP Jemmott, JB (reprint author), Univ Penn, Annenberg Sch Commun, Ctr Hlth Behav & Commun Res, 3535 Market St,Suite 520, Philadelphia, PA 19104 USA. EM jjemmott@asc.upenn.edu OI Carty, Craig Raymond/0000-0003-0767-3382 FU National Institute of Mental Health [1R01MH065867, 2R01MH065867] FX The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. This study was supported in part by the National Institute of Mental Health (1R01MH065867 and 2R01MH065867). We appreciate the contributions of Costa Gazi, Janet Hsu, Shasta Jones, Anthea Klopper, Pretty Ndyebi, Frans Radebe, and Lulama Sidloyi, without which this research would not have been possible. NR 36 TC 5 Z9 5 U1 3 U2 9 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0278-6133 EI 1930-7810 J9 HEALTH PSYCHOL JI Health Psychol. PD JUN PY 2015 VL 34 IS 6 BP 610 EP 621 DI 10.1037/hea0000140 PG 12 WC Psychology, Clinical; Psychology SC Psychology GA CJ2GM UT WOS:000355302200005 PM 25110841 ER PT J AU Zotti, ME Williams, AM Wako, E AF Zotti, Marianne E. Williams, Amy M. Wako, Etobssie TI Post-disaster Health Indicators for Pregnant and Postpartum Women and Infants SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Disaster; Indicators; Pregnant; Postpartum; Infant ID HURRICANE-KATRINA; OUTCOMES; DISASTERS AB United States (U.S.) pregnant and postpartum (P/PP) women and their infants may be particularly vulnerable to effects from disasters. In an effort to guide post-disaster assessment and surveillance, we initiated a collaborative process with nationwide expert partners to identify post-disaster epidemiologic indicators for these at-risk groups. This 12 month process began with conversations with partners at two national conferences to identify critical topics for P/PP women and infants affected by disaster. Next we hosted teleconferences with a 23 member Indicator Development Working Group (IDWG) to review and prioritize the topics. We then divided the IDWG into three population subgroups (pregnant women, postpartum women, and infants) that conducted at least three teleconferences to discuss the proposed topics and identify/develop critical indicators, measures for each indicator, and relevant questions for each measure for their respective population subgroup. Lastly, we hosted a full IDWG teleconference to review and approve the indicators, measures, and questions. The final 25 indicators and measures with questions (available online) are organized by population subgroup: pregnant women (indicators = 9; measures = 24); postpartum women (indicators = 10; measures = 36); and infants (indicators = 6; measures = 30). We encourage our partners in disaster-affected areas to test these indicators and measures for relevancy and completeness. In post-disaster surveillance, we envision that users will not use all indicators and measures but will select ones appropriate for their setting. These proposed indicators and measures promote uniformity of measurement of disaster effects among U.S. P/PP women and their infants and assist public health practitioners to identify their post-disaster needs. C1 [Zotti, Marianne E.] Ctr Dis Control & Prevent CDC, FSB, DRH,MANILA Consulting Grp Inc, DRH Program Emergency Preparedness & Response,NCC, Bella Vista, AR 72714 USA. [Williams, Amy M.; Wako, Etobssie] Ctr Dis Control & Prevent CDC, FSB, DRH, NCCDPHP,MANILA Consulting Grp Inc, Atlanta, GA USA. RP Zotti, ME (reprint author), Ctr Dis Control & Prevent CDC, FSB, DRH,MANILA Consulting Grp Inc, DRH Program Emergency Preparedness & Response,NCC, 36 Warwick Dr, Bella Vista, AR 72714 USA. EM Mbz1@cdc.gov FU Centers for Disease Control and Prevention, Office for Public Health Preparedness and Response FX The findings and conclusions in this paper are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Funding Sources: This publication was supported by funds made available from the Centers for Disease Control and Prevention, Office for Public Health Preparedness and Response. The authors do not possess any financial conflict of interests in relation to this paper. NR 26 TC 1 Z9 1 U1 2 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD JUN PY 2015 VL 19 IS 6 BP 1179 EP 1188 DI 10.1007/s10995-014-1643-4 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ1CU UT WOS:000355220400002 PM 25476606 ER PT J AU Sinclair, LB Taft, KE Sloan, ML Stevens, AC Krahn, GL AF Sinclair, Lisa B. Taft, Kate E. Sloan, Michelle L. Stevens, Alissa C. Krahn, Gloria L. TI Tools for Improving Clinical Preventive Services Receipt Among Women with Disabilities of Childbearing Ages and Beyond SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Clinical preventive services; Healthcare tools; Women's health; Women with disabilities ID PHYSICAL-DISABILITIES; INTELLECTUAL DISABILITIES; HEALTH DISPARITIES; PRIMARY-CARE; PEOPLE; PERSPECTIVES; FRAMEWORK; ATTITUDES AB Efforts to improve clinical preventive services (CPS) receipt among women with disabilities are poorly understood and not widely disseminated. The reported results represent a 2-year, Centers for Disease Control and Prevention and Association of Maternal and Child Health Programs partnership to develop a central resource for existing tools that are of potential use to maternal and child health practitioners who work with women with disabilities. Steps included contacting experts in the fields of disability and women's health, searching the Internet to locate examples of existing tools that may facilitate CPS receipt, convening key stakeholders from state and community-based programs to determine their potential use of the tools, and developing an online Toolbox. Nine examples of existing tools were located. The tools focused on facilitating use of the CPS guidelines, monitoring CPS receipt among women with disabilities, improving the accessibility of communities and local transportation, and training clinicians and women with disabilities. Stakeholders affirmed the relevance of these tools to their work and encouraged developing a Toolbox. The Toolbox, launched in May 2013, provides information and links to existing tools and accepts feedback and proposals for additional tools. This Toolbox offers central access to existing tools. Maternal and child health stakeholders and other service providers can better locate, adopt and implement existing tools to facilitate CPS receipt among adolescent girls with disabilities who are transitioning into adult care as well as women with disabilities of childbearing ages and beyond. C1 [Sinclair, Lisa B.; Sloan, Michelle L.; Stevens, Alissa C.; Krahn, Gloria L.] Ctr Dis Control & Prevent, Disabil & Hlth Branch, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil,US Dept HHS, Atlanta, GA 30333 USA. [Taft, Kate E.] Assoc Maternal & Child Hlth Programs, Children & Youth Special Hlth Care Needs, Washington, DC 20036 USA. RP Sinclair, LB (reprint author), Ctr Dis Control & Prevent, Disabil & Hlth Branch, Div Human Dev & Disabil, Natl Ctr Birth Defects & Dev Disabil,US Dept HHS, 1600 Clifton Rd,E-88, Atlanta, GA 30333 USA. EM lsinclair@cdc.gov; ktaft@amchp.org; jtq4@cdc.gov; fdx7@cdc.gov; gloriakrahn@live.com FU Disability and Health Branch as part of the CDC, Office for State, Tribal, Local and Territorial Support (OSTLTS) [HM08-805] FX This project was funded by the Disability and Health Branch as part of the CDC, Office for State, Tribal, Local and Territorial Support (OSTLTS) Cooperative Agreement HM08-805. We thank all of the meeting participants for their expertise in reviewing examples of the tools for the Toolbox and appreciate the opening presenters Michael Fraser, Coleen Boyle, Rosaly Correa-De-Arraujo, Nancy Lee, and Marilyn Hartzell, as well as the tool presenters Michelle Sloan (co-author), Michelle Camicia, Donna Smith, Daniel Bailey, Marsha Saxton, Susan Parish, and Adriane Griffin. We thank Jacqui Butler and Lauren Ramos who oversaw the CDC/AMCHP agreement, Alma Reyes who arranged the stakeholder meeting, Sheri Jordan who assisted with the meeting agenda layout, Vincent Campbell who researched the Census estimates, Arlene Vincent-Mark who provided comments on the appendix layout, Michelle Reyes who oversaw the meeting planning and reviewed the manuscript along with Lacy Farhenbach, Dianna Carroll, and Michael Fox. NR 57 TC 1 Z9 1 U1 0 U2 2 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD JUN PY 2015 VL 19 IS 6 BP 1189 EP 1201 DI 10.1007/s10995-014-1627-4 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ1CU UT WOS:000355220400003 PM 25359095 ER PT J AU Tong, VT Morello, P Aleman, A Johnson, C Dietz, PM Farr, SL Mazzoni, A Berrueta, M Colomar, M Ciganda, A Becu, A Gonzalez, MGB Llambi, L Gibbons, L Smith, RA Buekens, P Belizan, JM Althabe, F AF Tong, Van T. Morello, Paola Aleman, Alicia Johnson, Carolyn Dietz, Patricia M. Farr, Sherry L. Mazzoni, Agustina Berrueta, Mabel Colomar, Mercedes Ciganda, Alvaro Becu, Ana Bittar Gonzalez, Maria G. Llambi, Laura Gibbons, Luz Smith, Ruben A. Buekens, Pierre Belizan, Jose M. Althabe, Fernando TI Pregnant Women's Secondhand Smoke Exposure and Receipt of Screening and Brief Advice by Prenatal Care Providers in Argentina and Uruguay SO MATERNAL AND CHILD HEALTH JOURNAL LA English DT Article DE Environmental tobacco exposure; Pregnancy; Guidelines; Prenatal care ID TOBACCO-SMOKE; FREE LEGISLATION; PUBLIC PLACES; CESSATION; POLICIES AB Secondhand smoke (SHS) exposure has negative effects on maternal and infant health. SHS exposure among pregnant women in Argentina and Uruguay has not been previously described, nor has the proportion of those who have received screening and advice to avoid SHS during prenatal care. Women who attended one of 21 clusters of publicly-funded prenatal care clinics were interviewed regarding SHS exposure during pregnancy at their delivery hospitalization during 2011-2012. Analyses were conducted using SURVEYFREQ procedure in SAS version 9.3 to account for prenatal clinic clusters. Of 3,427 pregnant women, 43.4 % had a partner who smoked, 52.3 % lived with household members who smoked cigarettes, and 34.4 % had no or partial smoke-free home rule. Of 528 pregnant women who worked outside of the home, 21.6 % reported past month SHS exposure at work and 38.1 % reported no or partial smoke-free work policy. Overall, 35.9 % of women were exposed to SHS at home or work. In at least one prenatal care visit, 67.2 % of women were screened for SHS exposure, and 56.6 % received advice to avoid SHS. Also, 52.6 % of women always avoided SHS for their unborn baby's health. In summary, a third of pregnant women attending publicly-funded prenatal clinics were exposed to SHS, and only half of pregnant women always avoided SHS for their unborn baby's health. Provider screening and advice rates can be improved in these prenatal care settings, as all pregnant women should be screened and advised of the harms of SHS and how to avoid it. C1 [Tong, Van T.; Dietz, Patricia M.; Farr, Sherry L.; Smith, Ruben A.] Ctr Dis Control & Prevent, Div Reprod Hlth, NCCDPHP, Atlanta, GA 30341 USA. [Morello, Paola; Mazzoni, Agustina; Berrueta, Mabel; Becu, Ana; Gibbons, Luz; Belizan, Jose M.; Althabe, Fernando] Inst Clin Effectiveness & Hlth Policy, Buenos Aires, DF, Argentina. [Aleman, Alicia; Colomar, Mercedes; Ciganda, Alvaro] Montevideo Clin & Epidemiol Res Unit, Montevideo, Uruguay. [Johnson, Carolyn; Buekens, Pierre] Tulane Sch Publ Hlth & Trop Med, New Orleans, LA USA. [Bittar Gonzalez, Maria G.; Llambi, Laura] Univ Republica, Fac Med, Montevideo, Uruguay. RP Tong, VT (reprint author), Ctr Dis Control & Prevent, Div Reprod Hlth, NCCDPHP, 4770 Buford Hwy,NE,MS-F74, Atlanta, GA 30341 USA. EM vtong@cdc.gov OI Belizan, Jose/0000-0002-8412-3010 FU CDC [5U48DP001948-04(SIP09-18)] FX The study was supported through CDC cooperative agreement 5U48DP001948-04(SIP09-18) to Tulane University. The authors report no competing interests. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of CDC. We would like to acknowledge participating coordinators and hospitals: Argentina-D. Fernandez at Hospital Municipal Materno Infantil "Dr. Carlos Gianantonio"; J. Anton at Hospital Zonal General de Agudos "Heroes de Malvinas"; E. Macagno at Hospital Zonal General de Agudos "Dr. Carlos Bocalandro"; M. Ferrary at Hospital Zonal General de Agudos "Magdalena Villegas de Martinez"; V. Nicolaci at Instituto de Maternidad Santa Rosa; M.T. Moreno Hospital Zonal General de Agudos "San Roque"; M.R. Sabbadin at Hospital Zonal General de Agudos "Dr. Narciso Lopez"; S.M. Souza at Hospital Zonal General de Agudos "Evita Pueblo"; C. Muzzio at Hospital Municipal "Ostaciana B. de Lavignolle"; L. Frias at Hospital Zonal General de Agudos "Dr. Lucio Melendez." Uruguay-O. Grana and E. Gomez, at Administracion de los Servicios de Salud del Estado; A. Raggio at Banco de Prevision Social. NR 27 TC 2 Z9 2 U1 0 U2 3 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1092-7875 EI 1573-6628 J9 MATERN CHILD HLTH J JI Matern. Child Health J. PD JUN PY 2015 VL 19 IS 6 BP 1376 EP 1383 DI 10.1007/s10995-014-1642-5 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ1CU UT WOS:000355220400020 PM 25427876 ER PT J AU Wong, VK Baker, S Pickard, DJ Parkhill, J Page, AJ Feasey, NA Kingsley, RA Thomson, NR Keanel, JA Weill, FX Edwards, DJ Hawkey, J Harris, SR Mather, AE Cain, AK Hadfield, J Hart, PJ Thieu, NTV Klemm, EJ Glinos, DA Breiman, RF Watson, CH Kariuki, S Gordon, MA Heyderman, RS Okoro, C Jacobs, J Lunguya, O Edmunds, WJ Msefula, C Chabalgoity, JA Kama, M Jenkins, K Dutta, S Marks, F Campos, J Thompson, C Obaro, S MacLennan, CA Dolecek, C Keddy, KH Smith, AM Parry, CM Karkey, A Mulholland, EK Campbell, JI Dongol, S Basnyat, B Dufour, M Bandaranayake, D Naseri, TT Singh, SP Hatta, M Newton, P Onsare, RS Isaia, L Dance, D Davong, V Thwaites, G Wijedoru, L Crump, JA De Pinna, E Nair, S Nilles, EJ Thanh, DP Turner, P Soeng, S Valcanis, M Powling, J Dimovski, K Hogg, G Farrar, J Holt, KE Dougan, G AF Wong, Vanessa K. Baker, Stephen Pickard, Derek J. Parkhill, Julian Page, Andrew J. Feasey, Nicholas A. Kingsley, Robert A. Thomson, Nicholas R. Keanel, Jacqueline A. Weill, Francois-Xavier Edwards, David J. Hawkey, Jane Harris, Simon R. Mather, Alison E. Cain, Amy K. Hadfield, James Hart, Peter J. Nga Tran Vu Thieu Klemm, Elizabeth J. Glinos, Dafni A. Breiman, Robert F. Watson, Conall H. Kariuki, Samuel Gordon, Melita A. Heyderman, Robert S. Okoro, Chinyere Jacobs, Jan Lunguya, Octavie Edmunds, W. John Msefula, Chisorno Chabalgoity, Jose A. Kama, Mike Jenkins, Kylie Dutta, Shanta Marks, Florian Campos, Josefina Thompson, Corinne Obaro, Stephen MacLennan, Calman A. Dolecek, Christiane Keddy, Karen H. Smith, Anthony M. Parry, Christopher M. Karkey, Abhilasha Mulholland, E. Kim Campbell, James I. Dongol, Sabina Basnyat, Buddha Dufour, Muriel Bandaranayake, Don Naseri, Take Toleafoa Singh, Shalini Pravin Hatta, Mochammad Newton, Paul Onsare, Robert S. Isaia, Lupeoletalalei Dance, David Davong, Viengmon Thwaites, Guy Wijedoru, Lalith Crump, John A. De Pinna, Elizabeth Nair, Satheesh Nilles, Eric J. Duy Pham Thanh Turner, Paul Soeng, Sona Valcanis, Mary Powling, Joan Dimovski, Karolina Hogg, Geoff Farrar, Jeremy Holt, Kathryn E. Dougan, Gordon TI Phylogeographical analysis of the dominant multidrug-resistant H58 clade of Salmonella Typhi identifies inter- and intracontinental transmission events SO NATURE GENETICS LA English DT Article ID ENTERICA SEROVAR TYPHI; ANTIBIOTIC-RESISTANCE; INTERACTIVE TREE; INCHI1 PLASMIDS; FEVER; MUTATIONS; EVOLUTION; ANNOTATION; POPULATION; PARATYPHI AB The emergence of multidrug-resistant (MDR) typhoid is a major global health threat affecting many countries where the disease is endemic. Here whole-genome sequence analysis of 1,832 Salmonella enterica serovar Typhi (S. Typhi) identifies a single dominant MDR lineage, H58, that has emerged and spread throughout Asia and Africa over the last 30 years. Our analysis identifies numerous transmissions of H58, including multiple transfers from Asia to Africa and an ongoing, unrecognized MDR epidemic within Africa itself. Notably, our analysis indicates that H58 lineages are displacing antibiotic-sensitive isolates, transforming the global population structure of this pathogen. H58 isolates can harbor a complex MDR element residing either on transmissible IncHI1 plasmids or within multiple chromosomal integration sites. We also identify new mutations that define the H58 lineage. This phylogeographical analysis provides a framework to facilitate global management of MDR typhoid and is applicable to similar MDR lineages emerging in other bacterial species. C1 [Wong, Vanessa K.; Pickard, Derek J.; Page, Andrew J.; Kingsley, Robert A.; Keanel, Jacqueline A.; Mather, Alison E.; Cain, Amy K.; Hadfield, James; Klemm, Elizabeth J.; Glinos, Dafni A.; Okoro, Chinyere; MacLennan, Calman A.; Dougan, Gordon] Wellcome Trust Sanger Inst, Hinxton, England. [Wong, Vanessa K.] Univ Cambridge, Hosp Natl Hlth Serv NHS Fdn Trust, Addenbrookes Hosp, Dept Microbiol, Cambridge, England. [Baker, Stephen; Nga Tran Vu Thieu; Thompson, Corinne; Thwaites, Guy] Univ Oxford, Clin Res Unit, Wellcome Trust Major Overseas Programme, Hosp Trop Dis, Ho Chi Minh City, Vietnam. [Baker, Stephen; Thompson, Corinne; Dolecek, Christiane; Newton, Paul; Dance, David; Thwaites, Guy; Turner, Paul; Farrar, Jeremy] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England. [Baker, Stephen; Thomson, Nicholas R.; Mulholland, E. Kim] London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England. [Feasey, Nicholas A.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [Kingsley, Robert A.] Inst Food Res, Norwich, Norfolk, England. [Weill, Francois-Xavier] Inst Pasteur, Unite Bacteries Pathogenes Enter, Paris, France. [Edwards, David J.; Hawkey, Jane] Univ Melbourne, Mol Sci & Biotechnol Inst Bio21, Dept Biochem & Mol Biol, Melbourne, Vic, Australia. [Hawkey, Jane] Univ Melbourne, Fac Vet & Agr Sci, Melbourne, Vic, Australia. [MacLennan, Calman A.] Univ Birmingham, Coll Med & Dent Sci, Sch Immun & Infect, Inst Biomed Res, Birmingham, W Midlands, England. [Breiman, Robert F.; Kariuki, Samuel] Kenya Med Res Inst KEMRI, Nairobi, Kenya. [Breiman, Robert F.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Breiman, Robert F.] Emory Global Hlth Inst, Atlanta, GA USA. [Watson, Conall H.; Edmunds, W. John] London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Ctr Math Modelling Infect Dis, London WC1, England. [Gordon, Melita A.] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [Heyderman, Robert S.] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Program, Blantyre, Malawi. [Jacobs, Jan] Inst Trop Med, Dept Clin Sci, B-2000 Antwerp, Belgium. [Jacobs, Jan] Univ Leuven, Katholieke Univ KU Leuven, Dept Microbiol & Immunol, Leuven, Belgium. [Lunguya, Octavie] Natl Inst Biomed Res, Kinshasa, DEM REP CONGO. [Lunguya, Octavie] Univ Hosp Kinshasa, Kinshasa, DEM REP CONGO. [Msefula, Chisorno] Univ Malawi, Coll Med, Dept Microbiol, Blantyre, Malawi. [Chabalgoity, Jose A.] Inst Higiene, Facultad Medicina, Dept Desarrollo Biotecnol, Montevideo, Uruguay. [Kama, Mike] Minist Hlth, Suva, Fiji. [Jenkins, Kylie] Fiji Hlth Sector Support Program, Suva, Fiji. [Dutta, Shanta] Natl Inst Cholera & Enter Dis, Kolkata, India. [Marks, Florian] Int Vaccine Inst, Dept Epidemiol, Seoul, South Korea. [Campos, Josefina] Carlos G Malbran Inst, ANLIS, Enteropathogen Div, Buenos Aires, DF, Argentina. [Obaro, Stephen] Univ Nebraska, Med Ctr, Div Pediat Infect Dis, Omaha, NE 68182 USA. [Obaro, Stephen] Univ Abuja, Teaching Hosp, Abuja, Nigeria. [Obaro, Stephen] Bingham Univ, Karu, Nigeria. [MacLennan, Calman A.] Novartis Vaccines Inst Global Hlth, Siena, Italy. [Keddy, Karen H.; Smith, Anthony M.] Univ Witwatersrand, Ctr Enter Dis, Natl Inst Communicable Dis, Div Natl Hlth Lab Serv, Johannesburg, South Africa. [Parry, Christopher M.] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England. [Parry, Christopher M.] Nagasaki Univ, Grad Sch Trop Med & Global Hlth, Nagasaki 852, Japan. [Dongol, Sabina; Basnyat, Buddha] Univ Oxford, Clin Res Unit, Wellcome Trust Major Overseas Programme, Patan Acad Hlth Sci, Kathmandu, Nepal. [Mulholland, E. Kim] Murdoch Childrens Res Inst, Melbourne, Vic, Australia. [Dufour, Muriel] Inst Environm Sci & Res Ltd ESR, Enter & Leptospira Reference Lab, Porirua, New Zealand. [Bandaranayake, Don] Inst Environm Sci & Res, Natl Ctr Biosecur & Infect Dis, Porirua, New Zealand. [Singh, Shalini Pravin] WHO, Ctr Communicable Dis Control, Natl Influenza Ctr, Suva, Fiji. [Hatta, Mochammad] Hasanuddin Univ, Dept Microbiol, Makassar, Indonesia. [Newton, Paul; Dance, David; Davong, Viengmon] Mahosot Hosp, Microbiol Lab, Lao Oxford Mahosot Wellcome Trust Res Unit, Viangchan, Laos. [Wijedoru, Lalith; Turner, Paul] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok 10700, Thailand. [Wijedoru, Lalith] Chelsea & Westminster Hosp, Paediat Emergency Med, London, England. [Crump, John A.] Univ Otago, Ctr Int Hlth & Otago Int Hlth Res Network, Dunedin Sch Med, Dunedin, New Zealand. [De Pinna, Elizabeth; Nair, Satheesh] Publ Hlth England, Salmonella Reference Serv, London, England. [Nilles, Eric J.] WHO, Div Pacific Tech Support, Emerging Dis Surveillance & Response, Suva, Fiji. [Turner, Paul; Soeng, Sona] Angkor Hosp Children, Cambodia Oxford Med Res Unit, Siem Reap, Cambodia. [Valcanis, Mary; Powling, Joan; Dimovski, Karolina; Hogg, Geoff] Univ Melbourne, Microbiol Diagnost Unit, Dept Microbiol & Immunol, Doherty Inst Infect & Immun,Publ Hlth Lab, Melbourne, Vic, Australia. RP Wong, VK (reprint author), Wellcome Trust Sanger Inst, Hinxton, England. EM vw1@sanger.ac.uk RI MacLennan, Calman/L-9343-2014; Parkhill, Julian/G-4703-2011; Holt, Kathryn/A-8108-2012; OI MacLennan, Calman/0000-0001-9694-0846; Nair, Satheesh/0000-0002-7297-1485; Parkhill, Julian/0000-0002-7069-5958; Holt, Kathryn/0000-0003-3949-2471; Nilles, Eric/0000-0001-7044-5257; Dance, David/0000-0001-9189-7244; Dufour, Muriel/0000-0003-3638-4918; Page, Andrew/0000-0001-6919-6062; Weill, Francois-Xavier/0000-0001-9941-5799; Farrar, Jeremy/0000-0002-2700-623X; Hawkey, Jane/0000-0001-9661-5293; Thwaites, Guy/0000-0002-2858-2087; Watson, Conall/0000-0002-2469-791X; Turner, Paul/0000-0002-1013-7815 FU Wellcome Trust; Wellcome Trust award [098051]; Wellcome Trust research fellowship [WT092152MA]; Wellcome Trust for the Malawi-Liverpool Wellcome Trust Clinical Research Programme [101113/Z/13/Z]; Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme; Wellcome Trust (Major Overseas Programmes-Thailand Unit Core Grant); European Society for Paediatric Infectious Diseases; University of Oxford-Li Ka Shing Global Health Foundation; Wellcome Trust [089275/H/091Z]; National Health and Medical Research Council of Australia [1061409]; Victorian Life Sciences Computation Initiative (VLSCI) [VR0082]; Clinical Research Fellowship from GlaxoSmithKline; UK Medical Research Council PhD studentship; Institut Pasteur; Institut de Veille Sanitaire; French government 'Investissement d'Avenir' program (Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence) [ANR-10-LABX-62-IBEID]; UK Medical Research Council [MR/J003999/1, G1100100/1]; Society in Science; Branco Weiss Fellowship; antibiotic resistance surveillance project in the Democratic Republic of the Congo; Belgian Directorate General of Development Cooperation [2.01]; Institute of Tropical Medicine (Antwerp, Belgium) [2.01]; Bill and Melinda Gates Foundation; US National Institutes of Health-National Science Foundation Ecology and Evolution of Infectious Disease program [R01 TW009237]; UK Biotechnology and Biological Sciences Research Council (BBSRC) [BB/J010367/1]; UK BBSRC Zoonoses in Emerging Livestock Systems awards [BB/L017679, BB/L018926, BB/L018845]; US National Institutes of Health grant [R01 AI099525-02]; Royal Society [100087/Z/12/Z]; National Institute of Allergy and Infectious Diseases of the US National Institutes of Health [R01 AI097493] FX This work was supported by the Wellcome Trust. We would like to thank the members of the Pathogen Informatics Team and the core sequencing teams at the Wellcome Trust Sanger Institute (Cambridge, UK). We are grateful to D. Harris for his superb work in managing the sequence data. We also thank L. Fabre for her excellent technical assistance.; This work was supported by a number of organizations. The authors affiliated with the Wellcome Trust Sanger Institute were funded by Wellcome Trust award 098051; N.A.F. was supported by Wellcome Trust research fellowship WT092152MA. N.A.F., R.S.H. and this work were supported by a strategic award from the Wellcome Trust for the Malawi-Liverpool Wellcome Trust Clinical Research Programme (101113/Z/13/Z). C.M.P. was funded by the Wellcome Trust Mahidol University Oxford Tropical Medicine Research Programme, supported by the Wellcome Trust (Major Overseas Programmes-Thailand Unit Core Grant), the European Society for Paediatric Infectious Diseases and the University of Oxford-Li Ka Shing Global Health Foundation. D.D., P.N. and V.D. were supported by the Wellcome Trust (core grant 089275/H/091Z). K.E.H. was supported by the National Health and Medical Research Council of Australia (fellowship 1061409) and the Victorian Life Sciences Computation Initiative (VLSCI; grant VR0082). C.A.M. was supported by a Clinical Research Fellowship from GlaxoSmithKline, and P.J.H. was supported by a UK Medical Research Council PhD studentship. This work forms part of a European Union Framework Programme 7 Marie Curie Actions Industry Academia Partnerships and Pathways (LAPP) Consortium Programme, entitled GENDRIVAX (Genome-Driven Vaccine Development for Bacterial Infections), involving the Wellcome Trust Sanger Institute, KEMRI Nairobi and the Novartis Vaccines Institute for Global Health. The authors affiliated with the Institut Pasteur were funded by the Institut Pasteur, the Institut de Veille Sanitaire and the French government 'Investissement d'Avenir' program (Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence, grant ANR-10-LABX-62-IBEID). C.H.W. was supported by the UK Medical Research Council (MR/J003999/1). CO. was supported by Society in Science and the Branco Weiss Fellowship, administered by ETH Zurich. A.K.C. was supported by the UK Medical Research Council (G1100100/1). J.J. was supported by the antibiotic resistance surveillance project in the Democratic Republic of the Congo, funded by project 2.01 of the Third Framework Agreement between the Belgian Directorate General of Development Cooperation and the Institute of Tropical Medicine (Antwerp, Belgium). F.M. was supported by a research grant from the Bill and Melinda Gates Foundation. The findings and conclusions contained within this publication are those of the authors and do not necessarily reflect positions or policies of the Bill and Melinda Gates Foundation. J.A. Crump was supported by the joint US National Institutes of Health-National Science Foundation Ecology and Evolution of Infectious Disease program (R01 TW009237), the UK Biotechnology and Biological Sciences Research Council (BBSRC; BB/J010367/1) and UK BBSRC Zoonoses in Emerging Livestock Systems awards BB/L017679, BB/L018926 and BB/L018845. S.K. was supported by US National Institutes of Health grant R01 AI099525-02. S.B. is a Sir Henry Dale Fellow, jointly funded by the Wellcome Trust and the Royal Society (100087/Z/12/Z). S.O. was supported by the National Institute of Allergy and Infectious Diseases of the US National Institutes of Health (R01 AI097493). The content is solely the responsibility of the authors and does not necessarily represent the official views of the US National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. C.D.; was supported by the University of Oxford-Li Ka Shing Global Health Foundation. NR 73 TC 46 Z9 46 U1 1 U2 18 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1061-4036 EI 1546-1718 J9 NAT GENET JI Nature Genet. PD JUN PY 2015 VL 47 IS 6 BP 632 EP 639 DI 10.1038/ng.3281 PG 8 WC Genetics & Heredity SC Genetics & Heredity GA CJ3LW UT WOS:000355386500014 PM 25961941 ER PT J AU De Cock, KM El-Sadr, WM AF De Cock, Kevin M. El-Sadr, Wafaa M. TI A tale of two viruses: HIV, Ebola and health systems SO AIDS LA English DT Article C1 [De Cock, Kevin M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [El-Sadr, Wafaa M.] Columbia Univ, ICAP, Mailman Sch Publ Hlth, New York, NY 10032 USA. RP El-Sadr, WM (reprint author), Columbia Univ, ICAP, 722 West 168th St,Box 18,Room 1312, New York, NY 10032 USA. EM wme1@columbia.edu NR 5 TC 3 Z9 3 U1 0 U2 23 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD JUN PY 2015 VL 29 IS 9 BP 989 EP 991 DI 10.1097/QAD.0000000000000726 PG 3 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CI4OH UT WOS:000354730000001 PM 26125135 ER PT J AU Wilken, JA Jackson, R Materna, BL Windham, GC Enge, B Messenger, S Xia, DX Knust, B Buttke, D Roisman, R AF Wilken, Jason A. Jackson, Rebecca Materna, Barbara L. Windham, Gayle C. Enge, Barryett Messenger, Sharon Xia, Dongxiang Knust, Barbara Buttke, Danielle Roisman, Rachel CA Yosemite Hantavirus Outbreak TI Assessing prevention measures and sin nombre hantavirus seroprevalence among workers at Yosemite National Park SO AMERICAN JOURNAL OF INDUSTRIAL MEDICINE LA English DT Article DE hantavirus; Sin Nombre virus; disease transmission; infectious; occupational health ID SOUTHWESTERN UNITED-STATES; PULMONARY SYNDROME; OCCUPATIONAL RISK; EXPOSURE; INFECTIONS; ANTIBODIES; CALIFORNIA; PHYSICIANS; VIRUSES; FOREST AB BackgroundDuring 2012, a total of 10 overnight visitors to Yosemite National Park (Yosemite) became infected with a hantavirus (Sin Nombre virus [SNV]); three died. SNV infections have been identified among persons with occupational exposure to deer mice (Peromyscus maniculatus). MethodsWe assessed SNV infection prevalence, work and living environments, mice exposures, and SNV prevention training, knowledge, and practices among workers of two major employers at Yosemite during September-October, 2012 by voluntary blood testing and a questionnaire. ResultsOne of 526 participants had evidence of previous SNV infection. Participants reported frequently observing rodent infestations at work and home and not always following prescribed safety practices for tasks, including infestation cleanup. ConclusionAlthough participants had multiple exposures to deer mice, we did not find evidence of widespread SNV infections. Nevertheless, employees working around deer mice should receive appropriate training and consistently follow prevention policies for high-risk activities. Am. J. Ind. Med. 58:658-667, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Wilken, Jason A.; Jackson, Rebecca; Materna, Barbara L.; Windham, Gayle C.; Enge, Barryett; Messenger, Sharon; Xia, Dongxiang; Roisman, Rachel] Calif Dept Publ Hlth, Richmond, CA 94804 USA. [Wilken, Jason A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Jackson, Rebecca] Council State & Territorial Epidemiologists, Atlanta, GA USA. [Knust, Barbara] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Buttke, Danielle] Natl Pk Serv, Off Publ Hlth, Ft Collins, CO USA. RP Materna, BL (reprint author), Calif Dept Publ Hlth, Occupat Hlth Branch, 850 Marina Bay Pkwy,Bldg P3, Richmond, CA 94804 USA. EM barbara.materna@cdph.ca.gov FU Centers for Disease Control and Prevention (CDC) [5U38HM000414-5] FX This work was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists and funded by Centers for Disease Control and Prevention (CDC) Cooperative Agreement Number 5U38HM000414-5. We thank Yosemite employees who participated in this survey, and for phlebotomy assistance, the Mariposa County Public Health Department, Fresno County Public Health Department, Mammoth Hospital, and California Nurses Association. In addition to this article's authors, members of the investigation team include the following:; CDPH: Alberto Aparicio, Tracy Barreau, Matt Conens, Lori Copan, David Cottam, Dina Dobraca, Jennifer Flattery, Curtis Fritz, Christine Hannigan, Martha Harnly, Egils Kronlins, Mark Novak, Jonathan Nunez, Susan Payne, Alyce Ujihara, Duc Vugia, and Debra Wadford.; CDC: Brian Amman, Lynda Osadebe, Pierre Rollin, and Ute Stroher.; NPS: Kevin Killian, Jennifer Leggett, Tom Medema, David Pope, Matthew Weinburke, and David Wong.; The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of CDC. NR 23 TC 0 Z9 0 U1 1 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0271-3586 EI 1097-0274 J9 AM J IND MED JI Am. J. Ind. Med. PD JUN PY 2015 VL 58 IS 6 BP 658 EP 667 DI 10.1002/ajim.22445 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI0TH UT WOS:000354450400008 PM 25943457 ER PT J AU Lu, PJ O'Halloran, A Williams, WW AF Lu, Peng-jun O'Halloran, Alissa Williams, Walter W. TI Impact of Health Insurance Status on Vaccination Coverage Among Adult Populations SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID HEPATITIS-B VACCINATION; HIGH-RISK ADULTS; UNITED-STATES; SELF-REPORT; IMMUNIZATION PRACTICES; INFLUENZA SEASON; UNINSURED ADULTS; US; SURVEILLANCE; VALIDATION AB Introduction: Underinsurance is a barrier to vaccination among children. Information on vaccination among adults aged >= 18 years by insurance status is limited. This study assesses vaccination coverage among adults aged >= 18 years in the U.S. in 2012 by health insurance status and access to care characteristics. Methods: The 2012 National Health Interview Survey data were analyzed in 2014 to estimate vaccination coverage among adults aged >= 18 years by health insurance status for seven routinely recommended vaccines. Results: Influenza vaccination coverage among adults aged >= 18 years without or with health insurance was 14.4% versus 44.3%, respectively; pneumococcal vaccination coverage among adults aged 18-64 years with high-risk conditions was 9.8% versus 23.0%; tetanus and diphtheria toxoid (Td) coverage (age >= 18 years) was 53.2% versus 64.5%; tetanus, diphtheria, and acellular pertussis (Tdap) coverage (age >= 18 years) was 8.4% versus 15.7%; hepatitis A (HepA) coverage (age 18-49 years) was 16.6% versus 19.8%; hepatitis B (HepB) coverage (age 18-49 years) was 27.5% versus 38.0%; shingles coverage (age >= 60 years) was 6.1% versus 20.8%; and human papillomavirus (HPV) coverage (women aged 18-26 years) was 20.9% versus 39.8%. In addition, vaccination coverage differed by insurance type, whether respondents had a regular physician, and number of physician contacts. Conclusions: Overall, vaccination coverage among adults aged >= 18 years is lower among uninsured populations. Implementation of effective strategies is needed to help improve vaccination coverage among adults aged >= 18 years, especially those without health insurance. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Lu, Peng-jun; O'Halloran, Alissa; Williams, Walter W.] CDC, Natl Ctr Immunizat & Resp Dis, Immunizat Serv Div, Atlanta, GA 30333 USA. RP Lu, PJ (reprint author), CDC, Natl Ctr Immunizat & Resp Dis, 1600 Clifton Rd,Mail Stop A-19, Atlanta, GA 30333 USA. EM lhp8@cdc.gov NR 45 TC 5 Z9 5 U1 1 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUN PY 2015 VL 48 IS 6 BP 647 EP 661 DI 10.1016/j.amepre.2014.12.008 PG 15 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CI5EK UT WOS:000354776000003 PM 25890684 ER PT J AU Ackermann, RT Duru, OK Albu, JB Schmittdiel, JA Soumerai, SB Wharam, JF Ali, MK Mangione, CM Gregg, EW AF Ackermann, Ronald T. Duru, O. Kenrik Albu, Jeanine B. Schmittdiel, Julie A. Soumerai, Stephen B. Wharam, James F. Ali, Mohammed K. Mangione, Carol M. Gregg, Edward W. CA Next-D Study Grp TI Evaluating Diabetes Health Policies Using Natural Experiments The Natural Experiments for Translation in Diabetes Study SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Article ID QUALITY-OF-CARE; MANAGEMENT PROGRAMS; MEDICAID; INTERVENTIONS; METAANALYSIS; OUTCOMES; ADULTS; TRIAL; STATE; COST AB The high prevalence and costs of type 2 diabetes makes it a rapidly evolving focus of policy action. Health systems, employers, community organizations, and public agencies have increasingly looked to translate the benefits of promising research interventions into innovative polices intended to prevent or control diabetes. Though guided by research, these health policies provide no guarantee of effectiveness and may have opportunity costs or unintended consequences. Natural experiments use pragmatic and available data sources to compare specific policies to other policy alternatives or predictions of what would likely have happened in the absence of any intervention. The Natural Experiments for Translation in Diabetes (NEXT-D) Study is a network of academic, community, industry, and policy partners, collaborating to advance the methods and practice of natural experimental research, with a shared aim of identifying and prioritizing the best policies to prevent and control diabetes. This manuscript describes the NEXT-D Study group's multi-sector natural experiments in areas of diabetes prevention or control as case examples to illustrate the selection, design, analysis, and challenges inherent to natural experimental study approaches to inform development or evaluation of health policies. (C) 2015 American Journal of Preventive Medicine. All rights reserved. C1 [Ackermann, Ronald T.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. [Ackermann, Ronald T.] Northwestern Univ, Feinberg Sch Med, Dept Med Social Sci, Chicago, IL 60611 USA. [Duru, O. Kenrik; Mangione, Carol M.] Univ Calif Los Angeles, Div Gen Internal Med, Hlth Serv Res, Los Angeles, CA 90024 USA. [Schmittdiel, Julie A.] Kaiser Permanente No Calif, Div Res, Oakland, CA USA. [Albu, Jeanine B.] St Lukes Roosevelt Hosp, Dept Med, New York, NY USA. [Albu, Jeanine B.] St Lukes Roosevelt Hosp, New York Obes Res Ctr, New York, NY USA. [Soumerai, Stephen B.; Wharam, James F.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA USA. [Soumerai, Stephen B.; Wharam, James F.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA. [Ali, Mohammed K.] Emory Univ, Rollins Sch Publ Hlth, Hubert Dept Global Hlth, Atlanta, GA 30322 USA. [Ali, Mohammed K.; Gregg, Edward W.] CDC, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Diabet Translat, Atlanta, GA 30333 USA. RP Ackermann, RT (reprint author), Northwestern Univ, Feinberg Sch Med, 750 North Lake Shore Dr,10th Floor, Chicago, IL 60611 USA. EM r.ackermann@northwestern.edu OI French, Dustin/0000-0003-4064-3206; Ferrara, Assiamira/0000-0002-7505-4826 FU CDC; NIH/ National Institute of Diabetes and Digestive and Kidney Diseases [U58-DP002717, DP002718, DP002719, DP002721, DP002722] FX The Natural Experiments for Translation in Diabetes (NEXT-D) Study is funded jointly by CDC and the NIH/ National Institute of Diabetes and Digestive and Kidney Diseases under grant numbers U58-DP002717, DP002718, DP002719, DP002721, and DP002722. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of CDC or the NIH. NR 46 TC 8 Z9 8 U1 3 U2 7 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUN PY 2015 VL 48 IS 6 BP 747 EP 754 DI 10.1016/j.amepre.2014.12.010 PG 8 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CI5EK UT WOS:000354776000014 PM 25998925 ER PT J AU Sipe, TA Finnie, RKC Knopf, JA Qu, SL Reynolds, JA Thota, AB Hahn, RA Goetzel, RZ Hennessy, KD McKnight-Eily, LR Chapman, DP Anderson, CW Azrin, S Abraido-Lanza, AF Gelenberg, AJ Vernon-Smiley, ME Nease, DE AF Sipe, Theresa Ann Finnie, Ramona K. C. Knopf, John A. Qu, Shuli Reynolds, Jeffrey A. Thota, Anilkrishna B. Hahn, Robert A. Goetzel, Ron Z. Hennessy, Kevin D. McKnight-Eily, Lela R. Chapman, Daniel P. Anderson, Clinton W. Azrin, Susan Abraido-Lanza, Ana F. Gelenberg, Alan J. Vernon-Smiley, Mary E. Nease, Donald E., Jr. CA Community Prevent Serv Task Force TI Effects of Mental Health Benefits Legislation A Community Guide Systematic Review SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Review ID STATE PARITY LAWS; COMORBIDITY SURVEY REPLICATION; LARGE EMPLOYER GROUP; DSM-IV DISORDERS; FEDERAL-EMPLOYEES; INSURANCE PARITY; PREVENTIVE-SERVICES; MANAGED CARE; DRUG-ABUSE; COVERAGE AB Context: Health insurance benefits for mental health services typically have paid less than benefits for physical health services, resulting in potential underutilization or financial burden for people with mental health conditions. Mental health benefits legislation was introduced to improve financial protection (i.e., decrease financial burden) and to increase access to, and use of, mental health services. This systematic review was conducted to determine the effectiveness of mental health benefits legislation, including executive orders, in improving mental health. Evidence acquisition: Methods developed for the Guide to Community Preventive Services were used to identify, evaluate, and analyze available evidence. The evidence included studies published or reported from 1965 to March 2011 with at least one of the following outcomes: access to care, financial protection, appropriate utilization, quality of care, diagnosis of mental illness, morbidity and mortality, and quality of life. Analyses were conducted in 2012. Evidence synthesis: Thirty eligible studies were identified in 37 papers. Implementation of mental health benefits legislation was associated with financial protection (decreased out-of-pocket costs) and appropriate utilization of services. Among studies examining the impact of legislation strength, most found larger positive effects for comprehensive parity legislation or policies than for less-comprehensive ones. Few studies assessed other mental health outcomes. Conclusions: Evidence indicates that mental health benefits legislation, particularly comprehensive parity legislation, is effective in improving financial protection and increasing appropriate utilization of mental health services for people with mental health conditions. Evidence was limited for other mental health outcomes. Published by Elsevier Inc. on behalf of American Journal of Preventive Medicine C1 [Sipe, Theresa Ann; Finnie, Ramona K. C.; Knopf, John A.; Qu, Shuli; Reynolds, Jeffrey A.; Thota, Anilkrishna B.; Hahn, Robert A.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Community Guide Branch, Div Epidemiol Anal & Lib Serv, Atlanta, GA 30329 USA. [McKnight-Eily, Lela R.; Chapman, Daniel P.] CDC, Div Populat Hlth, Atlanta, GA 30329 USA. [Vernon-Smiley, Mary E.] CDC, Div Adolescent, Atlanta, GA 30329 USA. [Vernon-Smiley, Mary E.] CDC, Sch Hlth, Atlanta, GA 30329 USA. [Goetzel, Ron Z.] Emory Univ, Truven Hlth Analyt & Thomson Reuters, Atlanta, GA 30322 USA. [Anderson, Clinton W.] Amer Psychol Assoc, Washington, DC 20036 USA. [Hennessy, Kevin D.] Subst Abuse & Mental Hlth Serv Adm, Rockville, MD USA. [Azrin, Susan] NIMH, Bethesda, MD 20892 USA. [Abraido-Lanza, Ana F.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA. [Gelenberg, Alan J.] Penn State Hershey Med Ctr, Dept Psychiat, Hershey, PA USA. [Nease, Donald E., Jr.] Amer Acad Family Phys, Denver, CO USA. RP Sipe, TA (reprint author), CDC, Prevent Res Branch, Div HIV AIDS Prevent, 1600 Clifton Rd,Mailstop E 37, Atlanta, GA 30329 USA. EM tsipe@cdc.gov RI Nease, Donald/B-6206-2013 OI Nease, Donald/0000-0001-8323-3720 FU Oak Ridge Institute for Scientific Education (ORISE) FX The work of Ramona K.C. Finnie, John A. Knopf, Shuli Qu, Jeffrey A. Reynolds, Cristian Dumitru, Sierra Baker, Guthrie Byard, Su Su, and Elena Watzke was supported with funds from the Oak Ridge Institute for Scientific Education (ORISE). NR 79 TC 1 Z9 1 U1 3 U2 11 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUN PY 2015 VL 48 IS 6 BP 755 EP 766 DI 10.1016/j.amepre.2015.01.022 PG 12 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CI5EK UT WOS:000354776000015 PM 25998926 ER PT J AU Sipe, TA AF Sipe, Theresa Ann TI Recommendation for Mental Health Benefits Legislation Community Preventive Services Task Force SO AMERICAN JOURNAL OF PREVENTIVE MEDICINE LA English DT Editorial Material C1 CDC, Prevent Res Branch, Atlanta, GA 30329 USA. RP Sipe, TA (reprint author), CDC, Prevent Res Branch, 1600 Clifton Rd,Mailstop E-37, Atlanta, GA 30329 USA. EM tsipe@cdc.gov NR 20 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0749-3797 EI 1873-2607 J9 AM J PREV MED JI Am. J. Prev. Med. PD JUN PY 2015 VL 48 IS 6 BP 767 EP 770 DI 10.1016/j.amepre.2015.01.018 PG 4 WC Public, Environmental & Occupational Health; Medicine, General & Internal SC Public, Environmental & Occupational Health; General & Internal Medicine GA CI5EK UT WOS:000354776000016 ER PT J AU Jothikumar, N Mull, BJ Brant, SV Loker, ES Collinson, J Secor, WE Hill, VR AF Jothikumar, Narayanan Mull, Bonnie J. Brant, Sara V. Loker, Eric S. Collinson, Jeremy Secor, W. Evan Hill, Vincent R. TI Real-Time PCR and Sequencing Assays for Rapid Detection and Identification of Avian Schistosomes in Environmental Samples SO APPLIED AND ENVIRONMENTAL MICROBIOLOGY LA English DT Article ID CERCARIAL-DERMATITIS; SWIMMERS ITCH; GENUS TRICHOBILHARZIA; NORTH-AMERICA; WATER; DIVERSITY; ETIOLOGY; PARASITE; ICELAND; QUALITY AB Cercarial dermatitis, also known as swimmer's itch, is an allergenic skin reaction followed by intense itching caused by schistosome cercariae penetrating human skin. Cercarial dermatitis outbreaks occur globally and are frequently associated with freshwater lakes and are occasionally associated with marine or estuarine waters where birds reside year-round or where migratory birds reside. In this study, a broadly reactive TaqMan assay targeting 18S rRNA gene (ribosomal DNA [rDNA]) sequences that was based on a genetically diverse panel of schistosome isolates representing 13 genera and 20 species (the 18S rDNA TaqMan assay) was developed. A PCR assay was also developed to amplify a 28S rDNA region for subsequent sequencing to identify schistosomes. When applied to surface water samples seeded with Schistosoma mansoni cercariae, the 18S rDNA TaqMan assay enabled detection at a level of 5 Schistosoma mansoni cercariae in 100 liters of lake water. The 18S rDNA TaqMan and 28S rDNA PCR sequencing assays were also applied to 100-liter water samples collected from lakes in Nebraska and Wisconsin where there were reported dermatitis outbreaks. Avian schistosome DNA was detected in 11 of 34 lake water samples using the TaqMan assay. Further 28S rDNA sequence analysis of positive samples confirmed the presence of avian schistosome DNA and provided a preliminary identification of the avian schistosomes in 10 of the 11 samples. These data indicate that the broadly schistosome-reactive TaqMan assay can be effective for rapid screening of large-volume water samples for detection of avian schistosomes, thereby facilitating timely response actions to mitigate or prevent dermatitis outbreaks. Additionally, samples positive by the 18S rDNA TaqMan assay can be further assayed using the 28S rDNA sequencing assay to both confirm the presence of schistosomes and contribute to their identification. C1 [Jothikumar, Narayanan; Hill, Vincent R.] Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA 30322 USA. [Mull, Bonnie J.] Florida Dept Hlth, Food & Waterborne Dis Program, Bur Epidemiol, Tallahassee, FL USA. [Brant, Sara V.; Loker, Eric S.] Univ New Mexico, Dept Biol, COBRE Ctr Evolutionary & Theoret Immunol, Museum Southwestern Biol,Div Parasitol, Albuquerque, NM 87131 USA. [Collinson, Jeremy] Cent Dist Hlth Dept, Grand Isl, NE USA. [Secor, W. Evan] Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Ctr Global Hlth, Atlanta, GA USA. RP Jothikumar, N (reprint author), Ctr Dis Control & Prevent, Waterborne Dis Prevent Branch, Atlanta, GA 30322 USA. EM jin2@cdc.gov FU National Science Foundation grant [DEB 1021427]; NIH grant from the Institute Development Award program of the National Institute of General Medical Sciences [P30GM110907] FX This study was supported by a National Science Foundation grant to S.V.B. (DEB 1021427). Technical assistance at the University of New Mexico Molecular Biology Facility was supported by NIH grant P30GM110907 from the Institute Development Award program of the National Institute of General Medical Sciences. Specimens were provided by the Museum of Southwestern Biology, University of New Mexico. NR 31 TC 2 Z9 2 U1 0 U2 11 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0099-2240 EI 1098-5336 J9 APPL ENVIRON MICROB JI Appl. Environ. Microbiol. PD JUN PY 2015 VL 81 IS 12 BP 4207 EP 4215 DI 10.1128/AEM.00750-15 PG 9 WC Biotechnology & Applied Microbiology; Microbiology SC Biotechnology & Applied Microbiology; Microbiology GA CI6JC UT WOS:000354864000030 PM 25862226 ER PT J AU Weir, HK Thompson, TD Soman, A Moller, B Leadbetter, S AF Weir, Hannah K. Thompson, Trevor D. Soman, Ashwini Moller, Bjorn Leadbetter, Steven TI The past, present, and future of cancer incidence in the United States: 1975 through 2020 SO CANCER LA English DT Article DE cancer; cancer registries; surveillance; incidence; projections; predictions ID NORDIC COUNTRIES; PROSTATE-CANCER; LUNG-CANCER; NATION; BURDEN; TRENDS; BREAST; SURVEILLANCE; RATES; EPIDEMIOLOGY AB BACKGROUNDThe overall age-standardized cancer incidence rate continues to decline whereas the number of cases diagnosed each year increases. Predicting cancer incidence can help to anticipate future resource needs, evaluate primary prevention strategies, and inform research. METHODSSurveillance, Epidemiology, and End Results data were used to estimate the number of cancers (all sites) resulting from changes in population risk, age, and size. The authors projected to 2020 nationwide age-standardized incidence rates and cases (including the top 23 cancers). RESULTSSince 1975, incident cases increased among white individuals, primarily caused by an aging white population, and among black individuals, primarily caused by an increasing black population. Between 2010 and 2020, it is expected that overall incidence rates (proxy for risk) will decrease slightly among black men and stabilize in other groups. By 2020, the authors predict annual cancer cases (all races, all sites) to increase among men by 24.1% (-3.2% risk and 27.3% age/growth) to >1 million cases, and by 20.6% among women (1.2% risk and 19.4% age/growth) to >900,000 cases. The largest increases are expected for melanoma (white individuals); cancers of the prostate, kidney, liver, and urinary bladder in males; and the lung, breast, uterus, and thyroid in females. CONCLUSIONSOverall, the authors predict cancer incidence rates/risk to stabilize for the majority of the population; however, they expect the number of cancer cases to increase by >20%. A greater emphasis on primary prevention and early detection is needed to counter the effect of an aging and growing population on the burden of cancer. Cancer 2015;121:1827-1837. (c) 2015 American Cancer Society. Between 2010 and 2020, the cancer incidence rates/risk is predicted to stabilize for much of the US population. However, we expect the number of cancer cases to increase substantially. A greater emphasis on primary prevention and early detection is needed to counter the effect of an aging and growing population on the burden of cancer. C1 [Weir, Hannah K.; Thompson, Trevor D.; Leadbetter, Steven] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Soman, Ashwini] Northrop Grumman Corp, Atlanta, GA USA. [Moller, Bjorn] Canc Registry Norway, Dept Registrat, Oslo, Norway. RP Weir, HK (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, 4770 Buford Hwy,MS F76, Atlanta, GA 30341 USA. EM hbw4@cdc.gov FU Intramural CDC HHS [CC999999] NR 48 TC 37 Z9 37 U1 3 U2 15 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0008-543X EI 1097-0142 J9 CANCER-AM CANCER SOC JI Cancer PD JUN 1 PY 2015 VL 121 IS 11 BP 1827 EP 1837 DI 10.1002/cncr.29258 PG 11 WC Oncology SC Oncology GA CI5SO UT WOS:000354819900019 PM 25649671 ER PT J AU Scheminske, M Henninger, M Irving, SA Thompson, M Williams, J Shifflett, P Ball, SW Avalos, LA Naleway, AL AF Scheminske, Megan Henninger, Michelle Irving, Stephanie A. Thompson, Mark Williams, Jenny Shifflett, Pat Ball, Sarah W. Avalos, Lyndsay Ammon Naleway, Allison L. CA Pregnancy Influenza Project TI The Association Between Influenza Vaccination and Other Preventative Health Behaviors in a Cohort of Pregnant Women SO HEALTH EDUCATION & BEHAVIOR LA English DT Article DE alcohol use; preconception health behaviors; prenatal supplement use; seasonal influenza vaccination; smoking ID H1N1 INFLUENZA; A H1N1; UNITED-STATES; FOLIC-ACID; COVERAGE; IMMUNIZATION; CALIFORNIA; BELIEFS; SEASON; CARE AB Objectives. Although pregnant women are a high-priority group for seasonal influenza vaccination, vaccination rates in this population remain below target levels. Previous studies have identified sociodemographic predictors of vaccine choice, but relationships between preconception heath behaviors and seasonal influenza vaccination are poorly understood. This prospective cohort study followed pregnant women during the 2010-2011 influenza season to determine if certain health behaviors were associated with vaccination status. Method. Participants were pregnant women receiving prenatal care from Kaiser Permanente Northwest and Kaiser Permanente Northern California. Women were surveyed about preconception smoking, alcohol consumption, and vitamin/supplement use. Vaccination data were obtained from health plan databases and state immunization records. Results. Data from 1,204 women were included in this analysis. Most participants (1,204; 66.4%) received a seasonal influenza vaccine during the study period. Women vaccinated prior to pregnancy were more likely to use a supplement containing folic acid (80%) or vitamin D (30%) compared with women who were vaccinated during pregnancy (72% and 15%, respectively) or unvaccinated women (62% and 12%, respectively, p < .001). Women vaccinated prior to or during pregnancy were more likely (75%) to have never smoked compared with women who were not vaccinated (70%, p = .005). There were no significant differences in alcohol use or household cigarette smoke exposure by vaccination group. Conclusions. Women who engaged in specific preconception health behaviors were more likely to receive seasonal influenza vaccination. Failure to participate in these health behaviors could alert health care practitioners to patients' increased risk of remaining unvaccinated during pregnancy. C1 [Scheminske, Megan; Henninger, Michelle; Irving, Stephanie A.; Naleway, Allison L.] Kaiser Permanente Northwest, Portland, OR 97227 USA. [Thompson, Mark] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. [Williams, Jenny] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Shifflett, Pat; Ball, Sarah W.] Abt Associates Inc, Cambridge, MA USA. [Avalos, Lyndsay Ammon] Kaiser Permanente Northern Calif, Oakland, CA USA. RP Henninger, M (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 N Interstate Ave, Portland, OR 97227 USA. EM Michelle.L.Henninger@kpchr.org OI Irving, Stephanie/0000-0001-7437-6797 FU Centers for Disease Control and Prevention [200-2010-F-33132] FX The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Centers for Disease Control and Prevention (Contract 200-2010-F-33132 to Abt Associates, Inc.). NR 31 TC 4 Z9 4 U1 0 U2 2 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1090-1981 EI 1552-6127 J9 HEALTH EDUC BEHAV JI Health Educ. Behav. PD JUN PY 2015 VL 42 IS 3 BP 402 EP 408 DI 10.1177/1090198114560021 PG 7 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI8GE UT WOS:000355007600013 PM 25504630 ER PT J AU Tangka, FKL Subramanian, S Sabatino, SA Howard, DH Haber, S Hoover, S Richardson, LC AF Tangka, Florence K. L. Subramanian, Sujha Sabatino, Susan A. Howard, David H. Haber, Susan Hoover, Sonja Richardson, Lisa C. TI End-of-Life Medical Costs of Medicaid Cancer Patients SO HEALTH SERVICES RESEARCH LA English DT Article DE Econometrics; health care costs; Medicaid; chronic disease; cancer; end-of-life cost ID EARLY PALLIATIVE CARE; CELL LUNG-CANCER; LOW-INCOME-WOMEN; SOCIOECONOMIC-STATUS; PROVIDING-COVERAGE; UNITED-STATES; TREATMENT ACT; SURVIVAL; STAGE; DIAGNOSIS AB ObjectivesTo quantify end-of-life (EOL) medical costs for adult Medicaid beneficiaries diagnosed with cancer. Data SourcesWe linked Medicaid administrative data with 2000-2003 cancer registry data to identify 3,512 adult Medicaid beneficiaries who died after a cancer diagnosis and matched them to a cohort of beneficiaries without cancer who died during the same period. Study DesignWe used multivariable regression analysis to estimate incremental per-person EOL cost after controlling for beneficiaries' age, race/ethnicity, sex, cancer site, and state of residence. Principal FindingsEnd-of-life costs during the final 4months of life were about $10,000 higher for Medicaid cancer patients than for those without cancer. Medicaid cancer patients are more intensive users of inpatient and ambulatory services than are Medicaid patients without cancer. Medicaid cancer patients who die soon after diagnosis have higher costs of care and use inpatient services more intensely than do Medicaid patients without cancer. ConclusionsMedicaid cancer patients incur substantially higher EOL costs than noncancer patients. This increased cost may reflect the cost of palliative care. Future studies should assess the types and timing of services provided to Medicaid cancer patients at the EOL. C1 [Tangka, Florence K. L.; Sabatino, Susan A.; Richardson, Lisa C.] CDC, Div Canc Prevent & Control, Atlanta, GA 30341 USA. [Subramanian, Sujha; Sabatino, Susan A.; Hoover, Sonja] RTI Int, Waltham, MA USA. [Howard, David H.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. RP Tangka, FKL (reprint author), CDC, Div Canc Prevent & Control, 4770 Buford Highway NE,Mailstop F-76, Atlanta, GA 30341 USA. EM ftangka@cdc.gov FU Centers for Disease Control and Prevention [200-2002-00575] FX Joint Acknowledgment/Disclosure Statement: We thank the staff at the Georgia and Illinois cancer registries for their assistance with linking the Medicaid and cancer registry databases. This work was funded by Centers for Disease Control and Prevention Contract Number 200-2002-00575, Task Order 25. NR 47 TC 2 Z9 3 U1 3 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD JUN PY 2015 VL 50 IS 3 BP 690 EP 709 DI 10.1111/1475-6773.12259 PG 20 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CI6OA UT WOS:000354878300005 PM 25424134 ER PT J AU Leidner, AJ Chesson, HW Xu, FJ Ward, JW Spradling, PR Holmberg, SD AF Leidner, Andrew J. Chesson, Harrell W. Xu, Fujie Ward, John W. Spradling, Philip R. Holmberg, Scott D. TI Cost-effectiveness of hepatitis C treatment for patients in early stages of liver disease SO HEPATOLOGY LA English DT Article ID QUALITY-OF-LIFE; TREATMENT-NAIVE PATIENTS; VIRUS-INFECTION; UNITED-STATES; ANTIVIRAL THERAPY; VIRAL-HEPATITIS; FREE REGIMENS; IMPACT; HEALTH; COHORT AB New treatments for hepatitis C virus (HCV) may be highly effective but are associated with substantial costs that may compel clinicians and patients to consider delaying treatment. This study investigated the cost-effectiveness of these treatments with a focus on patients in early stages of liver disease. We developed a state-transition (or Markov) model to calculate costs incurred and quality-adjusted life-years (QALYs) gained following HCV treatment, and we computed incremental cost-effectiveness ratios (cost per QALY gained, in 2012 US dollars) for treatment at different stages of liver disease versus delaying treatment until the subsequent liver disease stage. Our analysis did not include the potential treatment benefits associated with reduced non-liver-related mortality or preventing HCV transmission. All parameter values, particularly treatment cost, were varied in sensitivity analyses. The base case scenario represented a 55-year-old patient with genotype 1 HCV infection with a treatment cost of $100,000 and treatment effectiveness of 90%. In this scenario, for a 55-year-old patient with moderate liver fibrosis (Metavir stage F2), the cost-effectiveness of immediately initiating treatment at F2 (versus delaying treatment until F3) was $37,300/QALY. For patients immediately treated at F0 (versus delaying treatment until F1), the threshold of treatment costs that yielded $50,000/QALY and $100,000/QALY cost-effectiveness ratios were $22,200 and $42,400, respectively. Conclusion: Immediate treatment of HCV-infected patients with moderate and advanced fibrosis appears to be cost-effective, and immediate treatment of patients with minimal or no fibrosis can be cost-effective as well, particularly when lower treatment costs are assumed. (Hepatology 2015;61:1860-1869) C1 [Leidner, Andrew J.; Xu, Fujie; Ward, John W.; Spradling, Philip R.; Holmberg, Scott D.] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Chesson, Harrell W.] Ctr Dis Control & Prevent, Div Sexually Transmitted Dis Prevent, Atlanta, GA 30333 USA. RP Leidner, AJ (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, 1600 Clifton Rd,Mailstop G-37, Atlanta, GA 30333 USA. EM aleidner@cdc.gov FU Centers for Disease Control Foundation; AbbVie; Abbott Laboratories; Genetech, a Member of the Roche Group; Janssen Pharmaceutical Companies of Johnson Johnson; Vertex Pharmaceuticals FX The Chronic Hepatitis Cohort Study is funded by the Centers for Disease Control Foundation, which received grants from AbbVie; Abbott Laboratories; Genetech, a Member of the Roche Group; Janssen Pharmaceutical Companies of Johnson & Johnson; and Vertex Pharmaceuticals. Granting corporations do not have access to study data and do not contribute to data analysis or the writing of manuscripts. NR 45 TC 34 Z9 36 U1 5 U2 14 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-9139 EI 1527-3350 J9 HEPATOLOGY JI Hepatology PD JUN PY 2015 VL 61 IS 6 BP 1860 EP 1869 DI 10.1002/hep.27736 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA CI5UG UT WOS:000354824700014 PM 25677072 ER PT J AU Wendorf, KA Kay, M Baliga, C Weissman, SJ Gluck, M Verma, P D'Angeli, M Swoveland, J Kang, MG Eckmann, K Ross, AS Duchin, J AF Wendorf, Kristen A. Kay, Meagan Baliga, Christopher Weissman, Scott J. Gluck, Michael Verma, Punam D'Angeli, Marisa Swoveland, Jennifer Kang, Mi-Gyeong Eckmann, Kaye Ross, Andrew S. Duchin, Jeffrey TI Endoscopic Retrograde Cholangiopancreatography-Associated AmpC Escherichia coli Outbreak SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; INTENSIVE-CARE-UNIT; PSEUDOMONAS-AERUGINOSA; BETA-LACTAMASE; HEALTH-CARE; NOSOCOMIAL INFECTIONS; COMPLICATIONS; DUODENOSCOPES; CONTAMINATION; EPIDEMIOLOGY AB BACKGROUND. We identified an outbreak of AmpC-producing Escherichia coli infections resistant to third-generation cephalosporins and carbapenems (CR) among 7 patients who had undergone endoscopic retrograde cholangiopancreatography at hospital A during November 2012-August 2013. Gene sequencing revealed a shared novel mutation in a bla(CMY) gene and a distinctive fumC/fimH typing profile. OBJECTIVE. To determine the extent and epidemiologic characteristics of the outbreak, identify potential sources of transmission, design and implement infection control measures, and determine the association between the CR E. coli and AmpC E. coli circulating at hospital A. METHODS. We reviewed laboratory, medical, and endoscopy reports, and endoscope reprocessing procedures. We obtained cultures from endoscopes after reprocessing as well as environmental samples and conducted pulsed-field gel electrophoresis and gene sequencing on phenotypic AmpC isolates from patients and endoscopes. Cases were those infected with phenotypic AmpC isolates (both carbapenemsusceptible and CR) and identical bla(CMY-2), fumC, and fimH alleles or related pulsed-field gel electrophoresis patterns. RESULTS. Thirty-five of 49 AmpC E. coli tested met the case definition, including all CR isolates. All cases had complicated biliary disease and had undergone at least 1 endoscopic retrograde cholangiopancreatography at hospital A. Mortality at 30 days was 16% for all patients and 56% for CR patients. Two of 8 reprocessed endoscopic retrograde cholangiopancreatography scopes harbored AmpC that matched case isolates by pulsed-field gel electrophoresis. Environmental cultures were negative. No breaches in infection control were identified. Endoscopic reprocessing exceeded manufacturer's recommended cleaning guidelines. CONCLUSION. Recommended reprocessing guidelines are not sufficient. C1 [Wendorf, Kristen A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Wendorf, Kristen A.; Kay, Meagan; Duchin, Jeffrey] Publ Hlth Seattle & King Cty, Div Communicable Dis & Immunizat, Seattle, WA 98104 USA. [Baliga, Christopher] Virginia Mason Med Ctr, Infect Dis & Infect Control, Seattle, WA 98101 USA. [Weissman, Scott J.] Seattle Childrens Res Inst, Ctr Global Infect Dis Res, Seattle, WA USA. [Gluck, Michael; Ross, Andrew S.] Virginia Mason Med Ctr, Dept Gastroenterol, Seattle, WA 98101 USA. [Verma, Punam] Virginia Mason Med Ctr, Dept Microbiol, Seattle, WA 98101 USA. [D'Angeli, Marisa; Swoveland, Jennifer; Kang, Mi-Gyeong; Eckmann, Kaye] Washington State Dept Hlth, Shoreline, WA USA. [Duchin, Jeffrey] Univ Washington, Seattle, WA 98195 USA. RP Wendorf, KA (reprint author), Publ Hlth Seattle & King Cty, Div Communicable Dis & Immunizat, 401 5th Ave,9th Fl, Seattle, WA 98104 USA. EM xea0@cdc.gov FU Virginia Mason Medical Center FX Investigative work was performed by Public Health-Seattle and King County and PFGE was performed by Washington State Department of Health. Virginia Mason Medical Center paid for the laboratory testing and materials used in the hospital during the investigation. NR 36 TC 31 Z9 33 U1 1 U2 5 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2015 VL 36 IS 6 BP 634 EP 642 DI 10.1017/ice.2015.66 PG 9 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CI7XZ UT WOS:000354981400004 PM 25817743 ER PT J AU Slayton, RB Scott, RD Baggs, J Lessa, FC McDonald, LC Jernigan, JA AF Slayton, Rachel B. Scott, R. Douglas, II Baggs, James Lessa, Fernanda C. McDonald, L. Clifford Jernigan, John A. TI The Cost-Benefit of Federal Investment in Preventing Clostridium difficile Infections through the Use of a Multifaceted Infection Control and Antimicrobial Stewardship Program SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID HEALTH-CARE EPIDEMIOLOGY; DISEASES SOCIETY; AMERICA IDSA; IMPACT; BURDEN; SHEA AB OBJECTIVE. To determine the potential epidemiologic and economic value of the implementation of a multifaceted Clostridium difficile infection (CDI) control program at US acute care hospitals DESIGN. Markov model with a 5-year time horizon PARTICIPANTS. Patients whose data were used in our simulations were limited to hospitalized Medicare beneficiaries >= 65 years old. BACKGROUND. CDI is an important public health problem with substantial associated morbidity, mortality, and cost. Multifaceted national prevention efforts in the United Kingdom, including antimicrobial stewardship, patient isolation, hand hygiene, environmental cleaning and disinfection, and audit, resulted in a 59% reduction in CDI cases reported from 2008 to 2012. METHODS. Our analysis was conducted from the federal perspective. The intervention we modeled included the following components: antimicrobial stewardship utilizing the Antimicrobial Use and Resistance module of the National Healthcare Safety Network (NHSN), use of contact precautions, and enhanced environmental cleaning. We parameterized our model using data from CDC surveillance systems, the AHRQ Healthcare Cost and Utilization Project, and literature reviews. To address uncertainty in our parameter estimates, we conducted sensitivity analyses for intervention effectiveness and cost, expenditures by other federal partners, and discount rate. Each simulation represented a cohort of 1,000 hospitalized patients over 1,000 trials. RESULTS. In our base case scenario with 50% intervention effectiveness, we estimated that 509,000 CDI cases and 82,000 CDI-attributable deaths would be prevented over a 5-year time horizon. Nationally, the cost savings across all hospitalizations would be $2.5 billion (95% credible interval: $1.2 billion to $4.0 billion). CONCLUSIONS. The potential benefits of a multifaceted national CDI prevention program are sizeable from the federal perspective. C1 [Slayton, Rachel B.; Scott, R. Douglas, II; Baggs, James; Lessa, Fernanda C.; McDonald, L. Clifford; Jernigan, John A.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA USA. RP Slayton, RB (reprint author), US Ctr Dis Control & Prevent, 1600 Clifton Rd,MS A-31, Atlanta, GA 30333 USA. EM via3@cdc.gov NR 31 TC 5 Z9 6 U1 2 U2 7 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2015 VL 36 IS 6 BP 681 EP 687 DI 10.1017/ice.2015.43 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CI7XZ UT WOS:000354981400011 PM 25783204 ER PT J AU Tabak, YP Johannes, RS Sun, XW Nunez, CM McDonald, LC AF Tabak, Ying P. Johannes, Richard S. Sun, Xiaowu Nunez, Carlos M. McDonald, L. Clifford TI Predicting the Risk for Hospital-Onset Clostridium difficile Infection (HO-CDI) at the Time of Inpatient Admission: HO-CDI Risk Score SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID AUTOMATED CLINICAL-DATA; VALIDATION; DISEASE; ADJUSTMENT; BURDEN; MODEL AB OBJECTIVE. To predict the likelihood of hospital-onset Clostridium difficile infection (HO-CDI) based on patient clinical presentations at admission DESIGN. Retrospective data analysis SETTING. Six US acute care hospitals PATIENTS. Adult inpatients METHODS. We used clinical data collected at the time of admission in electronic health record (EHR) systems to develop and validate a HO-CDI predictive model. The outcome measure was HO-CDI cases identified by a nonduplicate positive C. difficile toxin assay result with stool specimens collected >48 hours after inpatient admission. We fit a logistic regression model to predict the risk of HO-CDI. We validated the model using 1,000 bootstrap simulations. RESULTS. Among 78,080 adult admissions, 323 HO-CDI cases were identified (ie, a rate of 4.1 per 1,000 admissions). The logistic regression model yielded 14 independent predictors, including hospital community onset CDI pressure, patient age <= 65, previous healthcare exposures, CDI in previous admission, admission to the intensive care unit, albumin <= 3 g/dL, creatinine >2.0 mg/dL, bands >32%, platelets <= 150 or > 420 109/L, and white blood cell count >11,000 mm(3). The model had a c-statistic of 0.78 (95% confidence interval [CI], 0.76-0.81) with good calibration. Among 79% of patients with risk scores of 0-7, 19 HO-CDIs occurred per 10,000 admissions; for patients with risk scores > 20, 623 HO-CDIs occurred per 10,000 admissions (P<.0001). CONCLUSION. Using clinical parameters available at the time of admission, this HO-CDI model demonstrated good predictive ability, and it may have utility as an early risk identification tool for HO-CDI preventive interventions and outcome comparisons. C1 [Tabak, Ying P.; Johannes, Richard S.; Sun, Xiaowu; Nunez, Carlos M.] CareFusion, Clin Operat, Clin Res, San Diego, CA USA. [Johannes, Richard S.] Harvard Univ, Sch Med, Div Gastroenterol, Cambridge, MA 02138 USA. [Johannes, Richard S.] Brigham & Womens Hosp, Boston, MA 02115 USA. [Nunez, Carlos M.] San Diego State Univ, Biomed Informat Res Ctr, San Diego, CA 92182 USA. [McDonald, L. Clifford] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP McDonald, LC (reprint author), Ctr Dis Control & Prevent, Sci & Integr, Div Healthcare Qual Promot, Atlanta, GA 30341 USA. EM cmcdonald1@cdc.gov NR 20 TC 5 Z9 5 U1 1 U2 1 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD JUN PY 2015 VL 36 IS 6 BP 695 EP 701 DI 10.1017/ice.2015.37 PG 7 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA CI7XZ UT WOS:000354981400013 PM 25753106 ER PT J AU Butchart, A Mikton, C Dahlberg, LL Krug, EG AF Butchart, Alexander Mikton, Christopher Dahlberg, Linda L. Krug, Etienne G. TI Global status report on violence prevention 2014 SO INJURY PREVENTION LA English DT Editorial Material C1 [Butchart, Alexander; Mikton, Christopher; Krug, Etienne G.] WHO, Management Noncommunicable Dis Disabil Violence &, CH-1211 Geneva, Switzerland. [Dahlberg, Linda L.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. RP Butchart, A (reprint author), WHO, Management Noncommunicable Dis Disabil Violence &, CH-1211 Geneva, Switzerland. FU World Health Organization [001] NR 6 TC 0 Z9 0 U1 0 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1353-8047 EI 1475-5785 J9 INJURY PREV JI Inj. Prev. PD JUN PY 2015 VL 21 IS 3 BP 213 EP 213 DI 10.1136/injuryprev-2015-041640 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI6KJ UT WOS:000354867600012 PM 25995201 ER PT J AU Moore, BK Anyalechi, E van der Wait, M Smith, S Erasmus, L Lancaster, J Morris, S Ndjeka, N Ershova, J Ismail, N Burton, D Menzies, H AF Moore, B. K. Anyalechi, E. van der Wait, M. Smith, S. Erasmus, L. Lancaster, J. Morris, S. Ndjeka, N. Ershova, J. Ismail, N. Burton, D. Menzies, H. TI Epidemiology of drug-resistant tuberculosis among children and adolescents in South Africa, 2005-2010 SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE South Africa; drug resistance; pediatric; cohort review; Mycobacterium tuberculosis ID TREATMENT OUTCOMES; CHILDHOOD TUBERCULOSIS; CLINICAL-FEATURES; CAPE-TOWN; METAANALYSIS; CHALLENGES AB OBJECTIVE: To describe the demographic and clinical characteristics of children and adolescents diagnosed with resistance to any anti-tuberculosis drug (drug-resistant tuberculosis; DR-TB) in South Africa. DESIGN: We retrospectively reviewed medical records of all children (<13 years) and adolescents (13 to <18 years) with DR-TB at specialty hospitals in four South African provinces from 2005 to 2010. RESULTS: During the review period, 774 children and adolescents (median age 11.3 years) were diagnosed with DR-TB at selected facilities. A high proportion of patients had a history of previous TB treatment (285/631; 45.2%), human immunodeficiency virus (HIV) infection (375/685; 54.7%), contact with a TB case (347/454; 76.4%), and smear-positive (443/729; 60.8%), cavitary (253/680, 38.7%) disease. Eighty-two per cent of patients with HIV infection received antiretroviral therapy. Of 626 patients diagnosed with multidrug-resistant TB (MDR-TB), 561 (89.6%) received a regimen consistent with national guidelines; the median length of treatment was 22 months (IQR 16-25). Among 400 patients with any DR-TB and a known outcome, 20.3% died during treatment. CONCLUSION: Pediatric DR-113 in these provinces is characterized by complex clinical features at diagnosis, with one in five children dying during treatment. History of previous treatment and contact with a TB patient indicate opportunities for earlier diagnosis and treatment to improve outcomes. C1 [Moore, B. K.; Anyalechi, E.; Smith, S.; Morris, S.; Ershova, J.; Burton, D.; Menzies, H.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [van der Wait, M.; Lancaster, J.] South African Med Res Council, Cape Town, South Africa. [Erasmus, L.; Ismail, N.] Natl Inst Communicable Dis, Natl Hlth Lab Serv, Johannesburg, South Africa. [Ndjeka, N.] South Africa Natl Dept Hlth, Pretoria, South Africa. [Ismail, N.] Univ Pretoria, ZA-0002 Pretoria, South Africa. RP Moore, BK (reprint author), Ctr Dis Control & Prevent, MS-E99,1600 Clifton Rd, Atlanta, GA 30329 USA. EM bkmoore@cdc.gov FU US Agency for International Development; US Centers for Disease Control and Prevention (CDC); South Africa National Institute for Communicable Diseases; South African Medical Research Council FX This evaluation was supported with funding provided by the US Agency for International Development and the US Centers for Disease Control and Prevention (CDC), with additional support from the South Africa National Institute for Communicable Diseases and the South African Medical Research Council. The project team would like to thank the South African National Department of Health, participating Provincial Departments of Health, institutions, hospitals, clinics, staff, and students who assisted with the project design and data collection. We are particularly grateful to HS Schaaf for sharing his insights on the evaluation design, WAMTechnology CC (Stellenbosch, South Africa) for technical assistance with EDRWeb and ETR, and the tireless staff of the South African Medical Research Council (especially R Odendaal, S Masuku, J Kirsten, and L Olivier). NR 29 TC 6 Z9 6 U1 0 U2 4 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD JUN PY 2015 VL 19 IS 6 BP 663 EP 669 DI 10.5588/ijtld.14.0879 PG 7 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CI4WZ UT WOS:000354755900010 PM 25946356 ER PT J AU Musau, S McCarthy, K Okumu, A Shinnick, T Wandiga, S Williamson, J Cain, K AF Musau, S. McCarthy, K. Okumu, A. Shinnick, T. Wandiga, S. Williamson, J. Cain, K. TI Experience in implementing a quality management system in a tuberculosis laboratory, Kisumu, Kenya SO INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE LA English DT Article DE accreditation; ISO 15189; tuberculosis; laboratory; quality ID ACCREDITATION AB We implemented a quality management system (QMS) and documented our improvements in a tuberculosis (TB) laboratory in Kisumu, Kenya. After implementation of the QMS, a sustained reduction in culture contamination rates for solid (from 15.4% to 5.3%) and liquid media (from 15.2% to 9.3%) was observed, and waste from product expiry was reduced significantly. External quality assurance (EQA) results were satisfactory before and after QMS implementation, and a client survey after implementation revealed 98% satisfaction. The laboratory attained ISO 15189 accreditation in October 2013. The implementation of QMS facilitated the attainment of target quality indicators, reduced waste due to expiry and led to high client satisfaction. C1 [Musau, S.; Okumu, A.; Wandiga, S.] Kenya Med Res Inst KEMRI, Ctr Global Hlth Res, Kisumu, Kenya. [McCarthy, K.; Shinnick, T.; Williamson, J.; Cain, K.] US Ctr Dis Control & Prevent CDC, Div TB Eliminat, Atlanta, GA USA. [Cain, K.] CDC, Kisumu, Kenya. RP Musau, S (reprint author), KEMRI CDC, POB 1578, Kisumu 40100, Kenya. EM smusau@kemricdc.org FU TB branch management; United States Agency for International Development; Centers for Disease Control and Prevention FX The authors thank the Director of the Kenya Medical Research Institute Centre for Global Health Research, the tuberculosis laboratory team for their efforts and input in the implementation of the quality management system, and TB branch management and the United States Agency for International Development and the Centers for Disease Control and Prevention for providing the funding needed to help the laboratory gain accreditation. NR 9 TC 0 Z9 0 U1 0 U2 1 PU INT UNION AGAINST TUBERCULOSIS LUNG DISEASE (I U A T L D) PI PARIS PA 68 BOULEVARD SAINT-MICHEL,, 75006 PARIS, FRANCE SN 1027-3719 EI 1815-7920 J9 INT J TUBERC LUNG D JI Int. J. Tuberc. Lung Dis. PD JUN PY 2015 VL 19 IS 6 BP 693 EP 695 DI 10.5588/ijtld.14.0886 PG 3 WC Infectious Diseases; Respiratory System SC Infectious Diseases; Respiratory System GA CI4WZ UT WOS:000354755900015 PM 25946361 ER PT J AU Reidy, DE Smith-Darden, JP Cortina, KS Kernsmith, RM Kernsmith, PD AF Reidy, Dennis E. Smith-Darden, Joanne P. Cortina, Kai S. Kernsmith, Roger M. Kernsmith, Poco D. TI Masculine Discrepancy Stress, Teen Dating Violence, and Sexual Violence Perpetration Among Adolescent Boys SO JOURNAL OF ADOLESCENT HEALTH LA English DT Article DE Gender role stress; Discrepancy stress; Masculinity; Teen dating violence; Intimate partner violence ID INTIMATE PARTNER VIOLENCE; HEALTH; MEN; CONSEQUENCES; BEHAVIOR; SAMPLE; NORMS; WOMEN; RISK; AGE AB Purpose: Addressing gender norms is integral to understanding and ultimately preventing violence in both adolescent and adult intimate relationships. Males are affected by gender role expectations which require them to demonstrate attributes of strength, toughness, and dominance. Discrepancy stress is a form of gender role stress that occurs when boys and men fail to live up to the traditional gender norms set by society. Failure to live up to these gender role expectations may precipitate this experience of psychological distress in some males which, in turn, may increase the risk to engage in physically and sexually violent behaviors as a means of demonstrating masculinity. Methods: Five-hundred eighty-nine adolescent males from schools in Wayne County, Michigan completed a survey assessing self-perceptions of gender role discrepancy, the experience of discrepancy stress, and history of physical and sexual dating violence. Results: Logistic regression analyses indicated boys who endorsed gender role discrepancy and associated discrepancy stress were generally at greater risk to engage in acts of sexual violence but not necessarily physical violence. Conclusions: Boys who experience stress about being perceived as "sub-masculine" may be more likely to engage in sexual violence as a means of demonstrating their masculinity to self and/or others and thwarting potential "threats" to their masculinity by dating partners. Efforts to prevent sexual violence perpetration among male adolescents should perhaps consider the influence of gender socialization in this population and include efforts to reduce distress about masculine socialization in primary prevention strategies. Published by Elsevier Inc. on behalf of Society for Adolescent Health and Medicine. C1 [Reidy, Dennis E.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. [Smith-Darden, Joanne P.; Kernsmith, Poco D.] Wayne State Univ, Sch Social Work, Detroit, MI USA. [Cortina, Kai S.] Univ Michigan, Dept Psychol, Ann Arbor, MI USA. [Kernsmith, Roger M.] Eastern Michigan Univ, Dept Sociol Anthropol & Criminol, Ypsilanti, MI 48197 USA. RP Reidy, DE (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. EM dreidy@cdc.gov OI Kernsmith, Poco/0000-0002-5308-8566 FU Centers for Disease Control and Prevention [1U01CE002115-01] FX This work was funded by the Centers for Disease Control and Prevention, grant 1U01CE002115-01. NR 37 TC 4 Z9 4 U1 7 U2 23 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1054-139X EI 1879-1972 J9 J ADOLESCENT HEALTH JI J. Adolesc. Health PD JUN PY 2015 VL 56 IS 6 BP 619 EP 624 DI 10.1016/j.jadohealth.2015.02.009 PG 6 WC Psychology, Developmental; Public, Environmental & Occupational Health; Pediatrics SC Psychology; Public, Environmental & Occupational Health; Pediatrics GA CI6KK UT WOS:000354867700008 PM 26003576 ER PT J AU Barr, LK Sharer, LR Kunwar, EK Kapila, R Zaki, SR Drew, CP Bhatnagar, J Liu, JK Chew, D AF Barr, Luke K. Sharer, Leroy R. Kunwar, Erina Khadka Kapila, Rajendra Zaki, Sherif R. Drew, Clifton P. Bhatnagar, Julu Liu, James K. Chew, Debra TI Intraventricular granulomatous mass associated with Mycobacterium haemophilum: A rare central nervous system manifestation in a patient with human immunodeficiency virus infection SO JOURNAL OF CLINICAL NEUROSCIENCE LA English DT Article DE Central nervous system infection; Granuloma; HIV; Hydrocephalus; Intraventricular mass; Mycobacterium haemophilum AB We report a rare case of Mycobacterium haemophilum presenting as an intraventricular granulomatous mass with loculated hydrocephalus and seizures in a patient with human immunodeficiency virus. M. haemophilum, a slow-growing mycobacteria, causes localized and disseminated disease among immunocompromised hosts. Central nervous system infection with M. haemophilum is extremely rare. Preoperative laboratory testing of our patient for tuberculosis, toxoplasmosis, sarcoidosis and histoplasmosis were negative. Surgical resection of the mass revealed a caseating granuloma that stained positive for acid-fast bacillus suggesting possible tuberculoma. Despite negative testing for tuberculosis, a polymerase chain reaction analysis was ultimately performed from the resected mass which revealed M. haemophilum. To our knowledge, this is the first case of M. haemophilum presenting as an intraventricular mass. We review the clinical manifestations of this pathogen and discuss the medical and surgical management. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Barr, Luke K.; Liu, James K.] Rutgers New Jersey Med Sch, Dept Neurol Surg, Newark, NJ 07103 USA. [Sharer, Leroy R.] Rutgers New Jersey Med Sch, Dept Pathol & Lab Med, Newark, NJ 07103 USA. [Kunwar, Erina Khadka; Kapila, Rajendra; Chew, Debra] Rutgers New Jersey Med Sch, Div Infect Dis, Newark, NJ 07103 USA. [Zaki, Sherif R.; Drew, Clifton P.; Bhatnagar, Julu] Ctr Dis Control & Prevent, Infect Dis Pathol Branch, Atlanta, GA USA. RP Liu, JK (reprint author), Rutgers New Jersey Med Sch, Dept Neurol Surg, Suite 8100,90 Bergen St, Newark, NJ 07103 USA. EM james.liu.md@rutgers.edu NR 17 TC 2 Z9 2 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0967-5868 EI 1532-2653 J9 J CLIN NEUROSCI JI J. Clin. Neurosci. PD JUN PY 2015 VL 22 IS 6 BP 1057 EP 1060 DI 10.1016/j.jocn.2014.11.036 PG 4 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CI8VR UT WOS:000355050300030 PM 25818941 ER PT J AU Gounder, PP Harris, TG Anger, H Trieu, L Meissner, JS Cadwell, BL Shashkina, E Ahuja, SD AF Gounder, Prabhu P. Harris, Tiffany G. Anger, Holly Trieu, Lisa Meissner, Jeanne Sullivan Cadwell, Betsy L. Shashkina, Elena Ahuja, Shama D. TI Risk for Tuberculosis Disease Among Contacts with Prior Positive Tuberculin Skin Test: A retrospective Cohort Study, New York City SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE contact tracing; tuberculosis infection; prevention and control; epidemiology ID MYCOBACTERIUM-TUBERCULOSIS; PATTERN AB Patients with prior positive tuberculin skin test (TST) results may benefit from prophylaxis after repeat exposure to infectious tuberculosis (TB). To evaluate factors associated with active TB disease among persons with prior positive TST results named as contacts of persons with infectious TB. Population-based retrospective cohort study. A total of 2,933 contacts with prior positive TST results recently exposed to infectious TB identified in New York City's TB registry during the period from January 1, 1997 through December 31, 2003. Contacts developing active TB disease a parts per thousand currency sign 4 years after exposure were identified and compared with those who did not, using Poisson regression analysis. Genotyping was performed on selected Mycobacterium tuberculosis-positive isolates. Among contacts with prior positive TST results, 39 (1.3 %) developed active TB disease a parts per thousand currency sign 4 years after exposure (a parts per thousand currency sign2 years: 34). Risk factors for contacts that were independently associated with TB were age < 5 years (adjusted prevalence ratio [aPR] = 19.48; 95 % confidence interval [CI] = 7.15-53.09), household exposure (aPR = 2.60;CI = 1.30-5.21), exposure to infectious patients (i.e., cavities on chest radiograph, acid-fast bacilli on sputum smear; aPR = 1.9 3;CI = 1.01-3.71), and exposure to a U.S.-born index patient (aPR = 4.04; CI = 1.95-8.38). Receipt of more than1 month of treatment for latent TB infection following the current contact investigation was found to be protective (aPR = 0.27; CI = 0.08-0.93). Genotype results were concordant with the index patients among 14 of 15 contacts who developed active TB disease and had genotyping results available. Concordant genotype results and a high proportion of contacts developing active TB disease within 2 years of exposure indicate that those with prior positive TST results likely developed active TB disease from recent rather than remote infection. Healthcare providers should consider prophylaxis for contacts with prior TB infection, especially young children and close contacts of TB patients (e.g., those with household exposure). C1 [Gounder, Prabhu P.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Gounder, Prabhu P.; Cadwell, Betsy L.] Ctr Dis Control & Prevent, Sci Educ & Profess Dev Program Off, Atlanta, GA USA. [Harris, Tiffany G.; Anger, Holly; Trieu, Lisa; Meissner, Jeanne Sullivan; Ahuja, Shama D.] New York City Dept Hlth & Mental Hyg, Bur TB Control, Long Isl City, NY 11101 USA. [Shashkina, Elena] Rutgers State Univ, Publ Hlth Res Inst, Newark, NJ 07102 USA. RP Ahuja, SD (reprint author), New York City Dept Hlth & Mental Hyg, Bur TB Control, 42-09 28th St,21st Floor,CN72-B, Long Isl City, NY 11101 USA. EM sahuja@health.nyc.gov FU New York City Department of Health and Mental Hygiene, the Bureau of Tuberculosis Control program funds FX This work was supported by the New York City Department of Health and Mental Hygiene, the Bureau of Tuberculosis Control program funds, and in-kind personnel support from the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors, and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 16 TC 0 Z9 0 U1 1 U2 5 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD JUN PY 2015 VL 30 IS 6 BP 742 EP 748 DI 10.1007/s11606-015-3180-2 PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA CI7RE UT WOS:000354961100012 PM 25605533 ER PT J AU Parkman, AA Foland, J Anderson, B Duquette, D Sobotka, H Lynn, M Nottingham, S Dotson, WD Kolor, K Cox, SL AF Parkman, Alicia A. Foland, Joan Anderson, Beth Duquette, Debra Sobotka, Holly Lynn, Mary Nottingham, Shelley Dotson, William David Kolor, Katherine Cox, Summer L. TI Public Awareness of Genetic Nondiscrimination Laws in Four States and Perceived Importance of Life Insurance Protections SO JOURNAL OF GENETIC COUNSELING LA English DT Article DE GINA; Genetic discrimination; Genetic privacy; Insurance; Regulation ID HEREDITARY BREAST; DISCRIMINATION; INFORMATION; ACT; PERSPECTIVES; KNOWLEDGE; IMPACT AB Genetic testing has grown dramatically in the past decade and is becoming an integral part of health care. Genetic nondiscrimination laws have been passed in many states, and the Genetic Information Nondiscrimination Act (GINA) was passed at the federal level in 2008. These laws generally protect individuals from discrimination by health insurers or employers based on genetic information, including test results. In 2010, Connecticut, Michigan, Ohio, and Oregon added four questions to their Behavioral Risk Factor Surveillance System (BRFSS) survey to assess interest in genetic testing, awareness of genetic nondiscrimination laws, concern about genetic discrimination in determining life insurance eligibility and cost, and perceived importance of genetic nondiscrimination laws that address life insurance. Survey results showed that awareness of genetic nondiscrimination laws was low (less than 20 % of the adult population), while perceived importance of these types of laws was high (over 80 % of respondents rated them as very or somewhat important). Over two-thirds of respondents indicated they were very or somewhat concerned about life insurance companies using genetic test results to determine life insurance coverage and costs. Results indicate a need for more public education to raise awareness of protections provided through current genetic nondiscrimination laws. The high rate of concern about life insurance discrimination indicates an additional need for continued dialogue regarding the extent of legal protections in genetic nondiscrimination laws. C1 [Parkman, Alicia A.; Cox, Summer L.] Oregon Publ Hlth Div, Genet Program, Portland, OR 97232 USA. [Foland, Joan] Connecticut Dept Publ Hlth, Genom Off, Hartford, CT USA. [Anderson, Beth; Duquette, Debra] Michigan Dept Community Hlth, Canc Genom, Lansing, MI USA. [Sobotka, Holly] Ohio Dept Hlth, Chron Dis & Behav Epidemiol Program, Columbus, OH 43266 USA. [Lynn, Mary] Ohio Dept Hlth, Comprehens Canc Control Program, Columbus, OH 43266 USA. [Nottingham, Shelley] Ohio Dept Hlth, Genet Program, Columbus, OH 43266 USA. [Dotson, William David; Kolor, Katherine] Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA. RP Parkman, AA (reprint author), Oregon Publ Hlth Div, Genet Program, 800 NE Oregon St,Ste 370, Portland, OR 97232 USA. EM alicia.a.parkman@state.or.us OI Dotson, William David/0000-0002-9606-6594 FU Centers for Disease Control and Prevention, Office of Public Health Genomics FX This work was supported in part by the Centers for Disease Control and Prevention, Office of Public Health Genomics, which assisted with the creation of survey questions and provided financial assistance necessary for the questions to be added to the state surveys. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funding agencies. NR 25 TC 8 Z9 8 U1 0 U2 7 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1059-7700 EI 1573-3599 J9 J GENET COUNS JI J. Genet. Couns. PD JUN PY 2015 VL 24 IS 3 BP 512 EP 521 DI 10.1007/s10897-014-9771-y PG 10 WC Genetics & Heredity SC Genetics & Heredity GA CI3FR UT WOS:000354633500016 PM 25242499 ER PT J AU Visser, SN Bitsko, RH Danielson, ML Ghandour, RM Blumberg, SJ Schieve, LA Holbrook, JR Wolraich, ML Cuffe, SP AF Visser, Susanna N. Bitsko, Rebecca H. Danielson, Melissa L. Ghandour, Reem M. Blumberg, Stephen J. Schieve, Laura A. Holbrook, Joseph R. Wolraich, Mark L. Cuffe, Steven P. TI Treatment of Attention Deficit/Hyperactivity Disorder among Children with Special Health Care Needs SO JOURNAL OF PEDIATRICS LA English DT Article ID MEDICATION USE; PREVALENCE; TRENDS; ADHD; PERSPECTIVE AB Objectives To describe the parent-reported prevalence of treatments for attention deficit/hyperactivity disorder (ADHD) among a national sample of children with special health care needs (CSHCN), and assess the alignment of ADHD treatment with current American Academy of Pediatrics guidelines. Study design Parent-reported data from the 2009-2010 National Survey of Children with Special Health Care Needs allowed for weighted national and state-based prevalence estimates of medication, behavioral therapy, and dietary supplement use for ADHD treatment among CSHCN aged 4-17 years with current ADHD. National estimates were compared across demographic groups, ADHD severity, and comorbidities. Medication treatment by drug class was described. Results Of CSHCN with current ADHD, 74.0% had received medication treatment in the past week, 44.0% had received behavioral therapy in the past year, and 10.2% used dietary supplements for ADHD in the past year. Overall, 87.3% had received past week medication treatment or past year behavioral therapy (both, 30.7%; neither, 12.7%). Among preschool-aged CSHCN with ADHD, 25.4% received medication treatment alone, 31.9% received behavioral therapy alone, 21.2% received both treatments, and 21.4% received neither treatment. Central nervous system stimulants were the most common medication class (84.8%) among CSHCN with ADHD, followed by the selective norepinephrine reuptake inhibitor atomoxetine (8.4%). Conclusion These estimates provide a benchmark of clinical practice for the period directly preceding issuance of the American Academy of Pediatrics' 2011 ADHD guidelines. Most children with ADHD received medication treatment or behavioral therapy; just under one-third received both. Multimodal treatment was most common for CSHCN with severe ADHD and those with comorbidities. Approximately one-half of preschoolers received behavioral therapy, the recommended first-line treatment for this age group. C1 [Visser, Susanna N.; Bitsko, Rebecca H.; Danielson, Melissa L.; Schieve, Laura A.; Holbrook, Joseph R.] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Ghandour, Reem M.] US Hlth Resources & Serv Adm, Maternal & Child Hlth Bur, Rockville, MD 20857 USA. [Blumberg, Stephen J.] Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Wolraich, Mark L.] Univ Oklahoma, Ctr Child Study, Oklahoma City, OK USA. [Cuffe, Steven P.] Univ Florida, Coll Med, Dept Psychiat, Jacksonville, FL USA. RP Visser, SN (reprint author), E-88,1600 Clifton Rd, Atlanta, GA 30333 USA. EM svisser@cdc.gov OI Danielson, Melissa/0000-0001-9461-0341 FU Nextstim Oy FX S.C. receives support for research on navigated transcranial magnetic stimulation from Nextstim Oy. The other authors declare no conflicts of interest. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Health Resources and Services Administration. NR 22 TC 12 Z9 12 U1 2 U2 13 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-3476 EI 1097-6833 J9 J PEDIATR-US JI J. Pediatr. PD JUN PY 2015 VL 166 IS 6 BP 1423 EP 1430 DI 10.1016/j.jpeds.2015.02.018 PG 8 WC Pediatrics SC Pediatrics GA CI8JI UT WOS:000355018200020 PM 25841538 ER PT J AU Fry, AM Goswami, D Nahar, K Sharmin, AT Rahman, M Gubareva, L Trujillo, A Barnes, J Azim, T Bresee, J Luby, SP Brooks, WA AF Fry, Alicia M. Goswami, Doli Nahar, Kamrun Sharmin, Amina T. Rahman, Mustafizur Gubareva, Larisa Trujillo, Alma Barnes, John Azim, Tasnim Bresee, Joseph Luby, Stephen P. Brooks, W. Abdullah TI Effects of oseltamivir treatment of index patients with influenza on secondary household illness in an urban setting in Bangladesh: secondary analysis of a randomised, placebo-controlled trial SO LANCET INFECTIOUS DISEASES LA English DT Article ID VIRUS; TRANSMISSION; ZANAMIVIR; EFFICACY; PREVENTION; DURATION; CONTACTS; CHILDREN; SAFETY AB Background Antiviral drugs are a proposed medical intervention to reduce household transmission of influenza viruses. In a previously described randomised, placebo-controlled trial in Dhaka, Bangladesh, we showed that oseltamivir treatment of index patients was able to reduce influenza symptom duration and virus shedding. In a further analysis that is part of the same study, we aimed to assess efficacy of oseltamivir to reduce secondary household illnesses in the same cohort. Methods In this double-blind oseltamivir efficacy trial, we identified index patients aged older than 1 year through surveillance of households in Dhaka, Bangladesh. We randomly allocated eligible patients (1: 1) to receive oseltamivir or placebo twice-daily for 5 days, and we stratified them by enrolment 48 h versus 48-120 h since illness onset. Participants provided nasal wash specimens at enrolment and 2, 4, and 7 days after enrolment and were visited daily by a research assistant to record symptoms, both in index patients and in household members. For this part of the study, household members were asked to give respiratory specimens for influenza PCR testing. Our primary outcomes were household secondary illness and PCR-confirmed influenza virus infection, assessed in household members of all randomly allocated index patients. This trial is registered with ClinicalTrials.gov, number NCT00707941. Findings From May 11, 2008, to Dec 31, 2010, we enrolled 1190 index patients with 4694 household members. 592 patients were allocated to placebo (2292 household members) and 598 to oseltamivir (2402 household members). Household secondary illness was lower in the oseltamivir group (196 [8%] influenza cases) than in the placebo group (233 [10%]; odds ratio [OR] 0.77, 95% CI 0.60-0.98, p=0.031). PCR-confirmed influenza virus infection did not differ between the placebo (103 [5%]) and oseltamivir groups (92 [4%]; 0.84, 0.59-1.19, p=0.319); however, only 243 (57%) of ill household members gave a specimen for analysis. Interpretation In a crowded, low income setting, oseltamivir treatment of index patients resulted in a small reduction of secondary influenza in their households. Even this slight reduction, in the setting of widespread antiviral use during a community influenza outbreak, might result in reductions in overall disease burden. C1 [Fry, Alicia M.; Gubareva, Larisa; Trujillo, Alma; Barnes, John; Bresee, Joseph] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30307 USA. [Goswami, Doli; Nahar, Kamrun; Sharmin, Amina T.; Rahman, Mustafizur; Azim, Tasnim; Brooks, W. Abdullah] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Luby, Stephen P.] Stanford Univ, Stanford, CA 94305 USA. [Brooks, W. Abdullah] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MA USA. RP Fry, AM (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30307 USA. EM afry@cdc.gov OI Luby, Stephen/0000-0001-5385-899X FU Centers for Disease Control and Prevention (International Centre for Diarrhoeal Disease Research, Bangladesh) FX Centers for Disease Control and Prevention (in an agreement with the International Centre for Diarrhoeal Disease Research, Bangladesh). NR 17 TC 1 Z9 1 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD JUN PY 2015 VL 15 IS 6 BP 654 EP 662 DI 10.1016/S1473-3099(15)70041-1 PG 9 WC Infectious Diseases SC Infectious Diseases GA CI3HI UT WOS:000354638000030 PM 25788164 ER PT J AU Anstey, NM Price, RN Davis, TME Karunajeewa, HA Mueller, I Karunajeewa, HA D'Alessandro, U Massougbodji, A Nikiema, F Ouedraogo, JB Tinto, H Zongo, I Ouedraogo, JB Tinto, H Same-Ekobo, A Kone, M Menan, H Toure, AO Yavo, W Yavo, W Kofoed, PE Alemayehu, BH Jima, D Baudin, E Espie, E Nabasumba, C Pinoges, L Schramm, B Cot, M Deloron, P Faucher, JF Cot, M Deloron, P Faucher, JF Faucher, JF Guthmann, JP Lell, B Borrmann, S Lell, B Adjei, GO Kofoed, PE Ursing, J Tjitra, E Borrmann, S Marsh, K Peshu, J Juma, E Ogutu, BR Omar, SA Sawa, P Talisuna, AO Talisuna, AO Khanthavong, M Mayxay, M Newton, PN Mayxay, M Piola, P Djimde, AA Doumbo, OK Fofana, B Sagara, I Bassat, Q Gonzalez, R Menendez, C Smithuis, F Smithuis, F Bousema, T Kager, PA Mens, PF Mens, PF Schallig, HDFH Van den Broek, I Van Vugt, M Ibrahim, ML Falade, CO Meremikwu, M Meremikwu, M Gil, JP Karema, C Ba, MS Faye, B Faye, O Gaye, O Ndiaye, JL Pene, M Sow, D Sylla, K Tine, RCK Penali, LK Barnes, KI Workman, LJ Barnes, KI Workman, LJ Bassat, Q Gonzalez, R Menendez, C Mueller, I Lima, A Adam, I Gadalla, NB Malik, EFM Bjorkman, A Gil, JP Martensson, A Ngasala, BE Ursing, J Rombo, L Rombo, L Rombo, L Aliu, P Duparc, S Filler, S Genton, B Genton, B Hodel, EM Olliaro, P Abdulla, S Kamugisha, E Ngasala, BE Premji, Z Shekalaghe, SA Shekalaghe, SA Ashley, EA Carrara, VI McGready, R Nosten, F Ashley, EA Faiz, AM Lee, SJ White, NJ Carrara, VI Dondorp, AM Smith, JJ D'Alessandro, U Tarning, J Achan, J Bukirwa, H Yeka, A Arinaitwe, E Staedke, SG Kamya, MR Kironde, F Nabasumba, C Bousema, T Drakeley, CJ Gadalla, NB Oguike, M Sutherland, CJ Checchi, F Dahal, P Flegg, JA Guerin, PJ Moreira, C Newton, PN Nsanzabana, C Price, RN Sibley, CH Stepniewska, K Tarning, J Dahal, P Dondorp, AM Flegg, JA Guerin, PJ Lee, SJ Marsh, K McGready, R Moreira, C Newton, PN Nosten, F Nsanzabana, C Olliaro, P Price, RN Tarning, J White, NJ Gething, PW Hay, SI Greenwood, B Hodel, EM Ward, SA Staedke, SG Van den Broek, I Winstanley, PA Dorsey, G Greenhouse, B Rosenthal, PJ Gadalla, NB Gil, JP Grivoyannis, A Hamed, K Hwang, J Kachur, PS Hwang, J Sibley, CH Nambozi, M AF Anstey, N. M. Price, R. N. Davis, T. M. E. Karunajeewa, H. A. Mueller, I. Karunajeewa, H. A. D'Alessandro, U. Massougbodji, A. Nikiema, F. Ouedraogo, J-B Tinto, H. Zongo, I. Ouedraogo, J-B Tinto, H. Same-Ekobo, A. Kone, M. Menan, H. Toure, A. O. Yavo, W. Yavo, W. Kofoed, P-E Alemayehu, B. H. Jima, D. Baudin, E. Espie, E. Nabasumba, C. Pinoges, L. Schramm, B. Cot, M. Deloron, P. Faucher, J-F Cot, M. Deloron, P. Faucher, J-F Faucher, J-F Guthmann, J-P Lell, B. Borrmann, S. Lell, B. Adjei, G. O. Kofoed, P-E Ursing, J. Tjitra, E. Borrmann, S. Marsh, K. Peshu, J. Juma, E. Ogutu, B. R. Omar, S. A. Sawa, P. Talisuna, A. O. Talisuna, A. O. Khanthavong, M. Mayxay, M. Newton, P. N. Mayxay, M. Piola, P. Djimde, A. A. Doumbo, O. K. Fofana, B. Sagara, I. Bassat, Q. Gonzalez, R. Menendez, C. Smithuis, F. Smithuis, F. Bousema, T. Kager, P. A. Mens, P. F. Mens, P. F. Schallig, H. D. F. H. Van den Broek, I. Van Vugt, M. Ibrahim, M. L. Falade, C. O. Meremikwu, M. Meremikwu, M. Gil, J. P. Karema, C. Ba, M. S. Faye, B. Faye, O. Gaye, O. Ndiaye, J-L Pene, M. Sow, D. Sylla, K. Tine, R. C. K. Penali, L. K. Barnes, K. I. Workman, L. J. Barnes, K. I. Workman, L. J. Bassat, Q. Gonzalez, R. Menendez, C. Mueller, I. Lima, A. Adam, I. Gadalla, N. B. Malik, E. F. M. Bjorkman, A. Gil, J. P. Martensson, A. Ngasala, B. E. Ursing, J. Rombo, L. Rombo, L. Rombo, L. Aliu, P. Duparc, S. Filler, S. Genton, B. Genton, B. Hodel, E. M. Olliaro, P. Abdulla, S. Kamugisha, E. Ngasala, B. E. Premji, Z. Shekalaghe, S. A. Shekalaghe, S. A. Ashley, E. A. Carrara, V. I. McGready, R. Nosten, F. Ashley, E. A. Faiz, A. M. Lee, S. J. White, N. J. Carrara, V. I. Dondorp, A. M. Smith, J. J. D'Alessandro, U. Tarning, J. Achan, J. Bukirwa, H. Yeka, A. Arinaitwe, E. Staedke, S. G. Kamya, M. R. Kironde, F. Nabasumba, C. Bousema, T. Drakeley, C. J. Gadalla, N. B. Oguike, M. Sutherland, C. J. Checchi, F. Dahal, P. Flegg, J. A. Guerin, P. J. Moreira, C. Newton, P. N. Nsanzabana, C. Price, R. N. Sibley, C. H. Stepniewska, K. Tarning, J. Dahal, P. Dondorp, A. M. Flegg, J. A. Guerin, P. J. Lee, S. J. Marsh, K. McGready, R. Moreira, C. Newton, P. N. Nosten, F. Nsanzabana, C. Olliaro, P. Price, R. N. Tarning, J. White, N. J. Gething, P. W. Hay, S. I. Greenwood, B. Hodel, E. M. Ward, S. A. Staedke, S. G. Van den Broek, I. Winstanley, P. A. Dorsey, G. Greenhouse, B. Rosenthal, P. J. Gadalla, N. B. Gil, J. P. Grivoyannis, A. Hamed, K. Hwang, J. Kachur, P. S. Hwang, J. Sibley, C. H. Nambozi, M. CA Worldwide Antimalarial Resistance TI The effect of dose on the antimalarial efficacy of artemether-lumefantrine: a systematic review and pooled analysis of individual patient data SO LANCET INFECTIOUS DISEASES LA English DT Review ID PLASMODIUM-FALCIPARUM MALARIA; POPULATION PHARMACOKINETICS; UNCOMPLICATED MALARIA; AFRICAN INFANTS; CHILDREN; SAFETY; PHARMACODYNAMICS; CHLOROQUINE; ARTESUNATE; RESISTANCE AB Background Artemether-lumefantrine is the most widely used artemisinin-based combination therapy for malaria, although treatment failures occur in some regions. We investigated the effect of dosing strategy on efficacy in a pooled analysis from trials done in a wide range of malaria-endemic settings. Methods We searched PubMed for clinical trials that enrolled and treated patients with artemether-lumefantrine and were published from 1960 to December, 2012. We merged individual patient data from these trials by use of standardised methods. The primary endpoint was the PCR-adjusted risk of Plasmodium falciparum recrudescence by day 28. Secondary endpoints consisted of the PCR-adjusted risk of P falciparum recurrence by day 42, PCR-unadjusted risk of P falciparum recurrence by day 42, early parasite clearance, and gametocyte carriage. Risk factors for PCR-adjusted recrudescence were identified using Cox's regression model with frailty shared across the study sites. Findings We included 61 studies done between January, 1998, and December, 2012, and included 14 327 patients in our analyses. The PCR-adjusted therapeutic efficacy was 97.6% (95% CI 97.4-97.9) at day 28 and 96.0% (95.6-96.5) at day 42. After controlling for age and parasitaemia, patients prescribed a higher dose of artemether had a lower risk of having parasitaemia on day 1 (adjusted odds ratio [OR] 0.92, 95% CI 0.86-0.99 for every 1 mg/kg increase in daily artemether dose; p=0.024), but not on day 2 (p=0.69) or day 3 (0.087). In Asia, children weighing 10-15 kg who received a total lumefantrine dose less than 60 mg/kg had the lowest PCR-adjusted efficacy (91.7%, 95% CI 86.5-96.9). In Africa, the risk of treatment failure was greatest in malnourished children aged 1-3 years (PCR-adjusted efficacy 94.3%, 95% CI 92.3-96.3). A higher artemether dose was associated with a lower gametocyte presence within 14 days of treatment (adjusted OR 0.92, 95% CI 0.85-0.99; p=0.037 for every 1 mg/kg increase in total artemether dose). Interpretation The recommended dose of artemether-lumefantrine provides reliable efficacy in most patients with uncomplicated malaria. However, therapeutic efficacy was lowest in young children from Asia and young underweight children from Africa; a higher dose regimen should be assessed in these groups. C1 [Anstey, N. M.; Price, R. N.] Menzies Sch Hlth Res, Global & Trop Hlth Div, Darwin, NT, Australia. [Anstey, N. M.] Charles Darwin Univ, Darwin, NT 0909, Australia. [Davis, T. M. E.] Univ Western Australia, Sch Med & Pharmacol, Crawley, WA, Australia. [Karunajeewa, H. A.; Mueller, I.] Walter & Eliza Hall Inst Med Res, Infect & Immun Div, Melbourne, Vic, Australia. Western Hlth, Div Med, Melbourne, Vic, Australia. [D'Alessandro, U.] Inst Trop Med, Unit Malariol, B-2000 Antwerp, Belgium. [Massougbodji, A.] Univ dAbomey Calavi, Fac Sci Sante, Ctr Etud & Rech Paludisme Associe Grossesse & Enf, Cotonou, Benin. [Nikiema, F.; Ouedraogo, J-B; Tinto, H.] Inst Rech Sci Sante, Direct Reg Ouest, Bobo Dioulasso, Burkina Faso. Ctr Muraz, Bobo Dioulasso, Burkina Faso. [Same-Ekobo, A.] Univ Yaounde, Ctr Hosp, Fac Med & Sci Biomed, Yaounde, Cameroon. [Kone, M.; Menan, H.; Yavo, W.] Univ Cocody, Fac Pharm, Dept Parasitol & Mycol, Abidjan, Cote Ivoire. [Toure, A. O.] Inst Pasteur Cote Ivoire, Malariol Dept, Abidjan, Cote Ivoire. [Yavo, W.] Natl Inst Publ Hlth, Malaria Res & Control Ctr, Abidjan, Cote Ivoire. [Kofoed, P-E] Kolding Cty Hosp, Dept Paediat, Kolding, Denmark. [Alemayehu, B. H.] Int Ctr AIDS Care & Treatment Programs, Addis Ababa, Ethiopia. [Jima, D.] Fed Minist Hlth, Addis Ababa, Ethiopia. [Baudin, E.; Espie, E.; Nabasumba, C.; Pinoges, L.; Schramm, B.] Epictr, Paris, France. [Cot, M.; Deloron, P.; Faucher, J-F] Inst Rech Dev, Mother & Child Hlth Trop Res Unit, Paris, France. [Cot, M.; Deloron, P.; Faucher, J-F] Univ Paris 05, Sorbonne Paris Cite, PRES, Paris, France. [Faucher, J-F] Univ Besancon, Med Ctr, Dept Infect Dis, F-25030 Besancon, France. [Guthmann, J-P] Inst Veille Sanit, Dept Malad Infect, St Maurice, France. [Lell, B.] Ctr Rech Med Lambarene, Lambarene, Gabon. [Lell, B.; Borrmann, S.] Univ Tubingen, Inst Trop Med, Tubingen, Germany. [Adjei, G. O.] Univ Ghana, Sch Med, Ctr Trop Clin Pharmacol & Therapeut, Accra, Ghana. [Kofoed, P-E] Projecto Saude Bandim, Bissau, Guinea Bissau. [Tjitra, E.] Minist Hlth, Natl Inst Hlth Res & Dev, Jakarta, Indonesia. [Borrmann, S.; Marsh, K.; Peshu, J.] Kenya Govt Med Res Ctr, Kilifi, Kenya. [Borrmann, S.; Marsh, K.; Peshu, J.] Wellcome Trust Res Programme, Kilifi, Kenya. [Juma, E.] Kenya Govt Med Res Ctr, Nairobi, Kenya. [Ogutu, B. R.] Kenya Govt Med Res Ctr, Kisumu, Kenya. [Ogutu, B. R.] US Army Med Res Unit, Kisumu, Kenya. [Omar, S. A.; Sawa, P.] Int Ctr Insect Physiol & Ecol, Human Hlth Div, Mbita Point, Kenya. [Talisuna, A. O.] WWARN East Africa Reg Ctr, Nairobi, Kenya. [Talisuna, A. O.] Univ Oxford, KEMRI, Oxford OX3 7LJ, England. [Talisuna, A. O.] Wellcome Trust Res Programme, Nairobi, Kenya. [Khanthavong, M.] Ctr Malariol Parasitol & Entomol, Viangchan, Laos. [Mayxay, M.; Newton, P. N.] Oxford Univ Trop Med Res Collaborat, Mahosot Hosp, Wellcome Trust Mahosot Hosp, Viangchan, Laos. [Mayxay, M.] Natl Univ Laos, Fac Med Sci, Viangchan, Laos. [Piola, P.] Inst Pasteur Madagascar, Antananarivo, Madagascar. [Djimde, A. A.; Doumbo, O. K.; Fofana, B.; Sagara, I.] Univ Bamako, Fac Med Pharm & Odontostomatol, Dept Epidemiol Parasit Dis, Malaria Res & Training Ctr, Bamako, Mali. [Bassat, Q.; Gonzalez, R.; Menendez, C.] Ctr Invest Saude Manhica, Manhica, Mozambique. [Smithuis, F.] Myanmar Oxford Clin Res Unit, Yangon, Myanmar. [Smithuis, F.] Myanmar & Med Act Myanmar, Yangon, Myanmar. [Bousema, T.] Radboud Univ Nijmegen, Med Ctr, Dept Med Microbiol, Njimegen, Netherlands. [Kager, P. A.; Mens, P. F.] Univ Amsterdam, Acad Med Ctr, Ctr Infect & Immun Amsterdam CINEMA, Div Infect Dis Trop Med & AIDS, NL-1105 AZ Amsterdam, Netherlands. [Mens, P. F.; Schallig, H. D. F. H.] Royal Trop Inst, KIT Biomed Res, NL-1105 AZ Amsterdam, Netherlands. [Van den Broek, I.] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Control, NL-3720 BA Bilthoven, Netherlands. [Van Vugt, M.] Univ Amsterdam, Acad Med Ctr, Ctr Trop Med & Travel Med, Div Infect Dis, NL-1012 WX Amsterdam, Netherlands. [Ibrahim, M. L.] Ctr Rech Med & Sanit, Niamey, Niger. [Falade, C. O.] Univ Ibadan, Coll Med, Ibadan, Nigeria. [Meremikwu, M.] Univ Calabar, Dept Paediat, Calabar, Nigeria. Inst Trop Dis Res & Prevent, Calabar, Nigeria. [Gil, J. P.] Univ Lisbon, Fac Ciencias, Ctr Biodivers Funct & Integrat Genom, Drug Resistance & Pharmacogenet, P-1699 Lisbon, Portugal. [Karema, C.] Minist Hlth, Malaria & Other Parasit Dis Div RBC, Kigali, Rwanda. [Ba, M. S.; Faye, B.; Faye, O.; Gaye, O.; Ndiaye, J-L; Pene, M.; Sow, D.; Sylla, K.; Tine, R. C. K.] Univ Cheikh Anta Diop, Fac Med, Dept Parasitol & Mycol, Dakar, Senegal. [Penali, L. K.] WWARN West Africa Reg Ctr, Dakar, Senegal. [Barnes, K. I.; Workman, L. J.] WWARN, Pharmacol Module, Cape Town, South Africa. [Barnes, K. I.; Workman, L. J.] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7925 Cape Town, South Africa. [Bassat, Q.; Gonzalez, R.; Menendez, C.] Ctr Recerca Salut Int Barcelona, Barcelona, Spain. [Lima, A.] Medecins Sans Frontieres Operat Ctr Barcelona Ath, Barcelona, Spain. [Adam, I.] Univ Khartoum, Fac Med, Khartoum, Sudan. [Gadalla, N. B.] Natl Res Ctr, Res Inst Trop Med, Dept Epidemiol, Khartoum, Sudan. [Malik, E. F. M.] Fed Minist Hlth, Khartoum, Sudan. [Bjorkman, A.] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Infect Dis Unit, Stockholm, Sweden. [Gil, J. P.] Karolinska Inst, Dept Physiol & Pharmacol, Drug Resistance Unit, Pharmacogenet Sect, Stockholm, Sweden. [Ursing, J.; Martensson, A.; Ngasala, B. E.] Karolinska Inst, Dept Med Solna, Infect Dis Unit, Malaria Res, Stockholm, Sweden. [Martensson, A.] Karolinska Inst, Dept Publ Hlth Sci, Div Global Hlth, Stockholm, Sweden. [Rombo, L.] Karolinska Univ Hosp, Dept Med, Malaria Res Lab, Infect Dis Unit, Stockholm, Sweden. [Rombo, L.] Dept Infect Dis, Eskilstuna, Sweden. [Rombo, L.] Sormland Cty Council, Clin Res Ctr, Sormland, Sweden. [Aliu, P.] Novartis Pharma AG, Basel, Switzerland. [Duparc, S.] Med Malaria Venture, Geneva, Switzerland. [Filler, S.] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland. [Genton, B.] Swiss Trop & Publ Hlth Inst, Dept Epidemiol & Publ Hlth, Basel, Switzerland. [Genton, B.] Univ Lausanne Hosp, Div Infect Dis, Lausanne, Switzerland. [Genton, B.] Univ Lausanne Hosp, Dept Ambulatory Care & Community Med, Lausanne, Switzerland. [Hodel, E. M.] Swiss Trop & Publ Hlth Inst, Basel, Switzerland. [Olliaro, P.] UNDP, UNICEF, World Bank, Geneva, Switzerland. [Olliaro, P.] WHO, Special Programme Res & Training Trop Dis, CH-1211 Geneva, Switzerland. [Abdulla, S.] Ifakara Hlth Inst, Dar Es Salaam, Tanzania. [Kamugisha, E.] Catholic Univ Hlth & Allied Sci, Mwanza, Tanzania. [Ngasala, B. E.; Premji, Z.] Muhimbili Univ Hlth & Allied Sci, Dept Parasitol, Dar Es Salaam, Tanzania. [Shekalaghe, S. A.] Kilimanjaro Christian Med Ctr, Kilimanjaro Clin Med Res Inst, Moshi, Tanzania. [Shekalaghe, S. A.] Ifakara Hlth Inst, Bagamoyo, Tanzania. [Ashley, E. A.; Carrara, V. I.; McGready, R.; Nosten, F.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Shoklo Malaria Res Unit, Mae Sot, Thailand. [Ashley, E. A.; Faiz, A. M.; Lee, S. J.; White, N. J.] Mahidol Univ, Fac Trop Med, Bangkok, Thailand. [Carrara, V. I.; Dondorp, A. M.] Mahidol Univ, Mahidol Oxford Univ Res Unit, Bangkok, Thailand. [Smith, J. J.] WWARN Asia Reg Ctr, Bangkok, Thailand. MRC Unit, Fajara, Gambia. [Tarning, J.] Mahidol Univ, Fac Trop Med, Mahidol Oxford Trop Med Res Unit, Bangkok, Thailand. [Achan, J.; Bukirwa, H.; Yeka, A.] Uganda Malaria Surveillance Project, Kampala, Uganda. [Arinaitwe, E.; Staedke, S. G.] Infect Dis Res Collaborat, Kampala, Uganda. [Kamya, M. R.] Makerere Univ, Coll Hlth Sci, Kampala, Uganda. [Kironde, F.] Makerere Univ, Dept Biochem, Kampala, Uganda. [Nabasumba, C.] Mbarara Univ Sci & Technol, Fac Med, Mbarara, Uganda. [Bousema, T.; Gadalla, N. B.; Drakeley, C. J.; Oguike, M.; Sutherland, C. J.] London Sch Hyg & Trop Med, Immunol & Infect Dept, London WC1, England. [Checchi, F.] Save Children, Humanitarian Dept, London, England. [Newton, P. N.; Tarning, J.; Dahal, P.; Flegg, J. A.; Guerin, P. J.; Moreira, C.; Nsanzabana, C.; Sibley, C. H.; Stepniewska, K.] Worldwide Antimalarial Resistance Network, Oxford, England. [Marsh, K.; Newton, P. N.; Olliaro, P.; McGready, R.; Nosten, F.; Lee, S. J.; White, N. J.; Dondorp, A. M.; Tarning, J.; Dahal, P.; Flegg, J. A.; Guerin, P. J.; Moreira, C.; Nsanzabana, C.] Univ Oxford, Nuffield Dept Clin Med, Ctr Trop Med & Global Hlth, Oxford, England. [Gething, P. W.; Hay, S. I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford, England. [Greenwood, B.] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England. [Hodel, E. M.; Ward, S. A.] Univ Liverpool, Liverpool Sch Trop Med, Dept Parasitol, Liverpool L3 5QA, Merseyside, England. [Staedke, S. G.] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England. [Van den Broek, I.] Medecins Sans Frontieres, London, England. [Winstanley, P. A.] Univ Warwick, Warwick Med Sch, Coventry CV4 7AL, W Midlands, England. [Dorsey, G.; Greenhouse, B.; Rosenthal, P. J.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Gadalla, N. B.] NIAID, Rockville, MD USA. [Gil, J. P.] SUNY Binghamton, Harpur Coll Arts & Sci, Binghamton, NY USA. [Grivoyannis, A.] Univ Washington, Div Emergency Med, Seattle, WA 98195 USA. [Hamed, K.] Novartis, E Hanover, NJ USA. [Hwang, J.; Kachur, P. S.] US Ctr Dis Control & Prevent, Atlanta, GA USA. [Hwang, J.] Univ Calif San Francisco, Global Hlth Grp, San Francisco, CA 94143 USA. [Sibley, C. H.] Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA. [Nambozi, M.] Trop Dis Res Ctr, Ndola, Zambia. RP Price, RN (reprint author), Univ Oxford, Ctr Trop Med & Global Hlth, Worldwide Antimalarial Resistance Network, S Parks Rd, Oxford OX3 7LJ, England. EM ric.price@wwarn.org; christian.nsanzabana@wwarn.org RI Hodel, Eva Maria/E-1258-2014; Bousema, Teun/N-3574-2014; Ward, Steve/G-6003-2015; Hay, Simon/F-8967-2015; OI Price, Richard/0000-0003-2000-2874; Hodel, Eva Maria/0000-0001-5821-1685; Ward, Steve/0000-0003-2331-3192; Hay, Simon/0000-0002-0611-7272; GADALLA, NAHLA/0000-0002-6177-6705; Dahal, Prabin/0000-0002-2158-846X; Flegg, Jennifer/0000-0002-8809-726X; Nosten, Francois/0000-0002-7951-0745; McGready, Rose/0000-0003-1621-3257; Gething, Peter/0000-0001-6759-5449; Guerin, Philippe/0000-0002-6008-2963; Hamed, Kamal/0000-0003-1896-9736 FU Bill & Melinda Gates Foundation FX Bill & Melinda Gates Foundation. NR 32 TC 16 Z9 16 U1 3 U2 18 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD JUN PY 2015 VL 15 IS 6 BP 692 EP 702 DI 10.1016/S1473-3099(15)70024-1 PG 11 WC Infectious Diseases SC Infectious Diseases GA CI3HI UT WOS:000354638000034 ER PT J AU Bellan, SE Pulliam, JRC Pearson, CAB Champredon, D Fox, SJ Skrip, L Galvani, AP Gambhir, M Lopman, BA Porco, TC Meyers, LA Dushoff, J AF Bellan, Steven E. Pulliam, Juliet R. C. Pearson, Carl A. B. Champredon, David Fox, Spencer J. Skrip, Laura Galvani, Alison P. Gambhir, Manoj Lopman, Ben A. Porco, Travis C. Meyers, Lauren Ancel Dushoff, Jonathan TI Statistical power and validity of Ebola vaccine trials in Sierra Leone: a simulation study of trial design and analysis SO LANCET INFECTIOUS DISEASES LA English DT Article ID CLUSTER-RANDOMIZED-TRIALS; STEPPED WEDGE CLUSTER; ETHICAL-ISSUES; VIRUS DISEASE; SAMPLE-SIZE AB Background Safe and effective vaccines could help to end the ongoing Ebola virus disease epidemic in parts of west Africa, and mitigate future outbreaks of the virus. We assess the statistical validity and power of randomised controlled trial (RCT) and stepped-wedge cluster trial (SWCT) designs in Sierra Leone, where the incidence of Ebola virus disease is spatiotemporally heterogeneous, and is decreasing rapidly. Methods We projected district-level Ebola virus disease incidence for the next 6 months, using a stochastic model fitted to data from Sierra Leone. We then simulated RCT and SWCT designs in trial populations comprising geographically distinct clusters at high risk, taking into account realistic logistical constraints, and both individual-level and cluster-level variations in risk. We assessed false-positive rates and power for parametric and non-parametric analyses of simulated trial data, across a range of vaccine efficacies and trial start dates. Findings For an SWCT, regional variation in Ebola virus disease incidence trends produced increased false-positive rates (up to 0.15 at alpha=0.05) under standard statistical models, but not when analysed by a permutation test, whereas analyses of RCTs remained statistically valid under all models. With the assumption of a 6-month trial starting on Feb 18, 2015, we estimate the power to detect a 90% effective vaccine to be between 49% and 89% for an RCT, and between 6% and 26% for an SWCT, depending on the Ebola virus disease incidence within the trial population. We estimate that a 1-month delay in trial initiation will reduce the power of the RCT by 20% and that of the SWCT by 49%. Interpretation Spatiotemporal variation in infection risk undermines the statistical power of the SWCT. This variation also undercuts the SWCT's expected ethical advantages over the RCT, because an RCT, but not an SWCT, can prioritise vaccination of high-risk clusters. C1 [Bellan, Steven E.] Univ Texas Austin, Ctr Computat Biol & Bioinformat, Austin, TX 78712 USA. [Fox, Spencer J.; Meyers, Lauren Ancel] Univ Texas Austin, Dept Integrat Biol, Austin, TX 78712 USA. [Pulliam, Juliet R. C.] Univ Florida, Dept Biol, Gainesville, FL USA. [Pulliam, Juliet R. C.; Pearson, Carl A. B.] Univ Florida, Emerging Pathogens Inst, Gainesville, FL USA. [Champredon, David] McMaster Univ, Sch Computat Sci & Engn, Hamilton, ON, Canada. [Dushoff, Jonathan] McMaster Univ, Dept Biol, Hamilton, ON, Canada. [Skrip, Laura; Galvani, Alison P.] Yale Univ, Sch Publ Hlth, Ctr Infect Dis Modeling & Anal, New Haven, CT USA. [Galvani, Alison P.] Yale Univ, Dept Ecol & Evolut, New Haven, CT USA. [Gambhir, Manoj] Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia. [Gambhir, Manoj] Ctr Dis Control & Prevent, Natl Ctr Emerging & Zoonot Infect Dis, Div Preparedness & Emerging Infect, Atlanta, GA USA. [Lopman, Ben A.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. [Gambhir, Manoj] IHRC Inc, Atlanta, GA USA. [Lopman, Ben A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Porco, Travis C.] Univ Calif San Francisco, Francis I Proctor Fdn, San Francisco, CA 94143 USA. [Porco, Travis C.] Univ Calif San Francisco, Dept Ophthalmol, San Francisco, CA USA. [Porco, Travis C.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Meyers, Lauren Ancel] Santa Fe Inst, Santa Fe, NM 87501 USA. RP Bellan, SE (reprint author), Univ Texas Austin, Coll Nat Sci, Ctr Computat Biol & Bioinformat, 1 Univ Stn C4500, Austin, TX 78712 USA. EM steve.bellan@gmail.com RI Pulliam, Juliet/A-6516-2008; OI Pulliam, Juliet/0000-0003-3314-8223; Bellan, Steve/0000-0002-4110-272X FU US National Institutes of Health, US National Science Foundation; Canadian Institutes of Health Research FX US National Institutes of Health, US National Science Foundation, and Canadian Institutes of Health Research. NR 22 TC 16 Z9 16 U1 1 U2 14 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD JUN PY 2015 VL 15 IS 6 BP 703 EP 710 DI 10.1016/S1473-3099(15)70139-8 PG 8 WC Infectious Diseases SC Infectious Diseases GA CI3HI UT WOS:000354638000035 PM 25886798 ER PT J AU Nachman, S Ahmed, A Amanullah, F Becerra, MC Botgros, R Brigden, G Browning, R Gardiner, E Hafner, R Hesseling, A How, C Jean-Philippe, P Lessem, E Makhene, M Mbelle, N Marais, B McIlleron, H McNeeley, DF Mendel, C Murray, S Navarro, E Anyalechi, EG Porcalla, AR Powell, C Powell, M Rigaud, M Rouzier, V Samson, P Schaaf, HS Shah, S Starke, J Swaminathan, S Wobudeya, E Worrell, C AF Nachman, Sharon Ahmed, Amina Amanullah, Farhana Becerra, Mercedes C. Botgros, Radu Brigden, Grania Browning, Renee Gardiner, Elizabeth Hafner, Richard Hesseling, Anneke How, Cleotilde Jean-Philippe, Patrick Lessem, Erica Makhene, Mamodikoe Mbelle, Nontombi Marais, Ben McIlleron, Helen McNeeley, David F. Mendel, Carl Murray, Stephen Navarro, Eileen Anyalechi, E. Gloria Porcalla, Ariel R. Powell, Clydette Powell, Mair Rigaud, Mona Rouzier, Vanessa Samson, Pearl Schaaf, H. Simon Shah, Seema Starke, Jeff Swaminathan, Soumya Wobudeya, Eric Worrell, Carol TI Towards early inclusion of children in tuberculosis drugs trials: a consensus statement SO LANCET INFECTIOUS DISEASES LA English DT Review ID MULTIDRUG-RESISTANT TUBERCULOSIS; SOUTH-AFRICAN CHILDREN; CHILDHOOD TUBERCULOSIS; ANTITUBERCULOSIS AGENTS; MANAGEMENT CHALLENGES; WESTERN CAPE; RISK-FACTORS; HIV; RECOMMENDATIONS; MORTALITY AB Children younger than 18 years account for a substantial proportion of patients with tuberculosis worldwide. Available treatments for paediatric drug-susceptible and drug-resistant tuberculosis, albeit generally effective, are hampered by high pill burden, long duration of treatment, coexistent toxic effects, and an overall scarcity of suitable child-friendly formulations. Several new drugs and regimens with promising activity against both drug-susceptible and drug-resistant strains have entered clinical development and are either in various phases of clinical investigation or have received marketing authorisation for adults; however, none have data on their use in children. This consensus statement, generated from an international panel of opinion leaders on childhood tuberculosis and incorporating reviews of published literature from January, 2004, to May, 2014, addressed four key questions: what drugs or regimens should be prioritised for clinical trials in children? Which populations of children are high priorities for study? When can phase 1 or 2 studies be initiated in children? What are the relevant elements of clinical trial design? The consensus panel found that children can be included in studies at the early phases of drug development and should be an integral part of the clinical development plan, rather than studied after regulatory approval in adults is obtained. C1 [Nachman, Sharon] SUNY Stony Brook, Stony Brook, NY 11794 USA. [Ahmed, Amina] Carolinas Med Ctr, Levine Childrens Hosp, Charlotte, NC 28203 USA. [Amanullah, Farhana] Indus Hosp, Karachi, Pakistan. [Becerra, Mercedes C.] Harvard Univ, Sch Med, Boston, MA USA. [Botgros, Radu; Powell, Mair] European Med Agcy, London, England. [Brigden, Grania] Access Campaign, Medecins Sans Frontieres, Geneva, Switzerland. [Browning, Renee; Hafner, Richard; Makhene, Mamodikoe] NIAID, NIH, Div Aids, Bethesda, MD 20892 USA. [Gardiner, Elizabeth; Mendel, Carl; Murray, Stephen] TB Alliance, New York, NY USA. [Hesseling, Anneke; Schaaf, H. Simon] Univ Stellenbosch, Dept Paediat & Child Hlth, Desmond Tutu TB Ctr, Cape Town, South Africa. [How, Cleotilde] Univ Philippines, Dept Pharmacol & Toxicol, Manila, Philippines. [Jean-Philippe, Patrick] NIAID, Henry Jackson Fdn, Div Aids, NIH,Dept Hlth & Human Serv, Bethesda, MD 20892 USA. [Lessem, Erica] Treatment Act Grp, New York, NY USA. [Mbelle, Nontombi] Univ Pretoria, Dept Med Microbiol, ZA-0002 Pretoria, South Africa. [Marais, Ben] Univ Sydney, Marie Bashir Inst Infect Dis & Biosecur, Sydney, NSW 2006, Australia. [Marais, Ben] Univ Sydney, Sydney Emerging Infect Dis & Biosecur Inst, Sydney, NSW 2006, Australia. [Marais, Ben] Univ Sydney, Childrens Hosp Westmead, Sydney, NSW 2006, Australia. [McIlleron, Helen] Univ Cape Town, Dept Med, Div Clin Pharmacol, ZA-7700 Rondebosch, South Africa. [McNeeley, David F.] Novartis Pharmaceut, E Hanover, NJ USA. [Navarro, Eileen; Porcalla, Ariel R.] US FDA, Div Antiinfect Prod, Off Antimicrobial Prod, Off New Drugs, Silver Spring, MD USA. [Anyalechi, E. Gloria] US Ctr Dis Control & Prevent, Div TB Eliminat, Int Res & Programs Branch, Atlanta, GA USA. [Powell, Clydette] Agcy Int Dev, Washington, DC USA. [Rigaud, Mona] NYU, Sch Med, New York, NY 10003 USA. [Rouzier, Vanessa] GHESKIO, Port Au Prince, Haiti. [Samson, Pearl] Harvard Univ, Sch Publ Hlth, Ctr Biostat AIDS Res & Frontier Sci, Stat & Data Anal Ctr, Boston, MA 02115 USA. [Shah, Seema] NIH, Ctr Clin, Dept Bioeth, Bethesda, MD 20892 USA. [Starke, Jeff] Baylor Coll Med, Houston, TX 77030 USA. [Swaminathan, Soumya] Natl Inst Res TB, Madras, Tamil Nadu, India. [Wobudeya, Eric] Makerere Univ Johns Hopkins Res Collaborat, Kampala, Uganda. [Wobudeya, Eric] Mulago Natl Referral Hosp, Kampala, Uganda. [Worrell, Carol] Eunice Kennedy Schriver Natl Inst Child Hlth & Hu, NIH, Rockville, MD USA. RP Nachman, S (reprint author), Hlth Sci SUNY Stony Brook, Stony Brook Childrens Hosp, Dept Pediat, Stony Brook, NY 11794 USA. EM sharon.nachman@stonybrook.edu OI wobudeya, eric/0000-0001-9574-5539; McIlleron, Helen/0000-0002-0982-6226 FU National Institute of Allergy and Infectious Diseases; National Institute of Health; Department of Health and Human Services; HHS FX We thank the following individuals for assistance in the planning and conduct of the workshop or drafting of the manuscript, or both: Sheryl Zwerski, Sarah Read, Larry Fox, Devasena Gnanashanmugam, Judi Miller, Ellen O'Gara, Paul Sato, Peter Kim, Tyseaia Squirewell McFarlane, Rahel Abebe, and Andrea Williams. This work was funded by National Institute of Allergy and Infectious Diseases and National Institute of Health. This project has also been funded in part with federal funds from the Department of Health and Human Services. The views expressed in written conference materials or publications and by speakers and moderators at HHS-sponsored conferences, do not necessarily show the official policies of the Department of Health and Human Services (DHHS) or individual DHHS or other US government agencies including the National Institute of Health, the Center for Disease Control and Prevention, the Food and Drug Administration or the US Agency for International Development; nor does mention of trade names, commercial practices, or organisations imply endorsement by the US Government. The views expressed in this consensus statement are the personal views of the authors and cannot be understood or quoted as made on behalf of the position of the European Medicines Agency, or one of its committees or working parties. NR 75 TC 21 Z9 21 U1 1 U2 7 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1473-3099 EI 1474-4457 J9 LANCET INFECT DIS JI Lancet Infect. Dis. PD JUN PY 2015 VL 15 IS 6 BP 711 EP 720 DI 10.1016/S1473-3099(15)00007-9 PG 10 WC Infectious Diseases SC Infectious Diseases GA CI3HI UT WOS:000354638000036 PM 25957923 ER PT J AU Wendorf, KA Kay, M Ortega-Sanchez, IR Munn, M Duchin, J AF Wendorf, Kristen A. Kay, Meagan Ortega-Sanchez, Ismael R. Munn, Meaghan Duchin, Jeffrey TI Cost of Measles Containment in an Ambulatory Pediatric Clinic SO PEDIATRIC INFECTIOUS DISEASE JOURNAL LA English DT Article DE measles; costs and cost analysis; infant; measles-mumps-rubella vaccine ID UNITED-STATES; ECONOMIC-IMPACT; SETTINGS; OUTBREAK AB Background: Measles is highly infectious; prompt containment of illnesses is necessary to prevent spread. In August 2013, a 13-year-old male with measles exposed patients and employees in a pediatric clinic. We studied containment costs to identify avoidable costs. Methods: Measles exposure was defined as in-person contact with or presence in the same room <2 hours after the measles patient. Costs were calculated retrospectively using published costs of measles-mumps-rubella vaccine, cost-to-charge ratios for inpatient care in urban Washington State and local emergency department charges for post-exposure immunoglobulin (IG). Personnel costs were calculated by multiplying hourly wages by time for employees who worked on the response; overhead was excluded. Results: Fifty-two patients, 60 caretakers and 10 employees were exposed. Personnel time cost $1961. Exposed patients had a mean age of 9.6 years (range: 2 months-19 years); 34 (65%) were fully vaccinated, and 18 (35%) were < 12 months of age and too young to be vaccinated. Five patients (10%) were < 6 months of age and required IG; 13 infants (25%) 6-11 months of age required measles-mumps-rubella vaccination. Caretakers followed up with their physicians for evidence of immunity. One employee had documented evidence of immunity; 9 required measles antibody testing or vaccination. Management of exposed persons cost $3694; overall clinic costs were $5655. Conclusion: Responding to 1 measles case cost the pediatric clinic more than $5000, despite isolating the patient promptly after examination. Documentation of employee immunity, vaccination of eligible patients and strict infection control precautions might reduce ambulatory costs associated with measles containment. C1 [Wendorf, Kristen A.; Kay, Meagan; Munn, Meaghan; Duchin, Jeffrey] Publ Hlth Seattle & King Cty, Communicable Dis Epidemiol & Immunizat Sect, Seattle, WA USA. [Wendorf, Kristen A.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Ortega-Sanchez, Ismael R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Div Viral Dis, Atlanta, GA USA. [Munn, Meaghan] Council State & Terr Epidemiologists, Atlanta, GA USA. RP Wendorf, KA (reprint author), Publ Hlth Seattle & King Cty, 401 5th Ave,Suite 900, Seattle, WA 98104 USA. EM xea0@cdc.gov NR 26 TC 3 Z9 3 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0891-3668 EI 1532-0987 J9 PEDIATR INFECT DIS J JI Pediatr. Infect. Dis. J. PD JUN PY 2015 VL 34 IS 6 BP 589 EP 593 DI 10.1097/INF.0000000000000682 PG 5 WC Immunology; Infectious Diseases; Pediatrics SC Immunology; Infectious Diseases; Pediatrics GA CI4MB UT WOS:000354722300010 PM 25973936 ER PT J AU Jia, HM Zack, MM Thompson, WW Crosby, AE Gottesman, II AF Jia, Haomiao Zack, Matthew M. Thompson, William W. Crosby, Alex E. Gottesman, Irving I. TI Impact of depression on quality-adjusted life expectancy (QALE) directly as well as indirectly through suicide SO SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY LA English DT Article DE Depression; Suicide; Health-related quality of life (HRQOL); Quality-adjusted life expectancy (QALE); Life expectancy ID ALL-CAUSE MORTALITY; UNITED-STATES; MENTAL-DISORDERS; SYSTEMATIC ANALYSIS; GLOBAL BURDEN; SUBSTANCE USE; RISK-FACTORS; HEALTHY DAYS; OF-LIFE; DISEASE AB To estimate quality-adjusted life expectancy (QALE) loss among US adults due to depression and QALE losses associated with the increased risk of suicide attributable to depression. We ascertained depressive symptoms using the eight-item Patient Health Questionnaire (PHQ-8) on the 2006, 2008, and 2010 Behavioral Risk Factor Surveillance System (BRFSS) surveys. We estimated health-related quality of life (HRQOL) scores from BRFSS data (n = 276,442) and constructed life tables from US Compressed Mortality Files to calculate QALE by depression status. QALE loss due to depression is the difference in QALE between depressed and non-depressed adults. QALE loss associated with suicide deaths is the difference between QALE from only those deaths that did not have suicide recorded on the death certificate and QALE from all deaths including those with a suicide recorded on the death certificate. At age 18, QALE was 28.0 more years for depressed adults and 56.8 more years for non-depressed adults, a 28.9-year QALE loss due to depression. For depressed adults, only 0.41 years of QALE loss resulted from deaths by suicide, and only 0.26 years of this loss could be attributed to depression. Depression symptoms lead to a significant burden of disease from both mortality and morbidity as assessed by QALE loss. The 28.9-year QALE loss at age 18 associated with depression markedly exceeds estimates reported elsewhere for stroke (12.4-year loss), heart disease (10.3-year loss), diabetes mellitus (11.1-year loss), hypertension (6.3-year loss), asthma (7.0-year loss), smoking (11.0-year loss), and physical inactivity (8.0-year loss). C1 [Jia, Haomiao] Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY 10032 USA. [Jia, Haomiao] Columbia Univ, Sch Nursing, New York, NY 10032 USA. [Zack, Matthew M.; Thompson, William W.] Ctr Dis Control & Prevent, Div Populat Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Crosby, Alex E.] Ctr Dis Control & Prevent, Div Violence Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA USA. [Gottesman, Irving I.] Univ Minnesota, Dept Psychol, St Paul, MN USA. RP Jia, HM (reprint author), Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, 617 West 168th St, New York, NY 10032 USA. EM hj2198@columbia.edu; mmz1@cdc.gov; wct2@cdc.gov; aec1@cdc.gov; gotte003@umn.edu OI Gottesman, Irving/0000-0001-7584-621X FU CDC [200-2011-M-41977] FX This study (Jia) is supported by a CDC contract (No. 200-2011-M-41977). NR 57 TC 7 Z9 7 U1 2 U2 9 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 0933-7954 EI 1433-9285 J9 SOC PSYCH PSYCH EPID JI Soc. Psychiatry Psychiatr. Epidemiol. PD JUN PY 2015 VL 50 IS 6 BP 939 EP 949 DI 10.1007/s00127-015-1019-0 PG 11 WC Psychiatry SC Psychiatry GA CI7NZ UT WOS:000354951800010 PM 25660550 ER PT J AU Bragg, WA Lemire, SW Coleman, RM Hamelin, EI Johnson, RC AF Bragg, William A. Lemire, Sharon W. Coleman, Rebecca M. Hamelin, Elizabeth I. Johnson, Rudolph C. TI Detection of human exposure to saxitoxin and neosaxitoxin in urine by online-solid phase extraction-liquid chromatography-tandem mass spectrometry SO TOXICON LA English DT Article DE Marine toxins; Saxitoxin; Neosaxitoxin; LC-MS/MS; Online SPE ID PARALYTIC SHELLFISH TOXINS; POSTMORTEM ANALYSIS; POISONING TOXINS; 4-AMINOPYRIDINE; SAMPLES AB Saxitoxin (STX) and neosaxitoxin (NEO) are potent neurotoxins that cause paralytic shellfish poisoning (PSP). PSP typically occurs through the ingestion of bivalve shellfish that have consumed toxin producing dinoflagellates. Due to initial presentation of symptoms being nonspecific, a clinical measurement is needed to confirm exposure to these toxins. Our group has developed an online solid phase extraction hydrophilic interaction liquid chromatography (HILIC) method for the analysis of STX and NEO in human urine with tandem mass spectrometry. A unique feature of this online method is the incorporation of a new synthetic N-15(4)-STX labeled internal standard used for quantitation. Manual sample preparation time was reduced by approximately 70% for 98 urine samples as compared to a previously reported method. The lowest reportable limit for STX was improved from 5.0 ng/mL to 1.01 ng/mL and from 10.0 ng/mL to 2.62 ng/mL for NEO. Three analysts validated the method with 20 calibration curves total over 30 days with precision and accuracy within +/- 15% for all QCs. This new online method rapidly identifies SIX and NEO exposure with improved sensitivity, which can facilitate the work of public health authorities to confirm the cases of PSP, complementing the many shellfish monitoring programs worldwide. Published by Elsevier Ltd. C1 [Bragg, William A.; Lemire, Sharon W.; Hamelin, Elizabeth I.; Johnson, Rudolph C.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. [Coleman, Rebecca M.] Ctr Dis Control & Prevent, ORISE, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. RP Hamelin, EI (reprint author), Ctr Dis Control & Prevent, 4770 Buford Highway,MS F44, Atlanta, GA 30341 USA. EM eph3@cdc.gov NR 28 TC 3 Z9 4 U1 6 U2 32 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0041-0101 J9 TOXICON JI Toxicon PD JUN 1 PY 2015 VL 99 BP 118 EP 124 DI 10.1016/j.toxicon.2015.03.017 PG 7 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA CI8MD UT WOS:000355025500016 PM 25817003 ER PT J AU Doshi, S Silk, BJ Dutt, D Ahmed, M Cohen, AL Taylor, TH Brooks, WA Goswami, D Luby, SP Fry, AM Ram, PK AF Doshi, Saumil Silk, Benjamin J. Dutt, Dhiman Ahmed, Moshtaq Cohen, Adam L. Taylor, Thomas H. Brooks, W. Abdullah Goswami, Doli Luby, Stephen P. Fry, Alicia M. Ram, Pavani K. TI Household-level risk factors for influenza among young children in Dhaka, Bangladesh: a case-control study SO TROPICAL MEDICINE & INTERNATIONAL HEALTH LA English DT Article DE influenza; human; handwashing; prevention and control; Bangladesh; crowding; influenza; humain; lavage des mains; prevention et controle; Bangladesh; surpeuplement; influenza; humano; lavado de manos; prevencion y control; Bangladesh; hacinamiento ID RANDOMIZED CONTROLLED-TRIAL; RESPIRATORY-TRACT INFECTION; INDOOR AIR-QUALITY; HAND HYGIENE; PANDEMIC INFLUENZA; PARTICULATE MATTER; SEASONAL INFLUENZA; URBAN BANGLADESH; POOR FAMILIES; TRANSMISSION AB ObjectivesTo identify household-level factors associated with influenza among young children in a crowded community in Dhaka, Bangladesh. MethodsWe conducted a case-control study using existing active surveillance for respiratory illness. Cases were children aged 12-59months with laboratory-confirmed influenza. Controls were children frequency-matched by age group with no respiratory illness in the prior 6months. We interviewed caregivers and observed household handwashing behaviour. Soap consumption was estimated by summing weight differences of three bars of soap sequentially left in each household. We measured concentrations of airborne particulate matter <2.5g in diameter (PM2.5) in a subset of households. We used logistic regression to estimate adjusted odds ratios (aOR) and 95% confidence intervals (CI). ResultsWe enrolled 145 cases and 341 controls between March 2009 and April 2010. Case and control household members were observed to wash hands with similar frequency during a 5-h period (mean, 0.64 events vs. 0.63, P=0.87), and similar daily soap consumption per capita (mean 2.92 grams vs. 2.93, P=0.92). Case households were more likely than controls to have crowded (4 persons) sleeping areas (aOR=1.67, CI: 1.06-2.63) and cross-ventilated cooking spaces (aOR=1.75, CI: 1.16-2.63). Case and control households had similar median 24-h geometric mean PM2.5 concentrations in the cooking (69.2 vs. 69.6g/m(3), P=0.45) and sleeping (65.4 vs. 67.4g/m(3), P=0.19) spaces. ConclusionsHandwashing with soap was practiced infrequently and was not associated with paediatric influenza in this community. Interventions aimed at crowded households may reduce influenza incidence in young children. ObjectifsIdentifier les facteurs de risque a l'echelle des menages associes a l'influenza chez les jeunes enfants dans une communaute surpeuplee a Dhaka, au Bangladesh. MethodesNous avons mene une etude cas-temoins en utilisant une surveillance active existante pour les maladies respiratoires. Les cas etaient des enfants ages de 12 a 59 mois souffrant d'influenza confirmee au laboratoire. Les temoins etaient des enfants de frequence correspondante par groupe d'age sans maladie respiratoire au cours des six mois precedents. Nous avons interroge les soignants des enfants et observe le comportement de lavage des mains dans les menages. La consommation de savon a ete estimee en additionnant les differences de poids de trois barres de savon sequentiellement laissees dans chaque menage. Nous avons mesure les concentrations de particules en suspension <2,5g de diametre (PM2,5) dans un sous-ensemble des menages. Nous avons utilise la regression logistique pour estimer les rapports de cotes ajustes (aOR) avec des intervalles de confiance (IC) a 95%. ResultatsNous avons recrute 145 cas et 341 temoins entre mars 2009 et avril 2010. Les membres des menages des cas et des temoins ont ete observes se laver les mains avec une frequence similaire au cours d'une periode de cinq heures (moyenne: 0,64 vs 0,63 evenements; p=0,87) et avec une consommation quotidienne similaire de savon par habitant (moyenne: 2,92 grammes vs 2,93; p=0,92). Les menages des cas etaient plus susceptibles que ceux des temoins d'avoir des espaces de couchage surpeuples (4 personnes) (aOR=1,67; IC: 1,06 a 2,63) et co-ventiles avec des espaces de cuisine (a OR=1,75; IC: 1,16 a 2,63). Les menages des cas et ceux des temoins avaient des concentrations moyennes geometriques de PM2,5 mediane de 24heures similaires dans les espaces de cuisine (69,2 vs 69,6 mcg/m(3;) p = 0,45) et dans les espaces de couchage (65,4 vs 67,4mcg/m(3); p=0,19). ConclusionsLe lavage des mains avec du savon etait pratique rarement et n'etait pas associe a l'influenza pediatrique dans cette communaute. Les interventions visant les menages surpeuples pourraient reduire l'incidence de l'influenza chez les jeunes enfants. ObjetivosIdentificar los factores de riesgo en hogares asociados con la influenza en ninos pequenos de una comunidad hacinada en Dhaka, Bangladesh. MetodosHemos realizado un estudio caso control utilizando una vigilancia activa para enfermedades respiratorias ya existente. Los casos eran ninos con edades entre los 12-59 meses con influenza confirmada en laboratorio. Los controles fueron pareados por grupo de edad con ninos sin enfermedad respiratoria en los seis meses previos. Entrevistamos a los cuidadores y observamos el comportamiento de lavado de manos. El consumo de jabon se calculo sumando las diferencias en peso de tres barras de jabon dejadas secuencialmente en cada uno de los hogares. Hemos medido las concentraciones de particulas aereas con diametro <2.5g (PA(2.5)) en un subgrupo de hogares. Hemos utilizado una regresion logistica para calcular la razon de momios ajustada (aOR) y los intervalos de confianza del 95% (IC). ResultadosSe incluyeron 145 casos y 341 controles entre Marzo del 2009 y Abril 2010. Se observo que los miembros de hogares con casos y de hogares controles se lavaban las manos con una frecuencia similar durante un periodo de 5horas (media, 0.64 eventos vs. 0.63, p=0.87) y tenian un consumo diario de jabon similar per capita (media 2.92 gramos vs. 2.93, p=0.92). Los hogares tenian una mayor probabilidad que los controles de tener dormitorios hacinados (4 personas) (aOR=1.67, IC: 1.06-2.63) y espacios para cocinar con ventilacion cruzada (aOR=1.75, IC: 1.16-2.63). Los hogares con casos y los hogares controles tenian una media geometrica de concentracion de PA(2.5) durante 24-horas similares en los espacios de cocina (69.2 vs. 69.6mcg/m(3), p=0.45) y dormitorios (65.4 vs. 67.4mcg/m(3), p=0.19). ConclusionesEl lavado de manos con jabon era infrecuente y no estaba asociado con la influenza pediatrica en esta comunidad. Las intervenciones cuyo objetivo son los hogares hacinados podrian reducir la incidencia de influenza en ninos pequenos. C1 [Doshi, Saumil; Silk, Benjamin J.; Cohen, Adam L.; Taylor, Thomas H.; Luby, Stephen P.; Fry, Alicia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Doshi, Saumil] Howard Univ, Washington, DC 20059 USA. [Dutt, Dhiman; Ahmed, Moshtaq; Brooks, W. Abdullah; Goswami, Doli] Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh. [Luby, Stephen P.] Stanford Univ, Stanford, CA 94305 USA. [Ram, Pavani K.] SUNY Buffalo, Buffalo, NY 14260 USA. RP Doshi, S (reprint author), Howard Univ Hosp, Dept Med, 2041 Georgia Ave NW, Washington, DC 20060 USA. EM saumil.doshi@howard.edu OI Luby, Stephen/0000-0001-5385-899X NR 40 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1360-2276 EI 1365-3156 J9 TROP MED INT HEALTH JI Trop. Med. Int. Health PD JUN PY 2015 VL 20 IS 6 BP 719 EP 729 DI 10.1111/tmi.12475 PG 11 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CH7AC UT WOS:000354186900004 PM 25682788 ER PT J AU Bhat, G Beck, L Bergen, G Kresnow, MJ AF Bhat, Geeta Beck, Laurie Bergen, Gwen Kresnow, Marcie-jo TI Predictors of rear seat belt use among US adults, 2012 SO JOURNAL OF SAFETY RESEARCH LA English DT Article DE Safety; Transportation; Primary law; Motor vehicle; Injury ID MORTALITY; CRASHES; RISK; PASSENGERS; POSITION; DEATH AB Introduction: Seat belt use reduces the risk of injuries and fatalities among motor vehicle occupants in a crash, but belt use in rear seating positions is consistently lower than front seating positions. Knowledge is limited concerning factors associated with seat belt use among adult rear seat passengers. Methods: Data from the 2012 ConsumerStyles survey were used to calculate weighted percentages of self-reported rear seat belt use by demographic characteristics and type of rear seat belt use enforcement. Multivariable regression was used to calculate prevalence ratios for rear seat belt use, adjusting for person-, household- and geographic-level demographic variables as well as for type of seat belt law in place in the state. Results: Rear seat belt use varied by age, race, geographic region, metropolitan status, and type of enforcement. Multivariable regression showed that respondents living in states with primary (Adjusted Prevalence Ratio (APR): 1.23) and secondary (APR: 1.11) rear seat belt use enforcement laws were significantly more likely to report always wearing a seat belt in the rear seat compared with those living in a state with no rear seat belt use enforcement law. Conclusions and practical applications: Several factors were associated with self-reported seat belt use in rear seating positions. Evidence suggests that primary enforcement covering all seating positions is an effective intervention that can be employed to increase seat belt use and in turn prevent motor vehicle injuries to rear-seated occupants. (C) 2015 National Safety Council and Elsevier Ltd. All rights reserved. C1 [Bhat, Geeta; Beck, Laurie; Bergen, Gwen] Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30096 USA. [Kresnow, Marcie-jo] Ctr Dis Control & Prevent, Div Anal Res & Practice Integrat, Natl Ctr Injury Prevent & Control, Atlanta, GA 30096 USA. RP Bhat, G (reprint author), Ctr Dis Control & Prevent, Div Unintent Injury Prevent, Natl Ctr Injury Prevent & Control, 4770 Buford Highway NE,MS F62, Atlanta, GA 30096 USA. NR 19 TC 3 Z9 3 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-4375 EI 1879-1247 J9 J SAFETY RES JI J. Saf. Res. PD JUN PY 2015 VL 53 BP 103 EP 106 DI 10.1016/j.jsr.2015.03.011 PG 4 WC Ergonomics; Public, Environmental & Occupational Health; Social Sciences, Interdisciplinary; Transportation SC Engineering; Public, Environmental & Occupational Health; Social Sciences - Other Topics; Transportation GA CI2NQ UT WOS:000354584700013 PM 25934003 ER PT J AU Nwankwo, T Ostchega, Y Zhang, GY Hughes, JP AF Nwankwo, Tatiana Ostchega, Yechiam Zhang, Guangyu Hughes, Jeffery P. TI Validating prediction equations for mid-arm circumference measurements in adults: National Health and Nutrition Examination Survey, 2001-2012 SO BLOOD PRESSURE MONITORING LA English DT Article DE arm circumference; blood pressure cuff size; National Health and Nutrition Examination Survey (NHANES) ID BLOOD-PRESSURE-MEASUREMENT; CUFF WIDTH; WEIGHT; HEIGHT; TABLES AB Background Accurate measurement of blood pressure (BP) requires choosing an appropriate BP cuff size. Objectives The objective of this study was to examine the validity of regression equations to predict mid-arm circumference (mid-AC) using 2001-2012 National Health and Nutrition Examination Survey height and weight data. Methods National Health and Nutrition Examination Survey uses a complex multistage probability sample design to represent the civilian, noninstitutionalized US resident population. The sample consisted of 29 745 participants aged 20 years and older. Results For both men and women, the correlations between the predicted and measured mid-AC values were as follows: r = 0.91 and 0.92, P < 0.001, respectively. For both sexes, the difference between the predicted and measured mid-AC mean values was less than 1.5 cm. The overall percent agreement for selecting the appropriate BP cuff, using the American Heart Association cuff size criteria and comparing the predicted mid-AC values with measured values, was 83.0% for men and 80.0% for women. The percent agreement for small adult cuff was 10.0% for men and 54.0% for women; for adult cuff it was 87.0% for men and 88.0% for women; for large adult cuff it was 82.0% for men and 80.0% for women; and for thigh cuff it was 84.0% for men and 74.0% for women. All agreement statistics were above chance (for men, gamma = 0.96, and Kendall's Tau-b = 0.73; for women, gamma = 0.97, and Kendall's Tau-b = 0.76). Conclusion When possible, mid-AC should be directly measured for appropriate BP cuffing; however, the results of this validation study suggest that the prediction equations for mid-AC estimations were highly correlated and had an overall 80.0% agreement with measured mid-AC. Copyright (C) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Nwankwo, Tatiana; Ostchega, Yechiam; Hughes, Jeffery P.] Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Zhang, Guangyu] Ctr Dis Control & Prevent, Off Res & Methodol, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. RP Nwankwo, T (reprint author), Ctr Dis Control & Prevent, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, 3311 Toledo Rd,Rm 4318, Hyattsville, MD 20782 USA. EM bwt4@cdc.gov NR 26 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1359-5237 EI 1473-5725 J9 BLOOD PRESS MONIT JI Blood Press. Monit. PD JUN PY 2015 VL 20 IS 3 BP 157 EP 163 DI 10.1097/MBP.0000000000000107 PG 7 WC Peripheral Vascular Disease SC Cardiovascular System & Cardiology GA CH5WF UT WOS:000354105600008 PM 25647285 ER PT J AU Underwood, JM Richards, TB Henley, SJ Momin, B Houston, K Rolle, I Holmes, C Stewart, SL AF Underwood, J. Michael Richards, Thomas B. Henley, S. Jane Momin, Behnoosh Houston, Keisha Rolle, Italia Holmes, Carissa Stewart, Sherri L. TI Decreasing Trend in Tobacco-Related Cancer Incidence, United States 2005-2009 SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Epidemiology; Cancer; Neoplasm; Tobacco ID LUNG-CANCER; CIGARETTE-SMOKING; ADULTS AB More than 1 in 3 cancer-related deaths are associated with tobacco use; these include cancers of the lung and bronchus, oral cavity and pharynx, larynx, esophagus, stomach, pancreas, kidney and renal pelvis, urinary bladder, and cervix, and acute myeloid leukemia. In order to characterize the current cancer burden due to tobacco use, this study provides recent trends in tobacco-related cancer incidence across the US. We analyzed data from CDC's National Program of Cancer Registries and NCI's Surveillance, Epidemiology and End Results Program, covering 100 % of the US population during 2005-2009. Age-adjusted incidence rates, 95 % confidence intervals and annual percent change were calculated for each state, the District of Columbia, and the US. Tobacco-related cancer incidence in the US decreased significantly from 152.9 (per 100,000 persons) in 2005 to 145.8 in 2009. Men had higher incidence rates, but a greater decrease in tobacco-related cancers per year over the 5-year time period (-1.4 % in men, compared to -0.8 % in women). Incidence rates decreased the most per year for larynx (-2.4 %), lung and bronchus (-1.9 %) and stomach (-1.5 %) cancers during the study period. Tobacco-related cancer incidence trends varied by state. While tobacco-related cancer incidence in the United States decreased overall from 2005 to 2009, tobacco continued to account for a large cancer burden. Our findings suggest that continued efforts in tobacco prevention and control are needed to further reduce tobacco-related cancer burden in general and among targeted sub-populations in the US. C1 [Underwood, J. Michael; Richards, Thomas B.; Henley, S. Jane; Momin, Behnoosh; Houston, Keisha; Stewart, Sherri L.] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Rolle, Italia; Holmes, Carissa] Ctr Dis Control & Prevent, Off Smoking & Hlth, Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. RP Underwood, JM (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, 4770 Buford Highway NE, Atlanta, GA 30341 USA. EM jmunderwood@cdc.gov FU Centers for Disease Control and Prevention's Division of Cancer Prevention and Control; Office on Smoking and Health FX The authors of this report would like to acknowledge the CDC's Workgroup on Tobacco-Related Cancer for their contributions to this study, as well as state and regional cancer registry staff. This work was supported by the Centers for Disease Control and Prevention's Division of Cancer Prevention and Control, and Office on Smoking and Health. NR 19 TC 4 Z9 4 U1 0 U2 6 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD JUN PY 2015 VL 40 IS 3 BP 414 EP 418 DI 10.1007/s10900-014-9951-6 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CH7NB UT WOS:000354222400006 PM 25301588 ER PT J AU Gamba, RJ Schuchter, J Rutt, C Seto, EYW AF Gamba, Ryan J. Schuchter, Joseph Rutt, Candace Seto, Edmund Y. W. TI Measuring the Food Environment and its Effects on Obesity in the United States: A Systematic Review of Methods and Results SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE Food environment; Food access; Community nutrition environment; Obesity; Metrics ID BUILT ENVIRONMENT; INFORMATION-SYSTEMS; OUTLET DATABASES; US; ASSOCIATIONS; DISPARITIES; PREVALENCE; ACCESS; VALIDATION; OVERWEIGHT AB We identified fifty-one peer-reviewed studies that geospatially analyzed the relationship between the community nutrition environment (CNE) and obesity. Eighty percent of studies found at least one significant association between the CNE and obesity. However we calculated the proportion of studies that found at least one significant association between the CNE and obesity in the expected direction for each food store type and measurement technique, and the proportion across the different store types and measurement techniques was just 32 %. Different methods for classifying, locating, and analyzing food stores produced mixed results and challenged direct study level comparison. C1 [Gamba, Ryan J.] Univ Calif Berkeley, Berkeley Sch Publ Hlth, Dept Epidemiol, Berkeley, CA 94720 USA. [Schuchter, Joseph] Univ Calif Berkeley, Berkeley Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA. [Rutt, Candace] Ctr Dis Control & Prevent, Div Nutr Phys Act & Obes, Atlanta, GA 30341 USA. [Seto, Edmund Y. W.] Univ Washington, Sch Publ Hlth, Dept Environm & Occupat Hlth Sci, Seattle, WA 98195 USA. RP Gamba, RJ (reprint author), Univ Calif Berkeley, Berkeley Sch Publ Hlth, Dept Epidemiol, 50 Univ Hall, Berkeley, CA 94720 USA. EM ryangamba@gmail.com FU Centers for Disease Control and Prevention, Prevention Research Centers Program [1-U48-DP001908] FX This research was supported by Cooperative Agreement Number 1-U48-DP001908 from the Centers for Disease Control and Prevention, Prevention Research Centers Program. NR 48 TC 7 Z9 7 U1 2 U2 12 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD JUN PY 2015 VL 40 IS 3 BP 464 EP 475 DI 10.1007/s10900-014-9958-z PG 12 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CH7NB UT WOS:000354222400012 PM 25326425 ER PT J AU Walker, FJ Llata, E Doshani, M Taylor, MM Bertolli, J Weinstock, HS Hall, HI AF Walker, Frances J. Llata, Eloisa Doshani, Mona Taylor, Melanie M. Bertolli, Jeanne Weinstock, Hillard S. Hall, H. Irene TI HIV, Chlamydia, Gonorrhea, and Primary and Secondary Syphilis among American Indians and Alaska Natives Within Indian Health Service Areas in the United States, 2007-2010 SO JOURNAL OF COMMUNITY HEALTH LA English DT Article DE HIV/AIDS; Chlamydia; Gonorrhea; Syphilis; American Indians; Alaska Natives; Indian Health ID SEXUALLY-TRANSMITTED-DISEASES; INFECTION; RISK; SURVEILLANCE; PREVENTION; GUIDELINES; EXPOSURE; ARIZONA; WOMEN AB National rates from human immunodeficiency virus (HIV) and sexually transmitted disease (STD) surveillance may not effectively convey the impact of HIV and STDs on American Indian/Alaska Native (AI/AN) communities. Instead, we compared average annual diagnosis rates per 100,000 population of HIV, chlamydia (CT), gonorrhea (GC), and primary and secondary (P&S) syphilis, from 2007 to 2010, among AI/AN aged a parts per thousand yen13 years residing in 625 counties in the 12 Indian Health Service Areas, all AI/AN, and all races/ethnicities to address this gap. AI/AN comprised persons reported as AI/AN only, with or without Hispanic ethnicity. Out of 12 IHS Areas, 10 had higher case rates for CT, 3 for GC, and 4 for P&S syphilis compared to rates for all races/ethnicities. Eight Areas had higher HIV diagnosis rates than for all AI/AN, but HIV rates for all IHS Areas were lower than national rates for all races/ethnicities. Two IHS Areas ranking highest in rates of CT and GC and four Areas with highest P&S syphilis also had high HIV rates. STD and HIV rates among AI/AN were greater in certain IHS Areas than expected from observing national rates for AI/AN. Integrated surveillance of overlapping trends in STDs and HIV may be useful in guiding prevention efforts for AI/AN populations. C1 [Walker, Frances J.; Bertolli, Jeanne; Hall, H. Irene] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Llata, Eloisa; Taylor, Melanie M.; Weinstock, Hillard S.] Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Doshani, Mona] ICF Int, Atlanta, GA USA. [Taylor, Melanie M.] Indian Hlth Serv, Natl STD Program, Albuquerque, NM USA. [Taylor, Melanie M.] Arizona Dept Hlth Serv, Phoenix, AZ 85007 USA. RP Llata, E (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd NE,MS E-02, Atlanta, GA 30333 USA. EM gge3@cdc.gov NR 41 TC 2 Z9 2 U1 0 U2 3 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0094-5145 EI 1573-3610 J9 J COMMUN HEALTH JI J. Community Health PD JUN PY 2015 VL 40 IS 3 BP 484 EP 492 DI 10.1007/s10900-014-9961-4 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CH7NB UT WOS:000354222400014 PM 25371109 ER PT J AU Anderson, EJ Shippee, DB Tate, JE Larkin, B Bregger, MD Katz, BZ Noskin, GA Sederdahl, BK Shane, AL Parashar, UD Yogev, R AF Anderson, Evan J. Shippee, Deanna B. Tate, Jacqueline E. Larkin, Bruce Bregger, Melissa D. Katz, Ben Z. Noskin, Gary A. Sederdahl, Bethany K. Shane, Andi L. Parashar, Umesh D. Yogev, Ram TI Clinical characteristics and genotypes of rotavirus in adults SO JOURNAL OF INFECTION LA English DT Letter DE Rotavirus; Adult; Genotypes; Severity; Travel; HIV; Immunocompromised; G9P[4] ID INDIRECT PROTECTION; VACCINATION C1 [Anderson, Evan J.; Sederdahl, Bethany K.; Shane, Andi L.] Emory Univ, Sch Med, Dept Pediat, Atlanta, GA USA. [Anderson, Evan J.] Emory Univ, Sch Med, Dept Med, Atlanta, GA USA. [Shippee, Deanna B.; Larkin, Bruce; Katz, Ben Z.; Yogev, Ram] Northwestern Univ, Feinberg Sch Med, Dept Pediat, Chicago, IL 60611 USA. [Shippee, Deanna B.; Bregger, Melissa D.; Noskin, Gary A.] Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA. [Tate, Jacqueline E.; Parashar, Umesh D.] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. RP Anderson, EJ (reprint author), Div Pediat Infect Dis, 2015 Uppergate, Atlanta, GA 30323 USA. EM evanderson@emory.edu NR 11 TC 2 Z9 2 U1 0 U2 0 PU W B SAUNDERS CO LTD PI LONDON PA 32 JAMESTOWN RD, LONDON NW1 7BY, ENGLAND SN 0163-4453 EI 1532-2742 J9 J INFECTION JI J. Infect. PD JUN PY 2015 VL 70 IS 6 BP 683 EP 687 DI 10.1016/j.jinf.2014.11.012 PG 6 WC Infectious Diseases SC Infectious Diseases GA CH5ZT UT WOS:000354115600019 PM 25481405 ER PT J AU Jones, SE Brener, ND Bergren, MD AF Jones, S. Everett Brener, Nancy D. Bergren, Martha Dewey TI Association Between School District Policies That Address Chronic Health Conditions of Students and Professional Development for School Nurses on Such Policies SO JOURNAL OF SCHOOL NURSING LA English DT Article DE chronic diseases; school policies; professional development; continuing education AB Supportive school policies and well-prepared school nurses can best address the needs of students with chronic health conditions. We analyzed nationally representative data from the 2012 School Health Policies and Practices Study to examine whether districts with policies requiring that schools provide health services to students with chronic health conditions were more likely to provide funding for professional development (PD) or offer PD to school nurses on those health services than districts without such policies. Compared to districts without certain requirements for health services related to chronic health conditions, districts with those requirements were more likely to provide PD on related topics (for all comparisons, p .001). For some topics, however, regardless of district requirements, PD was fairly low and suggests the need for increases in the rates at which districts provide PD to support school nurses who deliver services to students with chronic health conditions. C1 [Jones, S. Everett; Brener, Nancy D.] Ctr Dis Control & Prevent, Atlanta, GA 30329 USA. [Bergren, Martha Dewey] Univ Illinois, Coll Nursing, Chicago, IL USA. RP Jones, SE (reprint author), Ctr Dis Control & Prevent, 1600 Clifton Rd NE,MS E75, Atlanta, GA 30329 USA. EM sce2@cdc.gov FU Intramural CDC HHS [CC999999] NR 13 TC 0 Z9 0 U1 0 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1059-8405 EI 1546-8364 J9 J SCH NURS JI J. Sch. Nurs. PD JUN PY 2015 VL 31 IS 3 BP 163 EP 166 DI 10.1177/1059840514547275 PG 4 WC Nursing SC Nursing GA CH4EG UT WOS:000353984700002 PM 25228667 ER PT J AU Shah, AS Dolan, LM Dabelea, D Stafford, JM D'Agostino, RB Mayer-Davis, EJ Marcovina, S Imperatore, G Wadwa, RP Daniels, SR Reynolds, K Hamman, RF Bowlby, DA Maahs, DM AF Shah, Amy S. Dolan, Lawrence M. Dabelea, Dana Stafford, Jeanette M. D'Agostino, Ralph B., Jr. Mayer-Davis, Elizabeth J. Marcovina, Santica Imperatore, Giuseppina Wadwa, R. Paul Daniels, Stephen R. Reynolds, Kristi Hamman, Richard F. Bowlby, Deborah A. Maahs, David M. CA SEARCH Diabet Youth Study TI Change in adiposity minimally affects the lipid profile in youth with recent onset type 1 diabetes SO PEDIATRIC DIABETES LA English DT Article DE body mass index; lipids; pediatrics ID INSULIN-RESISTANCE; YOUNG-ADULTS; CARDIOVASCULAR-DISEASE; SCIENTIFIC STATEMENT; RISK-FACTORS; ADOLESCENTS; CHILDREN; ASSOCIATION; OBESITY; ATHEROSCLEROSIS AB ObjectiveDyslipidemia contributes to the increased risk of cardiovascular disease in persons with type 1 diabetes (T1D). Weight control is commonly recommended as a treatment for dyslipidemia. However, the extent to which decreases in weight affect the lipid profile in youth with T1D is not known. Therefore, we tested the hypothesis that decreases in body mass index z-score (BMIz) were associated with concomitant changes in the lipid profile in youth with T1D. Study DesignWe studied 1142 youth with incident T1D, who had at least two fasting lipid measurements over 2 yr (initial visit mean: age = 10.8 3.9 yr, BMIz = 0.55 0.97, T1D duration = 10.7 +/- 7.6 months; 47.5% female, 77.9% non-Hispanic white) in the SEARCH for Diabetes in Youth Study. Longitudinal mixed models were used to examine the relationships between changes in BMIz and changes in total, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL cholesterol, and log triglycerides (TG) adjusted for initial age, sex, race/ethnicity, clinical site, season of study visit, T1D duration, and glycated hemoglobin A1c (HbA1c). Results

We found that over 2 yr all lipid levels, except LDL-C, increased significantly (p < 0.05). Decreases in BMIz were associated with favorable changes in HDL-C and TG only and the magnitude of these changes depended on the initial BMIz value (interaction p < 0.05), so that greater improvements were seen in those with higher BMIz. Conclusions

Our data suggest that weight loss may be an effective, but limited, therapeutic approach for dyslipidemia in youth with T1D. C1 [Shah, Amy S.; Dolan, Lawrence M.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH 45229 USA. [Dabelea, Dana; Hamman, Richard F.; Maahs, David M.] Colorado Sch Publ Hlth, Dept Epidemiol, Aurora, CO USA. [Stafford, Jeanette M.; D'Agostino, Ralph B., Jr.] Wake Forest Sch Med, Dept Biostat, Winston Salem, NC USA. [Mayer-Davis, Elizabeth J.] Univ N Carolina, Sch Med, Dept Nutr, Chapel Hill, NC USA. [Mayer-Davis, Elizabeth J.] UNC Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC USA. [Marcovina, Santica] Univ Washington, Northwest Lipid Metab & Diabet Res Labs, Seattle, WA 98195 USA. [Imperatore, Giuseppina] Ctr Dis Control & Prevent, Atlanta, GA USA. [Wadwa, R. Paul; Daniels, Stephen R.; Maahs, David M.] Univ Colorado Denver, Dept Pediat, Aurora, CO USA. [Reynolds, Kristi] Kaiser Permanente So Calif, Dept Res & Evaluat, Pasadena, CA 91101 USA. [Bowlby, Deborah A.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA. RP Shah, AS (reprint author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,ML 7012, Cincinnati, OH 45229 USA. EM amy.shah@cchmc.org RI Dagostino Jr, Ralph/C-4060-2017 OI Dagostino Jr, Ralph/0000-0002-3550-8395 FU Centers for Disease Control and Prevention [00097, DP-05-069, DP-10001]; National Institute of Diabetes and Digestive and Kidney Diseases; General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR) [UL1RR029882]; Children's Hospital and Regional Medical Center [M01RR00037]; Colorado Pediatric General Clinical Research Center [M01 RR00069]; Institutional Clinical and Translational Science Award (CTSA), NIH/NCRR at the University of Cincinnati [1UL1RR026314-01] FX The SEARCH for Diabetes in Youth Study is indebted to the many youth and their families, and their health care providers, whose participation made this study possible. SEARCH for Diabetes in Youth is funded by the Centers for Disease Control and Prevention (PA numbers 00097, DP-05-069, and DP-10001) and supported by the National Institute of Diabetes and Digestive and Kidney Diseases. The authors wish to acknowledge the involvement of General Clinical Research Centers (GCRC) at the South Carolina Clinical & Translational Research (SCTR) Institute, at the Medical University of South Carolina (NIH/NCRR Grant number UL1RR029882); Children's Hospital and Regional Medical Center (Grant Number M01RR00037); Colorado Pediatric General Clinical Research Center (Grant Number M01 RR00069) and the Barbara Davis Center at the University of Colorado at Denver (DERC NIH P30 DK57516); and the Institutional Clinical and Translational Science Award (CTSA), NIH/NCRR at the University of Cincinnati (Grant Number 1UL1RR026314-01); and the Children with Medical Handicaps program managed by the Ohio Department of Health. NR 25 TC 2 Z9 2 U1 0 U2 7 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1399-543X EI 1399-5448 J9 PEDIATR DIABETES JI Pediatr. Diabetes PD JUN PY 2015 VL 16 IS 4 BP 280 EP 286 DI 10.1111/pedi.12162 PG 7 WC Endocrinology & Metabolism; Pediatrics SC Endocrinology & Metabolism; Pediatrics GA CH6CL UT WOS:000354123300006 PM 25099744 ER PT J AU Kamal, RP Kumar, A Davis, CT Tzeng, WP Nguyen, T Donis, RO Katz, JM York, IA AF Kamal, Ram P. Kumar, Amrita Davis, Charles T. Tzeng, Wen-Pin Nguyen, Tung Donis, Ruben O. Katz, Jacqueline M. York, Ian A. TI Emergence of Highly Pathogenic Avian Influenza A(H5N1) Virus PB1-F2 Variants and Their Virulence in BALB/c Mice SO JOURNAL OF VIROLOGY LA English DT Article ID A H5N1 VIRUSES; PROTEIN PB1-F2; MITOCHONDRIAL-MEMBRANE; DIFFERENT STRAINS; SWINE; SEQUENCE; SURVEILLANCE; TRANSMISSION; INTERFERON; EXPRESSION AB Influenza A viruses (IAVs) express the PB1-F2 protein from an alternate reading frame within the PB1 gene segment. The roles of PB1-F2 are not well understood but appear to involve modulation of host cell responses. As shown in previous studies, we find that PB1-F2 proteins of mammalian IAVs frequently have premature stop codons that are expected to cause truncations of the protein, whereas avian IAVs usually express a full-length 90-amino-acid PB1-F2. However, in contrast to other avian IAVs, recent isolates of highly pathogenic H5N1 influenza viruses had a high proportion of PB1-F2 truncations (15% since 2010; 61% of isolates in 2013) due to several independent mutations that have persisted and expanded in circulating viruses. One natural H5N1 IAV containing a mutated PB1-F2 start codon (i.e., lacking ATG) was 1,000-fold more virulent for BALB/c mice than a closely related H5N1 containing intact PB1-F2. In vitro, we detected expression of an in-frame protein (C-terminal PB1-F2) from downstream ATGs in PB1-F2 plasmids lacking the well-conserved ATG start codon. Transient expression of full-length PB1-F2, truncated (24-amino-acid) PB1-F2, and PB1-F2 lacking the initiating ATG in mammalian and avian cells had no effect on cell apoptosis or interferon expression in human lung epithelial cells. Full-length and C-terminal PB1-F2 mutants colocalized with mitochondria in A549 cells. Close monitoring of alterations of PB1-F2 and their frequency in contemporary avian H5N1 viruses should continue, as such changes may be markers for mammalian virulence. IMPORTANCE Although most avian influenza viruses are harmless for humans, some (such as highly pathogenic H5N1 avian influenza viruses) are capable of infecting humans and causing severe disease with a high mortality rate. A number of risk factors potentially associated with adaptation to mammalian infection have been noted. Here we demonstrate that the protein PB1-F2 is frequently truncated in recent isolates of highly pathogenic H5N1 viruses. Truncation of PB1-F2 has been proposed to act as an adaptation to mammalian infection. We show that some forms of truncation of PB1-F2 may be associated with increased virulence in mammals. Our data support the assessment of PB1-F2 truncations for genomic surveillance of influenza viruses. C1 [Kamal, Ram P.; Kumar, Amrita; Davis, Charles T.; Tzeng, Wen-Pin; Donis, Ruben O.; Katz, Jacqueline M.; York, Ian A.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. [Kamal, Ram P.; Kumar, Amrita] Battelle Mem Inst, Atlanta, GA USA. [Nguyen, Tung] Natl Ctr Vet Diagnost, Dept Anim Hlth, Hanoi, Vietnam. RP York, IA (reprint author), Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. EM ITE1@cdc.gov OI York, Ian/0000-0002-3478-3344 FU ORISE FX We thank ORISE for supporting R.P.K. as a guest researcher at CDC. NR 48 TC 6 Z9 6 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD JUN PY 2015 VL 89 IS 11 BP 5835 EP 5846 DI 10.1128/JVI.03137-14 PG 12 WC Virology SC Virology GA CH3DU UT WOS:000353907900009 PM 25787281 ER PT J AU Devignot, S Bergeron, E Nichol, S Mirazimi, A Weber, F AF Devignot, Stephanie Bergeron, Eric Nichol, Stuart Mirazimi, Ali Weber, Friedemann TI A Virus-Like Particle System Identifies the Endonuclease Domain of Crimean-Congo Hemorrhagic Fever Virus SO JOURNAL OF VIROLOGY LA English DT Article ID TIME RT-PCR; REVERSE GENETICS; NONCODING REGIONS; NUCLEIC-ACID; RIG-I; TRANSCRIPTION; POLYMERASE; GENOME; REPLICATION; PROTEIN AB Crimean-Congo hemorrhagic fever virus (CCHFV; genus Nairovirus) is an extremely pathogenic member of the Bunyaviridae family. Since handling of the virus requires a biosafety level 4 (BSL-4) facility, little is known about pathomechanisms and host interactions. Here, we describe the establishment of a transcriptionally competent virus-like particle (tc-VLP) system for CCHFV. Recombinant polymerase (L), nucleocapsid protein (N) and a reporter minigenome expressed in human HuH-7 cells resulted in formation of transcriptionally active nucleocapsids that could be packaged by coexpressed CCHFV glycoproteins into tc-VLPs. The tc-VLPs resembled authentic virus particles in their protein composition and neutralization sensitivity to anti-CCHFV antibodies and could recapitulate all steps of the viral replication cycle. Particle attachment, entry, and primary transcription were modeled by infection of naive cells. The subsequent steps of genome replication, secondary transcription, and particle assembly and release can be obtained upon passaging the tc-VLPs on cells expressing CCHFV structural proteins. The utility of the VLP system was demonstrated by showing that the endonuclease domain of L is located around amino acid D693, as was predicted in silico by B. Morin et al. (PLoS Pathog 6:e1001038, 2010, http://dx.doi.org/10.1371/journal.ppat.1001038). The tc-VLP system will greatly facilitate studies and diagnostics of CCHFV under non-BSL-4 conditions. IMPORTANCE Crimean-Congo hemorrhagic fever virus (CCHFV) is an extremely virulent pathogen of humans. Since the virus can be handled only at the highest biosafety level, research is restricted to a few specialized laboratories. We developed a plasmid-based system to produce virus-like particles with the ability to infect cells and transcribe a reporter genome. Due to the absence of viral genes, the virus-like particles are unable to spread or cause disease, thus allowing study of aspects of CCHFV biology under relaxed biosafety conditions. C1 [Devignot, Stephanie; Weber, Friedemann] Univ Marburg, Inst Virol, D-35032 Marburg, Germany. [Bergeron, Eric; Nichol, Stuart] Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Special Pathogens Branch, Atlanta, GA USA. [Mirazimi, Ali] Publ Hlth Agcy Sweden, Stockholm, Sweden. [Mirazimi, Ali] Natl Vet Inst, S-75007 Uppsala, Sweden. [Mirazimi, Ali] Karolinska Inst, Dept Clin Microbiol, LABMED, Stockholm, Sweden. RP Weber, F (reprint author), Univ Giessen, Inst Virol, Vet Med FB10, D-35390 Giessen, Germany. EM friedemann.weber@vetmed.uni-giessen.de OI Devignot, Stephanie/0000-0002-0618-5611; Weber, Friedemann/0000-0001-9737-337X FU European Commission under the Health Cooperation Work Programme [260427] FX This work is part of the CCHFever Network (Collaborative Project) supported by the European Commission under the Health Cooperation Work Programme (grant agreement no. 260427 to A.M. and F.W.). NR 45 TC 7 Z9 7 U1 0 U2 4 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0022-538X EI 1098-5514 J9 J VIROL JI J. Virol. PD JUN PY 2015 VL 89 IS 11 BP 5957 EP 5967 DI 10.1128/JVI.03691-14 PG 11 WC Virology SC Virology GA CH3DU UT WOS:000353907900019 PM 25810550 ER PT J AU Silva, MJ Samandar, E Calafat, AM Ye, XY AF Silva, Manori J. Samandar, Ella Calafat, Antonia M. Ye, Xiaoyun TI Identification of di-2-ethylhexyl terephthalate (DEHTP) metabolites using human liver microsomes for biomonitoring applications SO TOXICOLOGY IN VITRO LA English DT Article DE Di-2-ethylhexyl terephthalate; DEHTP; Biomonitoring; Environmental exposure; Oxidative metabolites ID IN-VITRO METABOLISM; DI(2-ETHYLHEXYL) TEREPHTHALATE; EXPOSURE; RAT; TOXICOLOGY; URINE AB Di-2-ethylhexyl terephthalate (DEHTP), a structural isomer of the plasticizer di-2-ethylhexyl phthalate (DEHP), is used in food packaging and medical devices, among other applications, and is a potential replacement for DEHP and other ortho-phthalate plasticizers. Identifying sensitive and specific biomarkers of DEHTP is necessary to assess humans' background exposure to DEHTP. Using mass spectrometry, we investigated the metabolism of DEHTP by human liver microsomes to identify in vitro DEHTP metabolites. We unequivocally identified terephthalic acid (TPA) and mono-2-ethylhydroxyhexyl terephthalate (MEHHTP), using authentic standards, and tentatively identified mono-2-ethylhexyl terephthalate (MEHTP) and two other oxidative metabolites of DEHTP: mono-2-ethyloxohexyl terephthalate (MEOHTP), and mono-2-ethyl-5-carboxypentyl terephthalate (MECPTP) from their mass spectrometry fragmentation patterns. We also evaluated the formation of in vitro metabolites of DEHP. DEHTP and DEHP produced similar metabolites, but their metabolite profiles differed considerably. DEHTP metabolized to form TPA, a metabolite of several terephthalates, as the major in vitro metabolite, followed by MEHTP, MEHHTP, MEOHTP and MECPTP. MEHTP, MEHHTP, MEOHTP and MECPTP, which are specific metabolites of DEHTP, may be suitable biomarkers for assessing exposure to DEHTP. Nonetheless, data on the urinary excretion fraction and temporal stability of these metabolites, among other considerations, are needed to demonstrate their utility as exposure biomarkers. Published by Elsevier Ltd. C1 [Silva, Manori J.; Samandar, Ella; Calafat, Antonia M.; Ye, Xiaoyun] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA 30341 USA. RP Silva, MJ (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy,Mailstop F53, Atlanta, GA 30341 USA. EM zca2@cdc.gov FU Centers for Disease Control and Prevention; U.S. Department of Health and Human Services FX This work was supported by the Centers for Disease Control and Prevention, U.S. Department of Health and Human Services. NR 16 TC 3 Z9 3 U1 1 U2 16 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-2333 J9 TOXICOL IN VITRO JI Toxicol. Vitro PD JUN PY 2015 VL 29 IS 4 BP 716 EP 721 DI 10.1016/j.tiv.2015.02.002 PG 6 WC Toxicology SC Toxicology GA CH1AV UT WOS:000353754400009 PM 25687528 ER PT J AU O'Callaghan, JP Kelly, KA Locker, AR Miller, DB Lasley, SM AF O'Callaghan, James P. Kelly, Kimberly A. Locker, Alicia R. Miller, Diane B. Lasley, Steve M. TI Corticosterone primes the neuroinflammatory response to DFP in mice: potential animal model of Gulf War Illness SO JOURNAL OF NEUROCHEMISTRY LA English DT Article DE CORT; DFP; GWI; microglia; minocycline; neuroinflammation ID FIBRILLARY ACIDIC PROTEIN; NECROSIS-FACTOR-ALPHA; INDUCED SICKNESS BEHAVIOR; INDUCED NEURONAL DAMAGE; GENE-EXPRESSION; REPEATED STRESS; RAT-BRAIN; PYRIDOSTIGMINE BROMIDE; INDUCED NEUROTOXICITY; HIPPOCAMPAL DAMAGE AB Gulf War Illness (GWI) is a multi-symptom disorder with features characteristic of persistent sickness behavior. Among conditions encountered in the Gulf War (GW) theater were physiological stressors (e.g., heat/cold/physical activity/sleep deprivation), prophylactic treatment with the reversible AChE inhibitor, pyridostigmine bromide (PB), the insect repellent, N,N-diethyl-meta-toluamide (DEET), and potentially the nerve agent, sarin. Prior exposure to the anti-inflammatory glucocorticoid, corticosterone (CORT), at levels associated with high physiological stress, can paradoxically prime the CNS to produce a robust proinflammatory response to neurotoxicants and systemic inflammation; such neuroinflammatory effects can be associated with sickness behavior. Here, we examined whether CORT primed the CNS to mount neuroinflammatory responses to GW exposures as a potential model of GWI. Male C57BL/6 mice were treated with chronic (14days) PB/ DEET, subchronic (7-14days) CORT, and acute exposure (day 15) to diisopropyl fluorophosphate (DFP), a sarin surrogate and irreversible AChE inhibitor. DFP alone caused marked brain-wide neuroinflammation assessed by qPCR of tumor necrosis factor-, IL6, chemokine (C-C motif) ligand 2, IL-1, leukemia inhibitory factor, and oncostatin M. Pre-treatment with high physiological levels of CORT greatly augmented (up to 300-fold) the neuroinflammatory responses to DFP. Anti-inflammatory pre-treatment with minocycline suppressed many proinflammatory responses to CORT+DFP. Our findings are suggestive of a possible critical, yet unrecognized interaction between the stressor/environment of the GW theater and agent exposure(s) unique to this war. Such exposures may in fact prime the CNS to amplify future neuroinflammatory responses to pathogens, injury, or toxicity. Such occurrences could potentially result in the prolonged episodes of sickness behavior observed in GWI. C1 [O'Callaghan, James P.; Kelly, Kimberly A.; Locker, Alicia R.; Miller, Diane B.] NIOSH, Hlth Effects Lab Div, Ctr Dis Control & Prevent, Morgantown, WV 26505 USA. [Lasley, Steve M.] Univ Illinois, Coll Med Peoria, Dept Canc Biol & Pharmacol, Peoria, IL USA. RP O'Callaghan, JP (reprint author), NIOSH, Ctr Dis Control & Prevent, 1095 Willowdale Rd,Mailstop L-3014, Morgantown, WV 26505 USA. EM jdo5@cdc.gov RI Kelly, Kimberly/J-9834-2012 OI Kelly, Kimberly/0000-0002-1146-3137 FU CDMRP [W81XWH-09-2-0098]; Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health FX This work was funded by CDMRP grant number W81XWH-09-2-0098 and Intramural funds from the Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health. We appreciate the excellent technical assistance provided by Brenda K. Billig and Christopher M. Felton and the productive discussions and advice received from Dr Lindsay T. Michalovicz. We have no conflicts of interest to declare. NR 68 TC 7 Z9 7 U1 2 U2 10 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-3042 EI 1471-4159 J9 J NEUROCHEM JI J. Neurochem. PD JUN PY 2015 VL 133 IS 5 BP 708 EP 721 DI 10.1111/jnc.13088 PG 14 WC Biochemistry & Molecular Biology; Neurosciences SC Biochemistry & Molecular Biology; Neurosciences & Neurology GA CG8PH UT WOS:000353570500009 PM 25753028 ER PT J AU van Hasselt, M Kruger, J Han, B Caraballo, RS Penne, MA Loomis, B Gfroerer, JC AF van Hasselt, Martijn Kruger, Judy Han, Beth Caraballo, Ralph S. Penne, Michael A. Loomis, Brett Gfroerer, Joseph C. TI The relation between tobacco taxes and youth and young adult smoking: What happened following the 2009 US federal tax increase on cigarettes? SO ADDICTIVE BEHAVIORS LA English DT Article DE Tobacco; Youth smoking; Young adult smoking; Tax ID UNITED-STATES; PUBLIC-POLICY; PRICES; INITIATION; ACCESS; COMMUNITY; CESSATION; IMPACT AB Background: On April 1, 2009, the federal government raised cigarette taxes from $039 to $1.01 per pack. This study examines the impact of this increase on a range of smoking behaviors among youth aged 12 to 17 and young adults aged 18 to 25. Methods: Data from the 2002-2011 National Survey on Drug Use and Health (NSDUH) were used to estimate the impact of the tax increase on five smoking outcomes: (1) past year smoking initiation, (2) past-month smoking, (3) past year smoking cessation, (4) number of days cigarettes were smoked during the past month, and (5) average number of cigarettes smoked per day. Each model included individual and state-level covariates and other tobacco control policies that coincided with the tax increase. We examined the impact overall and by race and gender. Results: The odds of smoking initiation decreased for youth after the tax increase (odds ratio (OR) = 0.83, p < 0.0001). The odds of past-month smoking also decreased (youth: OR = 0.83, p < 0.0001; young adults: OR = 0.92, p < 0.0001), but the odds of smoking cessation remained unchanged. Current smokers smoked on fewer days (youth: coefficient = -0.97, p = 0.0001; young adults: coefficient = -0.84, p < 0.0001) and smoked fewer cigarettes per day after the tax increase (youth: coefficient = -1.02, p = 0.0011; young adults: coefficient = -0.92, p < 0.0001). Conclusions: The 2009 federal cigarette tax increase was associated with a substantial reduction in smoking among youths and young adults. The impact of the tax increase varied across male, female, white and black subpopulations. (C) 2015 Elsevier Ltd. All rights reserved. C1 [van Hasselt, Martijn] Univ N Carolina, Dept Econ, Greensboro, NC 27402 USA. [Kruger, Judy; Caraballo, Ralph S.] Ctr Dis Control & Prevent, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA. [Han, Beth; Gfroerer, Joseph C.] Subst Abuse & Mental Hlth Serv Adm, Ctr Behav Hlth Stat & Qual, Rockville, MD 20857 USA. [Penne, Michael A.; Loomis, Brett] RTI Int, Res Triangle Pk, NC 27709 USA. RP Loomis, B (reprint author), RTI Int, 3040 E Cornwallis Rd, Res Triangle Pk, NC 27709 USA. EM loomis@rti.org FU Substance Abuse and Mental Health Services Administration; Centers for Disease Control and Prevention FX This study was funded by a contract from the Substance Abuse and Mental Health Services Administration and the Centers for Disease Control and Prevention to RTI International. Co-authors from these agencies played an active role in the interpretation of the data, writing the manuscript, and decision to publish. NR 37 TC 11 Z9 11 U1 1 U2 15 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4603 EI 1873-6327 J9 ADDICT BEHAV JI Addict. Behav. PD JUN PY 2015 VL 45 BP 104 EP 109 DI 10.1016/j.addbeh.2015.01.023 PG 6 WC Psychology, Clinical; Substance Abuse SC Psychology; Substance Abuse GA CF6ON UT WOS:000352676100019 PM 25658771 ER PT J AU Benhafid, M Elomari, N Idrissi, MA Rguig, A Gentsch, JR Parashar, U Elaouad, R AF Benhafid, Mohammed Elomari, Nezha Idrissi, Meryem Azzouzi Rguig, Ahmed Gentsch, Jon R. Parashar, Umesh Elaouad, Rajae TI Effect of Monovalent Rotavirus Vaccine on Rotavirus Disease Burden and Circulating Rotavirus Strains Among Children in Morocco SO JOURNAL OF MEDICAL VIROLOGY LA English DT Article DE rotavirus; genotype; rotavirus vaccine; Morocco ID GROUP-A ROTAVIRUS; POLYMERASE-CHAIN-REACTION; 1ST 2 YEARS; GENOTYPE DISTRIBUTION; AFRICAN INFANTS; DOUBLE-BLIND; GASTROENTERITIS; DIVERSITY; DIARRHEA; POPULATION AB Rotarix(TM)vaccine was introduced into the National Program of Immunization of Morocco in October 2010, reaching quickly 87% of the target population of children nationally. The incidence of rotavirus gastroenteritis and the prevalence of circulating rotavirus strains has been monitored in three sentinel hospitals since June 2006. The average percentage of rotavirus positive cases among all children under 5 years old hospitalized for gastroenteritis during the pre-vaccine period (2006-2010) was 44%. This percentage dropped to 29%, 15% and 24% in the 3 years post vaccine introduction (2011, 2012 and 2013), which is a decline of 34%, 66%, and 45%, respectively. Declines in prevalence were greatest among children 0-1 years of age (53%) and were most prominent during the winter and autumn rotavirus season. The prevalence of the G2P[4] and G9P[8] genotype sharply increased in the post vaccine period (2011-2013) compared to the previous seasons (2006-2010). Rotavirus vaccines have reduced greatly the number of children hospitalized due to rotavirus infection at the three sentinel hospitals; it is however unclear if the predominance of G2P[4] and G9P[8] genotypes is related to the vaccine introduction, or if this is attributable to normal genotype fluctuations. Continued surveillance will be pivotal to answer this question in the future. J. Med. Virol. 87:944-953, 2015. (c) 2015 Wiley Periodicals, Inc. C1 [Benhafid, Mohammed; Idrissi, Meryem Azzouzi; Elaouad, Rajae] Natl Inst Hyg, Minist Hlth, Virol Lab, Rabat, Morocco. [Rguig, Ahmed] Minist Hlth, Epidemiol & Dis Control Dept, Rabat, Morocco. [Elaouad, Rajae] Mohamed V Univ, Sch Med & Pharm, UPR Immunol, Rabat, Morocco. [Gentsch, Jon R.; Parashar, Umesh] Ctr Dis Control & Prevent, Viral Gastroenteritis Div, Atlanta, GA USA. [Elomari, Nezha] Mohamed V Univ, Fac Sci, Rabat, Morocco. RP Benhafid, M (reprint author), Natl Inst Hyg, Minist Hlth, Virol Lab, 27 Rue Ibn Batouta, Rabat, Morocco. EM benhafidm@yahoo.fr FU Ministry of Health of Morocco; EMRO WHO FX Grant sponsor: Ministry of Health of Morocco; Grant sponsor: EMRO WHO. NR 51 TC 0 Z9 0 U1 0 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0146-6615 EI 1096-9071 J9 J MED VIROL JI J. Med. Virol. PD JUN PY 2015 VL 87 IS 6 BP 944 EP 953 DI 10.1002/jmv.24122 PG 10 WC Virology SC Virology GA CF8ER UT WOS:000352789200009 PM 25753952 ER PT J AU Nichols, M Takacs, N Ragsdale, J Levenson, D Marquez, C Roache, K Tarr, CL AF Nichols, M. Takacs, N. Ragsdale, J. Levenson, D. Marquez, C. Roache, K. Tarr, C. L. TI Listeria monocytogenes Infection in a Sugar Glider (Petaurus breviceps) - New Mexico, 2011 SO ZOONOSES AND PUBLIC HEALTH LA English DT Article DE Listeria monocytogenes; sugar glider (Petaurus breviceps) ID MULTISTATE OUTBREAK; UNITED-STATES AB Listeria monocytogenes is a Gram-positive, facultative anaerobic, rod-shaped bacterium that can infect and cause disease in many species. In this case report, we describe a case of L.monocytogenes infection causing sepsis in a sugar glider (Petaurus breviceps). The sugar glider consumed a varied diet consisting of human food items, including cantaloupe. A nationwide outbreak of L.monocytogenes foodborne illness associated with cantaloupes occurred simultaneously with this incident case. In this case, the bacterial strains from the outbreak and glider were genetically distinct. Although rare, veterinarians should be aware of the emergence of foodborne pathogens' ability to infect exotic animals residing in domestic environments. C1 [Nichols, M.] New Mexico Dept Hlth, Epidemiol & Response Div, Santa Fe, NM 87505 USA. [Takacs, N.; Ragsdale, J.] New Mexico Dept Agr, Vet Diagnost Serv, Albuquerque, NM USA. [Levenson, D.] Southwest Vet Med Ctr, Corrales, NM USA. [Marquez, C.] New Mexico Dept Hlth, Div Sci Lab, Albuquerque, NM USA. [Roache, K.; Tarr, C. L.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA USA. RP Nichols, M (reprint author), New Mexico Dept Hlth, Epidemiol & Response Div, 1190 St Francis Dr,Ste N-1350, Santa Fe, NM 87505 USA. EM megin.nichols@state.nm.us NR 12 TC 0 Z9 0 U1 1 U2 4 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1863-1959 EI 1863-2378 J9 ZOONOSES PUBLIC HLTH JI Zoonoses Public Health PD JUN PY 2015 VL 62 IS 4 BP 254 EP 257 DI 10.1111/zph.12134 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences SC Public, Environmental & Occupational Health; Infectious Diseases; Veterinary Sciences GA CG1SU UT WOS:000353055100002 PM 24815369 ER PT J AU Roellig, DM Salzer, JS Carroll, DS Ritter, JM Drew, C Gallardo-Romero, N Keckler, MS Langham, G Hutson, CL Karem, KL Gillespie, TR Visvesvara, GS Metcalfe, MG Damon, IK Xiao, LH AF Roellig, Dawn M. Salzer, Johanna S. Carroll, Darin S. Ritter, Jana M. Drew, Clifton Gallardo-Romero, Nadia Keckler, M. Shannon Langham, Gregory Hutson, Christina L. Karem, Kevin L. Gillespie, Thomas R. Visvesvara, Govinda S. Metcalfe, Maureen G. Damon, Inger K. Xiao, Lihua TI Identification of Giardia duodenalis and Enterocytozoon bieneusi in an epizoological investigation of a laboratory colony of prairie dogs, Cynomys ludovicianus SO VETERINARY PARASITOLOGY LA English DT Article DE Giardia duodenalis; Prairie dog; Enterocytozoon; Microsporidia; Cynomys ludovicianus; Giardiasis ID WILD ANIMALS; CRYPTOSPORIDIUM AB Since 2005, black-tailed prairie dogs (Cynomys ludovicianus) have been collected for use as research animals from field sites in Kansas, Colorado, and Texas. In January of 2012, Giardia trophozoites were identified by histology, thin-section electron microscopy, and immunofluorescent staining in the lumen of the small intestine and colon of a prairie dog euthanized because of extreme weight loss. With giardiasis suspected as the cause of weight loss, a survey of Giardia duodenalis in the laboratory colony of prairie dogs was initiated. Direct immunofluorescent testing of feces revealed active shedding of Giardia cysts in 40% (n = 60) of animals held in the vivarium. All tested fecal samples (n =29) from animals in another holding facility where the index case originated were PCR positive for G. duodenalis with assemblages A and B identified from sequencing triosephosphate isomerase (tpi), glutamate dehydrogenase (gdh), and beta-giardin (bg) genes. Both assemblages are considered zoonotic, thus the parasites in prairie dogs are potential human pathogens and indicate prairie dogs as a possible wildlife reservoir or the victims of pathogen spill-over. Molecular testing for other protozoan gastrointestinal parasites revealed no Gyptosporidium infections but identified a host-adapted Enterocytozoon bieneusi genotype group. (C) 2015 Published by Elsevier B.V. C1 [Roellig, Dawn M.; Visvesvara, Govinda S.; Xiao, Lihua] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Salzer, Johanna S.; Carroll, Darin S.; Ritter, Jana M.; Drew, Clifton; Gallardo-Romero, Nadia; Keckler, M. Shannon; Hutson, Christina L.; Karem, Kevin L.; Metcalfe, Maureen G.; Damon, Inger K.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. [Salzer, Johanna S.; Carroll, Darin S.; Gillespie, Thomas R.] Emory Univ, Dept Environm Sci, Atlanta, GA 30322 USA. [Salzer, Johanna S.; Gillespie, Thomas R.] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA. [Salzer, Johanna S.; Gillespie, Thomas R.] Emory Univ, Program Populat Biol Ecol & Evolut, Atlanta, GA 30322 USA. [Langham, Gregory] Ctr Dis Control & Prevent, Div Sci Resources, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA USA. RP Roellig, DM (reprint author), 1600 Clifton Rd,MS 066, Atlanta, GA 30333 USA. EM DMRoellig@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 FU Intramural CDC HHS [CC999999] NR 22 TC 1 Z9 1 U1 0 U2 6 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0304-4017 EI 1873-2550 J9 VET PARASITOL JI Vet. Parasitol. PD MAY 30 PY 2015 VL 210 IS 1-2 BP 91 EP 97 DI 10.1016/j.vetpar.2015.03.022 PG 7 WC Parasitology; Veterinary Sciences SC Parasitology; Veterinary Sciences GA CI8UF UT WOS:000355046500012 PM 25881801 ER PT J AU Chisha, Z Larsen, DA Burns, M Miller, JM Chirwa, J Mbwili, C Bridges, DJ Kamuliwo, M Hawela, M Tan, KR Craig, AS Winters, AM AF Chisha, Zunda Larsen, David A. Burns, Matthew Miller, John M. Chirwa, Jacob Mbwili, Clara Bridges, Daniel J. Kamuliwo, Mulakwa Hawela, Moonga Tan, Kathrine R. Craig, Allen S. Winters, Anna M. TI Enhanced surveillance and data feedback loop associated with improved malaria data in Lusaka, Zambia SO MALARIA JOURNAL LA English DT Article DE Surveillance; Malaria; Case management; Elimination; DHIS2; Zambia ID BURDEN; TANZANIA; AFRICA; OVERDIAGNOSIS; URBANIZATION; TRANSMISSION; TRENDS; IMPACT AB Background: Accurate and timely malaria data are crucial to monitor the progress towards and attainment of elimination. Lusaka, the capital city of Zambia, has reported very low malaria prevalence in Malaria Indicator Surveys. Issues of low malaria testing rates, high numbers of unconfirmed malaria cases and over consumption of anti-malarials were common at clinics within Lusaka, however. The Government of Zambia (GRZ) and its partners sought to address these issues through an enhanced surveillance and feedback programme at clinic level. Methods: The enhanced malaria surveillance programme began in 2011 to verify trends in reported malaria, as well as to implement a data feedback loop to improve data uptake, use, and quality. A process of monthly data collection and provision of feedback was implemented within all GRZ health clinics in Lusaka District. During clinic visits, clinic registers were accessed to record the number of reported malaria cases, malaria test positivity rate, malaria testing rate, and proportion of total suspected malaria that was confirmed with a diagnostic test. Results and discussion: Following the enhanced surveillance programme, the odds of receiving a diagnostic test for a suspected malaria case increased (OR = 1.54, 95 % CI = 0.96-2.49) followed by an upwardmonthly trend (OR= 1.05, 95 % CI = 1.01-1.09). The odds of a reported malaria case being diagnostically confirmed also increased monthly (1.09, 95 % CI 1.04-1.15). After an initial 140 % increase (95 % CI = 91-183 %), costs fell by 11 % each month (95 % CI = 5.7-10.9 %). Although the mean testing rate increased from 18.9 to 64.4 % over the time period, the proportion of reported malaria unconfirmed by diagnostic remained high at 76 %. Conclusions: Enhanced surveillance and implementation of a data feedback loop have substantially increased malaria testing rates and decreased the number of unconfirmed malaria cases and courses of ACT consumed in Lusaka District within just two years. Continued support of enhanced surveillance in Lusaka as well as national scale-up of the system is recommended to reinforce good case management and to ensure timely, reliable data are available to guide targeting of limited malaria prevention and control resources in Zambia. C1 [Chisha, Zunda; Larsen, David A.; Burns, Matthew; Bridges, Daniel J.; Winters, Anna M.] Akros, Cresta Golfview Grounds, Lusaka, Zambia. [Larsen, David A.] Syracuse Univ, Dept Publ Hlth Food Studies & Nutr, Syracuse, NY USA. [Miller, John M.] Chainama Hosp, Coll Grounds, PATH Malaria Control & Eliminat Partnership Afric, Natl Malaria Control Ctr, Lusaka, Zambia. [Chirwa, Jacob; Kamuliwo, Mulakwa; Hawela, Moonga] Minist Hlth, Natl Malaria Control Ctr, Dept Publ Hlth & Res, Lusaka, Zambia. [Mbwili, Clara] Minist Hlth, Lusaka Dist Hlth Management Team, Lusaka, Zambia. [Tan, Kathrine R.; Craig, Allen S.] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Tan, Kathrine R.; Craig, Allen S.] Ctr Dis Control & Prevent, US Presidents Malaria Initiat, Atlanta, GA USA. [Winters, Anna M.] Univ Montana, Sch Publ & Community Hlth Sci, Missoula, MO USA. RP Winters, AM (reprint author), Akros, Cresta Golfview Grounds, Great East Rd,Unit 5, Lusaka, Zambia. EM awinters@akros.com RI Larsen, David/D-4027-2016 OI Larsen, David/0000-0002-1876-6536 FU Ministry of Health; President's Malaria Initiative; U.S. Agency for International Development; PATH MACEPA; President's Malaria Initiative, U.S. Agency for International Development, under the terms of an Interagency Agreement; CDC FX Authors are grateful for the involvement of all MOH staff in the rollout of the enhanced surveillance programme. Specific recognition is given to Dr. Sichitamba Chibesa-Wamulume, whose tireless efforts towards the health of her country, including this programme, continue to inspire us all. Support for the enhanced malaria surveillance programme was provided by the Ministry of Health, the President's Malaria Initiative, the U.S. Agency for International Development, and PATH MACEPA. This publication was made possible through support provided by the President's Malaria Initiative, U.S. Agency for International Development, under the terms of an Interagency Agreement with CDC. The opinions expressed herein are those of the author (s) and do not necessarily reflect the views of the U.S. Agency for International Development and the Centers for Disease Control and Prevention. NR 25 TC 4 Z9 4 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAY 29 PY 2015 VL 14 AR 222 DI 10.1186/s12936-015-0735-y PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CL6MN UT WOS:000357081300001 PM 26017275 ER PT J AU Chriqui, J DeLong, H Gourdet, C Chaloupka, F Edwards, SM Xu, X Promoff, G AF Chriqui, Jamie DeLong, Hillary Gourdet, Camille Chaloupka, Frank Edwards, Sarah Matthes Xu, Xin Promoff, Gabbi TI Use of Tobacco Tax Stamps to Prevent and Reduce Illicit Tobacco Trade - United States, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Chriqui, Jamie] Univ Illinois, Div Hlth Policy & Adm, Chicago, IL USA. [Chriqui, Jamie; DeLong, Hillary; Gourdet, Camille; Chaloupka, Frank] Univ Illinois, Inst Hlth Res & Policy, Sch Publ Hlth, Chicago, IL USA. [Chaloupka, Frank] Univ Illinois, Dept Econ, Chicago, IL USA. [Edwards, Sarah Matthes; Xu, Xin; Promoff, Gabbi] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Edwards, SM (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM sedwards2@cdc.gov FU National Cancer Institute, National Institutes of Health [U01CA154248] FX National Cancer Institute, National Institutes of Health (grant no. U01CA154248). NR 8 TC 2 Z9 2 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 29 PY 2015 VL 64 IS 20 BP 541 EP 546 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ8VK UT WOS:000355781400001 PM 26020136 ER PT J AU Ross, H Husain, MJ Kostova, D Xu, X Edwards, SM Chaloupka, FJ Ahluwalia, IB AF Ross, Hana Husain, Muhammad Jami Kostova, Deliana Xu, Xin Edwards, Sarah M. Chaloupka, Frank J. Ahluwalia, Indu B. TI Approaches for Controlling Illicit Tobacco Trade - Nine Countries and the European Union SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Ross, Hana] Univ Cape Town, ZA-7700 Rondebosch, South Africa. [Husain, Muhammad Jami; Kostova, Deliana; Xu, Xin; Edwards, Sarah M.; Ahluwalia, Indu B.] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Chaloupka, Frank J.] Univ Illinois, Chicago, IL USA. RP Husain, MJ (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM MHusain@cdc.gov NR 10 TC 0 Z9 0 U1 0 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 29 PY 2015 VL 64 IS 20 BP 547 EP 550 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ8VK UT WOS:000355781400003 PM 26020137 ER PT J AU Mason, KL Retzer, KD Hill, R Lincoln, JM AF Mason, Krystal L. Retzer, Kyla D. Hill, Ryan Lincoln, Jennifer M. TI Occupational Fatalities During the Oil and Gas Boom - United States, 2003-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Mason, Krystal L.; Retzer, Kyla D.; Hill, Ryan; Lincoln, Jennifer M.] NIOSH, Off Adm & Management Serv, CDC, Atlanta, GA 30329 USA. RP Mason, KL (reprint author), NIOSH, Off Adm & Management Serv, CDC, Atlanta, GA 30329 USA. EM KLMason@cdc.gov NR 10 TC 1 Z9 1 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 29 PY 2015 VL 64 IS 20 BP 551 EP 554 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ8VK UT WOS:000355781400004 PM 26020138 ER PT J AU Beaudoin, A Edison, L Introcaso, CE Goh, L Marrone, J Mejia, A Van Beneden, C AF Beaudoin, Amanda Edison, Laura Introcaso, Camille E. Goh, Lucy Marrone, James Mejia, Amelita Van Beneden, Chris TI Acute Rheumatic Fever and Rheumatic Heart Disease Among Children - American Samoa, 2011-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID DIAGNOSIS; GUIDELINE; UPDATE C1 [Beaudoin, Amanda; Edison, Laura] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Introcaso, Camille E.] Penn Ctr Dermatol, Philadelphia, PA USA. [Goh, Lucy] SWLA Ctr Hlth Serv, Lake Charles, LA USA. [Marrone, James; Mejia, Amelita] Amer Samoa, Dept Pediat, Lyndon B Johnson Trop Med Ctr, Pago Pago, AS USA. [Van Beneden, Chris] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Beaudoin, A (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM beau0209@umn.edu NR 10 TC 4 Z9 4 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 29 PY 2015 VL 64 IS 20 BP 555 EP 558 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CJ8VK UT WOS:000355781400005 PM 26020139 ER PT J AU Leeman, J Calancie, L Hartman, MA Escoffery, CT Herrmann, AK Tague, LE Moore, AA Wilson, KM Schreiner, M Samuel-Hodge, C AF Leeman, Jennifer Calancie, Larissa Hartman, Marieke A. Escoffery, Cam T. Herrmann, Alison K. Tague, Lindsay E. Moore, Alexis A. Wilson, Katherine M. Schreiner, Michelle Samuel-Hodge, Carmen TI What strategies are used to build practitioners' capacity to implement community-based interventions and are they effective?: a systematic review SO IMPLEMENTATION SCIENCE LA English DT Review DE Capacity building; Prevention support; Interactive Systems Framework; Technical assistance; Evidence-based practice ID SKIN-CANCER PREVENTION; RANDOMIZED CONTROLLED-TRIAL; EVIDENCE-BASED PROGRAMS; TECHNICAL ASSISTANCE; SUPPORT-SYSTEM; PUBLIC-HEALTH; UNDERAGE DRINKING; PHYSICAL-ACTIVITY; DIFFUSION TRIAL; SUN PROTECTION AB Background: Numerous agencies are providing training, technical assistance, and other support to build community-based practitioners' capacity to adopt and implement evidence-based prevention interventions. Yet, little is known about how best to design capacity-building interventions to optimize their effectiveness. Wandersman et al. (Am J Community Psychol. 50: 445-59, 2102) proposed the Evidence-Based System of Innovation Support (EBSIS) as a framework to guide research and thereby strengthen the evidence base for building practitioners' capacity. The purpose of this review was to contribute to further development of the EBSIS by systematically reviewing empirical studies of capacity-building interventions to identify (1) the range of strategies used, (2) variations in the way they were structured, and (3) evidence for their effectiveness at increasing practitioners' capacity to use evidence-based prevention interventions. Methods: PubMed, EMBASE, and CINAHL were searched for English-language articles reporting findings of empirical studies of capacity-building interventions that were published between January 2000 and January 2014 and were intended to increase use of evidence-based prevention interventions in non-clinical settings. To maximize review data, studies were not excluded a priori based on design or methodological quality. Using the EBSIS as a guide, two researchers independently extracted data from included studies. Vote counting and meta-summary methods were used to summarize findings. Results: The review included 42 publications reporting findings from 29 studies. In addition to confirming the strategies and structures described in the EBSIS, the review identified two new strategies and two variations in structure. Capacity-building interventions were found to be effective at increasing practitioners' adoption (n = 10 of 12 studies) and implementation (n = 9 of 10 studies) of evidence-based interventions. Findings were mixed for interventions' effects on practitioners' capacity or intervention planning behaviors. Both the type and structure of capacity-building strategies may have influenced effectiveness. The review also identified contextual factors that may require variations in the ways capacity-building interventions are designed. Conclusions: Based on review findings, refinements are suggested to the EBSIS. The refined framework moves the field towards a more comprehensive and standardized approach to conceptualizing the types and structures of capacity-building strategies. This standardization will assist with synthesizing findings across studies and guide capacity-building practice and research. C1 [Leeman, Jennifer; Schreiner, Michelle] Univ N Carolina, Sch Nursing, Chapel Hill, NC 27599 USA. [Leeman, Jennifer; Tague, Lindsay E.] Univ N Carolina, Ctr Hlth Promot & Dis Prevent, Chapel Hill, NC 27599 USA. [Calancie, Larissa; Samuel-Hodge, Carmen] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Nutr, Chapel Hill, NC 27599 USA. [Hartman, Marieke A.] Univ Texas Sch Publ Hlth, Dept Behav Sci & Hlth Promot, Houston, TX 77054 USA. [Escoffery, Cam T.] Emory Univ, Rollins Sch Publ Hlth, Dept Behav Sci & Hlth Educ, Atlanta, GA 30322 USA. [Herrmann, Alison K.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, UCLA Kaiser Permanente Ctr Hlth Equ, Los Angeles, CA USA. [Moore, Alexis A.] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA. [Wilson, Katherine M.] Ctr Dis Control & Prevent, Div Epidemiol Anal & Lib Serv, Community Guide Branch, Atlanta, GA 30333 USA. RP Leeman, J (reprint author), Univ N Carolina, Sch Nursing, Carrington Hall,CB 7460, Chapel Hill, NC 27599 USA. EM jleeman@email.unc.edu FU Centers for Disease Control and Prevention [U48DP00194409, U48DP001949, U48DP0010909, U48DP001934]; National Cancer Institute to Cancer Prevention and Control Research Network sites; University of Texas School of Public Health Cancer Education and Career Development Program; National Cancer Institute (NIH Grant) [R25CA57712, R01CA163526]; National Institute of Nursing Research [5T32NR00856] FX This publication was supported by Cooperative Agreement Numbers U48DP00194409, U48DP001949, U48DP0010909, and U48DP001934 from the Centers for Disease Control and Prevention and the National Cancer Institute to Cancer Prevention and Control Research Network sites. Marieke A. Hartman was supported by the postdoctoral fellowship, University of Texas School of Public Health Cancer Education and Career Development Program, National Cancer Institute (NIH Grant R25CA57712) and NIH Grant R01CA163526. Michelle Schreiner was supported by the National Institute of Nursing Research (Grant 5T32NR00856). The findings and conclusions presented here are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Institutes of Health. NR 70 TC 11 Z9 11 U1 7 U2 22 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAY 29 PY 2015 VL 10 AR 80 DI 10.1186/s13012-015-0272-7 PG 15 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA CJ2IF UT WOS:000355306800001 PM 26018220 ER PT J AU Bar-Zeev, N Kapanda, L King, C Beard, J Phiri, T Mvula, H Crampin, AC Mwansambo, C Costello, A Parashar, U Tate, JE Verani, JR Whitney, CG Heyderman, RS Cunliffe, NA French, N AF Bar-Zeev, Naor Kapanda, Lester King, Carina Beard, James Phiri, Tambosi Mvula, Hazzie Crampin, Amelia C. Mwansambo, Charles Costello, Anthony Parashar, Umesh Tate, Jacqueline E. Verani, Jennifer R. Whitney, Cynthia G. Heyderman, Robert S. Cunliffe, Nigel A. French, Neil CA VacSurv Consortium TI Methods and challenges in measuring the impact of national pneumococcal and rotavirus vaccine introduction on morbidity and mortality in Malawi SO VACCINE LA English DT Article DE Vaccine; Effectiveness; Impact; Pneumococcal; Rotavirus; Malawi ID CONJUGATE VACCINE; CHILD-MORTALITY; NORTHERN MALAWI; EFFICACY; DISEASE; SAFETY; SURVEILLANCE; MENINGITIS; SEROTYPES; INFECTION AB Background: Pneumonia and gastroenteritis are leading causes of vaccine-preventable childhood morbidity and mortality. Malawi introduced pneumococcal conjugate and rotavirus vaccines to the immunisation programme in 2011 and 2012, respectively. Evaluating their effectiveness is vital to ensure optimal implementation and justify Sustained investment. Methods/Design: A national evaluation platform was established to determine vaccine effectiveness and impact in Malawi. Impact and effectiveness against vaccine-type invasive pneumococcal disease, radiological pneumonia and rotavirus gastroenteritis are investigated using before-after incidence comparisons and case-control designs, respectively. Mortality is assessed using a prospective population cohort. Cost-effectiveness evaluation is nested within the case-control studies. We describe platform characteristics including strengths and weaknesses for conducting vaccine evaluations. Discussion: Integrating data from individual level and ecological methods across multiple sites provides comprehensive information for policymakers on programme impact and vaccine effectiveness including changes in serotype/genotype distribution over time. Challenges to robust vaccine evaluation in real-world conditions include: vaccination ascertainment; pre-existing rapid decline in mortality and pneumococcal disease in the context of non-vaccine interventions; and the maintenance of completeness and quality of reporting at scale and over time. In observational non-randomised designs ascertainment of vaccine status may be biased particularly in infants with fatal outcomes. In the context of multiple population level interventions targeting study endpoints attribution of reduced incidence to vaccine impact may be flawed. Providing evidence from several independent but complementary studies will provide the greatest confidence in assigning impact. Welcome declines in disease incidence and in child mortality make accrual of required sample sizes difficult, necessitating large studies to detect the relatively small but potentially significant contribution of vaccines to mortality prevention. Careful evaluation of vaccine effectiveness and impact in such settings is critical to sustaining support for vaccine programmes. Our evaluation platform covers a large population with a high prevalence of HIV and malnutrition and its findings will be relevant to other settings in sub-Saharan Africa. (c) 2015 The Authors. Published by Elsevier Ltd. C1 [Bar-Zeev, Naor; Kapanda, Lester; Heyderman, Robert S.; French, Neil] Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre, Malawi. [Bar-Zeev, Naor; Beard, James; Cunliffe, Nigel A.; French, Neil] Univ Liverpool, Inst Infect & Global Hlth, Liverpool L69 3BX, Merseyside, England. [King, Carina; Beard, James; Phiri, Tambosi; Mwansambo, Charles] Mai Mwana Project, Mchinji, Malawi. [King, Carina; Beard, James; Costello, Anthony] UCL, Inst Global Hlth, London, England. [Mvula, Hazzie; Crampin, Amelia C.] Karonga Prevent Study, Chilumba, Malawi. [Mvula, Hazzie; Crampin, Amelia C.] London Sch Hyg & Trop Med, London WC1, England. [Mwansambo, Charles] Govt Malawi, Minist Hlth, Lilongwe, Malawi. [Parashar, Umesh; Tate, Jacqueline E.; Verani, Jennifer R.; Whitney, Cynthia G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Heyderman, Robert S.] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. RP Bar-Zeev, N (reprint author), Malawi Liverpool Wellcome Trust Clin Res Programm, Microbes Immun & Vaccines, POB 30096,Blantyre 3, Chichiri 3, Blantyre, Malawi. EM Naor.Bar-Zeev@liverpool.ac.uk; lkapanda@mlw.medcol.mw; c.king@ucl.ac.uk; j.beard@ucl.ac.uk; tambosiphiri@gmail.com; hazzie.mvula@kpsmw.org; mia.crampin@lshtm.ac.uk; cmwansambo@gmail.com; anthony.costello@ucl.ac.uk; uap2@cdc.gov; jqt8@cdc.gov; qzr7@cdc.gov; cgw3@cdc.gov; r.heyderman@liverpool.ac.uk; n.a.cunliffe@liverpool.ac.uk; french@liverpool.ac.uk OI Cunliffe, Nigel/0000-0002-5449-4988; Jere, Khuzwayo/0000-0003-3376-8529 FU Wellcome Trust; RSH NF [WT091909]; Malawi-Liverpool-Wellcome Trust Clinical Research Programme core grant; Karonga Prevention Study core grant; Strategic Award; Centers for Disease Control and Prevention, Atlanta; U.S. Agency for International Development (USAID), Washington, D.C.; Program for Appropriate Technology in Health, Seattle FX The authors wish to thank the collaborating members of the VacSurv Consortium (Miren Iturriza-Gomara (University of Liverpool, Liverpool, UK), Khuzwayo Jere (University of Liverpool), Osamu Nakagomi (Nagasaki University, Nagasaki, Japan), Sonia Lewycka (University of Auckland, New Zealand; formerly University College London, London, UK)). This work is supported by the Wellcome Trust through a programme grant to NAC, RSH & NF (grant WT091909), the Malawi-Liverpool-Wellcome Trust Clinical Research Programme core grant and the Karonga Prevention Study core grant, and Strategic Award to AC; and by the Centers for Disease Control and Prevention, Atlanta, the U.S. Agency for International Development (USAID), Washington, D.C.; and the Program for Appropriate Technology in Health, Seattle. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention, Atlanta USA. NR 46 TC 6 Z9 6 U1 0 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 28 PY 2015 VL 33 IS 23 BP 2637 EP 2645 DI 10.1016/j.vaccine.2015.04.053 PG 9 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CJ3AE UT WOS:000355355000002 PM 25917672 ER PT J AU Jain, S Finelli, L AF Jain, Seema Finelli, Lyn CA CDC EPIC Study Team TI Community-Acquired Pneumonia among US Children REPLY SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Letter ID ASTHMA C1 [Jain, Seema; Finelli, Lyn] Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. RP Jain, S (reprint author), Ctr Dis Control & Prevent CDC, Atlanta, GA 30333 USA. NR 5 TC 2 Z9 2 U1 0 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAY 28 PY 2015 VL 372 IS 22 BP 2167 EP 2168 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CJ0EI UT WOS:000355146800025 PM 26017833 ER PT J AU Kaur, H Allan, EL Mamadu, I Hall, Z Ibe, O El Sherbiny, M van Wyk, A Yeung, S Swamidoss, I Green, MD Dwivedi, P Culzoni, MJ Clarke, S Schellenberg, D Fernandez, FM Onwujekwe, O AF Kaur, Harparkash Allan, Elizabeth Louise Mamadu, Ibrahim Hall, Zoe Ibe, Ogochukwu El Sherbiny, Mohamed van Wyk, Albert Yeung, Shunmay Swamidoss, Isabel Green, Michael D. Dwivedi, Prabha Julia Culzoni, Maria Clarke, Sian Schellenberg, David Fernandez, Facundo M. Onwujekwe, Obinna TI Quality of Artemisinin-Based Combination Formulations for Malaria Treatment: Prevalence and Risk Factors for Poor Quality Medicines in Public Facilities and Private Sector Drug Outlets in Enugu, Nigeria SO PLOS ONE LA English DT Article ID ANTIMALARIAL-DRUGS; SOUTHEAST-ASIA; CAMBODIA; AFRICA AB Background Artemisinin-based combination therapies are recommended by the World Health Organisation (WHO) as first-line treatment for Plasmodium falciparum malaria, yet medication must be of good quality for efficacious treatment. A recent meta-analysis reported 35% (796/2, 296) of antimalarial drug samples from 21 Sub-Saharan African countries, purchased from outlets predominantly using convenience sampling, failed chemical content analysis. We used three sampling strategies to purchase artemisinin-containing antimalarials (ACAs) in Enugu metropolis, Nigeria, and compared the resulting quality estimates. Methods ACAs were purchased using three sampling approaches - convenience, mystery clients and overt, within a defined area and sampling frame in Enugu metropolis. The active pharmaceutical ingredients were assessed using high-performance liquid chromatography and confirmed by mass spectrometry at three independent laboratories. Results were expressed as percentage of APIs stated on the packaging and used to categorise each sample as acceptable quality, substandard, degraded, or falsified. Results Content analysis of 3024 samples purchased from 421 outlets using convenience (n=200), mystery (n=1,919) and overt (n=905) approaches, showed overall 90.8% ACAs to be of acceptable quality, 6.8% substandard, 1.3% degraded and 1.2% falsified. Convenience sampling yielded a significantly higher prevalence of poor quality ACAs, but was not evident by the mystery and overt sampling strategies both of which yielded results that were comparable between each other. Artesunate (n=135; 4 falsified) and dihydroartemisinin (n=14) monotherapy tablets, not recommended by WHO, were also identified. Conclusion Randomised sampling identified fewer falsified ACAs than previously reported by convenience approaches. Our findings emphasise the need for specific consideration to be given to sampling frame and sampling approach if representative information on drug quality is to be obtained. C1 [Kaur, Harparkash; Allan, Elizabeth Louise; Hall, Zoe; van Wyk, Albert; Yeung, Shunmay] London Sch Hyg & Trop Med, Dept Clin Res, London WC1, England. [Mamadu, Ibrahim; El Sherbiny, Mohamed; Yeung, Shunmay] London Sch Hyg & Trop Med, Dept Global Hlth & Dev, London WC1, England. [Ibe, Ogochukwu; Onwujekwe, Obinna] Univ Nigeria, Dept Pharmacol & Therapeut, Enugu, Nigeria. [Swamidoss, Isabel; Green, Michael D.] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. [Dwivedi, Prabha] Ctr Dis Control & Prevent, Atlanta, GA USA. [Julia Culzoni, Maria] Univ Nacl Litoral, Fac Bioquim & Ciencias Biol, Santa Fe, Argentina. [Julia Culzoni, Maria] Consejo Nacl Invest Cient & Tecn, Santa Fe, Argentina. [Clarke, Sian; Schellenberg, David] London Sch Hyg & Trop Med, Dept Dis Control, London WC1, England. [Fernandez, Facundo M.] Georgia Inst Technol, Sch Chem & Biochem, Atlanta, GA 30332 USA. RP Kaur, H (reprint author), London Sch Hyg & Trop Med, Dept Clin Res, Keppel St, London WC1, England. EM harparkash.kaur@lshtm.ac.uk RI Onwujekwe, Obinna/O-6232-2014 OI Onwujekwe, Obinna/0000-0002-1214-4285 FU Bill & Melinda Gates Foundation FX The authors are grateful to the Artemisinin Combination Therapy consortium via an award from the Bill & Melinda Gates Foundation to the London School of Hygiene and Tropical Medicine. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 25 TC 4 Z9 4 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 27 PY 2015 VL 10 IS 5 AR UNSP e0125577 DI 10.1371/journal.pone.0125577 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ0RO UT WOS:000355185600029 PM 26018221 ER PT J AU Scobie, HM Ray, A Routray, S Bose, A Bahl, S Sosler, S Wannemuehler, K Kumar, R Haldar, P Anand, A AF Scobie, Heather M. Ray, Arindam Routray, Satyabrata Bose, Anindya Bahl, Sunil Sosler, Stephen Wannemuehler, Kathleen Kumar, Rakesh Haldar, Pradeep Anand, Abhijeet TI Cluster Survey Evaluation of a Measles Vaccination Campaign in Jharkhand, India, 2012 SO PLOS ONE LA English DT Article ID ROUTINE IMMUNIZATION; POLIO ERADICATION; COVERAGE; ELIMINATION; STRATEGIES AB Introduction India was the last country in the world to implement a two-dose strategy for measles-containing vaccine (MCV) in 2010. As part of measles second-dose introduction, phased measles vaccination campaigns were conducted during 2010-2013, targeting 131 million children 9 months to < 10 years of age. We performed a post-campaign coverage survey to estimate measles vaccination coverage in Jharkhand state. Methods A multi-stage cluster survey was conducted 2 months after the phase 2 measles campaign occurred in 19 of 24 districts of Jharkhand during November 2011-March 2012. Vaccination status of children 9 months to < 10 years of age was documented based on vaccination card or mother's recall. Coverage estimates and 95% confidence intervals (95% CI) for 1,018 children were calculated using survey methods. Results In the Jharkhand phase 2 campaign, MCV coverage among children aged 9 months to < 10 years was 61.0% (95% CI: 54.4-67.7%). Significant differences in coverage were observed between rural (65.0%; 95% CI: 56.8-73.2%) and urban areas (45.6%; 95% CI: 37.3-53.9%). Campaign awareness among mothers was low (51.5%), and the most commonly reported reason for non-vaccination was being unaware of the campaign (69.4%). At the end of the campaign, 53.7% (95% CI: 46.5-60.9%) of children 12 months to < 10 years of age received >= 2 MCV doses, while a large proportion of children remained under-vaccinated (34.0%, 95% CI: 28.0-40.0%) or unvaccinated (12.3%, 95% CI: 9.3-16.2%). Conclusions Implementation of the national measles campaign was a significant achievement towards measles elimination in India. In Jharkhand, campaign performance was below the target coverage of >= 90% set by the Government of India, and challenges in disseminating campaign messages were identified. Efforts towards increasing two-dose MCV coverage are needed to achieve the recently adopted measles elimination goal in India and the South-East Asia region. C1 [Scobie, Heather M.; Wannemuehler, Kathleen; Anand, Abhijeet] Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30332 USA. [Scobie, Heather M.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Ray, Arindam; Routray, Satyabrata; Bose, Anindya; Bahl, Sunil; Sosler, Stephen] WHO, Country Off, Natl Polio Surveillance Project, New Delhi, India. [Kumar, Rakesh; Haldar, Pradeep] Govt India, Minist Hlth & Family Welf, New Delhi, India. RP Scobie, HM (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA 30332 USA. EM hscobie@cdc.gov FU National Polio Surveillance Project; World Health Organization Country Office; U.S. Centers for Disease Control and Prevention (CDC) FX Funding was provided by the National Polio Surveillance Project, World Health Organization Country Office and U.S. Centers for Disease Control and Prevention (CDC). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the U.S. CDC or other organizations. NR 24 TC 0 Z9 0 U1 0 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 26 PY 2015 VL 10 IS 5 AR e0127105 DI 10.1371/journal.pone.0127105 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ0QZ UT WOS:000355183900063 PM 26010084 ER PT J AU Skums, P Bunimovich, L Khudyakov, Y AF Skums, Pavel Bunimovich, Leonid Khudyakov, Yury TI Antigenic cooperation among intrahost HCV variants organized into a complex network of cross-immunoreactivity SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA LA English DT Article DE hepatitis C; viral quasispecies; cross-immunoreactivity; complex network; intrahost adaptation ID HEPATITIS-C VIRUS; HYPERVARIABLE REGION 1; ANTIBODY-MEDIATED NEUTRALIZATION; WEST NILE VIRUS; CHRONIC INFECTION; VIRAL POPULATION; GERMINAL-CENTERS; IN-VIVO; EVOLUTION; RESPONSES AB Hepatitis C virus (HCV) has the propensity to cause chronic infection. Continuous immune escape has been proposed as a mechanism of intrahost viral evolution contributing to HCV persistence. Although the pronounced genetic diversity of intrahost HCV populations supports this hypothesis, recent observations of long-term persistence of individual HCV variants, negative selection increase, and complex dynamics of viral subpopulations during infection as well as broad cross-immunoreactivity (CR) among variants are inconsistent with the immune-escape hypothesis. Here, we present a mathematical model of intrahost viral population dynamics under the condition of a complex CR network (CRN) of viral variants and examine the contribution of CR to establishing persistent HCV infection. The model suggests a mechanism of viral adaptation by antigenic cooperation (AC), with immune responses against one variant protecting other variants. AC reduces the capacity of the host's immune system to neutralize certain viral variants. CRN structure determines specific roles for each viral variant in host adaptation, with variants eliciting broad-CR antibodies facilitating persistence of other variants immunoreacting with these antibodies. The proposed mechanism is supported by empirical observations of intrahost HCV evolution. Interference with AC is a potential strategy for interruption and prevention of chronic HCV infection. C1 [Skums, Pavel; Khudyakov, Yury] Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. [Bunimovich, Leonid] Georgia Inst Technol, Sch Math, Atlanta, GA 30332 USA. RP Skums, P (reprint author), Ctr Dis Control & Prevent, Div Viral Hepatitis, Atlanta, GA 30333 USA. EM kki8@cdc.gov NR 56 TC 5 Z9 5 U1 0 U2 3 PU NATL ACAD SCIENCES PI WASHINGTON PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA SN 0027-8424 J9 P NATL ACAD SCI USA JI Proc. Natl. Acad. Sci. U. S. A. PD MAY 26 PY 2015 VL 112 IS 21 BP 6653 EP 6658 DI 10.1073/pnas.1422942112 PG 6 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CJ1AJ UT WOS:000355213200047 PM 25941392 ER PT J AU Kirtland, KA Saaddine, JB Geiss, LS Thompson, TJ Cotch, MF Lee, PP AF Kirtland, Karen A. Saaddine, Jinan B. Geiss, Linda S. Thompson, Ted J. Cotch, Mary F. Lee, Paul P. TI Geographic Disparity of Severe Vision Loss - United States, 2009-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID VISUAL IMPAIRMENT; US ADULTS; HEALTH C1 [Kirtland, Karen A.; Saaddine, Jinan B.; Geiss, Linda S.; Thompson, Ted J.] CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Cotch, Mary F.] NEI, NIH, Bethesda, MD USA. [Lee, Paul P.] Univ Michigan, Sch Med, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA. RP Kirtland, KA (reprint author), CDC, Div Diabet Translat, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM kkirtland@cdc.gov FU Intramural NIH HHS [Z99 EY999999] NR 10 TC 1 Z9 1 U1 1 U2 3 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 22 PY 2015 VL 64 IS 19 BP 513 EP 517 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI7PV UT WOS:000354957300002 PM 25996092 ER PT J AU Ahluwalia, IB Ding, H D'Angelo, D Shealy, KH Singleton, JA Liang, J Rosenberg, KD AF Ahluwalia, Indu B. Ding, Helen D'Angelo, Denise Shealy, Kristen H. Singleton, James A. Liang, Jennifer Rosenberg, Kenneth D. TI Tetanus, Diphtheria, Pertussis Vaccination Coverage Before, During, and After Pregnancy-16 States and New York City, 2011 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID IMMUNIZATION PRACTICES ACIP; INFLUENZA VACCINATION; ADVISORY-COMMITTEE; UNITED-STATES; WOMEN; RECOMMENDATIONS; ADULTS; TDAP C1 [Ahluwalia, Indu B.; D'Angelo, Denise] CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Ding, Helen; Shealy, Kristen H.] DB Consulting Grp Inc, Silver Spring, MD USA. [Singleton, James A.] CDC, Immunizat Serv Div, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Liang, Jennifer] CDC, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Rosenberg, Kenneth D.] Oregon Publ Hlth Div, PRAMS Oregon, Portland, OR USA. RP Ahluwalia, IB (reprint author), CDC, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM iahluwalia@cdc.gov NR 10 TC 7 Z9 7 U1 0 U2 0 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 22 PY 2015 VL 64 IS 19 BP 522 EP 526 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI7PV UT WOS:000354957300004 PM 25996094 ER PT J AU Hagan, JE Wassilak, SGF Craig, AS Tangermann, RH Diop, OM Burns, CC Quddus, A AF Hagan, Jose E. Wassilak, Steven G. F. Craig, Allen S. Tangermann, Rudolf H. Diop, Ousmane M. Burns, Cara C. Quddus, Arshad TI Progress Toward Polio Eradication - Worldwide, 2014-2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID POLIOMYELITIS ERADICATION C1 [Hagan, Jose E.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Hagan, Jose E.; Wassilak, Steven G. F.; Craig, Allen S.] CDC, Global Immunizat Div, Ctr Global Hlth, Atlanta, GA 30333 USA. [Tangermann, Rudolf H.; Diop, Ousmane M.; Quddus, Arshad] WHO, Polio Eradicat Dept, Geneva, Switzerland. [Burns, Cara C.] CDC, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Hagan, JE (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM jehagan@cdc.gov NR 9 TC 19 Z9 19 U1 2 U2 7 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 22 PY 2015 VL 64 IS 19 BP 527 EP 531 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI7PV UT WOS:000354957300005 PM 25996095 ER PT J AU Nguyen, K Marshall, L Hu, S Neff, L AF Nguyen, Kimberly Marshall, LaTisha Hu, Sean Neff, Linda TI State-Specific Prevalence of Current Cigarette Smoking and Smokeless Tobacco Use Among Adults Aged >= 18 Years - United States, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID COTININE C1 [Nguyen, Kimberly; Marshall, LaTisha; Hu, Sean; Neff, Linda] CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. RP Nguyen, K (reprint author), CDC, Off Smoking & Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM KNguyen2@cdc.gov NR 10 TC 17 Z9 18 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 22 PY 2015 VL 64 IS 19 BP 532 EP 536 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI7PV UT WOS:000354957300006 PM 25996096 ER PT J AU Browne, LB Menkir, Z Kahi, V Maina, G Asnakew, S Tubman, M Elyas, HZ Nigatu, A Dak, D Maung, UA Nakao, JH Bilukha, O Shahpar, C AF Browne, Lauren B. Menkir, Zeray Kahi, Vincent Maina, Gidraf Asnakew, Solomon Tubman, Michelle Elyas, Hajir Z. Nigatu, Alemayehu Dak, David Maung, U. Aye Nakao, Jolene H. Bilukha, Oleg Shahpar, Cyrus TI Hepatitis E Outbreak Among Refugees from South Sudan - Gambella, Ethiopia, April 2014-January 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Browne, Lauren B.] CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. [Browne, Lauren B.; Nakao, Jolene H.; Bilukha, Oleg; Shahpar, Cyrus] CDC, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA 30333 USA. [Menkir, Zeray] Adm Refugee & Returnee Affairs, Dollo Ado, Ethiopia. [Kahi, Vincent; Maina, Gidraf; Nigatu, Alemayehu; Dak, David; Maung, U. Aye] United Nations High Commissioner Refugees, Geneva, Switzerland. [Asnakew, Solomon; Tubman, Michelle] Med Sans Frontieres Operat Ctr Amsterdam, Amsterdam, Netherlands. RP Browne, LB (reprint author), CDC, Epidem Intelligence Serv, Atlanta, GA 30333 USA. EM LBBrowne@cdc.gov NR 2 TC 4 Z9 4 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 22 PY 2015 VL 64 IS 19 BP 537 EP 537 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI7PV UT WOS:000354957300007 PM 25996097 ER PT J AU Grytdal, SP Rimland, D Shirley, SH Rodriguez-Barradas, MC Goetz, MB Brown, ST Lucero-Obusan, C Holodniy, M Graber, C Parashar, U Vinje, J Lopman, B AF Grytdal, Scott P. Rimland, David Shirley, S. Hannah Rodriguez-Barradas, Maria C. Goetz, Matthew Bidwell Brown, Sheldon T. Lucero-Obusan, Cynthia Holodniy, Mark Graber, Christopher Parashar, Umesh Vinje, Jan Lopman, Ben TI Incidence of Medically-Attended Norovirus-Associated Acute Gastroenteritis in Four Veteran's Affairs Medical Center Populations in the United States, 2011-2012 SO PLOS ONE LA English DT Article ID INFECTIOUS INTESTINAL DISEASE; SURVEILLANCE; COMMUNITY; ENGLAND; DEATHS AB An estimated 179 million acute gastroenteritis (AGE) illnesses occur annually in the United States. The role of noroviruses in hospital-related AGE has not been well-documented in the U. S. We estimated the population incidence of community-acquired outpatient and inpatient norovirus AGE encounters, as well as hospital-acquired inpatient norovirus AGE among inpatients at four Veterans Affairs (VA) Medical Centers (VAMCs). Fifty (4%) of 1,160 stool specimens collected <= 7 days from symptom onset tested positive for norovirus. During a one year period, the estimated incidence of outpatient, community-and hospital-acquired inpatient norovirus AGE was 188 cases, 11 cases, and 54 cases/100,000 patients, respectively. This study demonstrates the incidence of outpatient and community- and hospital-acquired inpatient norovirus AGE among the VA population seeking care at these four VAMCs. C1 [Grytdal, Scott P.; Shirley, S. Hannah; Parashar, Umesh; Vinje, Jan; Lopman, Ben] Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. [Rimland, David] Atlanta VA Med Ctr, Atlanta, GA USA. [Rimland, David] Emory Univ, Sch Med, Atlanta, GA USA. [Shirley, S. Hannah] Atlanta Res & Educ Fdn, Decatur, GA USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Infect Dis Sect, Houston, TX 77030 USA. [Rodriguez-Barradas, Maria C.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Goetz, Matthew Bidwell; Graber, Christopher] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Goetz, Matthew Bidwell; Graber, Christopher] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Brown, Sheldon T.] James J Peters VA Med Ctr, Bronx, NY USA. [Lucero-Obusan, Cynthia; Holodniy, Mark] VA Off Publ Hlth, Washington, DC USA. [Lucero-Obusan, Cynthia; Holodniy, Mark] VA Off Publ Hlth, Palo Alto, CA USA. [Holodniy, Mark] Stanford Univ, Sch Med, Stanford, CA 94305 USA. RP Grytdal, SP (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Atlanta, GA 30333 USA. EM spgrytdal@cdc.gov OI Goetz, Matthew/0000-0003-4542-992X FU Centers for Disease Control and Prevention FX Funding provided by Centers for Disease Control and Prevention. The funders participated in the study design, data analysis, decision to publish, and preparation of the manuscript. NR 17 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 21 PY 2015 VL 10 IS 5 AR e0126733 DI 10.1371/journal.pone.0126733 PG 8 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CK7VW UT WOS:000356444000030 PM 25996826 ER PT J AU O'Neil, ME Eheman, C Babcock, F Morris, C Chen, V Styles, T AF O'Neil, Mary Elizabeth Eheman, Christie Babcock, Frances Morris, Cyllene Chen, Vivien Styles, Timothy TI Treatment and characteristics of stage II colon cancer patients residing in CDC Specialized Registry areas. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Ctr Dis Control & Prevent, Atlanta, GA USA. Calif Canc Reporting & Epidemiol Surveillance Cal, Sacramento, CA USA. LSU Hlth Sci Ctr, Sch Publ Hlth, Louisiana Tumor Registry, New Orleans, LA USA. LSU Hlth Sci Ctr, Sch Publ Hlth, Program Epidemiol, New Orleans, LA USA. Ctr Dis Control & Prevent, Div Canc Prevent & Control, Canc Surveillance Branch, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6554 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901469 ER PT J AU Rim, SH Hirsch, S Richards, TB Thomas, CC Westervelt, L Brewster, WR Stewart, SL AF Rim, Sun Hee Hirsch, Shawn Richards, Thomas B. Thomas, Cheryll C. Westervelt, Lauren Brewster, Wendy R. Stewart, Sherri L. TI Beneficial involvement of gynecologic oncologist in Medicare ovarian cancer patient's standard of care treatment receipt and survival. SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Ctr Dis Control & Prevent, Atlanta, GA USA. SciMetrika, Durham, NC USA. CDC, Atlanta, GA 30333 USA. Univ N Carolina, Chapel Hill, NC USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17661 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903614 ER PT J AU Styles, T Wu, MX Wilson, R Babcock, F Butterworth, D West, D Richardson, LC AF Styles, Timothy Wu, Manxia Wilson, Reda Babcock, Frances Butterworth, David West, Dee Richardson, Lisa Carolyn TI Population based testing and treatment characteristics for CML SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Ctr Dis Control & Prevent, Div Canc Prevent & Control, Canc Surveillance Branch, Atlanta, GA USA. Ctr Dis Control & Prevent, Atlanta, GA USA. Canc Registry Greater Calif, Sacramento, CA USA. Ctr Dis Control & Prevent, Decatur, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA e17609 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036903575 ER PT J AU Yabroff, KR Dowling, E Guy, G Banegas, M McNeel, TS Davidoff, AJ Chawla, N Hartigan, DB Han, XS Kent, EE Li, CY Virgo, KS Rodriguez, J de Moor, J Zheng, ZY Jemal, A Ekwueme, DU AF Yabroff, K. Robin Dowling, Emily Guy, Gery Banegas, Matthew McNeel, Timothy S. Davidoff, Amy J. Chawla, Neetu Hartigan, Danielle Blanch Han, Xuesong Kent, Erin E. Li, Chunyu Virgo, Katherine S. Rodriguez, Juan de Moor, Janet Zheng, Zhiyuan Jemal, Ahmedin Ekwueme, Donatus U. TI Financial hardship associated with cancer in the United States SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 NCI, Rockville, MD USA. Massachusetts Gen Hosp, Boston, MA 02114 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. IMS, Rockville, MD USA. Yale Univ, Sch Publ Hlth, New Haven, CT USA. Kaiser Permanente No Calif, Oakland, CA USA. Bentley Univ, Saugus, MA USA. Amer Canc Soc, Atlanta, GA 30329 USA. Emory Univ, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6608 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901522 ER PT J AU Zheng, ZY Jemal, A Guy, G Han, XS Banegas, M Li, CY Ekwueme, DU Yabroff, KR AF Zheng, Zhiyuan Jemal, Ahmedin Guy, Gery Han, Xuesong Banegas, Matthew Li, Chunyu Ekwueme, Donatus U. Yabroff, K. Robin TI Medical expenditures and productivity loss among colorectal, breast, and prostate cancer survivors in the US SO JOURNAL OF CLINICAL ONCOLOGY LA English DT Meeting Abstract CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) CY MAY 29-JUN 02, 2015 CL Chicago, IL SP Amer Soc Clin Oncol C1 Amer Canc Soc, Atlanta, GA 30329 USA. Ctr Dis Control & Prevent, Atlanta, GA USA. NCI, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU AMER SOC CLINICAL ONCOLOGY PI ALEXANDRIA PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA SN 0732-183X EI 1527-7755 J9 J CLIN ONCOL JI J. Clin. Oncol. PD MAY 20 PY 2015 VL 33 IS 15 SU S MA 6619 PG 1 WC Oncology SC Oncology GA CM9OA UT WOS:000358036901533 ER PT J AU Bagi, J Grisales, N Corkill, R Morgan, JC N'Fale, S Brogdon, WG Ranson, H AF Bagi, Judit Grisales, Nelson Corkill, Rebecca Morgan, John C. N'Fale, Sagnon Brogdon, William G. Ranson, Hilary TI When a discriminating dose assay is not enough: measuring the intensity of insecticide resistance in malaria vectors SO MALARIA JOURNAL LA English DT Article ID ANOPHELES-GAMBIAE-S.L.; GATED SODIUM-CHANNEL; PYRETHROID RESISTANCE; COTE-DIVOIRE; BURKINA-FASO; POPULATIONS; FUNESTUS; MOSQUITOS; MUTATION AB Background: Guidelines from the World Health Organization for monitoring insecticide resistance in disease vectors recommend exposing insects to a predetermined discriminating dose of insecticide and recording the percentage mortality in the population. This standardized methodology has been widely adopted for malaria vectors and has provided valuable data on the spread and prevalence of resistance. However, understanding the potential impact of this resistance on malaria control requires a more quantitative measure of the strength or intensity of this resistance. Methods: Bioassays were adapted to quantify the level of resistance to permethrin in laboratory colonies and field populations of Anopheles gambiae sensu lato. WHO susceptibility tube assays were used to produce data on mortality versus exposure time and CDC bottle bioassays were used to generate dose response data sets. A modified version of the CDC bottle bioassay, known as the Resistance Intensity Rapid Diagnostic Test (I-RDT), was also used to measure the knockdown and mortality after exposure to different multipliers of the diagnostic dose. Finally cone bioassays were used to assess mortality after exposure to insecticide treated nets. Results: The time response assays were simple to perform but not suitable for highly resistant populations. After initial problems with stability of insecticide and bottle washing were resolved, the CDC bottle bioassay provided a reproducible, quantitative measure of resistance but there were challenges performing this under field conditions. The I-RDT was simple to perform and interpret although the end point selected (immediate knockdown versus 24 h mortality) could dramatically affect the interpretation of the data. The utility of the cone bioassays was dependent on net type and thus appropriate controls are needed to interpret the operational significance of these data sets. Conclusions: Incorporating quantitative measures of resistance strength, and utilizing bioassays with field doses of insecticides, will help interpret the possible impact of resistance on vector control activities. Each method tested had different benefits and challenges and agreement on a common methodology would be beneficial so that data are generated in a standardized format. This type of quantitative data are an important prerequisite to linking resistance strength to epidemiological outcomes. C1 [Bagi, Judit; Grisales, Nelson; Corkill, Rebecca; Morgan, John C.; Ranson, Hilary] Univ Liverpool, Liverpool Sch Trop Med, Liverpool L3 5QA, Merseyside, England. [N'Fale, Sagnon] Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso. [Brogdon, William G.] Ctr Dis Control, Ctr Global Hlth, Div Parasit Dis & Malaria, Atlanta, GA 30329 USA. RP Ranson, H (reprint author), Univ Liverpool, Liverpool Sch Trop Med, Pembroke Pl, Liverpool L3 5QA, Merseyside, England. EM Hilary.Ranson@lstmed.ac.uk OI Ranson, Hilary/0000-0003-2332-8247 FU European Union Seventh Framework Programme FP7 [92007-2013, 265660 AvecNet]; Francisco Jose de Caldas' PhD fellowship from the Colombian Administrative Department of Science, Technology and Innovation (COLCIENCIAS) FX We thank Dr Moussa Guelbeogo for assistance in coordination of the field work and colleagues at LSTM for critical appraisal of the manuscript. We also thank Centre Suisse de Recherches Scientifiques for the Tiassale strain of mosquitoes used in this study. This study was supported by the European Union Seventh Framework Programme FP7 92007-2013) under grant agreement no. 265660 AvecNet and by the Francisco Jose de Caldas' PhD fellowship awarded to NG from the Colombian Administrative Department of Science, Technology and Innovation (COLCIENCIAS). The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of organizations they represent. NR 21 TC 12 Z9 12 U1 0 U2 11 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAY 20 PY 2015 VL 14 AR 210 DI 10.1186/s12936-015-0721-4 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CK0LV UT WOS:000355897600001 PM 25985896 ER PT J AU Nakamura, M Iso, H Kitamura, A Imano, H Kiyama, M Yokoyama, S Kayamori, Y Koyama, I Nishimura, K Nakai, M Dasti, M Vesper, HW Teramoto, T Miyamoto, Y AF Nakamura, Masakazu Iso, Hiroyasu Kitamura, Akihiko Imano, Hironori Kiyama, Masahiko Yokoyama, Shinji Kayamori, Yuzo Koyama, Isao Nishimura, Kunihiro Nakai, Michikazu Dasti, Mahnaz Vesper, Hubert W. Teramoto, Tamio Miyamoto, Yoshihiro TI Total cholesterol performance of Abell-Levy-Brodie-Kendall reference measurement procedure: Certification of Japanese in-vitro diagnostic assay manufacturers through CDC's Cholesterol Reference Method Laboratory Network SO CLINICA CHIMICA ACTA LA English DT Article DE TC; AK RMP; Certification; CRMLN; CDC ID DILUTION MASS-SPECTROMETRY; CORONARY-HEART-DISEASE; HIGH BLOOD CHOLESTEROL; ADULT TREATMENT PANEL; SERUM-CHOLESTEROL; EDUCATION-PROGRAM; DEFINITIVE METHOD; EXPERT PANEL; STANDARDIZATION; GLYCEROL AB Background: Accurate measurement of total cholesterol (TC) is important for cardiovascular disease risk management. The US Centers for Disease Control and Prevention (CDC) and Cholesterol Reference Method Laboratory Network (CRMLN) perform Abell-Levy-Brodie-Kendall (AK) reference measurement procedure (RMP) for TC as a secondary reference method, and implement Certification Protocol for Manufacturers. Japanese CRMLN laboratory at Osaka performed the AK RMP for 22 years, and conducted TC certification for reagent/calibrator/instrument systems of six Japanese manufacturers every 2 years for 16 years. Osaka TC performance was examined and compared to CDC's reference values. Methods: AK RMP involved sample hydrolysis, cholesterol extraction, and determination of cholesterol levels by spectrophotometry. The Certification Protocol for Manufacturers includes comparison with AK RMP using at least 40 fresh specimens. Demonstration of average bias <= 3% and total coefficient of variation <= 3% qualified an analytical system for certification. Results: In the AK RMP used in the Osaka CRMLN laboratory, the regression equation for measuring TC was y (Osaka) = 1.000x (CDC) + 0.032 (n = 619, R-2 = 1.000). Six Japanese manufacturers had allowable performance for certification. Conclusions: The AK RMP for TC measurement was accurate, precise, and stable for 22 years. Six Japanese manufacturers were certified for 16 years. (C) 2015 Elsevier B.V. All rights reserved. C1 [Nakamura, Masakazu; Koyama, Isao] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Lipid Reference Lab, Suita, Osaka 5658565, Japan. [Iso, Hiroyasu; Kitamura, Akihiko; Imano, Hironori] Osaka Univ, Grad Sch Med, Dept Social Med, Publ Hlth, Suita, Osaka 565, Japan. [Kiyama, Masahiko] Osaka Ctr Canc & Cardiovasc Dis Prevent, Osaka, Japan. [Yokoyama, Shinji] Chubu Univ, Nutr Hlth Sci Res Ctr, Kasugai, Aichi 487, Japan. [Kayamori, Yuzo] Kyushu Univ, Fac Med Sci, Dept Hlth Sci, Fukuoka 812, Japan. [Nishimura, Kunihiro; Nakai, Michikazu] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Med & Epidemiol Informat, Suita, Osaka 5658565, Japan. [Dasti, Mahnaz; Vesper, Hubert W.] Ctr Dis Control & Prevent, Div Sci Lab, Natl Ctr Environm Hlth, Atlanta, GA USA. [Teramoto, Tamio] Teikyo Univ, Teikyo Acad Res Ctr, Tokyo, Japan. [Miyamoto, Yoshihiro] Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Dept Prevent Med & Epidemiol Informat, Suita, Osaka 5658565, Japan. RP Nakamura, M (reprint author), Natl Cerebral & Cardiovasc Ctr, Dept Prevent Cardiol, Lipid Reference Lab, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan. EM nakamura.masakazu.hp@ncvc.go.jp FU Health and Labour Sciences Research Grant, Japan (Comprehensive Research on Lifestyle-Related Diseases Including Cardiovascular Diseases and Diabetes Mellitus) from the Ministry of Health, Labour, and Welfare of Japan FX This work was supported by a Health and Labour Sciences Research Grant, Japan (Comprehensive Research on Lifestyle-Related Diseases Including Cardiovascular Diseases and Diabetes Mellitus) from the Ministry of Health, Labour, and Welfare of Japan. The authors would like to thank Dr. Katsuyuki Nakajima and Dr. Ikunosuke Sakurabayashi for their valuable comments and discussion, and Ms. Yukari Ichikawa for her excellent help in providing the references and manuscript. NR 32 TC 1 Z9 1 U1 5 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD MAY 20 PY 2015 VL 445 BP 127 EP 132 DI 10.1016/j.cca.2015.03.026 PG 6 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CI8LP UT WOS:000355024100023 PM 25818239 ER PT J AU Miller, IM Lacher, DA Chen, TC Zipf, GW Gindi, RM Galinsky, AM Nwankwo, T Terry, AL AF Miller, Ivey M. Lacher, David A. Chen, Te-Ching Zipf, George W. Gindi, Renee M. Galinsky, Adena M. Nwankwo, Tatiana Terry, Ana L. TI Collection and laboratory methods for dried blood spots for hemoglobin A1c and total and high-density lipoprotein cholesterol in population-based surveys SO CLINICA CHIMICA ACTA LA English DT Article DE Dried blood spots; Survey methods; Laboratory method comparison; Diabetes; Lipids AB Background: The Health Measures at Home Study was a study designed to evaluate the feasibility of incorporating dried blood spots (DBS) collection into the National Health Interview Survey and to compare the proficiencies between field interviewers and health technicians in obtaining DES. Methods: DBS collection and venipuncture were attempted on 125 participants. The DBS were collected in the participant's home and venous blood was collected in the National Health and Nutrition Examination Survey (NHANES) mobile examination center. The DBS results were compared to venous results in the NHANES for the measurements of hemoglobin A1c (HbA1c) and total and high-density lipoprotein (HDL) cholesterol. Results: Field interviewers and health technicians were able to collect the DBS for greater than 95% of participants. For DBS, health technicians and field interviewers were highly correlated for HbA1c (r = 0.92) and total cholesterol (r = 0.89), but not for HDL cholesterol (r = 0.72). The DBS results of interviewers and health technicians compared to the venous method for HbA1c (r = 0.90), but did not compare well for HDL cholesterol (r = 0.64-0.66) and total cholesterol (r = 0.65-0.67). Conclusion: DBS was comparable to venous HbA1c, but not for total and HDL cholesterol. Health technicians and field interviewers had similar performance for DBS methods, except HDL cholesterol. Published by Elsevier B.V. C1 [Miller, Ivey M.; Lacher, David A.; Chen, Te-Ching; Zipf, George W.; Nwankwo, Tatiana; Terry, Ana L.] Ctr Dis Control & Prevent, Div Hlth Examinat Survey, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Gindi, Renee M.; Galinsky, Adena M.] Ctr Dis Control & Prevent, Div Hlth Interview Stat, Natl Ctr Hlth Stat, Hyattsville, MD USA. RP Miller, IM (reprint author), Natl Ctr Hlth Stat, 3311 Toledo Rd,Room 4306, Hyattsville, MD 20782 USA. EM IMiller1@cdc.gov NR 12 TC 2 Z9 2 U1 1 U2 7 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0009-8981 EI 1873-3492 J9 CLIN CHIM ACTA JI Clin. Chim. Acta PD MAY 20 PY 2015 VL 445 BP 143 EP 154 DI 10.1016/j.cca.2015.03.028 PG 12 WC Medical Laboratory Technology SC Medical Laboratory Technology GA CI8LP UT WOS:000355024100026 PM 25818242 ER PT J AU Rudolph, DL Sullivan, V Owen, SM Curtis, KA AF Rudolph, Donna L. Sullivan, Vickie Owen, S. Michele Curtis, Kelly A. TI Detection of Acute HIV-1 Infection by RT-LAMP SO PLOS ONE LA English DT Article ID MEDIATED ISOTHERMAL AMPLIFICATION; COMBO RAPID TEST; REVERSE-TRANSCRIPTION; VISUAL DETECTION; UNITED-STATES; VIRUS; DIAGNOSIS; SEROCONVERSION; IMMUNOASSAY; PERFORMANCE AB A rapid, cost-effective diagnostic test for the detection of acute HIV-1 infection is highly desired. Isothermal amplification techniques, such as reverse-transcription loop-mediated isothermal amplification (RT-LAMP), exhibit characteristics that are ideal for the development of a rapid nucleic acid amplification test (NAAT) because they are quick, easy to perform and do not require complex, dedicated equipment and laboratory space. In this study, we assessed the ability of the HIV-1 RT-LAMP assay to detect acute HIV infection as compared to a representative rapid antibody test and several FDA-approved laboratory-based assays. The HIV-1 RT-LAMP assay detected seroconverting individuals one to three weeks earlier than a rapid HIV antibody test and up to two weeks earlier than a lab-based antigen/antibody (Ag/Ab) combo enzyme immunoassay (EIA). RT-LAMP was not as sensitive as a lab-based qualitative RNA assay, which could be attributed to the significantly smaller nucleic acid input volume. To our knowledge, this is the first demonstration of detecting acute HIV infection using the RT-LAMP assay. The availability of a rapid NAAT, such as the HIV-1 RT-LAMP assay, at the point of care (POC) or in laboratories that do not have access to large platform NAAT could increase the percentage of individuals who receive an acute HIV infection status or confirmation of their HIV status, while immediately linking them to counseling and medical care. In addition, early knowledge of HIV status could lead to reduced high-risk behavior at a time when individuals are at a higher risk for transmitting the virus. C1 [Rudolph, Donna L.; Sullivan, Vickie; Owen, S. Michele; Curtis, Kelly A.] Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Branch Lab, Atlanta, GA 30329 USA. RP Curtis, KA (reprint author), Ctr Dis Control & Prevent, Natl Ctr HIV AIDS Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Branch Lab, Atlanta, GA 30329 USA. EM czv2@cdc.gov NR 45 TC 7 Z9 7 U1 4 U2 18 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 20 PY 2015 VL 10 IS 5 AR e0126609 DI 10.1371/journal.pone.0126609 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI7CV UT WOS:000354921400068 PM 25993381 ER PT J AU Sears, D Mpimbaza, A Kigozi, R Sserwanga, A Chang, MA Kapella, BK Yoon, S Kamya, MR Dorsey, G Ruel, T AF Sears, David Mpimbaza, Arthur Kigozi, Ruth Sserwanga, Asadu Chang, Michelle A. Kapella, Bryan K. Yoon, Steven Kamya, Moses R. Dorsey, Grant Ruel, Theodore TI Quality of Inpatient Pediatric Case Management for Four Leading Causes of Child Mortality at Six Government-Run Ugandan Hospitals SO PLOS ONE LA English DT Article ID PLACEBO-CONTROLLED TRIAL; RAPID DIAGNOSTIC-TEST; SEVERE MALARIA; HEALTH-CARE; INFORMATION-SYSTEMS; DIARRHEA; KENYA; MALNUTRITION; BACTEREMIA; SERVICES AB Background A better understanding of case management practices is required to improve inpatient pediatric care in resource-limited settings. Here we utilize data from a unique health facilitybased surveillance system at six Ugandan hospitals to evaluate the quality of pediatric case management and the factors associated with appropriate care. Methods All children up to the age of 14 years admitted to six district or regional hospitals over 15 months were included in the study. Four case management categories were defined for analysis: suspected malaria, selected illnesses requiring antibiotics, suspected anemia, and diarrhea. The quality of case management for each category was determined by comparing recorded treatments with evidence-based best practices as defined in national guidelines. Associations between variables of interest and the receipt of appropriate case management were estimated using multivariable logistic regression. Results A total of 30,351 admissions were screened for inclusion in the analysis. Ninety-two percent of children met criteria for suspected malaria and 81% received appropriate case management. Thirty-two percent of children had selected illnesses requiring antibiotics and 89% received appropriate antibiotics. Thirty percent of children met criteria for suspected anemia and 38% received appropriate case management. Twelve percent of children had diarrhea and 18% received appropriate case management. Multivariable logistic regression revealed large differences in the quality of care between health facilities. There was also a strong association between a positive malaria diagnostic test result and the odds of receiving appropriate case management for comorbid non-malarial illnesses - children with a positive malaria test were more likely to receive appropriate care for anemia and less likely for illnesses requiring antibiotics and diarrhea. Conclusions Appropriate management of suspected anemia and diarrhea occurred infrequently. Pediatric quality improvement initiatives should target deficiencies in care unique to each health facility, and interventions should focus on the simultaneous management of multiple diagnoses. C1 [Sears, David; Dorsey, Grant] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94117 USA. [Mpimbaza, Arthur; Kigozi, Ruth; Sserwanga, Asadu] Uganda Malaria Surveillance Project, Kampala, Uganda. [Mpimbaza, Arthur] Makerere Univ, Child Hlth & Dev Ctr, Kampala, Uganda. [Chang, Michelle A.; Kapella, Bryan K.; Yoon, Steven] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. [Yoon, Steven] Ctr Dis Control & Prevent, US Presidents Malaria Initiat, Atlanta, GA USA. [Kamya, Moses R.] Makerere Univ, Coll Hlth Sci, Dept Med, Kampala, Uganda. [Ruel, Theodore] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA. RP Sears, D (reprint author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Med, San Francisco, CA 94117 USA. EM dsears@labiomed.org FU Malaria Initiative, U.S. Agency for International Development; Centers for Disease Control and Prevention (CDC) [1U51CK000117]; National Institutes of Health [2T32AI007641, NIH U19AI089674]; Eunice Kennedy Shriver National Institute of Child Health and Human Development at the National Institutes of Health [K23 HD60459] FX The UMSP sentinel site surveillance system and this work were made possible through support provided by the President's Malaria Initiative, U.S. Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (CDC) (1U51CK000117), the National Institutes of Health (2T32AI007641, D.A.S., and NIH U19AI089674), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (K23 HD60459, T.D.R.) at the National Institutes of Health. The opinions expressed herein are those of the authors and do not necessarily reflect the views of CDC or the U.S. Agency for International Development. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 48 TC 1 Z9 1 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 19 PY 2015 VL 10 IS 5 AR e0127192 DI 10.1371/journal.pone.0127192 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI7BT UT WOS:000354918600054 PM 25992620 ER PT J AU Ned-Sykes, R Johnson, C Ridderhof, JC Perlman, E Pollock, A DeBoy, JM AF Ned-Sykes, Renee Johnson, Catherine Ridderhof, John C. Perlman, Eva Pollock, Anne DeBoy, John M. TI Competency Guidelines for Public Health Laboratory Professionals CDC and the Association of Public Health Laboratories SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID AGRICULTURAL LABORATORIES; WORKFORCE; CURRICULUM; LEADERSHIP; FRAMEWORK; EDUCATION; PERSONNEL; CAPACITY; ETHICS; MODEL AB These competency guidelines outline the knowledge, skills, and abilities necessary for public health laboratory (PHL) professionals to deliver the core services of PHLs efficiently and effectively. As part of a 2-year workforce project sponsored in 2012 by CDC and the Association of Public Health Laboratories (APHL), competencies for 15 domain areas were developed by experts representing state and local PHLs, clinical laboratories, academic institutions, laboratory professional organizations, CDC, and APHL. The competencies were developed and reviewed by approximately 170 subject matter experts with diverse backgrounds and experiences in laboratory science and public health. The guidelines comprise general, cross-cutting, and specialized domain areas and are divided into four levels of proficiency: beginner, competent, proficient, and expert. The 15 domain areas are 1) Quality Management System, 2) Ethics, 3) Management and Leadership, 4) Communication, 5) Security, 6) Emergency Management and Response, 7) Workforce Training, 8) General Laboratory Practice, 9) Safety, 10) Surveillance, 11) Informatics, 12) Microbiology, 13) Chemistry, 14) Bioinformatics, and 15) Research. These competency guidelines are targeted to scientists working in PHLs, defined as governmental public health, environmental, and agricultural laboratories that provide analytic biological and/or chemical testing and testing-related services that protect human populations against infectious diseases, foodborne and waterborne diseases, environmental hazards, treatable hereditary disorders, and natural and human-made public health emergencies. The competencies support certain PHL workforce needs such as identifying job responsibilities, assessing individual performance, and providing a guiding framework for producing education and training programs. Although these competencies were developed specifically for the PHL community, this does not preclude their broader application to other professionals in a variety of different work settings. C1 [Ned-Sykes, Renee; Ridderhof, John C.] CDC, Ctr Surveillance Epidemiol & Lab Serv, Ctr Surveillance Epidemiol, Atlanta, GA 30333 USA. [Johnson, Catherine; Perlman, Eva; DeBoy, John M.] Associat Publ Hlth Labs, Silver Spring, MD USA. [Pollock, Anne] CDC, Off Publ Hlth Sci Serv, Ctr Surveillance Epidemiol & Lab Serv, Div Lab Syst, Atlanta, GA 30333 USA. RP Ned-Sykes, R (reprint author), CDC, Ctr Surveillance Epidemiol & Lab Serv, Ctr Surveillance Epidemiol, Atlanta, GA 30333 USA. EM RNed@cdc.gov NR 81 TC 2 Z9 2 U1 1 U2 12 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 15 PY 2015 VL 64 IS 1 SU S BP 1 EP 95 PG 95 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CO2TU UT WOS:000359010300001 PM 25974716 ER PT J AU Ohmit, SE Petrie, JG Malosh, RE Fry, AM Thompson, MG Monto, AS AF Ohmit, Suzanne E. Petrie, Joshua G. Malosh, Ryan E. Fry, Alicia M. Thompson, Mark G. Monto, Arnold S. TI Influenza Vaccine Effectiveness in Households With Children During the 2012-2013 Season: Assessments of Prior Vaccination and Serologic Susceptibility SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza; vaccine effectiveness; households with children; serologic susceptibility ID IMMUNIZATION PRACTICES ACIP; TEST-NEGATIVE DESIGN; UNITED-STATES; NEURAMINIDASE ANTIBODY; ADVISORY-COMMITTEE; PREVENTION; PROTECTION; EFFICACY; RECOMMENDATIONS AB Methods.aEuro integral We recruited 321 households with 1426 members, including 833 children, and followed them during the 2012-2013 influenza season; specimens were collected from subjects with reported acute respiratory illnesses. We estimated the effectiveness of documented influenza vaccination in preventing laboratory-confirmed influenza, using adjusted Cox proportional hazards models. Antibody titers in a subset of subjects were determined by a hemagglutination inhibition assay to determine the subjects' preseason susceptibility to influenza. Results.aEuro integral Influenza was identified in 76 (24%) households and 111 (8%) individuals. VE point estimates indicated significant protection in adults (48%; 95% confidence interval [CI], 1%-72%), similar protection in children aged 9-17 years (49%; 95% CI, -16% to 78%), but no evidence of effectiveness in children aged < 9 years (-4%; 95% CI, -110% to 49%). Lower VE was observed in those vaccinated in both the current and prior seasons, compared with those vaccinated in the current season only; susceptibility titers against type A but not type B were consistent with this observation. Residual protection from vaccination in the prior season was indicated by both VE and serologic results. Conclusions.aEuro integral Prior vaccination appears to modify VE by both residual protection and reduced vaccine response. C1 [Ohmit, Suzanne E.; Petrie, Joshua G.; Malosh, Ryan E.; Monto, Arnold S.] Univ Michigan, Sch Publ Hlth, Dept Epidemiol, Ann Arbor, MI 48109 USA. [Fry, Alicia M.; Thompson, Mark G.] Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA USA. RP Ohmit, SE (reprint author), Univ Michigan, Sch Publ Hlth, 1415 Washington Hts, Ann Arbor, MI 48109 USA. EM sohmit@umich.edu FU CDC [U01 IP000474]; National Institute of Allergy and Infectious Diseases [R01 AI097150] FX This work was supported by the CDC (U01 IP000474) and the National Institute of Allergy and Infectious Diseases (R01 AI097150). NR 27 TC 27 Z9 27 U1 1 U2 11 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2015 VL 211 IS 10 BP 1519 EP 1528 DI 10.1093/infdis/jiu650 PG 10 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4MG UT WOS:000354723000002 PM 25416812 ER PT J AU McLean, HQ Thompson, MG Sundaram, ME Kieke, BA Gaglani, M Murthy, K Piedra, PA Zimmerman, RK Nowalk, MP Raviotta, JM Jackson, ML Jackson, L Ohmit, SE Petrie, JG Monto, AS Meece, JK Thaker, SN Clippard, JR Spencer, SM Fry, AM Belongia, EA AF McLean, Huong Q. Thompson, Mark G. Sundaram, Maria E. Kieke, Burney A. Gaglani, Manjusha Murthy, Kempapura Piedra, Pedro A. Zimmerman, Richard K. Nowalk, Mary Patricia Raviotta, Jonathan M. Jackson, Michael L. Jackson, Lisa Ohmit, Suzanne E. Petrie, Joshua G. Monto, Arnold S. Meece, Jennifer K. Thaker, Swathi N. Clippard, Jessie R. Spencer, Sarah M. Fry, Alicia M. Belongia, Edward A. TI Influenza Vaccine Effectiveness in the United States During 2012-2013: Variable Protection by Age and Virus Type SO JOURNAL OF INFECTIOUS DISEASES LA English DT Article DE influenza; vaccine effectiveness; medically attended influenza ID TEST-NEGATIVE DESIGN; SEASON; CIRCULATION; EFFICACY; INTERIM AB Methods.aEuro integral Patients with acute cough illness for a parts per thousand currency sign7 days were prospectively enrolled and had swab samples obtained at outpatient clinics in 5 states. Influenza vaccination dates were confirmed by medical records. The vaccine effectiveness (VE) was estimated as [100% x (1 - adjusted odds ratio)] for vaccination in cases versus test-negative controls. Results.aEuro integral Influenza was detected in 2307 of 6452 patients (36%); 1292 (56%) had influenza A(H3N2), 582 (25%) had influenza B/Yamagata, and 303 (13%) had influenza B/Victoria. VE was 49% (95% confidence interval [CI], 43%-55%) overall, 39% (95% CI, 29%-47%) against influenza A(H3N2), 66% (95% CI, 58%-73%) against influenza B/Yamagata (vaccine lineage), and 51% (95% CI, 36%-63%) against influenza B/Victoria. VE against influenza A(H3N2) was highest among persons aged 50-64 years (52%; 95% CI, 33%-65%) and persons aged 6 months-8 years (51%; 95% CI, 32%-64%) and lowest among persons aged a parts per thousand yen65 years (11%; 95% CI, -41% to 43%). In younger age groups, there was evidence of residual protection from receipt of the 2011-2012 vaccine 1 year earlier. Conclusions.aEuro integral The 2012-2013 vaccines were moderately effective in most age groups. Cross-lineage protection and residual effects from prior vaccination were observed and warrant further investigation. C1 [McLean, Huong Q.; Sundaram, Maria E.; Kieke, Burney A.; Meece, Jennifer K.; Belongia, Edward A.] Marshfield Clin Res Fdn, Marshfield, WI USA. [Thompson, Mark G.; Thaker, Swathi N.; Clippard, Jessie R.; Spencer, Sarah M.; Fry, Alicia M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gaglani, Manjusha; Murthy, Kempapura] Baylor Scott & White Hlth, Texas A&M Hlth Sci Ctr, Coll Med, Temple, TX USA. [Piedra, Pedro A.] Baylor Coll Med, Houston, TX 77030 USA. [Zimmerman, Richard K.; Nowalk, Mary Patricia; Raviotta, Jonathan M.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Jackson, Michael L.; Jackson, Lisa] Grp Hlth Cooperat Puget Sound, Seattle, WA USA. [Ohmit, Suzanne E.; Petrie, Joshua G.; Monto, Arnold S.] Univ Michigan, Ann Arbor, MI 48109 USA. RP McLean, HQ (reprint author), Marshfield Clin Res Fdn ML2, 1000 N Oak Ave, Marshfield, WI 54449 USA. EM mclean.huong@marshfieldclinic.org RI Raviotta, Jonathan/O-9109-2016; OI Raviotta, Jonathan/0000-0001-7551-0628; Zimmerman, Richard/0000-0001-5941-6092 FU CDC [U01 IP000474, U01 IP000466, U01 IP000471, U01 IP000467, U01 IP000473]; National Institutes of Health [UL1 RR024153, UL1TR000005] FX This work was supported by the CDC, through cooperative agreements with the University of Michigan (U01 IP000474), Group Health Research Institute (U01 IP000466), Marshfield Clinic Research Foundation (U01 IP000471), University of Pittsburgh (U01 IP000467), and Baylor Scott and White Health (U01 IP000473); and by the National Institutes of Health (grants UL1 RR024153 and UL1TR000005 to the University of Pittsburgh). NR 30 TC 45 Z9 45 U1 0 U2 13 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-1899 EI 1537-6613 J9 J INFECT DIS JI J. Infect. Dis. PD MAY 15 PY 2015 VL 211 IS 10 BP 1529 EP 1540 DI 10.1093/infdis/jiu647 PG 12 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CI4MG UT WOS:000354723000003 PM 25406334 ER PT J AU Chen, I Poirot, E Newman, M Kandula, D Shah, R Hwang, J Cohen, JM Gosling, R Rooney, L AF Chen, Ingrid Poirot, Eugenie Newman, Mark Kandula, Deepika Shah, Renee Hwang, Jimee Cohen, Justin M. Gosling, Roly Rooney, Luke TI An assessment of the supply, programmatic use, and regulatory issues of single low-dose primaquine as a Plasmodium falciparum gametocytocide for sub-Saharan Africa SO MALARIA JOURNAL LA English DT Article DE Primaquine; 8-aminoquinoline; Plasmodium falciparum; Africa; Glucose-6-phosphate dehydrogenase deficiency; G6PD; Drug dosing; Drug production; Drug manufacturing; Drug regulation; Malaria transmission ID MALARIA; TRANSMISSION; EPIDEMIOLOGY; DEFICIENCY; RATIONALE AB Background: Global ambitions to eliminate malaria are intensifying, underscoring a critical need for transmission blocking tools. In 2012, the WHO recommended the use of 0.25 mg/kg of single low-dose (SLD) primaquine to stop Plasmodium falciparum transmission. To ensure the availability of SLD primaquine to countries in need of this tool, more information on the supply, programmatic, and regulatory barriers to the rollout of SLD primaquine is required. Methods: Challenges to the rollout of SLD primaquine in sub-Saharan Africa were established through semi-structured qualitative interviews with three primaquine manufacturers, 43 key informants from Ethiopia, Senegal, Swaziland, Zambia, and Tanzania, and 16 malaria research experts. Results: Sanofi and Remedica are the only two sources of SRA-approved primaquine suitable for procurement by international donors. Neither manufacturer produces primaquine tablet strengths suitable for the transmission blocking indication. In-country key informants revealed that the WHO weight-based recommendation to use SLD primaquine is challenging to implement in actual field settings. Malaria programmes expressed safety concerns of SLD primaquine use in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, as well as potential interactions between primaquine and co-morbidities, and drug-drug interactions with HIV and/or tuberculosis treatments. Regulatory processes are a major barrier to the rollout of SLD primaquine, requiring multiple steps at both the country and global level. Despite these barriers, demand for SLD primaquine is growing, and malaria researchers are interested in primaquine deployment through mass screen and treat and/or mass drug administration campaigns. Conclusion: Demand for primaquine as a transmission blocking agent is growing rapidly yet multiple barriers to SLD primaquine use exist. Research is needed to define the therapeutic dose range, which will guide dosing regimens in the field, inform the development of new, lower strength primaquine tablets and/or formulation(s), and allay programmatic safety concerns in individuals with G6PD deficiency. Potential interactions between primaquine and co-morbidities and treatments should be explored. To minimize regulatory delays, countries need to prepare for product registration at an early stage, WHO prequalification for suitable primaquine tablet strengths and/or new formulations should be sought, and in the meanwhile only Stringent Regulatory Authority (SRA)-approved primaquine should be used. C1 [Chen, Ingrid; Poirot, Eugenie; Hwang, Jimee; Gosling, Roly] Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94158 USA. [Newman, Mark; Kandula, Deepika; Shah, Renee; Cohen, Justin M.; Rooney, Luke] Clinton Hlth Access Initiat, Boston, MA USA. [Hwang, Jimee] Ctr Dis Control & Prevent, Malaria Branch, Atlanta, GA USA. RP Chen, I (reprint author), Univ Calif San Francisco, Global Hlth Sci, 550 16th St,3rd Floor, San Francisco, CA 94158 USA. EM Ingrid.Chen@ucsf.edu OI Cohen, Justin/0000-0003-4481-6784 FU UCSF Global Health Group through a grant from the Bill & Melinda Gates Foundation; United Kingdom Department for International Development; President's Malaria Initiative FX This study was supported by the UCSF Global Health Group through a grant from the Bill & Melinda Gates Foundation. LR, DK, MN, RS, and JC also acknowledge support for this work from the United Kingdom Department for International Development. JH receives salary support from the President's Malaria Initiative. The authors would like to thank our key informants for their participation in lengthy meetings and interviews, in particular members of the National Malarial Control Programmes of Senegal (Mady Ba, Moustapha Cisse, Alioune Badara Gueye, Lamine Diouf), Zambia (Christine M. Wamulume), Tanzania (Shija J. Shija, Dr. Haji, Mwinyi Msellem, Abdullah Ali), and Swaziland (Mbongiseni Mathobela, Sarah Darteh, Simon Kunene, Quinton Dlamini); NR 22 TC 6 Z9 6 U1 0 U2 3 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAY 15 PY 2015 VL 14 AR 204 DI 10.1186/s12936-015-0714-3 PG 10 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CJ2IJ UT WOS:000355307200001 PM 25971688 ER PT J AU King, JC Gao, YH Quinn, CP Dreier, TM Vianney, C Espeland, EM AF King, James C., Jr. Gao, Yonghong Quinn, Conrad P. Dreier, Thomas M. Vianney, Cabrini Espeland, Eric M. TI Evaluation of anthrax vaccine safety in 18 to 20 year olds: A first step towards age de-escalation studies in adolescents SO VACCINE LA English DT Article DE Pediatric medical countermeasure research; Anthrax vaccine; Presidential Ethics Committee; Children ID ACELLULAR PERTUSSIS-VACCINE; LETHAL TOXIN NEUTRALIZATION; BACILLUS-ANTHRACIS; PROTECTIVE ANTIGEN; ANTIBODY-RESPONSE; POSTEXPOSURE PROPHYLAXIS; RANDOMIZED-TRIAL; ADVERSE EVENTS; IMMUNOGENICITY; DIPHTHERIA AB Background/objectives: Anthrax vaccine adsorbed (AVA, BioThrae (R)) is recommended for post-exposure prophylaxis administration for the US population in response to large-scale Bacillus anthracis spore exposure. However, no information exists on AVA use in children and ethical barriers exist to performing pre-event pediatric AVA studies. A Presidential Ethics Commission proposed a potential pathway for such studies utilizing an age de-escalation process comparing safety and immunogenicity data from 18 to 20 year-olds to older adults and if acceptable proceeding to evaluations in younger adolescents. We conducted exploratory summary re-analyses of existing databases from 18 to 20 year-olds (n=74) compared to adults aged 21 to 29 years (n=243) who participated in four previous US government funded AVA studies. Methods: Data extracted from studies included elicited local injection-site and systemic adverse events (AEs) following AVA doses given subcutaneously at 0, 2, and 4 weeks. Additionally, proportions of subjects with >= 4-fold antibody rises from baseline to post-second and post-third AVA doses (seroresponse) were obtained. Results: Rates of any elicited local AEs were not significantly different between younger and older age groups for local events (79.2% vs. 83.8%, P= 0.120) or systemic events (45.4% vs. 50.5%, P=0.188). Robust and similar proportions of seroresponses to vaccination were observed in both age groups. Conclusions: AVA was safe and immunogenic in 18 to 20 year-olds compared to 21 to 29 year-olds. These results provide initial information to anthrax and pediatric specialists if AVA studies in adolescents are required. (C) 2015 Elsevier Ltd. All rights reserved. C1 [King, James C., Jr.; Dreier, Thomas M.] BARDA, ASPR, Tunnel Contracting Serving Miss, HHS, Washington, DC 20024 USA. [Gao, Yonghong; Espeland, Eric M.] BARDA, ASPR, HHS, Washington, DC 20024 USA. [Quinn, Conrad P.] Ctr Dis Control & Prevent, MPIR Lab, MVPD, DBD,NCIRD, Atlanta, GA 30333 USA. [Vianney, Cabrini] BARDA, ASPR, GAP Solut Inc Supporting Miss, HHS, Washington, DC 20024 USA. RP King, JC (reprint author), BARDA, ASPR, Tunnel Contracting Serving Miss, HHS, Thomas P ONeill Fed Bldg FOB8,200 C St SW, Washington, DC 20024 USA. EM james.king@hhs.gov FU Centers for Disease Control and Prevention; Health and Human Services [HHS100200700037C] FX Studies utilized in this Special Article were funded by:; Centers for Disease Control and Prevention.; Health and Human Services contract number: HHS100200700037C. NR 41 TC 3 Z9 3 U1 1 U2 5 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 15 PY 2015 VL 33 IS 21 BP 2470 EP 2476 DI 10.1016/j.vaccine.2015.03.071 PG 7 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CJ3AB UT WOS:000355354700012 PM 25850022 ER PT J AU Gomes, BAQ da Silva, LFD Gomes, ARQ Moreira, DR Dolabela, MF Santos, RS Green, MD Carvalho, EP Percario, S AF Quadros Gomes, Bruno A. da Silva, Lucio F. D. Quadros Gomes, Antonio R. Moreira, Danilo R. Dolabela, Maria Fani Santos, Rogerio S. Green, Michael D. Carvalho, Eliete P. Percario, Sandro TI N-acetyl cysteine and mushroom Agaricus sylvaticus supplementation decreased parasitaemia and pulmonary oxidative stress in a mice model of malaria SO MALARIA JOURNAL LA English DT Article DE Antioxidants; Oxidative stress; Agaricus sylvaticus; N-acetyl cysteine; Nitric oxide; Plasmodium berghei; Malaria ID NITRIC-OXIDE SYNTHASE; PLASMODIUM-FALCIPARUM MALARIA; RESPIRATORY-DISTRESS-SYNDROME; CEREBRAL MALARIA; PATHOLOGIC PHYSIOLOGY; ANTIOXIDANT ACTIVITY; LUNG INJURY; IN-VITRO; BERGHEI; EXPRESSION AB Background: Malaria infection can cause high oxidative stress, which could lead to the development of severe forms of malaria, such as pulmonary malaria. In recent years, the role of reactive oxygen species in the pathogenesis of the disease has been discussed, as well as the potential benefit of antioxidants supplementation. The aim of this study was to investigate the effects of N-acetyl cysteine (NAC) or mushroom Agaricus sylvaticus supplementation on the pulmonary oxidative changes in an experimental model of malaria caused by Plasmodium berghei strain ANKA. Methods: Swiss male mice were infected with P. berghei and treated with NAC or AS. Samples of lung tissue and whole blood were collected after one, three, five, seven or ten days of infection for the assessment of thiobarbituric acid reactive substances (TBARS), trolox equivalent antioxidant capacity (TEAC), nitrites and nitrates (NN) and to assess the degree of parasitaemia. Results: Although parasitaemia increased progressively with the evolution of the disease in all infected groups, there was a significant decrease from the seventh to the tenth day of infection in both antioxidant-supplemented groups. Results showed significant higher levels of TEAC in both supplemented groups, the highest occurring in the group supplemented with A. sylvaticus. In parallel, TBARS showed similar levels among all groups, while levels of NN were higher in animals supplemented with NAC in relation to the positive control groups and A. sylvaticus, whose levels were similar to the negative control group. Conclusion: Oxidative stress arising from plasmodial infection was attenuated by supplementation of both antioxidants, but A. sylvaticus proved to be more effective and has the potential to become an important tool in the adjuvant therapy of malaria. C1 [Quadros Gomes, Bruno A.; da Silva, Lucio F. D.; Quadros Gomes, Antonio R.; Moreira, Danilo R.; Santos, Rogerio S.; Carvalho, Eliete P.; Percario, Sandro] Fed Univ Para, Inst Biol Sci, Oxidat Stress Res Lab, BR-66059 Belem, Para, Brazil. [Dolabela, Maria Fani] Fed Univ Para, Inst Hlth Sci, BR-66059 Belem, Para, Brazil. [Green, Michael D.] US Ctr Dis Control & Prevent, Div Parasit Dis & Malaria, Atlanta, GA USA. RP Percario, S (reprint author), Fed Univ Para, Inst Biol Sci, Oxidat Stress Res Lab, BR-66059 Belem, Para, Brazil. EM spercario49@gmail.com OI Percario, Sandro/0000-0002-9528-0361 FU Fundacao Amazonia de Amparo a Pesquisas do Para (FAPESPA); Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES); FAPESPA [EMD0100015]; Pro-Reitoria de Pesquisa e Pos-Graduacao of the Universidade Federal do Para (PROPESP/UFPA); Fundacao de Amparo ao Desenvolvimento da Pesquisa (FADESP) FX The authors are grateful to Cogumelo do Sol Com, Exp. e Imp. Ltda. for allowing the collection of Agaricus sylvaticus samples employed in this study; to the Neurochemistry Laboratory of UFPA for providing the parasite strain and to Evandro Chagas Institute for providing the experimental animals. Scholarship to BAQG was provided by Fundacao Amazonia de Amparo a Pesquisas do Para (FAPESPA) and to LFDS by Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES). Funding was provided to SP by FAPESPA (EMD0100015). Editorial expenses were provided by Pro-Reitoria de Pesquisa e Pos-Graduacao of the Universidade Federal do Para (PROPESP/UFPA) and Fundacao de Amparo ao Desenvolvimento da Pesquisa (FADESP). NR 72 TC 0 Z9 0 U1 1 U2 5 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAY 15 PY 2015 VL 14 AR 202 DI 10.1186/s12936-015-0717-0 PG 12 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CI6DI UT WOS:000354848500002 ER PT J AU Zlot, A Simckes, M Vines, J Reynolds, L Sullivan, A Scott, MK McLuckie, JM Kromer, D Hill, VR Yoder, JS Hlavsa, MC AF Zlot, Amy Simckes, Maayan Vines, Jennifer Reynolds, Laura Sullivan, Amy Scott, Magdalena Kendall McLuckie, J. Michael Kromer, Dan Hill, Vincent R. Yoder, Jonathan S. Hlavsa, Michele C. TI Norovirus Outbreak Associated with a Natural Lake Used for Recreation - Oregon, 2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; WATER C1 [Zlot, Amy; Simckes, Maayan; Vines, Jennifer; Reynolds, Laura; Sullivan, Amy; McLuckie, J. Michael] Multnomah Cty Hlth Dept, Portland, OR 97204 USA. [Simckes, Maayan] Appl Epidemiol Fellowship Program, CDC CSTE, Portland, OR USA. [Scott, Magdalena Kendall] Oregon Publ Hlth Div, Portland, OR USA. [Kromer, Dan] Metro, Fairview, OR USA. [Yoder, Jonathan S.; Hlavsa, Michele C.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Zlot, A (reprint author), Multnomah Cty Hlth Dept, Portland, OR 97204 USA. EM amy.zlot@multco.us FU Applied Epidemiology Fellowship Program; CDC [5U38HM000414-5] FX This study was supported in part by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists (CSTE) and funded by CDC Cooperative Agreement Number 5U38HM000414-5. NR 9 TC 2 Z9 2 U1 1 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 15 PY 2015 VL 64 IS 18 BP 485 EP 490 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AK UT WOS:000354688400001 PM 25974632 ER PT J AU Paone, D Tuazon, E Kattan, J Nolan, ML O'Brien, DB Dowell, D Farley, TA Kunins, HV AF Paone, Denise Tuazon, Ellenie Kattan, Jessica Nolan, Michelle L. O'Brien, Daniella Bradley Dowell, Deborah Farley, Thomas A. Kunins, Hillary V. TI Decrease in Rate of Opioid Analgesic Overdose Deaths - Staten Island, New York City, 2011-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID PRESCRIPTION C1 [Paone, Denise; Tuazon, Ellenie; Kattan, Jessica; Nolan, Michelle L.; O'Brien, Daniella Bradley; Kunins, Hillary V.] New York City Dept Hlth & Mental Hyg, Bur Alcohol Drug Use Prevent Care & Treatment, New York, NY 10013 USA. [Dowell, Deborah] CDC, Off Noncommunicable Dis Injury & Environm Hlth, Natl Ctr Injury Prevent & Control, New York, NY USA. [Farley, Thomas A.] Publ Good Projects, New York, NY USA. RP Paone, D (reprint author), New York City Dept Hlth & Mental Hyg, Bur Alcohol Drug Use Prevent Care & Treatment, New York, NY 10013 USA. EM dpaone@health.nyc.gov OI Paone, Nicola/0000-0002-1228-8967 NR 10 TC 9 Z9 9 U1 0 U2 2 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 15 PY 2015 VL 64 IS 18 BP 491 EP 494 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AK UT WOS:000354688400002 PM 25974633 ER PT J AU Crim, SM Griffin, PM Tauxe, R Marder, EP Gilliss, D Cronquist, AB Cartter, M Tobin-D'Angelo, M Blythe, D Smith, K Lathrop, S Zansky, S Cieslak, PR Dunn, J Holt, KG Wolpert, B Henao, OL AF Crim, Stacy M. Griffin, Patricia M. Tauxe, Robert Marder, Ellyn P. Gilliss, Debra Cronquist, Alicia B. Cartter, Matthew Tobin-D'Angelo, Melissa Blythe, David Smith, Kirk Lathrop, Sarah Zansky, Shelley Cieslak, Paul R. Dunn, John Holt, Kristin G. Wolpert, Beverly Henao, Olga L. TI Preliminary Incidence and Trends of Infection with Pathogens Transmitted Commonly Through Food - Foodborne Diseases Active Surveillance Network, 10 US Sites, 2006-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES C1 [Crim, Stacy M.; Griffin, Patricia M.; Tauxe, Robert; Marder, Ellyn P.; Henao, Olga L.] CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Marder, Ellyn P.] Atlanta Res & Educ Fdn, Atlanta, GA USA. [Gilliss, Debra] Calif Dept Publ Hlth, Richmond, CA USA. [Cronquist, Alicia B.] Colorado Dept Publ Hlth & Environm, Denver, CO USA. [Cartter, Matthew] Connecticut Dept Publ Hlth, Hartford, CT USA. [Tobin-D'Angelo, Melissa] Georgia Dept Publ Hlth, Marietta, GA USA. [Blythe, David] Maryland Dept Hlth & Mental Hyg, Baltimore, MD 21201 USA. [Smith, Kirk] Minnesota Dept Hlth, Minneapolis, MN 55414 USA. [Lathrop, Sarah] Univ New Mexico, Albuquerque, NM 87131 USA. [Zansky, Shelley] New York State Dept Hlth, Albany, NY 12237 USA. [Cieslak, Paul R.] Oregon Hlth Author, Portland, OR USA. [Dunn, John] Tennessee Dept Hlth, Nashville, TN USA. [Holt, Kristin G.] Food Safety & Inspect Serv, USDA, Washington, DC USA. [Wolpert, Beverly] US FDA, Ctr Food Safety & Appl Nutr, Rockville, MD 20857 USA. RP Henao, OL (reprint author), CDC, Div Foodborne Waterborne & Environm Dis, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM ohenao@cdc.gov NR 9 TC 26 Z9 27 U1 1 U2 13 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 15 PY 2015 VL 64 IS 18 BP 495 EP 499 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AK UT WOS:000354688400003 PM 25974634 ER PT J AU Nyenswah, T Fallah, M Sieh, S Kollie, K Badio, M Gray, A Dilah, P Shannon, M Duwor, S Ihekweazu, C Cordier-Lasalle, T Shinde, SA Hamblion, E Davies-Wayne, G Ratnesh, M Dye, C Yoder, JS McElroy, P Hoots, B Christie, A Vertefeuille, J Olsen, SJ Laney, AS Neal, JJ Navin, TR Coulter, S Pordell, P Lo, T Kinkade, C Mahoney, F AF Nyenswah, Tolbert Fallah, Mosoka Sieh, Sonpon Kollie, Karsor Badio, Moses Gray, Alvin Dilah, Priscilla Shannon, Marnijina Duwor, Stanley Ihekweazu, Chikwe Cordier-Lasalle, Thierry Shinde, Shivam A. Hamblion, Esther Davies-Wayne, Gloria Ratnesh, Murugan Dye, Christopher Yoder, Jonathan S. McElroy, Peter Hoots, Brooke Christie, Athalia Vertefeuille, John Olsen, Sonja J. Laney, A. Scott Neal, Joyce J. Navin, Thomas R. Coulter, Stewart Pordell, Paran Lo, Terrence Kinkade, Carl Mahoney, Frank TI Controlling the Last Known Cluster of Ebola Virus Disease - Liberia, January-February 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Nyenswah, Tolbert; Fallah, Mosoka; Sieh, Sonpon; Kollie, Karsor; Badio, Moses; Gray, Alvin; Dilah, Priscilla; Shannon, Marnijina; Duwor, Stanley] Minist Hlth & Social Welf, Monrovia, Liberia. [Ihekweazu, Chikwe; Cordier-Lasalle, Thierry; Shinde, Shivam A.; Hamblion, Esther; Davies-Wayne, Gloria; Ratnesh, Murugan; Dye, Christopher] WHO, Geneva, Switzerland. [Yoder, Jonathan S.; McElroy, Peter; Hoots, Brooke; Christie, Athalia; Vertefeuille, John; Olsen, Sonja J.; Laney, A. Scott; Neal, Joyce J.; Navin, Thomas R.; Coulter, Stewart; Pordell, Paran; Lo, Terrence; Kinkade, Carl; Mahoney, Frank] CDC, Atlanta, GA 30333 USA. RP Yoder, JS (reprint author), CDC, Atlanta, GA 30333 USA. EM jyoder@cdc.gov OI Hamblion, Esther/0000-0003-4250-3696 NR 6 TC 14 Z9 15 U1 0 U2 6 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 15 PY 2015 VL 64 IS 18 BP 500 EP 504 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AK UT WOS:000354688400004 PM 25974635 ER PT J AU Nyenswah, T Massaquoi, M Gbanya, MZ Fallah, M Amegashie, F Kenta, A Johnson, KL Yahya, D Badini, M Soro, L Pessoa-Silva, CL Roger, I Selvey, L VanderEnde, K Murphy, M Cooley, LA Olsen, SJ Christie, A Vertefeuille, J Navin, T McElroy, P Park, BJ Esswein, E Fagan, R Mahoney, F AF Nyenswah, Tolbert Massaquoi, Moses Gbanya, Miatta Zenabu Fallah, Mosoka Amegashie, Fred Kenta, Adolphus Johnson, Kumblytee L. Yahya, Disu Badini, Mehboob Soro, Lacina Pessoa-Silva, Carmem L. Roger, Isabelle Selvey, Linda VanderEnde, Kristin Murphy, Matthew Cooley, Laura A. Olsen, Sonja J. Christie, Athalia Vertefeuille, John Navin, Thomas McElroy, Peter Park, Benjamin J. Esswein, Eric Fagan, Ryan Mahoney, Frank TI Initiation of a Ring Approach to Infection Prevention and Control at Non-Ebola Health Care Facilities - Liberia, January-February 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article C1 [Nyenswah, Tolbert; Massaquoi, Moses; Gbanya, Miatta Zenabu] Minist Hlth & Social Work, Monrovia, Liberia. [Fallah, Mosoka] Montserrado Incident Management Syst, Geneva, Switzerland. [Amegashie, Fred; Kenta, Adolphus] Montserrado Cty Hlth Team, Bensonville, Liberia. [Johnson, Kumblytee L.] CH Rennie Hosp, Kakata, Margibi, Liberia. [Yahya, Disu] African Union, Johannesburg, South Africa. [Badini, Mehboob; Soro, Lacina; Pessoa-Silva, Carmem L.; Roger, Isabelle; Selvey, Linda] WHO, Geneva, Switzerland. [VanderEnde, Kristin; Murphy, Matthew; Cooley, Laura A.; Olsen, Sonja J.; Christie, Athalia; Vertefeuille, John; Navin, Thomas; McElroy, Peter; Park, Benjamin J.; Fagan, Ryan; Mahoney, Frank] CDC, Atlanta, GA 30333 USA. [VanderEnde, Kristin] Epidem Intelligence Serv, Atlanta, GA USA. [Esswein, Eric] CDC, NIOSH, Atlanta, GA 30333 USA. [Esswein, Eric] Univ Witwatersrand, ZA-2050 Johannesburg, South Africa. RP VanderEnde, K (reprint author), CDC, Atlanta, GA 30333 USA. EM ydj3@cdc.gov RI Selvey, Linda/B-8473-2017 OI Selvey, Linda/0000-0001-8493-0974 NR 5 TC 4 Z9 4 U1 0 U2 1 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 15 PY 2015 VL 64 IS 18 BP 505 EP 508 PG 4 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AK UT WOS:000354688400005 PM 25974636 ER PT J AU Okoth, SA Abdallah, JF Ceron, N Adhin, MR Chandrabose, J Krishnalall, K Huber, CS Goldman, IF de Oliveira, AM Barnwell, JW Udhayakumar, V AF Okoth, Sheila Akinyi Abdallah, Joseph F. Ceron, Nicolas Adhin, Malti R. Chandrabose, Javin Krishnalall, Karanchand Huber, Curtis S. Goldman, Ira F. de Oliveira, Alexandre Macedo Barnwell, John W. Udhayakumar, Venkatachalam TI Variation in Plasmodium falciparum Histidine-Rich Protein 2 (Pfhrp2) and Plasmodium falciparum Histidine-Rich Protein 3 (Pfhrp3) Gene Deletions in Guyana and Suriname SO PLOS ONE LA English DT Article ID RAPID DIAGNOSTIC-TESTS; MULTILOCUS GENOTYPE DATA; MICROSATELLITE MARKERS; MALARIA PARASITES; AMAZON REGION; SOUTH-AMERICA; ORIGIN; RESISTANCE; INFERENCE; PERU AB Guyana and Suriname have made important progress in reducing the burden of malaria. While both countries use microscopy as the primary tool for clinical diagnosis, malaria rapid diagnostic tests (RDTs) are useful in remote areas of the interior where laboratory support may be limited or unavailable. Recent reports indicate that histidine-rich protein 2 (PfHRP2)-based diagnostic tests specific for detection of P. falciparum may provide false negative results in some parts of South America due to the emergence of P. falciparum parasites that lack the pfhrp2 gene, and thus produce no PfHRP2 antigen. Pfhrp2 and pfhrp3 genes were amplified in parasite isolates collected from Guyana and Suriname to determine if there were circulating isolates with deletions in these genes. Pfhrp3 deletions were monitored because some monoclonal antibodies utilized in PfHRP2-based RDTs cross-react with the PfHRP3 protein. We found that all 97 isolates from Guyana that met the inclusion criteria were both pfhrp2- and pfhrp3-positive. In Suriname (N = 78), 14% of the samples tested were pfhrp2-negative while 4% were pfhrp3-negative. Furthermore, analysis of the genomic region proximal to pfhrp2 and pfhrp3 revealed that genomic deletions extended to the flanking genes. We also investigated the population substructure of the isolates collected to determine if the parasites that had deletions of pfhrp2 and pfhrp3 belonged to any genetic subtypes. Cluster analysis revealed that there was no predominant P. falciparum population substructure among the isolates from either country, an indication of genetic admixture among the parasite populations. Furthermore, the pfhrp2-deleted parasites from Suriname did not appear to share a single, unique genetic background. C1 [Okoth, Sheila Akinyi; Abdallah, Joseph F.; Huber, Curtis S.; Goldman, Ira F.; de Oliveira, Alexandre Macedo; Barnwell, John W.; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30322 USA. [Okoth, Sheila Akinyi] Atlanta Res & Educ Fdn, Decatur, GA USA. [Ceron, Nicolas] Pan Amer Hlth Org Guyana, Georgetown, Guyana. [Adhin, Malti R.] Univ Suriname, Dept Biochem, Anton Kom ADEK, Paramaribo, Surinam. [Chandrabose, Javin; Krishnalall, Karanchand] Guyana Minist Hlth, Georgetown, Guyana. RP Udhayakumar, V (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA 30322 USA. EM vxu0@cdc.gov FU Amazon Malaria Initiative of the United States Agency for International Development; American Society for Microbiology/CDC Fellowship; Atlanta Research and Education Foundation FX This study was funded by the Amazon Malaria Initiative of the United States Agency for International Development. SAO was supported by the American Society for Microbiology/CDC Fellowship and the Atlanta Research and Education Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 37 TC 5 Z9 5 U1 2 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 15 PY 2015 VL 10 IS 5 AR e0126805 DI 10.1371/journal.pone.0126805 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI7AU UT WOS:000354916100103 ER PT J AU Sukumaran, L McNeil, MM Moro, PL Lewis, PW Winiecki, SK Shimabukuro, TT AF Sukumaran, Lakshmi McNeil, Michael M. Moro, Pedro L. Lewis, Paige W. Winiecki, Scott K. Shimabukuro, Tom T. TI Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013 SO CLINICAL INFECTIOUS DISEASES LA English DT Article DE measles; mumps; rubella; MMR vaccine; Vaccine Adverse Event Reporting System (VAERS) ID IMMUNIZATION SAFETY DATA; GUILLAIN-BARRE-SYNDROME; SCHEDULE-UNITED-STATES; FEBRILE SEIZURES; CASE DEFINITIONS; COLLECTION; GUIDELINES; JANUARY; RISK AB Background. Limited data exist on the safety of the measles, mumps, and rubella (MMR) vaccine in adults. We reviewed reports of adverse events (AEs) to the Vaccine Adverse Event Reporting System (VAERS) to assess safety in this previously understudied group. Methods. VAERS is the national spontaneous vaccine safety surveillance system coadministered by the Centers for Disease Control and Prevention and the US Food and Drug Administration. We searched the VAERS database for US reports of adults aged >= 19 years who received the MMR vaccine from 1 January 2003 to 31 July 2013. We clinically reviewed reports and available medical records for serious AEs, pregnancy reports, and reports for selected prespecified outcomes. Results. During this period, VAERS received 3175 US reports after MMR vaccine in adults. Of these, 168 (5%) were classified as serious, including 7 reports of death. Females accounted for 77% of reports. The most common signs and symptoms for all reports were pyrexia (19%), rash (17%), pain (13%), and arthralgia (13%). We did not detect any new safety findings in empirical Bayesian data mining. We identified 131 reports of MMR vaccine administered to a pregnant woman; the majority of these vaccinations were in the first trimester and in 83 (62%), no AE was reported. Conclusions. In our review of VAERS data, we did not detect any new or unexpected safety concerns for MMR vaccination in adults. We identified reports of pregnant women exposed to MMR, which is a group in whom the vaccine is contraindicated, suggesting the need for continued provider education on vaccine recommendations and screening. C1 [Sukumaran, Lakshmi; McNeil, Michael M.; Moro, Pedro L.; Lewis, Paige W.; Shimabukuro, Tom T.] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Immunizat Safety Off, Atlanta, GA 30333 USA. [Sukumaran, Lakshmi] Emory Univ, Sch Med, Atlanta, GA USA. [Winiecki, Scott K.] US FDA, Off Biostat & Epidemiol, Ctr Biol Evaluat & Res, Silver Spring, MD USA. RP Sukumaran, L (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS D-26, Atlanta, GA 30333 USA. EM xfq3@cdc.gov FU NIAID [T32AI074492] FX This work was supported by the NIAID (award number T32AI074492). NR 29 TC 6 Z9 6 U1 2 U2 22 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1058-4838 EI 1537-6591 J9 CLIN INFECT DIS JI Clin. Infect. Dis. PD MAY 15 PY 2015 VL 60 IS 10 BP E58 EP E65 DI 10.1093/cid/civ061 PG 8 WC Immunology; Infectious Diseases; Microbiology SC Immunology; Infectious Diseases; Microbiology GA CH0ON UT WOS:000353721300002 PM 25637587 ER PT J AU Marks, G Gardner, LI Rose, CE Zinski, A Moore, RD Holman, S Rodriguez, AE Sullivan, M Giordano, TP AF Marks, Gary Gardner, Lytt I. Rose, Charles E. Zinski, Anne Moore, Richard D. Holman, Susan Rodriguez, Allan E. Sullivan, Meg Giordano, Thomas P. TI Time above 1500 copies: a viral load measure for assessing transmission risk of HIV-positive patients in care SO AIDS LA English DT Article DE cohort study; HIV; person-time; transmission; viral load ID HETEROSEXUAL TRANSMISSION; ANTIRETROVIRAL THERAPY; SEXUAL TRANSMISSION; UNITED-STATES; BLIPS; METAANALYSIS; INFECTION; RETENTION; UNAWARE; VIRUS AB Objective: We examined HIV transmission potential of patients in care by analyzing the amount of person-time spent above a viral load threshold that increases risk for transmission. Design: Observational cohort and supplemental data. Methods: The cohort included HIV patients who received care at six HIV clinics in the United States, from 1 April 2009 to 31 March 2013, and had two or more viral load tests during this interval. Person-time (in days) above a viral load of 1500 copies/ml out of the total observation time was determined by inspecting consecutive pairs of viral load results and the time intervals between those pairs. The person-time rate ratios comparing demographic and clinical subgroups were estimated with Poisson regression. Results: The cohort included 14 532 patients observed for a median of 1073 days with a median of nine viral load records. Ninety percent of the patients had been prescribed antiretroviral therapy. On average, viral load exceeded 1500 copies/ml during 23% of the patients' observation time (average of 84 days per year, per patient). Percentage of person-time above the threshold was higher among patients who had more than a fourth of their viral load pairs exceeding a 6-month interval (34% of observation time), patients not on antiretroviral therapy (58% of time), new/re-engaging patients (34% of time), patients 16-39 years of age (32% of time), and patients of black race (26% of time). Conclusion: HIV patients in care spent an average of nearly a quarter of their time with viral loads above 1500 copies/ml, higher among some subgroups, placing them at risk for potentially transmitting HIV to others. Copyright (c) 2015 Wolters Kluwer Health, Inc. All rights reserved. C1 [Marks, Gary; Gardner, Lytt I.; Rose, Charles E.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Atlanta, GA 30333 USA. [Zinski, Anne] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA. [Moore, Richard D.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA. [Holman, Susan] Suny Downstate Med Ctr, Brooklyn, NY 11203 USA. [Rodriguez, Allan E.] Univ Miami, Miller Sch Med, Div Infect Dis, Coral Gables, FL 33124 USA. [Sullivan, Meg] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Giordano, Thomas P.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA. [Giordano, Thomas P.] Michael E DeBakey VA Med Ctr, Ctr Innovat Qual Effectiveness & Safety, Houston, TX USA. RP Marks, G (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, 1600 Clifton Rd,MS E-45, Atlanta, GA 30333 USA. EM gmarks@cdc.gov FU NIAID NIH HHS [P30 AI036211, P30 AI094189, P30 AI073961] NR 17 TC 7 Z9 7 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0269-9370 EI 1473-5571 J9 AIDS JI Aids PD MAY 15 PY 2015 VL 29 IS 8 BP 947 EP 954 DI 10.1097/QAD.0000000000000640 PG 8 WC Immunology; Infectious Diseases; Virology SC Immunology; Infectious Diseases; Virology GA CH2TR UT WOS:000353878100010 PM 25768835 ER PT J AU Scobie, HM Ilunga, BK Mulumba, A Shidi, C Coulibaly, T Obama, R Tamfum, JJM Simbu, EP Smit, SB Masresha, B Perry, RT Alleman, MM Kretsinger, K Goodson, J AF Scobie, Heather Melissa Ilunga, Benoit Kebela Mulumba, Audry Shidi, Calixte Coulibaly, Tiekoura Obama, Ricardo Tamfum, Jean-Jacques Muyembe Simbu, Elisabeth Pukuta Smit, Sheilagh Brigitte Masresha, Balcha Perry, Robert Tyrrell Alleman, Mary Margaret Kretsinger, Katrina Goodson, James TI Antecedent causes of a measles resurgence in the Democratic Republic of the Congo SO PAN AFRICAN MEDICAL JOURNAL LA English DT Article DE Measles; outbreak; elimination; immunization; vaccination; surveillance; DRC; RDC ID AFRICAN REGION; OUTBREAK; ELIMINATION; CHALLENGES; VACCINES; PROGRESS; NIGERIA AB Introduction: Despite accelerated measles control efforts, a massive measles resurgence occurred in the Democratic Republic of the Congo (DRC) starting in mid-2010, prompting an investigation into likely causes. Methods: We conducted a descriptive epidemiological analysis using measles immunization and surveillance data to understand the causes of the measles resurgence and to develop recommendations for elimination efforts in DRC. Results: During 2004-2012, performance indicator targets for case-based surveillance and routine measles vaccination were not met. Estimated coverage with the routine first dose of measles-containing vaccine (MCV1) increased from 57% to 73%. Phased supplementary immunization activities (SIAs) were conducted starting in 2002, in some cases with sub-optimal coverage (<= 95%). In 2010, SIAs in five of 11 provinces were not implemented as planned, resulting in a prolonged interval between SIAs, and a missed birth cohort in one province. During July 1, 2010-December 30, 2012, high measles attack rates (>100 cases per 100,000 population) occurred in provinces that had estimated MCV1 coverage lower than the national estimate and did not implement planned 2010 SIAs. The majority of confirmed case-patients were aged <10 years (87%) and unvaccinated or with unknown vaccination status (75%). Surveillance detected two genotype B3 and one genotype B2 measles virus strains that were previously identified in the region. Conclusion: The resurgence was likely caused by an accumulation of unvaccinated, measles-susceptible children due to low MCV1 coverage and suboptimal SIA implementation. To achieve the regional goal of measles elimination by 2020, efforts are needed in DRC to improve case-based surveillance and increase two-dose measles vaccination coverage through routine services and SIAs. C1 [Scobie, Heather Melissa; Alleman, Mary Margaret; Kretsinger, Katrina; Goodson, James] Ctr Dis Control & Prevent, Atlanta, GA USA. [Scobie, Heather Melissa] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Ilunga, Benoit Kebela; Mulumba, Audry; Shidi, Calixte] Minist Publ Hlth, Kinshasa, DEM REP CONGO. [Coulibaly, Tiekoura; Obama, Ricardo] World Hlth Org, Kinshasa, DEM REP CONGO. [Tamfum, Jean-Jacques Muyembe; Simbu, Elisabeth Pukuta] Natl Inst Biomed Res, Kinshasa, DEM REP CONGO. [Smit, Sheilagh Brigitte] Natl Inst Communicable Dis, Johannesburg, South Africa. [Masresha, Balcha] World Hlth Org, African Reg Off, Brazzaville, Rep Congo. [Perry, Robert Tyrrell] World Hlth Org, Geneva, Switzerland. RP Scobie, HM (reprint author), Ctr Dis Control & Prevent, Global Immunizat Div, Atlanta, GA USA. FU World Health Organization [001] NR 41 TC 2 Z9 2 U1 1 U2 1 PU AFRICAN FIELD EPIDEMIOLOGY NETWORK-AFENET PI KAMPALA PA PO BOX 12874, KAMPALA, 00000, UGANDA SN 1937-8688 J9 PAN AFR MED J JI Pan Afr. Med. J. PD MAY 15 PY 2015 VL 21 AR 30 DI 10.11604/pamj.2015.21.30.6335 PG 14 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA DM9WD UT WOS:000376715500001 PM 26401224 ER PT J AU Cook, MB Rosenberg, PS McCarty, FA Wu, MX King, J Eheman, C Anderson, WF AF Cook, Michael B. Rosenberg, Philip S. McCarty, Frances A. Wu, Manxia King, Jessica Eheman, Christie Anderson, William F. TI Racial Disparities in Prostate Cancer Incidence Rates by Census Division in the United States, 1999-2008 SO PROSTATE LA English DT Article DE prostate cancer; incidence rate; census division; regional variation; epidemiology; SEER program ID OVERLAPPING REGIONS; NATIONAL PROGRAM; COMPARING TRENDS; SEER PROGRAM; WHITE MEN; BLACK-MEN; AGE; EPIDEMIOLOGY; SURVEILLANCE; COMPLETENESS AB BACKGROUNDBlack men have a higher incidence of prostate cancer than white men in the U.S., but little is known whether incidence or racial differences vary geographically. Understanding these differences may assist future studies on causes of prostate cancer. To address such, we leverage the unique resource of the National Program of Cancer Registries (NPCR) combined with Surveillance, Epidemiology and End Results (SEER). METHODSProstate cancer counts and population denominators by race (black, white), age, calendar year, and U.S. census division, for the period 1999-2008, were extracted from NPCR and SEER. We calculated age-standardized incidence rates (ASR) and estimated annual percent changes (EAPC) by race and census division. We assessed black-to-white incidence rate ratios (BWIRR) by census division and by calendar period. RESULTSThis analysis included 1,713,471 prostate cancer cases and 1,217 million person-years. Black ASRs ranged from 176 per 100,000 person-years in Mountain division to 259 in Middle Atlantic. BWIRRs ranged from 1.20 in Western divisions to 1.72 in Southeastern divisions. EAPCs indicated that prostate cancer incidence is not decreasing in East South Central, unlike all other divisions. White EAPCs displayed similar variations by census division, resulting in modest temporal changes in BWIRRs. CONCLUSIONSWithin the U.S., there exists significant geographic variability in prostate cancer incidence rates. Although there are large geographic differences in BWIRRs, temporal trends are fairly stable. This may indicate that primary factors affecting prostate cancer incidence rates vary geographically but affect both black and white men to a similar degree. Prostate 75: 758-763, 2015. Published 2015. This article is a U.S. Government work and is in the public domain in the USA. C1 [Cook, Michael B.; Rosenberg, Philip S.; Anderson, William F.] NCI, Div Canc Epidemiol & Genet, NIH, DHHS, Bethesda, MD 20892 USA. [McCarty, Frances A.] Ctr Dis Control & Prevent, Res Data Ctr, Natl Ctr Hlth Stat, Hyattsville, MD USA. [Wu, Manxia; King, Jessica; Eheman, Christie] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Div Canc Prevent & Control, Atlanta, GA USA. RP Cook, MB (reprint author), NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Genet, NIH,DHHS, 9609 Med Ctr Dr,Rm 7-E106,MSC 9774, Bethesda, MD 20892 USA. EM michael.cook@nih.gov RI Cook, Michael/A-5641-2009 OI Cook, Michael/0000-0002-0533-7302 FU Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services FX Grant sponsor: The Intramural Research Program of the Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services. NR 18 TC 6 Z9 6 U1 0 U2 1 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0270-4137 EI 1097-0045 J9 PROSTATE JI Prostate PD MAY 15 PY 2015 VL 75 IS 7 BP 758 EP 763 DI 10.1002/pros.22958 PG 6 WC Endocrinology & Metabolism; Urology & Nephrology SC Endocrinology & Metabolism; Urology & Nephrology GA CF7DL UT WOS:000352716300008 PM 25619191 ER PT J AU Sutcliffe, J Colborn, KL AF Sutcliffe, James Colborn, Kathryn L. TI Video studies of passage by Anopheles gambiae mosquitoes through holes in a simulated bed net: effects of hole size, hole orientation and net environment SO MALARIA JOURNAL LA English DT Article DE Anopheles; Mosquito behaviour; Host-seeking; Hole passage; Bed nets; ITN; LLIN ID LASTING INSECTICIDAL NETS; MALARIA VECTORS; HOUSEHOLD USE; TREATED NETS; RESPONSES; TANZANIA; HUMIDITY; BEHAVIOR; CURTAINS; BEDNETS AB Background: Holes in netting provide potential routes for mosquitoes to enter ITNs. Despite this, there is little information on how mosquitoes respond to holes in bed nets and how their responses are affected by hole size, shape and orientation or by ambient conditions around the net. Methods: Female Anopheles gambiae (G3) were recorded in a simulated bed net consisting of two sizes of untreated netting- covered behavioural arenas placed above and beside (to simulate the bed net roof and sides respectively) the experimenter who was a source of host cues from 'inside' the net. A round hole of 9 mm or 13 mm diameter was cut into the centre of the netting of each arena. Videos of unfed female mosquitoes in arenas were analysed for time spent flying, walking and standing still and for exit through the hole. The effects of the experimenter on temperature and relative humidity around the simulated net were also measured. Results: Mosquitoes were significantly more active in overhead arenas than in arenas to the side. Hole passage was significantly more likely in smaller arenas than larger ones and for larger holes than smaller ones. In arenas to the side, hole passage rate through small holes was about 50 % less likely than what could be explained by area alone. Passage rate through holes in overhead arenas was consistent with hole area. Temperature in arenas did not strongly reflect the experimenter's presence in the simulated net. Relative humidity and absolute humidity in overhead arenas, but not in arenas to the side, were immediately affected by experimenter presence. Conclusions: Higher levels of activity in overhead arenas than in arenas to the side were likely due to the rising heat and humidity plume from the experimenter. Lower than expected passage rates through smaller vertically oriented holes may have been be due to an edge effect that does not apply to horizontally oriented holes. Results suggest that current methods of assessing the importance of physical damage to ITNs may not accurately reflect mosquito entry risk in all cases. C1 [Sutcliffe, James] Trent Univ, Dept Biol, Peterborough, ON K9J 7B2, Canada. [Sutcliffe, James] US Ctr Dis Control & Prevent, Entomol Branch, Atlanta, GA 30341 USA. [Colborn, Kathryn L.] Univ Calif Berkeley, Grad Grp Biostat, Berkeley, CA 94720 USA. RP Sutcliffe, J (reprint author), Trent Univ, Dept Biol, Peterborough, ON K9J 7B2, Canada. EM jsutcliffe@trentu.ca FU CDC Entomology Branch FX The authors gratefully acknowledge the CDC Entomology Branch for financial and facilities support for this research and the staff of the Malaria and Entomology Branches of the CDC for mosquitoes used in experiments. The quality of this paper was aided by discussions with Ellen Dotson, Tony Fiore, John Gimnig, Seth Irish, Gabriel Ponce de Leon, Steve Smith and Bob Wirtz of the CDC and Brian Byrd of the Environmental and Health Sciences Program at Western Carolina University. NR 25 TC 3 Z9 3 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAY 13 PY 2015 VL 14 AR 199 DI 10.1186/s12936-015-0713-4 PG 13 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CK1MS UT WOS:000355972000001 PM 25962596 ER PT J AU Gutman, J Mwandama, D Wiegand, RE Abdallah, J Iriemenam, NC Shi, YP Mathanga, DP Skarbinski, J AF Gutman, Julie Mwandama, Dyson Wiegand, Ryan E. Abdallah, Joseph Iriemenam, Nnaemeka C. Shi, Ya Ping Mathanga, Don P. Skarbinski, Jacek TI In vivo efficacy of sulphadoxine-pyrimethamine for the treatment of asymptomatic parasitaemia in pregnant women in Machinga District, Malawi SO MALARIA JOURNAL LA English DT Article DE Malaria; Pregnancy; Intermittent-preventive treatment; Sulphadoxine-pyrimethamine; in vivo; Malawi ID INTERMITTENT PREVENTIVE TREATMENT; PLASMODIUM-FALCIPARUM MALARIA; MOLECULAR MARKERS; DRUG-RESISTANCE; BIRTH OUTCOMES; INFECTION; QUEERPAM; THERAPY; WEIGHT; ZAMBIA AB Background: The effectiveness of sulphadoxine-pyrimethamine (SP) intermittent preventive treatment of malaria in pregnancy (IPTp) might be compromised by high prevalence of resistance-associated Plasmodium falciparum dihydrofolate reductase (dhfr) and dihydropteroate synthase (dhps) mutations. As a proxy for IPTp-SP effectiveness, the in vivo efficacy of SP to clear parasitaemia and prevent reinfection in asymptomatic parasitaemic pregnant women in an area with high SP resistance prevalence was assessed. Methods: Pregnant women 16-26 weeks' gestation with asymptomatic parasitaemia presenting for antenatal care were given IPTp-SP and followed for 42 days. The primary outcome was polymerase chain reaction (PCR) uncorrected 42-day survival rate; the per cent of patients without recrudescence or reinfection by day 42. PCR was used to distinguish recrudescence from reinfection. DNA was sequenced to detect resistance-associated dhfr and dhps mutations. Results: Of 245 pregnant women included in the intention-to-treat analysis, 93.9% cleared their parasitaemia by day 7. The day 42 PCR-uncorrected survival rate was 58.1% (95% confidence interval (CI) 51.5-65.7) and day 42 PCR-corrected survival was 68.7% (CI 61.4-76.0). Recrudescence was more common among primi- than among multigravid women; recrudescence rate 33.3% (CI 25.1-42.4%) versus 21.4% (CI 15.0-29.0%) (log rank test p-value 0.006). The quintuple mutant was present in nearly all samples (95%), while 2% were sextuple mutants with an additional mutation at dhps A581G. Conclusions: SP efficacy for acute malaria treatment has been compromised by resistance, but SP retains partial activity among pregnant women with asymptomatic parasitaemia, and thus might be useful for IPTp. Nonetheless, research on non-SP IPTp regimens should continue. C1 [Gutman, Julie; Wiegand, Ryan E.; Iriemenam, Nnaemeka C.; Shi, Ya Ping; Skarbinski, Jacek] Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, Atlanta, GA 30333 USA. [Mwandama, Dyson; Mathanga, Don P.] Univ Malawi, Coll Med, Malaria Alert Ctr, Blantyre, Malawi. [Abdallah, Joseph] Emory Univ, Rwanda Zambia HIV Res Grp, Atlanta, GA 30322 USA. [Mathanga, Don P.] Coll Med, Dept Community Hlth, Lilongwe, Malawi. RP Gutman, J (reprint author), Ctr Dis Control & Prevent, Malaria Branch, Div Parasit Dis & Malaria, 4770 Buford Highway,Mail Stop F-12, Atlanta, GA 30333 USA. EM jgutman@cdc.gov FU US President's Malaria Initiative, US Agency for International Development [5 U01 CI000189] FX The authors wish to thank Georgina Makuta, Orpha Malunga, Lameck Chimkango and all the staff at the ANC clinic of Machinga District Hospital, as well as the community members who participated in or otherwise contributed to these studies. This work was supported by the US President's Malaria Initiative, US Agency for International Development, under the terms of an Interagency Agreement with the Centers for Disease Control and Prevention (CDC) and through a Cooperative Agreement (Number 5 U01 CI000189) between the CDC and the Malaria Alert Centre, College of Medicine. The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all of the data in the study and had final responsibility for the decision to submit for publication. NR 34 TC 2 Z9 2 U1 0 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1475-2875 J9 MALARIA J JI Malar. J. PD MAY 13 PY 2015 VL 14 AR 197 DI 10.1186/s12936-015-0710-7 PG 9 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CI6DE UT WOS:000354848100001 PM 25962439 ER PT J AU Gustin, KM Belser, JA Veguilla, V Zeng, H Katz, JM Tumpey, TM Maines, TR AF Gustin, Kortney M. Belser, Jessica A. Veguilla, Vic Zeng, Hui Katz, Jacqueline M. Tumpey, Terrence M. Maines, Taronna R. TI Environmental Conditions Affect Exhalation of H3N2 Seasonal and Variant Influenza Viruses and Respiratory Droplet Transmission in Ferrets SO PLOS ONE LA English DT Article ID UNITED-STATES; H5N1 VIRUSES; PATHOGENESIS; INFECTION; HUMIDITY; AEROSOLS; HUMANS; TEMPERATURE; VIRULENCE; IMPACT AB The seasonality of influenza virus infections in temperate climates and the role of environmental conditions like temperature and humidity in the transmission of influenza virus through the air are not well understood. Using ferrets housed at four different environmental conditions, we evaluated the respiratory droplet transmission of two influenza viruses (a seasonal H3N2 virus and an H3N2 variant virus, the etiologic virus of a swine to human summertime infection) and concurrently characterized the aerosol shedding profiles of infected animals. Comparisons were made among the different temperature and humidity conditions and between the two viruses to determine if the H3N2 variant virus exhibited enhanced capabilities that may have contributed to the infections occurring in the summer. We report here that although increased levels of H3N2 variant virus were found in ferret nasal wash and exhaled aerosol samples compared to the seasonal H3N2 virus, enhanced respiratory droplet transmission was not observed under any of the environmental settings. However, overall environmental conditions were shown to modulate the frequency of influenza virus transmission through the air. Transmission occurred most frequently at 23 degrees C/30% RH, while the levels of infectious virus in aerosols exhaled by infected ferrets agree with these results. Improving our understanding of how environmental conditions affect influenza virus infectivity and transmission may reveal ways to better protect the public against influenza virus infections. C1 [Gustin, Kortney M.; Belser, Jessica A.; Veguilla, Vic; Zeng, Hui; Katz, Jacqueline M.; Tumpey, Terrence M.; Maines, Taronna R.] Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. RP Maines, TR (reprint author), Natl Ctr Immunizat & Resp Dis, Ctr Dis Control & Prevent, Influenza Div, Atlanta, GA 30329 USA. EM tmaines@cdc.gov NR 41 TC 3 Z9 3 U1 1 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 13 PY 2015 VL 10 IS 5 AR UNSP e0125874 DI 10.1371/journal.pone.0125874 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI1ZP UT WOS:000354544200088 PM 25969995 ER PT J AU Singh, N Mishra, AK Chand, SK Bharti, PK Singh, MP Nanda, N Singh, OP Sodagiri, K Udhyakumar, V AF Singh, Neeru Mishra, Ashok K. Chand, Sunil K. Bharti, Praveen K. Singh, Mrigendra P. Nanda, Nutan Singh, Om P. Sodagiri, Kranti Udhyakumar, Venkatachalam TI Relative Abundance and Plasmodium Infection Rates of Malaria Vectors in and around Jabalpur, a Malaria Endemic Region in Madhya Pradesh State, Central India SO PLOS ONE LA English DT Article ID ANOPHELES-CULICIFACIES COMPLEX; RIBOSOMAL DNA; MEMBERS; IDENTIFICATION; TRANSMISSION; FLUVIATILIS; DYNAMICS; DIFFERENTIATION; SPOROZOITES; CULICIDAE AB Background This study was undertaken in two Primary Health Centers (PHCs) of malaria endemic district Jabalpur in Madhya Pradesh (Central India). Methods In this study we had investigated the relative frequencies of the different anopheline species collected within the study areas by using indoor resting catches, CDC light trap and human landing methods. Sibling species of malaria vectors were identified by cytogenetic and molecular techniques. The role of each vector and its sibling species in the transmission of the different Plasmodium species was ascertained by using sporozoite ELISA. Results A total of 52,857 specimens comprising of 17 anopheline species were collected by three different methods (39,964 by indoor resting collections, 1059 by human landing and 11,834 by CDC light trap). Anopheles culicifacies was most predominant species in all collections (55, 71 and 32% in indoor resting, human landing and light trap collections respectively) followed by An. subpictus and An. annularis. All five sibling species of An. culicifacies viz. species A, B, C, D and E were found while only species T and S of An. fluviatilis were collected. The overall sporozoite rate in An. culicifacies and An. fluviatilis were 0.42% (0.25% for P. falciparum and 0.17% for P. vivax) and 0.90% (0.45% for P. falciparum and 0.45% for P. vivax) respectively. An. culicifacies and An. fluviatilis were found harbouring both P. vivax variants VK-210 and VK-247, and P. falciparum. An. culicifacies sibling species C and D were incriminated as vectors during most part of the year while sibling species T of An. fluviatilis was identified as potential vector in monsoon and post monsoon season. Conclusions An. culicifacies species C (59%) was the most abundant species followed by An. culicifacies D (24%), B (8.7%), E (6.7%) and A (1.5%). Among An. fluviatilis sibling species, species T was common (99%) and only few specimens of S were found. Our study provides crucial information on the prevalence of An. culicifacies and An. fluviatilis sibling species and their potential in malaria transmission which will assist in developing strategic control measures against these vectors. C1 [Singh, Neeru; Bharti, Praveen K.; Sodagiri, Kranti] Reg Med Res Ctr Tribals, Natl Inst Res Tribal Hlth, Jabalpur, Madhya Pradesh, India. [Mishra, Ashok K.; Chand, Sunil K.; Singh, Mrigendra P.] ICMR, Natl Inst Malaria Res, Field Stn, Jabalpur, Madhya Pradesh, India. [Nanda, Nutan; Singh, Om P.] Natl Inst Malaria Res, New Delhi, India. [Udhyakumar, Venkatachalam] CDC, Genet & Immunol Lab, Malaria Branch, DPD,NCZVED,CCID, Atlanta, GA USA. RP Singh, N (reprint author), Reg Med Res Ctr Tribals, Natl Inst Res Tribal Hlth, Nagpur Rd, Jabalpur, Madhya Pradesh, India. EM neeru.singh@gmail.com RI Singh, Om/B-7958-2011 OI Singh, Om/0000-0001-5135-6654 FU Indian Council of Medical Research, New Delhi, India (ICMR Task Force Grant) FX The study was funded by Indian Council of Medical Research, New Delhi, India (ICMR Task Force Grant). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 2 Z9 2 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 13 PY 2015 VL 10 IS 5 AR e0126932 DI 10.1371/journal.pone.0126932 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI1ZP UT WOS:000354544200140 PM 25970291 ER PT J AU Worwa, G Wheeler, SS Brault, AC Reisen, WK AF Worwa, Gabriella Wheeler, Sarah S. Brault, Aaron C. Reisen, William K. TI Comparing Competitive Fitness of West Nile Virus Strains in Avian and Mosquito Hosts SO PLOS ONE LA English DT Article ID EXPERIMENTAL-INFECTION; DIPTERA-CULICIDAE; VECTOR COMPETENCE; CULEX-TARSALIS; AMERICAN CROWS; UNITED-STATES; NEW-YORK; IN-VIVO; CALIFORNIA; TRANSMISSION AB Enzootic transmission of West Nile virus (WNV; Flaviviridae, Flavivirus) involves various species of birds and ornithophilic mosquitoes. Single nucleotide substitutions in the WNV genome may impact viral fitness necessary for WNV adaptation and evolution as previously shown for the WN02 genotype. In an effort to study phenotypic change, we developed an in vivo fitness competition model in two biologically relevant hosts for WNV. The House Finch (HOFI; Haemorhous mexicanus) and Culex tarsalis mosquitoes represent moderately susceptible hosts for WNV, are highly abundant in Western North America and frequently are infected with WNV in nature. Herein, we inoculated HOFIs and Culex tarsalis competitively (dually) and singly with infectious-clone derived viruses of the founding California isolate COAV997-2003 (COAV997-IC), the founding North American isolate NY99 (NY99-IC), and a 2004 field isolate from California (CA-04), and compared the replicative capacities (fitness) of these viruses to a genetically marked virus of COAV997 (COAV997-5nt) by measuring RNA copy numbers. COAV997 and COAV997-5nt exhibited neutral fitness in HOFIs and Culex tarsalis, and the temperature-sensitive phenotype of COAV997 did not affect replication in HOFIs as none of the infected birds became febrile. The NY99 and CA-04 isolates demonstrated elevated fitness in HOFIs compared to COAV997-5nt, whereas all viruses replicated to similar titers and RNA copies in Culex tarsalis, and the only fitness differences were related to infection rates. Our data demonstrated that competitive replication allows for the sensitive comparison of fitness differences among two genetically closely related viruses using relevant hosts of WNV while eliminating host-to-host differences. In conclusion, our approach may be helpful in understanding the extent of phenotypic change in fitness associated with genetic changes in WNV. C1 [Worwa, Gabriella; Wheeler, Sarah S.; Reisen, William K.] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Ctr Vectorborne Dis, Davis, CA 95616 USA. [Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. RP Reisen, WK (reprint author), Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Ctr Vectorborne Dis, Davis, CA 95616 USA. EM wkreisen@ucdavis.edu FU Swiss National Science Foundation [PBBEP3_128345]; Swiss Foundation for Grants in Biology and Medicine [PASMP3_137034]; US National Institutes of Health Allergy and Infectious Diseases [RO1-AI55607] FX G. Worwa was supported by the Swiss National Science Foundation through grant PBBEP3_128345 and the Swiss Foundation for Grants in Biology and Medicine through grant PASMP3_137034. Funding for these studies also was provided, in part, by US National Institutes of Health Allergy and Infectious Diseases Grant RO1-AI55607. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 1 Z9 1 U1 3 U2 18 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 12 PY 2015 VL 10 IS 5 AR e0125668 DI 10.1371/journal.pone.0125668 PG 23 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI1ZI UT WOS:000354543500024 PM 25965850 ER PT J AU Duncan, C Gill, VA Worman, K Burek-Huntington, K Pabilonia, KL Johnson, S Fitzpatrick, KA Weller, C Kersh, GJ AF Duncan, Colleen Gill, Verena A. Worman, Kristin Burek-Huntington, Kathy Pabilonia, Kristy L. Johnson, Sam Fitzpatrick, Kelly A. Weller, Christina Kersh, Gilbert J. TI Coxiella burnetii exposure in northern sea otters Enhydra lutris kenyoni SO DISEASES OF AQUATIC ORGANISMS LA English DT Article DE Northern sea otters; Enhydra lutris kenyoni; Coxiella burnetii ID LONG-TERM PERSISTENCE; PRIMARY Q-FEVER; ST-PAUL ISLAND; ENDOCARDITIS; INFECTION; ALASKA; POPULATION; NEREIS AB Valvular endocarditis has been well described in northern sea otters Enhydra lutris kenyoni of Alaska and in many cases no cause has been identified. It is also one of the most common conditions observed in people with chronic Coxiella burnetii infection. Given the high levels of C. burnetii exposure in marine mammals distributed throughout the same geographic range as the northern sea otter, and the presence of valvular lesions seen in otters, the objective of this study was to determine the level of C. burnetii exposure in otters and investigate any association between exposure, infection and valvular disease in this species. Archived serum from 75 live captured, apparently healthy otters (25 from each of 3 stocks) and 30 dead otters were tested for C. burnetii antibodies by indirect florescent antibody assay (IFA). Archived bone marrow and heart valves were tested for C. burnetii DNA by real-time PCR (qPCR). Overall, the seroprevalence in live otters was 17%, with significantly more exposed animals in the south central (40%) stock relative to the southwest (8%) and southeast (4%). The seroprevalence of animals sampled post mortem was 27%, although none of the bone marrow or heart valve samples were positive by qPCR. Results of this study failed to demonstrate a significant association between C. burnetii infection and valvular endocarditis in sea otters; however, the differing seroprevalence suggests that exposure opportunities vary geographically. C1 [Duncan, Colleen; Pabilonia, Kristy L.; Johnson, Sam; Weller, Christina] Colorado State Univ, Diagnost Med Ctr, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Gill, Verena A.] Bur Ocean Energy Management, Anchorage, AK 99503 USA. [Gill, Verena A.; Worman, Kristin] US Fish & Wildlife Serv, Marine Mammals Management, Anchorage, AK 99503 USA. [Burek-Huntington, Kathy] Alaska Vet Pathol Serv, Eagle River, AK 99577 USA. [Fitzpatrick, Kelly A.; Kersh, Gilbert J.] Ctr Dis Control & Prevent, Rickettsial Zoonoses Branch, Atlanta, GA 30333 USA. RP Duncan, C (reprint author), Colorado State Univ, Diagnost Med Ctr, Dept Microbiol Immunol & Pathol, 300 West Drake Ave, Ft Collins, CO 80523 USA. EM colleen.duncan@colostate.edu FU North Pacific Research Board [525] FX This project was supported by funding from the North Pacific Research Board (publication no. 525). The findings and conclusions in this article are those of the authors(s) and do not necessarily represent the views of the US Fish & Wildlife Service. NR 26 TC 1 Z9 1 U1 0 U2 5 PU INTER-RESEARCH PI OLDENDORF LUHE PA NORDBUNTE 23, D-21385 OLDENDORF LUHE, GERMANY SN 0177-5103 EI 1616-1580 J9 DIS AQUAT ORGAN JI Dis. Aquat. Org. PD MAY 11 PY 2015 VL 114 IS 1 BP 83 EP 87 DI 10.3354/dao02857 PG 5 WC Fisheries; Veterinary Sciences SC Fisheries; Veterinary Sciences GA CJ0FB UT WOS:000355149700008 PM 25958809 ER PT J AU Bennett, SD Otieno, R Ayers, TL Odhiambo, A Faith, SH Quick, R AF Bennett, Sarah D. Otieno, Ronald Ayers, Tracy L. Odhiambo, Aloyce Faith, Sitnah H. Quick, Robert TI Acceptability and Use of Portable Drinking Water and Hand Washing Stations in Health Care Facilities and Their Impact on Patient Hygiene Practices, Western Kenya SO PLOS ONE LA English DT Article ID ANTENATAL SERVICES; MALAWI; INTEGRATION; PROMOTION; SCALE AB Many health care facilities (HCF) in developing countries lack access to reliable hand washing stations and safe drinking water. To address this problem, we installed portable, low-cost hand washing stations (HWS) and drinking water stations (DWS), and trained healthcare workers (HCW) on hand hygiene, safe drinking water, and patient education techniques at 200 rural HCFs lacking a reliable water supply in western Kenya. We performed a survey at baseline and a follow-up evaluation at 15 months to assess the impact of the intervention at a random sample of 40 HCFs and 391 households nearest to these HCFs. From baseline to follow-up, there was a statistically significant increase in the percentage of dispensaries with access to HWSs with soap (42% vs. 77%, p<0.01) and access to safe drinking water (6% vs. 55%, p<0.01). Female heads of household in the HCF catchment area exhibited statistically significant increases from baseline to follow-up in the ability to state target times for hand washing (10% vs. 35%, p<0.01), perform all four hand washing steps correctly (32% vs. 43%, p = 0.01), and report treatment of stored drinking water using any method (73% vs. 92%, p<0.01); the percentage of households with detectable free residual chlorine in stored drinking water did not change (6%, vs. 8%, p = 0.14). The installation of low-cost, low-maintenance, locally-available, portable hand washing and drinking water stations in rural HCFs without access to 24-hour piped water helped assure that health workers had a place to wash their hands and provide safe drinking water. This HCF intervention may have also contributed to the improvement of hand hygiene and reported safe drinking water behaviors among households nearest to HCFs. C1 [Bennett, Sarah D.; Ayers, Tracy L.; Quick, Robert] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. [Bennett, Sarah D.] Ctr Dis Control & Prevent, Epidem Intelligence Serv, Atlanta, GA USA. [Otieno, Ronald; Odhiambo, Aloyce; Faith, Sitnah H.] Safe Water & AIDS Project, Kisumu, Nyanza Province, Kenya. RP Quick, R (reprint author), Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30329 USA. EM rxq1@cdc.gov OI Ayers, Tracy/0000-0003-4140-3263 FU UNICEF Kenya FX Funding was provided by UNICEF Kenya. Recipients were Christian Health Association of Kenya and Safe Water and AIDS Project. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 19 TC 0 Z9 0 U1 3 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 11 PY 2015 VL 10 IS 5 AR e0126916 DI 10.1371/journal.pone.0126916 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CI1YY UT WOS:000354542500157 PM 25961293 ER PT J AU Smith, M Peacock, G Uyeki, TM Moore, C AF Smith, Michael Peacock, Georgina Uyeki, Timothy M. Moore, Cynthia TI Influenza vaccination in children with neurologic or neurodevelopmental disorders SO VACCINE LA English DT Article DE Influenza; Immunization; Neurologic; High-risk; Disability ID CHRONIC MEDICAL CONDITIONS; 2009 PANDEMIC INFLUENZA; UNITED-STATES; SEASONAL INFLUENZA; PEDIATRIC DEATHS; IMMUNIZATION; PARENTS; ASTHMA; ATTITUDES; COVERAGE AB Background: Children with neurologic or neurodevelopmental disorders (NNDDs) are at increased risk of complications from influenza. Although the Advisory Committee on Immunization Practices (ACIP) has recognized NNDDs as high-risk conditions for influenza complications since 2005, little is known about influenza vaccination practices in this population. Methods: CDC collaborated with Family Voices, a national advocacy group for children with special health-care needs, to recruit parents of children with chronic medical conditions. Parents were surveyed about their knowledge, attitudes, and practices surrounding influenza vaccination. The primary outcome of interest was parental report of vaccination, or intent to vaccinate, at. the time of survey participation. CDC also collaborated with the American Academy of Pediatrics to recruit primary care and specialty physicians who provide care for high-risk children, specifically those with neurologic conditions. The primary outcome was physician recognition of ACIP high-risk influenza conditions. Results: 2138 surveys were completed by parents of children with high-risk conditions, including 1143 with at least one NNDD. Overall, 50% of children with an NNDD were vaccinated, or their parents planned to have them vaccinated against influenza. Among all 2138 children, in multivariable analysis, the presence of a respiratory condition and prior seasonal influenza vaccination was significantly associated with receipt or planned current season influenza vaccination, but the presence of an NNDD was not. 412 pediatricians completed the provider survey. Cerebral palsy was recognized as a high-risk influenza condition by 74% of physician respondents, but epilepsy (51%) and intellectual disability (46%) were less commonly identified. Conclusions: Our estimates of influenza vaccination in children with NNDDs are comparable to published reports of vaccination in healthy children, which continue to be suboptimal. Education of parents of children with NNDDs and healthcare providers about influenza and the benefit of annual influenza vaccination is needed. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Smith, Michael] Univ Louisville, Sch Med, Dept Pediat, Louisville, KY 40202 USA. [Peacock, Georgina; Moore, Cynthia] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Hyattsville, MD USA. [Uyeki, Timothy M.] Ctr Dis Control & Prevent, Influenza Div, Natl Ctr Immunizat & Resp Dis, Hyattsville, MD USA. RP Smith, M (reprint author), Univ Louisville, Sch Med, Div Pediat Infect Dis, 571 S Floyd St,Suite 321, Louisville, KY 40202 USA. EM mjsmit22@louisville.edu FU Sanofi; Novartis FX M.J.S. has received research support for vaccine clinical trials from Sanofi and Novartis. All authors have no conflict of interest. NR 15 TC 1 Z9 1 U1 1 U2 8 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 11 PY 2015 VL 33 IS 20 BP 2322 EP 2327 DI 10.1016/j.vaccine.2015.03.050 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CI8LO UT WOS:000355024000005 PM 25835574 ER PT J AU Oscherwitz, J Quinn, CP Cease, KB AF Oscherwitz, Jon Quinn, Conrad P. Cease, Kemp B. TI Anthrax vaccine recipients lack antibody against the loop neutralizing determinant: A protective neutralizing epitope from Bacillus anthracis protective antigen SO VACCINE LA English DT Article DE AVA; Epitope; Vaccine; Protective antigen; Antibody ID EXPERIMENTAL INHALATION ANTHRAX; DOMAIN 2; TOXIN; RABBITS; IMMUNITY AB Background: Epitope-focused immunogens can elicit antibody against the loop neutralizing determinant (LND), a neutralizing epitope found within the 2 beta 2-2 beta 3 loop of protective antigen (PA), which can protect rabbits from high-dose inhalation challenge with Bacillus anthracis Ames strain. Interestingly, data suggests that this epitope is relatively immunosilent in rabbits and non-human primates immunized with full length PA. Methods: To determine whether the LND is immunosilent among humans vaccinated with PA, we screened antisera from AVA- or placebo-vaccinees from a clinical trial for antibody reactive with the LND. Results: AVA-vaccinee sera had significant PA-specific antibody compared to placebo-vaccinee sera; however, sera from the two cohorts were indistinguishable with regard to the frequency of individuals with antibody specific for the LND. Conclusions: AVA-vaccinees have a low frequency of antibody reactive with the LND. As with rabbits and non-human primates, the elicitation of LND-specific antibody in humans appears to require immunization with an epitope-focused vaccine. (C) 2015 Elsevier Ltd. All rights reserved. C1 [Oscherwitz, Jon; Cease, Kemp B.] Univ Michigan, Sch Med, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48105 USA. [Oscherwitz, Jon; Cease, Kemp B.] Vet Adm Ann Arbor Healthcare Syst, Ann Arbor, MI 48105 USA. [Quinn, Conrad P.] Ctr Dis Control & Prevent, Div Bacterial Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Oscherwitz, J (reprint author), Vet Adm Ann Arbor Healthcare Syst, Res Serv 151, 2215 Fuller Rd, Ann Arbor, MI 48105 USA. EM joscher@umich.edu FU National Institutes of Allergy and Infectious Diseases [UO1-AI56580] FX This work was supported by Award UO1-AI56580 to K.B.C from the National Institutes of Allergy and Infectious Diseases. NR 19 TC 2 Z9 2 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 11 PY 2015 VL 33 IS 20 BP 2342 EP 2346 DI 10.1016/j.vaccine.2015.03.037 PG 5 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CI8LO UT WOS:000355024000008 PM 25820066 ER PT J AU Gapstur, SM Patel, AV Banks, E Dal Maso, L Talamini, R Chetrit, A Hirsh-Yechezkel, G Lubin, F Sadetzki, S Beral, V Bull, D Cairns, B Crossley, B Gaitskell, K Goodill, A Green, J Hermon, C Key, T Moser, K Reeves, G Sitas, F Collins, R Peto, R Gonzalez, CA Lee, N Marchbanks, P Ory, HW Peterson, HB Wingo, PA Martin, N Silpisornkosol, S Theetranont, C Boosiri, B Chutivongse, S Jimakorn, P Virutamasen, P Wongsrichanalai, C Goodman, MT Lidegaard, O Kjaer, SK Morch, LS Kjaer, SK Tjonneland, A Byers, T Rohan, T Mosgaard, B Vessey, M Yeates, D Freudenheim, JL Titus, LJ Chang-Claude, J Kaaks, R Anderson, KE Lazovich, D Robien, K Hampton, J Newcomb, PA Rossing, MA Thomas, DB Weiss, NS Lokkegaard, E Riboli, E Clavel-Chapelon, F Cramer, D Hankinson, SE Tamimi, RM Tworoger, SS Franceschi, S La Vecchia, C Negri, E Adami, HO Magnusson, C Riman, T Weiderpass, E Wolk, A Schouten, LJ van den Brandt, PA Chantarakul, N Koetsawang, S Rachawat, D Palli, D Black, A Brinton, LA Freedman, DM Hartge, P Hsing, AW Jnr, JVL Lissowska, J Hoover, RN Schairer, C Babb, C Urban, M Graff-Iversen, S Selmer, R Bain, CJ Green, AC Purdie, DM Siskind, V Webb, PM Moysich, K McCann, SE Hannaford, P Kay, C Binns, CW Lee, AH Zhang, M Ness, RB Nasca, P Coogan, PF Palmer, JR Rosenberg, L Whittemore, A Katsouyanni, K Trichopoulou, A Trichopoulos, D Tzonou, A Dabancens, A Martinez, L Molina, R Salas, O Lurie, G Carney, ME Wilkens, LR Hartman, L Manjer, J Olsson, H Kumle, M Grisso, JA Morgan, M Wheeler, JE Edwards, RP Kelley, JL Modugno, F Onland-Moret, NC Peeters, PHM Casagrande, J Pike, MC Wu, AH Canfell, K Miller, AB Gram, IT Lund, E McGowan, L Shu, XO Zheng, W Farley, TMM Holck, S Meirik, O Risch, HA AF Gapstur, S. M. Patel, A. V. Banks, E. Dal Maso, L. Talamini, R. Chetrit, A. Hirsh-Yechezkel, G. Lubin, F. Sadetzki, S. Beral, V. Bull, D. Cairns, B. Crossley, B. Gaitskell, K. Goodill, A. Green, J. Hermon, C. Key, T. Moser, K. Reeves, G. Sitas, F. Collins, R. Peto, R. Gonzalez, C. A. Lee, N. Marchbanks, P. Ory, H. W. Peterson, H. B. Wingo, P. A. Martin, N. Silpisornkosol, S. Theetranont, C. Boosiri, B. Chutivongse, S. Jimakorn, P. Virutamasen, P. Wongsrichanalai, C. Goodman, M. T. Lidegaard, O. Kjaer, S. K. Morch, L. S. Kjaer, S. K. Tjonneland, A. Byers, T. Rohan, T. Mosgaard, B. Vessey, M. Yeates, D. Freudenheim, J. L. Titus, L. J. Chang-Claude, J. Kaaks, R. Anderson, K. E. Lazovich, D. Robien, K. Hampton, J. Newcomb, P. A. Rossing, M. A. Thomas, D. B. Weiss, N. S. Lokkegaard, E. Riboli, E. Clavel-Chapelon, F. Cramer, D. Hankinson, S. E. Tamimi, R. M. Tworoger, S. S. Franceschi, S. La Vecchia, C. Negri, E. Adami, H. O. Magnusson, C. Riman, T. Weiderpass, E. Wolk, A. Schouten, L. J. van den Brandt, P. A. Chantarakul, N. Koetsawang, S. Rachawat, D. Palli, D. Black, A. Brinton, L. A. Freedman, D. M. Hartge, P. Hsing, A. W. Jnr, J. V. Lacey Lissowska, J. Hoover, R. N. Schairer, C. Babb, C. Urban, M. Graff-Iversen, S. Selmer, R. Bain, C. J. Green, A. C. Purdie, D. M. Siskind, V. Webb, P. M. Moysich, K. McCann, S. E. Hannaford, P. Kay, C. Binns, C. W. Lee, A. H. Zhang, M. Ness, R. B. Nasca, P. Coogan, P. F. Palmer, J. R. Rosenberg, L. Whittemore, A. Katsouyanni, K. Trichopoulou, A. Trichopoulos, D. Tzonou, A. Dabancens, A. Martinez, L. Molina, R. Salas, O. Lurie, G. Carney, M. E. Wilkens, L. R. Hartman, L. Manjer, J. Olsson, H. Kumle, M. Grisso, J. A. Morgan, M. Wheeler, J. E. Edwards, R. P. Kelley, J. L. Modugno, F. Onland-Moret, N. C. Peeters, P. H. M. Casagrande, J. Pike, M. C. Wu, A. H. Canfell, K. Miller, A. B. Gram, I. T. Lund, E. McGowan, L. Shu, X. O. Zheng, W. Farley, T. M. M. Holck, S. Meirik, O. Risch, H. A. CA Collaborative Grp Epidemiological TI Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies SO LANCET LA English DT Article ID WOMEN; THERAPY; HEALTH AB Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with <5 years of use (RR 1.43, 95% CI 1.31-1.56; p<0.0001). Combining current-or-recent use (any duration, but stopped <5 years before diagnosis) resulted in an RR of 1.37 (95% CI 1.29-1.46; p<0.0001); this risk was similar in European and American prospective studies and for oestrogen-only and oestrogen-progestagen preparations, but differed across the four main tumour types (heterogeneity p<0.0001), being definitely increased only for the two most common types, serous (RR 1.53, 95% CI 1.40-1.66; p<0.0001) and endometrioid (1.42, 1.20-1.67; p<0.0001). Risk declined the longer ago use had ceased, although about 10 years after stopping long-duration hormone therapy use there was still an excess of serous or endometrioid tumours (RR 1.25, 95% CI 1.07-1.46, p=0.005). Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users. C1 [Gapstur, S. M.; Patel, A. V.] Amer Canc Soc, Atlanta, GA 30329 USA. [Banks, E.] Australian Natl Univ, Caberra, ACT, Australia. [Dal Maso, L.; Talamini, R.] Aviano Canc Ctr, I-33081 Aviano, Italy. [Chetrit, A.; Hirsh-Yechezkel, G.; Lubin, F.; Sadetzki, S.] Gertner Inst, Tel Hashomer, Israel. [Beral, V.; Bull, D.; Cairns, B.; Crossley, B.; Gaitskell, K.; Goodill, A.; Green, J.; Hermon, C.; Key, T.; Moser, K.; Reeves, G.] Canc Epidemiol Unit, Oxford, England. [Sitas, F.] NSW Canc Council, Woolloomooloo, NSW, Australia. [Collins, R.; Peto, R.] Radcliffe Infirm, Clin Trial Serv Unit, Oxford OX2 6HE, England. [Collins, R.; Peto, R.] Epidemiol Studies Unit CTSU, Oxford, England. [Gonzalez, C. A.] Catalan Inst Oncol, Barcelona, Spain. [Lee, N.; Marchbanks, P.; Ory, H. W.; Peterson, H. B.; Wingo, P. A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Martin, N.; Silpisornkosol, S.; Theetranont, C.] Chiang Mai Univ, Chiang Mai, Thailand. [Boosiri, B.; Chutivongse, S.; Jimakorn, P.; Virutamasen, P.; Wongsrichanalai, C.] Chulalongkorn Univ, Bangkok, Thailand. [Goodman, M. T.] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. [Lidegaard, O.; Kjaer, S. K.; Morch, L. S.] Copenhagen Univ Hosp, Copenhagen, Denmark. [Kjaer, S. K.; Tjonneland, A.] Danish Canc Soc Res Ctr, Copenhagen, Denmark. [Byers, T.] Colorado Sch Publ Hlth, Denver, CO USA. [Rohan, T.] Albert Einstein Coll Med, Bronx, NY 10467 USA. [Mosgaard, B.] Herlev Univ Hosp, Copenhagen, Denmark. [Vessey, M.; Yeates, D.] Dept Publ Hlth, Oxford, England. [Freudenheim, J. L.] SUNY Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA. [Titus, L. J.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Chang-Claude, J.; Kaaks, R.] German Canc Res Ctr, Heidelberg, Germany. [Anderson, K. E.; Lazovich, D.; Robien, K.] Univ Minnesota, Sch Publ Hlth, Minneapolis, MN USA. [Hampton, J.; Newcomb, P. A.; Rossing, M. A.; Thomas, D. B.; Weiss, N. S.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA. [Lokkegaard, E.] Univ Copenhagen, Hillerod Hosp, DK-1168 Copenhagen, Denmark. [Riboli, E.] Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England. [Clavel-Chapelon, F.] INSERM, U1018, Villejuif, France. [Clavel-Chapelon, F.] Paris South Univ, Inst Gustave Roussy, Villejuif, France. [Cramer, D.; Hankinson, S. E.; Tamimi, R. M.; Tworoger, S. S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA. [Franceschi, S.] Int Agcy Res Canc, F-69372 Lyon, France. [La Vecchia, C.; Negri, E.] Univ Milan, Ist Ric Farmacol Mario Negri, I-20122 Milan, Italy. [Adami, H. O.; Magnusson, C.; Riman, T.; Weiderpass, E.; Wolk, A.] Karolinska Inst, Stockholm, Sweden. [Schouten, L. J.; van den Brandt, P. A.] Maastricht Univ, NL-6200 MD Maastricht, Netherlands. [Chantarakul, N.; Koetsawang, S.; Rachawat, D.] Mahidol Univ, Bangkok 10700, Thailand. [Palli, D.] Canc Res & Prevent Inst, Florence, Italy. [Black, A.; Brinton, L. A.; Freedman, D. M.; Hartge, P.; Hsing, A. W.; Jnr, J. V. Lacey; Lissowska, J.; Hoover, R. N.; Schairer, C.] NCI, Bethesda, MD 20892 USA. [Babb, C.; Urban, M.] MRC, Canc Epidemiol Res Grp, Natl Hlth Lab Serv, Johannesburg, South Africa. [Graff-Iversen, S.; Selmer, R.] Norwegian Inst Publ Hlth, Oslo, Norway. [Bain, C. J.; Green, A. C.; Purdie, D. M.; Siskind, V.; Webb, P. M.] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia. [Bain, C. J.; Green, A. C.; Purdie, D. M.; Siskind, V.; Webb, P. M.] Univ Queensland, Brisbane, Qld, Australia. [Moysich, K.; McCann, S. E.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA. [Hannaford, P.; Kay, C.] Royal Coll Gen Practitioners Oral Contracept Stud, London, England. [Binns, C. W.; Lee, A. H.; Zhang, M.] Curtin Univ, Sch Publ Hlth, Perth, WA 6845, Australia. [Ness, R. B.] Univ Texas Houston, Sch Publ Hlth, Houston, TX USA. [Nasca, P.] Univ Massachusetts, Sch Publ Hlth & Hlth Sci, Boston, MA 02125 USA. [Coogan, P. F.; Palmer, J. R.; Rosenberg, L.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA. [Whittemore, A.] Stanford Univ, Stanford, CA 94305 USA. [Katsouyanni, K.; Trichopoulou, A.; Trichopoulos, D.; Tzonou, A.] Univ Athens, Sch Med, GR-11527 Athens, Greece. [Dabancens, A.; Martinez, L.; Molina, R.; Salas, O.] Univ Chile, Santiago, Chile. [Lurie, G.; Carney, M. E.; Wilkens, L. R.] Univ Hawaii, Honolulu, HI 96822 USA. [Hartman, L.; Manjer, J.; Olsson, H.] Univ Lund Hosp, S-22185 Lund, Sweden. [Kumle, M.] Univ Hosp North Norway, Tromso, Norway. [Grisso, J. A.; Morgan, M.; Wheeler, J. E.] Univ Penn, Philadelphia, PA 19104 USA. [Edwards, R. P.; Kelley, J. L.; Modugno, F.] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Onland-Moret, N. C.; Peeters, P. H. M.] Univ Med Ctr, Utrecht, Netherlands. [Casagrande, J.; Pike, M. C.; Wu, A. H.] Univ So Calif, Los Angeles, CA USA. [Canfell, K.] Univ New S Wales, Sydney, NSW 2052, Australia. [Miller, A. B.] Univ Toronto, Toronto, ON M5S 1A1, Canada. [Gram, I. T.; Lund, E.] Arctic Univ Tromso, Tromso, Norway. [McGowan, L.] George Washington Univ, Washington, DC USA. [Shu, X. O.; Zheng, W.] Vanderbilt Univ, Nashville, TN 37235 USA. [Farley, T. M. M.; Holck, S.; Meirik, O.] WHO, CH-1211 Geneva, Switzerland. [Risch, H. A.] Yale Univ, Sch Publ Hlth, New Haven, CT 06520 USA. RP Gapstur, SM (reprint author), NDPH, Canc Epidemiol Unit, Richard Doll Bldg, Oxford OX3 7LF, England. EM collaborations@ceu.ox.ac.uk RI Brinton, Louise/G-7486-2015; Onland-Moret, N. Charlotte/G-9185-2011; Weiderpass, Elisabete/M-4029-2016; OI Brinton, Louise/0000-0003-3853-8562; Weiderpass, Elisabete/0000-0003-2237-0128; Lokkegaard, Ellen/0000-0003-4149-5663; Babb, Chantal/0000-0003-1334-1819; Kjaer, Susanne/0000-0002-8347-1398; dal maso, luigino/0000-0001-6163-200X; La Vecchia, Carlo/0000-0003-1441-897X FU Medical Research Council, Cancer Research UK; Cancer Research UK; UK Medical Research Council FX Medical Research Council, Cancer Research UK.; The chief acknowledgment is to the participants and to the investigators in these studies. Data checking and analysis in the Oxford Cancer Epidemiology Unit was supported by Cancer Research UK and the UK Medical Research Council. Adrian Goodill drew the graphs. NR 16 TC 49 Z9 51 U1 3 U2 21 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD MAY 9 PY 2015 VL 385 IS 9980 BP 1835 EP 1842 DI 10.1016/S0140-6736(14)61687-1 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA CH6ZE UT WOS:000354184500027 ER PT J AU Heymann, DL Chen, L Takemi, K Fidler, DP Tappero, JW Thomas, MJ Kenyon, TA Frieden, TR Yach, D Nishtar, S Kalache, A Olliaro, PL Horby, P Torreele, E Gostin, LRO Ndomondo-Sigonda, M Carpenter, D Rushton, S Lillywhite, L Devkota, B Koser, K Yates, R Dhillon, RS Rannan-Eliya, RP AF Heymann, David L. Chen, Lincoln Takemi, Keizo Fidler, David P. Tappero, Jordan W. Thomas, Mathew J. Kenyon, Thomas A. Frieden, Thomas R. Yach, Derek Nishtar, Sania Kalache, Alex Olliaro, Piero L. Horby, Peter Torreele, Els Gostin, Law Rence O. Ndomondo-Sigonda, Margareth Carpenter, Daniel Rushton, Simon Lillywhite, Louis Devkota, Bhimsen Koser, Khalid Yates, Rob Dhillon, Ranu S. Rannan-Eliya, Ravi P. TI Global health security: the wider lessons from the west African Ebola virus disease epidemic SO LANCET LA English DT Article ID PUBLIC-HEALTH; OBESOGENIC ENVIRONMENTS; INFECTIOUS-DISEASES; ARMED CONFLICT; SEPTEMBER 2014; FRAMEWORK; INTERVENTIONS; PREVENTION; OUTBREAK; WORLD AB The Ebola virus disease outbreak in West Africa was unprecedented in both its scale and impact. Out of this human calamity has come renewed attention to global health security-its definition, meaning, and the practical implications for programmes and policy. For example, how does a government begin to strengthen its core public health capacities, as demanded by the International Health Regulations? What counts as a global health security concern? In the context of the governance of global health, including WHO reform, it will be important to distil lessons learned from the Ebola outbreak. The Lancet invited a group of respected global health practitioners to reflect on these lessons, to explore the idea of global health security, and to off er suggestions for next steps. Their contributions describe some of the major threats to individual and collective human health, as well as the values and recommendations that should be considered to counteract such threats in the future. Many different perspectives are proposed. Their common goal is a more sustainable and resilient society for human health and wellbeing. C1 [Heymann, David L.] Univ London London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, London WC1E 7HT, England. [Heymann, David L.; Koser, Khalid] Ctr Global Hlth Secur, London, England. [Rushton, Simon; Lillywhite, Louis; Devkota, Bhimsen; Yates, Rob] Royal Inst Int Affairs, London, England. [Chen, Lincoln] China Med Board, Cambridge, MA USA. [Takemi, Keizo] Japan House Councillors, Tokyo, Japan. [Fidler, David P.] Indiana Univ, Maurer Sch Law, Bloomington, IN USA. [Tappero, Jordan W.; Thomas, Mathew J.] US Ctr Dis Control & Prevent, Div Global Hlth Protect, Atlanta, GA USA. [Kenyon, Thomas A.] US Ctr Dis Control & Prevent, Ctr Global Hlth, Atlanta, GA USA. [Yach, Derek] Vital Inst, New York, NY USA. [Yach, Derek] World Econ Forum Global Agenda Council Ageing, Geneva, Switzerland. [Nishtar, Sania] Heartfile, Islamabad, Pakistan. [Kalache, Alex] Int Longev Ctr ILC Global Alliance, Rio De Janeiro, Brazil. [Kalache, Alex] ILC Brazil, Rio De Janeiro, Brazil. [Kalache, Alex] New York Acad Med, New York, NY USA. [Kalache, Alex] HelpAge Int, London, England. [Olliaro, Piero L.] WHO, UNICEF UNDP World Bank WHO Special Programme Res, CH-1211 Geneva, Switzerland. [Olliaro, Piero L.; Horby, Peter] Univ Oxford, Nuffield Dept Med, Ctr Trop Med & Global Hlth, Oxford, England. [Torreele, Els] Open Soc Fdn, Publ Hlth Program, New York, NY USA. [Gostin, Law Rence O.] Georgetown Univ, Ctr Law, ONeill Inst Natl & Global Hlth Law, Washington, DC USA. [Ndomondo-Sigonda, Margareth] New Partnership Africas Dev, Pretoria, South Africa. [Carpenter, Daniel] Harvard Univ, Dept Govt, Cambridge, MA 02138 USA. [Rushton, Simon] Univ Sheffield, Dept Polit, Sheffield, S Yorkshire, England. [Devkota, Bhimsen] Tribhuvan Univ, Kathmandu, Nepal. [Dhillon, Ranu S.] Brigham & Womens Hosp, Div Global Hlth Equ, Boston, MA 02115 USA. [Dhillon, Ranu S.] Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA. [Dhillon, Ranu S.] Columbia Univ, Earth Inst, New York, NY USA. [Rannan-Eliya, Ravi P.] Inst Hlth Policy, Colombo, Sri Lanka. RP Heymann, DL (reprint author), Univ London London Sch Hyg & Trop Med, Dept Infect Dis Epidemiol, Fac Epidemiol & Populat Hlth, Keppel St, London WC1E 7HT, England. EM david.heymann@lshtm.ac.uk FU European Union [607960] FX PLO is a WHO staff member; the authors alone are responsible for the views expressed in this publication and they do not necessarily represent the decisions, policy, or views of WHO. LOG, MN-S, and DC thank Daniel A Hougendobler for his contributions to this Public Policy paper. SR, LL, and BD prepared their chapter as part of a European Union's Seventh Framework grant agreement no 607960 "Evidence based policy for post crisis stabilization: bridging the gap". NR 122 TC 36 Z9 37 U1 6 U2 45 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0140-6736 EI 1474-547X J9 LANCET JI Lancet PD MAY 9 PY 2015 VL 385 IS 9980 BP 1884 EP 1901 PG 18 WC Medicine, General & Internal SC General & Internal Medicine GA CH6ZE UT WOS:000354184500032 PM 25987157 ER PT J AU Zibbell, JE Iqbal, K Suryaprasad, RCP Sanders, KJ Mo, L Serrecchia, J Blankenship, S John Holtzman, D AF Zibbell, Jon E. Iqbal, Kashif Suryaprasad, Rajiv C. Par Sanders, Kathy J. Mo, Loretta Serrecchia, Jamie Blankenship, Steven John Holtzman, Deborah TI Increases in Hepatitis C Virus Infection Related to Injection Drug Use Among Persons Aged <= 30 Years - Kentucky, Tennessee, Virginia, and West Virginia, 2006-2012 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID UNITED-STATES; YOUNG-ADULTS; EPIDEMIC C1 [Zibbell, Jon E.; Iqbal, Kashif; Suryaprasad, Rajiv C. Par; Holtzman, Deborah] CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Sanders, Kathy J.] Kentucky Dept Publ Hlth, Frankfort, KY USA. [Mo, Loretta] Tennessee Dept Hlth, Nashville, TN USA. [Serrecchia, Jamie] Virginia Dept Hlth, Danville, PA USA. [Blankenship, Steven] West Virginia Dept Hlth, Beckley, WV USA. RP Zibbell, JE (reprint author), CDC, Div Viral Hepatitis, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM jzibbell@cdc.gov NR 10 TC 54 Z9 54 U1 1 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 8 PY 2015 VL 64 IS 17 BP 453 EP 458 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI2RP UT WOS:000354595000002 PM 25950251 ER PT J AU Coyle, C Viner, K Hughes, E Kwakwa, H Zibbell, JE Vellozzi, C Holtzman, D AF Coyle, Catelyn Viner, Kendra Hughes, Elizabeth Kwakwa, Helena Zibbell, Jon E. Vellozzi, Claudia Holtzman, Deborah TI Identification and Linkage to Care of HCV-Infected Persons in Five Health Centers - Philadelphia, Pennsylvania, 2012-2014 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID HEPATITIS-C; UPDATE C1 [Coyle, Catelyn] CDC, Natl Nursing Ctr Consortium, Atlanta, GA 30333 USA. [Viner, Kendra; Kwakwa, Helena] CDC, Philadelphia Dept Publ Hlth, Atlanta, GA 30333 USA. [Hughes, Elizabeth; Zibbell, Jon E.; Vellozzi, Claudia; Holtzman, Deborah] CDC, Div Viral Hepatitis, Atlanta, GA 30333 USA. RP Coyle, C (reprint author), CDC, Natl Nursing Ctr Consortium, Atlanta, GA 30333 USA. EM ccoyle@nncc.us NR 10 TC 13 Z9 13 U1 0 U2 5 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 8 PY 2015 VL 64 IS 17 BP 459 EP 463 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI2RP UT WOS:000354595000003 PM 25950252 ER PT J AU Sabatino, SA White, MC Thompson, TD Klabunde, CN AF Sabatino, Susan A. White, Mary C. Thompson, Trevor D. Klabunde, Carrie N. TI Cancer Screening Test Use - United States, 2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID INCOME C1 [Sabatino, Susan A.; White, Mary C.; Thompson, Trevor D.] CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Klabunde, Carrie N.] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA. RP Sabatino, SA (reprint author), CDC, Div Canc Prevent & Control, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. EM ssabatino@cdc.gov NR 10 TC 41 Z9 41 U1 1 U2 4 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 8 PY 2015 VL 64 IS 17 BP 464 EP 468 PG 5 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI2RP UT WOS:000354595000004 PM 25950253 ER PT J AU Dominguez, K Penman-Aguilar, A Chang, MH Moonesinghe, R Castellanos, T Rodriguez-Lainz, A Schieber, R AF Dominguez, Kenneth Penman-Aguilar, Ana Chang, Man-Huei Moonesinghe, Ramal Castellanos, Ted Rodriguez-Lainz, Alfonso Schieber, Richard TI Vital Signs: Leading Causes of Death, Prevalence of Diseases and Risk Factors, and Use of Health Services Among Hispanics in the United States-2009-2013 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID CANCER AB Background: Hispanics and Latinos (Hispanics) are estimated to represent 17.7% of the U.S. population. Published national health estimates stratified by Hispanic origin and nativity are lacking. Methods: Four national data sets were analyzed to compare Hispanics overall, non-Hispanic whites (Whites), and Hispanic country/region of origin subgroups (Hispanic origin subgroups) for leading causes of death,,prevalence of diseases and associated risk factors, and use of health services. Analyses were generally restricted to ages 18-64 years and were further stratified when possible by sex and nativity, Results: Hispanics were on average nearly 15 years younger than whites; they were more likely to live below the poverty line and not to have completed high school. Hispanics showed a 24% lower all-cause death rate and lower death rates for Pine of the 15 leading causes of death, but higher death rates from diabetes (51% higher), chronic liver disease and cirrhosis (48%), essential hypertension and hypertensive renal disease (8%), and homicide (96%) and higher prevalence of diabetes (133%) and obesity (23%) compared with whites. In all, 41.5% of Hispanics lacked health insurance (15.1% of whites), and 15.5% of Hispanics reported delay or nonreceipt of needed medical care because of cost concerns (13.6% of whites). Among Hispanics, self-reported smoking prevalences varied by Hispanic origin and by sex. U.S.-born Hispanics had higher prevalences of obesity, hypertension, smoking, heart disease, and cancer than foreign-born Hispanics: 30% higher, 40%, 72%, 89%, and 93%, respectively. Conclusion: Hispanics had better health outcomes than whites for most analyzed health factors, despite facing worse socioeconomic barriers, but they had much higher death rates from diabetes, chronic liver disease/cirrhosis, and homicide, and a higher prevalence of Obesity, There were substantial differences among Hispanics by origin, nativity, and sex, Implications for Public Health: Differences by origin, nativity, and sex are important considerations when targeting health programs to specific audiences, Increasing the proportions of Hispanics with health insurance and a medical home (patient-centered, team-based, comprehensive, coordinated health care with enhanced access) is critical. A feasible and systematic data collection strategy is heeded to reflect health diversity among Hispanic origin subgroups, including by nativity, C1 [Dominguez, Kenneth; Chang, Man-Huei] CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. [Penman-Aguilar, Ana; Moonesinghe, Ramal] CDC, Off Minor Hlth & Hlth Equ, Off Director, Atlanta, GA 30333 USA. [Castellanos, Ted] CDC, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Rodriguez-Lainz, Alfonso] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. [Schieber, Richard] CDC, Ctr Surveillance Epidemiol & Lab Serv, Atlanta, GA 30333 USA. RP Penman-Aguilar, A (reprint author), CDC, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30333 USA. EM bpv4@cdc.gov NR 25 TC 26 Z9 26 U1 0 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 8 PY 2015 VL 64 IS 17 BP 469 EP 478 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI2RP UT WOS:000354595000005 PM 25950254 ER PT J AU Christie, A Davies-Wayne, GJ Cordier-Lasalle, T Blackley, DJ Laney, AS Williams, DE Shinde, SA Badio, M Lo, T Mate, SE Ladner, JT Wiley, MR Kugelman, JR Palacios, G Holbrook, MR Janosko, KB de Wit, E van Doremalen, N Munster, VJ Pettitt, J Schoepp, RJ Verhenne, L Evlampidou, I Kollie, KK Sieh, SB Gasasira, A Bolay, F Kateh, FN Nyenswah, TG De Cock, KM AF Christie, Athalia Davies-Wayne, Gloria J. Cordier-Lasalle, Thierry Blackley, David J. Laney, A. Scott Williams, Desmond E. Shinde, Shivam A. Badio, Moses Lo, Terrence Mate, Suzanne E. Ladner, Jason T. Wiley, Michael R. Kugelman, Jeffrey R. Palacios, Gustavo Holbrook, Michael R. Janosko, Krisztina B. de Wit, Emmie van Doremalen, Neeltje Munster, Vincent J. Pettitt, James Schoepp, Randal J. Verhenne, Leen Evlampidou, Iro Kollie, Karsor K. Sieh, Sonpon B. Gasasira, Alex Bolay, Fatorma Kateh, Francis N. Nyenswah, Tolbert G. De Cock, Kevin M. TI Possible Sexual Transmission of Ebola Virus - Liberia, 2015 SO MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT LA English DT Article ID OUTBREAK; KIKWIT; CONGO C1 [Christie, Athalia; Blackley, David J.; Laney, A. Scott; Williams, Desmond E.; Lo, Terrence; De Cock, Kevin M.] CDC, Atlanta, GA 30333 USA. [Davies-Wayne, Gloria J.; Cordier-Lasalle, Thierry; Shinde, Shivam A.; Gasasira, Alex] World Hlth Org, Geneva, Switzerland. [Badio, Moses; Kollie, Karsor K.; Sieh, Sonpon B.; Kateh, Francis N.; Nyenswah, Tolbert G.] Minist Hlth & Social Welf, Monrovia, Liberia. [Mate, Suzanne E.; Ladner, Jason T.; Wiley, Michael R.; Kugelman, Jeffrey R.; Palacios, Gustavo; Schoepp, Randal J.] US Army Med Res Inst Infect Dis, Ft Detrick, MD USA. [Holbrook, Michael R.; Janosko, Krisztina B.; de Wit, Emmie; van Doremalen, Neeltje; Munster, Vincent J.; Pettitt, James] NIH, Bethesda, MD USA. [Verhenne, Leen; Evlampidou, Iro] Med Sans Frontieres, Paris, France. [Bolay, Fatorma] Liberian Inst Biomed Res, Monrovia, Liberia. RP Christie, A (reprint author), CDC, Atlanta, GA 30333 USA. EM akc9@cdc.gov RI Palacios, Gustavo/I-7773-2015; OI Palacios, Gustavo/0000-0001-5062-1938; de Wit, Emmie/0000-0002-9763-7758; Munster, Vincent/0000-0002-2288-3196 NR 9 TC 58 Z9 60 U1 0 U2 30 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 0149-2195 EI 1545-861X J9 MMWR-MORBID MORTAL W JI MMWR-Morb. Mortal. Wkly. Rep. PD MAY 8 PY 2015 VL 64 IS 17 BP 479 EP 481 PG 3 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI2RP UT WOS:000354595000006 PM 25950255 ER PT J AU Jauregui, B Garcia, AGF Janusz, CB Blau, J Munier, A Atherly, D Mvundura, M Hajjeh, R Lopman, B Clark, AD Baxter, L Hutubessy, R de Quadros, C Andrus, JK AF Jauregui, Barbara Garcia, Ana Gabriela Felix Janusz, Cara Bess Blau, Julia Munier, Aline Atherly, Deborah Mvundura, Mercy Hajjeh, Rana Lopman, Benjamin Clark, Andrew David Baxter, Louise Hutubessy, Raymond de Quadros, Ciro Andrus, Jon Kim TI Evidence-based decision-making for vaccine introductions: Overview of the ProVac International Working Group's experience SO VACCINE LA English DT Article DE Immunization program; Economic evaluations; Cost-effectiveness analysis; Evidence-based policy; Immunization policy ID AMERICA; MODEL AB Introduction: Pan American Health Organization's (PAHO) ProVac Initiative aims to strengthen countries' technical capacity to make evidence-based immunization policy. With financial support from the Bill and Melinda Gates Foundation, PAHO established the ProVac International Working Group (IWG), a platform created for two years to transfer the ProVac Initiative's tools and methods to support decisions in non-PAHO regions. Methods: In 2011, WHO Regional Offices and partner agencies established the IWG to transfer the Pro Vac framework for new vaccine decision support, including tools and trainings to other regions of the world. During the two year period, PAHO served as the coordinating secretariat and partner agencies played implementing or advisory roles. Results: Fifty nine national professionals from 17 countries received training on the use of economic evaluations to aid vaccine policy making through regional workshops. The IWG provided direct technical support to nine countries to develop cost-effectiveness analyses to inform decisions. All nine countries introduced the new vaccine evaluated or their NITAGs have made a recommendation to the Ministry of Health to introduce the new vaccine. Discussion: Developing countries around the world are increasingly interested in weighing the potential health impact due to new vaccine introduction against the investments required. During the two years, the ProVac approach proved valuable and timely to aid the national decision making processes, even despite the different challenges and idiosyncrasies encountered in each region. The results of this work suggest that: (1) there is great need and demand for technical support and for capacity building around economic evaluations; and (2) the ProVac method of supporting country-owned analyses is as effective in other regions as it has been in the PAHO region. Conclusion: Decision support for new vaccine introduction in low- and middle-income countries is critical to guiding the efficient use of resources and prioritizing high impact vaccination programs. (C) 2015 Published by Elsevier Ltd. C1 [Jauregui, Barbara; Garcia, Ana Gabriela Felix; Janusz, Cara Bess; Andrus, Jon Kim] Pan Amer Hlth Org, Washington, DC 20007 USA. [Blau, Julia; Munier, Aline] Agence Med Prevent, Paris, France. [Atherly, Deborah; Mvundura, Mercy] PATH, Seattle, WA USA. [Hajjeh, Rana; Lopman, Benjamin] Ctr Dis Control & Prevent, Atlanta, GA USA. [Clark, Andrew David; Baxter, Louise] Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England. [de Quadros, Ciro] Sabin Vaccine Inst, Washington, DC USA. [Hutubessy, Raymond] WHO, Initiat Vaccine Res, CH-1211 Geneva, Switzerland. RP Jauregui, B (reprint author), Pan Amer Hlth Org, Washington, DC 20007 USA. EM jauregub@paho.org FU Bill and Melinda Gates Foundation [OPP1032888] FX We would like to acknowledge the financial support provided by the Bill and Melinda Gates Foundation through grant number OPP1032888 to create the IWG and the two-year activities it conducted. We also acknowledge the relevant contributions provided by Liudmila Mosina, WHO EURO; Amos Petu, WHO AFRO; and Irtaza Chaudhri, WHO EMRO. NR 14 TC 4 Z9 4 U1 0 U2 4 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 7 PY 2015 VL 33 SU 1 BP A28 EP A33 DI 10.1016/j.vaccine.2014.10.090 PG 6 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CI8PP UT WOS:000355034500009 PM 25919170 ER PT J AU Sibak, M Moussa, I El-Tantawy, N Badr, S Chaudhri, I Allam, E Baxter, L Freikha, SA Hoestlandt, C Lara, C Hajjeh, R Munier, A AF Sibak, Mohammed Moussa, Ibrahim El-Tantawy, Nasr Badr, Shaza Chaudhri, Irtaza Allam, Essam Baxter, Louise Freikha, Saiyed Abo Hoestlandt, Celine Lara, Carlos Hajjeh, Rana Munier, Aline TI Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013 SO VACCINE LA English DT Article DE Pneumococcal conjugate vaccine; Cost-effectiveness; Egypt; Immunization program; vaccine ID NONTYPABLE HAEMOPHILUS-INFLUENZAE; BACTERIAL-MENINGITIS; PROTEIN-D; STREPTOCOCCUS-PNEUMONIAE; PHID-CV; ANTIMICROBIAL SUSCEPTIBILITY; OTITIS-MEDIA; CHILDREN; IMMUNOGENICITY; MORTALITY AB Introduction: Pneumonia is one of the most important causes of morbidiojr and mortality in children under 5 in Egypt, and the Ministry of Health of Egypt is considering introducing pneumococcal conjugate vaccine (PCV) in its national immunization program. We performed an economic analysis to evaluate the cost-effectiveness of this vaccine in Egypt and to provide the decision-makers with needed evidence. Methods: The analysis was done using the TRIVAC model. Data included demographic characteristics, burden of disease, coverage and efficacy of the vaccine, health resource utilization, and costs of pneumococcal disease vaccination and treatment. Whenever possible, we used national or regional data. Two alternatives were compared: (1) general vaccination of children younger than 5 years with the 13-valent pneumococcal conjugate vaccine (PCV13), using a three-dose schedule without booster, and (2) no vaccination. Outcomes of 10 cohorts from birth to 5 years were analyzed. The study was performed from the governmental perspective and selected public health providers. Results: In comparison to no vaccine, the introduction of PCV13 would be cost-effective, with an incremental cost-effectiveness ratio of US$ 3916 per disability-adjusted life-year (DALY) averted (government perspective). The total incremental cost of the PCV vaccination program (10 cohorts) would be approximately US$ 1.09 billion. Over the 10 cohorts, the program would avert 8583 pneumococcal deaths - 42% of all pneumococcal-related deaths. Conclusion: The introduction of PCV13 would be a good value for money from the government perspective. It would represent a high-impact public health intervention for Egypt and respond to the National Immunization Technical Advisory Group (NITAG) resolution on reducing pneumonia burden and overall child mortality. Strengthening surveillance will be critical to generating high-quality national data, improving future economic analyses that support evidence-based decisions for introducing vaccines and public health interventions, and to monitoring their impact. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Chaudhri, Irtaza] WHO, Reg Off Eastern Mediterranean, Cairo, Egypt. [Allam, Essam] UNICEF, Cairo, Egypt. [Baxter, Louise] London Sch Hyg & Trop Med, Dept Hlth Serv Res & Policy, London WC1, England. [Freikha, Saiyed Abo] Gharbiya Hlth Directorate, Gharbiya, Egypt. [Hoestlandt, Celine; Lara, Carlos; Munier, Aline] Agence Med Prevent, Paris, France. [Hajjeh, Rana] Ctr Dis Control & Prevent CDC, Atlanta, GA USA. EM sibakmohammed@gmail.com FU Bill and Melinda Gates Foundation [OPP1032888] FX This study is part of the ProVac IWG and was funded by a grant from the Bill and Melinda Gates Foundation to the PAHO:OPP1032888. The Agence de Medecine Preventive (AMP) was PAHO's sub-grantee and implemented the project in the WHO Eastern Mediterranean region (EMRO) and the European region (EURO). NR 45 TC 3 Z9 3 U1 0 U2 2 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 7 PY 2015 VL 33 SU 1 BP A182 EP A191 DI 10.1016/j.vaccine.2014.12.044 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CI8PP UT WOS:000355034500029 PM 25919159 ER PT J AU Kes, A Ogwang, S Pande, RP Douglas, Z Karuga, R Odhiambo, FO Laserson, K Schaffer, K AF Kes, Aslihan Ogwang, Sheila Pande, Rohini Prabha Douglas, Zayid Karuga, Robinson Odhiambo, Frank O. Laserson, Kayla Schaffer, Kathleen TI The economic burden of maternal mortality on households: evidence from three 32E5978076V sub-counties in rural western Kenya SO REPRODUCTIVE HEALTH LA English DT Article ID DEVELOPING-COUNTRIES; HIV/AIDS; IMPACT; ILLNESS AB Background: This study explores the consequences of a maternal death to households in rural Western Kenya focusing particularly on the immediate financial and economic impacts. Methods: Between September 2011 and March 2013 all households in the study area with a maternal death were surveyed. Data were collected on the demographic characteristics of the deceased woman; household socioeconomic status; a history of the pregnancy and health care access and utilization; and disruption to household functioning due to the maternal death. These data were supplemented by in-depth and focus group discussions. Results: The health service utilization costs associated with maternal deaths were significantly higher, due to more frequent service utilization as well as due to the higher cost of each visit suggesting more involved treatments and interventions were sought with these women. The already high costs incurred by cases during pregnancy were further increased during delivery and postpartum mainly a result of higher facility-based fees and expenses. Households who experienced a maternal death spent about one-third of their annual per capita consumption expenditure on healthcare access and use as opposed to at most 12% among households who had a health pregnancy and delivery. Funeral costs were often higher than the healthcare costs and altogether forced households to dis-save, liquidate assets and borrow money. What is more, the surviving members of the households had significant redistribution of labor and responsibilities to make up for the lost contributions of the deceased women. Conclusion: Kenya is in the process of instituting free maternity services in all public facilities. Effectively implemented, this policy can lift a major economic burden experienced by a very large number of household who seek maternal health services which can be catastrophic in complicated cases that result in maternal death. There needs to be further emphasis on insurance schemes that can support households through catastrophic health spending. C1 [Kes, Aslihan; Douglas, Zayid] ICRW, Washington, DC 20036 USA. [Ogwang, Sheila; Odhiambo, Frank O.] Kenya Med Res Inst KEMRI, Kisumu, Kenya. [Karuga, Robinson] LVCT Hlth, Tivoli Ctr, Kisumu, Kenya. [Laserson, Kayla] CDC, Global Dis Detect Program, Atlanta, GA 30329 USA. [Schaffer, Kathleen] Family Care Int, New York, NY 10012 USA. RP Kes, A (reprint author), ICRW, 1120 20th St NW,Suite 500 North, Washington, DC 20036 USA. EM akes@icrw.org FU Department for International Development (DFID); MacArthur Foundation; WHO's Partnership for Maternal and Child Health FX The research study underlying this paper was funded by the Department for International Development (DFID), the MacArthur Foundation and the WHO's Partnership for Maternal and Child Health. We would like to thank the following individuals for their contribution to this paper. At ICRW, many thanks to Robin Hayes for her hard work on data analysis and tables, to Kirrin Gill and Anne M. Golla for comments and input on study design and NR 29 TC 3 Z9 3 U1 0 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4755 J9 REPROD HEALTH JI Reprod. Health PD MAY 6 PY 2015 VL 12 SU 1 AR S3 DI 10.1186/1742-4755-12-S1-S3 PG 10 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH4DW UT WOS:000353983500003 PM 26000953 ER PT J AU Pande, RP Ogwang, S Karuga, R Rajan, R Kes, A Odhiambo, FO Laserson, K Schaffer, K AF Pande, Rohini Prabha Ogwang, Sheila Karuga, Robinson Rajan, Radha Kes, Aslihan Odhiambo, Frank O. Laserson, Kayla Schaffer, Kathleen TI Continuing with " ... a heavy heart" - consequences of maternal death in rural Kenya SO REPRODUCTIVE HEALTH LA English DT Article ID MISS OBSTETRIC COMPLICATIONS; BURKINA-FASO; CHILD SURVIVAL; MORTALITY; BANGLADESH; HEALTH; CARE; INFANT; IMPACT AB Background: This study analyzes the consequences of maternal death to households in Western Kenya, specifically, neonatal and infant survival, childcare and schooling, disruption of daily household activities, the emotional burden on household members, and coping mechanisms. Methods: The study is a combination of qualitative analysis with matched and unmatched quantitative analysis using surveillance and survey data. Between September 2011 and March 2013 all households in the study area with a maternal death were surveyed. Data were collected on the demographic characteristics of the deceased woman; household socio-economic status; a history of the pregnancy that led to the death; schooling experiences of surviving school-age children; and disruption to household functioning due to the maternal death. These data were supplemented by in-depth and focus group discussions. Quantitative data on neonatal and infant survival from a demographic surveillance system in the study area were also used. Descriptive and bivariate analyses were conducted with the quantitative data, and qualitative data were analyzed through text analysis using NVivo. Results: More than three-quarters of deceased women performed most household tasks when healthy. After the maternal death, the responsibility for these tasks fell primarily on the deceased's husbands, mothers, and mothers-in- law. Two-thirds of the individuals from households that suffered a maternal death had to shift into another household. Most children had to move away, mostly to their grandmother's home. About 37% of live births to women who died of maternal causes survived till age 1 year, compared to 65% of live births to a matched sample of women who died of non-maternal causes and 93% of live births to surviving women. Older, surviving children missed school or did not have enough time for schoolwork, because of increased housework or because the loss of household income due to the maternal death meant school fees could not be paid. Respondents expressed grief, frustration, anger and a sense of loss. Generous family and community support during the funeral and mourning periods was followed by little support thereafter. Conclusion: The detrimental consequences of a maternal death ripple out from the woman's spouse and children to the entire household, and across generations. C1 [Ogwang, Sheila; Odhiambo, Frank O.] Kenya Med Res Inst KEMRI, Kisumu, Kenya. [Karuga, Robinson] LVCT Hlth, Tivoli Ctr, Kisumu, Kenya. [Rajan, Radha] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD 21231 USA. [Kes, Aslihan] ICRW, Washington, DC 20036 USA. [Laserson, Kayla] Ctr Dis Control, Global Dis Detect Program, Atlanta, GA 30329 USA. [Schaffer, Kathleen] Family Care Int, New York, NY 10012 USA. RP Pande, RP (reprint author), 7118 Willow Ave, Takoma Pk, MD 20912 USA. FU U.K. Government; John D. and Catherine T. MacArthur Foundation; Partnership for Maternal, Newborn Child Health FX The work presented in this paper was performed under a KEMRI and CDC Collaboration in western Kenya. The U.K. Government, the John D. and Catherine T. MacArthur Foundation, and the Partnership for Maternal, Newborn & Child Health funded the research study from which this paper originates. We would like to thank the following individuals. At ICRW, many thanks to Robin Hayes for her hard work on data analysis and tables, to Kirrin Gill and Anne M. Golla for comments and input on study design and methodology, to Sophie Namy for materials that helped in designing the qualitative study instrument, Ellen Weiss for editing, and Allison McGonagle and Laurie Calhoun for their assistance in getting critical articles and reports. Thanks also to Ken Hill at the Harvard School of Public Health for his review of an earlier draft, and to Cynthia Stanton and Jennifer Blum for their valuable comments as peer reviewers for this draft of the manuscript. At KEMRI/CDC, we would like to thank the study community and particularly all those who participated in the interviews; many thanks also to the entire HDSS team and especially the following interviewers: Eunice Ottaye, Pamela Simiyu and Apollo Okal. We thank the HDSS field and office staff for their hard work collecting and evaluating HDSS data. KEMRI/CDC HDSS is a member of the INDEPTH network. Dr John Vulule is thanked for his advice and support. The Director of KEMRI has approved this manuscript. Elizabeth Westley from FCI-New York provided food for thought with her insightful questions, and Angela Mutunga from FCI-Kenya kept us on track with our timeline. NR 30 TC 3 Z9 3 U1 0 U2 6 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1742-4755 J9 REPROD HEALTH JI Reprod. Health PD MAY 6 PY 2015 VL 12 SU 1 AR S2 DI 10.1186/1742-4755-12-S1-S2 PG 12 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CH4DW UT WOS:000353983500002 PM 26000827 ER PT J AU Krause, PR Bryant, PR Clark, T Dempsey, W Henchal, E Michael, NL Regules, JA Gruber, MF AF Krause, Philip R. Bryant, Paula R. Clark, Thomas Dempsey, Walla Henchal, Erik Michael, Nelson L. Regules, Jason A. Gruber, Marion F. TI Immunology of protection from Ebola virus infection SO SCIENCE TRANSLATIONAL MEDICINE LA English DT Article ID NONHUMAN-PRIMATES; WEST-AFRICA; IMMUNITY; ANTIBODIES; CHALLENGE; DISEASE AB A December 2014 meeting reviewed Ebola virus immunology relevant to vaccine development, including Ebola prevention, immunity, assay standardization, and regulatory considerations. Vaccinated humans appear to achieve immune responses comparable in magnitude with those associated with protection in nonhuman primates, suggesting that immunological data could be used to demonstrate vaccine efficacy. C1 [Krause, Philip R.; Henchal, Erik; Gruber, Marion F.] US FDA, Off Vaccines Res & Review, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA. [Bryant, Paula R.; Dempsey, Walla] NIAID, Div Microbial & Infect Dis, NIH, Bethesda, MD 20892 USA. [Clark, Thomas] Ctr Dis Control & Prevent, Atlanta, GA USA. [Michael, Nelson L.; Regules, Jason A.] Walter Reed Army Inst Res, Silver Spring, MD USA. RP Krause, PR (reprint author), US FDA, Off Vaccines Res & Review, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA. EM philip.krause@fda.hhs.gov FU FDA; NIAID; CDC; Biomedical Advanced Research and Development Authority; U.S. Department of Defense FX We appreciate financial and logistical support for the meeting from FDA, NIAID, CDC, Biomedical Advanced Research and Development Authority, and U.S. Department of Defense. NR 25 TC 2 Z9 2 U1 1 U2 15 PU AMER ASSOC ADVANCEMENT SCIENCE PI WASHINGTON PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA SN 1946-6234 EI 1946-6242 J9 SCI TRANSL MED JI Sci. Transl. Med. PD MAY 6 PY 2015 VL 7 IS 286 AR 286ps11 DI 10.1126/scitranslmed.aaa8202 PG 4 WC Cell Biology; Medicine, Research & Experimental SC Cell Biology; Research & Experimental Medicine GA CI0MP UT WOS:000354431600003 PM 25947159 ER PT J AU Gould, CV AF Gould, Carolyn V. TI In Pursuit of Appropriate Urinary Catheter Indications: Details Matter SO ANNALS OF INTERNAL MEDICINE LA English DT Editorial Material ID TRACT-INFECTION C1 [Gould, Carolyn V.] Ctr Dis Control & Prevent, Atlanta, GA 30333 USA. RP Gould, CV (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,Mailstop A-31, Atlanta, GA 30333 USA. EM CGould@cdc.gov NR 12 TC 1 Z9 1 U1 0 U2 2 PU AMER COLL PHYSICIANS PI PHILADELPHIA PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA SN 0003-4819 EI 1539-3704 J9 ANN INTERN MED JI Ann. Intern. Med. PD MAY 5 PY 2015 VL 162 IS 9 SU S BP S35 EP S36 DI 10.7326/M14-1610 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CI8IA UT WOS:000355014300002 PM 25938929 ER PT J AU Dinh, TH Delaney, KP Goga, A Jackson, D Lombard, C Woldesenbet, S Mogashoa, M Pillay, Y Shaffer, N AF Dinh, Thu-Ha Delaney, Kevin P. Goga, Ameena Jackson, Debra Lombard, Carl Woldesenbet, Selamawit Mogashoa, Mary Pillay, Yogan Shaffer, Nathan TI Impact of Maternal HIV Seroconversion during Pregnancy on Early Mother to Child Transmission of HIV (MTCT) Measured at 4-8 Weeks Postpartum in South Africa 2011-2012: A National Population-Based Evaluation SO PLOS ONE LA English DT Article ID INCIDENT HIV; INFECTION; VIRUS; PREVENTION; THERAPY; UGANDA; RAKAI; WOMEN; TRIAL AB Background Mother-to-child transmission of HIV (MTCT) depends on the timing of HIV infection. We estimated HIV-seroconversion during pregnancy (HSP) after having a HIV-negative result antenatally, and its contribution to early MTCT in South Africa (SA). Methods and Findings Between August 2011 and March 2012, we recruited a nationally representative sample of mother-infant pairs with infants aged 4-to-8 weeks from 578 health facilities. Data collection included mother interviews, child health-card reviews, and infant dried-blood-spots sample (iDBS). iDBS were tested for HIV antibodies and HIV-deoxyribonucleic-acid (HIV-DNA). HSP was defined as maternal self-report of an HIV-negative test during this pregnancy, no documented use of antiretroviral drugs and a matched HIV sero-positive iDBS. We used 20 imputations from a uniform distribution for time from reported antenatal HIV-negative result to delivery to estimate time of HSP. Early MTCT was defined based on detection of HIV-DNA in iDBS. Estimates were adjusted for clustering, nonresponse, and weighted by SA's 2011 live-births. Results Of 9802 mother-infant pairs, 2738 iDBS were HIV sero-positive, including 212 HSP, resulting in a nationally weighted estimate of 3.3% HSP (95% Confidence Interval: 2.8%-3.8%). Median time of HIV-seroconversion was 32.8weeks gestation; 28.3% (19.7%-36.9%) estimated to be >36 weeks. Early MTCT was 10.7% for HSP (6.2%-16.8%) vs. 2.2% (1.7%2.8%) for mothers with known HIV-positive status. Although they represent 2.2% of all mothers and 6.7% of HIV-infected mothers, HSP accounted for 26% of early MTCT. Multivariable analysis indicated the highest risk for HSP was among women who knew the baby's father was HIV-infected (adjusted-hazard ratio (aHR) 4.71; 1.49-14.99), or who had been screened for tuberculosis (aHR 1.82; 1.43-2.32). Conclusions HSP risk is high and contributes significantly to early MTCT. Identification of HSP by repeat-testing at 32 weeks gestation, during labor, 6 weeks postpartum, in tuberculosis-exposed women, and in discordant couples might reduce MTCT. C1 [Dinh, Thu-Ha] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA. [Delaney, Kevin P.] Ctr Dis Control & Prevent, Natl Ctr HIV Hepatitis STD & TB Prevent, Div HIV AIDS Prevent, Atlanta, GA USA. [Goga, Ameena] MRC, Pretoria, South Africa. [Goga, Ameena] Univ Pretoria, Dept Paediat & Child Hlth, Kalafong Hosp, ZA-0002 Pretoria, South Africa. [Jackson, Debra] MRC, Cape Town, South Africa. [Lombard, Carl; Woldesenbet, Selamawit] Univ Western Cape, Sch Publ Hlth, ZA-7535 Bellville, South Africa. [Mogashoa, Mary] US Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Pretoria, South Africa. [Pillay, Yogan] Natl Dept Hlth, Pretoria, South Africa. [Shaffer, Nathan] WHO, CH-1211 Geneva, Switzerland. [Jackson, Debra] United Nations Childrens Fund, New York, NY USA. RP Dinh, TH (reprint author), Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global HIV AIDS, Atlanta, GA 30333 USA. EM dvt1@cdc.gov FU Centers for Disease Control and Prevention (CDC) [1U2GPS001137-02, 1U2GPS001137-03]; MRC [1U2GPS001137-02, 1U2GPS001137-03] FX This evaluation was primarily supported by the President's Emergency Plan for AIDS Relief (PEPFAR) under a Cooperative Agreement between Centers for Disease Control and Prevention (CDC) and MRC (1U2GPS001137-02 and 1U2GPS001137-03). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 30 TC 12 Z9 12 U1 1 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 5 PY 2015 VL 10 IS 5 AR e0125525 DI 10.1371/journal.pone.0125525 PG 17 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH3PT UT WOS:000353943400041 PM 25942423 ER PT J AU Smith, TG Siirin, M Wu, XF Hanlon, CA Bronshtein, V AF Smith, Todd G. Siirin, Marina Wu, Xianfu Hanlon, Cathleen A. Bronshtein, Victor TI Rabies vaccine preserved by vaporization is thermostable and immunogenic SO VACCINE LA English DT Article DE Rabies virus; Preservation by vaporization; Stability; Efficacy; Immunogenicity ID VIRUS; GLYCOPROTEIN; STABILITY; ANTIBODY; FOXES AB A rabies vaccine that is thermostable over a range of ambient environmental temperatures would be highly advantageous, especially for tropical regions with challenging cold-chain storage where canine rabies remains enzootic resulting in preventable human mortality. Live attenuated rabies virus (RABV) strain ERAG333 (R333E) was preserved by vaporization (PBV) in a dry, stable foam. RABV stabilized using this process remains viable for at least 23 months at 22 degrees C, 15 months at 37 degrees C, and 3h at 80 degrees C. An antigen capture assay revealed RABV PBV inactivated by irradiation contained similar levels of antigen as a commercial vaccine. Viability and antigen capture testing confirmed that the PBV process stabilized RABV with no significant loss in titer or antigen content. Live attenuated and inactivated RABV PBV both effectively induced RABV neutralizing antibodies and protected mice from peripheral RABV challenge. These results demonstrate that PBV is an efficient method for RABV stabilization. Published by Elsevier Ltd. C1 [Smith, Todd G.; Wu, Xianfu; Hanlon, Cathleen A.] Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, Atlanta, GA 30329 USA. [Siirin, Marina; Bronshtein, Victor] Univ Stabilizat Technol Inc, San Diego, CA 92121 USA. RP Smith, TG (reprint author), Ctr Dis Control & Prevent, Div High Consequence Pathogens & Pathol, Poxvirus & Rabies Branch, 1600 Clifton Rd NE, Atlanta, GA 30329 USA. EM tgsmith1@cdc.gov FU National Institutes of Health [R44AI080035]; U.S. Department of Energy; CDC FX We thank past and present members of the Poxvirus and Rabies Branch for their assistance. This work was supported by National Institutes of Health grant no. R44AI080035 to VB and in part by an appointment to the Research Participation Program at CDC administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC. NR 22 TC 1 Z9 1 U1 0 U2 12 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAY 5 PY 2015 VL 33 IS 19 BP 2203 EP 2206 DI 10.1016/j.vaccine.2015.03.025 PG 4 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA CH0TI UT WOS:000353734900002 PM 25812841 ER PT J AU Marin, M Yawn, BP Hales, CM Wollan, PC Bialek, SR Zhang, J Kurland, MJ Harpaz, R AF Marin, Mona Yawn, Barbara P. Hales, Craig M. Wollan, Peter C. Bialek, Stephanie R. Zhang, John Kurland, Marge J. Harpaz, Rafael TI Herpes zoster vaccine effectiveness and manifestations of herpes zoster and associated pain by vaccination status SO HUMAN VACCINES & IMMUNOTHERAPEUTICS LA English DT Article DE breakthrough zoster; herpes zoster; postherpetic neuralgia; PHN; shingles; vaccine; zoster vaccine; Zostavax; zoster pain ID QUALITY-OF-LIFE; POSTHERPETIC NEURALGIA; OLDER-ADULTS; COMPLICATION RATES; COST-EFFECTIVENESS; UNITED-STATES; IMPACT; EPIDEMIOLOGY; POPULATION; EFFICACY AB Options for managing herpes zoster (HZ)-related pain and complications have limited effectiveness, making HZ prevention through vaccination an important strategy. Limited data are available on HZ vaccine effectiveness against confirmed HZ and manifestations of HZ among vaccinated persons. We conducted a matched case-control study to assess HZ vaccine effectiveness for prevention of HZ and other HZ-related outcomes and a cohort study of persons with HZ to compare HZ-related outcomes by vaccination status. Cases were identified through active surveillance among persons age >= 60 years with HZ onset and health-care encounters during 2010-2011 in Southeastern Minnesota. Controls were age- and sex-matched to cases. Data were collected by medical record review and from participants via interviews and daily pain diaries. 266 HZ case-patients and 362 matched controls were enrolled in the vaccine effectiveness studies and 303 case-patients in the cohort study of HZ characteristics by vaccination status. Vaccination was associated with 54% (95% CI:32%-69%) reduction in HZ incidence, 58% (95% CI:31%-75%) reduction in HZ prodromal symptoms, and 70% (95% CI:33%-87%) reduction in medically-attended prodrome. HZ vaccine was statistically significant effective at preventing postherpetic neuralgia (PHN) measured at 30 d after rash onset, 61% (95% CI: 22%-80%). Among persons who developed HZ, no differences were found by vaccination status in severity or duration of HZ pain after rash onset. In this population-based study, HZ vaccination was associated with >50% reduction in HZ, HZ prodrome, and medically-attended prodrome. C1 [Marin, Mona; Hales, Craig M.; Bialek, Stephanie R.; Zhang, John; Harpaz, Rafael] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. [Yawn, Barbara P.; Wollan, Peter C.; Kurland, Marge J.] Olmsted Med Ctr, Dept Res, Rochester, MN USA. RP Marin, M (reprint author), Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM mmarin@cdc.gov FU Centers for Disease Control and Prevention; American Recovery and Reconstruction Act; National Institute on Aging of the National Institutes of Health FX This study was funded by the Centers for Disease Control and Prevention with funds from the American Recovery and Reconstruction Act of 2009. Additionally, the study used the resources of the Rochester Epidemiology Project, which is supported by the National Institute on Aging of the National Institutes of Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. NR 29 TC 9 Z9 9 U1 1 U2 16 PU TAYLOR & FRANCIS INC PI PHILADELPHIA PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA SN 2164-5515 EI 2164-554X J9 HUM VACC IMMUNOTHER JI Human Vaccines Immunother. PD MAY 4 PY 2015 VL 11 IS 5 BP 1157 EP 1164 DI 10.1080/21645515.2015.1016681 PG 8 WC Biotechnology & Applied Microbiology; Immunology SC Biotechnology & Applied Microbiology; Immunology GA CI9VC UT WOS:000355117100025 PM 25874632 ER PT J AU Chadha, MS Potdar, VA Saha, S Koul, PA Broor, S Dar, L Chawla-Sarkar, M Biswas, D Gunasekaran, P Abraham, AM Shrikhande, S Jain, A Anukumar, B Lal, RB Mishra, AC AF Chadha, Mandeep S. Potdar, Varsha A. Saha, Siddhartha Koul, Parvaiz A. Broor, Shobha Dar, Lalit Chawla-Sarkar, Mamta Biswas, Dipankar Gunasekaran, Palani Abraham, Asha Mary Shrikhande, Sunanda Jain, Amita Anukumar, Balakrishnan Lal, Renu B. Mishra, Akhilesh C. TI Dynamics of Influenza Seasonality at Sub-Regional Levels in India and Implications for Vaccination Timing SO PLOS ONE LA English DT Article ID PATTERNS; TRANSMISSION; ASIA AB Background Influenza surveillance is an important tool to identify emerging/reemerging strains, and defining seasonality. We describe the distinct patterns of circulating strains of the virus in different areas in India from 2009 to 2013. Methods Patients in ten cities presenting with influenza like illness in out-patient departments of dispensaries/hospitals and hospitalized patients with severe acute respiratory infections were enrolled. Nasopharangeal swabs were tested for influenza viruses by real-time RT-PCR, and subtyping; antigenic and genetic analysis were carried out using standard assays. Results Of the 44,127 ILI/SARI cases, 6,193 (14.0%) were positive for influenza virus. Peaks of influenza were observed during July-September coinciding with monsoon in cities Delhi and Lucknow (north), Pune (west), Allaphuza (southwest), Nagpur (central), Kolkata (east) and Dibrugarh (northeast), whereas Chennai and Vellore (southeast) revealed peaks in October- November, coinciding with the monsoon months in these cities. In Srinagar (Northern most city at 34 degrees N latitude) influenza circulation peaked in January-March in winter months. The patterns of circulating strains varied over the years: whereas A/H1N1pdm09 and type B co-circulated in 2009 and 2010, H3N2 was the predominant circulating strain in 2011, followed by circulation of A/H1N1pdm09 and influenza B in 2012 and return of A/H3N2 in 2013. Antigenic analysis revealed that most circulating viruses were close to vaccine selected viral strains. Conclusions Our data shows that India, though physically located in northern hemisphere, has distinct seasonality that might be related to latitude and environmental factors. While cities with temperate seasonality will benefit from vaccination in September-October, cities with peaks in the monsoon season in July-September will benefit from vaccination in April-May. Continued surveillance is critical to understand regional differences in influenza seasonality at regional and sub-regional level, especially in countries with large latitude span. C1 [Chadha, Mandeep S.; Potdar, Varsha A.; Mishra, Akhilesh C.] Natl Inst Virol, Pune, Maharashtra, India. [Saha, Siddhartha; Lal, Renu B.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Koul, Parvaiz A.] Sheri Kashmir Inst Med Sci, Srinagar, Jammu & Kashmir, India. [Broor, Shobha; Dar, Lalit] All India Inst Med Sci, New Delhi, India. [Chawla-Sarkar, Mamta] Natl Inst Cholera & Enter Dis, Kolkata, India. [Biswas, Dipankar] Reg Med Res Ctr, Dibrugarh, Assam, India. [Gunasekaran, Palani] King Inst Prevent Med & Res, Madras, Tamil Nadu, India. [Abraham, Asha Mary] Christian Med Coll & Hosp, Vellore, Tamil Nadu, India. [Shrikhande, Sunanda] Indira Gandhi Med Coll, Nagpur, Maharashtra, India. [Jain, Amita] King George Med Univ, Lucknow, Uttar Pradesh, India. [Anukumar, Balakrishnan] Natl Inst Virol, Alappuzha, India. RP Chadha, MS (reprint author), Natl Inst Virol, Pune, Maharashtra, India. EM mscniv@gmail.com FU Department of Health and Human Services-Centers for Disease Control and Prevention (DHHS-CDC) Cooperative [1U51000333]; Indian Council of Medical Research, New Delhi FX This study was funded by Department of Health and Human Services-Centers for Disease Control and Prevention (DHHS-CDC) Cooperative agreement number 1U51000333 and Indian Council of Medical Research, New Delhi. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 23 TC 9 Z9 9 U1 0 U2 3 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 4 PY 2015 VL 10 IS 5 AR e0124122 DI 10.1371/journal.pone.0124122 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH3PP UT WOS:000353943000017 PM 25938466 ER PT J AU Durant, JT Boivin, TG Pohl, HR Sinks, TH AF Durant, James T. Boivin, Thomas G. Pohl, Hana R. Sinks, Thomas H. TI Public health assessment of dioxin-contaminated fish at former US airbase, Bien Hoa, Vietnam SO INTERNATIONAL JOURNAL OF ENVIRONMENTAL HEALTH RESEARCH LA English DT Article DE international issues; fish; 2,3,7,8-tetrachloro-dibenzo-p-dioxin contamination; dioxin contamination; risk assessment; Agent Orange ID AGENT-ORANGE; 2,3,7,8-TETRACHLORODIBENZO-P-DIOXIN; EXPOSURE AB Ponds at the former US airbase at Ben Hoa, Vietnam are contaminated with Agent Orange. The ponds had been used for aquaculture, and in all likelihood, fish from those ponds have been sold to the public. We assessed human exposure to 2,3,7,8-tetrachloro-dibenzo-dioxin (2,3,7,8-TCDD) in fish samples from the ponds. For on-base tilapia, muscle concentrations 2,3,7,8-TCDD ranged from 1.4 to 32.7 pg/g. Fat concentrations ranged from 73.3 to 3990 pg/g. Estimated human exposure doses exceed international guidelines and exceed 2,3,7,8-TCDD's lowest adverse effect levels. The Bien Hoa fishponds are a completed human pathway for TCDD exposure. C1 [Durant, James T.] Agcy Tox Subst & Dis Registry, Div Community Hlth Invest, Atlanta, GA 30341 USA. [Boivin, Thomas G.] Hatfield Consultants Partnership, N Vancouver, BC, Canada. [Pohl, Hana R.] Agcy Tox Subst & Dis Registry, DTHHS, Atlanta, GA USA. [Sinks, Thomas H.] Agcy Tox Subst & Dis Registry, Natl Ctr Environm Hlth, Atlanta, GA USA. RP Durant, JT (reprint author), Agcy Tox Subst & Dis Registry, Div Community Hlth Invest, Atlanta, GA 30341 USA. EM hzd3@cdc.gov FU Ford Foundation [1100-0530] FX The work of Hatfield consultants was funded by the Ford Foundation grant 1100-0530. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Agency for Toxic Substances and Disease Registry. NR 31 TC 0 Z9 0 U1 2 U2 8 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND SN 0960-3123 EI 1369-1619 J9 INT J ENVIRON HEAL R JI Int. J. Environ. Health Res. PD MAY 4 PY 2015 VL 25 IS 3 BP 254 EP 264 DI 10.1080/09603123.2014.938026 PG 11 WC Environmental Sciences; Public, Environmental & Occupational Health SC Environmental Sciences & Ecology; Public, Environmental & Occupational Health GA CG7SF UT WOS:000353504500003 PM 25087452 ER PT J AU Li, BS Luo, JY Tan, HL Ke, BX He, DM Ke, CW Klena, JD Zhang, YH AF Li, Baisheng Luo, Jinyan Tan, Hailing Ke, Bixia He, Dongmei Ke, Changwen Klena, John D. Zhang, Yonghui TI Phenotypic and phylogenetic analysis of Vibrio parahaemolyticus isolates recovered from diarrhea cases in Guangdong Province, China SO INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY LA English DT Article DE Vibrio parahaemolyticus; Multilocus sequence typing; Phylogenetic analysis ID STRAINS; O3-K6; HEMOLYSIN; SPREAD; TDH; PCR AB Vibrio parahaemolyticus has emerged as a common foodborne pathogen of global concern. In this study, 108 V. parahaemolyticus isolates that recovered from diarrhea cases (n = 96) and seafood products (n = 12) in Guangdong Province from 2007 to 2011 were characterized by serotyping, tdh and trh toxin gene detection and multilocus sequence typing (MIST). The dominant serotypes from the cases were O3:1(6, O4:K8 and 01: MUT (untyped). However, most isolates recovered from seafood products belonged to other serotypes. None of the isolates carried the trh gene, while the major isolates from the cases were tdh positive. MIST analysis revealed 31 sequence types (STs); 17 STs were unique in this study. eBURST analysis revealed four clonal complexes (CC), The majority of the isolates (n = 58, all from cases and tdh+) were grouped into the CC3, which included O3:K6,O4:K68 and O1:KUT isolates. The CC3 was the most prevalent clonal complex, and all of the CC3 isolates were recovered from clinical cases of geographically diverse origin. As to the CC345, which was completely constituted by O4:K8, was another important clonal complex affecting Guangdong Province. Ongoing surveillance of V. parahaemolyticus in diarrhea patients and seafood products remains a public health priority for Guangdong Province, China. (C) 2015 Elsevier B.V. All rights reserved. C1 [Li, Baisheng; Luo, Jinyan; Tan, Hailing; Ke, Bixia; He, Dongmei; Ke, Changwen; Zhang, Yonghui] Ctr Dis Control & Prevent Guangdong Prov, Shenzhen, Peoples R China. [Luo, Jinyan] Ctr Dis Control & Prevent Nanshan, Shenzhen, Peoples R China. [Klena, John D.] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Global Hlth Protect, Global Dis Detect Branch, Atlanta, GA USA. [Klena, John D.] US Ctr Dis Control & Prevent, Int Emerging Infect Program, Beijing, Peoples R China. RP Zhang, YH (reprint author), Ctr Dis Control & Prevent Guangdong Prov, Shenzhen, Peoples R China. EM zyh@cdcp.org.cn FU Mega-projects of Science and Technology Research of China [2012ZX10004-213]; Guangdong Province Medical Research Foundation [A2014090] FX This work was funded by the Mega-projects of Science and Technology Research of China (No. 2012ZX10004-213) and the Guangdong Province Medical Research Foundation (No. A2014090). NR 14 TC 4 Z9 5 U1 1 U2 11 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-1605 EI 1879-3460 J9 INT J FOOD MICROBIOL JI Int. J. Food Microbiol. PD MAY 4 PY 2015 VL 200 BP 13 EP 17 DI 10.1016/j.ijfoodmicro.2014.12.009 PG 5 WC Food Science & Technology; Microbiology SC Food Science & Technology; Microbiology GA CE7VO UT WOS:000352050200003 PM 25662708 ER PT J AU Annambhotla, P Gurbaxani, B Kuehnert, M Basavaraju, S AF Annambhotla, P. Gurbaxani, B. Kuehnert, M. Basavaraju, S. TI Development of a Risk Assessment Model for HIV Among Increased Risk Deceased Donors With Negative Nucleic Acid Testing SO AMERICAN JOURNAL OF TRANSPLANTATION LA English DT Meeting Abstract CT American Transplant Congress CY MAY 02-06, 2015 CL Philadelphia, PA C1 [Annambhotla, P.; Gurbaxani, B.; Kuehnert, M.; Basavaraju, S.] Ctr Dis Control & Prevent, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1600-6135 EI 1600-6143 J9 AM J TRANSPLANT JI Am. J. Transplant. PD MAY PY 2015 VL 15 SU 3 SI SI MA 73 PG 1 WC Surgery; Transplantation SC Surgery; Transplantation GA DD7SK UT WOS:000370124200020 ER PT J AU Smith, DK Pan, Y Rose, CE Pals, SL Mehta, SH Kirk, GD Herbst, JH AF Smith, Dawn K. Pan, Yi Rose, Charles E. Pals, Sherri L. Mehta, Shruti H. Kirk, Gregory D. Herbst, Jeffrey H. TI A Brief Screening Tool to Assess the Risk of Contracting HIV Infection Among Active Injection Drug Users SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE HIV; IDUs; PrEP; risk; screening ID PRIMARY-CARE; ANTIRETROVIRAL PROPHYLAXIS; PREEXPOSURE PROPHYLAXIS; UNITED-STATES; MEN; PREVENTION; MORTALITY; SEX; SETTINGS; CITIES AB Objective: To incorporate preexposure prophylaxis and other biomedical or intensive behavioral interventions into the care of injection drug users (IDUs), health care providers need validated, rapid, risk screening tools for identifying persons at highest risk of incident HIV infection. Methods: To develop and validate a brief screening tool for assessing the risk of contracting HIV (ARCH), we included behavioral and HIV test data from 1904 initially HIV/uninfected men and women enrolled and followed in the AIDS Linked to the Intravenous Experience prospective cohort study between 1988 and 2008. Using logistic regression analyses with generalized estimating equations, we identified significant predictors of incident HIV infection, then rescaled and summed their regression coefficients to create a risk score. Results: The final logistic regression model included age, engagement in a methadone maintenance program, and a composite injection risk score obtained by counting the number of the following 5 behaviors reported during the past 6 months: injection of heroin, injection of cocaine, sharing a cooker, sharing needles, or visiting a shooting gallery. The area under the receiver operating characteristic curve was 0.720; possible scores on the index ranged from 0 to 100 and a score 46 or greater had a sensitivity of 86.2% and a specificity of 42.5%, appropriate for a screening tool. Discussion: We developed an easy to administer 7-question screening tool with a cutoff that is predictive of incident HIV infection in a large prospective cohort of IDUs in Baltimore. The ARCH-IDUs screening tool can be used to prioritize persons who are injecting illicit drugs for consideration of preexposure prophylaxis and other intensive HIV prevention efforts. C1 [Smith, Dawn K.; Pan, Yi; Rose, Charles E.; Pals, Sherri L.; Herbst, Jeffrey H.] Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent NCH, CDC, Atlanta, GA 30333 USA. [Mehta, Shruti H.; Kirk, Gregory D.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. RP Smith, DK (reprint author), Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV Viral Hepatitis STD & TB Prevent, 1600 Clifton Rd,Mail Stop E-45, Atlanta, GA 30333 USA. EM dsmith1@cdc.gov FU NIAID NIH HHS [K24 AI118591]; NIDA NIH HHS [R01 DA012568, U01 DA036297] NR 34 TC 2 Z9 2 U1 1 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD MAY-JUN PY 2015 VL 9 IS 3 BP 226 EP 232 DI 10.1097/ADM.0000000000000123 PG 7 WC Substance Abuse SC Substance Abuse GA DD1VH UT WOS:000369710200010 PM 25961495 ER PT J AU Wise, ME Bancroft, E Clement, EJ Hathaway, S High, P Kim, M Lutterloh, E Perz, JF Sehulster, LM Tyson, C White-Comstock, MB Montana, B AF Wise, Matthew E. Bancroft, Elizabeth Clement, Ernest J. Hathaway, Susan High, Patricia Kim, Moon Lutterloh, Emily Perz, Joseph F. Sehulster, Lynne M. Tyson, Clara White-Comstock, Mary Beth Montana, Barbara TI Infection Prevention and Control in the Podiatric Medical Setting Challenges to Providing Consistently Safe Care SO JOURNAL OF THE AMERICAN PODIATRIC MEDICAL ASSOCIATION LA English DT Article ID HEPATITIS-C VIRUS; HEALTH-CARE; TRANSMISSION; OUTBREAK; SYRINGES; VIALS; CONTAMINATION AB Unsafe practices are an underestimated contributor to the disease burden of bloodborne viruses. Outbreaks associated with failures in basic infection prevention have been identified in nonhospital settings with increased frequency in the United States during the past 15 years, representing an alarming trend and indicating that the challenge of providing consistently safe care is not always met. As has been the case with most medical specialties, public health investigations by state and local health departments, and the Centers for Disease Control and Prevention, have identified some instances of unsafe practices that have placed podiatric medical patients at risk for viral, bacterial, and fungal infections. All health-care providers, including podiatric physicians, must make infection prevention a priority in any setting in which care is delivered. C1 [Wise, Matthew E.; Perz, Joseph F.; Sehulster, Lynne M.; White-Comstock, Mary Beth] Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. [Bancroft, Elizabeth; Hathaway, Susan; Kim, Moon; Tyson, Clara] Los Angeles Cty Dept Publ Hlth, Acute Communicable Dis Control Program, Los Angeles, CA USA. [Clement, Ernest J.; Lutterloh, Emily] New York State Dept Hlth, Bur Healthcare Associated Infect, Albany, NY USA. [High, Patricia] Ocean Cty Hlth Dept, Clin Serv, Publ Hlth Nursing, Toms River, NJ USA. [Montana, Barbara] New Jersey Dept Hlth, Communicable Dis Serv, Trenton, NJ USA. RP Wise, ME (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,MS A-35, Atlanta, GA 30333 USA. EM cxx4@cdc.gov NR 40 TC 1 Z9 1 U1 0 U2 2 PU AMER PODIATRIC MED ASSOC PI BETHESDA PA 9312 OLD GEORGETOWN ROAD, BETHESDA, MD 20814-1621 USA SN 8750-7315 EI 1930-8264 J9 J AM PODIAT MED ASSN JI J. Am. Podiatr. Med. Assoc. PD MAY-JUN PY 2015 VL 105 IS 3 BP 264 EP 272 PG 9 WC Orthopedics SC Orthopedics GA DA3CZ UT WOS:000367674900011 PM 26146975 ER PT J AU Miller, TL Wilson, FA Pang, JW Beavers, S Hoger, S Sharnprapai, S Pagaoa, M Katz, DJ Weis, SE AF Miller, Thaddeus L. Wilson, Fernando A. Pang, Jenny W. Beavers, Suzanne Hoger, Sally Sharnprapai, Sharon Pagaoa, Melissa Katz, Dolly J. Weis, Stephen E. CA TB Epidemiologic Studies TI Mortality Hazard and Survival After Tuberculosis Treatment SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID NUTRITION EXAMINATION SURVEY; PULMONARY TUBERCULOSIS; UNITED-STATES; FOLLOW-UP; NATIONAL-HEALTH; LUNG-FUNCTION; INFECTION; POPULATION; IMPAIRMENT; THERAPY AB Objectives. We compared mortality among tuberculosis (TB) survivors and a similar population. Methods. We used local health authority records from 3 US sites to identify 3853 persons who completed adequate treatment of TB and 7282 individuals diagnosed with latent TB infection 1993 to 2002. We then retrospectively observed mortality after 6 to 16 years of observation. We ascertained vital status as of December 31, 2008, using the Centers for Disease Control and Prevention's National Death Index. We analyzed mortality rates, hazards, and associations using Cox regression. Results. We traced 11 135 individuals over 119 772 person-years of observation. We found more all-cause deaths (20.7% vs 3.1%) among posttreatment TB patients than among the comparison group, an adjusted average excess of 7.6 deaths per 1000 person-years (8.8 vs 1.2; P <.001). Mortality among posttreatment TB patients varied with observable factors such as race, site of disease, HIV status, and birth country. Conclusions. Fully treated TB is still associated with substantial mortality risk. Cure as currently understood may be insufficient protection against TB-associated mortality in the years after treatment, and TB prevention may be a valuable opportunity to modify this risk. C1 [Miller, Thaddeus L.] Univ N Texas, Hlth Sci Ctr, Dept Hlth Management & Policy, Ft Worth, TX USA. [Weis, Stephen E.] Univ N Texas, Hlth Sci Ctr, Dept Med, Ft Worth, TX USA. [Wilson, Fernando A.] Univ Nebraska Med Ctr, Dept Hlth Serv Res & Adm, Omaha, NE USA. [Pang, Jenny W.] Univ Washington, Sch Publ Hlth, Dept Epidemiol, Seattle, WA 98195 USA. [Beavers, Suzanne; Pagaoa, Melissa; Katz, Dolly J.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Hoger, Sally] Tarleton State Univ, Dept Med Lab Sci, Ft Worth, TX USA. [Sharnprapai, Sharon] Massachusetts Dept Publ Hlth, Boston, MA USA. RP Miller, TL (reprint author), UNTHSC, Sch Publ Hlth, Dept Hlth Management & Policy, 3500 Camp Bowie Blvd, Ft Worth, TX 76107 USA. EM thaddeus.miller@unthsc.edu FU US Centers for Disease Control and Prevention's Division of Tuberculosis Elimination (DTBE) and its Tuberculosis Epidemiologic Studies Consortium FX The authors gratefully acknowledge the financial, intellectual, and philosophical support of the US Centers for Disease Control and Prevention's Division of Tuberculosis Elimination (DTBE) and its Tuberculosis Epidemiologic Studies Consortium, which made this work possible. NR 44 TC 3 Z9 3 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2015 VL 105 IS 5 BP 930 EP 937 DI 10.2105/AJPH.2014.302431 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN3AN UT WOS:000358295600036 PM 25790407 ER PT J AU Fountain, C Zhang, YJ Kissin, DM Schieve, LA Jamieson, DJ Rice, C Bearman, P AF Fountain, Christine Zhang, Yujia Kissin, Dmitry M. Schieve, Laura A. Jamieson, Denise J. Rice, Catherine Bearman, Peter TI Association Between Assisted Reproductive Technology Conception and Autism in California, 1997-2007 SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID IN-VITRO FERTILIZATION; DE-NOVO MUTATIONS; SINGLE-EMBRYO-TRANSFER; LOW-BIRTH-WEIGHT; SPECTRUM DISORDERS; CHILDREN BORN; SOCIOECONOMIC-STATUS; PERINATAL OUTCOMES; INFANTILE-AUTISM; CEREBRAL-PALSY AB Objectives. We assessed the association between assisted reproductive technology (ART) and diagnosed autistic disorder in a population-based sample of California births. Methods. We performed an observational cohort study using linked records from the California Birth Master Files for 1997 through 2007, the California Department of Developmental Services autismcaseload for 1997 through 2011, and the Centers for Disease Control and Prevention's National ART Surveillance System for live births in 1997 through 2007. Participants were all 5 926 251 live births, including 48 865 ART-originated infants and 32 922 cases of autism diagnosed by the Department of Developmental Services. We compared births originated using ART with births originated without ART for incidence of autism. Results. In the full population, the incidence of diagnosed autism was twice as high for ART as non-ART births. The association was diminished by excluding mothers unlikely to use ART; adjustment for demographic and adverse prenatal and perinatal outcomes reduced the association substantially, although statistical significance persisted for mothers aged 20 to 34 years. Conclusions. The association between ART and autism is primarily explained by adverse prenatal and perinatal outcomes and multiple births. C1 [Fountain, Christine] Fordham Univ, Dept Sociol & Anthropol, New York, NY 10023 USA. [Zhang, Yujia; Kissin, Dmitry M.; Jamieson, Denise J.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Schieve, Laura A.; Rice, Catherine] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. [Bearman, Peter] Columbia Univ, Interdisciplinary Ctr Innovat Theory & Empir, New York, NY USA. RP Bearman, P (reprint author), Columbia Univ, Dept Sociol, 606 West 122nd St,Knox Hall,MC 9649, New York, NY 10027 USA. EM psb17@columbia.edu RI Rice, Catherine/D-6305-2016 FU National Institutes of Health [1 DP1 OD003635-01]; National Institutes of Mental Health [R21MH096122] FX This research is supported by the National Institutes of Health Director's Pioneer Award program (grant 1 DP1 OD003635-01) and the National Institutes of Mental Health (award R21MH096122). NR 50 TC 7 Z9 7 U1 2 U2 8 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2015 VL 105 IS 5 BP 963 EP 971 DI 10.2105/AJPH.2014.302383 PG 9 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN3AN UT WOS:000358295600040 PM 25790396 ER PT J AU Doll, MK Rosen, JB Bialek, SR Szeto, H Zimmerman, CM AF Doll, Margaret K. Rosen, Jennifer B. Bialek, Stephanie R. Szeto, Hiram Zimmerman, Christopher M. TI An Evaluation of Voluntary 2-Dose Varicella Vaccination Coverage in New York City Public Schools SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID UNITED-STATES; IMMUNIZATION COVERAGE; INTERVAL ESTIMATION; ETHNIC DISPARITIES; DAY-CARE; CHILDREN; KINDERGARTEN; ENTRY; TIME; REQUIREMENT AB Objectives. We assessed coverage for 2-dose varicella vaccination, which is not required for school entry, among New York City public school students and examined characteristics associated with receipt of 2 doses. Methods. We measured receipt of either at least 1 or 2 doses of varicella vaccine among students aged 4 years and older in a sample of 336 public schools (n = 223 864 students) during the 2010 to 2011 school year. Data came from merged student vaccination records from 2 administrative data systems. We conducted multivariable regression to assess associations of age, gender, race/ethnicity, and school location with 2-dose prevalence. Results. Coverage with at least 1 varicella dose was 96.2% (95% confidence interval [CI] = 96.2%, 96.3%); coverage with at least 2 doses was 64.8% (95% CI = 64.6%, 64.9%). Increasing student age, non-Hispanic White race/ethnicity, and attendance at school in Staten Island were associated with lower 2-dose coverage. Conclusions. A 2-dose varicella vaccine requirement for school entry would likely improve 2-dose coverage, eliminate coverage disparities, and prevent disease. C1 [Doll, Margaret K.; Rosen, Jennifer B.; Zimmerman, Christopher M.] Bur Immunizat, New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. [Szeto, Hiram] Bur Sch Hlth, New York City Dept Hlth & Mental Hyg, Queens, NY 11101 USA. [Bialek, Stephanie R.] Ctr Dis Control & Prevent, Natl Ctr Immunizat & Resp Dis, Atlanta, GA USA. RP Rosen, JB (reprint author), Bur Immunizat, New York City Dept Hlth & Mental Hyg, 42-09 28th St,FL 5, Queens, NY 11101 USA. EM jrosen4@health.nyc.gov OI Doll, Margaret/0000-0002-2125-7820 FU CDC; American Recovery and Reinvestment Act FX This research was funded by a grant from the CDC, with funding from the American Recovery and Reinvestment Act. NR 59 TC 0 Z9 0 U1 0 U2 3 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2015 VL 105 IS 5 BP 972 EP 979 DI 10.2105/AJPH.2014.302229 PG 8 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN3AN UT WOS:000358295600041 PM 25521904 ER PT J AU Housey, M DeGuire, P Lyon-Callo, S Wang, L Marder, W McCune, WJ Helmick, CG Gordon, C Dhar, JP Leisen, J Somers, EC AF Housey, Michelle DeGuire, Peter Lyon-Callo, Sarah Wang, Lu Marder, Wendy McCune, W. Joseph Helmick, Charles G. Gordon, Caroline Dhar, J. Patricia Leisen, James Somers, Emily C. TI Incidence and Prevalence of Systemic Lupus Erythematosus Among Arab and Chaldean Americans in Southeastern Michigan: The Michigan Lupus Epidemiology and Surveillance Program SO AMERICAN JOURNAL OF PUBLIC HEALTH LA English DT Article ID REVISED CRITERIA; CLASSIFICATION; HEALTH AB Objectives. We assessed the burden of systemic lupus erythematosus (SLE) among Arab and Chaldean Americans residing in southeast Michigan. Methods. For those meeting SLE criteria from the Michigan Lupus Epidemiology and Surveillance Registry, we determined Arab or Chaldean ethnicity by links with demographic data from birth certificates and with a database of Arab and Chaldean names. We compared prevalence and incidence of SLE for Arab and Chaldean Americans with estimates for non-Arab and non-Chaldean American Whites and Blacks. Results. We classified 54 individuals with SLE as Arab and Chaldean Americans. The age-adjusted incidence and prevalence estimates for Arab and Chaldean Americans were 7.6 and 62.6 per 100 000, respectively. Arab and Chaldean Americans had a 2.1-fold excess SLE incidence compared with non-Arab and non-Chaldean American Whites. Arab and Chaldean American women had both significantly higher incidence rates (5.0-fold increase) and prevalence estimates (7.4-fold increase) than did Arab and Chaldean American men. Conclusions. Recognizing that Arab and Chaldean Americans experience different disease burdens from Whites is a first step toward earlier diagnosis and designing targeted interventions. Better methods of assigning ethnicity would improve research in this population. C1 [Housey, Michelle; DeGuire, Peter; Lyon-Callo, Sarah] Michigan Dept Community Hlth, Lansing, MI USA. [Wang, Lu] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA. [Marder, Wendy; McCune, W. Joseph; Somers, Emily C.] Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA. [Helmick, Charles G.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Gordon, Caroline] Univ Birmingham, Birmingham, W Midlands, England. [Dhar, J. Patricia] Cent Michigan Univ, Coll Med, Mt Pleasant, MI 48859 USA. [Leisen, James] Henry Ford Hlth Syst, Div Rheumatol, Detroit, MI USA. RP Housey, M (reprint author), NCRC, 2800 Plymouth Rd,Bldg 16 G000S-12, Ann Arbor, MI 48109 USA. EM mhousey@med.umich.edu OI Somers, Emily/0000-0001-5234-3978 FU Centers for Disease Control and Prevention ([CDC]) [5U38HM000414-5, U58/CCU522826, U58/DP001441]; National Institutes of Health ([NIH]) [UL1-RR-024986]; NIH, National Institute of Environmental Health Sciences [K01 ES019909]; Arthritis Foundation; NIH [BIRCWH K12HD001438] FX This work was supported by an appointment to the Applied Epidemiology Fellowship Program administered by the Council of State and Territorial Epidemiologists; the Centers for Disease Control and Prevention ([CDC]; cooperative agreements 5U38HM000414-5, U58/CCU522826, U58/DP001441); and the National Institutes of Health ([NIH] award UL1-RR-024986). E. C. Somers was supported in part by the NIH, National Institute of Environmental Health Sciences (award K01 ES019909) and an Arthritis Foundation New Investigator award. W. Marder was supported in part by the NIH (award BIRCWH K12HD001438). NR 26 TC 3 Z9 3 U1 0 U2 2 PU AMER PUBLIC HEALTH ASSOC INC PI WASHINGTON PA 800 I STREET, NW, WASHINGTON, DC 20001-3710 USA SN 0090-0036 EI 1541-0048 J9 AM J PUBLIC HEALTH JI Am. J. Public Health PD MAY PY 2015 VL 105 IS 5 BP E74 EP E79 DI 10.2105/AJPH.2014.302423 PG 6 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CN3AN UT WOS:000358295600018 PM 25790387 ER PT J AU Brault, AC Fang, Y Reisen, WK AF Brault, Aaron C. Fang, Ying Reisen, William K. TI Multiplex qRT-PCR for the Detection of Western Equine Encephalomyelitis, St. Louis Encephalitis, and West Nile Viral RNA in Mosquito Pools (Diptera: Culicidae) SO JOURNAL OF MEDICAL ENTOMOLOGY LA English DT Article DE multiplex; surveillance; West Nile virus; western equine encephalitis virus; St. Louis encephalitis virus ID SAN-JOAQUIN VALLEY; UNITED-STATES; AMPLIFICATION ASSAYS; VIRUS TRANSMISSION; RAPID DETECTION; CALIFORNIA; EASTERN; PERSISTENCE; EPIDEMIC; ETIOLOGY AB Following the introduction of West Nile virus into California during the summer of 2003, public health and vector control programs expanded surveillance efforts and were in need of diagnostics capable of rapid, sensitive, and specific detection of arbovirus infections of mosquitoes to inform decision support for intervention. Development of a multiplex TaqMan or real-time semiquantitative reverse transcription polymerase chain reaction (RT-PCR) assay in which three virus specific primer-probe sets were used in the same reaction is described herein for the detection of western equine encephalomyelitis, St. Louis encephalitis and West Nile viral RNA. Laboratory validation and field data from 10 transmission seasons are reported. The comparative sensitivity and specificity of this multiplex assay to singleplex RT-PCR as well as an antigen detection (rapid analyte measurement platform) and standard plaque assays indicate this assay to be rapid and useful in providing mosquito infection data to estimate outbreak risk. C1 [Brault, Aaron C.; Fang, Ying; Reisen, William K.] Univ Calif Davis, Sch Vet Med, Ctr Vectorborne Dis, Davis, CA 95616 USA. [Brault, Aaron C.; Fang, Ying; Reisen, William K.] Univ Calif Davis, Sch Vet Med, Dept Pathol Microbiol & Immunol, Davis, CA 95616 USA. [Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO 80512 USA. RP Reisen, WK (reprint author), Univ Calif Davis, Sch Vet Med, Ctr Vectorborne Dis, Davis, CA 95616 USA. EM wkreisen@ucdavis.edu FU California Mosquito Research Program; Pacific Southwest NIH Regional Centers for Excellence (PSWRCE); National Institute of Allergy and Infectious Diseases, National Institute of Health [RO1AI-055607]; Epidemiology and Laboratory Capacity funds from the Centers for Disease Control and Prevention to the California Department of Public Health FX This work was supported by grants from the California Mosquito Research Program, as well as the Pacific Southwest NIH Regional Centers for Excellence (PSWRCE), National Institute of Allergy and Infectious Diseases, National Institute of Health grant RO1AI-055607, and Epidemiology and Laboratory Capacity funds from the Centers for Disease Control and Prevention to the California Department of Public Health. We thank the Mosquito and Vector Control Districts within the state of California for providing speciated mosquito pools that were used for standardization and testing of these assay systems. Robert Chiles (former CVEC Laboratory Manager), Sandra Garcia, Emily N. Green, Marzi Shafii, Sharon Clark, Siranoosh Ashtari, Nadira Chouicha, Helen Lu, Maureen Dannen, Amy Roth, Keira Simmons, and Andrew Chow provided technical assistance. NR 35 TC 4 Z9 4 U1 3 U2 6 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0022-2585 EI 1938-2928 J9 J MED ENTOMOL JI J. Med. Entomol. PD MAY PY 2015 VL 52 IS 3 BP 491 EP 499 DI 10.1093/jme/tjv021 PG 9 WC Entomology; Veterinary Sciences SC Entomology; Veterinary Sciences GA CL1RC UT WOS:000356720600026 PM 26334826 ER PT J AU Johnston, LG McFarland, W Sabin, ML Prybylski, D Sabin, K Baral, S Kim, AA Raymond, HF AF Johnston, Lisa G. McFarland, Willi Sabin, Miriam Lewis Prybylski, Dimitri Sabin, Keith Baral, Stefan Kim, Andrea A. Raymond, H. Fisher TI Measuring self-reported HIV status in bio-behavioural surveys SO BULLETIN OF THE WORLD HEALTH ORGANIZATION LA English DT Editorial Material C1 [Johnston, Lisa G.] Univ Calif San Francisco, Global Hlth Sci, San Francisco, CA 94158 USA. [McFarland, Willi; Raymond, H. Fisher] San Francisco Dept Publ Hlth, San Francisco, CA USA. [Sabin, Miriam Lewis] Global Fund Fight AIDS TB & Malaria, Geneva, Switzerland. [Prybylski, Dimitri] US Ctr Dis Control & Prevent, Global AIDS Program Asia Reg Off, Nonthaburi, Thailand. [Sabin, Keith] Joint United Nations Programme HIV AIDS, Geneva, Switzerland. [Baral, Stefan] Johns Hopkins Sch Publ Hlth, Ctr Publ Hlth & Human Rights, Dept Epidemiol, Baltimore, MD USA. [Kim, Andrea A.] US Ctr Dis Control & Prevent, Div Global HIV AIDS, Atlanta, GA USA. RP Johnston, LG (reprint author), Univ Calif San Francisco, Global Hlth Sci, 550-16th St 3rd Floor, San Francisco, CA 94158 USA. EM lsjohnston.global@gmail.com OI Sabin, Keith/0000-0002-2290-8621 NR 0 TC 1 Z9 1 U1 0 U2 0 PU WORLD HEALTH ORGANIZATION PI GENEVA 27 PA MARKETING AND DISSEMINATION, CH-1211 GENEVA 27, SWITZERLAND SN 0042-9686 EI 1564-0604 J9 B WORLD HEALTH ORGAN JI Bull. World Health Organ. PD MAY PY 2015 VL 93 IS 5 BP 287 EP 287 DI 10.2471/BLT.15.153064 PG 1 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CL0OB UT WOS:000356640900002 PM 26229196 ER PT J AU Stone, ND AF Stone, Nimalie D. TI Revisiting Standard Precautions to Reduce Antimicrobial Resistance in Nursing Homes SO JAMA INTERNAL MEDICINE LA English DT Editorial Material ID FACILITIES C1 Ctr Dis Control & Prevent, Div Healthcare Qual Promot, Atlanta, GA 30333 USA. RP Stone, ND (reprint author), Ctr Dis Control & Prevent, Div Healthcare Qual Promot, 1600 Clifton Rd NE,Bldg 16,Mail Stop A-31, Atlanta, GA 30333 USA. EM nstone@cdc.gov NR 7 TC 2 Z9 2 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD MAY PY 2015 VL 175 IS 5 BP 723 EP 724 DI 10.1001/jamainternmed.2015.137 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA CK4FQ UT WOS:000356178400009 PM 25774622 ER PT J AU Zhao, SH Mukherjee, S Chen, YS Li, C Young, S Warren, M Abbott, J Friedman, S Kabera, C Karlsson, M McDermott, PF AF Zhao, Shaohua Mukherjee, Sampa Chen, Yuansha Li, Cong Young, Shenia Warren, Melissa Abbott, Jason Friedman, Sharon Kabera, Claudine Karlsson, Maria McDermott, Patrick F. TI Novel gentamicin resistance genes in Campylobacter isolated from humans and retail meats in the USA SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE Campylobacter; gentamicin resistance; NARMS; PCR; WGS ID AMINOGLYCOSIDE RESISTANCE; UNITED-STATES; ANTIMICROBIAL RESISTANCE; ENTEROCOCCUS-FAECALIS; JEJUNI; IDENTIFICATION; ANTIBIOTICS; DIVERSITY; GENETICS; PLASMID AB Objectives: To understand the molecular epidemiology of gentamicin-resistant Campylobacter and investigate aminoglycoside resistance mechanisms. Methods: One-hundred-and-fifty-one gentamicin-resistant Campylobacter isolates from humans (n = 38 Campylobacter jejuni; n = 41, Campylobacter coli) and retail chickens (n = 72 C. coli), were screened for the presence of gentamicin resistance genes by PCR and subtyped using PFGE. A subset of the isolates (n = 41) was analysed using WGS. Results: Nine variants of gentamicin resistance genes were identified: aph(2 ''')-Ib, Ic, Ig, If, If1, If(3), Ih, aac(6')-Ie/aph(2 '')-Ia and aac(6')-Ie/aph(2 '')-If(2). The aph(2 '')-Ib, Ic, If1, If(3), Ih and aac(6')-Ie/aph(2 '')-If(2) variants were identified for the first time in Campylobacter. Human isolates showed more diverse aminoglycoside resistance genes than did retail chicken isolates, in which only aph(2 '')-Ic and -Ig were identified. The aph(2 '')-Ig gene was only gene shared by C. coli isolates from human (n = 27) and retail chicken (n = 69). These isolates displayed the same resistance profile and similar PFGE patterns, suggesting that contaminated retail chicken was probably the source of human C. coli infections. Human isolates were genetically diverse and generally more resistant than the retail chicken isolates. The most frequent co-resistance was to tetracycline (78/79, 98.7%), followed by ciprofloxacin/nalidixic acid (46/79, 58.2%), erythromycin and azithromycin (36/79, 45.6%), telithromycin (32/79, 40.5%) and clindamycin (18/79, 22.8%). All human and retail meat isolates were susceptible to florfenicol. Conclusions: This study demonstrated that several new aminoglycoside resistance genes underlie the recent emergence of gentamicin-resistant Campylobacter, and that, in addition to contaminated retail chicken, other sources have also contributed to gentamicin-resistant Campylobacter infections in humans. C1 [Zhao, Shaohua; Mukherjee, Sampa; Chen, Yuansha; Li, Cong; Young, Shenia; Warren, Melissa; Abbott, Jason; Friedman, Sharon; Kabera, Claudine; McDermott, Patrick F.] US FDA, Div Anim & Food Microbiol, Res Off, Ctr Vet Med, Laurel, MD USA. [Karlsson, Maria] Ctr Dis Control & Prevent, Div Foodborne Waterborne & Environm Dis, Atlanta, GA USA. RP Zhao, SH (reprint author), US FDA, Div Anim & Food Microbiol, Res Off, Ctr Vet Med, Laurel, MD USA. EM shaohua.zhao@fda.hhs.gov NR 32 TC 3 Z9 3 U1 3 U2 8 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD MAY PY 2015 VL 70 IS 5 BP 1314 EP 1321 DI 10.1093/jac/dkv001 PG 8 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA CK0YW UT WOS:000355932800007 PM 25645207 ER PT J AU Massud, I Martin, A Dinh, C Mitchell, J Jenkins, L Heneine, W Pau, CP Garcia-Lerma, JG AF Massud, Ivana Martin, Amy Dinh, Chuong Mitchell, James Jenkins, Leecresia Heneine, Walid Pau, Chou-Pong Garcia-Lerma, J. Gerardo TI Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques SO JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY LA English DT Article DE integrase inhibitors; non-human primates; antiviral activity ID MULTIPLE-DOSE PHARMACOKINETICS; HIV-NEGATIVE WOMEN; IMMUNODEFICIENCY-VIRUS; GENITAL-TRACT; ANTIRETROVIRAL PROPHYLAXIS; PREEXPOSURE PROPHYLAXIS; TREATMENT-NAIVE; INTEGRASE; PREVENTION; TRANSMISSION AB Objectives: Pharmacokinetic studies in animal models are important for assessing the prophylactic potential of antiretroviral drugs for HIV prevention. This study sought to identify clinically relevant doses of the marketed integrase inhibitors raltegravir, elvitegravir and dolutegravir in macaques and investigate drug penetration and antiviral activity in mucosal secretions. Methods: Macaques received one oral dose of raltegravir, elvitegravir or dolutegravir alone or in combination with emtricitabine and tenofovir disoproxil fumarate followed by drug level measurements in blood and rectal and vaginal secretions. Antiviral activity was investigated in TZM-bl cells exposed to SHIV162p3 in the presence of rectal secretions collected from treated animals. Results: Plasma drug concentrations with 50 mg/kg raltegravir or elvitegravir were within the range seen in humans receiving 400-800 mg of raltegravir or 800 mg of unboosted elvitegravir but lower than with 150 mg of elvitegravir boosted with cobicistat. AUC(0-24) values for dolutegravir increased proportionally with the dose, with a calculated human-equivalent dose of 20 mg/kg. Elvitegravir showed the highest penetration in rectal and vaginal fluids despite the absence of pharmacological boosting, followed by raltegravir and dolutegravir. Rectal secretions collected at 24 h from treated macaques blocked infection of TZM-bl cells by 50% at dilutions of 1/1000 (raltegravir), 1/800 (dolutegravir) and >1/30000 (elvitegravir). Conclusions: We defined macaque doses of HIV integrase inhibitors that recapitulate human clinical doses, which will facilitate efficacy and dose escalation studies in macaques. High and sustained drug concentrations and activity in mucosal secretions suggest that integrase inhibitors are promising candidates for HIV prevention. C1 [Massud, Ivana; Martin, Amy; Dinh, Chuong; Mitchell, James; Jenkins, Leecresia; Heneine, Walid; Pau, Chou-Pong; Garcia-Lerma, J. Gerardo] Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30329 USA. RP Garcia-Lerma, JG (reprint author), Ctr Dis Control & Prevent, Branch Lab, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, 1600 Clifton Rd, Atlanta, GA 30329 USA. EM ggarcia-lerma@cdc.gov FU CDC [Y1-AI-0681-02]; NIH [Y1-AI-0681-02] FX This work was partially supported by Interagency Agreement Y1-AI-0681-02 between CDC and NIH. NR 41 TC 6 Z9 6 U1 1 U2 6 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0305-7453 EI 1460-2091 J9 J ANTIMICROB CHEMOTH JI J. Antimicrob. Chemother. PD MAY PY 2015 VL 70 IS 5 BP 1473 EP 1481 DI 10.1093/jac/dku556 PG 9 WC Infectious Diseases; Microbiology; Pharmacology & Pharmacy SC Infectious Diseases; Microbiology; Pharmacology & Pharmacy GA CK0YW UT WOS:000355932800025 PM 25630643 ER PT J AU Pandey, JP Kistner-Griffin, E Radwan, FF Kaur, N Namboodiri, AM Black, L Butler, MA Carreon, T Ruder, AM AF Pandey, Janardan P. Kistner-Griffin, Emily Radwan, Faisal F. Kaur, Navtej Namboodiri, Aryan M. Black, Laurel Butler, Mary Ann Carreon, Tania Ruder, Avima M. TI Endogenous antibody responsiveness to epidermal growth factor receptor is associated with immunoglobulin allotypes and overall survival of patients with glioblastoma SO NEURO-ONCOLOGY LA English DT Article DE antibody; EGFR; EGFRvIII; glioblastoma; GM allotypes ID HUMORAL IMMUNITY; PROSTATE-CANCER; BREAST-CANCER; GM ALLOTYPES; FC; RESPONSES; EGFRVIII; ANTIGEN; IGG; POLYMORPHISMS AB Background. Immunoglobulin gamma marker (GM) and kappa marker (KM) allotypes, hereditary antigenic determinants of gamma and kappa chains, respectively, have been shown to be associated with immunity to a variety of self and nonself antigens, but their possible contribution to immunity to the tumor-associated antigens epidermal growth factor receptor (EGFR) and EGFR variant (v)III has not been evaluated. The aim of the present investigation was to determine whether the interindividual variation in endogenous antibody responsiveness to EGFR and EGFRvIII is associated with particular GM, KM, and Fc gamma receptor (Fc gamma R) genotypes and whether antibody levels were associated with the overall survival of patients with glioblastoma. Methods. A total of 126 Caucasian participants with glioblastoma were genotyped for several GM, KM, and Fc gamma R alleles and characterized for IgG antibodies to EGFR and EGFRvIII antigens. Results. The anti-EGFR antibody levels associated with GM 3/3 homozygotes and GM 3/17 heterozygotes were similar (15.9 vs 16.4 arbitrary units [AU]/mu L) and significantly lower than those associated with GM 17/17 homozygotes (19.6 AU/mu L; nominal P = .007). Participants homozygous for the GM 21 allele also had significantly higher levels of anti-EGFR antibodies than GM 5/5 homozygotes and GM 5/21 heterozygotes (20.1 vs 16.0 and 16.3 AU/mu L; nominal P = .005). Similar associations were found with immune responsiveness to EGFRvIII. Higher anti-EGFR and anti-EGFRvIII antibody levels were associated with enhanced overall survival (16 vs 11 mo, nominal P = .038 and 20 vs 11 mo, nominal P = .004, respectively). Conclusions. GM allotypes contribute to humoral immunity to EGFR in glioblastoma. C1 [Pandey, Janardan P.; Radwan, Faisal F.; Kaur, Navtej; Namboodiri, Aryan M.; Black, Laurel] Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Kistner-Griffin, Emily] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA. [Butler, Mary Ann; Carreon, Tania; Ruder, Avima M.] NIOSH, Ctr Dis Control & Prevent, Cincinnati, OH 45226 USA. RP Pandey, JP (reprint author), Med Univ S Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. EM pandeyj@musc.edu FU National Institute of Neurological Disorders and Stroke [NS078545]; National Institute for Occupational Safety and Health FX This work was supported in part by the National Institute of Neurological Disorders and Stroke (NS078545) and the National Institute for Occupational Safety and Health. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the National Institute for Occupational Safety and Health. NR 35 TC 1 Z9 1 U1 0 U2 1 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 1522-8517 EI 1523-5866 J9 NEURO-ONCOLOGY JI Neuro-Oncology PD MAY PY 2015 VL 17 IS 5 BP 678 EP 684 DI 10.1093/neuonc/nou298 PG 7 WC Oncology; Clinical Neurology SC Oncology; Neurosciences & Neurology GA CK5KO UT WOS:000356263100008 PM 25326496 ER PT J AU Kalb, SR Baudys, J Wang, DX Barr, JR AF Kalb, Suzanne R. Baudys, Jakub Wang, Dongxia Barr, John R. TI Recommended Mass Spectrometry-Based Strategies to Identify Botulinum Neurotoxin-Containing Samples SO TOXINS LA English DT Article ID NEUROTRANSMITTER RELEASE; ENDOPEP-MS; SEROTYPE-A; SNAP-25; CLEAVES; PROTEIN; BOND; VAMP/SYNAPTOBREVIN; DIFFERENTIATION; PROTEOLYSIS AB Botulinum neurotoxins (BoNTs) cause the disease called botulism, which can be lethal. BoNTs are proteins secreted by some species of clostridia and are known to cause paralysis by interfering with nerve impulse transmission. Although the human lethal dose of BoNT is not accurately known, it is estimated to be between 0.1 mu g to 70 mu g, so it is important to enable detection of small amounts of these toxins. Our laboratory previously reported on the development of Endopep-MS, a mass-spectrometric ‑based endopeptidase method to detect, differentiate, and quantify BoNT immunoaffinity purified from complex matrices. In this work, we describe the application of Endopep-MS for the analysis of thirteen blinded samples supplied as part of the EQuATox proficiency test. This method successfully identified the presence or absence of BoNT in all thirteen samples and was able to successfully differentiate the serotype of BoNT present in the samples, which included matrices such as buffer, milk, meat extract, and serum. Furthermore, the method yielded quantitative results which had z-scores in the range of -3 to +3 for quantification of BoNT/A containing samples. These results indicate that Endopep-MS is an excellent technique for detection, differentiation, and quantification of BoNT in complex matrices. C1 [Kalb, Suzanne R.; Baudys, Jakub; Wang, Dongxia; Barr, John R.] Ctr Dis Control & Prevent, Atlanta, GA 30341 USA. RP Barr, JR (reprint author), Ctr Dis Control & Prevent, 4770 Buford Hwy NE, Atlanta, GA 30341 USA. EM skalb@cdc.gov; jbaudys@cdc.gov; dov2@cdc.gov; jbarr@cdc.gov OI Kalb, Suzanne/0000-0002-8067-136X NR 34 TC 10 Z9 10 U1 2 U2 9 PU MDPI AG PI BASEL PA POSTFACH, CH-4005 BASEL, SWITZERLAND SN 2072-6651 J9 TOXINS JI Toxins PD MAY PY 2015 VL 7 IS 5 BP 1765 EP 1778 DI 10.3390/toxins7051765 PG 14 WC Toxicology SC Toxicology GA CK5CU UT WOS:000356240600020 PM 25996606 ER PT J AU Vagi, KJ Olsen, EO Basile, KC Vivolo-Kantor, AM AF Vagi, Kevin J. Olsen, Emily O'Malley Basile, Kathleen C. Vivolo-Kantor, Alana M. TI Teen Dating Violence (Physical and Sexual) Among US High School Students Findings From the 2013 National Youth Risk Behavior Survey SO JAMA PEDIATRICS LA English DT Article ID SUBSTANCE USE; UNITED-STATES; SAFE DATES; ADOLESCENT; VICTIMIZATION; PERPETRATION; ABUSE; SURVEILLANCE; PREVALENCE; HEALTH AB IMPORTANCE National estimates of teen dating violence (TDV) reveal high rates of victimization among high school populations. The Centers for Disease Control and Prevention's national Youth Risk Behavior Survey has provided often-cited estimates of physical TDV since 1999. In 2013, revisions were made to the physical TDV question to capture more serious forms of physical TDV and to screen out students who did not date. An additional question was added to assess sexual TDV. OBJECTIVES To describe the content of new physical and sexual TDV victimization questions first administered in the 2013 national Youth Risk Behavior Survey, to share data on the prevalence and frequency of TDV (including the first-ever published overall "both physical and sexual TDV" and "any TDV" national estimates using these new questions), and to assess associations of TDV experience with health-risk behaviors. DESIGN, SETTING, AND PARTICIPANTS Secondary data analysis of a cross-sectional survey of 9900 students who dated, from a nationally representative sample of US high school students, using the 2013 national Youth Risk Behavior Survey. MAIN OUTCOMES AND MEASURES Two survey questions separately assessed physical and sexual TDV; this analysis combined them to create a 4-level TDV measure and a 2-level TDV measure. The 4-level TDV measure includes "physical TDV only," "sexual TDV only," "both physical and sexual TDV," and "none." The 2-level TDV measure includes "any TDV" (either or both physical and sexual TDV) and "none." Sex-stratified bivariate and multivariable analyses assessed associations between TDV and health-risk behaviors. RESULTS In 2013, among students who dated, 20.9% of female students (95% CI, 19.0%-23.0%) and 10.4% of male students (95% CI, 9.0%-11.7%) experienced some form of TDV during the 12 months before the survey. Female students had a higher prevalence than male students of physical TDV only, sexual TDV only, both physical and sexual TDV, and any TDV. All health-risk behaviors were most prevalent among students who experienced both forms of TDV and were least prevalent among students who experienced none (all P < .001). CONCLUSIONS AND RELEVANCE The 2013 TDV questions allowed for new prevalence estimates of TDV to be established that represent a more complete measure of TDV and are useful in determining associations with health-risk behaviors among youth exposed to these different forms of TDV. C1 [Vagi, Kevin J.; Olsen, Emily O'Malley; Basile, Kathleen C.; Vivolo-Kantor, Alana M.] Ctr Dis Control & Prevent, Div Violence Prevent, Atlanta, GA 30341 USA. RP Vagi, KJ (reprint author), Ctr Dis Control & Prevent, Div Violence Prevent, 4770 Buford Hwy NE,MS F-63, Atlanta, GA 30341 USA. EM kvagi@cdc.gov NR 35 TC 23 Z9 24 U1 2 U2 19 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6203 EI 2168-6211 J9 JAMA PEDIATR JI JAMA Pediatr. PD MAY PY 2015 VL 169 IS 5 BP 474 EP 482 DI 10.1001/jamapediatrics.2014.3577 PG 9 WC Pediatrics SC Pediatrics GA CJ8EX UT WOS:000355734000017 PM 25730143 ER PT J AU Alroy, KA Huang, C Gilman, RH Quispe-Machaca, VR Marks, MA Ancca-Juarez, J Hillyard, M Verastegui, M Sanchez, G Cabrera, L Vidal, E Billig, EMW Cama, VA Naquira, C Bern, C Levy, MZ AF Alroy, Karen A. Huang, Christine Gilman, Robert H. Quispe-Machaca, Victor R. Marks, Morgan A. Ancca-Juarez, Jenny Hillyard, Miranda Verastegui, Manuela Sanchez, Gerardo Cabrera, Lilia Vidal, Elisa Billig, Erica M. W. Cama, Vitaliano A. Naquira, Cesar Bern, Caryn Levy, Michael Z. CA Working Grp Chagas Dis Peru TI Prevalence and Transmission of Trypanosoma cruzi in People of Rural Communities of the High Jungle of Northern Peru SO PLOS NEGLECTED TROPICAL DISEASES LA English DT Article ID TARGETED SCREENING STRATEGIES; CHAGAS-DISEASE TRANSMISSION; EXCRETED-SECRETED ANTIGENS; POLYMERASE-CHAIN-REACTION; TRIATOMA-INFESTANS; INFECTION; DOGS; AREQUIPA; ARGENTINA; VECTORS AB Background Vector-borne transmission of Trypanosoma cruzi is seen exclusively in the Americas where an estimated 8 million people are infected with the parasite. Significant research in southern Peru has been conducted to understand T. cruzi infection and vector control, however, much less is known about the burden of infection and epidemiology in northern Peru. Methodology A cross-sectional study was conducted to estimate the seroprevalence of T. cruzi infection in humans (n=611) and domestic animals [dogs (n=106) and guinea pigs (n=206)] in communities of Cutervo Province, Peru. Sampling and diagnostic strategies differed according to species. An entomological household study (n=208) was conducted to identify the triatomine burden and species composition, as well as the prevalence of T. cruzi in vectors. Electrocardiograms (EKG) were performed on a subset of participants (n=90 T. cruzi infected participants and 170 age and sex-matched controls). The seroprevalence of T. cruzi among humans, dogs, and guinea pigs was 14.9%(95% CI: 12.2 -18.0%), 19.8% (95% CI: 12.728.7%) and 3.3% (95% CI: 1.4 -6.9%) respectively. In one community, the prevalence of T. cruzi infection was 17.2% (95% CI: 9.6 -24.7%) among participants < 15 years, suggesting recent transmission. Increasing age, positive triatomines in a participant's house, and ownership of a T. cruzi positive guinea pig were independent correlates of T. cruzi infection. Only one species of triatomine was found, Panstrongylus lignarius, formerly P. herreri. Approximately forty percent (39.9%, 95% CI: 33.2 - 46.9%) of surveyed households were infested with this vector and 14.9% (95% CI: 10.4 - 20.5%) had at least one triatomine positive for T. cruzi. The cardiac abnormality of right bundle branch block was rare, but only identified in seropositive individuals. Conclusions Our research documents a substantial prevalence of T. cruzi infection in Cutervo and highlights a need for greater attention and vector control efforts in northern Peru. C1 [Alroy, Karen A.] Natl Sci Fdn, AAAS Sci & Technol Policy Fellow, Div Environm Biol, Arlington, VA 22230 USA. [Alroy, Karen A.; Gilman, Robert H.; Marks, Morgan A.; Hillyard, Miranda; Vidal, Elisa] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA. [Huang, Christine] Univ Arizona, Dept Pediat, Tucson, AZ 85721 USA. [Huang, Christine] Univ Arizona, Dept Emergency Med, Tucson, AZ USA. [Gilman, Robert H.; Quispe-Machaca, Victor R.; Ancca-Juarez, Jenny; Verastegui, Manuela; Sanchez, Gerardo; Cabrera, Lilia; Naquira, Cesar; Levy, Michael Z.] Univ Peruana Cayetano Heredia, Urbanizac Ingn, Fac Sci & Philosophy Alberto Cazorla Talleri, Lima, Peru. [Billig, Erica M. W.; Levy, Michael Z.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA. [Cama, Vitaliano A.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Bern, Caryn] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. RP Alroy, KA (reprint author), Natl Sci Fdn, AAAS Sci & Technol Policy Fellow, Div Environm Biol, 4201 Wilson Blvd, Arlington, VA 22230 USA. EM mzlevy@mail.med.upenn.edu FU Fogarty International Clinical Research Scholars Program at Vanderbilt University [R24 TW007988]; National Institutes of Health Office of the Director; Fogarty International Center; Office of AIDS Research; National Cancer Center; National Eye Institute; National Heart, Blood, and Lung Institute; National Institute of Dental & Craniofacial Research; National Institute On Drug Abuse; National Institute of Mental Health; National Institute of Allergy and Infectious Diseases Health; NIH Office of Women's Health and Research; American Relief and Recovery Act; National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH-NIAID) [5R01AI101229]; National Institutes of Allergy and Infectious Diseases of the National Institutes of Health (NIH-NIAID) [5T32AI007532-17] FX KAA and VRQM were 2010-2011 scholars and CH and MH were 2009-2010 scholars in the Fogarty International Clinical Research Scholars Program at Vanderbilt University (R24 TW007988 & http://www.nih.gov/), supported by the National Institutes of Health Office of the Director, Fogarty International Center, Office of AIDS Research, National Cancer Center, National Eye Institute, National Heart, Blood, and Lung Institute, National Institute of Dental & Craniofacial Research, National Institute On Drug Abuse, National Institute of Mental Health, National Institute of Allergy and Infectious Diseases Health, NIH Office of Women's Health and Research, and the American Relief and Recovery Act. MZL was supported by a grant from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH-NIAID) (5R01AI101229 & http://www.niaid.nih.gov/). EMWB was supported by a training grant from the National Institutes of Allergy and Infectious Diseases of the National Institutes of Health (NIH-NIAID) (5T32AI007532-17 & http://www.niaid.nih.gov/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 53 TC 1 Z9 1 U1 1 U2 4 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1935-2735 J9 PLOS NEGLECT TROP D JI Plos Neglect. Trop. Dis. PD MAY PY 2015 VL 9 IS 5 AR e0003779 DI 10.1371/journal.pntd.0003779 PG 17 WC Infectious Diseases; Parasitology; Tropical Medicine SC Infectious Diseases; Parasitology; Tropical Medicine GA CJ2HA UT WOS:000355303600042 PM 26000770 ER PT J AU Bergeron, E Zivcec, M Chakrabarti, AK Nichol, ST Albarino, CG Spiropoulou, CF AF Bergeron, Eric Zivcec, Marko Chakrabarti, Ayan K. Nichol, Stuart T. Albarino, Cesar G. Spiropoulou, Christina F. TI Recovery of Recombinant Crimean Congo Hemorrhagic Fever Virus Reveals a Function for Non-structural Glycoproteins Cleavage by Furin SO PLOS PATHOGENS LA English DT Article ID EBOLA-VIRUS; TERMINAL CLEAVAGE; CDNA; IDENTIFICATION; REPLICATION; GENERATION; PROTEASES; PROTEIN; RESCUE; SKI-1 AB Crimean Congo hemorrhagic fever virus (CCHFV) is a negative-strand RNA virus of the family Bunyaviridae (genus: Nairovirus). In humans, CCHFV causes fever, hemorrhage, severe thrombocytopenia, and high fatality. A major impediment in precisely determining the basis of CCHFV's high pathogenicity has been the lack of methodology to produce recombinant CCHFV. We developed a reverse genetics system based on transfecting plasmids into BSR-T7/5 and Huh7 cells. In our system, bacteriophage T7 RNA polymerase produced complementary RNA copies of the viral S, M, and L segments that were encapsidated with the support, in trans, of CCHFV nucleoprotein and L polymerase. The system was optimized to systematically recover high yields of infectious CCHFV. Additionally, we tested the ability of the system to produce specifically designed CCHFV mutants. The M segment encodes a polyprotein that is processed by host proprotein convertases (PCs), including the site-1 protease (S1P) and furin-like PCs. S1P and furin cleavages are necessary for producing the non-structural glycoprotein GP38, while S1P cleavage yields structural Gn. We studied the role of furin cleavage by rescuing a recombinant CCHFV encoding a virus glycoprotein precursor lacking a functional furin cleavage motif (RSKR mutated to ASKA). The ASKA mutation blocked glycoprotein precursor's maturation to GP38, and Gn precursor's maturation to Gn was slightly diminished. Furin cleavage was not essential for replication, as blocking furin cleavage resulted only in transient reduction of CCHFV titers, suggesting that either GP38 and/or decreased Gn maturation accounted for the reduced virion production. Our data demonstrate that nairoviruses can be produced by reverse genetics, and the utility of our system uncovered a function for furin cleavage. This viral rescue system could be further used to study the CCHFV replication cycle and facilitate the development of efficacious vaccines to counter this biological and public health threat. C1 [Bergeron, Eric; Zivcec, Marko; Chakrabarti, Ayan K.; Nichol, Stuart T.; Albarino, Cesar G.; Spiropoulou, Christina F.] Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Bergeron, E (reprint author), Ctr Dis Control & Prevent, Viral Special Pathogens Branch, Div High Consequence Pathogens & Pathol, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM ebergeron@cdc.gov OI Zivcec, Marko/0000-0003-4337-8487 FU CDC; CDC foundation - NIAID [R01AI109008] FX These studies were supported by CDC and CDC foundation project funded by NIAID grant R01AI109008. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 34 TC 7 Z9 7 U1 2 U2 8 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD MAY PY 2015 VL 11 IS 5 AR e1004879 DI 10.1371/journal.ppat.1004879 PG 19 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CJ1UF UT WOS:000355269300028 PM 25933376 ER PT J AU Grubaugh, ND Smith, DR Brackney, DE Bosco-Lauth, AM Fauver, JR Campbell, CL Felix, TA Romo, H Duggal, NK Dietrich, EA Eike, T Beane, JE Bowen, RA Black, WC Brault, AC Ebel, GD AF Grubaugh, Nathan D. Smith, Darci R. Brackney, Doug E. Bosco-Lauth, Angela M. Fauver, Joseph R. Campbell, Corey L. Felix, Todd A. Romo, Hannah Duggal, Nisha K. Dietrich, Elizabeth A. Eike, Tyler Beane, Jennifer E. Bowen, Richard A. Black, William C. Brault, Aaron C. Ebel, Gregory D. TI Experimental Evolution of an RNA Virus in Wild Birds: Evidence for Host-Dependent Impacts on Population Structure and Competitive Fitness SO PLOS PATHOGENS LA English DT Article ID WEST-NILE-VIRUS; STRONG PURIFYING SELECTION; NEW-YORK-STATE; ALPHA/BETA-INTERFERON; PHYLOGENETIC ANALYSIS; SEQUENCING DATA; AMERICAN CROWS; HOUSE SPARROWS; DENGUE VIRUS; MOSQUITOS AB Within hosts, RNA viruses form populations that are genetically and phenotypically complex. Heterogeneity in RNA virus genomes arises due to error-prone replication and is reduced by stochastic and selective mechanisms that are incompletely understood. Defining how natural selection shapes RNA virus populations is critical because it can inform treatment paradigms and enhance control efforts. We allowed West Nile virus (WNV) to replicate in wild-caught American crows, house sparrows and American robins to assess how natural selection shapes RNA virus populations in ecologically relevant hosts that differ in susceptibility to virus-induced mortality. After five sequential passages in each bird species, we examined the phenotype and population diversity of WNV through fitness competition assays and next generation sequencing. We demonstrate that fitness gains occur in a species-specific manner, with the greatest replicative fitness gains in robin-passaged WNV and the least in WNV passaged in crows. Sequencing data revealed that intrahost WNV populations were strongly influenced by purifying selection and the overall complexity of the viral populations was similar among passaged hosts. However, the selective pressures that control WNV populations seem to be bird species-dependent. Specifically, crow-passaged WNV populations contained the most unique mutations (similar to 1.7x more than sparrows, similar to 3.4x more than robins) and defective genomes (similar to 1.4x greater than sparrows, similar to 2.7x greater than robins), but the lowest average mutation frequency (about equal to sparrows, similar to 2.6x lower than robins). Therefore, our data suggest that WNV replication in the most disease-susceptible bird species is positively associated with virus mutational tolerance, likely via complementation, and negatively associated with the strength of selection. These differences in genetic composition most likely have distinct phenotypic consequences for the virus populations. Taken together, these results reveal important insights into how different hosts may contribute to the emergence of RNA viruses. C1 [Grubaugh, Nathan D.; Smith, Darci R.; Brackney, Doug E.; Bosco-Lauth, Angela M.; Fauver, Joseph R.; Campbell, Corey L.; Romo, Hannah; Eike, Tyler; Black, William C.; Ebel, Gregory D.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. [Felix, Todd A.] US Anim & Plant Hlth Inspect Serv, USDA, Wildlife Serv, Lakewood, CO USA. [Romo, Hannah; Duggal, Nisha K.; Dietrich, Elizabeth A.; Brault, Aaron C.] Ctr Dis Control & Prevent, Div Vector Borne Dis, Ft Collins, CO USA. [Beane, Jennifer E.] Boston Univ, Sch Med, Sect Computat Biomed, Boston, MA 02118 USA. [Bowen, Richard A.] Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Biomed Sci, Ft Collins, CO 80523 USA. RP Grubaugh, ND (reprint author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA. EM gregory.ebel@colostate.edu RI Ebel, Gregory/D-8324-2017; OI Beane-Ebel, Jennifer/0000-0002-6699-2132 FU National Institute of Allergy and Infectious Disease, National Institutes of Health [AI067380] FX This work was funded by a grant from the National Institute of Allergy and Infectious Disease, National Institutes of Health under grant number AI067380 (GDE). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. NR 56 TC 10 Z9 10 U1 4 U2 13 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD MAY PY 2015 VL 11 IS 5 AR e1004874 DI 10.1371/journal.ppat.1004874 PG 19 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CJ1UF UT WOS:000355269300025 PM 25993022 ER PT J AU Latner, DR Hickman, CJ AF Latner, Donald R. Hickman, Carole J. TI Remembering Mumps SO PLOS PATHOGENS LA English DT Article ID VACCINATED POPULATIONS; RUBELLA VACCINE; UNITED-STATES; B-CELLS; VIRUS; ANTIBODY; MEASLES; OUTBREAK; EPIDEMIOLOGY; INFECTION C1 [Latner, Donald R.; Hickman, Carole J.] Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. RP Latner, DR (reprint author), Ctr Dis Control & Prevent, Div Viral Dis, Natl Ctr Immunizat & Resp Dis, Atlanta, GA 30333 USA. EM dlatner@cdc.gov NR 23 TC 2 Z9 2 U1 0 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD MAY PY 2015 VL 11 IS 5 AR e1004791 DI 10.1371/journal.ppat.1004791 PG 4 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CJ1UF UT WOS:000355269300006 PM 25951183 ER PT J AU Litvintseva, AP Brandt, ME Mody, RK Lockhart, SR AF Litvintseva, Anastasia P. Brandt, Mary E. Mody, Rajal K. Lockhart, Shawn R. TI Investigating Fungal Outbreaks in the 21st Century SO PLOS PATHOGENS LA English DT Article ID INFECTION; MUCORMYCOSIS C1 [Litvintseva, Anastasia P.; Brandt, Mary E.; Mody, Rajal K.; Lockhart, Shawn R.] Ctr Dis Control & Prevent, Mycot Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. RP Litvintseva, AP (reprint author), Ctr Dis Control & Prevent, Mycot Dis Branch, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM frq8@cdc.gov FU CDC FX This study was funded by CDC internal funding. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 21 TC 4 Z9 4 U1 1 U2 7 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1553-7366 EI 1553-7374 J9 PLOS PATHOG JI PLoS Pathog. PD MAY PY 2015 VL 11 IS 5 AR UNSP e1004804 DI 10.1371/journal.ppat.1004804 PG 6 WC Microbiology; Parasitology; Virology SC Microbiology; Parasitology; Virology GA CJ1UF UT WOS:000355269300008 PM 25996829 ER PT J AU Smith, TJ Hill, KK Raphael, BH AF Smith, Theresa J. Hill, Karen K. Raphael, Brian H. TI Historical and current perspectives on Clostridium botulinum diversity SO RESEARCH IN MICROBIOLOGY LA English DT Article DE Clostridium botulinum; Botulinum neurotoxins; Genomics; Serotype ID REAL-TIME PCR; TANDEM-REPEAT ANALYSIS; FRAGMENT LENGTH POLYMORPHISM; NUCLEOTIDE-SEQUENCE ANALYSIS; FIELD GEL-ELECTROPHORESIS; NEUROTOXIN GENE CLUSTERS; AMINO-ACID-SEQUENCE; SEROTYPE-A SUBTYPES; INFANT BOTULISM; GROUP-II AB For nearly one hundred years, researchers have attempted to categorize botulinum neurotoxin-producing clostridia and the toxins that they produce according to biochemical characterizations, serological comparisons, and genetic analyses. Throughout this period the bacteria and their toxins have defied such attempts at categorization. Below is a description of both historic and current Clostridium botulinum strain and neurotoxin information that illustrates how each new finding has significantly added to the knowledge of the botulinum neurotoxin-containing clostridia and their diversity. Published by Elsevier Masson SAS on behalf of Institut Pasteur. C1 [Smith, Theresa J.] United States Army Med Res Inst Infect Dis, Mol & Translat Sci, Ft Detrick, MD 21702 USA. [Hill, Karen K.] Los Alamos Natl Lab, Biosci Div, Los Alamos, NM 87545 USA. [Raphael, Brian H.] Ctr Dis Control & Prevent, Enter Dis Lab Branch, Atlanta, GA 30329 USA. RP Smith, TJ (reprint author), United States Army Med Res Inst Infect Dis, Mol & Translat Sci, Ft Detrick, MD 21702 USA. EM theresa.j.smith.civ@mail.mil OI Raphael, Brian/0000-0003-2778-2623 FU Department of Homeland Security Science and Technology [HSHQDC-10-C-00139]; NIAID [IAA 120.B18]; Office of Public Health Preparedness and Emergency Response, Centers for Disease Control and Prevention FX Funding for this research was provided by the Department of Homeland Security Science and Technology Directorate contract HSHQDC-10-C-00139 and NIAID IAA 120.B18 and the Office of Public Health Preparedness and Emergency Response, Centers for Disease Control and Prevention. Los Alamos National Laboratory strongly supports academic freedom and a researcher's right to publish; however the Laboratory as an institution does not necessarily endorse the viewpoint of a publication or guarantee its technical correctness. Opinions, interpretations, conclusions and recommendations are those of the authors and not necessarily endorsed by the Centers for Disease Control and Prevention, the United States Army, the National Institute of Allergy and Infectious Diseases, or the National Institutes of Health. NR 144 TC 12 Z9 12 U1 2 U2 9 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0923-2508 EI 1769-7123 J9 RES MICROBIOL JI Res. Microbiol. PD MAY PY 2015 VL 166 IS 4 SI SI BP 290 EP 302 DI 10.1016/j.resmic.2014.09.007 PG 13 WC Microbiology SC Microbiology GA CI8QZ UT WOS:000355038100008 PM 25312020 ER PT J AU Feldstein, LR Brownstein, JS Brady, OJ Hay, SI Johansson, MA AF Feldstein, Leora R. Brownstein, John S. Brady, Oliver J. Hay, Simon I. Johansson, Michael A. TI Dengue on islands: a Bayesian approach to understanding the global ecology of dengue viruses SO TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE LA English DT Article DE Dengue; Ecology; Epidemiology; Islands; Transmission dynamics ID TIME-SERIES ANALYSIS; AEDES-AEGYPTI; INFECTIOUS-DISEASES; CLIMATE VARIABILITY; TRANSMISSION; FEVER; VARIABLES; THAILAND; MEXICO; TEMPERATURE AB Background: Transmission of dengue viruses (DENV), the most common arboviral pathogens globally, is influenced by many climatic and socioeconomic factors. However, the relative contributions of these factors on a global scale are unclear. Methods: We randomly selected 94 islands stratified by socioeconomic and geographic characteristics. With a Bayesian model, we assessed factors contributing to the probability of islands having a history of any dengue outbreaks and of having frequent outbreaks. Results: Minimum temperature was strongly associated with suitability for DENV transmission. Islands with a minimum monthly temperature of greater than 14.8A degrees C (95% CI: 12.4-16.6A degrees C) were predicted to be suitable for DENV transmission. Increased population size and precipitation were associated with increased outbreak frequency, but did not capture all of the variability. Predictions for 48 testing islands verified these findings. Conclusions: This analysis clarified two key components of DENV ecology: minimum temperature was the most important determinant of suitability; and endemicity was more likely in areas with high precipitation and large, but not necessarily dense, populations. Wealth and connectivity, in contrast, had no discernable effects. This model adds to our knowledge of global determinants of dengue risk and provides a basis for understanding the ecology of dengue endemicity. C1 [Feldstein, Leora R.; Brownstein, John S.] Boston Childrens Hosp, Childrens Hosp Informat Program, Boston, MA 02215 USA. [Feldstein, Leora R.] Fred Hutchinson Canc Res Ctr, Vaccine & Infect Dis Div, Ctr Stat & Quantitat Infect Dis, Seattle, WA 98104 USA. [Brownstein, John S.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02215 USA. [Brady, Oliver J.; Hay, Simon I.] Univ Oxford, Dept Zool, Spatial Ecol & Epidemiol Grp, Oxford OX1 3PS, England. [Hay, Simon I.] NIH, Fogarty Int Ctr, Bethesda, MD 20892 USA. [Johansson, Michael A.] CDC, Dengue Branch, Div Vector Borne Dis, San Juan, PR 00920 USA. RP Johansson, MA (reprint author), CDC, Dengue Branch, Div Vector Borne Dis, 1324 Calle Canada, San Juan, PR 00920 USA. EM mjohansson@cdc.gov RI Hay, Simon/F-8967-2015; OI Hay, Simon/0000-0002-0611-7272; Brady, Oliver/0000-0002-3235-2129 FU National Institutes of Health, National Library of Medicine [R01LM010812]; Wellcome Trust [095066]; Bill & Melinda Gates Foundation [OPP1093011]; RAPIDD program of the Science & Technology Directorate; Department of Homeland Security, National Institutes of Health; Fogarty International Center; Biotechnology and Biological Sciences Research Council FX This work is supported by the National Institutes of Health, National Library of Medicine [R01LM010812 to JSB], the Wellcome Trust [#095066 to SIH], the Bill & Melinda Gates Foundation [#OPP1093011 to SIH and JSB], RAPIDD program of the Science & Technology Directorate (to SIH), the Department of Homeland Security, National Institutes of Health (to SIH), the Fogarty International Center (to SIH), and the Biotechnology and Biological Sciences Research Council (to OJB). NR 63 TC 3 Z9 3 U1 2 U2 17 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0035-9203 EI 1878-3503 J9 T ROY SOC TROP MED H JI Trans. Roy. Soc. Trop. Med. Hyg. PD MAY PY 2015 VL 109 IS 5 BP 303 EP 312 DI 10.1093/trstmh/trv012 PG 10 WC Public, Environmental & Occupational Health; Tropical Medicine SC Public, Environmental & Occupational Health; Tropical Medicine GA CJ1YB UT WOS:000355279900004 PM 25771261 ER PT J AU Ekwueme, D Hoerger, T Miller, J Allaire, B Subramanian, S Sabatino, S Royalty, J Li, C AF Ekwueme, D. Hoerger, T. Miller, J. Allaire, B. Subramanian, S. Sabatino, S. Royalty, J. Li, C. TI COST-EFFECTIVENES OF BREAST CANCER SCREENING IN THE NATIONAL BREAST AND CERVICAL CANCER EARLY DETECTION PROGRAM IN THE UNITED STATES SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Ekwueme, D.] Ctr Dis Control & Prevent, Chamblee, GA USA. [Hoerger, T.; Allaire, B.] RTI Int, Res Triangle Pk, NC USA. [Miller, J.; Sabatino, S.; Royalty, J.; Li, C.] US Ctr Dis Control & Prevent, Chamblee, GA USA. [Subramanian, S.] RTI Int, Waltham, MA USA. NR 0 TC 0 Z9 0 U1 0 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2015 VL 18 IS 3 MA PHS64 BP A258 EP A258 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CI1IZ UT WOS:000354498504184 ER PT J AU Guy, G Ekwueme, D Li, R Rim, SH Yabroff, KR AF Guy, G. Ekwueme, D. Li, R. Rim, S. H. Yabroff, K. R. TI THE IMPACT OF CHRONIC CONDITIONS ON THE ECONOMIC BURDEN OF CANCER SURVIVORSHIP IN THE UNITED STATES SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Guy, G.; Li, R.; Rim, S. H.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ekwueme, D.] Ctr Dis Control & Prevent, Chamblee, GA USA. [Yabroff, K. R.] NCI, Rockville, MD USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2015 VL 18 IS 3 MA CN1 BP A5 EP A5 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CI1IZ UT WOS:000354498500022 ER PT J AU Hung, M Ekwueme, D Wang, J AF Hung, M. Ekwueme, D. Wang, J. TI ESTIMATING THE HEALTH BENEFITS OF MEETING THE HEALTHY PEOPLE 2020 OBJECTIVES FOR REDUCING INVASIVE COLORECTAL CANCER INCIDENCE IN THE UNITED STATES SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Hung, M.] US Ctr Dis Control & Prevent, Div Canc Prevent & Control, Chamblee, GA USA. [Ekwueme, D.] Ctr Dis Control & Prevent, Chamblee, GA USA. [Wang, J.] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan. NR 0 TC 0 Z9 0 U1 2 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2015 VL 18 IS 3 MA PHS154 BP A273 EP A273 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CI1IZ UT WOS:000354498504267 ER PT J AU Xu, X Dube, SR Pesko, MF AF Xu, X. Dube, S. R. Pesko, M. F. TI AN EVALUATION OF SMOKERS' PREFERENCE FOR CHARACTERISTICS OF TOBACCO CESSATION MEDICATIONS: A WILLINGNESS TO PAY APPROACH SO VALUE IN HEALTH LA English DT Meeting Abstract C1 [Xu, X.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Dube, S. R.] Georgia State Univ, Atlanta, GA 30303 USA. [Pesko, M. F.] Weill Cornell Med Coll, New York, NY USA. NR 0 TC 0 Z9 0 U1 0 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1098-3015 EI 1524-4733 J9 VALUE HEALTH JI Value Health PD MAY PY 2015 VL 18 IS 3 MA PRS44 BP A177 EP A177 PG 1 WC Economics; Health Care Sciences & Services; Health Policy & Services SC Business & Economics; Health Care Sciences & Services GA CI1IZ UT WOS:000354498503051 ER PT J AU Boulet, SL Mneimneh, AS Zhang, Y Crawford, S Sunderam, S Mckane, P Cohen, B Stone, C Jamieson, DJ Kissin, DM AF Boulet, S. L. Mneimneh, A. S. Zhang, Y. Crawford, S. Sunderam, S. Mckane, P. Cohen, B. Stone, C. Jamieson, D. J. Kissin, D. M. TI States Monitoring Assisted Reproductive Technology (SMART) Collaborative: Promoting State-Based Surveillance of ART and Infertility SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Boulet, S. L.; Mneimneh, A. S.; Zhang, Y.; Crawford, S.; Sunderam, S.; Jamieson, D. J.; Kissin, D. M.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Mckane, P.] Massachusetts Dept Publ Hlth, Boston, MA USA. [Cohen, B.] Michigan Dept Community Hlth, Lansing, MI USA. [Stone, C.] Connecticut Dept Publ Hlth & Addict Serv, Hartford, CT 06106 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2015 VL 103 IS 5 MA S13 BP 357 EP 357 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CI4SD UT WOS:000354742400017 ER PT J AU Rosenthal, J Ramirez, N Lopez-Palacios, E Sniezek, J Vellozzi, C AF Rosenthal, J. Ramirez, N. Lopez-Palacios, E. Sniezek, J. Vellozzi, C. TI Red Blood Cell Folate Insufficiency (RBCFI) among Nonpregnant Women of Childbearing Age (WCBA) in Guatemala 2009-2010: Predicted Risk of Neural Tube Defects (NTDs) SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Rosenthal, J.; Sniezek, J.; Vellozzi, C.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Ramirez, N.] Minist Hlth, Guatemala City, Guatemala. [Lopez-Palacios, E.] World Food Program, Guatemala City, Guatemala. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2015 VL 103 IS 5 MA 19 BP 385 EP 385 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CI4SD UT WOS:000354742400068 ER PT J AU Sekkarie, A Zaganjor, I Tsang, BL Cannon, M Sniezek, J Mulinare, J Williams, J Razzaghi, H Rosenthal, J AF Sekkarie, A. Zaganjor, I Tsang, B. L. Cannon, M. Sniezek, J. Mulinare, J. Williams, J. Razzaghi, H. Rosenthal, J. TI Global Update on the Impact of Folic Acid Fortification on Neural Tube Defects SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Sekkarie, A.; Zaganjor, I; Tsang, B. L.; Cannon, M.; Sniezek, J.; Williams, J.; Rosenthal, J.] CDC, NCBDDD, Atlanta, GA 30333 USA. [Mulinare, J.; Razzaghi, H.] Carter Consulting Inc, Atlanta, GA USA. NR 0 TC 0 Z9 0 U1 1 U2 3 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2015 VL 103 IS 5 MA 20 BP 385 EP 385 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CI4SD UT WOS:000354742400069 ER PT J AU Carmichael, SL Yang, W Gilboa, S Ailes, E Correa, A Botto, L Feldkamp, M Shaw, GM AF Carmichael, S. L. Yang, W. Gilboa, S. Ailes, E. Correa, A. Botto, L. Feldkamp, M. Shaw, G. M. TI Diet Quality, Obesity, and Birth Defects SO BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY LA English DT Meeting Abstract C1 [Carmichael, S. L.; Yang, W.; Shaw, G. M.] Stanford Univ, Stanford, CA 94305 USA. [Gilboa, S.; Ailes, E.] Ctr Dis Control & Prevent, Atlanta, GA USA. [Correa, A.] Univ Mississippi, Med Ctr, Jackson, MS 39216 USA. [Botto, L.; Feldkamp, M.] Univ Utah, Sch Med, Salt Lake City, UT USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU WILEY-BLACKWELL PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1542-0752 EI 1542-0760 J9 BIRTH DEFECTS RES A JI Birth Defects Res. Part A-Clin. Mol. Teratol. PD MAY PY 2015 VL 103 IS 5 MA P55 BP 429 EP 429 PG 1 WC Developmental Biology; Toxicology SC Developmental Biology; Toxicology GA CI4SD UT WOS:000354742400155 ER PT J AU Tedla, Z Nguyen, ML Sibanda, T Nyirenda, S Agizew, TB Girde, S Rose, CE Samandari, T AF Tedla, Zegabriel Nguyen, Minh-Ly Sibanda, Thabisa Nyirenda, Samba Agizew, Tefera B. Girde, Sonali Rose, Charles E. Samandari, Taraz TI Isoniazid-Associated Hepatitis in Adults Infected With HIV Receiving 36 Months of Isoniazid Prophylaxis in Botswana SO CHEST LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; LATENT TUBERCULOSIS INFECTION; ANTIRETROVIRAL THERAPY; PREVENTIVE THERAPY; CONTROLLED-TRIAL; UGANDAN ADULTS; UNITED-STATES; HEPATOTOXICITY; PATHOGENESIS; REGIMENS AB BACKGROUND: The World Health Organization recommends 36 months of isoniazid preventive therapy (36IPT) for adults infected with HIV living in TB-endemic countries. We determined the rates and risk factors for isoniazid-associated hepatitis with the use of 36IPT. METHODS: One thousand six adults infected with HIV received 36IPT during a pragmatic randomized trial set in Botswana public health clinics providing HIV care. Enrollment exclusion criteria included jaundice or elevations of serum transaminases (ESTs) > 2.5-fold the upper limit of normal (ULN). Participants with any CD4(+) lymphocyte count were eligible and received antiretroviral therapy (ART) when CD4(+) < 200 cells/mu L. 36IPT was stopped for severe hepatitis (more than fivefold ULN EST) but not for moderate hepatitis (2.5-fold to fivefold ULN EST). RESULTS: Pharmacy refill records showed 2,237 person-years of isoniazid receipt; 48% of participants initiated ART by 36 months. A total of 1.9% (19 of 1,006) of participants were diagnosed with severe hepatitis; three had jaundice and two of these developed hepatic encephalopathy. Another 3.1% (31 of 1,006) of participants experienced moderate hepatitis. Thirty-eight percent (19 of 50) of participants with moderate to severe hepatitis concomitantly received ART. Forty percent (20 of 50) of moderate to severe cases occurred within the first 2 months of IPT and during this period were not associated with receipt of ART at baseline (hazard ratio, 1.49; 95% CI, 0.20-11.1; P = .70). CONCLUSIONS: Adults infected with HIV receiving 36IPT did not have an increased incidence of moderate to severe hepatitis or hepatic encephalopathy compared with published reports among people infected with HIV, people not infected with HIV in trials or public health programs. Compared with participants not receiving ART, the risk of moderate to severe hepatitis was not increased by ART. C1 [Tedla, Zegabriel; Sibanda, Thabisa; Agizew, Tefera B.; Samandari, Taraz] CDC Botswana, Gaborone, Botswana. [Nguyen, Minh-Ly; Samandari, Taraz] Ctr Dis Control & Prevent, Div TB Eliminat, Atlanta, GA USA. [Girde, Sonali; Rose, Charles E.] Div HIV AIDS Prevent, Atlanta, GA 30329 USA. [Nyirenda, Samba] CDC Botswana, Francistown, Botswana. [Girde, Sonali] ICF Int Inc, Atlanta, GA USA. RP Samandari, T (reprint author), Ctr Dis Control & Prevent, 1600 Clift Rd NE,Mailstop E-45, Atlanta, GA 30329 USA. EM tts0@edc.gov FU US Centers for Disease Control and Prevention; US Agency for International Development FX This study was funded by the US Centers for Disease Control and Prevention and the US Agency for International Development. NR 33 TC 1 Z9 1 U1 1 U2 3 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD MAY PY 2015 VL 147 IS 5 BP 1376 EP 1384 DI 10.1378/chest.14-0215 PG 9 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA CI2VW UT WOS:000354606600043 PM 25340318 ER PT J AU Gee, GC de Castro, AB Wang, MC Crespi, CM Morey, BN Fujishiro, K AF Gee, Gilbert C. de Castro, A. B. Wang, May C. Crespi, Catherine M. Morey, Brittany N. Fujishiro, Kaori TI Feasibility of Conducting a Longitudinal, Transnational Study of Filipino Migrants to the United States: A Dual-Cohort Design SO JOURNAL OF HEALTH CARE FOR THE POOR AND UNDERSERVED LA English DT Article DE Immigrant; prospective; Asian American; obesity; study design; transnational; comparative ID BODY-MASS INDEX; DEVELOPING-COUNTRIES; IMMIGRANT ENCLAVES; ASIAN-AMERICANS; US ADULTS; OBESITY; HEALTH; ACCULTURATION; STRESS; ASSIMILATION AB Most studies of immigrant health are cross-sectional and fail to collect information prior to migration, leading to potential bias and confounding. The present pilot study examines the feasibility of studying migrants prospectively, with baseline data collected before migration. The study followed two cohorts of Filipinos for one year, a migrant cohort (n=27) that emigrated to the U.S. and a second non-migrant cohort (n=26) that remained in the Philippines. The one-year retention rate was 96%. The migrant cohort arrived in the U.S. within two months of their baseline assessment. Migrants and non-migrants did not differ with regard to body mass index, waist circumference, or waist to hip ratio at baseline or at follow-up. It is feasible to conduct a transnational, longitudinal study of two cohorts of Filipinos. This design provides important pre-migration information, is analogous to a natural experiment, can be upscaled, and allows for a rigorous examination of immigrant health. C1 [Gee, Gilbert C.; Wang, May C.; Crespi, Catherine M.; Morey, Brittany N.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Los Angeles, CA 90077 USA. [de Castro, A. B.] Univ Washington Bothell, Sch Nursing & Hlth Studies, Bothell, WA 98011 USA. [Fujishiro, Kaori] NIOSH, Ctr Dis Control & Prevent, Pittsburgh, PA 15236 USA. RP Gee, GC (reprint author), Univ Calif Los Angeles, Fielding Sch Publ Hlth, 650 Charles E Young Dr South, Los Angeles, CA 90077 USA. FU NCATS NIH HHS [UL1 TR000124]; NCI NIH HHS [R21 CA137297]; NCRR NIH HHS [KL2 RR025015]; NICHD NIH HHS [R24 HD041022, R24 HD042828] NR 49 TC 3 Z9 3 U1 4 U2 9 PU JOHNS HOPKINS UNIV PRESS PI BALTIMORE PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD 21218-4363 USA SN 1049-2089 EI 1548-6869 J9 J HEALTH CARE POOR U JI J. Health Care Poor Underserved PD MAY PY 2015 VL 26 IS 2 BP 488 EP 504 PG 17 WC Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA CI2OQ UT WOS:000354587300017 PM 25913346 ER PT J AU Wang, CY Carriquiry, AL Chen, TC Loria, CM Pfeiffer, CM Liu, K Sempos, CT Perrine, CG Cogswell, ME AF Wang, Chia-Yih Carriquiry, Alicia L. Chen, Te-Ching Loria, Catherine M. Pfeiffer, Christine M. Liu, Kiang Sempos, Christopher T. Perrine, Cria G. Cogswell, Mary E. TI Estimating the Population Distribution of Usual 24-Hour Sodium Excretion from Timed Urine Void Specimens Using a Statistical Approach Accounting for Correlated Measurement Errors SO JOURNAL OF NUTRITION LA English DT Article DE sodium; population distribution; nutrition survey; calibration; 24-hour urine collection; timed urine void; usual sodium intake ID DAILY SALT INTAKE; POTASSIUM EXCRETION; UNITED-STATES; ADULTS; SPOT; COLLECTION; SAMPLES AB Background: High US sodium intake and national reduction efforts necessitate developing a feasible and valid monitoring method across the distribution of low-to-high sodium intake. Objective: We examined a statistical approach using timed urine voids to estimate the population distribution of usual 24-h sodium excretion. Methods: A sample of 407 adults, aged 18-39 y (54% female, 48% black), collected each void in a separate container for 24 h; 133 repeated the procedure 4-11 d later. Four timed voids (morning, afternoon, evening, overnight) were selected from each 24-h collection. We developed gender-specific equations to calibrate total sodium excreted in each of the one-void (e.g., morning) and combined two-void (e.g., morning + afternoon) urines to 24-h sodium excretion. The calibrated sodium excretions were used to estimate the population distribution of usual 24-h sodium excretion. Participants were then randomly assigned to modeling (n = 160) or validation (n = 247) groups to examine the bias in estimated population percentiles. Results: Median bias in predicting selected percentiles (5th, 25th, 50th, 75th, 95th) of usual 24-h sodium excretion with one-void urines ranged from 367 to 284 mg (-7.7 to 12.2% of the observed usual excretions) for men and 604 to 486 mg (-14.6 to 23.7%) for women, and with two-void urines from 338 to 263 mg (-6.9 to 10.4%) and -166 to 153 mg (-4.1 to 8.1%), respectively. Four of the 6 two-void urine combinations produced no significant bias in predicting selected percentiles. Conclusions: Our approach to estimate the population usual 24-h sodium excretion, which uses calibrated timed-void sodium to account for day-to-day variation and covariance between measurement errors, produced percentile estimates with relatively low biases across low-to-high sodium excretions. This may provide a low-burden, low-cost alternative to 24-h collections in monitoring population sodium intake among healthy young adults and merits further investigation in other population subgroups. This study was registered at clinicaltrials.gov as NCT01631240. C1 [Wang, Chia-Yih; Chen, Te-Ching] CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. [Carriquiry, Alicia L.] Iowa State Univ, Dept Stat, Ames, IA USA. [Loria, Catherine M.] NHLBI, Bethesda, MD 20892 USA. [Sempos, Christopher T.] NIH, Off Dietary Supplements, Bethesda, MD 20892 USA. [Pfeiffer, Christine M.] CDC, Div Lab Sci, Natl Ctr Environm Hlth, Atlanta, GA 30333 USA. [Perrine, Cria G.] CDC, Div Nutr Phys Act & Obes, Atlanta, GA 30333 USA. [Cogswell, Mary E.] CDC, Div Heart Dis & Stroke Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30333 USA. [Liu, Kiang] Northwestern Univ, Feinberg Sch Med, Dept Prevent Med, Chicago, IL 60611 USA. RP Wang, CY (reprint author), CDC, Div Hlth & Nutr Examinat Surveys, Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA. EM cwang@cdc.gov FU CDC FX The data collection and laboratory analyses of sodium and creatinine were funded by the CDC. NR 29 TC 2 Z9 2 U1 0 U2 3 PU AMER SOC NUTRITION-ASN PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3166 EI 1541-6100 J9 J NUTR JI J. Nutr. PD MAY PY 2015 VL 145 IS 5 BP 1017 EP 1024 DI 10.3945/jn.114.206250 PG 8 WC Nutrition & Dietetics SC Nutrition & Dietetics GA CH4OO UT WOS:000354013000025 PM 25833885 ER PT J AU Yang, Z Wilsey, B Bohm, M Weyrich, M Roy, K Ritley, D Jones, C Melnikow, J AF Yang, Zhuo Wilsey, Barth Bohm, Michele Weyrich, Meghan Roy, Kakoli Ritley, Dominique Jones, Christopher Melnikow, Joy TI Defining Risk of Prescription Opioid Overdose: Pharmacy Shopping and Overlapping Prescriptions Among Long-Term Opioid Users in Medicaid SO JOURNAL OF PAIN LA English DT Article DE Prescription opioids; overlapping prescriptions; pharmacy shopping; overdose risk factors ID NONCANCER PAIN; CONTROLLED SUBSTANCES; THERAPY; DEATHS; TROUP; BENZODIAZEPINES; ENROLLEES; BEHAVIOR; COHORT; TRENDS AB Use of multiple pharmacies concurrently (pharmacy shopping) and overlapping prescriptions may be indicators of potential misuse or abuse of prescription opioid medications. To evaluate strategies for identifying patients at high risk, we first compared different definitions of pharmacy shopping and then added the indicator of overlapping opioid prescriptions. We identified a cohort of 90,010 Medicaid enrollees who used >= 3 opioid prescriptions for >= 90 days during 2008 to 2010 from a multistate Medicaid claims database. We compared the diagnostic odds ratios for opioid overdose events of 9 pharmacy shopping definitions. Within a 90-day interval, a threshold of 4 pharmacies had the highest diagnostic odds ratio and was used to define pharmacy shopping. The overdose rate was higher in the subgroup with overlapping prescriptions (18.5 per 1,000 person-years [PYs]) than in the subgroup with pharmacy shopping as the sole indicator (10.7 per 1,000 PYs). Among the subgroup with both conditions, the overdose rate was 26.3 per 1,000 PYs, compared with 4.3 per 1,000 PYs for those with neither condition. Overlapping opioid prescriptions and pharmacy shopping measures had adjusted hazard ratios of 3.0 and 1.8, respectively, for opioid overdose. Using these measures will improve accurate identification of patients at highest risk of opioid overdose, the first step in implementing targeted prevention policies. Perspective: Long-term prescription opioid use may lead to adverse events, including overdose. Both pharmacy shopping and overlapping opioid prescriptions are associated with adverse outcomes. This study demonstrates that using both indicators will better identify those at high risk of overdose. Published by Elsevier Inc. on behalf of the American Pain Society C1 [Yang, Zhuo; Roy, Kakoli] Ctr Dis Control & Prevent, Off Associate Director Policy, Atlanta, GA 30333 USA. [Wilsey, Barth] VA Northern Calif Hlth Care Syst, Dept Phys Med, Mather, CA USA. [Wilsey, Barth] VA Northern Calif Hlth Care Syst, Dept Rehabil, Mather, CA USA. [Wilsey, Barth] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA. [Bohm, Michele] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Atlanta, GA 30333 USA. [Weyrich, Meghan; Ritley, Dominique; Melnikow, Joy] Univ Calif Davis, Sch Med, Ctr Healthcare Policy & Res, Sacramento, CA 95817 USA. [Jones, Christopher] US FDA, Off Commissioner, Silver Spring, MD USA. RP Yang, Z (reprint author), Ctr Dis Control & Prevent, Policy Res Anal & Dev Off, Off Associate Director Policy, 1600 Clifton Rd,MS D-28, Atlanta, GA 30333 USA. EM xco2@cdc.gov FU ODCDC CDC HHS [1U58CD001370-01] NR 28 TC 8 Z9 8 U1 0 U2 1 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD MAY PY 2015 VL 16 IS 5 BP 445 EP 453 DI 10.1016/j.jpain.2015.01.475 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA CH6KA UT WOS:000354144300005 PM 25681095 ER PT J AU Painter, JE Hlavsa, MC Collier, SA Xiao, LH Yoder, JS AF Painter, Julia E. Hlavsa, Michele C. Collier, Sarah A. Xiao, Lihua Yoder, Jonathan S. TI Cryptosporidiosis Surveillance - United States, 2011-2012 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID RECREATIONAL WATER; SPORADIC CRYPTOSPORIDIOSIS; CLINICAL-MANIFESTATIONS; ASYMPTOMATIC CARRIAGE; DISEASE OUTBREAKS; HEALTHY-ADULTS; CARE-CENTERS; PARVUM; INFECTION; GIARDIA AB Problem/Condition: Cryptosporidiosis is a nationally notifiable gastrointestinal illness caused by extremely chlorine-tolerant protozoa of the genus Cryptosporidium. Reporting Period: 2011-2012. Description of System: Fifty state and two metropolitan public health agencies voluntarily report cases of cryptosporidiosis through CDC's National Notifiable Diseases Surveillance System. Results: For 2011, a total of 9,313 cryptosporidiosis cases (confirmed and nonconfirmed) were reported; for 2012, a total of 8,008 cases were reported; 5.8% and 5.3%, respectively, were associated with a detected outbreak. The rates of reported nonconfirmed cases were 1.0 and 0.9 per 100,000 population in 2011 and 2012, respectively, compared with an average of 0.0 during 1995-2004, and 0.3 during 2005-2010. The highest overall reporting rates were observed in the Midwest; 10 states reported >3.5 cases per 100,000 population in 2011 and in 2012. During 2011-2012, reported cases were highest among children aged 1-4 years (6.6 per 100,000 population), followed for the first time by elderly adults aged >= 80 years (3.4), and 75-79 years (3.3). Overall, cryptosporidiosis rates were higher among females than males during both years. For specific age groups, rates were higher among males than females aged <15 years and higher among females than males aged >= 15 years. Cryptosporidiosis symptom onset increased 4.4 fold during late summer. Interpretation: Cryptosporidiosis incidence rates remain elevated nationally, and rates of nonconfirmed cases have increased. Rates remain highest in young children, although rates among elderly adults are increasing. Transmission of Cryptosporidium occurs throughout the United States, with increased reporting occurring in Midwestern states. Seasonal onset peaks coincide with the summer recreational water season and might reflect increased use of communal swimming venues. Public Health Action: Future research is needed to address the evolving epidemiology of cryptosporidiosis cases, with a specific focus on the increase in nonconfirmed cases and increasing incidence rates among elderly adults. National systematic genotyping and subtyping of Cryptosporidium isolates could also help elucidate Cryptosporidium transmission and thus cryptosporidiosis epidemiology in the United States. C1 [Painter, Julia E.; Hlavsa, Michele C.; Collier, Sarah A.; Xiao, Lihua; Yoder, Jonathan S.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Hlavsa, MC (reprint author), Natl Ctr Emerging & Zoonot Infect Diseases, Div Foodborne Waterborne & Environm Dis, New York, NY 10013 USA. EM acz3@cdc.gov RI Xiao, Lihua/B-1704-2013 OI Xiao, Lihua/0000-0001-8532-2727 NR 89 TC 11 Z9 11 U1 2 U2 10 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD MAY 1 PY 2015 VL 64 IS 3 BP 1 EP 13 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AR UT WOS:000354689200001 PM 25928581 ER PT J AU Painter, JE Gargano, JW Collier, SA Yoder, JS AF Painter, Julia E. Gargano, Julia W. Collier, Sarah A. Yoder, Jonathan S. TI Giardiasis Surveillance - United States, 2011-2012 SO MMWR SURVEILLANCE SUMMARIES LA English DT Article ID IRRITABLE-BOWEL-SYNDROME; DAY-CARE-CENTERS; ENDEMIC GIARDIASIS; PARVUM ANTIGENS; RISK-FACTORS; CRYPTOSPORIDIUM; LAMBLIA; CHILDREN; WATER; EPIDEMIOLOGY AB Problem/Condition: Giardiasis is a nationally notifiable gastrointestinal illness caused by the protozoan parasite Giardia intestinalis. Reporting Period: 2011-2012. Description of System: Forty-four states, the District of Columbia, New York City, the Commonwealth of Puerto Rico, and Guam voluntarily reported cases of giardiasis to CDC through the National Notifiable Diseases Surveillance System (NNDSS). Results: For 2011, a total of 16,868 giardiasis cases (98.8% confirmed and 1.2% nonconfirmed) were reported; for 2012, a total of 15,223 cases (98.8% confirmed and 1.3% nonconfirmed) were reported. In 2011 and 2012, 1.5% and 1.3% of cases, respectively, were associated with a detected outbreak. The incidence rates of all reported cases were 6.4 per 100,000 population in 2011 and 5.8 per 100,000 population in 2012. This represents a slight decline from the relatively steady rates observed during 2005-2010 (range: 7.1-7.9 cases per 100,000 population). In both 2011 and 2012, cases were most frequently reported in children aged 1-4 years, followed by those aged 5-9 years and adults aged 45-49 years. Incidence of giardiasis was highest in Northwest states. Peak onset of illness occurred annually during early summer through early fall. Interpretation: For the first time since 2002, giardiasis rates appear to be decreasing. Possible reasons for the decrease in rates during 2011-2012 could include changes in transmission patterns, a recent change in surveillance case definition, increased uptake of strategies to reduce waterborne transmission, or a combination of these factors. Transmission of giardiasis occurs throughout the United States, with more frequent diagnosis or reporting occurring in northern states. Geographical differences might suggest actual regional differences in giardiasis transmission or variation in surveillance capacity across states. Six states did not report giardiasis cases in 2011-2012, representing the largest number of nonreporting states since giardiasis became nationally notifiable in 2002. Giardiasis is reported more frequently in young children, which might reflect increased contact with contaminated water or ill persons, or a lack of immunity. Public Health Action: Educational efforts to decrease exposure to unsafe drinking and recreational water and prevent person-toperson transmission have the potential to reduce giardiasis transmission. The continual decrease in jurisdictions opting to report giardiasis cases could negatively impact the ability to interpret national surveillance data; thus, further investigation is needed to identify barriers to and facilitators of giardiasis case reporting. Existing state and local public health infrastructure supported through CDC (e.g., Epidemiology and Laboratory Capacity grants and CDC-sponsored Council of State and Territorial Epidemiologists Applied Epidemiology Fellows) could provide resources to enhance understanding of giardiasis epidemiology. C1 [Painter, Julia E.; Gargano, Julia W.; Collier, Sarah A.; Yoder, Jonathan S.] CDC, Natl Ctr Emerging & Zoonot Infect Dis, Div Foodborne Waterborne & Environm Dis, Atlanta, GA 30333 USA. RP Gargano, JW (reprint author), CDC, Natl Ctr Emerging & Zoonot Infect Dis, Atlanta, GA 30333 USA. EM igc5@cdc.gov NR 64 TC 17 Z9 18 U1 3 U2 8 PU CENTERS DISEASE CONTROL PI ATLANTA PA 1600 CLIFTON RD, ATLANTA, GA 30333 USA SN 1545-8636 J9 MMWR SURVEILL SUMM JI MMWR Surv. Summ. PD MAY 1 PY 2015 VL 64 IS 3 BP 15 EP 25 PG 11 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA CI4AR UT WOS:000354689200002 PM 25928582 ER PT J AU Boulet, SL Mehta, A Kissin, DM Warner, L Kawwass, JF Jamieson, DJ AF Boulet, Sheree L. Mehta, Akanksha Kissin, Dmitry M. Warner, Lee Kawwass, Jennifer F. Jamieson, Denise J. TI Trends in Use of and Reproductive Outcomes Associated With Intracytoplasmic Sperm Injection SO OBSTETRICAL & GYNECOLOGICAL SURVEY LA English DT Editorial Material AB Since its introduction in 1992, intracytoplasmic sperminjection (ICSI) has been increasingly used in patients without severe male factor infertility despite the lack of clear evidence of a benefit over conventional in vitro fertilization (IVF). Compared with pregnancies resulting from conventional IVF, pregnancies resulting from the use of ICSI are associated with 1.5 to 4 times increased risk of chromosomal abnormalities, birth defects, intellectual disabilities, imprinting disorders, and autism. Intracytoplasmic sperm injection is considerably more expensive than conventional IVF. The aim of this retrospective observational study was to assess national trends and reproductive outcomes of fresh IVF cycles associated with the use of ICSI compared with conventional IVF with respect to clinical indications for ICSI use. Although only fresh embryos were transferred, it is unlikely that outcomes for frozen-thawed embryos would differ. Data were obtained from the US National Assisted Reproductive Technology Surveillance System for all fresh and ICSI cycles performed during 1996 to 2012. The primary study outcomes were (1) trends in use of ICSI during 1996 to 2012 with respect to male factor infertility, unexplained infertility, maternal age 38 years or older, low oocyte yield (<5 oocytes retrieved), and 2 or more prior assisted reproductive technology cycles and no prior live birth, and (2) reproductive outcomes during 2008 to 2012 for conventional IVF and ICSI cycles, stratified by the presence or absence of male factor infertility. A total of 1,395,634 fresh IVF cycles were identified between 1996 and 2012; 908,767 (65.1%) used ICSI, and 486,867 cycles (34.9%) used conventional IVF. Male factor infertility was identified in 499,135 (35.8%) of fresh cycles. During 2006 to 2012, ICSI use among cycles with male factor infertility increased from 76.3% (10,876/14,259) to 93.3% (32,191/34,506) (P < 0.001), whereas its use for those without male factor infertility increased from 15.4% (4,197/27,191) to 66.9% (42,321/63,250) (P < 0.001). During 2008 to 2012, 494,907 fresh IVF cycles were identified, 74.6% of which used ICSI. Male factor infertility was reported in 35.7% (176,911/494,907) of fresh cycles. The risk for multiple births among these cycles was significantly lower in those undergoing ICSI compared with conventional IVF (30.9% vs 34.2%); the adjusted relative risk (RR) was 0.87, with a 95% confidence interval (CI) of 0.83 to 0.91. Compared with conventional IVF, ICSI use among cycles without male factor infertility (n = 317,996) was associated with lower rates of implantation (23.0% vs 25.2%; adjusted RR, 0.93; 95% CI, 0.91-0.95), live birth (36.5% vs 39.2%; adjusted RR, 0.95; 95% CI, 0.93-0.97), and multiple live births (30.1% vs 31.0%; adjusted RR, 0.93; 95% CI, 0.91-0.95). These findings show that ICSI use among fresh IVF cycles in the United States increased from 36.4% to 76.2% between 1996 and 2012. The largest relative increase occurred in cycles without male factor infertility. The data show no improvement in postfertilization reproductive outcomes with use of ICSI over conventional IVF in the absence of male factor infertility, irrespective of male factor infertility diagnosis. C1 [Boulet, Sheree L.; Mehta, Akanksha; Kissin, Dmitry M.; Warner, Lee; Kawwass, Jennifer F.; Jamieson, Denise J.] Emory Univ, Sch Med, Div Reprod Hlth, Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. [Mehta, Akanksha] Emory Univ, Sch Med, Dept Urol, Atlanta, GA USA. [Kissin, Dmitry M.; Kawwass, Jennifer F.; Jamieson, Denise J.] Emory Univ, Sch Med, Dept Obstet & Gynecol, Atlanta, GA USA. RP Boulet, SL (reprint author), Emory Univ, Sch Med, Div Reprod Hlth, Ctr Dis Control & Prevent, Atlanta, GA 30322 USA. NR 0 TC 0 Z9 0 U1 1 U2 10 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7828 EI 1533-9866 J9 OBSTET GYNECOL SURV JI Obstet. Gynecol. Surv. PD MAY PY 2015 VL 70 IS 5 BP 325 EP 326 PG 2 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CI4MZ UT WOS:000354725300016 ER PT J AU Ross, CE Tao, GY Patton, M Hoover, KW AF Ross, Christine E. Tao, Guoyu Patton, Monica Hoover, Karen W. TI Screening for Human Immunodeficiency Virus and Other Sexually Transmitted Diseases Among US Women With Prenatal Care SO OBSTETRICS AND GYNECOLOGY LA English DT Article ID ADVERSE OUTCOMES; PREGNANCY; SYPHILIS; RECOMMENDATIONS AB OBJECTIVE: To estimate prenatal sexually transmitted disease-human immunodeficiency virus (HIV) screening rates among insured women with prenatal care and the association of chlamydia and gonorrhea screening with Pap testing. METHODS: We estimated prenatal screening rates for syphilis, hepatitis B, HIV, chlamydia, and gonorrhea among women aged 15-44 years using a 2009-2010 U.S. administrative claims database that captures information for health services provided for both Medicaid- and commercially insured persons. Procedural and diagnostic codes were used to identify pregnant women with a live birth in 2010 with continuous insurance coverage at least 210 days before delivery and at least one typical prenatal blood test. Strengths of association between chlamydia and gonorrhea screening and Pap testing were measured using a chi(2) test of independence. RESULTS: Among 98,709 Medicaid-insured pregnant women, 95,064 (96.3%) were screened for syphilis, 95,082 (96.3%) for hepatitis B, 81,339 (82.4%) for HIV, 82,047 (83.1%) for chlamydia, and 73,799 (74.8%) for gonorrhea. Among 266,012 commercially insured women, 260,079 (97.8%) were screened for syphilis, 257,675 (96.8%) for hepatitis B, 227,276 (85.4%) for HIV, 187,071 (70.3%) for chlamydia, and 182,400 (68.6%) for gonorrhea. Prenatal screening for chlamydia and gonorrhea among both groups of women was more likely to be performed if a Pap test was also done (P<.001). CONCLUSION: Prenatal screening for syphilis and hepatitis B was nearly universal among Medicaid-and commercially insured women; HIV screening rates were much lower and varied by insurance type and demographic characteristics. Chlamydia screening was suboptimal and most often occurred with Pap testing. C1 Ctr Dis Control & Prevent, Div STD Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30316 USA. Ctr Dis Control & Prevent, Div HIV AIDS Prevent, Natl Ctr HIV AIDS Viral Hepatitis STD & TB Preven, Atlanta, GA 30316 USA. Ctr Dis Control & Prevent, Epidem Intelligence Serv, Off Workforce & Career Dev, Atlanta, GA 30316 USA. RP Ross, CE (reprint author), Ctr Dis Control & Prevent, Div STD Prevent, 1600 Clifton Rd,MS E02, Atlanta, GA 30316 USA. EM wiz6@cdc.gov NR 22 TC 4 Z9 4 U1 0 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0029-7844 J9 OBSTET GYNECOL JI Obstet. Gynecol. PD MAY PY 2015 VL 125 IS 5 BP 1211 EP 1216 DI 10.1097/AOG.0000000000000756 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA CI7SP UT WOS:000354965200030 PM 25932850 ER PT J AU Banu, S Rahman, MT Uddin, MKM Khatun, R Khan, MSR Rahman, MM Uddin, SI Ahmed, T Heffelfinger, JD AF Banu, Sayera Rahman, Md. Toufiq Uddin, Mohammad Khaja Mafij Khatun, Razia Khan, Md. Siddiqur Rahman Rahman, Md. Mojibur Uddin, Syed Iftekhar Ahmed, Tahmeed Heffelfinger, James D. TI Effect of Active Case Finding on Prevalence and Transmission of Pulmonary Tuberculosis in Dhaka Central Jail, Bangladesh SO PLOS ONE LA English DT Article ID MYCOBACTERIUM-TUBERCULOSIS; MOLECULAR EPIDEMIOLOGY; PRISON; STRAIN AB Background Understanding tuberculosis (TB) transmission dynamics is essential for establishing effective TB control strategies in settings where the burden and risk of transmission are high. The objectives of this study were to evaluate the effect of active screening on controlling TB transmission and also to characterize Mycobacterium tuberculosis strains for investigating transmission dynamics in a correctional setting. Methods The study was carried out in Dhaka Central Jail (DCJ), from October 2005 to February 2010. An active case finding strategy for pulmonary TB was established both at the entry point to the prison and inside the prison. Three sputum specimens were collected from all pulmonary TB suspects and subjected to smear microscopy, culture, and drug susceptibility testing as well as genotyping which included deletion analysis, spoligotyping and analysis of mycobacterial interspersed repetitive units (MIRU). Results A total of 60,585 inmates were screened during the study period. We found 466 inmates with pulmonary TB of whom 357 (77%) had positive smear microscopy results and 109 (23%) had negative smear microscopy results but had positive results on culture. The number of pulmonary TB cases declined significantly, from 49 cases during the first quarter to 8 cases in the final quarter of the study period (p=0.001). Deletion analysis identified all isolates as M. tuberculosis and further identified 229 (70%) strains as 'modern' and 100 (30%) strains as 'ancestral'. Analysis of MIRU showed that 347 strains (85%) exhibited unique patterns, whereas 61 strains (15%) clustered into 22 groups. The largest cluster comprised eight strains of the Beijing M. tuberculosis type. The rate of recent transmission was estimated to be 9.6%. Conclusions Implementation of active screening for TB was associated with a decline in TB cases in DCJ. Implementation of active screening in prison settings might substantially reduce the national burden of TB in Bangladesh. C1 [Banu, Sayera; Rahman, Md. Toufiq; Uddin, Mohammad Khaja Mafij; Khatun, Razia; Khan, Md. Siddiqur Rahman; Ahmed, Tahmeed; Heffelfinger, James D.] Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh. [Rahman, Md. Mojibur] Directorate Gen Hlth Serv, Natl TB Control Program, Dhaka, Bangladesh. [Uddin, Syed Iftekhar] Directorate Prisons, Dhaka, Bangladesh. [Heffelfinger, James D.] US Ctr Dis Control & Prevent, Global Dis Detect Branch, Div Global Hlth Protect, Ctr Global Hlth, Atlanta, GA USA. RP Banu, S (reprint author), Int Ctr Diarrhoeal Dis Res, Dhaka, Bangladesh. EM sbanu@icddrb.org FU Government of the People's Republic of Bangladesh (GoB); [GR-00410] FX This research protocol was funded by Government of the People's Republic of Bangladesh (GoB). The grant number was GR-00410 and SB received the grant. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 33 TC 3 Z9 3 U1 1 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 1 PY 2015 VL 10 IS 5 AR e0124976 DI 10.1371/journal.pone.0124976 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH2XA UT WOS:000353887100069 PM 25933377 ER PT J AU Berendes, D Levy, K Knee, J Handzel, T Hill, VR AF Berendes, David Levy, Karen Knee, Jackie Handzel, Thomas Hill, Vincent R. TI Ascaris and Escherichia coli Inactivation in an Ecological Sanitation System in Port-au-Prince, Haiti SO PLOS ONE LA English DT Article ID SEWAGE-SLUDGE; COMPOSTING LATRINES; FECAL SLUDGE; SUUM EGGS; SURVIVAL; AMMONIA; TOILETS; URINE; EFFICIENCY; FECES AB The goal of this study was to evaluate the microbial die-off in a latrine waste composting system in Port-au-Prince, Haiti. Temperature data and samples were collected from compost aged 0 - 12+ months. Samples collected from compost bin centers and corners at two depths were assessed for moisture content, E. coli concentration, and Ascaris spp. viability. Center temperatures in compost bins were all above 58 degrees C, while corner temperatures were 10 - 20 degrees C lower. Moisture content was 67 +/- 10% in all except the oldest compost. A 4-log reduction in E. coli was observed over the first sixteen weeks of composting at both locations and depths, after which E. coli was undetectable (LOD: 142 MPN g(-1) dry weight). In new compost, 10.4% and 8.3% of Ascaris eggs were viable and fully embryonated, respectively. Percent viability dropped to zero in samples older than six weeks. These findings indicate that the Haitian EcoSan composting process was effective in inactivating E. coliand Ascaris spp. in latrine waste within sixteen weeks. This study is one of the first to document efficacy of an ecological sanitation system under field conditions and provides insight into composting methods and monitoring for other international settings. C1 [Berendes, David; Levy, Karen] Emory Univ, Rollins Sch Publ Hlth, Dept Environm Hlth, Atlanta, GA 30322 USA. [Berendes, David; Handzel, Thomas] Ctr Dis Control & Prevent, Emergency Response & Recovery Branch, Div Global Hlth Protect, Atlanta, GA USA. [Hill, Vincent R.] Ctr Dis Control & Prevent, Environm Microbiol Lab, Waterborne Dis Prevent Branch, Div Food Waterborne & Environm Dis, Atlanta, GA 30329 USA. RP Hill, VR (reprint author), Ctr Dis Control & Prevent, Environm Microbiol Lab, Waterborne Dis Prevent Branch, Div Food Waterborne & Environm Dis, Atlanta, GA 30329 USA. EM veh2@cdc.gov FU Emergency Response and Recovery Branch in the Division of Global Health Protection; Environmental Microbiology Laboratory of the Waterborne Disease Prevention Branch in the Division of Food, Waterborne, and Environmental Diseases at the Centers for Disease Control and Prevention FX Materials, salaries, travel, and logistics for this work were supported by funds from the Emergency Response and Recovery Branch in the Division of Global Health Protection and the Environmental Microbiology Laboratory of the Waterborne Disease Prevention Branch in the Division of Food, Waterborne, and Environmental Diseases at the Centers for Disease Control and Prevention. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 40 TC 0 Z9 0 U1 4 U2 12 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAY 1 PY 2015 VL 10 IS 5 AR e0125336 DI 10.1371/journal.pone.0125336 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA CH2XA UT WOS:000353887100100 PM 25932948 ER PT J AU Mann, JR Royer, JA Turk, MA McDermott, S Holland, MM Ozturk, OD Hardin, JW Thibadeau, JK AF Mann, Joshua R. Royer, Julie A. Turk, Margaret A. McDermott, Suzanne Holland, Margaret M. Ozturk, Orgul D. Hardin, James W. Thibadeau, Judy K. TI Inpatient and Emergency Room Visits for Adolescents and Young Adults With Spina Bifida Living in South Carolina SO PM&R LA English DT Article ID HEALTH-CARE; NEUROGENIC BLADDER; MANAGEMENT; TRANSITION; CHILDREN; PERSPECTIVES; POPULATION; OUTCOMES; QUALITY; YOUTH AB Objective: To compare emergency room (ER) and inpatient hospital (IP) use rates for persons with spina bifida (SB) to peers without SB, when transition from pediatric to adult health care is likely to occur; and to analyze those ER and IP rates by age, race, socioeconomic status, gender, and type of residential area. Design: A retrospective cohort study. Setting: Secondary data analysis in South Carolina. Participants: We studied individuals who were between 15 and 24 years old and enrolled in the State Health Plan (SHP) or state Medicaid during the 2000-2010 study period. Methods: Individuals with SB were identified using ICD-9 billing codes (741.0, 741.9) in SHP, Medicaid, and hospital uniform billing (UB) data. ER and IP encounters were identified using UB data. Multivariable Generalized Estimating Equation (GEE) Poisson models were estimated to compare rates of ER and IP use among the SB group to the comparison group. Main Outcome Measures: Total ER rate and IP rate, in addition to cause-specific rates for ambulatory care sensitive conditions (ACSC) and other condition categories. Results: We found higher rates of ER and IP use in persons with SB compared to the control group. Among individuals with SB, young adults (those 20-24 years old) had higher rates of ER use due to all ACSC (P = .023), other ACSC (P = .04), and urinary tract infections (UTI; P = .002) compared to adolescents (those 15-19 years old). Conclusions: Young adulthood is associated with increased ER use overall, as well as in specific condition categories (most notably UTI) in individuals 15-24 years old with SB. This association may be indicative of changing healthcare access as people with SB move from adolescent to adult health care, and/or physiologic changes during the age range studied. C1 [Mann, Joshua R.] Univ S Carolina, Dept Family & Prevent Med, Sch Med, Columbia, SC 29203 USA. [Royer, Julie A.] South Carolina Revenue & Fiscal Affairs Off, Columbia, SC USA. [Turk, Margaret A.] SUNY Upstate Med Univ, Dept Phys Med & Rehabil, Columbia, SC USA. [McDermott, Suzanne; Holland, Margaret M.; Hardin, James W.] Univ S Carolina, Dept Epidemiol & Biostat, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [Ozturk, Orgul D.] Univ S Carolina, Dept Econ, Darla Moore Sch Business, Columbia, SC 29208 USA. [Thibadeau, Judy K.] Natl Ctr Birth Defects & Dev Disabil, Ctr Dis Control & Prevent, Atlanta, GA USA. RP Mann, JR (reprint author), Univ S Carolina, Dept Family & Prevent Med, Sch Med, 3209 Colonial Dr, Columbia, SC 29203 USA. EM joshua.mann@uscmed.sc.edu RI Dalla Zuanna, Teresa/G-3133-2015; Hardin, James/Q-7617-2016 OI Hardin, James/0000-0003-0506-5500 FU National Center on Birth Defects and Developmental Disabilities (Centers for Disease Control and Prevention) [U01-DD000776-02] FX Disclosures related to this publication: grant from the National Center on Birth Defects and Developmental Disabilities (Centers for Disease Control and Prevention; grant #U01-DD000776-02) NR 32 TC 2 Z9 2 U1 1 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1934-1482 EI 1934-1563 J9 PM&R JI PM&R PD MAY PY 2015 VL 7 IS 5 BP 499 EP + DI 10.1016/j.pmrj.2014.11.011 PG 13 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA CI2LD UT WOS:000354578200007 PM 25511690 ER PT J AU Carrel, M Patel, J Taylor, SM Janko, M Mwandagalirwa, MK Tshefu, AK Escalante, AA McCollum, A Alam, MT Udhayakumar, V Meshnick, S Emch, M AF Carrel, Margaret Patel, Jaymin Taylor, Steve M. Janko, Mark Mwandagalirwa, Melchior Kashamuka Tshefu, Antoinette K. Escalante, Ananias A. McCollum, Andrea Alam, Md Tauqeer Udhayakumar, Venkatachalam Meshnick, Steven Emch, Michael TI The geography of malaria genetics in the Democratic Republic of Congo: A complex and fragmented landscape SO SOCIAL SCIENCE & MEDICINE LA English DT Article DE Democratic Republic of Congo; Disease ecology; Landscape genetics; Malaria ID RESISTANT PLASMODIUM-FALCIPARUM; MICROSATELLITE MARKERS; MOLECULAR EVOLUTION; ELIMINATION; RISK; TRANSMISSION; IMPORTATION; REGRESSION; EMERGENCE; ALLELES AB Understanding how malaria parasites move between populations is important, particularly given the potential for malaria to be reintroduced into areas where it was previously eliminated. We examine the distribution of malaria genetics across seven sites within the Democratic Republic of Congo (DRC) and two nearby countries, Ghana and Kenya, in order to understand how the relatedness of malaria parasites varies across space, and whether there are barriers to the flow of malaria parasites within the DRC or across borders. Parasite DNA was retrieved from dried blood spots from 7 Demographic and Health Survey sample clusters in the DRC. Malaria genetic characteristics of parasites from Ghana and Kenya were also obtained. For each of 9 geographic sites (7 DRC, 1 Ghana and 1 Kenya), a pair-wise R-ST statistic was calculated, indicating the genetic distance between malaria parasites found in those locations. Mapping genetics across the spatial extent of the study area indicates a complex genetic landscape, where relatedness between two proximal sites may be relatively high (R-ST > 0.64) or low (R-ST < 0.05), and where distal sites also exhibit both high and low genetic similarity. Mantel's tests suggest that malaria genetics differ as geographic distances increase. Principal Coordinate Analysis suggests that genetically related samples are not co-located. Barrier analysis reveals no significant barriers to gene flow between locations. Malaria genetics in the DRC have a complex and fragmented landscape. Limited exchange of genes across space is reflected in greater genetic distance between malaria parasites isolated at greater geographic distances. There is, however, evidence for close genetic ties between distally located sample locations, indicating that movement of malaria parasites and flow of genes is being driven by factors other than distance decay. This research demonstrates the contributions that spatial disease ecology and landscape genetics can make to understanding the evolutionary dynamics of infectious diseases. (C) 2014 Elsevier Ltd. All rights reserved. C1 [Carrel, Margaret] Univ Iowa, Dept Geog & Sustainabil Sci, Iowa City, IA 52245 USA. [Patel, Jaymin; Taylor, Steve M.; Mwandagalirwa, Melchior Kashamuka; Meshnick, Steven] Univ N Carolina, Gillings Sch Global Publ Hlth, Dept Epidemiol, Chapel Hill, NC USA. [Taylor, Steve M.] Duke Univ, Med Ctr, Div Infect Dis & Int Hlth, Durham, NC USA. [Taylor, Steve M.] Duke Global Hlth Inst, Durham, NC USA. [Janko, Mark; Emch, Michael] Univ N Carolina, Dept Geog, Chapel Hill, NC USA. [Tshefu, Antoinette K.] Univ Kinshasa, Fac Med, Ecole Sante Publ, Kinshasa, Zaire. [Escalante, Ananias A.] Arizona State Univ, Biodesign Inst, Ctr Evolutionary Med & Informat, Tempe, AZ USA. [McCollum, Andrea; Alam, Md Tauqeer; Udhayakumar, Venkatachalam] Ctr Dis Control & Prevent, Ctr Global Hlth, Div Parasit Dis & Malaria, Malaria Branch, Atlanta, GA USA. RP Carrel, M (reprint author), Univ Iowa, Dept Geog & Sustainabil Sci, 303 Jessup Hall, Iowa City, IA 52245 USA. EM margaret-carrel@uiowa.edu FU NSF; Gillings Innovative Laboratory Fund; NIH; NSF [BCS-1339949]; NIH [1R56AI097609-01]; National Institute of Allergy and Infectious Diseases of the NIH [K08AI100924] FX This project was supported by grants from the NSF, the Gillings Innovative Laboratory Fund and the NIH. MC and ME are supported by NSF under award number BCS-1339949. JP and SM are supported by NIH award number 1R56AI097609-01. SMT is supported by the National Institute of Allergy and Infectious Diseases of the NIH under award number K08AI100924. We thank Dr. Augustin Okenge (Programme National de Lutte Contre le SIDA, Kinshasa, DRC), Dr. Jeremie Mwonga (Laboratoire National de Reference SIDA et IST, Kinshasa, DRC), and Ann Way, Mohamed Ayad, and Martin Vaessen (all of MeasureDHS, Calverton, MD) for help in obtaining access to the dried blood spots. NR 46 TC 1 Z9 1 U1 3 U2 18 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0277-9536 J9 SOC SCI MED JI Soc. Sci. Med. PD MAY PY 2015 VL 133 SI SI BP 233 EP 241 DI 10.1016/j.socscimed.2014.10.037 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA CI2LT UT WOS:000354579800032 PM 25459204 ER PT J AU McDermott, S Hardin, JW Royer, JA Mann, JR Tong, X Ozturk, OD Ouyang, LJ AF McDermott, Suzanne Hardin, James W. Royer, Julie A. Mann, Joshua R. Tong, Xin Ozturk, Orgul D. Ouyang, Lijing TI Emergency Department and Inpatient Hospitalizations for Young People With Fragile X Syndrome SO AJIDD-AMERICAN JOURNAL ON INTELLECTUAL AND DEVELOPMENTAL DISABILITIES LA English DT Article DE intellectual disability; fragile X syndrome; adolescents; health care; health status ID CARE SENSITIVE CONDITIONS; HEALTH-CARE; PARENT SURVEY; EPILEPSY; TRANSITION; PREVALENCE; SEIZURES; CHILDREN; DISABILITIES; ADOLESCENTS AB We compared hospital encounters between adolescents and young adults with fragile X syndrome (FXS) to peers with intellectual disability (ID) from other causes, autism spectrum disorder (ASD), and a comparison group without these conditions matched by gender, age, and insurance coverage. Those with FXS, ASD, or ID were more likely to have had hospital encounters. In terms of age groups, we found mental illness hospitalizations decreased during adulthood as compared to adolescence for those with FXS, and we found that for conditions unrelated to FXS (e.g., respiratory, genitourinary, gastroenteritis, and pneumonia) adolescents had higher rates of hospitalization compared to their peers with FXS, ID, or ASD. We analyzed epilepsy, common among people with FXS and designated as an ambulatory care sensitive condition that can be treated outside the hospital, and found that people with FXS, ID, and ASD had higher odds of hospitalization due to epilepsy in both age groups than did the comparison group. C1 [McDermott, Suzanne; Hardin, James W.; Tong, Xin] Univ S Carolina, Arnold Sch Publ Hlth, Columbia, SC 29208 USA. [Royer, Julie A.] Univ S Carolina, South Carolina Revenue & Fiscal Affairs Off, Columbia, SC 29208 USA. [Mann, Joshua R.] Univ S Carolina, Sch Med, Columbia, SC 29208 USA. [Ozturk, Orgul D.] Univ S Carolina, Moore Sch Business, Columbia, SC 29208 USA. [Ouyang, Lijing] Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA USA. RP McDermott, S (reprint author), Univ S Carolina, Dept Epidemiol & Biostat, Arnold Sch Publ Hlth, 915 Greene St, Columbia, SC 29208 USA. EM smcdermo@mailbox.sc.edu RI Hardin, James/Q-7617-2016; OI Hardin, James/0000-0003-0506-5500; Tong, Xin/0000-0003-1340-0823 FU Centers for Disease Control and Prevention FX This research was supported by a cooperative agreement from the Centers for Disease Control and Prevention. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the Centers for Disease Control and Prevention, the South Carolina Budget and Control Board Division of Research and Statistics, the South Carolina Department of Health and Human Services, the South Carolina Public Employee Benefit Authority, the South Carolina Department of Education, or the South Carolina Department of Social Services. NR 38 TC 0 Z9 0 U1 1 U2 6 PU AMER ASSOC INTELLECTUAL DEVELOPMENTAL DISABILITIES PI WASHINGTON PA 444 N CAPITOL ST, NW STE 846, WASHINGTON, DC 20001-1512 USA SN 1944-7515 EI 1944-7558 J9 AJIDD-AM J INTELLECT JI AJIDD-Am. J. Intellect. Dev. Disabil. PD MAY PY 2015 VL 120 IS 3 BP 230 EP 243 DI 10.1352/1944-7558-120.3.230 PG 14 WC Education, Special; Rehabilitation SC Education & Educational Research; Rehabilitation GA CI2VF UT WOS:000354604800004 PM 25928435 ER PT J AU Guy, GP Tangka, FKL Hall, IJ Miller, JW Royalty, J AF Guy, Gery P., Jr. Tangka, Florence K. L. Hall, Ingrid J. Miller, Jacqueline W. Royalty, Janet TI The Reach and Health Impacts of the National Breast and Cervical Cancer Early Detection Program FORWARD SO CANCER CAUSES & CONTROL LA English DT Editorial Material C1 [Guy, Gery P., Jr.; Tangka, Florence K. L.; Hall, Ingrid J.; Miller, Jacqueline W.; Royalty, Janet] Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30329 USA. RP Guy, GP (reprint author), Ctr Dis Control & Prevent, Div Canc Prevent & Control, Atlanta, GA 30329 USA. EM gguy@cdc.gov FU Intramural CDC HHS [CC999999] NR 17 TC 2 Z9 2 U1 1 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0957-5243 EI 1573-7225 J9 CANCER CAUSE CONTROL JI Cancer Causes Control PD MAY PY 2015 VL 26 IS 5 SI SI BP 649 EP 650 DI 10.1007/s10552-015-0561-0 PG 2 WC Oncology; Public, Environmental & Occupational Health SC Oncology; Public, Environmental & Occupational Health GA CH9RP UT WOS:000354374200001 PM 25794898 ER EF